{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6057-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May timeframe.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6057", "0641-6059", "0641-6056", "0641-6061", "0641-6063", "0641-6060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-04", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-04)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-87", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-671", "25021-652"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6004-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA213784"], "brand_name": ["FLUPHENAZINE HYDROCHLORIDE"], "generic_name": ["FLUPHENAZINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories,LLC"], "product_ndc": ["0832-6004", "0832-6003", "0832-6005", "0832-6006"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUPHENAZINE HYDROCHLORIDE"], "rxcui": ["859841", "860918", "865117", "865123"], "spl_id": ["3bb74f82-8872-9829-e063-6294a90aeace"], "spl_set_id": ["f07bb3f1-c68c-441b-9de4-99a219f2500a"], "package_ndc": ["0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11"], "unii": ["ZOU145W1XL"]}, "update_date": "09/18/2025", "therapeutic_category": ["Neurology", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 2.5 mg (NDC 0832-6004-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0306-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/185612/download?attachment", "contact_info": "610-937-6172", "availability": "Available", "openfda": {"brand_name": ["TEGLUTIK"], "generic_name": ["RILUZOLE"], "manufacturer_name": ["EDW PHARMA"], "product_ndc": ["70726-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RILUZOLE"], "rxcui": ["2058147", "2675565"], "spl_id": ["4746bb53-bb35-7aa0-e063-6394a90a647b"], "spl_set_id": ["1a3aeb59-d589-8d12-e063-6394a90a0a3a"], "package_ndc": ["70726-0306-1"], "nui": ["N0000175740", "M0483511"], "pharm_class_epc": ["Benzothiazole [EPC]"], "pharm_class_cs": ["Benzothiazoles [CS]"], "unii": ["7LJ087RS6F"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9045-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071168"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9045", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-31", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Not available at this time.", "openfda": {"application_number": ["ANDA070553", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-03", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA089646"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-04", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA090108"], "brand_name": ["CLINDAMYCIN"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["1737244", "1737578", "1737581"], "spl_id": ["4662502b-ce7c-4278-854d-cf8632ac9b83"], "spl_set_id": ["7a6967b3-5563-4bed-9eee-d400f800e799"], "package_ndc": ["25021-115-02", "25021-115-04", "25021-115-06"], "unii": ["EH6D7113I8"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "63323-032-00", "generic_name": "Sodium Acetate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206687"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-032"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["312965"], "spl_id": ["37c19fc5-c1ce-4ea0-9cba-4cdf32112091"], "spl_set_id": ["d7fabf08-d4e0-4bb5-8416-2e8ffe27c04b"], "package_ndc": ["63323-032-04", "63323-032-00"], "unii": ["4550K0SC9B"]}, "update_date": "04/23/2026", "therapeutic_category": ["Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-0367-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Product will be made available as it is released.", "openfda": {"application_number": ["ANDA087702"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-0367", "0641-6145", "0641-6146"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["02bf3273-f0c8-448c-9f74-eb009fee9299"], "spl_set_id": ["0277cc0a-2fd4-4605-a310-b613be84ee26"], "package_ndc": ["0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/12/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0143-9144-03", "generic_name": "Liraglutide Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": {"application_number": ["ANDA215503"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9144"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["5088d0a8-f7aa-476c-8cc1-149955781409"], "spl_set_id": ["2100ec49-57b2-4330-ab5f-057ce9b7e4d0"], "package_ndc": ["0143-9144-01", "0143-9144-03", "0143-9144-02"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-36", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-36", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-552-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-552", "64850-550", "64850-551", "64850-553", "64850-554", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-725-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA076772"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-725", "62037-734", "62037-726", "62037-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "spl_id": ["24aa9277-3773-489d-8459-f9215140c53f"], "spl_set_id": ["85ef422d-af27-4126-9841-6892af1871d6"], "package_ndc": ["62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/28/2026", "update_type": "New", "initial_posting_date": "01/28/2026", "package_ndc": "0023-6118-03", "generic_name": "Podofilox Topical Gel", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020529"], "brand_name": ["CONDYLOX"], "generic_name": ["PODOFILOX"], "manufacturer_name": ["Allergan, Inc."], "product_ndc": ["0023-6118"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["PODOFILOX"], "rxcui": ["312466", "351750"], "spl_id": ["9f2892be-8330-4fd1-930e-b4d204df4e03"], "spl_set_id": ["032e4bcb-b1ed-4029-b2a6-e92f3bf5cc37"], "package_ndc": ["0023-6118-03"], "nui": ["N0000008732"], "pharm_class_pe": ["Decreased Mitosis [PE]"], "unii": ["L36H50F353"]}, "update_date": "01/28/2026", "therapeutic_category": ["Dermatology", "Other"], "dosage_form": "Topical Gel", "presentation": "Condylox , Topical Gel, 0.5% (NDC 0023-6118-03)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-669-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076374"], "brand_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-669", "62135-667", "62135-668"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["0c3f4504-d57e-aa79-e063-6294a90ad5b8"], "spl_set_id": ["2eae533f-d0af-47e8-a1f2-94bc8cc89b5a"], "package_ndc": ["62135-667-90", "62135-668-90", "62135-669-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-171-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-171", "55150-167", "55150-168", "55150-169", "55150-170", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/06/2026", "update_type": "New", "initial_posting_date": "05/06/2026", "package_ndc": "0409-1208-01", "generic_name": "Cisatracurium Besylate Injection", "contact_info": "844-646-4398", "related_info": "Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203238"], "brand_name": ["CISATRACURIUM BESYLATE"], "generic_name": ["CISATRACURIUM BESYLATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1208", "0409-1098", "0409-1103"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CISATRACURIUM BESYLATE"], "rxcui": ["199211", "199212", "1730194"], "spl_id": ["0ec666c8-db68-4a59-9da4-e0abd8e209c5"], "spl_set_id": ["67908e20-044d-454d-9c51-bf106e817bd0"], "package_ndc": ["0409-1098-12", "0409-1098-02", "0409-1103-11", "0409-1103-01", "0409-1208-11", "0409-1208-01"], "unii": ["80YS8O1MBS"]}, "update_date": "05/06/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-152", "72888-153", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-05)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0127-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-201-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088586"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-201", "63323-202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1737757"], "spl_id": ["d19c26f4-1214-40f7-9680-43c885613306"], "spl_set_id": ["cddb2b22-fce3-8967-6e54-dca3df5ac4b3"], "package_ndc": ["63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02"], "unii": ["V13007Z41A"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-022-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 22.5 mg/.4 mL (NDC 82497-022-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "76045-004-11", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi, USA LLC", "Fresenius Kabi USA, LLC"], "product_ndc": ["76045-004", "76045-005", "76045-006", "76045-007", "76045-008"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "894914", "998212", "998213", "1442790"], "spl_id": ["286bce70-23cd-4d5b-989b-230d6cdd5a91", "e064585d-2d2d-41cd-a0f1-43494ce4775b"], "spl_set_id": ["1f53de80-efc8-4930-b3e3-fba0d026af05", "b62ee1ef-db55-417a-a02e-b103890f9c4b"], "package_ndc": ["76045-004-01", "76045-004-11", "76045-005-01", "76045-005-11", "76045-006-01", "76045-006-11", "76045-007-01", "76045-007-11", "76045-008-01", "76045-008-11", "76045-004-02", "76045-004-12", "76045-005-02", "76045-005-12", "76045-006-02", "76045-006-12", "76045-007-00", "76045-007-10", "76045-008-00", "76045-008-10"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0973-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0973", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-734-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA076772"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-734", "62037-725", "62037-726", "62037-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "spl_id": ["24aa9277-3773-489d-8459-f9215140c53f"], "spl_set_id": ["85ef422d-af27-4126-9841-6892af1871d6"], "package_ndc": ["62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "55150-209-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5117-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5117", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5116"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0185-2099-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Limited Availability, 2 weeks", "related_info": "Low supply of Amphetamine combo 30mg due to packaging delays", "openfda": {"application_number": ["ANDA040439"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0185-2099", "0185-0831", "0185-0842", "0185-0853", "0185-0864", "0185-2098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577961"], "spl_id": ["9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd"], "spl_set_id": ["288dafc4-fe6e-4891-832f-511022c87445"], "package_ndc": ["0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)", "company_name": "Sandoz Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2859", "0781-2868"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-386-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6061-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May 2026 timeframe.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6061", "0641-6057", "0641-6059", "0641-6056", "0641-6063", "0641-6060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-197-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-197", "55150-195", "55150-196", "55150-198", "55150-199", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-50", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088400"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-185"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["42c6c812-706a-425b-b8cb-931006e40484"], "spl_set_id": ["e71c6c83-d518-496c-b2ab-efd5987e4783"], "package_ndc": ["63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/23/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0870-26", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: December 2028", "openfda": {"application_number": ["NDA050441"], "brand_name": ["CLEOCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0870", "0009-0775", "0009-0902", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582", "205964", "309335", "309336", "309339", "685574"], "spl_id": ["dd9fa453-a2ca-4a53-b39b-c59a44a888aa"], "spl_set_id": ["05a75685-0af5-407c-ac57-e380c882b49d"], "package_ndc": ["0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01"], "unii": ["EH6D7113I8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)", "company_name": "Pfizer Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-382-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070552", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-22", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3073", "0009-3475"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-723-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-723", "59651-722", "59651-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 59651-723-01)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "83634-600-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": {"application_number": ["ANDA209065"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Avenacy Inc."], "product_ndc": ["83634-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["3e30e931-4d42-465c-9e4b-cd3137ba5fe2"], "spl_set_id": ["eee6145b-d83f-4596-92d3-733934d8a3a4"], "package_ndc": ["83634-600-41", "83634-600-02"], "unii": ["1018WH7F9I"]}, "update_date": "04/06/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0143-9532-25", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA205046"], "brand_name": ["DEXMEDETOMIDINE HCL"], "generic_name": ["DEXMEDETOMIDINE HCL"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9532"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "spl_id": ["8cb1c4c8-48b4-471f-b443-5f03896a3fb7"], "spl_set_id": ["de6f01a2-9f2d-4c68-9c02-06643704acb1"], "package_ndc": ["0143-9532-01", "0143-9532-25"], "unii": ["1018WH7F9I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-553-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-553", "64850-550", "64850-551", "64850-552", "64850-554", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-557-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "Lupin Pharmaceuticals, Inc.", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077690"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-557", "68180-556", "68180-558", "68180-554", "68180-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["a9598a21-6f99-4c86-ace6-b5638da2bec8"], "spl_set_id": ["8ded0773-3aec-4e89-9836-d22a5a84abf0"], "package_ndc": ["68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA076515"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2234"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["200329"], "spl_id": ["fe6aa833-89e6-4679-a7b8-6600e92c1bed"], "spl_set_id": ["5a09ce48-7139-4fc7-9b6e-439459c8e866"], "package_ndc": ["0781-2234-10", "0781-2234-01", "0781-2234-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-287-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-287", "63323-286", "63323-288", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "65219-445-20", "generic_name": "Etomidate Injection", "contact_info": "800-551-7176", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-445", "65219-447"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["446487f1-002e-41d3-846a-67570e797171", "30488a7e-ea9e-4a27-95a9-a07149c50282"], "spl_set_id": ["f38fad46-f2dd-4692-a2a9-a13d0a717bf8", "d07efb9e-5264-461d-96d8-e11fa71c5751"], "package_ndc": ["65219-445-12", "65219-445-22", "65219-445-01", "65219-445-10", "65219-447-02", "65219-447-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 40 mg/20 mL (NDC 65219-445-20)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4744-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4744", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "23155-600-41", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA090696"], "brand_name": ["MIDAZOLAM HYDROCHLORIDE"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "spl_id": ["0703352c-df9e-40fb-be00-0742a2511a7d"], "spl_set_id": ["8b690f5c-2923-4c34-a8f7-11af5f546b62"], "package_ndc": ["23155-600-31", "23155-600-41"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-25", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb"], "spl_set_id": ["abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f"], "package_ndc": ["0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "76045-211-20", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA203460"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-211", "76045-001", "76045-002", "76045-003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["998211", "1551393", "1551395"], "spl_id": ["ec9c9aee-b95f-4645-bf17-df7f1e3967d3"], "spl_set_id": ["1cc9ba6e-fa1b-405e-9de8-720c567b2a73"], "package_ndc": ["76045-211-00", "76045-211-20", "76045-001-00", "76045-001-20", "76045-002-00", "76045-002-10", "76045-003-00", "76045-003-20"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "64253-400-91", "generic_name": "Atropine Sulfate Injection", "contact_info": "630-682-4600", "availability": "Available", "openfda": {"application_number": ["ANDA214970"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE INJECTION"], "manufacturer_name": ["Medefil, Inc."], "product_ndc": ["64253-400"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546"], "spl_id": ["46a6a31f-46ab-a437-e063-6394a90a4ad0"], "spl_set_id": ["fbfdf718-befe-ad22-e053-6294a90a3715"], "package_ndc": ["64253-400-30", "64253-400-91"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/15/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)", "company_name": "Medefil, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-7299-25", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["1859490"], "spl_id": ["013001c4-5584-4d8c-8bf6-917d2a919aa4", "10c75a24-9542-431a-84f8-44611bc916df"], "spl_set_id": ["ce9a7469-c4ba-4f60-8f7a-47ef0974316e", "c91ede49-c7cc-47b7-0f93-e6841dd5916a"], "package_ndc": ["0409-7299-45", "0409-7299-25", "0409-7299-83", "0409-7299-73"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)", "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-1505-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "company_name": "Lannett Company, Inc.", "contact_info": "844-834-0530", "availability": "Available", "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "status": "Current", "dosage_form": "Tablet", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "68025-095-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-095", "68025-088", "68025-089", "68025-096", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "25021-131-82", "generic_name": "Metronidazole Injection", "contact_info": "866-625-1618", "availability": "Available", "related_info": "Labeler: Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206191"], "brand_name": ["METRONIDAZOLE"], "generic_name": ["METRONIDAZOLE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["METRONIDAZOLE"], "rxcui": ["311683"], "spl_id": ["cad111bb-2009-422a-b16e-87d75ade4e4c"], "spl_set_id": ["d46870f5-e2b1-46bd-8413-4a0a8bcf3175"], "package_ndc": ["25021-131-82"], "nui": ["N0000175435", "M0014907"], "pharm_class_epc": ["Nitroimidazole Antimicrobial [EPC]"], "pharm_class_cs": ["Nitroimidazoles [CS]"], "unii": ["140QMO216E"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/25/2020", "package_ndc": "0088-2102-24", "generic_name": "Rifapentine Tablet, Film Coated", "contact_info": "800-633-1610 Option 7", "availability": "Available", "openfda": {"application_number": ["NDA021024"], "brand_name": ["PRIFTIN"], "generic_name": ["RIFAPENTINE"], "manufacturer_name": ["sanofi-aventis U.S. LLC"], "product_ndc": ["0088-2102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAPENTINE"], "rxcui": ["242671", "261101"], "spl_id": ["83c11919-ca6d-49f5-8f9f-7b8405fcbaec"], "spl_set_id": ["3a64fb70-b85e-43d9-8bcd-7e893f568ae1"], "package_ndc": ["0088-2102-01", "0088-2102-24"], "nui": ["N0000175501", "M0019113"], "pharm_class_epc": ["Rifamycin Antimycobacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["XJM390A33U"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-4916-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5815-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA090866"], "brand_name": ["VALSARTAN"], "generic_name": ["VALSARTAN"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-5815", "0378-5807", "0378-5813", "0378-5814"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VALSARTAN"], "rxcui": ["349199", "349200", "349201", "349483"], "spl_id": ["a5384d58-48c7-494a-a8a8-c296b316bd91"], "spl_set_id": ["73e01dc6-7dd4-421a-a4f6-137e75f69f9a"], "package_ndc": ["0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77"], "nui": ["N0000000070", "N0000175561"], "pharm_class_moa": ["Angiotensin 2 Receptor Antagonists [MoA]"], "pharm_class_epc": ["Angiotensin 2 Receptor Blocker [EPC]"], "unii": ["80M03YXJ7I"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 320 mg (NDC 0378-5815-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "21586-011-02", "generic_name": "Cefotaxime Sodium Powder, for Solution", "related_info_link": "https://www.fda.gov/media/152896/download", "contact_info": "800-881-3550", "availability": "Available", "openfda": {"brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME INJECTION"], "manufacturer_name": ["SteriMax Inc."], "product_ndc": ["21586-011", "21586-012"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["1656313", "1656318"], "spl_id": ["425c90b3-5006-427e-95f6-93ee7918fb8b"], "spl_set_id": ["8efe3bd0-c43a-2bd6-e053-2a95a90a92fa"], "package_ndc": ["21586-011-01", "21586-011-02", "21586-012-01", "21586-012-02"], "unii": ["258J72S7TZ"]}, "update_date": "04/30/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)", "company_name": "SteriMax, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6003-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA213784"], "brand_name": ["FLUPHENAZINE HYDROCHLORIDE"], "generic_name": ["FLUPHENAZINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories,LLC"], "product_ndc": ["0832-6003", "0832-6004", "0832-6005", "0832-6006"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUPHENAZINE HYDROCHLORIDE"], "rxcui": ["859841", "860918", "865117", "865123"], "spl_id": ["3bb74f82-8872-9829-e063-6294a90aeace"], "spl_set_id": ["f07bb3f1-c68c-441b-9de4-99a219f2500a"], "package_ndc": ["0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11"], "unii": ["ZOU145W1XL"]}, "update_date": "09/18/2025", "therapeutic_category": ["Neurology", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 1 mg (NDC 0832-6003-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-136-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-136", "16729-137", "16729-138"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 16729-136-00)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7938-19", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7938-19", "openfda": {"application_number": ["NDA018080"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7938"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477"], "spl_id": ["43f81a41-0a45-45f5-840c-768d768edd3b"], "spl_set_id": ["cb578dba-094c-4787-951d-763d12fd06e1"], "package_ndc": ["0990-7938-19"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-4615-01", "generic_name": "Doxylamine Succinate and Pyridoxine  Hydrochloride Tablet, Delayed Release", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA207825"], "brand_name": ["DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE"], "generic_name": ["DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-4615"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DOXYLAMINE SUCCINATE", "PYRIDOXINE HYDROCHLORIDE"], "rxcui": ["1375948"], "spl_id": ["948c17d8-e019-4e4e-b93b-a775ec327a6d"], "spl_set_id": ["957865a2-efcf-43a6-92a8-f9f980892833"], "package_ndc": ["0378-4615-01"], "unii": ["V9BI9B5YI2", "68Y4CF58BV"]}, "update_date": "01/12/2026", "therapeutic_category": ["Other"], "dosage_form": "Tablet", "presentation": "Doxylamine Succinate and Pyridoxine  Hydrochloride, Tablet, Delayed Release, 10 mg; 10 mg (NDC 0378-4615-01)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "0143-9830-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": {"application_number": ["ANDA040632"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9830"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE"], "rxcui": ["311625"], "spl_id": ["49eb25b2-c59c-4374-a216-076767fe1126"], "spl_set_id": ["b080eb92-fc72-4ce6-a7ab-3f9ce2415526"], "package_ndc": ["0143-9830-01"], "nui": ["N0000175584", "N0000000111"], "pharm_class_epc": ["Folate Analog Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Folic Acid Metabolism Inhibitors [MoA]"], "unii": ["YL5FZ2Y5U1"]}, "update_date": "05/12/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "71357-008-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": {"application_number": ["ANDA214805"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE INJECTION, USP, 200 MEQ/100 ML"], "manufacturer_name": ["MILLA PHARMACEUTICALS INC."], "product_ndc": ["71357-008", "71357-007", "71357-009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["237371", "312965"], "spl_id": ["47d8d0e7-6db5-950d-e063-6294a90ab1bf"], "spl_set_id": ["1ea1466d-a492-4056-e063-6394a90a80bf"], "package_ndc": ["71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10"], "unii": ["4550K0SC9B"]}, "update_date": "05/15/2026", "therapeutic_category": ["Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)", "company_name": "Milla Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "0338-9557-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA208532"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9557", "0338-9555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["594e9faa-bc32-42e0-9c0a-8fa9460b1e24"], "spl_set_id": ["8ccb45a7-8290-469c-9644-a4dca967d88f"], "package_ndc": ["0338-9555-24", "0338-9557-12"], "unii": ["1018WH7F9I"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0551-11", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020179"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-0551"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616"], "spl_id": ["e702be26-651e-4d4a-9d79-4df9f53821c9"], "spl_set_id": ["7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e"], "package_ndc": ["0338-0551-11", "0338-0551-18"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-0111-00", "generic_name": "Amantadine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076186"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0111"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849395"], "spl_id": ["45af44df-1a9b-32b6-e063-6394a90acdaf"], "spl_set_id": ["63d9d4aa-5f92-45b0-98d0-d6ec38b727cb"], "package_ndc": ["0832-0111-00", "0832-0111-50", "0832-0111-89", "0832-0111-03"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Tablet", "presentation": "Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-00)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "0378-4415-01", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "1-844-874-7464", "availability": "Unavailable", "related_info": "Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.", "update_date": "01/14/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)", "company_name": "Rising Pharma Holdings, Inc.", "shortage_reason": "Regulatory delay", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/12/2025", "update_type": "New", "initial_posting_date": "11/12/2025", "package_ndc": "0603-3718-34", "generic_name": "Frovatriptan Succinate Tablet", "contact_info": "800-828-9393", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/12/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Frova, Tablet, 2.5 mg (NDC 0603-3718-34)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-101-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 10 mg (NDC 59417-101-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-455-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-455", "63323-452", "63323-454", "63323-458", "63323-451"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011", "1732136", "2003714"], "spl_id": ["dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc"], "spl_set_id": ["582f42e5-444e-4246-af8c-e7e28097c69a"], "package_ndc": ["63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-035-02", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["NDA020630"], "brand_name": ["ULTIVA"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["72078-035", "72078-034", "72078-036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729581", "1729584", "1729586", "1729710", "1729712"], "spl_id": ["594087a1-25f2-4f68-aea6-ad7df40559ab"], "spl_set_id": ["8b4c8696-e23e-4c51-a4d2-babab5bd945a"], "package_ndc": ["72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05"], "unii": ["5V444H5WIC"]}, "update_date": "05/05/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 2 mg (NDC 72078-035-02)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1434-01", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1434", "0409-1660", "0409-1638", "0409-1596", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-161-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-161", "55150-162", "55150-163", "55150-164", "55150-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-116-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-116", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6045-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6045", "0641-6044", "0641-6046", "0641-6047"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100", "238101", "1665188", "1665326"], "spl_id": ["7c73dbc6-2623-4443-9b05-97dec7a0be2e"], "spl_set_id": ["e9b54e42-04cf-4c62-90e1-36f7b31a4e81"], "package_ndc": ["0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-312-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA091695"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["62175-312", "62175-310", "62175-311", "62175-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001564", "2001565", "2001566", "2001568"], "spl_id": ["8b133cd2-e3c6-4742-b402-2393b56ffc93"], "spl_set_id": ["3d1f5aff-5d39-496c-b5ed-7f3c70ec641c"], "package_ndc": ["62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37"], "unii": ["4B3SC438HI"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)", "company_name": "Lannett Company, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0306-12", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0306", "0009-0274", "0009-0280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/27/2025", "update_type": "New", "initial_posting_date": "10/27/2025", "package_ndc": "0310-6627-02", "generic_name": "Pramlintide Acetate Injection", "contact_info": "800-236-9933", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA021332"], "brand_name": ["SYMLINPEN"], "generic_name": ["PRAMLINTIDE ACETATE"], "manufacturer_name": ["AstraZeneca Pharmaceuticals LP"], "product_ndc": ["0310-6627", "0310-6615"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PRAMLINTIDE ACETATE"], "rxcui": ["861042", "861043", "861044", "861045"], "spl_id": ["a84753f1-6ac5-4a47-a382-29972938ccaa"], "spl_set_id": ["4aea30ff-eb0d-45c1-b114-3127966328ff"], "package_ndc": ["0310-6615-02", "0310-6627-02"], "unii": ["726I6TE06G"]}, "update_date": "10/27/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "SymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02)", "company_name": "AstraZeneca AB", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-35", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1755-50", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1755", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-1209-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA088571"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/04/2025", "update_type": "New", "initial_posting_date": "08/04/2025", "package_ndc": "45963-614-51", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "800-545-8800", "related_info": "Product not anticipated to be available beyond mid-late October 2025", "openfda": {"application_number": ["ANDA078589"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["45963-614"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["3bbdb61c-9194-416e-9034-5d2b11b5b8ee"], "spl_set_id": ["5e1fdcaa-918f-4cd8-9c7a-4c538d866198"], "package_ndc": ["45963-614-51", "45963-614-55"], "unii": ["042LAQ1IIS"]}, "update_date": "08/04/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-709-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-709", "13811-706", "13811-707", "13811-708", "13811-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6125-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May 2026 timeframe.", "openfda": {"application_number": ["ANDA205758"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6125", "0641-6126", "0641-6127"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011"], "spl_id": ["fa18221d-2353-4cf6-a210-fb33ee79d3d9"], "spl_set_id": ["6023606c-150c-40c5-9175-598efe2a56c3"], "package_ndc": ["0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-5322-11", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-5322", "0832-5323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953"], "spl_id": ["39e726b1-eab8-fcf4-e063-6394a90a950a"], "spl_set_id": ["616f0de7-8843-44a1-8fa6-274d889286aa"], "package_ndc": ["0832-5322-11", "0832-5322-10", "0832-5323-11", "0832-5323-10"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-05", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA084916"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1116927", "1812194"], "spl_id": ["a832bff9-0bb3-4350-abb5-d57b9417070c", "9dd90418-e564-4bc5-9077-506a1c2c1bce"], "spl_set_id": ["2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e"], "package_ndc": ["63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-501-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-501", "64850-500", "64850-502", "64850-503", "64850-504", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0591-2679-30", "generic_name": "Lidocaine Patch", "contact_info": "800-545-8800", "related_info": "Discontinuation is for the “NovaPlus” label product only.", "openfda": {"application_number": ["ANDA200675"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2679"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["LIDOCAINE"], "rxcui": ["1745091"], "spl_id": ["e0683309-89ba-4804-887f-12fcaf59a2ca"], "spl_set_id": ["c18799cd-9e11-4196-9ab1-0a2a84585e56"], "package_ndc": ["0591-2679-11", "0591-2679-30"], "nui": ["N0000175682", "M0000897", "N0000175426", "N0000175976"], "pharm_class_epc": ["Amide Local Anesthetic [EPC]", "Antiarrhythmic [EPC]"], "pharm_class_cs": ["Amides [CS]"], "pharm_class_pe": ["Local Anesthesia [PE]"], "unii": ["98PI200987"]}, "update_date": "07/17/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Patch", "presentation": "Lidocaine, Patch, 5% (NDC 0591-2679-30)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "63323-413-10", "generic_name": "Neostigmine Methylsulfate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA203629"], "brand_name": ["NEOSTIGMINE METHYLSULFATE"], "generic_name": ["NEOSTIGMINE METHYLSULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-413", "63323-415"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NEOSTIGMINE METHYLSULFATE"], "rxcui": ["311935", "311936"], "spl_id": ["3abc0611-0e8c-49f9-9678-e4b2fda3d8ed", "1efedce1-b2c3-4652-a289-6ea596b039e2"], "spl_set_id": ["6448229c-e650-47ba-bb00-cba3604502c5", "d0e11e4c-41c3-4874-b567-579db655fba3"], "package_ndc": ["63323-413-01", "63323-413-10", "63323-415-01", "63323-415-10", "63323-413-36", "63323-415-36"], "unii": ["98IMH7M386"]}, "update_date": "01/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9413-92", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA062738"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9413", "0781-9412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["1721475", "1721476"], "spl_id": ["f1afd007-8e8c-40e2-b353-8def35a0ce8b"], "spl_set_id": ["f77db491-31c4-4a7c-a114-0f3244c97090"], "package_ndc": ["0781-9412-15", "0781-9412-92", "0781-9413-15", "0781-9413-92"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "60505-3947-3", "generic_name": "Adefovir Dipivoxil Tablet", "contact_info": "800-706-5575", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA205459"], "brand_name": ["ADEFOVIR DIPIVOXIL"], "generic_name": ["ADEFOVIR DIPIVOXIL"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-3947"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ADEFOVIR DIPIVOXIL"], "rxcui": ["881341"], "spl_id": ["bd0233d0-e141-a321-66a5-4afd09dbabfe"], "spl_set_id": ["08e07fae-3191-b6a3-c894-d3a8cc53923f"], "package_ndc": ["60505-3947-3"], "unii": ["U6Q8Z01514"]}, "update_date": "07/29/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Adefovir Dipivoxil, Tablet, 10 mg (NDC 60505-3947-3)", "company_name": "Apotex Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9935-01", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA065071"], "brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9935"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["309065"], "spl_id": ["e25af43f-54cb-4526-a8a5-6bef0a7939c7"], "spl_set_id": ["ef1a6dc6-bc3d-4f09-8f92-7ff328f56561"], "package_ndc": ["0143-9935-01"], "unii": ["258J72S7TZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-408-41", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-408", "61703-350"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"], "spl_set_id": ["0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab"], "package_ndc": ["61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA075154", "ANDA208878"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-412", "63323-411"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552", "cca4b16a-900d-4c74-86f5-bb9e5587a02a"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc", "09daf48f-1d44-4b7b-bb53-bd5635b93ca6"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10", "63323-412-00"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-20", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018801"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4887"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["055437a7-5be5-414a-a97a-946e2730fe12"], "spl_set_id": ["2b9ea23a-f9e9-48a8-25b7-519e3bbd6828"], "package_ndc": ["0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4933-10", "generic_name": "Epinephrine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Cardiovascular", "Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4742-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4742", "60505-4739", "60505-4740", "60505-4741", "60505-4743", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-700-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA050141"], "brand_name": ["BICILLIN L-A"], "generic_name": ["PENICILLIN G BENZATHINE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["60793-700", "60793-701", "60793-702"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PENICILLIN G BENZATHINE"], "rxcui": ["731564", "731566", "731567", "731568", "731570", "731571"], "spl_id": ["4b3694af-9d77-487f-8838-b75aec6636da"], "spl_set_id": ["012d46f1-d0a0-4676-a879-cd320297ab16"], "package_ndc": ["60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10"], "unii": ["RIT82F58GK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "39822-4200-2", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-390-4411", "availability": "Available", "related_info": "Tamarang is the application holder and X-Gen is the distributor/labeler", "openfda": {"application_number": ["ANDA091115"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-4200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["eedcfb07-4e23-3152-e053-2995a90a6e6a"], "spl_set_id": ["b73f192c-2912-4ec3-9b4f-05a58d9b35ba"], "package_ndc": ["39822-4200-1", "39822-4200-2", "39822-4200-5", "39822-4200-6"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/09/2026", "update_type": "New", "initial_posting_date": "01/09/2026", "package_ndc": "63323-469-01", "generic_name": "Haloperidol Decanoate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074893"], "brand_name": ["HALOPERIDOL DECANOATE"], "generic_name": ["HALOPERIDOL DECANOATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-469", "63323-471"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["HALOPERIDOL DECANOATE"], "rxcui": ["859867", "859871", "1719803", "1719862"], "spl_id": ["86dff2aa-2ab3-42fc-989e-619b13ace573"], "spl_set_id": ["ca9896e0-fb2e-46a4-8700-20d144c14764"], "package_ndc": ["63323-469-01", "63323-469-05", "63323-471-01", "63323-471-05"], "unii": ["AC20PJ4101"]}, "update_date": "01/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Injection", "presentation": "Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-05", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-05)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-726-52", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216039"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-726", "71288-723"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["0949c302-51ce-4fc9-8b99-1df94e693718"], "spl_set_id": ["fe340f98-a0f3-446e-b281-47fd91c1e537"], "package_ndc": ["71288-723-52", "71288-726-52"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-284-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA202747"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["36000-284", "36000-063", "36000-064", "36000-065", "36000-282", "36000-283"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53"], "spl_set_id": ["c71371a7-75c5-45b8-b762-8d782d4c71bc"], "package_ndc": ["36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-493-97", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE MPF"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-493", "63323-492", "63323-496"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764"], "spl_id": ["fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df"], "spl_set_id": ["d5e0d06f-ba1e-44d4-aa89-39d6c146dc23"], "package_ndc": ["63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97"], "unii": ["EC2CNF7XFP"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-089-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-089", "68025-088", "68025-095", "68025-096", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0222-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-00", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3983-05", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3983", "0591-3982", "0591-3984", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 100 mg (NDC 0591-3983-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-180-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Unavailable", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 30 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-180", "47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-179"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-084-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-084", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0591-2729-01", "generic_name": "Potassium Citrate Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue.", "openfda": {"application_number": ["ANDA209758"], "brand_name": ["POTASSIUM CITRATE"], "generic_name": ["POTASSIUM CITRATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2729", "0591-2682", "0591-2742"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CITRATE"], "rxcui": ["199376", "199381", "898490"], "spl_id": ["309b143e-7142-4a21-859e-715ba61e82f7"], "spl_set_id": ["ac173781-486b-461c-97ae-8b5c69e20792"], "package_ndc": ["0591-2682-01", "0591-2729-01", "0591-2742-01"], "unii": ["EE90ONI6FF"]}, "update_date": "07/17/2025", "therapeutic_category": ["Renal"], "dosage_form": "Tablet", "presentation": "Potassium Citrate, Tablet, Extended Release, 10 meq (NDC 0591-2729-01)", "company_name": "Watson Pharma Private Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9392-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA210594"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9392", "0143-9391", "0143-9393"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["5c5e498b-d829-4f78-bcca-466631014767"], "spl_set_id": ["9d289052-1eb6-4ba2-a3ca-d2e542a052ae"], "package_ndc": ["0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10"], "unii": ["5V444H5WIC"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1761-62", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018692"], "brand_name": ["MARCAINE SPINAL"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1761"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBARACHNOID"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724784", "1724792"], "spl_id": ["f3862f77-3621-4730-923e-9efbfa18e03f"], "spl_set_id": ["9679cc05-2f8a-4e88-53b5-6e9122c8b8c0"], "package_ndc": ["0409-1761-19", "0409-1761-02", "0409-1761-18", "0409-1761-62", "0409-1761-05", "0409-1761-10"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3984-01", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3984", "0591-3982", "0591-3983", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 200 mg (NDC 0591-3984-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43598-975-58", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "Distributed by DRL", "availability": "Available", "related_info": "Distributed by DRL", "openfda": {"application_number": ["ANDA209307"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Dr.Reddy's Laboratories Inc"], "product_ndc": ["43598-975", "43598-976"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["5785a11f-7784-4ae0-8029-f50b782eaf4a"], "spl_set_id": ["d174c19d-56f1-4ef4-087c-23c26db8e40b"], "package_ndc": ["43598-976-11", "43598-976-58", "43598-975-11", "43598-975-58"], "unii": ["1018WH7F9I"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-554-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-554", "64850-550", "64850-551", "64850-552", "64850-553", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6053-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA080445"], "brand_name": ["MEPERIDINE HYDROCHLORIDE"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6053", "0641-6054", "0641-6052"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["861476", "1665685", "1665697"], "spl_id": ["9566d54d-7343-4695-94ff-8b5f2d384c81"], "spl_set_id": ["e0e998da-f056-4fce-be8e-ed60cf3b461b"], "package_ndc": ["0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25"], "unii": ["N8E7F7Q170"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "0781-8017-01", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021192"], "brand_name": ["FLUVASTATIN SODIUM ER"], "generic_name": ["FLUVASTATIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-8017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUVASTATIN SODIUM"], "rxcui": ["360507"], "spl_id": ["37375ca6-3a81-4d10-9b39-9aee948e51a4"], "spl_set_id": ["5ab4296c-87c2-4c64-b218-d620eef51310"], "package_ndc": ["0781-8017-31", "0781-8017-01"], "unii": ["PYF7O1FV7F"]}, "update_date": "01/27/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-132-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-132", "72205-133", "72205-134", "72205-135", "72205-136", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3073", "0009-3475"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "04/22/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)", "company_name": "Pfizer Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6019-10", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["NDA018565"], "brand_name": ["DURAMORPH"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6019", "0641-6020"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892473", "892489", "1728783", "1728800"], "spl_id": ["aa74af85-7068-4254-9a79-c7f3792044a6"], "spl_set_id": ["ebb18761-e5c4-4238-bb84-f9549f500210"], "package_ndc": ["0641-6020-01", "0641-6020-10", "0641-6019-01", "0641-6019-10"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-0928-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-0928", "0641-0929"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992858"], "spl_id": ["9f14d3f5-ad01-44b5-a2b7-16ed5f501f87"], "spl_set_id": ["4bf3912c-8339-401e-9711-dad6acf15f11"], "package_ndc": ["0641-0928-21", "0641-0928-25", "0641-0929-21", "0641-0929-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/09/2026", "update_type": "New", "initial_posting_date": "04/09/2026", "package_ndc": "0069-4061-01", "generic_name": "Azithromycin Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050711"], "brand_name": ["ZITHROMAX"], "generic_name": ["AZITHROMYCIN DIHYDRATE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-4061", "0069-3060", "0069-3070", "0069-3110", "0069-3120", "0069-3130", "0069-3140"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AZITHROMYCIN DIHYDRATE"], "rxcui": ["105260", "141963", "211307", "212446", "226827", "248656", "308459", "308460", "749780", "749783", "750149", "750157"], "spl_id": ["e15f2173-8700-4392-96a4-8560772b6f8a"], "spl_set_id": ["db52b91e-79f7-4cc1-9564-f2eee8e31c45"], "package_ndc": ["0069-3060-30", "0069-3060-75", "0069-3060-86", "0069-3070-30", "0069-3070-75", "0069-3110-19", "0069-3120-19", "0069-3130-19", "0069-3140-19", "0069-4061-01", "0069-4061-75", "0069-4061-89"], "unii": ["5FD1131I7S"]}, "update_date": "04/09/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Zithromax, Tablet, 250 mg (NDC 0069-4061-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-09", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-09", "openfda": {"application_number": ["NDA018080"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7930", "0990-7923", "0990-7922"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-102-15", "generic_name": "Insulin Aspart Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Aspart 3 mL PenFill® cartridge will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA020986"], "brand_name": ["INSULIN ASPART"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-102", "73070-100", "73070-103"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["311040", "1653196", "1653202"], "spl_id": ["393af9a3-df9a-40b2-a5e6-bfa5434a2552"], "spl_set_id": ["bee5b358-c863-420b-be73-ced2e920c499"], "package_ndc": ["73070-100-11", "73070-102-10", "73070-102-15", "73070-103-10", "73070-103-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Aspart, Injection, 3 mL Insulin Aspart PenFill® cartridge (NDC 73070-102-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-001-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X2ML) is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-1445-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA075629"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-1445", "0406-1473"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091145", "1091225"], "spl_id": ["7bfd27d5-70ed-440b-949a-140aa3304d4a"], "spl_set_id": ["ed004cf0-eb23-43d2-96dc-20c4ad63824f"], "package_ndc": ["0406-1445-01", "0406-1473-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-454-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-454", "63323-452", "63323-455", "63323-458", "63323-451"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011", "1732136", "2003714"], "spl_id": ["dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc"], "spl_set_id": ["582f42e5-444e-4246-af8c-e7e28097c69a"], "package_ndc": ["63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2868", "0781-2859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-560-05", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-560", "62037-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-01", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-799", "42806-801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "43598-305-62", "generic_name": "Azacitidine Injection", "contact_info": "866-732-3952", "availability": "Available", "related_info": "Available to existing customers", "openfda": {"application_number": ["ANDA201537"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Dr. Reddy's Laboratories Inc."], "product_ndc": ["43598-305"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["35e92030-ae2f-04b2-c3de-69f8c8da6b82"], "spl_set_id": ["71d8d758-86c9-b571-aed1-719654fd4b82"], "package_ndc": ["43598-305-62"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "04/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 43598-305-62)", "company_name": "Dr. Reddy's Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "53746-468-19", "generic_name": "Clindamycin Palmitate Hydrochloride Injection", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203513"], "brand_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE (PEDIATRIC)"], "generic_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals of New York LLC"], "product_ndc": ["53746-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE"], "rxcui": ["562266"], "spl_id": ["b9016023-7843-48e3-8ff6-2e5a70aa5daf"], "spl_set_id": ["faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"], "package_ndc": ["53746-468-19"], "unii": ["VN9A8JM7M7"]}, "update_date": "02/27/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-583-25", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 150 mg (NDC 23155-583-25)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0520-74", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0520"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["2e960a62-b5d8-4fad-a17c-9d07bdbe06d1"], "spl_set_id": ["76e4fe6a-afd4-4f68-b12d-0b094f750615"], "package_ndc": ["0574-0520-04", "0574-0520-08", "0574-0520-74", "0574-0520-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-397-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-503-15", "generic_name": "Insulin Degludec Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Degludec 3 mL U-200 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA203314"], "brand_name": ["INSULIN DEGLUDEC"], "generic_name": ["INSULIN DEGLUDEC"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-503", "73070-403", "73070-400"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN DEGLUDEC"], "rxcui": ["1670011", "1670021", "2107520"], "spl_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "spl_set_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "package_ndc": ["73070-403-15", "73070-503-15", "73070-400-11"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["54Q18076QB"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Degludec, Injection, 3 mL Insulin Degludec 200 units/mL (U-200) FlexTouch® (NDC 73070-503-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-08", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4312", "0002-4491"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-08)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-602-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-602", "60951-700", "60951-712", "60951-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2308-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075857"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2308", "0409-2305", "0409-0001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666800", "1666814", "1666823", "1666798"], "spl_id": ["b303a281-6633-47d5-bf29-5e9055e26da6", "74093865-864a-49e8-99b9-c985fe72afb2"], "spl_set_id": ["b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240"], "package_ndc": ["0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9931-25", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA065072"], "brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9931", "0143-9933", "0143-9930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["309068", "1656313", "1656318"], "spl_id": ["7e0897ec-2275-4438-9cc5-4c951e52ad97"], "spl_set_id": ["ed23b6bc-32c7-4c50-a53d-313ae78e5623"], "package_ndc": ["0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10"], "unii": ["258J72S7TZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "59310-805-06", "generic_name": "Fluticasone Propionate; Salmeterol Xinafoate Powder", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA208799"], "brand_name": ["AIRDUO RESPICLICK"], "generic_name": ["FLUTICASONE PROPIONATE AND SALMETEROL"], "manufacturer_name": ["Teva Respiratory, LLC"], "product_ndc": ["59310-805", "59310-812", "59310-822"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE"], "rxcui": ["1918194", "1918199", "1918203", "1918205", "1918209", "1918211"], "spl_id": ["b597bc2d-bf1e-4f9b-826a-b3e39ed56545"], "spl_set_id": ["9c122b91-a11f-49ca-80bb-3eec5112db87"], "package_ndc": ["59310-805-06", "59310-805-08", "59310-812-06", "59310-812-08", "59310-822-06", "59310-822-08"], "unii": ["6EW8Q962A5", "O2GMZ0LF5W"]}, "update_date": "06/13/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Powder", "presentation": "AirDuo RespiClick, Powder, 55 ug; 14 ug (NDC 59310-805-06)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-851", "63323-852", "63323-853", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4903-34", "generic_name": "Lidocaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9409-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA061395"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9409"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["789980"], "spl_id": ["86e9a3cc-bc65-4d4f-916d-98c916588730"], "spl_set_id": ["5308ddfa-4a5b-4f7b-83ce-9d1b528e050d"], "package_ndc": ["0781-9409-46", "0781-9409-95"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-0167-02", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/12/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-02)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "0264-9872-10", "generic_name": "Heparin Sodium Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019953"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9872"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["48e17807-e73d-4ea2-81bc-901355903aa7"], "spl_set_id": ["a3041c04-0ea8-4d36-81ce-c5091c906316"], "package_ndc": ["0264-9872-10", "0264-9872-00"], "unii": ["ZZ45AB24CA"]}, "update_date": "05/08/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "39822-0355-6", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "03/26/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-190-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-710-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-710", "13811-709", "13811-706", "13811-707", "13811-708"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0591-2742-01", "generic_name": "Potassium Citrate Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue.", "openfda": {"application_number": ["ANDA209758"], "brand_name": ["POTASSIUM CITRATE"], "generic_name": ["POTASSIUM CITRATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2742", "0591-2682", "0591-2729"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CITRATE"], "rxcui": ["199376", "199381", "898490"], "spl_id": ["309b143e-7142-4a21-859e-715ba61e82f7"], "spl_set_id": ["ac173781-486b-461c-97ae-8b5c69e20792"], "package_ndc": ["0591-2682-01", "0591-2729-01", "0591-2742-01"], "unii": ["EE90ONI6FF"]}, "update_date": "07/17/2025", "therapeutic_category": ["Renal"], "dosage_form": "Tablet", "presentation": "Potassium Citrate, Tablet, Extended Release, 15 meq (NDC 0591-2742-01)", "company_name": "Watson Pharma Private Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0223-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-76", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209448"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-824"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481"], "spl_id": ["0591ab74-99a6-40ee-af96-80bc2ef423dc"], "spl_set_id": ["3b8f2692-4371-4f1a-95af-b41842131fdd"], "package_ndc": ["63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/07/2026", "update_type": "New", "initial_posting_date": "04/07/2026", "package_ndc": "61958-1702-1", "generic_name": "Idelalisib Tablet", "contact_info": "800-445-3235", "related_info": "Discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA205858"], "brand_name": ["ZYDELIG"], "generic_name": ["IDELALISIB"], "manufacturer_name": ["Gilead Sciences, Inc."], "product_ndc": ["61958-1702", "61958-1701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IDELALISIB"], "rxcui": ["1544465", "1544471", "1544473", "1544475"], "spl_id": ["ca3e7112-6dfe-403f-af6f-a0051e77d125"], "spl_set_id": ["efbdafa9-d18c-4e85-b4a2-1e620fc74e50"], "package_ndc": ["61958-1701-1", "61958-1702-1"], "nui": ["N0000175605", "N0000175082", "N0000190114"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["YG57I8T5M0"]}, "update_date": "04/07/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Zydelig, Tablet, 150 mg (NDC 61958-1702-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-62", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4491", "0002-4312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-62)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6625-35", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: June 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA202432"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6625"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868486"], "spl_id": ["dcc55d90-d55e-4e1a-9e48-5703cbc74a52", "c39c0ef6-4140-4c6c-91c4-e43d67872b05"], "spl_set_id": ["8664c7ce-707b-4c6c-9ce4-7160b5f877f8", "084f5572-8c1f-4802-b179-ca0cc838fc68"], "package_ndc": ["0409-6625-30", "0409-6625-35", "0409-6625-22", "0409-6625-14"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0972-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0972", "0555-0971", "0555-0775", "0555-0776", "0555-0777", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-30", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-799", "42806-801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-30)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-564-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-564", "47781-562", "47781-563", "47781-565", "47781-566", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "66993-081-69", "generic_name": "Sumatriptan Nasal Spray", "contact_info": "866-525-0688", "related_info": "This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately February 28, 2026.", "openfda": {"application_number": ["NDA020626"], "brand_name": ["SUMATRIPTAN"], "generic_name": ["SUMATRIPTAN"], "manufacturer_name": ["Prasco Laboratories"], "product_ndc": ["66993-081", "66993-082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["NASAL"], "substance_name": ["SUMATRIPTAN"], "rxcui": ["313159", "314227"], "spl_id": ["06b6df24-20eb-4b22-b8e3-591ae1f3518a"], "spl_set_id": ["f63e616b-ae0c-432b-badc-8c45023aa725"], "package_ndc": ["66993-081-69", "66993-082-69"], "nui": ["N0000175763", "N0000175764", "N0000175765"], "pharm_class_moa": ["Serotonin 1b Receptor Agonists [MoA]", "Serotonin 1d Receptor Agonists [MoA]"], "pharm_class_epc": ["Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]"], "unii": ["8R78F6L9VO"]}, "update_date": "09/08/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Nasal Spray", "presentation": "Imitrex, Nasal Spray, 5 mg/100 uL (NDC 66993-081-69)", "company_name": "Prasco Laboratories", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-130-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-130", "57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "0409-3189-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3189", "0409-7037"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["c96726ef-f1fa-4ebb-ba33-3479c3902a8e"], "spl_set_id": ["c96726ef-f1fa-4ebb-ba33-3479c3902a8e"], "package_ndc": ["0409-3189-05", "0409-3189-10", "0409-7037-01", "0409-7037-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA075880"], "brand_name": ["PREMASOL - SULFITE-FREE (AMINO ACID)"], "generic_name": ["LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1130", "0338-1131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "CYSTEINE HYDROCHLORIDE", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801395", "801398", "801403", "801405"], "spl_id": ["c874a813-b145-4f7f-833e-97d6c4dd727c"], "spl_set_id": ["9afdcc3e-0d06-47f4-86ca-40da48b2b02b"], "package_ndc": ["0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "ZT934N0X4W", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "44567-610-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-493-0861", "availability": "Available", "related_info": "Please check wholesalers and distributors for inventory.", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)", "company_name": "WG Critical Care", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/06/2018", "package_ndc": "76329-1912-1", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": {"application_number": ["ANDA202861"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-1912"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "spl_id": ["99799101-d92b-485b-93ec-f2b5a2e5ca26"], "spl_set_id": ["1034467f-d436-4b87-a902-c7e8885daa8a"], "package_ndc": ["76329-1912-0", "76329-1912-1"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-12", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA206775"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-295"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["35cf6068-f31a-211b-e063-6294a90a6b53"], "spl_set_id": ["48aa7ef3-9f44-2a08-e054-00144ff88e88"], "package_ndc": ["16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/11/2024", "package_ndc": "0338-0719-06", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020047"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0719"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["237656"], "spl_id": ["aa64f648-e931-4a99-9b81-791a3827272c"], "spl_set_id": ["0332f34a-7038-47cc-ba59-d55cad6b73ca"], "package_ndc": ["0338-0719-06"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-600-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": {"application_number": ["ANDA214456"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Alembic Pharmaceuticals Inc."], "product_ndc": ["62332-600", "62332-599", "62332-601"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["9030f496-5021-4454-ac16-dbb376315608"], "spl_set_id": ["419cf756-3c96-4bb8-ae96-6aea5a5f3afd"], "package_ndc": ["62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/15/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "61570-075-50", "generic_name": "Esterified Estrogens Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/29/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Menest, Tablet, 2.5 mg (NDC 61570-075-50)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "76329-3390-1", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-423-4136", "availability": "Limited Availability", "related_info": "old NDC 0548-3390-00", "openfda": {"application_number": ["ANDA083173"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-3390"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1012068"], "spl_id": ["3d910bb6-792f-41f3-8b28-b33bcbec5ccb"], "spl_set_id": ["5d3e9984-cef9-46f2-a6c9-3be8b26f45b3"], "package_ndc": ["76329-3390-1"], "unii": ["V13007Z41A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6028-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6028", "0641-6024", "0641-6027", "0641-6025", "0641-6026", "0641-6029", "0641-6030", "0641-6247", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-117-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-117", "70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-116"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-05", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb"], "spl_set_id": ["abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f"], "package_ndc": ["0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-064-39", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-064", "65862-062", "65862-063"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-39)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0409-0323-20", "generic_name": "Bleomycin Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA065031"], "brand_name": ["BLEOMYCIN"], "generic_name": ["BLEOMYCIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0323", "0409-0332"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAPLEURAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["BLEOMYCIN SULFATE"], "rxcui": ["1726673", "1726676"], "spl_id": ["d9e9c332-1b3f-469c-83b8-41e15183e635"], "spl_set_id": ["e629ba5a-4e08-4249-9551-af6dbd98a7e4"], "package_ndc": ["0409-0323-20", "0409-0332-20"], "unii": ["7DP3NTV15T"]}, "update_date": "06/13/2025", "therapeutic_category": ["Hematology", "Oncology", "Pediatric"], "dosage_form": "Injection", "presentation": "Bleomycin Sulfate, Injection, 30 [USP'U] (NDC 0409-0323-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-0127-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA202608"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-0127", "0406-0136", "0406-0154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001565", "2001566", "2001568"], "spl_id": ["7a3a8731-e545-455e-83c3-888f4923e901"], "spl_set_id": ["b1b0f2ff-d9df-42ab-b471-226ecf97e075"], "package_ndc": ["0406-0127-01", "0406-0136-01", "0406-0154-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 27 mg (NDC 0406-0127-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-50", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2634"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["50886ad5-eeca-4fe7-beb0-01305f92c65d"], "spl_set_id": ["3832ede8-d3fc-455d-ecab-3b77be5869f5"], "package_ndc": ["0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-252-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-252", "55150-251", "55150-254", "55150-255", "55150-253", "55150-256"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/03/2023", "package_ndc": "69784-200-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Limited Availability", "related_info": "No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2", "update_date": "05/08/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)", "company_name": "Ailex Pharmaceuticals", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5092-16", "generic_name": "Ceftazidime Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA064032"], "brand_name": ["TAZICEF"], "generic_name": ["CEFTAZIDIME"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5092", "0409-5093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CEFTAZIDIME"], "rxcui": ["1659283", "1659287", "1659292", "1659294"], "spl_id": ["3f749ee0-db14-4ed0-9056-d545a38bbe3b"], "spl_set_id": ["9b73979c-c95a-4433-0a9d-f9cea3cb557f"], "package_ndc": ["0409-5092-11", "0409-5092-16", "0409-5093-14", "0409-5093-11"], "unii": ["9M416Z9QNR"]}, "update_date": "11/14/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Tazicef, Injection, 1 g (NDC 0409-5092-16)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-472-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070554"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-472", "63323-463", "63323-461", "63323-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620"], "spl_id": ["cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-33", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA206775"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-295"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["35cf6068-f31a-211b-e063-6294a90a6b53"], "spl_set_id": ["48aa7ef3-9f44-2a08-e054-00144ff88e88"], "package_ndc": ["16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-137-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-137", "72205-132", "72205-133", "72205-134", "72205-135", "72205-136"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/19/2026", "update_type": "New", "initial_posting_date": "03/19/2026", "package_ndc": "64764-805-30", "generic_name": "Ramelteon Tablet", "contact_info": "877-825-3327", "related_info": "Product is expected to be available through June 2027.", "openfda": {"application_number": ["NDA021782"], "brand_name": ["ROZEREM"], "generic_name": ["RAMELTEON"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["64764-805"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RAMELTEON"], "rxcui": ["577348", "603162"], "spl_id": ["2021e7fb-108a-4783-9a37-8bc05bf28b28"], "spl_set_id": ["9de82310-70e8-47b9-b1fc-6c6848b99455"], "package_ndc": ["64764-805-30", "64764-805-10", "64764-805-22"], "nui": ["N0000175743", "N0000000250"], "pharm_class_epc": ["Melatonin Receptor Agonist [EPC]"], "pharm_class_moa": ["Melatonin Receptor Agonists [MoA]"], "unii": ["901AS54I69"]}, "update_date": "03/19/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Rozerem, Tablet, 8 mg (NDC 64764-805-30)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3814-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA208084"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-3814", "0338-3410", "0338-3612"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["c8906ab2-37d2-4fde-9784-0442bf7b9565"], "spl_set_id": ["78832ac6-04c5-45e0-ae4d-f56d7920dda9"], "package_ndc": ["0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0054-0390-41", "generic_name": "Oxycodone Hydrochloride Oral Solution", "contact_info": "800-631-2174", "related_info": "Hikma has permanently discontinued (NDC 0054-0390-41) for the 15 mL bottle configuration. Hikma will continue to distribute Oxycodone Hydrochloride Oral Solution 5 mg/5 mL in the 500 mL bottle (NDC 0054-0390-63).", "openfda": {"application_number": ["ANDA204037"], "brand_name": ["OXYCODONE HYDROCHLORIDE"], "generic_name": ["OXYCODONE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmceuticals USA Inc."], "product_ndc": ["0054-0390"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049604"], "spl_id": ["47e856d4-de7d-49aa-8671-d1b4a35bad4d"], "spl_set_id": ["d8e87c66-f872-4e1d-9ade-ef11490af63b"], "package_ndc": ["0054-0390-41", "0054-0390-63"], "unii": ["C1ENJ2TE6C"]}, "update_date": "09/11/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Oral Solution", "presentation": "Oxycodone Hydrochloride, Oral Solution, 5 mg/5 mL (NDC 0054-0390-41)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6027-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6027", "0641-6024", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6030", "0641-6247", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-451-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-451", "63323-452", "63323-454", "63323-455", "63323-458"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011", "1732136", "2003714"], "spl_id": ["dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc"], "spl_set_id": ["582f42e5-444e-4246-af8c-e7e28097c69a"], "package_ndc": ["63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-56", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: September 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-339"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0ddf4411-7138-412a-908a-fadf22bdfb79"], "spl_set_id": ["c3ae9880-44bb-4f4e-93d8-8a5e21708a30"], "package_ndc": ["61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-67", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA019465"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7101", "0409-7132"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807547", "1807631", "1807632", "1807633"], "spl_id": ["f233e72c-072d-4a43-857a-f4d5791e1a73"], "spl_set_id": ["a2a964f7-c3ec-4dfb-e3a0-6d8136a80397"], "package_ndc": ["0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02"], "unii": ["451W47IQ8X"]}, "update_date": "12/03/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 100 mL  ADD-Vantage® Flexible Container (NDC 0409-7101-67)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-500-08", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070017"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-500", "16729-501", "16729-502"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1cfab300-d796-6a68-e063-6394a90a73f9"], "spl_set_id": ["f6f64972-714c-4ee9-8a5e-9ffcab41a73b"], "package_ndc": ["16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-212-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care de Mexico, S.A. de C.V."], "product_ndc": ["46163-212", "46163-209", "46163-206"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["444fd7c1-1ed5-25c7-e063-6394a90a3bfe"], "spl_set_id": ["a98facd6-9daa-4d37-8209-63a0599dbfaa"], "package_ndc": ["46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-447-45", "generic_name": "Carboplatin Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0641-6261-01", "generic_name": "Sodium Acetate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA216920"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6261"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["1859490"], "spl_id": ["3493d4c1-4f73-44e8-94bc-7b55fe4fd436"], "spl_set_id": ["8a338072-6f1e-460c-b9ec-59cef4f3f597"], "package_ndc": ["0641-6261-01"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-171-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020712"], "brand_name": ["CARBATROL"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["54092-171", "54092-172", "54092-173"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["200131", "200133", "308977", "313931", "388311", "404742"], "spl_id": ["39171a32-c78d-4130-be53-638e19cf2261"], "spl_set_id": ["bc03e499-5bac-4293-bff4-6864153a624d"], "package_ndc": ["54092-171-12", "54092-172-12", "54092-173-12"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "12/19/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-004-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X2ML)  is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-0167-13", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/12/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-13)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8213-05", "generic_name": "Insulin Lispro Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["BLA020563"], "brand_name": ["HUMALOG TEMPO PEN"], "generic_name": ["INSULIN LISPRO"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8213", "0002-7510", "0002-7533", "0002-8799", "0002-7516", "0002-7714", "0002-0800", "0002-7712", "0002-8208"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN LISPRO"], "rxcui": ["242120", "865098", "1652239", "1652242", "1652639", "1652640", "1652644", "1652646", "1926331", "1926332", "2621571", "2621572"], "spl_id": ["d0a38a0f-9d29-44eb-bfd1-c83cbcba1008"], "spl_set_id": ["c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f"], "package_ndc": ["0002-7510-01", "0002-7510-17", "0002-7510-99", "0002-7533-01", "0002-8799-01", "0002-8799-59", "0002-8799-61", "0002-7516-01", "0002-7516-59", "0002-7516-99", "0002-7714-01", "0002-7714-59", "0002-7714-61", "0002-8213-01", "0002-8213-05", "0002-0800-01", "0002-7712-01", "0002-7712-27", "0002-7712-61", "0002-8208-01", "0002-8208-27"], "nui": ["N0000004931", "N0000175453"], "pharm_class_cs": ["Insulin [Chemical/Ingredient]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["059QF0KO0R", "GFX7QIS1II"]}, "update_date": "10/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-288", "63323-286", "63323-287", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/13/2017", "package_ndc": "83301-0081-2", "generic_name": "Bumetanide Injection", "contact_info": "800-673-9839", "availability": "Limited Availability", "related_info": "Additional lots are currently in the manufacturing process and will be available upon release.", "openfda": {"application_number": ["ANDA219116"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Mullan Pharmaceutical Inc."], "product_ndc": ["83301-0081", "83301-0080"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["4c241a3e-649b-4414-e063-6294a90a3a32"], "spl_set_id": ["b7cd724b-817b-4b45-8133-1ebf505867e7"], "package_ndc": ["83301-0080-1", "83301-0080-2", "83301-0081-1", "83301-0081-2"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)", "company_name": "Mullan Pharmaceutical Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/04/2024", "package_ndc": "0591-2888-30", "generic_name": "Hydroxocobalamin Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: June 2026", "openfda": {"application_number": ["ANDA085998"], "brand_name": ["HYDROXOCOBALAMIN"], "generic_name": ["HYDROXOCOBALAMIN"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2888"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["HYDROXOCOBALAMIN ACETATE"], "rxcui": ["317106"], "spl_id": ["c47477bf-6413-4699-ab77-c5441a9d1557"], "spl_set_id": ["a3087a39-f218-4f16-a1e7-17c39bb2eb69"], "package_ndc": ["0591-2888-30"], "unii": ["S535M27N3Q"]}, "update_date": "05/01/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0373-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0373", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2868", "0781-2859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0535-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 40 mg (NDC 0071-0535-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "47335-932-44", "generic_name": "Vecuronium Bromide Injection", "contact_info": "800-818-4555", "related_info": "The 10 mg presentation remains available.", "openfda": {"application_number": ["ANDA079001"], "brand_name": ["VECURONIUM BROMIDE"], "generic_name": ["VECURONIUM BROMIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-932", "47335-931"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VECURONIUM BROMIDE"], "rxcui": ["859437"], "spl_id": ["82d6bc45-04a5-409a-9223-da1884b2468f"], "spl_set_id": ["a14da3ee-a731-4282-be9d-407473517470"], "package_ndc": ["47335-931-40", "47335-931-44", "47335-932-40", "47335-932-44"], "unii": ["7E4PHP5N1D"]}, "update_date": "09/08/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Vecuronium Bromide, Injection, 20 mg (NDC 47335-932-44)", "company_name": "Sun Pharmaceutical Industries Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6041-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA075772"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6041", "0641-6043", "0641-6042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["25d6c438-45d2-4162-91c2-b5caa0f86bf3"], "spl_set_id": ["0c2c75c9-ed7b-46a8-9543-429bf2d8f090"], "package_ndc": ["0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "0069-3150-83", "generic_name": "Azithromycin Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA050733"], "brand_name": ["ZITHROMAX"], "generic_name": ["AZITHROMYCIN DIHYDRATE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-3150"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AZITHROMYCIN DIHYDRATE"], "rxcui": ["1668238", "1668240"], "spl_id": ["b0eb7eb4-90fe-4add-a327-e8be68165a3b"], "spl_set_id": ["3b631aa1-2d46-40bc-a614-d698301ea4f9"], "package_ndc": ["0069-3150-84", "0069-3150-83"], "unii": ["5FD1131I7S"]}, "update_date": "01/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/28/2025", "update_type": "New", "initial_posting_date": "05/28/2025", "package_ndc": "0472-0804-60", "generic_name": "Desonide Cream", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA019048"], "brand_name": ["DESONIDE"], "generic_name": ["DESONIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-0804", "0472-0803"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DESONIDE"], "rxcui": ["197572", "349351"], "spl_id": ["f3953b9e-138f-4d86-8eea-0fc03c3c2747"], "spl_set_id": ["ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99"], "package_ndc": ["0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["J280872D1O"]}, "update_date": "05/28/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Cream", "presentation": "Desowen, Cream, .5 mg/1 g (NDC 0472-0804-60)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6039-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May 2026 timeframe.", "openfda": {"application_number": ["NDA018565"], "brand_name": ["INFUMORPH 200"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6039", "0641-6040"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892652", "1731522", "1731998", "1731999"], "spl_id": ["b1c060cb-5c5b-495f-90b5-044e04f2a3f2"], "spl_set_id": ["db9ac9e3-d761-4a99-9f34-4946ebe8f255"], "package_ndc": ["0641-6039-01", "0641-6040-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/10/2025", "update_type": "New", "initial_posting_date": "10/10/2025", "package_ndc": "0781-3519-90", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214657"], "brand_name": ["PEMETREXED"], "generic_name": ["PEMETREXED DISODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3519", "0781-3518", "0781-3520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PEMETREXED DISODIUM"], "rxcui": ["2602363", "2602365", "2602366"], "spl_id": ["764ab64b-c642-4314-83a9-efee79fe83a3"], "spl_set_id": ["7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3"], "package_ndc": ["0781-3518-76", "0781-3519-90", "0781-3520-91"], "unii": ["2PKU919BA9"]}, "update_date": "10/10/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Pemetrexed Disodium, Injection, 500 mg/20 mL (NDC 0781-3519-90)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-7201-10", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7201", "0093-0771", "0093-7202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0093-3750-28", "generic_name": "Tobramycin Solution", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210915"], "brand_name": ["TOBRAMYCIN"], "generic_name": ["TOBRAMYCIN"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3750"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["TOBRAMYCIN"], "rxcui": ["1314763"], "spl_id": ["8aa98982-a156-4bc8-8d31-9a39b88808ed"], "spl_set_id": ["d03079d2-5617-4628-92b9-3caa757b22c0"], "package_ndc": ["0093-3750-28", "0093-3750-63"], "nui": ["N0000175477", "M0000946"], "pharm_class_epc": ["Aminoglycoside Antibacterial [EPC]"], "pharm_class_cs": ["Aminoglycosides [CS]"], "unii": ["VZ8RRZ51VK"]}, "update_date": "06/16/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-28)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)", "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7810-22", "generic_name": "Dopamine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6026-05", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-402-05", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA206935"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Ingenus Pharmaceuticals, LLC"], "product_ndc": ["50742-402", "50742-401"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["3c841594-8a93-4728-b184-0f4bfac73390"], "spl_set_id": ["d04f2471-3085-4fc8-a657-bb3918d48e6e"], "package_ndc": ["50742-401-02", "50742-402-05"], "unii": ["042LAQ1IIS"]}, "update_date": "02/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-344-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-344", "42806-339", "42806-341", "42806-343", "42806-345"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "66993-066-02", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 66993-066-02)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "76329-3340-1", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": {"application_number": ["ANDA212461"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-3340"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546"], "spl_id": ["697aa53c-f31f-463a-a752-d2faaad354db"], "spl_set_id": ["b72d0a82-6163-460f-965a-12f6da47370a"], "package_ndc": ["76329-3340-1"], "unii": ["03J5ZE7KA5"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-02", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d"], "spl_set_id": ["3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75"], "package_ndc": ["63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-150-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-150", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 150 ug (NDC 72305-150-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-495-07", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-0154-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA202608"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-0154", "0406-0127", "0406-0136"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001565", "2001566", "2001568"], "spl_id": ["7a3a8731-e545-455e-83c3-888f4923e901"], "spl_set_id": ["b1b0f2ff-d9df-42ab-b471-226ecf97e075"], "package_ndc": ["0406-0127-01", "0406-0136-01", "0406-0154-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 54 mg (NDC 0406-0154-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-115-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-115", "57844-105", "57844-117", "57844-110", "57844-112", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-206-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care de Mexico, S.A. de C.V."], "product_ndc": ["46163-206", "46163-209", "46163-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["444fd7c1-1ed5-25c7-e063-6394a90a3bfe"], "spl_set_id": ["a98facd6-9daa-4d37-8209-63a0599dbfaa"], "package_ndc": ["46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/04/2025", "update_type": "New", "initial_posting_date": "12/04/2025", "package_ndc": "0093-7353-01", "generic_name": "Calcitriol Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug", "openfda": {"application_number": ["ANDA075765"], "brand_name": ["CALCITRIOL"], "generic_name": ["CALCITRIOL"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7353", "0093-7352"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CALCITRIOL"], "rxcui": ["308867", "308868"], "spl_id": ["9e6df585-e3d1-4a89-bc02-8e4b223578c4"], "spl_set_id": ["ec93b667-aad2-4e3a-adc6-952f070a0c0a"], "package_ndc": ["0093-7352-01", "0093-7353-01"], "nui": ["M0004229", "N0000175908"], "pharm_class_cs": ["Cholecalciferol [CS]"], "pharm_class_epc": ["Vitamin D3 Analog [EPC]"], "unii": ["FXC9231JVH"]}, "update_date": "12/04/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Calcitriol, Capsule, .5 ug (NDC 0093-7353-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "72572-076-24", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "related_info": "Civica Label", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Civica, Inc."], "product_ndc": ["72572-076", "72572-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336"], "spl_id": ["e40b6e7f-1d37-4d0a-ace3-e5accc461e02"], "spl_set_id": ["80217bd6-2bc4-401c-9345-22532b36a24f"], "package_ndc": ["72572-074-01", "72572-074-24", "72572-076-01", "72572-076-24"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-406", "43547-407", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "0409-1985-30", "generic_name": "Lorazepam Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA074243"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1985", "0409-1539"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["763028", "763029"], "spl_id": ["e90a536c-421f-4774-8f88-013e18a8163e"], "spl_set_id": ["20140b19-846b-425f-b191-670e17809945"], "package_ndc": ["0409-1539-03", "0409-1539-31", "0409-1985-03", "0409-1985-30"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "44567-611-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-493-0861", "availability": "Available", "related_info": "Please check wholesalers and distributors for inventory.", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)", "company_name": "WG Critical Care", "status": "Current", "source": "drug_shortages"}
{"presentation": "Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1560-29", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "16729-138-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-138", "16729-136", "16729-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 16729-138-00)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-1630-10", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: July 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA021146"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1630", "0409-9630", "0409-4910", "0409-4911"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["ab573c15-9504-48d1-bf4a-d8b8d7ae748a"], "spl_set_id": ["ad8916e7-206e-409e-2582-30d072845dd4"], "package_ndc": ["0409-1630-15", "0409-1630-10", "0409-9630-15", "0409-9630-05", "0409-4910-11", "0409-4910-34", "0409-4911-11", "0409-4911-34"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/06/2026", "update_type": "New", "initial_posting_date": "05/06/2026", "package_ndc": "0409-1103-01", "generic_name": "Cisatracurium Besylate Injection", "contact_info": "844-646-4398", "related_info": "Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203236"], "brand_name": ["CISATRACURIUM BESYLATE"], "generic_name": ["CISATRACURIUM BESYLATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1103", "0409-1098", "0409-1208"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CISATRACURIUM BESYLATE"], "rxcui": ["199211", "199212", "1730194"], "spl_id": ["0ec666c8-db68-4a59-9da4-e0abd8e209c5"], "spl_set_id": ["67908e20-044d-454d-9c51-bf106e817bd0"], "package_ndc": ["0409-1098-12", "0409-1098-02", "0409-1103-11", "0409-1103-01", "0409-1208-11", "0409-1208-01"], "unii": ["80YS8O1MBS"]}, "update_date": "05/06/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/01/2025", "update_type": "New", "initial_posting_date": "07/01/2025", "package_ndc": "64950-217-10", "generic_name": "Isoniazid Tablet", "contact_info": "610-782-9780", "related_info": "Product expected to be available until August 2025.", "openfda": {"application_number": ["ANDA080937"], "brand_name": ["ISONIAZID"], "generic_name": ["ISONIAZID"], "manufacturer_name": ["Genus Lifesciences"], "product_ndc": ["64950-217", "64950-216"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ISONIAZID"], "rxcui": ["197832", "311166"], "spl_id": ["6ea58bc8-a5a8-47a1-81e1-f769924e1502"], "spl_set_id": ["f0b46d1d-2300-457d-a7bd-a88a3f8d2235"], "package_ndc": ["64950-216-10", "64950-217-03", "64950-217-10"], "nui": ["N0000175483"], "pharm_class_epc": ["Antimycobacterial [EPC]"], "unii": ["V83O1VOZ8L"]}, "update_date": "07/01/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Isoniazid, Tablet, 300 mg (NDC 64950-217-10)", "company_name": "Genus Lifesciences", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4276-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088299"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4276", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-165-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-165", "42858-161", "42858-162", "42858-163", "42858-164", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2023", "package_ndc": "63323-604-01", "generic_name": "Propranolol Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075826"], "brand_name": ["PROPRANOLOL"], "generic_name": ["PROPRANOLOL HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-604"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PROPRANOLOL HYDROCHLORIDE"], "rxcui": ["856443"], "spl_id": ["505851c4-b18c-4cd7-805c-4e923cc1fa7e"], "spl_set_id": ["f14ea537-dd5c-4c78-9037-9a85e9e610ef"], "package_ndc": ["63323-604-01"], "unii": ["F8A3652H1V"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/29/2025", "update_type": "New", "initial_posting_date": "12/29/2025", "package_ndc": "69238-2391-1", "generic_name": "Sodium Oxybate Solution", "contact_info": "800-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/29/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Solution", "presentation": "Sodium Oxybate, Solution, .5 g/1 mL (NDC 69238-2391-1)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "64850-300-30", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-300"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["cae1ac14-ab22-42d1-8449-5e36c137b905"], "spl_set_id": ["5f188bdc-2009-43aa-ad32-f06dbfac2642"], "package_ndc": ["64850-300-30", "64850-300-01"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 64850-300-30)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5315-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5315", "0245-5316"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-01)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "54288-167-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC", "openfda": {"application_number": ["ANDA207324"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["BPI Labs LLC"], "product_ndc": ["54288-167", "54288-165", "54288-166", "54288-164"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["c0a7463c-d90f-4060-a54e-6a4888e8af0e"], "spl_set_id": ["5484d2f0-0cc2-4bba-8f26-c7f6539a9606"], "package_ndc": ["54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-0111-03", "generic_name": "Amantadine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076186"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0111"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849395"], "spl_id": ["45af44df-1a9b-32b6-e063-6394a90acdaf"], "spl_set_id": ["63d9d4aa-5f92-45b0-98d0-d6ec38b727cb"], "package_ndc": ["0832-0111-00", "0832-0111-50", "0832-0111-89", "0832-0111-03"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Tablet", "presentation": "Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-03)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9930-10", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA065072"], "brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9930", "0143-9931", "0143-9933"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["309068", "1656313", "1656318"], "spl_id": ["7e0897ec-2275-4438-9cc5-4c951e52ad97"], "spl_set_id": ["ed23b6bc-32c7-4c50-a53d-313ae78e5623"], "package_ndc": ["0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10"], "unii": ["258J72S7TZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-152", "72888-153", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-30)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "0378-4430-01", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "1-844-874-7464", "availability": "Unavailable", "related_info": "Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.", "update_date": "01/14/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)", "company_name": "Rising Pharma Holdings, Inc.", "shortage_reason": "Regulatory delay", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "0409-5160-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5160", "0409-1403"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["f01f9986-43f9-40e8-9506-11bfe78f9242"], "spl_set_id": ["f01f9986-43f9-40e8-9506-11bfe78f9242"], "package_ndc": ["0409-1403-05", "0409-1403-10", "0409-5160-01", "0409-5160-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0016-12", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0016", "0009-0825", "0009-0011", "0009-0013", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-114-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-114", "70010-111", "70010-112", "70010-113", "70010-115", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-107-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-107", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 70 mg (NDC 59417-107-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0776-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0776", "0555-0971", "0555-0775", "0555-0972", "0555-0777", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0832-0273-11", "generic_name": "Morphine Sulfate Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210610"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0273", "0832-0274"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892582", "892672"], "spl_id": ["46a682fc-0430-5a66-e063-6294a90a6179"], "spl_set_id": ["5ceb3205-2f8d-4ba3-9f27-dc328bab4fa1"], "package_ndc": ["0832-0273-11", "0832-0274-11"], "unii": ["X3P646A2J0"]}, "update_date": "12/22/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "54288-164-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC;  Customer service number:  (727) 471-0850 Ext 270", "availability": "Unavailable", "related_info": "Discontinued; Distributed by BPI Labs, LLC", "openfda": {"application_number": ["ANDA207324"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["BPI Labs LLC"], "product_ndc": ["54288-164", "54288-165", "54288-166", "54288-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["c0a7463c-d90f-4060-a54e-6a4888e8af0e"], "spl_set_id": ["5484d2f0-0cc2-4bba-8f26-c7f6539a9606"], "package_ndc": ["54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/09/2026", "update_type": "New", "initial_posting_date": "01/09/2026", "package_ndc": "63323-469-05", "generic_name": "Haloperidol Decanoate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074893"], "brand_name": ["HALOPERIDOL DECANOATE"], "generic_name": ["HALOPERIDOL DECANOATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-469", "63323-471"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["HALOPERIDOL DECANOATE"], "rxcui": ["859867", "859871", "1719803", "1719862"], "spl_id": ["86dff2aa-2ab3-42fc-989e-619b13ace573"], "spl_set_id": ["ca9896e0-fb2e-46a4-8700-20d144c14764"], "package_ndc": ["63323-469-01", "63323-469-05", "63323-471-01", "63323-471-05"], "unii": ["AC20PJ4101"]}, "update_date": "01/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Injection", "presentation": "Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-5212-23", "generic_name": "Hydrochlorothiazide; Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 12.5 mg; 20 mg (NDC 0071-5212-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-162-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075784"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-162", "63323-161"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4"], "spl_set_id": ["ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c"], "package_ndc": ["63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4276-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088299"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4276", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4745-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4745", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4744"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "43066-015-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-015", "43066-019", "43066-023", "43066-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734084", "1734207", "1734475", "1734483"], "spl_id": ["a8d08579-825f-40d9-b1e3-e47b73765ae6"], "spl_set_id": ["781d4b7f-7556-4695-8d48-7772d7a0d8e9"], "package_ndc": ["43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10"], "unii": ["V910P86109"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)", "company_name": "Caplin Steriles, Ltd.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0487-6105-01", "generic_name": "Sterile Water Injection", "contact_info": "800-443-4313", "availability": "Unavailable", "related_info": "Product can be manufactured as requested", "openfda": {"application_number": ["ANDA211222"], "brand_name": ["STERILE WATER"], "generic_name": ["STERILE WATER"], "manufacturer_name": ["Nephron Pharmaceuticals Corporation"], "product_ndc": ["0487-6105"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["39ada97d-53b0-5144-e063-6294a90a91ba"], "spl_set_id": ["bc04a883-babc-87a6-e053-2995a90a3dfd"], "package_ndc": ["0487-6105-01"], "unii": ["059QF0KO0R"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)", "company_name": "Nephron Pharmaceuticals Corporation", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-430-01", "generic_name": "Decitabine Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Decitabine, Injection, 50 mg (NDC 50742-430-01)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "25021-700-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-700", "25021-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["cb23332a-48fa-458b-93ab-c4eef189a051"], "spl_set_id": ["62591551-a644-4b2c-a0de-982e906fabc3"], "package_ndc": ["25021-700-01", "25021-701-01", "25021-701-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-026-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-026", "65162-023", "65162-024", "65162-025", "65162-027", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1181-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021171"], "brand_name": ["DEMEROL"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1181", "0409-1176", "0409-1178", "0409-1179", "0409-1180", "0409-1362", "0409-1418"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192"], "spl_id": ["c1704eaf-f0a8-4ba3-89a1-2836ba7e5ee6"], "spl_set_id": ["b31d1308-28c3-43f4-e0a6-2f3ed76b8975"], "package_ndc": ["0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01"], "unii": ["N8E7F7Q170"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-8035-01", "generic_name": "Glyburide Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074686"], "brand_name": ["GLYBURIDE"], "generic_name": ["GLYBURIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8035", "0093-8034", "0093-8036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLYBURIDE"], "rxcui": ["310536", "310539", "314000"], "spl_id": ["d734cd0e-df7b-40a2-a511-fc04308a764d"], "spl_set_id": ["e84c0dfc-a4e9-4c89-b6ea-45732eb412f5"], "package_ndc": ["0093-8034-01", "0093-8035-01", "0093-8035-05", "0093-8036-01"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["SX6K58TVWC"]}, "update_date": "06/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0062-30", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0062", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0078", "0338-0074", "0338-0066", "0338-0070", "0338-0082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["66eb82f8-6755-42aa-b20c-192a640e8068"], "spl_set_id": ["36e9478c-5df0-4b47-b97d-de3626d7cb29"], "package_ndc": ["0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0591-5553-05", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA062421"], "brand_name": ["DOXYCYCLINE HYCLATE"], "generic_name": ["DOXYCYCLINE HYCLATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5553"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DOXYCYCLINE HYCLATE"], "rxcui": ["1650143"], "spl_id": ["0fb9a3f8-9ebb-4c21-8a73-9f082b39039c"], "spl_set_id": ["a569ba80-ffea-40b2-9fbe-a42810b1fccb"], "package_ndc": ["0591-5553-50", "0591-5553-05"], "unii": ["19XTS3T51U"]}, "update_date": "06/13/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-209-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care Renal Therapies Group, LLC"], "product_ndc": ["49230-209", "49230-206", "49230-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["44506bb0-e5f3-2a05-e063-6294a90ab2c9", "43cd31e0-97ed-1eeb-e063-6294a90a0b3d"], "spl_set_id": ["bbc5b820-4973-11e2-a192-0002a5d5c51b", "c29bdfa0-4976-11e2-939b-0002a5d5c51b"], "package_ndc": ["49230-206-20", "49230-206-30", "49230-206-32", "49230-206-50", "49230-206-60", "49230-206-62", "49230-206-52", "49230-209-23", "49230-209-30", "49230-209-32", "49230-209-50", "49230-209-60", "49230-209-62", "49230-209-52", "49230-212-23", "49230-212-30", "49230-212-32", "49230-212-50", "49230-212-60", "49230-212-62", "49230-212-52", "49230-206-92", "49230-206-94", "49230-206-95", "49230-209-92", "49230-209-94", "49230-209-95", "49230-212-92", "49230-212-94", "49230-212-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3443-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": {"application_number": ["ANDA206812"], "brand_name": ["FONDAPARINUX SODIUM"], "generic_name": ["FONDAPARINUX SODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3443", "0781-3454", "0781-3465", "0781-3476"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FONDAPARINUX SODIUM"], "rxcui": ["861356", "861360", "861363", "861365"], "spl_id": ["3d5a4b69-462b-7e51-e063-6294a90a0721"], "spl_set_id": ["baa50757-a927-4d56-a933-5d7798fe6ab0"], "package_ndc": ["0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95"], "unii": ["X0Q6N9USOZ"]}, "update_date": "09/29/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-068-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-073", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-161-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA075784"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-161", "63323-162"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4"], "spl_set_id": ["ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c"], "package_ndc": ["63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0532-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 20 mg (NDC 0071-0532-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-251-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202881"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-251"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["7c66a6ac-0548-4555-b9d1-077feb277c37"], "spl_set_id": ["ebdfe2e8-30ca-4f18-935a-41bcbbce4937"], "package_ndc": ["67457-251-00", "67457-251-02"], "unii": ["1018WH7F9I"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6003-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["ATIVAN"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6003", "0641-6002", "0641-6001", "0641-6000"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327"], "spl_id": ["209b0091-c890-4f69-a693-d0594c2606fe"], "spl_set_id": ["5fc0e987-61c9-40c4-b0d5-fcea07c8733e"], "package_ndc": ["0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "0228-2801-11", "generic_name": "Pilocarpine Hydrochloride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA020237"], "brand_name": ["PILOCARPINE HYDROCHLORIDE"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2801", "0228-2837"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "rxcui": ["1000913", "1001004"], "spl_id": ["7db72b88-d664-4f26-901c-46c901b20d80"], "spl_set_id": ["610022b7-7dc9-405a-a580-104657f43bdf"], "package_ndc": ["0228-2801-11", "0228-2837-11"], "unii": ["0WW6D218XJ"]}, "update_date": "09/19/2025", "therapeutic_category": ["Other"], "dosage_form": "Tablet", "presentation": "Salagen, Tablet, 5 mg (NDC 0228-2801-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6637-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202494"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6637", "0409-4916"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["727995", "792582"], "spl_id": ["f79ec8cb-b6a3-4ffb-bccf-d39f59d65621"], "spl_set_id": ["ea20a5eb-641e-48cd-bcfa-74c04c45dfda"], "package_ndc": ["0409-4916-24", "0409-4916-14", "0409-6637-24", "0409-6637-14"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0502-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA020512"], "brand_name": ["CLINISOL"], "generic_name": ["LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0502"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["800584", "800588"], "spl_id": ["7eab93b5-5590-4381-8674-113a05edeff0"], "spl_set_id": ["65ffc962-7538-41ea-9afb-4af5fbce4c5b"], "package_ndc": ["0338-0502-03", "0338-0502-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43598-976-58", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "Distributed by DRL", "availability": "Available", "related_info": "Distributed by DRL", "openfda": {"application_number": ["ANDA209307"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Dr.Reddy's Laboratories Inc"], "product_ndc": ["43598-976", "43598-975"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["5785a11f-7784-4ae0-8029-f50b782eaf4a"], "spl_set_id": ["d174c19d-56f1-4ef4-087c-23c26db8e40b"], "package_ndc": ["43598-976-11", "43598-976-58", "43598-975-11", "43598-975-58"], "unii": ["1018WH7F9I"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/27/2025", "update_type": "New", "initial_posting_date": "08/27/2025", "package_ndc": "0409-2344-88", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074086"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["e71e9520-871b-479d-9652-1857fceca863", "5d6b1dfe-d679-4aea-97a6-3d074a202afe"], "spl_set_id": ["dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58"], "package_ndc": ["0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88"], "unii": ["0WR771DJXV"]}, "update_date": "08/27/2025", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-700-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["NDA216117"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-700", "13811-711"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2605796", "2605798"], "spl_id": ["ba649db4-df0d-4587-8370-3f866e66e54b"], "spl_set_id": ["dd8d7b6e-c23d-4e16-bb53-959e9127ebc6"], "package_ndc": ["13811-711-30", "13811-700-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9311-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Novaplus label", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9311", "0143-9310"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["c15bd8c1-34e3-40f2-b31a-634136fe197c"], "spl_set_id": ["4312e3c3-34de-4cb3-8abd-c24d24a4bea1"], "package_ndc": ["0143-9310-01", "0143-9310-10", "0143-9311-01", "0143-9311-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1312-36", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1312", "0409-1283", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-343-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-343", "42806-339", "42806-341", "42806-344", "42806-345"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "43066-007-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA091115"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-007", "43066-013"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["9e0317de-2d78-4fd8-8926-4c7b476f3ed4"], "spl_set_id": ["31e15c3f-aefa-4379-b684-7707744fe40d"], "package_ndc": ["43066-007-10", "43066-013-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0002-8011-27", "generic_name": "Mirikizumab-mrkz Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.", "openfda": {"application_number": ["BLA761279"], "brand_name": ["OMVOH"], "generic_name": ["MIRIKIZUMAB-MRKZ"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8011", "0002-7575", "0002-8870", "0002-7717", "0002-7722", "0002-3116", "0002-1442"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["MIRIKIZUMAB"], "rxcui": ["2668391", "2668398", "2668405", "2668410", "2680728", "2680732", "2703047", "2703048", "2703049", "2703050", "2703051", "2703052", "2703053", "2703054"], "spl_id": ["e1015232-2dfd-4b5d-b1d0-e0302e49c55a"], "spl_set_id": ["472cbe04-263e-433d-9a0f-58c1b50b715a"], "package_ndc": ["0002-7575-01", "0002-8011-01", "0002-8011-27", "0002-8011-61", "0002-8870-01", "0002-8870-27", "0002-7717-11", "0002-7717-61", "0002-3116-01", "0002-7722-11", "0002-1442-01", "0002-3116-11", "0002-3116-61", "0002-1442-11"], "nui": ["N0000192799", "N0000192798"], "pharm_class_epc": ["Interleukin-23 Antagonist [EPC]"], "pharm_class_moa": ["Interleukin-23 Antagonists [MoA]"], "unii": ["Z7HVY03PHP"]}, "update_date": "12/22/2025", "therapeutic_category": ["Gastroenterology", "Other"], "dosage_form": "Injection", "presentation": "Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-034-01", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["NDA020630"], "brand_name": ["ULTIVA"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["72078-034", "72078-035", "72078-036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729581", "1729584", "1729586", "1729710", "1729712"], "spl_id": ["594087a1-25f2-4f68-aea6-ad7df40559ab"], "spl_set_id": ["8b4c8696-e23e-4c51-a4d2-babab5bd945a"], "package_ndc": ["72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05"], "unii": ["5V444H5WIC"]}, "update_date": "05/05/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-421-30", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA040803"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-421", "67457-423", "67457-422", "67457-420"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["dd5c82b6-a194-462c-9626-34a9b410cfea"], "spl_set_id": ["dff598e8-e662-411f-978d-4ba3fb8ef7db"], "package_ndc": ["67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5113-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Unavailable", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5113", "0406-5111", "0406-5112", "0406-5114", "0406-5115", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "70069-752-25", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": {"application_number": ["ANDA217792"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-752", "70069-753"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["2b24af95-6f20-4945-bf8c-742f1d6f2721"], "spl_set_id": ["bcaab86f-20f0-4482-8d73-e29b36dced58"], "package_ndc": ["70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-04", "generic_name": "Furosemide Injection", "contact_info": "Sagent Pharmaceuticals: 866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0011-04", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0011", "0009-0825", "0009-0013", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-495-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0766-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Limited Availability", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0766", "0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0764", "0527-0765"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)", "company_name": "Lannett Company, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0781-3220-92", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA079195"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3220"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["eaf32464-7950-434a-e053-2a95a90aa2dc"], "spl_set_id": ["cb28d869-6510-4402-9462-f6bb25fa0fa8"], "package_ndc": ["0781-3220-70", "0781-3220-92", "0781-3220-75", "0781-3220-95"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "72205-101-01", "generic_name": "Bumetanide Injection", "contact_info": "Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA215364"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-101", "72205-102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "spl_set_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "package_ndc": ["72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/02/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)", "company_name": "MSN Laboratories Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-052-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-052", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4661-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3570-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3570", "0480-3565", "0480-3566", "0480-3567", "0480-3568", "0480-3569", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-310-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA091695"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["62175-310", "62175-311", "62175-312", "62175-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001564", "2001565", "2001566", "2001568"], "spl_id": ["8b133cd2-e3c6-4742-b402-2393b56ffc93"], "spl_set_id": ["3d1f5aff-5d39-496c-b5ed-7f3c70ec641c"], "package_ndc": ["62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37"], "unii": ["4B3SC438HI"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/08/2025", "update_type": "New", "initial_posting_date": "07/08/2025", "package_ndc": "0409-1893-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1893", "0409-1890", "0409-1891", "0409-1892", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "07/08/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3984-05", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3984", "0591-3982", "0591-3983", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 200 mg (NDC 0591-3984-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1005-03", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA019615"], "brand_name": ["DOPAMINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1005", "0338-1007", "0338-1009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1292887", "1743869", "1743871", "1743877", "1743879"], "spl_id": ["edc9a091-4cb5-4ec7-b6f9-44d2d588bab9"], "spl_set_id": ["cb97d4a0-89ed-407c-a763-209386b6f75c"], "package_ndc": ["0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02"], "unii": ["7L3E358N9L"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-02", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: July 2026; Estimated Recovery: September 2026; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089644"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-42", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-473"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c14acada-333e-43bb-b1cf-81d569e3e918"], "spl_set_id": ["1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec"], "package_ndc": ["23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-852-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-852", "63323-851", "63323-853", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "68025-096-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-096", "68025-088", "68025-089", "68025-095", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0078-0406-05", "generic_name": "Amlodipine Besylate; Benazepril Hydrochloride Capsule", "contact_info": "888-669-6682", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA020364"], "brand_name": ["LOTREL"], "generic_name": ["AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "product_ndc": ["0078-0406", "0078-0405", "0078-0364", "0078-0379"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMLODIPINE BESYLATE", "BENAZEPRIL HYDROCHLORIDE"], "rxcui": ["898342", "898344", "898346", "898348", "898353", "898355", "898356", "898358"], "spl_id": ["b9db75d9-9d1e-4b2d-9876-5f5520feaecc"], "spl_set_id": ["94ae6054-b7ae-4212-a567-4f803af8f2c7"], "package_ndc": ["0078-0405-05", "0078-0406-05", "0078-0364-05", "0078-0379-05"], "unii": ["864V2Q084H", "N1SN99T69T"]}, "update_date": "06/24/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Lotrel, Capsule, 5 mg; 20 mg (NDC 0078-0406-05)", "company_name": "Novartis Pharmaceuticals Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6005-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA213784"], "brand_name": ["FLUPHENAZINE HYDROCHLORIDE"], "generic_name": ["FLUPHENAZINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories,LLC"], "product_ndc": ["0832-6005", "0832-6004", "0832-6003", "0832-6006"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUPHENAZINE HYDROCHLORIDE"], "rxcui": ["859841", "860918", "865117", "865123"], "spl_id": ["3bb74f82-8872-9829-e063-6294a90aeace"], "spl_set_id": ["f07bb3f1-c68c-441b-9de4-99a219f2500a"], "package_ndc": ["0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11"], "unii": ["ZOU145W1XL"]}, "update_date": "09/18/2025", "therapeutic_category": ["Neurology", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 5 mg (NDC 0832-6005-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6855-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6855", "0378-6854", "0378-6856", "0378-6857", "0378-6858", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-9137-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA040302"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9137", "0409-4903", "0409-4904", "0409-1323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1012066", "1012068"], "spl_id": ["b386f7fc-ec89-4d73-aba6-2019a9cb1d4a"], "spl_set_id": ["ad1ef0a8-88db-4648-c098-d009eaeb4e5b"], "package_ndc": ["0409-4903-11", "0409-4903-34", "0409-4904-11", "0409-4904-34", "0409-1323-15", "0409-1323-05", "0409-9137-11", "0409-9137-05"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-473-64", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-473", "61314-454", "61314-476", "61314-509", "61314-517", "61314-531"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ADALIMUMAB"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-555-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-555", "64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-383-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/06/2018", "package_ndc": "72266-119-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["FOSUN PHARMA USA INC"], "product_ndc": ["72266-119", "72266-234", "72266-118"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["228ec94a-f777-f61b-e063-6394a90a21a5"], "spl_set_id": ["1aae6a4d-0909-4672-aa26-e3f2d8c4d413"], "package_ndc": ["72266-234-01", "72266-234-25", "72266-118-01", "72266-118-25", "72266-119-01", "72266-119-25"], "unii": ["4EVE5946BQ"]}, "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-18", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "72516-011-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Available", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-011", "72516-016", "72516-015", "72516-014", "72516-013", "72516-012"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)", "company_name": "Oryza Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-50", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-851", "63323-852", "63323-853", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "55150-297-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-7202-10", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7202", "0093-0771", "0093-7201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-604-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA201791"], "brand_name": ["LAMOTRIGINE EXTENDED RELEASE"], "generic_name": ["LAMOTRIGINE EXTENDED RELEASE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-604", "49884-561", "49884-562", "49884-563", "49884-564", "49884-605"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LAMOTRIGINE"], "rxcui": ["850087", "850091", "900156", "900164", "1098608", "1146690"], "spl_id": ["9c5e0c2a-800e-47e9-a26b-582b98a05957"], "spl_set_id": ["fb59c76a-9b6f-40ea-ac3a-58c3195c4377"], "package_ndc": ["49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05"], "nui": ["N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191"], "pharm_class_epc": ["Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]"], "unii": ["U3H27498KS"]}, "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-66", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-671", "25021-652"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-706-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-706", "13811-709", "13811-707", "13811-708", "13811-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0185-0853-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA040439"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0185-0853", "0185-0831", "0185-0842", "0185-0864", "0185-2099", "0185-2098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577961"], "spl_id": ["9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd"], "spl_set_id": ["288dafc4-fe6e-4891-832f-511022c87445"], "package_ndc": ["0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-61", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "0143-9606-01", "generic_name": "Azacitidine Injection", "contact_info": "1-800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA209337"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9606"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["592a688f-2e42-4e91-a3ea-34befe2a4e07"], "spl_set_id": ["ff73515d-bd55-4eb5-992b-d2138c80887e"], "package_ndc": ["0143-9606-01"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/12/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0395-14", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050162"], "brand_name": ["CLEOCIN HYDROCHLORIDE"], "generic_name": ["CLINDAMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0395", "0009-0331", "0009-0225"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN HYDROCHLORIDE"], "rxcui": ["197518", "284215", "309329", "748746", "748748", "748750"], "spl_id": ["51cea3cd-28cf-455e-ba27-5a0d8e052858"], "spl_set_id": ["df9a2a41-b132-4f43-8940-b2d773b1369a"], "package_ndc": ["0009-0331-02", "0009-0225-02", "0009-0395-14"], "unii": ["T20OQ1YN1W"]}, "update_date": "02/25/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/05/2026", "update_type": "New", "initial_posting_date": "01/05/2026", "package_ndc": "0093-2401-01", "generic_name": "Hydroxychloroquine Sulfate Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040081"], "brand_name": ["HYDROXYCHLOROQUINE SULFATE"], "generic_name": ["HYDROXYCHLOROQUINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-2401"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROXYCHLOROQUINE SULFATE"], "rxcui": ["979092"], "spl_id": ["0c6c28a5-e86f-4643-bb22-f7eb5b1f440d"], "spl_set_id": ["5f3e49b2-dc11-40a9-b366-c88e36a471e5"], "package_ndc": ["0093-2401-01"], "unii": ["8Q2869CNVH"]}, "update_date": "01/05/2026", "therapeutic_category": ["Anti-Infective", "Other", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Hydroxychloroquine Sulfate, Tablet, 200 mg (NDC 0093-2401-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-605-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA201791"], "brand_name": ["LAMOTRIGINE EXTENDED RELEASE"], "generic_name": ["LAMOTRIGINE EXTENDED RELEASE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-605", "49884-561", "49884-562", "49884-563", "49884-564", "49884-604"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LAMOTRIGINE"], "rxcui": ["850087", "850091", "900156", "900164", "1098608", "1146690"], "spl_id": ["9c5e0c2a-800e-47e9-a26b-582b98a05957"], "spl_set_id": ["fb59c76a-9b6f-40ea-ac3a-58c3195c4377"], "package_ndc": ["49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05"], "nui": ["N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191"], "pharm_class_epc": ["Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]"], "unii": ["U3H27498KS"]}, "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/17/2023", "change_date": "01/27/2026", "package_ndc": "68308-115-01", "generic_name": "Methamphetamine Hydrochloride Tablet", "contact_info": "866-732-3952", "resolved_note": "Available", "openfda": {"application_number": ["ANDA091189"], "brand_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "generic_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "manufacturer_name": ["Mayne Pharma Commercial LLC"], "product_ndc": ["68308-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "rxcui": ["977860"], "spl_id": ["ffc2cd39-e42b-5821-e053-6394a90a9974"], "spl_set_id": ["f31f580f-1f08-4a0f-b078-0b9e3308f712"], "package_ndc": ["68308-115-01"], "unii": ["997F43Z9CV"]}, "update_date": "01/27/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 68308-115-01)", "company_name": "Dr. Reddy's Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-21", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-288", "63323-286", "63323-287", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-10", "generic_name": "Furosemide Injection", "contact_info": "866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0007-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 0378-0007-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-485-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3815-12", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: June 2026; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA073510"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3815", "0409-3814"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1728783", "1728800"], "spl_id": ["0a2ba20b-448f-4412-9899-b82040ebfa7d"], "spl_set_id": ["1d181906-f3ec-4222-1883-e61577a3122e"], "package_ndc": ["0409-3814-11", "0409-3814-12", "0409-3815-11", "0409-3815-12"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7767-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210050"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7767", "0093-7766", "0093-7768", "0093-7769"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["aa521933-950a-441b-9146-93e479a4dde7"], "spl_set_id": ["e3bca36b-29ed-4a2b-a1be-a57b6af805f6"], "package_ndc": ["0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "03/02/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 0093-7767-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9933-25", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA065072"], "brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9933", "0143-9931", "0143-9930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["309068", "1656313", "1656318"], "spl_id": ["7e0897ec-2275-4438-9cc5-4c951e52ad97"], "spl_set_id": ["ed23b6bc-32c7-4c50-a53d-313ae78e5623"], "package_ndc": ["0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10"], "unii": ["258J72S7TZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0990-4179-05", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-4179-05", "openfda": {"application_number": ["NDA019492"], "brand_name": ["AMINOSYN-PF"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-4179"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["800341", "800345"], "spl_id": ["2d8f2280-bc20-45ba-bdf3-12c055684017"], "spl_set_id": ["46e74ce4-cd7e-437f-bf54-ca9b98eb2663"], "package_ndc": ["0990-4179-05"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-602-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "71288-718-11", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA213453"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-718", "71288-700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["aad39c88-2e2c-49a6-aa13-de852483661f", "37295b13-65a4-40fa-8d6c-53aeb45e2939"], "spl_set_id": ["b23aa80e-2af2-4a66-92ed-b1c8863be704", "b9abaf64-760d-43e0-8669-a9ca70feab11"], "package_ndc": ["71288-700-91", "71288-700-92", "71288-718-91", "71288-718-92", "71288-700-05", "71288-700-06", "71288-718-10", "71288-718-11"], "unii": ["I65MW4OFHZ"]}, "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0781-3220-95", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA079195"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3220"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["eaf32464-7950-434a-e053-2a95a90aa2dc"], "spl_set_id": ["cb28d869-6510-4402-9462-f6bb25fa0fa8"], "package_ndc": ["0781-3220-70", "0781-3220-92", "0781-3220-75", "0781-3220-95"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"presentation": "Adipex-P, Tablet, 37.5 mg (NDC 57844-140-01)", "discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "57844-140-01", "generic_name": "Phentermine Hydrochloride Tablet", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "update_date": "06/13/2025", "therapeutic_category": ["Other"], "status": "To Be Discontinued", "dosage_form": "Tablet", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5316-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5316", "0245-5315"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-01)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "68001-313-56", "generic_name": "Azacitidine Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA208216"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["BluePoint Laboratories"], "product_ndc": ["68001-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["36080e4e-a0fe-ba15-e063-6394a90aed5c"], "spl_set_id": ["5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a"], "package_ndc": ["68001-313-56"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 68001-313-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-6648-02", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019445"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6648", "0409-7517"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["727517", "1795514"], "spl_id": ["2f05a8f1-4651-405c-a66b-8e96a46c1db8"], "spl_set_id": ["4ed365da-4e62-4329-c1b9-c197ab4fb6e1"], "package_ndc": ["0409-7517-66", "0409-7517-16", "0409-6648-16", "0409-6648-02"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-04", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d"], "spl_set_id": ["3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75"], "package_ndc": ["63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-563-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-496-97", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE MPF"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-496", "63323-492", "63323-493"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764"], "spl_id": ["fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df"], "spl_set_id": ["d5e0d06f-ba1e-44d4-aa89-39d6c146dc23"], "package_ndc": ["63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97"], "unii": ["EC2CNF7XFP"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5168-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5168", "0603-5165", "0603-5166", "0603-5167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4910-34", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-167-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2596-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA075293"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2596", "0409-2587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["6c075a2d-b68b-41a7-aa0c-bcf9894e3f76"], "spl_set_id": ["affecd4d-1f78-4bbe-5a8d-86849bbdc520"], "package_ndc": ["0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-728-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-728", "71288-721", "71288-722", "71288-724", "71288-725", "71288-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-411-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": {"application_number": ["ANDA205823"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Solco Healthcare US, LLC"], "product_ndc": ["43547-411", "43547-410", "43547-412", "43547-413"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["b8f1731a-cbac-4f64-a8d4-320b80b335e1"], "spl_set_id": ["cd46691d-5593-4a9f-a937-999c6803e312"], "package_ndc": ["43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-4910-34", "generic_name": "Atropine Sulfate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "55150-386-01", "generic_name": "Carboplatin Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; check wholesalers for inventory", "openfda": {"application_number": ["ANDA205487"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-386", "55150-333", "55150-334", "55150-335"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["6029d051-ee8d-44cc-8dae-b91c3385d4c3", "5abfcb87-bb02-4384-9c9d-7d0e3e809311"], "spl_set_id": ["f5fe9a20-47a5-45b9-ab06-c6158d9b6aca", "5abfcb87-bb02-4384-9c9d-7d0e3e809311"], "package_ndc": ["55150-333-01", "55150-334-01", "55150-335-01", "55150-386-01", "55150-335-00", "55150-386-00"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4246-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA077269"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4246", "0703-4244", "0703-4248", "0703-4239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c"], "spl_set_id": ["f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37"], "package_ndc": ["0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4665-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4665", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-012-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 12.5 mg/.4 mL (NDC 82497-012-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-287-21", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-287", "63323-286", "63323-288", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "55150-304-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA210966"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1812079"], "spl_id": ["5d97a8a3-fd79-4fd1-8a0f-c8cf95d40964"], "spl_set_id": ["29947f67-7868-40af-8ad2-a61f7149b44c"], "package_ndc": ["55150-304-01", "55150-304-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-8036-01", "generic_name": "Glyburide Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074686"], "brand_name": ["GLYBURIDE"], "generic_name": ["GLYBURIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8036", "0093-8034", "0093-8035"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLYBURIDE"], "rxcui": ["310536", "310539", "314000"], "spl_id": ["d734cd0e-df7b-40a2-a511-fc04308a764d"], "spl_set_id": ["e84c0dfc-a4e9-4c89-b6ea-45732eb412f5"], "package_ndc": ["0093-8034-01", "0093-8035-01", "0093-8035-05", "0093-8036-01"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["SX6K58TVWC"]}, "update_date": "06/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glyburide (Micronized), Tablet, 6 mg (NDC 0093-8036-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-103-15", "generic_name": "Insulin Aspart Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Aspart 3 mL FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA020986"], "brand_name": ["INSULIN ASPART"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-103", "73070-100", "73070-102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["311040", "1653196", "1653202"], "spl_id": ["393af9a3-df9a-40b2-a5e6-bfa5434a2552"], "spl_set_id": ["bee5b358-c863-420b-be73-ced2e920c499"], "package_ndc": ["73070-100-11", "73070-102-10", "73070-102-15", "73070-103-10", "73070-103-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Aspart, Injection, 3 mL Insulin Aspart FlexPen® (NDC 73070-103-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2410-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": {"application_number": ["NDA021514"], "brand_name": ["METHYLPHENIDATE TRANSDERMAL SYSTEM"], "generic_name": ["METHYLPHENIDATE"], "manufacturer_name": ["PADAGIS US LLC"], "product_ndc": ["0574-2410", "0574-2415", "0574-2420", "0574-2430"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["METHYLPHENIDATE"], "rxcui": ["753436", "753438", "753440", "753441"], "spl_id": ["b743ef45-2fc0-4086-8a02-6078e6a09eaa"], "spl_set_id": ["7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb"], "package_ndc": ["0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65"], "nui": ["N0000175739", "N0000175729"], "pharm_class_epc": ["Central Nervous System Stimulant [EPC]"], "pharm_class_pe": ["Central Nervous System Stimulation [PE]"], "unii": ["207ZZ9QZ49"]}, "update_date": "05/07/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "23155-601-41", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA090850"], "brand_name": ["MIDAZOLAM HYDROCHLORIDE"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-601"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311702"], "spl_id": ["e20feff9-3aca-4bc1-a5c3-44fff8a9459c"], "spl_set_id": ["843cc25e-45ea-4372-ae34-843f805fa869"], "package_ndc": ["23155-601-31", "23155-601-41", "23155-601-32", "23155-601-42"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-554-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077690"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-554", "68180-556", "68180-557", "68180-558", "68180-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["a9598a21-6f99-4c86-ace6-b5638da2bec8"], "spl_set_id": ["8ded0773-3aec-4e89-9836-d22a5a84abf0"], "package_ndc": ["68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/04/2021", "package_ndc": "59137-570-01", "generic_name": "Triamcinolone Hexacetonide Injection", "related_info_link": "https://www.fda.gov/media/154709/download", "contact_info": "1-855-336-3322 Option 9", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"brand_name": ["HEXATRIONE 2%"], "generic_name": ["TRIAMCINOLONE HEXACETONIDE"], "manufacturer_name": ["Medexus Pharma, Inc."], "product_ndc": ["59137-570"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR"], "substance_name": ["TRIAMCINOLONE HEXACETONIDE"], "rxcui": ["2539176", "2539181"], "spl_id": ["4970c1c8-aa33-7c54-e063-6294a90a6167"], "spl_set_id": ["bc07ae9f-8a74-6bc8-e053-2995a90afc0d"], "package_ndc": ["59137-570-01"], "unii": ["I7GT1U99Y9"]}, "update_date": "04/30/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)", "company_name": "Medexus", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-1015-00", "generic_name": "Amantadine Hydrochloride Capsule", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA070589"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-1015"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849389"], "spl_id": ["398493aa-8a67-10e2-e063-6394a90aef8d"], "spl_set_id": ["5232b933-1df9-43b4-8ac2-61bfa4855e68"], "package_ndc": ["0832-1015-00", "0832-1015-50"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Capsule", "presentation": "Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-00)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "69516-005-30", "generic_name": "Obeticholic Acid Tablet", "contact_info": "1-844-782-4278", "related_info": "Business decision. Products will not be available after November 14, 2025.", "update_date": "09/19/2025", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Tablet", "presentation": "Ocaliva, Tablet, 5 mg (NDC 69516-005-30)", "company_name": "Intercept Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/06/2026", "update_type": "New", "initial_posting_date": "04/06/2026", "package_ndc": "64380-844-06", "generic_name": "Ursodiol Capsule", "contact_info": "877-244-9825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210344"], "brand_name": ["URSODIOL"], "generic_name": ["URSODIOL"], "manufacturer_name": ["Strides Pharma Science Limited"], "product_ndc": ["64380-844"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["URSODIOL"], "rxcui": ["858747"], "spl_id": ["46e8718f-fb37-4590-ad7e-7a55913fddf4"], "spl_set_id": ["9a6c1928-2d52-4d9a-8e83-f71892a7e98d"], "package_ndc": ["64380-844-06", "64380-844-07", "64380-844-04"], "nui": ["N0000175802", "M0002475"], "pharm_class_epc": ["Bile Acid [EPC]"], "pharm_class_cs": ["Bile Acids and Salts [CS]"], "unii": ["724L30Y2QR"]}, "update_date": "04/06/2026", "therapeutic_category": ["Other"], "dosage_form": "Capsule", "presentation": "Ursodiol, Capsule, 300 mg (NDC 64380-844-06)", "company_name": "Strides Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-168-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-168", "55150-167", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0005-01", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0005", "0009-0825", "0009-0011", "0009-0013", "0009-0016"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "change_date": "01/03/2025", "package_ndc": "0641-0121-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0185-2098-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA040439"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0185-2098", "0185-0831", "0185-0842", "0185-0853", "0185-0864", "0185-2099"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577961"], "spl_id": ["9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd"], "spl_set_id": ["288dafc4-fe6e-4891-832f-511022c87445"], "package_ndc": ["0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/11/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0002-8870-27", "generic_name": "Mirikizumab-mrkz Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.", "openfda": {"application_number": ["BLA761279"], "brand_name": ["OMVOH"], "generic_name": ["MIRIKIZUMAB-MRKZ"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8870", "0002-7575", "0002-8011", "0002-7717", "0002-7722", "0002-3116", "0002-1442"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["MIRIKIZUMAB"], "rxcui": ["2668391", "2668398", "2668405", "2668410", "2680728", "2680732", "2703047", "2703048", "2703049", "2703050", "2703051", "2703052", "2703053", "2703054"], "spl_id": ["e1015232-2dfd-4b5d-b1d0-e0302e49c55a"], "spl_set_id": ["472cbe04-263e-433d-9a0f-58c1b50b715a"], "package_ndc": ["0002-7575-01", "0002-8011-01", "0002-8011-27", "0002-8011-61", "0002-8870-01", "0002-8870-27", "0002-7717-11", "0002-7717-61", "0002-3116-01", "0002-7722-11", "0002-1442-01", "0002-3116-11", "0002-3116-61", "0002-1442-11"], "nui": ["N0000192799", "N0000192798"], "pharm_class_epc": ["Interleukin-23 Antagonist [EPC]"], "pharm_class_moa": ["Interleukin-23 Antagonists [MoA]"], "unii": ["Z7HVY03PHP"]}, "update_date": "12/22/2025", "therapeutic_category": ["Gastroenterology", "Other"], "dosage_form": "Injection", "presentation": "Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-65", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0264-2101-00", "generic_name": "Sterile Water Irrigant", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA016734"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-2101"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["969bdf41-6565-42fb-8ac1-8661a928cc22"], "spl_set_id": ["f4284eb6-e553-46d4-90d8-efc80a90a480"], "package_ndc": ["0264-2101-00", "0264-2101-10", "0264-2101-50", "0264-2101-70"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "25021-321-04", "generic_name": "Bumetanide Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Product in transit, expected to arrive last week of April 2026", "openfda": {"application_number": ["ANDA074441"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-321"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["befc1cf3-b71c-4228-bc42-3495b1d4b00d"], "spl_set_id": ["c38a404d-a919-4a2c-9fbb-d0655dee9516"], "package_ndc": ["25021-321-04", "25021-321-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-02", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-02", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-119-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207934"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-119", "49884-125", "49884-127", "49884-128"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["b474c768-50e2-44da-accf-f1bd3d49ab20"], "spl_set_id": ["45d54974-3fc4-4237-a2fa-3158ca1a8105"], "package_ndc": ["49884-119-52", "49884-119-91", "49884-125-52", "49884-125-91", "49884-127-52", "49884-127-91", "49884-128-52", "49884-128-91"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "01/06/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2.5 mg (NDC 49884-119-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-397-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4903-34", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only)  100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/20/2025", "update_type": "New", "initial_posting_date": "10/20/2025", "package_ndc": "0781-3317-80", "generic_name": "Oxaliplatin Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078817"], "brand_name": ["OXALIPLATIN"], "generic_name": ["OXALIPLATIN"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3317", "0781-3315"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["OXALIPLATIN"], "rxcui": ["1736776", "1736781"], "spl_id": ["f3766495-fce3-461c-8c95-e890f5e3383f"], "spl_set_id": ["ab162009-6f84-4d56-ab56-5e84409ec814"], "package_ndc": ["0781-3315-70", "0781-3317-80"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["04ZR38536J"]}, "update_date": "10/20/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-162-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078450"], "brand_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-162", "65862-161", "65862-163"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["5842ecc2-874a-481b-8997-afa9d862dc5d"], "spl_set_id": ["50a58159-9572-4445-9859-b392632597da"], "package_ndc": ["65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2020", "package_ndc": "16729-484-45", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA212868"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Accord Healthcare, Inc.,"], "product_ndc": ["16729-484", "16729-483"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["4082a1cf-1e1b-6f40-e063-6294a90aec06"], "spl_set_id": ["c82cb295-ffce-47d6-97ad-a8aa723f4e4f"], "package_ndc": ["16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3493-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": {"application_number": ["ANDA209065"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3493", "0781-3494", "0781-3495"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["fdf227d9-008e-60f8-e053-6294a90af5c4"], "spl_set_id": ["809e8f77-390f-4cc8-8c8a-4f67a249c9df"], "package_ndc": ["0781-3493-95", "0781-3494-95", "0781-3495-95"], "unii": ["1018WH7F9I"]}, "update_date": "04/06/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL  (NDC 0781-3493-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-505-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-505", "64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "63323-854-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-854", "63323-851", "63323-852", "63323-853"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-454-68", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-454", "61314-473", "61314-476", "61314-509", "61314-517", "61314-531"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ADALIMUMAB"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2020", "package_ndc": "55150-393-01", "generic_name": "Azacitidine Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA215066"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-393"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["e89b9510-86df-4095-b6d3-4eb05b613c4f"], "spl_set_id": ["ecd108bd-bb5f-4b2e-ad91-210fca452e9b"], "package_ndc": ["55150-393-01"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/05/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-605-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-605", "43547-602", "43547-603", "43547-604", "43547-606", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0002-7623-01", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-545-5979", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021462"], "brand_name": ["ALIMTA"], "generic_name": ["PEMETREXED DISODIUM"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-7623", "0002-7640"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PEMETREXED DISODIUM HEPTAHYDRATE"], "rxcui": ["1728072", "1728075", "1728077", "1728079"], "spl_id": ["3af0bc84-13d6-46aa-a4c0-c62410b73bc6"], "spl_set_id": ["f5a860f3-37ec-429c-ae04-9c88d7c55c08"], "package_ndc": ["0002-7640-01", "0002-7623-01"], "unii": ["9T47E4OM16"]}, "update_date": "10/16/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Alimta, Injection, 500 mg/20 mL (NDC 0002-7623-01)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4933-01", "generic_name": "Epinephrine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Cardiovascular", "Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4277-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088327"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4277", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/14/2026", "update_type": "New", "initial_posting_date": "05/14/2026", "package_ndc": "0480-7250-46", "generic_name": "Liraglutide Injection", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA214568"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-7250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["2735350"], "spl_id": ["4df44cd9-cb11-46b6-ba6c-88ff963ec414"], "spl_set_id": ["625ac780-70a9-41e4-a892-bcba0f803f1c"], "package_ndc": ["0480-7250-46"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "05/14/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6859-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6859", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-652-87", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-652", "25021-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA075880"], "brand_name": ["PREMASOL - SULFITE-FREE (AMINO ACID)"], "generic_name": ["LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1130", "0338-1131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "CYSTEINE HYDROCHLORIDE", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801395", "801398", "801403", "801405"], "spl_id": ["c874a813-b145-4f7f-833e-97d6c4dd727c"], "spl_set_id": ["9afdcc3e-0d06-47f4-86ca-40da48b2b02b"], "package_ndc": ["0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "ZT934N0X4W", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/14/2022", "package_ndc": "66220-160-10", "generic_name": "Conivaptan Hydrochloride Injection", "contact_info": "615-255-0068", "availability": "Unavailable", "update_date": "05/11/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)", "company_name": "Cumberland Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "71357-007-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": {"application_number": ["ANDA214805"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["MILLA PHARMACEUTICALS INC."], "product_ndc": ["71357-007", "71357-008", "71357-009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["237371", "312965"], "spl_id": ["47d8d0e7-6db5-950d-e063-6294a90ab1bf"], "spl_set_id": ["1ea1466d-a492-4056-e063-6394a90a80bf"], "package_ndc": ["71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10"], "unii": ["4550K0SC9B"]}, "update_date": "05/15/2026", "therapeutic_category": ["Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)", "company_name": "Milla Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070583"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596"], "spl_id": ["fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3212-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: October 2026", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3212", "0093-0832", "0093-3213"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6030-01", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the May 2026 timeframe.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6030", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6247", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9594-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019830"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9594", "0264-9598"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e352802-107c-4f90-babe-4f69c7dc892e"], "spl_set_id": ["7dff29d9-522d-40eb-a9d9-42377912d640"], "package_ndc": ["0264-9598-20", "0264-9594-20", "0264-9594-10"], "unii": ["EC2CNF7XFP", "LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4279-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088329"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4279", "0409-4713", "0409-4278", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-047-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-047-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6001-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Lots are being manufactured to meet demand", "openfda": {"application_number": ["NDA018140"], "brand_name": ["ATIVAN"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6001", "0641-6003", "0641-6002", "0641-6000"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327"], "spl_id": ["209b0091-c890-4f69-a693-d0594c2606fe"], "spl_set_id": ["5fc0e987-61c9-40c4-b0d5-fcea07c8733e"], "package_ndc": ["0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "63323-123-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["ANDA040263"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-123"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1946772"], "spl_id": ["880c2caa-1b11-45ce-a54e-a3733da367f0"], "spl_set_id": ["b585f621-f6c9-4735-ab61-bd1b401f3df0"], "package_ndc": ["63323-123-10"], "unii": ["3IG1E710ZN"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-196-99", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-196", "55150-195", "55150-197", "55150-198", "55150-199", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1388-8", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Inventory available 2 to 6 weeks as per current demand. Next supply: week of 2/23/2026", "openfda": {"application_number": ["ANDA207551"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1388", "70121-1389"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["795f643f-855c-4ba4-9bad-a96334c1a2fb"], "spl_set_id": ["eb1ba463-ab42-4f49-9ebe-3ad5af108326"], "package_ndc": ["70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7"], "unii": ["1018WH7F9I"]}, "update_date": "02/09/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6006-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA213784"], "brand_name": ["FLUPHENAZINE HYDROCHLORIDE"], "generic_name": ["FLUPHENAZINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories,LLC"], "product_ndc": ["0832-6006", "0832-6004", "0832-6003", "0832-6005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUPHENAZINE HYDROCHLORIDE"], "rxcui": ["859841", "860918", "865117", "865123"], "spl_id": ["3bb74f82-8872-9829-e063-6294a90aeace"], "spl_set_id": ["f07bb3f1-c68c-441b-9de4-99a219f2500a"], "package_ndc": ["0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11"], "unii": ["ZOU145W1XL"]}, "update_date": "09/18/2025", "therapeutic_category": ["Neurology", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 10 mg (NDC 0832-6006-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-502-43", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070017"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-502", "16729-500", "16729-501"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1cfab300-d796-6a68-e063-6394a90a73f9"], "spl_set_id": ["f6f64972-714c-4ee9-8a5e-9ffcab41a73b"], "package_ndc": ["16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-283-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA202747"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["36000-283", "36000-063", "36000-064", "36000-065", "36000-282", "36000-284"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53"], "spl_set_id": ["c71371a7-75c5-45b8-b762-8d782d4c71bc"], "package_ndc": ["36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/08/2025", "update_type": "New", "initial_posting_date": "07/08/2025", "package_ndc": "0409-1892-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/08/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/14/2026", "update_type": "New", "initial_posting_date": "04/14/2026", "package_ndc": "58914-301-80", "generic_name": "Nitroglycerin Ointment", "contact_info": "800-678-1605", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021359"], "brand_name": ["RECTIV"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["Allergan, Inc."], "product_ndc": ["58914-301"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RECTAL"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["1114466", "1114470"], "spl_id": ["a2f0ef5a-c3b6-4330-9b33-131369431ddd"], "spl_set_id": ["603aa9ed-54c4-4a35-ade4-690fa44850e4"], "package_ndc": ["58914-301-80", "58914-301-85"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "04/14/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Ointment", "presentation": "Rectiv, Ointment, 0.4% (NDC 58914-301-80)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-75", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209448"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-824"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481"], "spl_id": ["0591ab74-99a6-40ee-af96-80bc2ef423dc"], "spl_set_id": ["3b8f2692-4371-4f1a-95af-b41842131fdd"], "package_ndc": ["63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "New", "initial_posting_date": "08/27/2025", "package_ndc": "0409-7809-24", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018826"], "brand_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7809", "0409-7810", "0409-0042", "0409-1858"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "spl_id": ["188ce800-ff3a-4b22-9a95-2273c3bc99ae"], "spl_set_id": ["08f23f6e-150d-45ea-098e-f2edf64c21a1"], "package_ndc": ["0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12"], "unii": ["7L3E358N9L"]}, "update_date": "08/27/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-203-05", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA212803"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-203"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b06d36f6-507c-4b04-b79d-d6370a30a551", "53a09c30-7295-4337-89a4-93d3748d6ea3"], "spl_set_id": ["a2e3c748-28ce-4c50-a182-721912919840", "3aadaca7-3661-4bfe-87f8-6368e4ab6536"], "package_ndc": ["71288-203-02", "71288-203-03", "71288-203-04", "71288-203-05", "71288-203-10", "71288-203-11", "71288-203-91", "71288-203-92", "71288-203-93", "71288-203-94"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-098-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-098", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2859", "0781-2868"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0532-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 20 mg (NDC 0071-0532-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-667-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076374"], "brand_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-667", "62135-668", "62135-669"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["0c3f4504-d57e-aa79-e063-6294a90ad5b8"], "spl_set_id": ["2eae533f-d0af-47e8-a1f2-94bc8cc89b5a"], "package_ndc": ["62135-667-90", "62135-668-90", "62135-669-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-02", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated availability: May 2026", "openfda": {"application_number": ["NDA017428"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0004", "0338-0003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["97390588-b679-4caa-b7f3-3d2e11074d0e"], "spl_set_id": ["ef3e79c5-3f58-4b36-a296-64b7d9a651c1"], "package_ndc": ["0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "76045-109-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209192"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-109", "76045-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["2099700"], "spl_id": ["6fd9ed0e-dddc-4e73-9442-49da54685f7b"], "spl_set_id": ["4dd55929-fe0a-4884-ae0d-6f9435920eb7"], "package_ndc": ["76045-109-01", "76045-109-10", "76045-212-00", "76045-212-10"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-109-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-3301-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3301", "0409-1454", "0409-1174", "0409-2815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["8d48de06-361f-418b-bfec-8ef85f94d5bc"], "spl_set_id": ["4419162d-81d4-49bd-96de-1729440bdb74"], "package_ndc": ["0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-386-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-10", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d"], "spl_set_id": ["3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75"], "package_ndc": ["63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "change_date": "01/02/2025", "package_ndc": "0409-1283-31", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1283", "0409-1312", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-203-15", "generic_name": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin aspart protamine and insulin aspart FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA021172"], "brand_name": ["INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-203", "73070-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["351297", "847191"], "spl_id": ["ec67820c-4008-4894-b933-34b28704221d"], "spl_set_id": ["fc94baa4-3606-48bc-a781-9617ab6960ef"], "package_ndc": ["73070-200-11", "73070-203-10", "73070-203-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injectable Suspension", "presentation": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 3 mL vial Insulin aspart protamine and insulin aspart Mix 70/30 FlexPen® (NDC 73070-203-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-586-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": {"application_number": ["NDA021121"], "brand_name": ["CONCERTA"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-586", "50458-585", "50458-588", "50458-587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212"], "spl_id": ["64d7c1e1-e7ed-4d74-a44d-13b4da64af9a"], "spl_set_id": ["1a88218c-5b18-4220-8f56-526de1a276cd"], "package_ndc": ["50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "63323-750-10", "generic_name": "Oxaliplatin Injection", "contact_info": "847-550-2300", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA078811"], "brand_name": ["OXALIPLATIN"], "generic_name": ["OXALIPLATIN"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-750"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["OXALIPLATIN"], "rxcui": ["1736776", "1736781"], "spl_id": ["504bf43e-4c28-4375-a6f4-285b2357f7f7"], "spl_set_id": ["e12e2850-4980-48de-af58-15e559fb921f"], "package_ndc": ["63323-750-10", "63323-750-20"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["04ZR38536J"]}, "update_date": "02/25/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/13/2026", "update_type": "New", "initial_posting_date": "03/13/2026", "package_ndc": "65219-284-12", "generic_name": "Plerixafor Injection", "contact_info": "888-391-6300 www.fresenius-kabi.com", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["NDA022311"], "brand_name": ["PLERIXAFOR"], "generic_name": ["PLERIXAFOR"], "manufacturer_name": ["Fresenius Kabi Usa, LLC"], "product_ndc": ["65219-284"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PLERIXAFOR"], "rxcui": ["828700"], "spl_id": ["ba468eca-fb47-497b-8aed-a1576249ea6a"], "spl_set_id": ["5d670cb4-163e-498c-b5fa-c193ea9d55c0"], "package_ndc": ["65219-284-12"], "nui": ["N0000178326", "N0000178324"], "pharm_class_epc": ["Hematopoietic Stem Cell Mobilizer [EPC]"], "pharm_class_pe": ["Increased Hematopoietic Stem Cell Mobilization [PE]"], "unii": ["S915P5499N"]}, "update_date": "03/13/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6024-10", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "66794-228-41", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-414-1901", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA210437"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM"], "manufacturer_name": ["Piramal Critical Care Inc"], "product_ndc": ["66794-228", "66794-229"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["3f9e12e4-d3c5-fba6-e063-6294a90a7fd6"], "spl_set_id": ["98255b70-51f9-8d16-e053-2995a90a8f97"], "package_ndc": ["66794-229-02", "66794-229-41", "66794-228-02", "66794-228-41"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)", "company_name": "Piramal Critical Care Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-456-60", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholealers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-456", "65219-464", "65219-458", "65219-460", "65219-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-52", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0280", "0009-0274", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-12", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA075154"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-411", "63323-412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA076515"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2234"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["200329"], "spl_id": ["fe6aa833-89e6-4679-a7b8-6600e92c1bed"], "spl_set_id": ["5a09ce48-7139-4fc7-9b6e-439459c8e866"], "package_ndc": ["0781-2234-10", "0781-2234-01", "0781-2234-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-620-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202725"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL HYDROCHLORIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-620", "65862-617", "65862-618", "65862-619"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["5263abd5-ce46-4918-9bb0-9632861bcbc9"], "spl_set_id": ["93e6e668-5306-4f26-81d8-cbc3a7a5e787"], "package_ndc": ["65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78"], "unii": ["33067B3N2M"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "65649-311-12", "generic_name": "Chlorothiazide Oral Suspension", "contact_info": "800-321-4576", "openfda": {"application_number": ["NDA011870"], "brand_name": ["DIURIL"], "generic_name": ["CHLOROTHIAZIDE"], "manufacturer_name": ["Salix Pharmaceuticals, Inc"], "product_ndc": ["65649-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CHLOROTHIAZIDE"], "rxcui": ["213439", "309198"], "spl_id": ["e311f727-9882-4c42-bd5b-e8e38ee54466"], "spl_set_id": ["bd936e35-1af8-42da-bcc0-f22489d68574"], "package_ndc": ["65649-311-12"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["77W477J15H"]}, "update_date": "02/10/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Oral Suspension", "presentation": "Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12)", "company_name": "Salix Pharmaceuticals, a division of Bausch Health US, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-563-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-563", "47781-562", "47781-564", "47781-565", "47781-566", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5011-4", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": {"application_number": ["ANDA211091"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Exela Pharma Sciences, LLC"], "product_ndc": ["51754-5011", "51754-5001", "51754-5002", "51754-5012"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["807284", "1868486", "1923484", "2198792"], "spl_id": ["4da0ba66-756d-4b4d-8018-81ca16578ef1"], "spl_set_id": ["e9698a4f-1a95-4f28-a945-e8009d1d6dd4"], "package_ndc": ["51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4"], "unii": ["8MDF5V39QO"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-074-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 OR CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-074", "13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-073"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2305-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026", "openfda": {"application_number": ["ANDA075857"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2305", "0409-2308", "0409-0001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666800", "1666814", "1666823", "1666798"], "spl_id": ["b303a281-6633-47d5-bf29-5e9055e26da6", "74093865-864a-49e8-99b9-c985fe72afb2"], "spl_set_id": ["b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240"], "package_ndc": ["0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/08/2025", "update_type": "New", "initial_posting_date": "07/08/2025", "package_ndc": "0004-0802-85", "generic_name": "Oseltamivir Phosphate Capsule", "contact_info": "800-551-2231", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021087"], "brand_name": ["TAMIFLU"], "generic_name": ["OSELTAMIVIR PHOSPHATE"], "manufacturer_name": ["Genentech, Inc."], "product_ndc": ["0004-0802", "0004-0801", "0004-0800", "0004-0822"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OSELTAMIVIR PHOSPHATE"], "rxcui": ["261315", "312122", "728109", "728111", "728113", "728115", "1115698", "1115700"], "spl_id": ["94a312ac-c47a-4437-8dd3-6bcd7e08e42c"], "spl_set_id": ["ee3c9555-60f2-4f82-a760-11983c86e97b"], "package_ndc": ["0004-0802-85", "0004-0801-85", "0004-0800-85", "0004-0800-07", "0004-0800-08", "0004-0822-05"], "unii": ["4A3O49NGEZ"]}, "update_date": "07/08/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Capsule", "presentation": "Tamiflu, Capsule, 30 mg (NDC 0004-0802-85)", "company_name": "Genentech, Inc", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9393-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA210594"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9393", "0143-9391", "0143-9392"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["5c5e498b-d829-4f78-bcca-466631014767"], "spl_set_id": ["9d289052-1eb6-4ba2-a3ca-d2e542a052ae"], "package_ndc": ["0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10"], "unii": ["5V444H5WIC"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-178-76", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209689"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-178"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["WATER"], "spl_id": ["d40f0ff2-4abf-4030-b4e1-2b85ad7448a0"], "spl_set_id": ["b45e9f1d-9c48-4b46-8541-d846b89540df"], "package_ndc": ["63323-178-76"], "unii": ["059QF0KO0R"]}, "update_date": "04/23/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-0144-11", "generic_name": "Azithromycin Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA065500"], "brand_name": ["AZITHROMYCIN"], "generic_name": ["AZITHROMYCIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0144"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AZITHROMYCIN MONOHYDRATE"], "rxcui": ["1668238"], "spl_id": ["0daee3b8-efec-4ff2-aedf-87035563373f"], "spl_set_id": ["d2f4907f-b952-403b-229e-cc5b8327a773"], "package_ndc": ["0409-0144-21", "0409-0144-11"], "unii": ["JTE4MNN1MD"]}, "update_date": "09/09/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Azithromycin, Injection, 500 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-0144-11)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1389-1", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "openfda": {"application_number": ["ANDA207551"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1389", "70121-1388"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["795f643f-855c-4ba4-9bad-a96334c1a2fb"], "spl_set_id": ["eb1ba463-ab42-4f49-9ebe-3ad5af108326"], "package_ndc": ["70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7"], "unii": ["1018WH7F9I"]}, "update_date": "02/09/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "67457-902-10", "generic_name": "Etomidate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA201044"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-902", "67457-903"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["25fc0aef-d4b3-4b33-897c-81cc7cdae470"], "spl_set_id": ["461e34d1-b862-4a02-9727-548c907aac48"], "package_ndc": ["67457-902-00", "67457-902-10", "67457-903-00", "67457-903-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-165-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-165", "55150-161", "55150-162", "55150-163", "55150-164"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/13/2022", "package_ndc": "47335-993-01", "generic_name": "Metronidazole Injection", "contact_info": "Distributed by Sun Pharma", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA212435"], "brand_name": ["METRONIDAZOLE"], "generic_name": ["METRONIDAZOLE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-993"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["METRONIDAZOLE"], "rxcui": ["311683"], "spl_id": ["9549fa19-5d89-4ad8-82ac-5d023072b126"], "spl_set_id": ["7187779a-1f4c-4607-af53-4119e324aad5"], "package_ndc": ["47335-993-01"], "nui": ["N0000175435", "M0014907"], "pharm_class_epc": ["Nitroimidazole Antimicrobial [EPC]"], "pharm_class_cs": ["Nitroimidazoles [CS]"], "unii": ["140QMO216E"]}, "update_date": "04/27/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "51224-206-30", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["TAGI Pharma Inc."], "product_ndc": ["51224-206"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["75a00517-674b-4e87-b37b-598486aedf03"], "spl_set_id": ["60276f5c-657a-4b60-bcd0-44234903d7e0"], "package_ndc": ["51224-206-30", "51224-206-50"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-30)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5165-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5165", "0603-5166", "0603-5167", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1176-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA021171"], "brand_name": ["DEMEROL"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1176", "0409-1181", "0409-1178", "0409-1179", "0409-1180", "0409-1362", "0409-1418"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192"], "spl_id": ["c1704eaf-f0a8-4ba3-89a1-2836ba7e5ee6"], "spl_set_id": ["b31d1308-28c3-43f4-e0a6-2f3ed76b8975"], "package_ndc": ["0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01"], "unii": ["N8E7F7Q170"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/08/2026", "update_type": "New", "initial_posting_date": "04/08/2026", "package_ndc": "0006-3066-03", "generic_name": "Aprepitant Oral Powder for Suspension", "contact_info": "800-672-6372", "related_info": "To be discontinued in approximately November 2026.", "openfda": {"application_number": ["NDA207865"], "brand_name": ["EMEND"], "generic_name": ["APREPITANT"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "product_ndc": ["0006-3066", "0006-0461", "0006-0462", "0006-3862", "0006-0464"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["APREPITANT"], "rxcui": ["403810", "403811", "404465", "404466", "644088", "644278", "754508", "754509", "1729308", "1729311"], "spl_id": ["428f7828-6d1c-438b-a17d-b4af0700c740"], "spl_set_id": ["696f9e80-9cae-403b-de9e-078343ce4713"], "package_ndc": ["0006-0461-02", "0006-0461-01", "0006-0461-06", "0006-0461-12", "0006-0462-01", "0006-0462-06", "0006-3862-03", "0006-3862-13", "0006-0464-01", "0006-0464-10", "0006-0464-05", "0006-3066-01", "0006-3066-03"], "nui": ["N0000010262", "N0000175786", "N0000182141", "N0000185507", "N0000185506"], "pharm_class_moa": ["Neurokinin 1 Antagonists [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 3A4 Inducers [MoA]"], "pharm_class_epc": ["Substance P/Neurokinin-1 Receptor Antagonist [EPC]"], "unii": ["1NF15YR6UY"]}, "update_date": "04/08/2026", "therapeutic_category": ["Gastroenterology"], "presentation": "Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03)", "company_name": "Merck Sharp & Dohme LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6625-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA202432"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6625"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868486"], "spl_id": ["dcc55d90-d55e-4e1a-9e48-5703cbc74a52", "c39c0ef6-4140-4c6c-91c4-e43d67872b05"], "spl_set_id": ["8664c7ce-707b-4c6c-9ce4-7160b5f877f8", "084f5572-8c1f-4802-b179-ca0cc838fc68"], "package_ndc": ["0409-6625-30", "0409-6625-35", "0409-6625-22", "0409-6625-14"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/22/2026", "update_type": "New", "initial_posting_date": "04/22/2026", "package_ndc": "0069-0188-21", "generic_name": "Palbociclib Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.", "openfda": {"application_number": ["NDA207103"], "brand_name": ["IBRANCE"], "generic_name": ["PALBOCICLIB"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-0188", "0069-0187", "0069-0189"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PALBOCICLIB"], "rxcui": ["1601380", "1601386", "1601388", "1601390", "1601392", "1601394"], "spl_id": ["fb858b80-8bd4-43a6-8871-9819a35ca03f"], "spl_set_id": ["e0e6412f-50b4-4fd4-9364-62818d121a07"], "package_ndc": ["0069-0187-21", "0069-0188-21", "0069-0189-21"], "nui": ["N0000175605", "N0000175082", "N0000190114"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["G9ZF61LE7G"]}, "update_date": "04/22/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Capsule", "presentation": "Ibrance, Capsule, 100 mg (NDC 0069-0188-21)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-02", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA019465"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7101", "0409-7132"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807547", "1807631", "1807632", "1807633"], "spl_id": ["f233e72c-072d-4a43-857a-f4d5791e1a73"], "spl_set_id": ["a2a964f7-c3ec-4dfb-e3a0-6d8136a80397"], "package_ndc": ["0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02"], "unii": ["451W47IQ8X"]}, "update_date": "12/03/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 250 mL  ADD-Vantage® Flexible Container (NDC 0409-7101-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "61570-073-01", "generic_name": "Esterified Estrogens Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/29/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Menest, Tablet, .625 mg (NDC 61570-073-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-120-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-120", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-01", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA084916"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1116927", "1812194"], "spl_id": ["a832bff9-0bb3-4350-abb5-d57b9417070c", "9dd90418-e564-4bc5-9077-506a1c2c1bce"], "spl_set_id": ["2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e"], "package_ndc": ["63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-00", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA208129"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["27411591-44a1-44c4-89c3-dd8c2687f0e2"], "spl_set_id": ["4d5d2294-89a0-4b6f-aa00-d39a0393b6a8"], "package_ndc": ["63323-671-02", "63323-671-20", "63323-671-05", "63323-671-50", "63323-671-01", "63323-671-00"], "unii": ["1018WH7F9I"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-468-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "6, 7 & 8 month expiry available upon request. Check wholesaler for inventory", "openfda": {"application_number": ["ANDA070966"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-468", "63323-472", "63323-463", "63323-461"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1867594", "1867596", "1867618", "1867620", "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810"], "spl_id": ["b671015d-f620-4930-a890-5e27a40ae42f", "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["b671015d-f620-4930-a890-5e27a40ae42f", "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-468-08", "63323-468-38", "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-8034-01", "generic_name": "Glyburide Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074686"], "brand_name": ["GLYBURIDE"], "generic_name": ["GLYBURIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8034", "0093-8035", "0093-8036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLYBURIDE"], "rxcui": ["310536", "310539", "314000"], "spl_id": ["d734cd0e-df7b-40a2-a511-fc04308a764d"], "spl_set_id": ["e84c0dfc-a4e9-4c89-b6ea-45732eb412f5"], "package_ndc": ["0093-8034-01", "0093-8035-01", "0093-8035-05", "0093-8036-01"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["SX6K58TVWC"]}, "update_date": "06/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glyburide (Micronized), Tablet, 1.5 mg (NDC 0093-8034-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0338-0409-03", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018461"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0409", "0338-0411"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e9121a0-25dd-46ba-a2b7-6f71fc3ff9cd"], "spl_set_id": ["f21512ea-c7c3-4766-b976-b2c0b5616bf0"], "package_ndc": ["0338-0409-03", "0338-0409-02", "0338-0411-02"], "unii": ["V13007Z41A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1179-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA021171"], "brand_name": ["DEMEROL"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1179", "0409-1181", "0409-1176", "0409-1178", "0409-1180", "0409-1362", "0409-1418"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192"], "spl_id": ["c1704eaf-f0a8-4ba3-89a1-2836ba7e5ee6"], "spl_set_id": ["b31d1308-28c3-43f4-e0a6-2f3ed76b8975"], "package_ndc": ["0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01"], "unii": ["N8E7F7Q170"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-063-01", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-063", "65862-062", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-01)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-005-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X5ML)  is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-110-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-110", "57844-105", "57844-117", "57844-112", "57844-115", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "68180-658-06", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA090034"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-658", "68180-659"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["5ed1edac-e11e-4f87-b390-e770a69a9b37"], "spl_set_id": ["b56004f0-f23d-47f6-80c7-39884fccbccc"], "package_ndc": ["68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 68180-658-06)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-065-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesaler for inventory.", "openfda": {"application_number": ["ANDA078651"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-065"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["68f8f5e7-46a8-47f9-a622-6339df1a3d1b"], "spl_set_id": ["209a654d-f92d-4242-bfef-2dcc90a30d3f"], "package_ndc": ["65219-065-02", "65219-065-05"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1746-10", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1746", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-2815-01", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2815", "0409-1454", "0409-3301", "0409-1174"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["8d48de06-361f-418b-bfec-8ef85f94d5bc"], "spl_set_id": ["4419162d-81d4-49bd-96de-1729440bdb74"], "package_ndc": ["0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-500-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018931"], "brand_name": ["TRAVASOL"], "generic_name": ["LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0644"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801644", "801648"], "spl_id": ["e0279078-016d-48fd-8de1-c894422b33ff"], "spl_set_id": ["8543b5be-0f43-4891-9e56-d7c39fe839b5"], "package_ndc": ["0338-0644-03", "0338-0644-04", "0338-0644-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "JNJ23Q2COM", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-00", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Information pending", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-152", "72888-153", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-00)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2308-01", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075857"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2308", "0409-2305", "0409-0001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666800", "1666814", "1666823", "1666798"], "spl_id": ["b303a281-6633-47d5-bf29-5e9055e26da6", "74093865-864a-49e8-99b9-c985fe72afb2"], "spl_set_id": ["b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240"], "package_ndc": ["0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "63323-723-03", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release April 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA206223"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-723", "63323-724", "63323-725"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["406a07e3-a3f8-4fef-901e-021d00743c40", "2f27e51f-2b55-47ee-bd4a-001b71c60622"], "spl_set_id": ["5b8025d2-3424-477b-9cff-3990a98c2a65", "d2374b84-81c9-44f9-a4a9-1071281b2531"], "package_ndc": ["63323-723-04", "63323-723-06", "63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10"], "unii": ["5V444H5WIC"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-34", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA206775"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-295"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["35cf6068-f31a-211b-e063-6294a90a6b53"], "spl_set_id": ["48aa7ef3-9f44-2a08-e054-00144ff88e88"], "package_ndc": ["16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0499-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020849"], "brand_name": ["PROSOL"], "generic_name": ["VALINE, LYSINE, HISTIDINE, ISOLEUCINE, LEUCINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0499"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801133", "801136"], "spl_id": ["ee240b46-c2a9-42e0-8750-a5a554becea3"], "spl_set_id": ["cc2ace81-5881-43f1-ba94-41b674adc2fc"], "package_ndc": ["0338-0499-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2853-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA200881"], "brand_name": ["GUANFACINE"], "generic_name": ["GUANFACINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2853", "0228-2850", "0228-2851", "0228-2855"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GUANFACINE HYDROCHLORIDE"], "rxcui": ["862006", "862013", "862019", "862025"], "spl_id": ["b9040df2-42e8-404d-9b90-331dd3efc38c"], "spl_set_id": ["3a171942-37af-430d-8b9d-bb678ca2be4b"], "package_ndc": ["0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11"], "unii": ["PML56A160O"]}, "update_date": "11/13/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 3 mg (NDC 0228-2853-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7510", "0264-7520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0409-1805-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1805", "0409-1283", "0409-1312", "0409-4264"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3294-50", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070434"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-3294", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3298"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FUROSEMIDE"], "rxcui": ["197730", "197731", "197732", "310429", "313988"], "spl_id": ["bc62ddda-7639-4090-99f0-7dd4d13518f3"], "spl_set_id": ["9e493331-dddd-496e-abf8-61747fb67aba"], "package_ndc": ["0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-115-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-115", "70010-111", "70010-112", "70010-113", "70010-114", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6854-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-017-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 17.5 mg/.4 mL (NDC 82497-017-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-607-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "openfda": {"application_number": ["ANDA205135"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-607", "57664-606", "57664-608", "57664-609"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210"], "spl_id": ["509cf8be-4306-9755-e063-6294a90ab425"], "spl_set_id": ["d048e52d-7406-4fc1-9a72-c073bafc7439"], "package_ndc": ["57664-606-88", "57664-607-88", "57664-608-88", "57664-609-88"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-023-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-023", "65162-024", "65162-025", "65162-026", "65162-027", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/17/2021", "package_ndc": "0068-0597-01", "generic_name": "Rifampin Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Rifampin%20Injection&st=d", "contact_info": "800-633-1610", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050627"], "brand_name": ["RIFADIN IV"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Sanofi-Aventis U.S. LLC"], "product_ndc": ["0068-0597"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["RIFAMPIN"], "rxcui": ["207436", "312821"], "spl_id": ["d5ee3f24-779e-4fd0-ba26-e870acbd1111"], "spl_set_id": ["036ab68e-5085-4edc-bd83-784b43d64eab"], "package_ndc": ["0068-0597-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)", "company_name": "Sanofi-Aventis U.S. LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "72516-013-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Available", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-013", "72516-016", "72516-015", "72516-014", "72516-012", "72516-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)", "company_name": "Oryza Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-31", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0305-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/177206/download", "contact_info": "610-937-6172", "availability": "Available", "openfda": {"brand_name": ["TEGLUTIK"], "generic_name": ["RILUZOLE"], "manufacturer_name": ["EDW PHARMA"], "product_ndc": ["70726-0305"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RILUZOLE"], "rxcui": ["2058147", "2675565"], "spl_id": ["4746c4d8-402a-0390-e063-6294a90a7fc2"], "spl_set_id": ["125fdd37-02f7-a610-e063-6294a90a009d"], "package_ndc": ["70726-0305-1"], "nui": ["N0000175740", "M0483511"], "pharm_class_epc": ["Benzothiazole [EPC]"], "pharm_class_cs": ["Benzothiazoles [CS]"], "unii": ["7LJ087RS6F"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "68025-097-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-097", "68025-088", "68025-089", "68025-095", "68025-096", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1587-50", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1587", "0409-1559", "0409-1560", "0409-1582", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1587-50)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1005-02", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA019615"], "brand_name": ["DOPAMINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1005", "0338-1007", "0338-1009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1292887", "1743869", "1743871", "1743877", "1743879"], "spl_id": ["edc9a091-4cb5-4ec7-b6f9-44d2d588bab9"], "spl_set_id": ["cb97d4a0-89ed-407c-a763-209386b6f75c"], "package_ndc": ["0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02"], "unii": ["7L3E358N9L"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0143-9251-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA204679"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9251", "0143-9250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["76957fea-9b26-42a6-ad71-c8752142a08b"], "spl_set_id": ["d3a172a5-01ab-47d8-92ac-a8539b1d4dc4"], "package_ndc": ["0143-9250-01", "0143-9250-10", "0143-9251-01", "0143-9251-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-559-05", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-559", "62037-560"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1160-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070590"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1160", "0409-1159", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/19/2025", "update_type": "New", "initial_posting_date": "08/19/2025", "package_ndc": "0093-7355-05", "generic_name": "Finasteride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076511"], "brand_name": ["FINASTERIDE"], "generic_name": ["FINASTERIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7355"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FINASTERIDE"], "rxcui": ["310346"], "spl_id": ["4c152e0f-55b3-4357-b983-897ecaf878af"], "spl_set_id": ["77589cc3-c440-4695-800c-82a0e5128a6c"], "package_ndc": ["0093-7355-56", "0093-7355-98", "0093-7355-05"], "nui": ["N0000175836", "N0000000126"], "pharm_class_epc": ["5-alpha Reductase Inhibitor [EPC]"], "pharm_class_moa": ["5-alpha Reductase Inhibitors [MoA]"], "unii": ["57GNO57U7G"]}, "update_date": "08/19/2025", "therapeutic_category": ["Urology"], "dosage_form": "Tablet", "presentation": "Finasteride, Tablet, 5 mg (NDC 0093-7355-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "66794-160-02", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-414-1901", "availability": "Available", "openfda": {"application_number": ["ANDA204393"], "brand_name": ["MITIGO"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Piramal Critical Care, Inc."], "product_ndc": ["66794-160", "66794-162"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731522", "1731998", "2055307", "2055311"], "spl_id": ["495a6a51-d35d-2b96-e063-6394a90ac5f3"], "spl_set_id": ["728f3d83-9a63-0c1f-e053-2a91aa0ac7db"], "package_ndc": ["66794-160-02", "66794-162-02"], "unii": ["X3P646A2J0"]}, "update_date": "05/07/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)", "company_name": "Piramal Critical Care Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-119-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-119", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-725-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-725", "71288-721", "71288-722", "71288-724", "71288-727", "71288-728"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-44", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-473"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c14acada-333e-43bb-b1cf-81d569e3e918"], "spl_set_id": ["1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec"], "package_ndc": ["23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9594-25", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA084625"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9594", "0143-9595"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737566", "1737761"], "spl_id": ["a7da0a25-5efb-48fa-9063-f7c0423f820f"], "spl_set_id": ["1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1"], "package_ndc": ["0143-9595-01", "0143-9595-25", "0143-9594-01", "0143-9594-25"], "unii": ["V13007Z41A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA076515"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2234"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["200329"], "spl_id": ["fe6aa833-89e6-4679-a7b8-6600e92c1bed"], "spl_set_id": ["5a09ce48-7139-4fc7-9b6e-439459c8e866"], "package_ndc": ["0781-2234-10", "0781-2234-01", "0781-2234-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0990-7139-09", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "Allocated to Contracted Customers Only. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7139-09", "openfda": {"application_number": ["NDA017513"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7139", "0990-6139", "0990-7973"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["90930d29-6b1a-438c-b719-c5e7484dcad5"], "spl_set_id": ["e3484bc6-ed7f-43ef-9d49-c131a8dff2dd"], "package_ndc": ["0990-6139-22", "0990-6139-03", "0990-7139-09", "0990-7139-36", "0990-7973-05", "0990-7973-07", "0990-7973-08"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-186-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Available", "related_info": "Please check wholesalers for inventory", "openfda": {"application_number": ["ANDA208266"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["42023-186", "42023-146", "42023-187"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710", "1718906", "1718909"], "spl_id": ["54174211-6684-4fb9-a605-be12b94e2948"], "spl_set_id": ["1ee59985-4c1d-48f7-b8f9-5584c2d55e08"], "package_ndc": ["42023-146-25", "42023-186-20", "42023-187-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)", "company_name": "Par Health, USA LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2346-32", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA020201"], "brand_name": ["DOBUTAMINE IN DEXTROSE"], "generic_name": ["DOBUTAMINE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2346", "0409-2347", "0409-3724", "0409-0025", "0409-0151", "0409-1100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["1c7cc97c-e244-4a4b-a4a1-8b70ca812107"], "spl_set_id": ["9943a961-3b50-4847-8a84-d8414ce38daa"], "package_ndc": ["0409-2347-31", "0409-2347-32", "0409-2346-31", "0409-2346-32", "0409-3724-11", "0409-3724-32", "0409-0025-01", "0409-0025-10", "0409-0151-01", "0409-0151-10", "0409-1100-01", "0409-1100-10"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-562-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-063-99", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-063", "65862-062", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-99)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-484-60", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076803"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-484", "62135-485", "62135-486", "62135-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["09cd5cb9-4fdf-f133-e063-6294a90af691"], "spl_set_id": ["dbc43dbd-94aa-40e2-a9ea-766110cc8687"], "package_ndc": ["62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90"], "unii": ["33067B3N2M"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "0071-0737-20", "generic_name": "Gemfibrozil Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA018422"], "brand_name": ["LOPID"], "generic_name": ["GEMFIBROZIL"], "manufacturer_name": ["Parke-Davis Div of Pfizer Inc"], "product_ndc": ["0071-0737"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GEMFIBROZIL"], "rxcui": ["205751", "310459"], "spl_id": ["e23c4bc1-151b-469a-a7a6-99c13bb666ce"], "spl_set_id": ["c48855b7-215e-453b-b3b1-a0f9dee7221f"], "package_ndc": ["0071-0737-20", "0071-0737-30"], "nui": ["N0000175596", "N0000175375", "M0543661"], "pharm_class_epc": ["Peroxisome Proliferator Receptor alpha Agonist [EPC]"], "pharm_class_moa": ["Peroxisome Proliferator-activated Receptor alpha Agonists [MoA]"], "pharm_class_cs": ["Fibric Acids [CS]"], "unii": ["Q8X02027X3"]}, "update_date": "02/10/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Lopid, Tablet, 600 mg (NDC 0071-0737-20)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-810-60", "generic_name": "Ivabradine Hydrochloride Tablet", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA206143"], "brand_name": ["CORLANOR"], "generic_name": ["IVABRADINE"], "manufacturer_name": ["Amgen Inc"], "product_ndc": ["55513-810", "55513-800", "55513-813"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IVABRADINE HYDROCHLORIDE"], "rxcui": ["1649485", "1649491", "1649493", "1649495", "2168592", "2168596"], "spl_id": ["8ab000cd-0258-489a-b1bb-4cc1ca359d6c"], "spl_set_id": ["92018a65-38f6-45f7-91d4-a34921b81d0d"], "package_ndc": ["55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28"], "unii": ["TP19837BZK"]}, "update_date": "03/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60)", "company_name": "Amgen Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-125-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-125", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 125 ug (NDC 72305-125-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "16729-277-30", "generic_name": "Methotrexate Sodium Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: 30 days", "openfda": {"application_number": ["ANDA040716"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-277"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["2bae3cfe-7aa0-c14c-e063-6294a90a19f4"], "spl_set_id": ["dd035a9f-cd40-4314-b9d8-2294b8a924e2"], "package_ndc": ["16729-277-30", "16729-277-03", "16729-277-35"], "nui": ["N0000175584", "N0000000111"], "pharm_class_epc": ["Folate Analog Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Folic Acid Metabolism Inhibitors [MoA]"], "unii": ["YL5FZ2Y5U1"]}, "update_date": "05/01/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-609-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "openfda": {"application_number": ["ANDA205135"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-609", "57664-606", "57664-607", "57664-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210"], "spl_id": ["509cf8be-4306-9755-e063-6294a90ab425"], "spl_set_id": ["d048e52d-7406-4fc1-9a72-c073bafc7439"], "package_ndc": ["57664-606-88", "57664-607-88", "57664-608-88", "57664-609-88"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-60", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-799", "42806-801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-60)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/21/2018", "package_ndc": "84898-911-02", "generic_name": "Sodium Chloride 0.9% Injection", "related_info_link": "https://www.fda.gov/media/183850/download", "contact_info": "855-826-4885", "availability": "Available", "related_info": "Call to Order 855-826-4885", "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sodium Chloride, Injection, 9 g/1000 mL (NDC 84898-911-02)", "company_name": "Sichuan Kelun Pharmaceutical Co., Ltd", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2587-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075293"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2587", "0409-2596"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["6c075a2d-b68b-41a7-aa0c-bcf9894e3f76"], "spl_set_id": ["affecd4d-1f78-4bbe-5a8d-86849bbdc520"], "package_ndc": ["0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "71288-563-85", "generic_name": "Liraglutide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA218115"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-563"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["c4f6adef-1b2a-4e7c-b7a9-b19d4ed1df36"], "spl_set_id": ["0efc3a89-211a-4496-baab-e8265e07de2b"], "package_ndc": ["71288-563-84", "71288-563-85"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "08/19/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "63481-627-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-107-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA203242"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-107", "76045-104", "76045-105", "76045-209"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860113", "860114", "860115"], "spl_id": ["0dab642d-7fcf-4301-8ac9-10e64a040c6b"], "spl_set_id": ["3d88cbe6-5230-47aa-80af-0c41283d1f00"], "package_ndc": ["76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-350-38", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-350", "61703-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"], "spl_set_id": ["0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab"], "package_ndc": ["61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "39822-5525-3", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "866-390-4411", "availability": "Available", "openfda": {"application_number": ["ANDA040737"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-5525"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460"], "spl_id": ["0e3526e1-38be-1d89-e063-6294a90a775d"], "spl_set_id": ["1d02d52b-84bb-4e81-b352-125029eb39f6"], "package_ndc": ["39822-5525-2", "39822-5525-3"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Other", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-608-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "openfda": {"application_number": ["ANDA205135"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-608", "57664-606", "57664-607", "57664-609"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210"], "spl_id": ["509cf8be-4306-9755-e063-6294a90ab425"], "spl_set_id": ["d048e52d-7406-4fc1-9a72-c073bafc7439"], "package_ndc": ["57664-606-88", "57664-607-88", "57664-608-88", "57664-609-88"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0409-1061-01", "generic_name": "Pemetrexed Ditromethamine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "07/17/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Pemetrexed Ditromethamine, Injection, 500 mg Single Dose Vial (NDC 0409-1061-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-602-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": {"application_number": ["NDA206628"], "brand_name": ["DEXMEDETOMIDINE IN DEXTROSE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["WG Critical Care, LLC"], "product_ndc": ["44567-602", "44567-600", "44567-601", "44567-603"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909", "1788947"], "spl_id": ["e6fa3e27-b374-49b6-a678-a5954f5beae8"], "spl_set_id": ["0d2710f2-ee47-4114-ab5c-8dca74cdcb8d"], "package_ndc": ["44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)", "company_name": "HQ Specialty Pharma", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-560-90", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-560", "62037-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-90)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4900-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/19/2026", "update_type": "New", "initial_posting_date": "03/19/2026", "package_ndc": "64764-805-10", "generic_name": "Ramelteon Tablet", "contact_info": "877-825-3327", "related_info": "Product is expected to be available through February 2027.", "openfda": {"application_number": ["NDA021782"], "brand_name": ["ROZEREM"], "generic_name": ["RAMELTEON"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["64764-805"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RAMELTEON"], "rxcui": ["577348", "603162"], "spl_id": ["2021e7fb-108a-4783-9a37-8bc05bf28b28"], "spl_set_id": ["9de82310-70e8-47b9-b1fc-6c6848b99455"], "package_ndc": ["64764-805-30", "64764-805-10", "64764-805-22"], "nui": ["N0000175743", "N0000000250"], "pharm_class_epc": ["Melatonin Receptor Agonist [EPC]"], "pharm_class_moa": ["Melatonin Receptor Agonists [MoA]"], "unii": ["901AS54I69"]}, "update_date": "03/19/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Rozerem, Tablet, 8 mg (NDC 64764-805-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3290-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3290", "0781-3288", "0781-3289"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a"], "spl_set_id": ["231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca"], "package_ndc": ["0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/18/2020", "package_ndc": "63323-771-39", "generic_name": "Azacitidine Injection", "contact_info": "1-888-386-1300", "availability": "Available", "related_info": "Check wholesaler inventory", "openfda": {"application_number": ["ANDA207518"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-771"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["4becda8d-8042-4cf1-bef3-c0ec3c23eebe"], "spl_set_id": ["3b594aba-e798-4105-b801-0b0d970747c1"], "package_ndc": ["63323-771-39"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3612-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA208084"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-3612", "0338-3410", "0338-3814"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["c8906ab2-37d2-4fde-9784-0442bf7b9565"], "spl_set_id": ["78832ac6-04c5-45e0-ae4d-f56d7920dda9"], "package_ndc": ["0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-153", "72888-152", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-05)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-423-12", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA040803"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-423", "67457-422", "67457-421", "67457-420"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["dd5c82b6-a194-462c-9626-34a9b410cfea"], "spl_set_id": ["dff598e8-e662-411f-978d-4ba3fb8ef7db"], "package_ndc": ["67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6000-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["ATIVAN"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6000", "0641-6003", "0641-6002", "0641-6001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327"], "spl_id": ["209b0091-c890-4f69-a693-d0594c2606fe"], "spl_set_id": ["5fc0e987-61c9-40c4-b0d5-fcea07c8733e"], "package_ndc": ["0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0517-1004-25", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-645-1706", "availability": "Available", "openfda": {"application_number": ["ANDA216120"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["American Regent, Inc."], "product_ndc": ["0517-1004", "0517-1001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190795", "1666781"], "spl_id": ["1c500ed9-94a9-472c-bfb7-50e1fcfc31fb"], "spl_set_id": ["6fee1727-52b7-4f73-ab45-ef47d6a1c5bb"], "package_ndc": ["0517-1004-01", "0517-1004-25", "0517-1001-01", "0517-1001-25"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)", "company_name": "American Regent, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-0832-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0832", "0093-3212", "0093-3213"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "55566-2500-0", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Spray", "presentation": "Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/05/2026", "update_type": "New", "initial_posting_date": "01/05/2026", "package_ndc": "0409-4350-03", "generic_name": "Diltiazem Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075853"], "brand_name": ["DILTIAZEM HYDROCHLORIDE"], "generic_name": ["DILTIAZEM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4350", "0409-1171"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DILTIAZEM HYDROCHLORIDE"], "rxcui": ["1791230", "1791240"], "spl_id": ["18648c0d-5f60-4195-92f0-1dffc1452d4c"], "spl_set_id": ["bba03666-ff4f-4bf6-fa92-78e1ec2d9073"], "package_ndc": ["0409-1171-11", "0409-1171-01", "0409-1171-12", "0409-1171-02", "0409-4350-13", "0409-4350-03"], "unii": ["OLH94387TE"]}, "update_date": "01/05/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-4350-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6046-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6046", "0641-6044", "0641-6045", "0641-6047"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100", "238101", "1665188", "1665326"], "spl_id": ["7c73dbc6-2623-4443-9b05-97dec7a0be2e"], "spl_set_id": ["e9b54e42-04cf-4c62-90e1-36f7b31a4e81"], "package_ndc": ["0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/20/2023", "package_ndc": "0527-4666-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4666", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "55150-226-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206206"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-226", "55150-225"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["30f618bf-fbbd-4489-acbb-204e8ed78dca"], "spl_set_id": ["116385ea-69fc-4f44-b463-6210291032df"], "package_ndc": ["55150-225-05", "55150-226-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070553", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-134-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-134", "72205-132", "72205-133", "72205-135", "72205-136", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-146-25", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Available", "related_info": "Please check wholesalers for inventory", "openfda": {"application_number": ["ANDA203972"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["42023-146", "42023-186", "42023-187"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710", "1718906", "1718909"], "spl_id": ["54174211-6684-4fb9-a605-be12b94e2948"], "spl_set_id": ["1ee59985-4c1d-48f7-b8f9-5584c2d55e08"], "package_ndc": ["42023-146-25", "42023-186-20", "42023-187-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)", "company_name": "Par Health, USA LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-172-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-172", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-464-50", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-464", "65219-456", "65219-458", "65219-460", "65219-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "0143-9519-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA089340"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9519", "0143-9518", "0143-9517", "0143-9516"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE"], "rxcui": ["1655959", "1655960", "1655967", "1655968"], "spl_id": ["3046ff78-3565-46d1-a88b-283e5ff6e7c3"], "spl_set_id": ["3989d30d-56e5-4e8d-9379-c30fecc894f2"], "package_ndc": ["0143-9519-10", "0143-9518-01", "0143-9517-01", "0143-9516-01"], "nui": ["N0000175584", "N0000000111"], "pharm_class_epc": ["Folate Analog Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Folic Acid Metabolism Inhibitors [MoA]"], "unii": ["YL5FZ2Y5U1"]}, "update_date": "05/12/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "47335-326-18", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-818-4555", "resolved_note": "Available", "openfda": {"application_number": ["ANDA090356"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["b0c2b60a-dc96-483b-933e-2fed58b64372"], "spl_set_id": ["0f30f885-d0cd-4fa6-a8e0-142f08a56792"], "package_ndc": ["47335-326-83", "47335-326-88", "47335-326-08", "47335-326-18"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-18)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-617-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202725"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL HYDROCHLORIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-617", "65862-618", "65862-619", "65862-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["5263abd5-ce46-4918-9bb0-9632861bcbc9"], "spl_set_id": ["93e6e668-5306-4f26-81d8-cbc3a7a5e787"], "package_ndc": ["65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78"], "unii": ["33067B3N2M"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0009-0017-58", "generic_name": "Triazolam Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA017892"], "brand_name": ["HALCION"], "generic_name": ["TRIAZOLAM"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TRIAZOLAM"], "rxcui": ["198318", "208681"], "spl_id": ["632e2836-1da3-4c6d-a954-e452580587e2"], "spl_set_id": ["a0da0dba-a56d-486b-a45b-e8a7cdfbeac6"], "package_ndc": ["0009-0017-55", "0009-0017-58"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["1HM943223R"]}, "update_date": "09/29/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Halcion, Tablet, .25 mg (NDC 0009-0017-58)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-1015-50", "generic_name": "Amantadine Hydrochloride Capsule", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA070589"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-1015"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849389"], "spl_id": ["398493aa-8a67-10e2-e063-6394a90aef8d"], "spl_set_id": ["5232b933-1df9-43b4-8ac2-61bfa4855e68"], "package_ndc": ["0832-1015-00", "0832-1015-50"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Capsule", "presentation": "Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-50)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"presentation": "Zovia 1/50E-28, Tablet, Kit (NDC 0093-8073-16)", "discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-8073-16", "generic_name": "Ethinyl Estradiol; Ethinyl Diacetate Tablet", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "update_date": "06/13/2025", "therapeutic_category": ["Reproductive"], "status": "To Be Discontinued", "dosage_form": "Tablet", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0763-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0763", "0527-0760", "0527-0761", "0527-0762", "0527-0764", "0527-0765", "0527-0766"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8893-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8893", "0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-04", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"presentation": "Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1559-10", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-250-50", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207183"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-250", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-925-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA212571"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-925", "67457-924"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["b51a1fb0-fcee-4a76-9eaf-91c35813c242"], "spl_set_id": ["f140de5a-f13d-46b4-a742-049c63e474f5"], "package_ndc": ["67457-924-00", "67457-924-50", "67457-925-00", "67457-925-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/11/2024", "package_ndc": "0264-7387-50", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7387"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE"], "rxcui": ["237656"], "spl_id": ["200c4b9e-283a-4dea-b33a-9bb4936b2b99"], "spl_set_id": ["8ccb10fe-75a5-440b-8cd4-b11f4e98f7b0"], "package_ndc": ["0264-7387-50"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0338-0072-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA209900"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0072", "0338-0069", "0338-0076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2da4dd8a-1b18-481d-b733-9c031d9ea7e3"], "spl_set_id": ["4b58836d-9d58-4539-9691-9e11c505ef2a"], "package_ndc": ["0338-0069-10", "0338-0072-25", "0338-0076-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-0090-01", "generic_name": "Carbamazepine Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA070541"], "brand_name": ["EPITOL"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0090"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["211817", "308979"], "spl_id": ["5c31da75-fc21-4ab2-9487-64169767ebd0"], "spl_set_id": ["32bbe864-7374-44da-8c6e-e733f0648243"], "package_ndc": ["0093-0090-01"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "06/10/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Epitol, Tablet, 200 mg (NDC 0093-0090-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-050-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-050", "72305-025", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 50 ug (NDC 72305-050-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "47335-326-08", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-818-4555", "resolved_note": "Available", "openfda": {"application_number": ["ANDA090356"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["b0c2b60a-dc96-483b-933e-2fed58b64372"], "spl_set_id": ["0f30f885-d0cd-4fa6-a8e0-142f08a56792"], "package_ndc": ["47335-326-83", "47335-326-88", "47335-326-08", "47335-326-18"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-08)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "80789-117-50", "generic_name": "Vigabatrin Oral Solution", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/16/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Solution", "presentation": "Vigpoder, Oral Solution, 50 mg/1 mL (NDC 80789-117-50)", "company_name": "Pyros Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-605-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": {"application_number": ["NDA017533"], "brand_name": ["KLONOPIN"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["H2-Pharma, LLC"], "product_ndc": ["61269-605", "61269-610", "61269-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529", "206157", "206159", "206160"], "spl_id": ["63cfdab9-fb3d-4c2b-bf88-8ba841dba839"], "spl_set_id": ["cfa0d79a-843c-4b88-95a1-e9511d649ca1"], "package_ndc": ["61269-605-10", "61269-610-10", "61269-620-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, .5 mg (NDC 61269-605-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/26/2025", "update_type": "New", "initial_posting_date": "06/26/2025", "package_ndc": "0093-5539-01", "generic_name": "Eszopiclone Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA091169"], "brand_name": ["ESZOPICLONE"], "generic_name": ["ESZOPICLONE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5539", "0093-5537", "0093-5538"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ESZOPICLONE"], "rxcui": ["485440", "485442", "485465"], "spl_id": ["efcf4106-ac0a-4f8b-bcd0-743e45e66924"], "spl_set_id": ["2435e2f1-bc52-488f-80e9-f1758e354aae"], "package_ndc": ["0093-5537-56", "0093-5538-01", "0093-5539-01"], "unii": ["UZX80K71OE"]}, "update_date": "06/26/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Eszopiclone, Tablet, 3 mg (NDC 0093-5539-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/11/2024", "package_ndc": "42858-167-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-167", "42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-166"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA075154"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-411", "63323-412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/23/2026", "update_type": "New", "initial_posting_date": "03/23/2026", "package_ndc": "39822-3050-2", "generic_name": "Pentamidine Isethionate Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA206982"], "brand_name": ["PENTAMIDINE ISETHIONATE"], "generic_name": ["PENTAMIDINE ISETHIONATE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-3050"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PENTAMIDINE ISETHIONATE"], "rxcui": ["861601"], "spl_id": ["0fcb7bdf-013e-a77c-e063-6394a90ad20f"], "spl_set_id": ["860c799c-5199-4f0c-b21b-9910273474d9"], "package_ndc": ["39822-3050-2"], "unii": ["V2P3K60DA2"]}, "update_date": "03/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Pentamidine Isethionate, Injection, 300 mg/3 mL (NDC 39822-3050-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0169-7703-21", "generic_name": "Somatropin Injection", "contact_info": "833-493-4689", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["BLA021148"], "brand_name": ["NORDITROPIN"], "generic_name": ["SOMATROPIN"], "manufacturer_name": ["Novo Nordisk"], "product_ndc": ["0169-7703", "0169-7704", "0169-7705", "0169-7708"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["SOMATROPIN"], "rxcui": ["847243", "847245", "847247", "847348", "849850", "849851", "1736262", "1736329"], "spl_id": ["b67c2419-4feb-4ce1-b97e-88760a8e1aee"], "spl_set_id": ["1058e17c-9261-459c-a3e6-fae38d196c14"], "package_ndc": ["0169-7704-21", "0169-7704-92", "0169-7705-21", "0169-7705-92", "0169-7708-21", "0169-7708-92", "0169-7703-11", "0169-7703-91", "0169-7703-21", "0169-7703-92"], "nui": ["N0000175606", "M0028842"], "pharm_class_epc": ["Recombinant Human Growth Hormone [EPC]"], "pharm_class_cs": ["Human Growth Hormone [CS]"], "unii": ["NQX9KB6PCL"]}, "update_date": "11/14/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0764-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0764", "0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0765", "0527-0766"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-708-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-708", "13811-709", "13811-706", "13811-707", "13811-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-517-36", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-517", "61314-454", "61314-473", "61314-476", "61314-509", "61314-531"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, Kit (NDC 61314-517-36)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0480-7270-98", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077793"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-7270"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904481"], "spl_id": ["95e8c960-5096-43a9-8807-89cdf404a214"], "spl_set_id": ["f66cb1c1-5ff1-4b0b-89d0-8ecaee26b0b8"], "package_ndc": ["0480-7270-98", "0480-7270-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-05", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-799", "42806-801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-05)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "66794-229-41", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-414-1901", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA210437"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM"], "manufacturer_name": ["Piramal Critical Care Inc"], "product_ndc": ["66794-229", "66794-228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["3f9e12e4-d3c5-fba6-e063-6294a90a7fd6"], "spl_set_id": ["98255b70-51f9-8d16-e053-2995a90a8f97"], "package_ndc": ["66794-229-02", "66794-229-41", "66794-228-02", "66794-228-41"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)", "company_name": "Piramal Critical Care Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3289-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Unavailable", "related_info": "Estimated full recovery: August 2026", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3289", "0781-3288", "0781-3290"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a"], "spl_set_id": ["231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca"], "package_ndc": ["0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)", "company_name": "Sandoz Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/17/2023", "change_date": "01/27/2026", "package_ndc": "0054-0389-25", "generic_name": "Methamphetamine Hydrochloride Tablet", "contact_info": "800-631-2174", "resolved_note": "Available", "openfda": {"application_number": ["ANDA203846"], "brand_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "generic_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0389"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "rxcui": ["977860"], "spl_id": ["9f3c9287-0615-4d2e-823d-673b33586e06"], "spl_set_id": ["90c02ac6-e5e2-4c97-8c68-81e4e389a195"], "package_ndc": ["0054-0389-25"], "unii": ["997F43Z9CV"]}, "update_date": "01/27/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 0054-0389-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-191-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-191", "11534-190", "11534-192", "11534-193", "11534-194", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-588-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": {"application_number": ["NDA021121"], "brand_name": ["CONCERTA"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-588", "50458-585", "50458-586", "50458-587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212"], "spl_id": ["64d7c1e1-e7ed-4d74-a44d-13b4da64af9a"], "spl_set_id": ["1a88218c-5b18-4220-8f56-526de1a276cd"], "package_ndc": ["50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0472-0803-02", "generic_name": "Desonide Lotion", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA072354"], "brand_name": ["DESONIDE"], "generic_name": ["DESONIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-0803", "0472-0804"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DESONIDE"], "rxcui": ["197572", "349351"], "spl_id": ["f3953b9e-138f-4d86-8eea-0fc03c3c2747"], "spl_set_id": ["ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99"], "package_ndc": ["0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["J280872D1O"]}, "update_date": "09/18/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Lotion", "presentation": "Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-02)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-385-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9391-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA210594"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9391", "0143-9392", "0143-9393"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["5c5e498b-d829-4f78-bcca-466631014767"], "spl_set_id": ["9d289052-1eb6-4ba2-a3ca-d2e542a052ae"], "package_ndc": ["0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10"], "unii": ["5V444H5WIC"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/04/2025", "update_type": "New", "initial_posting_date": "12/04/2025", "package_ndc": "0093-7352-01", "generic_name": "Calcitriol Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug", "openfda": {"application_number": ["ANDA075765"], "brand_name": ["CALCITRIOL"], "generic_name": ["CALCITRIOL"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7352", "0093-7353"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CALCITRIOL"], "rxcui": ["308867", "308868"], "spl_id": ["9e6df585-e3d1-4a89-bc02-8e4b223578c4"], "spl_set_id": ["ec93b667-aad2-4e3a-adc6-952f070a0c0a"], "package_ndc": ["0093-7352-01", "0093-7353-01"], "nui": ["M0004229", "N0000175908"], "pharm_class_cs": ["Cholecalciferol [CS]"], "pharm_class_epc": ["Vitamin D3 Analog [EPC]"], "unii": ["FXC9231JVH"]}, "update_date": "12/04/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Calcitriol, Capsule, .25 ug (NDC 0093-7352-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-150-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-150", "61703-360", "61703-262", "61703-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["5aa72c15-8033-4559-b257-373371b18958"], "spl_set_id": ["47677091-fd20-49af-933c-c9dd2be21de9"], "package_ndc": ["61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8235-05", "generic_name": "Insulin Lispro-aabc Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["BLA761109"], "brand_name": ["LYUMJEV TEMPO PEN"], "generic_name": ["INSULIN LISPRO-AABC"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8235", "0002-7728", "0002-7726", "0002-8207", "0002-8351", "0002-8228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN LISPRO"], "rxcui": ["2380231", "2380236", "2380248", "2380250", "2380254", "2380256", "2380259", "2380260", "2380265", "2380266", "2380267", "2380268"], "spl_id": ["567d0b77-239e-4a05-9d84-8364e0e1ef7a"], "spl_set_id": ["c5a056e2-b568-4ca6-9ed8-79c010942d00"], "package_ndc": ["0002-7728-01", "0002-7728-99", "0002-7726-01", "0002-7726-05", "0002-8207-01", "0002-8207-05", "0002-8207-61", "0002-8351-01", "0002-8351-05", "0002-8235-01", "0002-8235-05", "0002-8235-99", "0002-8228-01", "0002-8228-27"], "nui": ["N0000004931", "N0000175453"], "pharm_class_cs": ["Insulin [Chemical/Ingredient]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["GFX7QIS1II"]}, "update_date": "10/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-112-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-112", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 112 ug (NDC 72305-112-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-254-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-254", "55150-251", "55150-252", "55150-255", "55150-253", "55150-256"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-491-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE MPF"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-491", "63323-492", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-350-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-350", "61703-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"], "spl_set_id": ["0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab"], "package_ndc": ["61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "0409-1403-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1403", "0409-5160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["f01f9986-43f9-40e8-9506-11bfe78f9242"], "spl_set_id": ["f01f9986-43f9-40e8-9506-11bfe78f9242"], "package_ndc": ["0409-1403-05", "0409-1403-10", "0409-5160-01", "0409-5160-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4916-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-61", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "83634-302-02", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Avenacy Inc."], "product_ndc": ["83634-302"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1b3f2803-b618-4447-b5ac-cd2bdc7de3e8"], "spl_set_id": ["7d0db0f7-bf4f-4b0b-9359-2a838626e04b"], "package_ndc": ["83634-302-42", "83634-302-02", "83634-302-43", "83634-302-04", "83634-302-41", "83634-302-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL; 2mL vial (NDC 83634-302-02)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-820-05", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Estimated availability: May 2026", "openfda": {"application_number": ["ANDA201835"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-820", "25021-821"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["13e1ca54-4fc4-4e93-a52d-c9320865e3cb"], "spl_set_id": ["f98314ea-a4e4-4f78-987b-3e9b45a08bb4"], "package_ndc": ["25021-820-05", "25021-820-10", "25021-821-05"], "unii": ["43502P7F0P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-410-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": {"application_number": ["ANDA205823"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Solco Healthcare US, LLC"], "product_ndc": ["43547-410", "43547-411", "43547-412", "43547-413"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["b8f1731a-cbac-4f64-a8d4-320b80b335e1"], "spl_set_id": ["cd46691d-5593-4a9f-a937-999c6803e312"], "package_ndc": ["43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/20/2026", "update_type": "New", "initial_posting_date": "04/20/2026", "package_ndc": "0068-0597-01", "generic_name": "Rifampin Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050627"], "brand_name": ["RIFADIN IV"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Sanofi-Aventis U.S. LLC"], "product_ndc": ["0068-0597"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["RIFAMPIN"], "rxcui": ["207436", "312821"], "spl_id": ["d5ee3f24-779e-4fd0-ba26-e870acbd1111"], "spl_set_id": ["036ab68e-5085-4edc-bd83-784b43d64eab"], "package_ndc": ["0068-0597-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5814-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA090866"], "brand_name": ["VALSARTAN"], "generic_name": ["VALSARTAN"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-5814", "0378-5807", "0378-5813", "0378-5815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VALSARTAN"], "rxcui": ["349199", "349200", "349201", "349483"], "spl_id": ["a5384d58-48c7-494a-a8a8-c296b316bd91"], "spl_set_id": ["73e01dc6-7dd4-421a-a4f6-137e75f69f9a"], "package_ndc": ["0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77"], "nui": ["N0000000070", "N0000175561"], "pharm_class_moa": ["Angiotensin 2 Receptor Antagonists [MoA]"], "pharm_class_epc": ["Angiotensin 2 Receptor Blocker [EPC]"], "unii": ["80M03YXJ7I"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 160 mg (NDC 0378-5814-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2022", "package_ndc": "76204-027-01", "generic_name": "Albuterol Sulfate Solution", "contact_info": "803-806-3300", "availability": "Available", "openfda": {"application_number": ["ANDA218386"], "brand_name": ["ALBUTEROL SULFATE INHALATION SOLUTION, 0.5%"], "generic_name": ["ALBUTEROL SULFATE"], "manufacturer_name": ["Ritedose Pharmaceuticals, LLC"], "product_ndc": ["76204-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["ALBUTEROL SULFATE"], "rxcui": ["245314"], "spl_id": ["4e7f86ab-55bc-c123-e063-6394a90abd8d"], "spl_set_id": ["fdb4ac5a-bf0d-4896-89f7-1828c081b79e"], "package_ndc": ["76204-027-11", "76204-027-01"], "unii": ["021SEF3731"]}, "update_date": "05/04/2026", "therapeutic_category": ["Pediatric", "Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)", "company_name": "Ritedose Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "55150-335-01", "generic_name": "Carboplatin Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; check wholesalers for inventory", "openfda": {"application_number": ["ANDA205487"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-335", "55150-333", "55150-334", "55150-386"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["6029d051-ee8d-44cc-8dae-b91c3385d4c3", "5abfcb87-bb02-4384-9c9d-7d0e3e809311"], "spl_set_id": ["f5fe9a20-47a5-45b9-ab06-c6158d9b6aca", "5abfcb87-bb02-4384-9c9d-7d0e3e809311"], "package_ndc": ["55150-333-01", "55150-334-01", "55150-335-01", "55150-386-01", "55150-335-00", "55150-386-00"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4244-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA077269"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4244", "0703-4246", "0703-4248", "0703-4239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c"], "spl_set_id": ["f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37"], "package_ndc": ["0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-11", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-407", "43547-406", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-11)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4902-34", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0591-5553-50", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA062421"], "brand_name": ["DOXYCYCLINE HYCLATE"], "generic_name": ["DOXYCYCLINE HYCLATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5553"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DOXYCYCLINE HYCLATE"], "rxcui": ["1650143"], "spl_id": ["0fb9a3f8-9ebb-4c21-8a73-9f082b39039c"], "spl_set_id": ["a569ba80-ffea-40b2-9fbe-a42810b1fccb"], "package_ndc": ["0591-5553-50", "0591-5553-05"], "unii": ["19XTS3T51U"]}, "update_date": "06/13/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0338-0431-03", "generic_name": "Heparin Sodium Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018609"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0431", "0338-0433", "0338-0424", "0338-0428"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["68b37381-6db4-4ac0-ba6b-3204add02665"], "spl_set_id": ["0d929726-76c3-48fc-b4e7-fd06409f9fb3"], "package_ndc": ["0338-0431-03", "0338-0433-04", "0338-0424-18", "0338-0428-12"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/20/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/04/2025", "update_type": "New", "initial_posting_date": "06/04/2025", "package_ndc": "0003-3638-10", "generic_name": "Atazanavir Sulfate Oral Powder", "contact_info": "1-800-332-2056; for Medical Inquiries (1-800-321-1335)", "related_info": "Permanent discontinuation", "openfda": {"application_number": ["NDA206352"], "brand_name": ["REYATAZ"], "generic_name": ["ATAZANAVIR"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "product_ndc": ["0003-3638", "0003-3624", "0003-3631", "0003-3622"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ATAZANAVIR SULFATE"], "rxcui": ["402093", "402094", "402246", "402247", "664741", "664743", "1598985", "1598989"], "spl_id": ["510c2d51-4943-401c-a008-ea22f61c6938"], "spl_set_id": ["165cff62-b284-4a27-a65d-9ec8a5bfcdd8"], "package_ndc": ["0003-3624-12", "0003-3631-12", "0003-3622-12", "0003-3638-10"], "unii": ["4MT4VIE29P"]}, "update_date": "06/04/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Oral Powder", "presentation": "Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "0409-9633-05", "generic_name": "Verapamil Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075136"], "brand_name": ["VERAPAMIL HYDROCHLORIDE"], "generic_name": ["VERAPAMIL HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9633", "0409-1144", "0409-4011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VERAPAMIL HYDROCHLORIDE"], "spl_id": ["fec5ce65-a6c8-4945-9f22-47b00be775ba"], "spl_set_id": ["1c993365-1b62-4524-e781-d307f28f63bc"], "package_ndc": ["0409-1144-62", "0409-1144-02", "0409-1144-65", "0409-1144-05", "0409-4011-61", "0409-4011-01", "0409-9633-65", "0409-9633-05"], "unii": ["V3888OEY5R"]}, "update_date": "11/21/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-38", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-176-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Unavailable", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 10 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-176", "47781-174", "47781-175", "47781-177", "47781-178", "47781-179", "47781-180"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-6535-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA062933"], "brand_name": ["VANCOMYCIN HYDROCHLORIDE"], "generic_name": ["VANCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6535", "0409-6531", "0409-6534"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VANCOMYCIN HYDROCHLORIDE"], "rxcui": ["1807513", "1807516", "1807518"], "spl_id": ["771a44e0-5858-449c-be36-438a9ff52e67"], "spl_set_id": ["2fd9de3f-a95f-451c-a687-d2e1306e53bf"], "package_ndc": ["0409-6531-11", "0409-6531-01", "0409-6535-11", "0409-6535-01", "0409-6534-11", "0409-6534-01"], "unii": ["71WO621TJD"]}, "update_date": "09/09/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 1 g Single Dose ADD-Vantage® Glass Vial (NDC 0409-6535-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9506-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9506", "0143-9507"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["98560882-bfdf-404e-ab8b-3ee2a6875830"], "spl_set_id": ["75bf0494-7cb9-4e8a-8edd-af62f035d236"], "package_ndc": ["0143-9506-01", "0143-9506-10", "0143-9507-01", "0143-9507-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-179-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Unavailable", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 20 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-179", "47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-180"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "47335-326-83", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-818-4555", "resolved_note": "Available", "openfda": {"application_number": ["ANDA090356"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["b0c2b60a-dc96-483b-933e-2fed58b64372"], "spl_set_id": ["0f30f885-d0cd-4fa6-a8e0-142f08a56792"], "package_ndc": ["47335-326-83", "47335-326-88", "47335-326-08", "47335-326-18"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-83)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-18", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: September 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-339"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0ddf4411-7138-412a-908a-fadf22bdfb79"], "spl_set_id": ["c3ae9880-44bb-4f4e-93d8-8a5e21708a30"], "package_ndc": ["61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/03/2023", "package_ndc": "42571-132-52", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(908) 484-7410", "availability": "Available", "openfda": {"application_number": ["ANDA202745"], "brand_name": ["CROMOLYN SODIUM"], "generic_name": ["CROMOLYN SODIUM"], "manufacturer_name": ["Micro Labs Limited"], "product_ndc": ["42571-132"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261"], "spl_id": ["22ffea9c-cd39-22dd-e063-6394a90aae4b"], "spl_set_id": ["93f80edb-3b38-423e-8cd6-5b5cb4393ec2"], "package_ndc": ["42571-132-21", "42571-132-52"], "unii": ["Q2WXR1I0PK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)", "company_name": "Micro Labs LTD", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "60505-0815-0", "generic_name": "Desmopressin Acetate Spray", "contact_info": "800-706-5575", "availability": "Available", "openfda": {"application_number": ["ANDA076703"], "brand_name": ["DESMOPRESSIN ACETATE"], "generic_name": ["DESMOPRESSIN ACETATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-0815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["NASAL"], "substance_name": ["DESMOPRESSIN ACETATE"], "rxcui": ["849506"], "spl_id": ["f90935bd-bb23-2f9c-3271-8508e92d45c4"], "spl_set_id": ["1ac423b8-27a6-4cef-4a82-c50bf81b4f49"], "package_ndc": ["60505-0815-0"], "unii": ["XB13HYU18U"]}, "update_date": "05/08/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Spray", "presentation": "Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)", "company_name": "Apotex Corp.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/01/2026", "update_type": "New", "initial_posting_date": "04/01/2026", "package_ndc": "61474-9711-1", "generic_name": "Icosapent Ethyl Capsule", "contact_info": "800-706-5575", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Icosapent Ethyl, Capsule, 1 g (NDC 61474-9711-1)", "company_name": "Apotex Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6042-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA075772"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6042", "0641-6043", "0641-6041"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["25d6c438-45d2-4162-91c2-b5caa0f86bf3"], "spl_set_id": ["0c2c75c9-ed7b-46a8-9543-429bf2d8f090"], "package_ndc": ["0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-163-30", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-163", "55150-161", "55150-162", "55150-164", "55150-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0220-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-128-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/06/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 10 mg (NDC 49884-128-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-164-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-164", "55150-161", "55150-162", "55150-163", "55150-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5116-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5116", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9630-05", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021146"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9630", "0409-1630", "0409-4910", "0409-4911"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["ab573c15-9504-48d1-bf4a-d8b8d7ae748a"], "spl_set_id": ["ad8916e7-206e-409e-2582-30d072845dd4"], "package_ndc": ["0409-1630-15", "0409-1630-10", "0409-9630-15", "0409-9630-05", "0409-4910-11", "0409-4910-34", "0409-4911-11", "0409-4911-34"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4275-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA088325"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4275", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4664-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4664", "0527-4661", "0527-4662", "0527-4663", "0527-4665", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "63323-725-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206223"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-725", "63323-723", "63323-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["2f27e51f-2b55-47ee-bd4a-001b71c60622"], "spl_set_id": ["d2374b84-81c9-44f9-a4a9-1071281b2531"], "package_ndc": ["63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10"], "unii": ["5V444H5WIC"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "69489-721-05", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018738"], "brand_name": ["EXELDERM"], "generic_name": ["SULCONAZOLE NITRATE"], "manufacturer_name": ["Journey Medical Corporation"], "product_ndc": ["69489-721"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["SULCONAZOLE NITRATE"], "rxcui": ["208118", "313125"], "spl_id": ["af026933-9a3d-4027-90f6-57fe4349d11e"], "spl_set_id": ["5b73e83e-8d3c-4d96-b4f6-9f854430add8"], "package_ndc": ["69489-721-30", "69489-721-05"], "unii": ["1T89100D5U"]}, "update_date": "05/08/2026", "therapeutic_category": ["Dermatology"], "dosage_form": "Solution", "presentation": "Exelderm, Solution, 1.0% 5 mL (NDC 69489-721-05)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-724-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-724", "59651-722", "59651-723"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 59651-724-01)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3181-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089645"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3181", "0409-1209", "0409-3177", "0409-3178", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-050-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-050", "72305-025", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 50 ug (NDC 72305-050-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-531-64", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-531", "61314-454", "61314-473", "61314-476", "61314-509", "61314-517"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, Kit (NDC 61314-531-64)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075604"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-720", "62037-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["1801294", "1801298"], "spl_id": ["01fbdb24-0987-40f6-a920-f36349f6ba61"], "spl_set_id": ["db002ae3-f54c-40a4-9cb4-e5681bf426e3"], "package_ndc": ["62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10"], "unii": ["660YQ98I10"]}, "update_date": "11/21/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9045-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071168"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9045", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4776-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA080408"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4776", "0409-4713", "0409-4278", "0409-4279", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-159-74", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA203040"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-159", "55150-158", "55150-160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737566", "1737568", "1737757"], "spl_id": ["cc439f66-fdd6-41f9-8a08-3f623898f20c"], "spl_set_id": ["5524cbfd-d6e6-42eb-aaa5-22495e0a86b6"], "package_ndc": ["55150-158-72", "55150-159-74", "55150-160-72"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)", "company_name": "Eugia US LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8894-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8894", "0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8893"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5315-11", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5315", "0245-5316"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "43066-023-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Limited supply; Check wholesalers for inventory; Marketed by Baxter", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-023", "43066-015", "43066-019", "43066-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734084", "1734207", "1734475", "1734483"], "spl_id": ["a8d08579-825f-40d9-b1e3-e47b73765ae6"], "spl_set_id": ["781d4b7f-7556-4695-8d48-7772d7a0d8e9"], "package_ndc": ["43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10"], "unii": ["V910P86109"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)", "company_name": "Caplin Steriles, Ltd.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0990-6139-03", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "Allocated to Contracted Customers Only. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6139-03", "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-170-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-170", "55150-167", "55150-168", "55150-169", "55150-171", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0990-4178-03", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-4178-03", "openfda": {"application_number": ["NDA019398"], "brand_name": ["AMINOSYN-PF"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-4178"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["831426", "831430"], "spl_id": ["488d78ac-3cd2-4593-8968-2992fe59bb49"], "spl_set_id": ["2d212e10-7e08-4aeb-b63f-dcc927897769"], "package_ndc": ["0990-4178-03"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0409-6695-02", "generic_name": "Etomidate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018227"], "brand_name": ["AMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6695"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008", "1654009", "1654011"], "spl_id": ["b59f4852-2843-4a8f-a597-306ebddb259a"], "spl_set_id": ["b7ed5bf8-ba75-44dc-8f81-96b4ad5766be"], "package_ndc": ["0409-6695-11", "0409-6695-01", "0409-6695-12", "0409-6695-02"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1418-01", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Shortage per Manufacturer: Manufacturing Delay", "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-064-01", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-064", "65862-062", "65862-063"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-01)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6127-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA205758"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6127", "0641-6126", "0641-6125"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011"], "spl_id": ["fa18221d-2353-4cf6-a210-fb33ee79d3d9"], "spl_set_id": ["6023606c-150c-40c5-9175-598efe2a56c3"], "package_ndc": ["0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/24/2025", "package_ndc": "82154-0449-1", "generic_name": "Peginterferon alfa-2a Injection", "contact_info": "800-506-8501, email: medinfo.us@pharmaand.com", "availability": "Limited Availability", "related_info": "Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.", "openfda": {"application_number": ["BLA103964"], "brand_name": ["PEGASYS"], "generic_name": ["PEGINTERFERON ALFA-2A"], "manufacturer_name": ["pharmaand GmbH"], "product_ndc": ["82154-0449", "82154-0451"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PEGINTERFERON ALFA-2A"], "rxcui": ["351270", "352297", "731326", "731328"], "spl_id": ["3c18e4a2-193f-ef4e-e063-6394a90a56b2"], "spl_set_id": ["d9290e5b-6d40-2318-e053-2995a90a9916"], "package_ndc": ["82154-0449-1", "82154-0451-4"], "nui": ["N0000175521", "M0025711"], "pharm_class_epc": ["Interferon alpha [EPC]"], "pharm_class_cs": ["Interferon-alpha [CS]"], "unii": ["Q46947FE7K"]}, "update_date": "08/19/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)", "company_name": "pharmaand GmbH (pharma&)", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0025-0325-01", "generic_name": "Adalimumab-afzb Injection", "contact_info": "800-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["BLA761118"], "brand_name": ["ABRILADA"], "generic_name": ["ADALIMUMAB-AFZB"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0025-0325", "0025-0328", "0025-0333", "0025-0347", "0025-0319"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["797544", "2668064", "2668071", "2668074", "2668078", "2668095", "2668096", "2668105", "2668106", "2668109", "2668113"], "spl_id": ["0989d777-c225-46a6-854e-01bdf4f19679"], "spl_set_id": ["5ef1c7cf-466f-495e-8d13-82e2ddfa7a4f"], "package_ndc": ["0025-0325-01", "0025-0325-02", "0025-0318-01", "0069-1111-01", "0025-0328-01", "0025-0328-02", "0025-0317-01", "0025-0333-02", "0025-0329-01", "0025-0347-02", "0025-0331-01", "0025-0319-01"]}, "update_date": "10/09/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Abrilada, Injection, Kit (NDC 0025-0325-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1163-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070597"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1163", "0409-1159", "0409-1160", "0409-1162", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-1", "generic_name": "Carboplatin Injection", "related_info_link": "https://dps.fda.gov/drugshortages/discontinuations/carboplatin-injection", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Available", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.)", "openfda": {"application_number": ["ANDA077861"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-6282"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0e68e276-b0df-4f03-e063-6394a90a22b9"], "spl_set_id": ["1c275825-0275-4c73-b650-e4c1519f13b8"], "package_ndc": ["60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)", "company_name": "Teyro Labs", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-3051-02", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA208129"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["27411591-44a1-44c4-89c3-dd8c2687f0e2"], "spl_set_id": ["4d5d2294-89a0-4b6f-aa00-d39a0393b6a8"], "package_ndc": ["63323-671-02", "63323-671-20", "63323-671-05", "63323-671-50", "63323-671-01", "63323-671-00"], "unii": ["1018WH7F9I"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "16729-526-08", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/28/2025", "update_type": "New", "initial_posting_date": "05/28/2025", "package_ndc": "0472-0804-15", "generic_name": "Desonide Cream", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA019048"], "brand_name": ["DESONIDE"], "generic_name": ["DESONIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-0804", "0472-0803"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DESONIDE"], "rxcui": ["197572", "349351"], "spl_id": ["f3953b9e-138f-4d86-8eea-0fc03c3c2747"], "spl_set_id": ["ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99"], "package_ndc": ["0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["J280872D1O"]}, "update_date": "05/28/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Cream", "presentation": "Desowen, Cream, .5 mg/1 g (NDC 0472-0804-15)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7766-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210050"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7766", "0093-7767", "0093-7768", "0093-7769"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["aa521933-950a-441b-9146-93e479a4dde7"], "spl_set_id": ["e3bca36b-29ed-4a2b-a1be-a57b6af805f6"], "package_ndc": ["0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "03/02/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9595-25", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA084625"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9595", "0143-9594"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737566", "1737761"], "spl_id": ["a7da0a25-5efb-48fa-9063-f7c0423f820f"], "spl_set_id": ["1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1"], "package_ndc": ["0143-9595-01", "0143-9595-25", "0143-9594-01", "0143-9594-25"], "unii": ["V13007Z41A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-408-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-408", "43547-406", "43547-407"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 43547-408-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0069-1975-40", "generic_name": "Tafamidis Meglumine Capsule", "contact_info": "800-879-3477", "related_info": "Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025.", "openfda": {"application_number": ["NDA211996"], "brand_name": ["VYNDAQEL"], "generic_name": ["TAFAMIDIS MEGLUMINE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-1975", "0069-8730"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TAFAMIDIS MEGLUMINE"], "spl_id": ["67f1031d-c298-4cf9-9051-bb8f99e56442"], "spl_set_id": ["1b4121ee-a733-4456-a917-be2603477839"], "package_ndc": ["0069-1975-12", "0069-1975-40", "0069-8730-01", "0069-8730-30"], "unii": ["8FG9H9D31J", "ZU7CF08A1A"]}, "update_date": "09/29/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-1975-40)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72266-147-10", "generic_name": "Etomidate Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": {"application_number": ["ANDA209058"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE INJECTION"], "manufacturer_name": ["Fosun Pharma USA Inc"], "product_ndc": ["72266-147", "72266-146"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["2b365133-b609-3285-e063-6394a90a69a6"], "spl_set_id": ["8b6c54d8-3f3f-4290-841c-976bea01086f"], "package_ndc": ["72266-146-01", "72266-146-10", "72266-147-01", "72266-147-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0472-1030-16", "generic_name": "Homatropine Methylbromide and Hydrocodone Bitartrate Syrup", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA088017"], "brand_name": ["HYDROMET"], "generic_name": ["HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-1030"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HOMATROPINE METHYLBROMIDE", "HYDROCODONE BITARTRATE"], "rxcui": ["992668", "992675"], "spl_id": ["7937f983-1f1c-475b-ab10-76a582d1bedd"], "spl_set_id": ["a324c912-a3ef-4296-b9a8-b0fec687eb06"], "package_ndc": ["0472-1030-16"], "unii": ["68JRS2HC1C", "NO70W886KK"]}, "update_date": "09/11/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Syrup", "presentation": "Hydromet, Syrup, 1.5 mg/5 mL; 5 mg/5 mL (NDC 0472-1030-16)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-727-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA076655"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-727", "62037-725", "62037-734", "62037-726"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "spl_id": ["24aa9277-3773-489d-8459-f9215140c53f"], "spl_set_id": ["85ef422d-af27-4126-9841-6892af1871d6"], "package_ndc": ["62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/21/2020", "package_ndc": "16729-306-10", "generic_name": "Azacitidine Injection", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA207475"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["28604daf-46a3-ef6c-e063-6394a90a4b27"], "spl_set_id": ["70140e11-33f1-2240-e053-2991aa0a0480"], "package_ndc": ["16729-306-10"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 16729-306-10)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1165-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070585"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1165", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-61", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-61", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "16729-239-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexmedetomidine%20Hydrochloride%20Injection&st=d", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA204023"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["2de0daf8-b7a3-1dca-e063-6394a90a4d0a"], "spl_set_id": ["2b9881f0-4a66-660f-e054-00144ff88e88"], "package_ndc": ["16729-239-30", "16729-239-93"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-400-11", "generic_name": "Insulin Degludec Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Degludec 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA203314"], "brand_name": ["INSULIN DEGLUDEC"], "generic_name": ["INSULIN DEGLUDEC"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-400", "73070-403", "73070-503"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN DEGLUDEC"], "rxcui": ["1670011", "1670021", "2107520"], "spl_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "spl_set_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "package_ndc": ["73070-403-15", "73070-503-15", "73070-400-11"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["54Q18076QB"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Degludec, Injection, 10 mL Insulin Degludec vial (NDC 73070-400-11)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-76", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE AQUA"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0521"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["0bc2d27e-e0d0-4c85-a5e1-808c625b6f93"], "spl_set_id": ["c85dc235-3f42-4361-9bd2-1aaff798ad75"], "package_ndc": ["0574-0521-04", "0574-0521-08", "0574-0521-25", "0574-0521-74", "0574-0521-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-154", "72888-152", "72888-153"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-01)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA074086"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["e71e9520-871b-479d-9652-1857fceca863", "5d6b1dfe-d679-4aea-97a6-3d074a202afe"], "spl_set_id": ["dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58"], "package_ndc": ["0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-31", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4713-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA080408"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9412-92", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA062738"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9412", "0781-9413"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["1721475", "1721476"], "spl_id": ["f1afd007-8e8c-40e2-b353-8def35a0ce8b"], "spl_set_id": ["f77db491-31c4-4a7c-a114-0f3244c97090"], "package_ndc": ["0781-9412-15", "0781-9412-92", "0781-9413-15", "0781-9413-92"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/17/2025", "update_type": "New", "initial_posting_date": "11/17/2025", "package_ndc": "78206-170-01", "generic_name": "Montelukast Sodium Tablet, Chewable", "contact_info": "844-674-3200", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020830"], "brand_name": ["SINGULAIR"], "generic_name": ["MONTELUKAST SODIUM"], "manufacturer_name": ["Organon LLC"], "product_ndc": ["78206-170", "78206-171", "78206-173", "78206-172"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["MONTELUKAST SODIUM"], "rxcui": ["153892", "153893", "200224", "242438", "261367", "311759", "351246", "404406"], "spl_id": ["57a12189-3bb3-4a5d-b5fe-fc57db87c134"], "spl_set_id": ["482dcc92-b47f-4ea6-854a-f5ac2aea7842"], "package_ndc": ["78206-171-01", "78206-170-01", "78206-173-01", "78206-172-01", "78206-172-02"], "unii": ["U1O3J18SFL"]}, "update_date": "11/17/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Tablet, Chewable", "presentation": "Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01)", "company_name": "Organon", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5807-93", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA090866"], "brand_name": ["VALSARTAN"], "generic_name": ["VALSARTAN"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-5807", "0378-5813", "0378-5814", "0378-5815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VALSARTAN"], "rxcui": ["349199", "349200", "349201", "349483"], "spl_id": ["a5384d58-48c7-494a-a8a8-c296b316bd91"], "spl_set_id": ["73e01dc6-7dd4-421a-a4f6-137e75f69f9a"], "package_ndc": ["0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77"], "nui": ["N0000000070", "N0000175561"], "pharm_class_moa": ["Angiotensin 2 Receptor Antagonists [MoA]"], "pharm_class_epc": ["Angiotensin 2 Receptor Blocker [EPC]"], "unii": ["80M03YXJ7I"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 40 mg (NDC 0378-5807-93)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3410-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA208084"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-3410", "0338-3612", "0338-3814"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["c8906ab2-37d2-4fde-9784-0442bf7b9565"], "spl_set_id": ["78832ac6-04c5-45e0-ae4d-f56d7920dda9"], "package_ndc": ["0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-137-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-137", "16729-136", "16729-138"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 16729-137-00)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72572-161-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Distributed by Civica", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Civica, Inc."], "product_ndc": ["72572-161", "72572-160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["380f0c88-03f8-4cfa-8823-4766c2f7700c"], "spl_set_id": ["98002094-f065-4b5f-963f-2c34b5241316"], "package_ndc": ["72572-160-01", "72572-160-10", "72572-161-01", "72572-161-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-02", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016694"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0023", "0338-0017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-408-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-408", "43547-406", "43547-407"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 43547-408-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-560-01", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-560", "62037-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-599-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": {"application_number": ["ANDA214456"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Alembic Pharmaceuticals Inc."], "product_ndc": ["62332-599", "62332-600", "62332-601"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["9030f496-5021-4454-ac16-dbb376315608"], "spl_set_id": ["419cf756-3c96-4bb8-ae96-6aea5a5f3afd"], "package_ndc": ["62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/15/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "63323-426-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA078651"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-426"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["d6e2ff8d-838d-4c27-8e73-230548b09d63", "3f4d5e11-2c14-4406-8954-04dba2fc65ff"], "spl_set_id": ["f1933332-1ae0-4dc1-be4c-694849e6c9f9", "fb9524b2-c353-4747-8954-7ca2529eabb2"], "package_ndc": ["63323-426-02", "63323-426-05", "63323-426-01", "63323-426-10", "63323-426-12", "63323-426-15"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/27/2025", "update_type": "New", "initial_posting_date": "06/27/2025", "package_ndc": "0591-3713-19", "generic_name": "Ezetimibe Tablet", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the product", "openfda": {"application_number": ["ANDA200831"], "brand_name": ["EZETIMIBE"], "generic_name": ["EZETIMIBE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3713"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EZETIMIBE"], "rxcui": ["349556"], "spl_id": ["24aaf5ca-08e0-4db8-9734-cf2a606f8e57"], "spl_set_id": ["f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba"], "package_ndc": ["0591-3713-30", "0591-3713-19", "0591-3713-05"], "nui": ["N0000008553", "N0000175911"], "pharm_class_pe": ["Decreased Cholesterol Absorption [PE]"], "pharm_class_epc": ["Dietary Cholesterol Absorption Inhibitor [EPC]"], "unii": ["EOR26LQQ24"]}, "update_date": "06/27/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Ezetimibe, Tablet, 10 mg (NDC 0591-3713-19)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-116-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-116", "70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-03", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016694"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0023", "0338-0017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-006-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X10ML) is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/17/2025", "update_type": "New", "initial_posting_date": "10/17/2025", "package_ndc": "0006-3074-02", "generic_name": "Elbasvir; Grazoprevir Tablet", "contact_info": "800-672-6372", "related_info": "To be discontinued December 1, 2025", "openfda": {"application_number": ["NDA208261"], "brand_name": ["ZEPATIER"], "generic_name": ["ELBASVIR AND GRAZOPREVIR"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "product_ndc": ["0006-3074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ELBASVIR", "GRAZOPREVIR ANHYDROUS"], "rxcui": ["1734636", "1734642"], "spl_id": ["227ae348-5f6f-44d8-a6dc-103e63d28102"], "spl_set_id": ["164dc02a-9180-426a-b8b5-04ab39d2bbd4"], "package_ndc": ["0006-3074-01", "0006-3074-02"], "nui": ["N0000191256", "N0000190113", "N0000182638", "N0000182639", "N0000190114"], "pharm_class_epc": ["Hepatitis C Virus NS5A Inhibitor [EPC]", "Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]"], "pharm_class_moa": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "HCV NS3/4A Protease Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["632L571YDK", "8YE81R1X1J"]}, "update_date": "10/17/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Zepatier, Tablet, 50 mg; 100 mg (NDC 0006-3074-02)", "company_name": "Merck Sharp & Dohme LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3465-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": {"application_number": ["ANDA206812"], "brand_name": ["FONDAPARINUX SODIUM"], "generic_name": ["FONDAPARINUX SODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3465", "0781-3443", "0781-3454", "0781-3476"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FONDAPARINUX SODIUM"], "rxcui": ["861356", "861360", "861363", "861365"], "spl_id": ["3d5a4b69-462b-7e51-e063-6294a90a0721"], "spl_set_id": ["baa50757-a927-4d56-a933-5d7798fe6ab0"], "package_ndc": ["0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95"], "unii": ["X0Q6N9USOZ"]}, "update_date": "09/29/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/01/2025", "update_type": "New", "initial_posting_date": "07/01/2025", "package_ndc": "64950-217-03", "generic_name": "Isoniazid Tablet", "contact_info": "610-782-9780", "related_info": "Product expected to be available until August 2025.", "openfda": {"application_number": ["ANDA080937"], "brand_name": ["ISONIAZID"], "generic_name": ["ISONIAZID"], "manufacturer_name": ["Genus Lifesciences"], "product_ndc": ["64950-217", "64950-216"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ISONIAZID"], "rxcui": ["197832", "311166"], "spl_id": ["6ea58bc8-a5a8-47a1-81e1-f769924e1502"], "spl_set_id": ["f0b46d1d-2300-457d-a7bd-a88a3f8d2235"], "package_ndc": ["64950-216-10", "64950-217-03", "64950-217-10"], "nui": ["N0000175483"], "pharm_class_epc": ["Antimycobacterial [EPC]"], "unii": ["V83O1VOZ8L"]}, "update_date": "07/01/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Isoniazid, Tablet, 300 mg (NDC 64950-217-03)", "company_name": "Genus Lifesciences", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-23", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3073", "0009-3475"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-486-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076803"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-486", "62135-484", "62135-485", "62135-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["09cd5cb9-4fdf-f133-e063-6294a90af691"], "spl_set_id": ["dbc43dbd-94aa-40e2-a9ea-766110cc8687"], "package_ndc": ["62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90"], "unii": ["33067B3N2M"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0775-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0775", "0555-0971", "0555-0972", "0555-0776", "0555-0777", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5543-01", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018832"], "brand_name": ["ALLOPURINOL"], "generic_name": ["ALLOPURINOL"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5543", "0591-5544"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ALLOPURINOL"], "spl_id": ["f7e04d88-1d9b-47e6-a9ad-deb08af3c098"], "spl_set_id": ["a80fe56f-8d03-423f-8e2a-7ec8c9e5045b"], "package_ndc": ["0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05"], "nui": ["N0000175698", "N0000000206"], "pharm_class_epc": ["Xanthine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Xanthine Oxidase Inhibitors [MoA]"], "unii": ["63CZ7GJN5I"]}, "update_date": "02/19/2026", "therapeutic_category": ["Oncology", "Renal", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 100 mg (NDC 0591-5543-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "70069-021-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207442"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-021"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1812079"], "spl_id": ["73618326-ff56-4a30-9d6d-6b019b61c2cd"], "spl_set_id": ["799028e2-c0e4-494f-89ff-1b786babc34a"], "package_ndc": ["70069-021-01", "70069-021-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "66993-082-69", "generic_name": "Sumatriptan Nasal Spray", "contact_info": "866-525-0688", "related_info": "This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately March 16, 2026.", "openfda": {"application_number": ["NDA020626"], "brand_name": ["SUMATRIPTAN"], "generic_name": ["SUMATRIPTAN"], "manufacturer_name": ["Prasco Laboratories"], "product_ndc": ["66993-082", "66993-081"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["NASAL"], "substance_name": ["SUMATRIPTAN"], "rxcui": ["313159", "314227"], "spl_id": ["06b6df24-20eb-4b22-b8e3-591ae1f3518a"], "spl_set_id": ["f63e616b-ae0c-432b-badc-8c45023aa725"], "package_ndc": ["66993-081-69", "66993-082-69"], "nui": ["N0000175763", "N0000175764", "N0000175765"], "pharm_class_moa": ["Serotonin 1b Receptor Agonists [MoA]", "Serotonin 1d Receptor Agonists [MoA]"], "pharm_class_epc": ["Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]"], "unii": ["8R78F6L9VO"]}, "update_date": "09/08/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Nasal Spray", "presentation": "Imitrex, Nasal Spray, 20 mg/100 uL (NDC 66993-082-69)", "company_name": "Prasco Laboratories", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-406", "43547-407", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0182-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA200795"], "brand_name": ["GEMCITABINE"], "generic_name": ["GEMCITABINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0182", "0409-0181", "0409-0183"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["GEMCITABINE HYDROCHLORIDE"], "rxcui": ["1720960", "1720975", "1720977"], "spl_id": ["3a284abb-8c57-47dc-a138-5a6e6ab92b05", "9c9d382b-8f9a-4fbe-a231-44d73ec83b61"], "spl_set_id": ["dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"], "package_ndc": ["0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25"], "unii": ["U347PV74IL"]}, "update_date": "09/11/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-25", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE AQUA"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0521"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["0bc2d27e-e0d0-4c85-a5e1-808c625b6f93"], "spl_set_id": ["c85dc235-3f42-4361-9bd2-1aaff798ad75"], "package_ndc": ["0574-0521-04", "0574-0521-08", "0574-0521-25", "0574-0521-74", "0574-0521-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-62", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4312", "0002-4491"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-62)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4904-34", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "68025-098-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-098", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5166-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5166", "0603-5165", "0603-5167", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-10", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075604"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-720", "62037-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["1801294", "1801298"], "spl_id": ["01fbdb24-0987-40f6-a920-f36349f6ba61"], "spl_set_id": ["db002ae3-f54c-40a4-9cb4-e5681bf426e3"], "package_ndc": ["62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10"], "unii": ["660YQ98I10"]}, "update_date": "11/21/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/12/2022", "package_ndc": "0703-4636-01", "generic_name": "Streptozocin Powder, For Solution", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Powder, For Solution", "presentation": "Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4239-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA077269"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4239", "0703-4244", "0703-4246", "0703-4248"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c"], "spl_set_id": ["f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37"], "package_ndc": ["0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-311-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA091695"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["62175-311", "62175-310", "62175-312", "62175-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001564", "2001565", "2001566", "2001568"], "spl_id": ["8b133cd2-e3c6-4742-b402-2393b56ffc93"], "spl_set_id": ["3d1f5aff-5d39-496c-b5ed-7f3c70ec641c"], "package_ndc": ["62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37"], "unii": ["4B3SC438HI"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-606-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "openfda": {"application_number": ["ANDA205135"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-606", "57664-607", "57664-608", "57664-609"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210"], "spl_id": ["509cf8be-4306-9755-e063-6294a90ab425"], "spl_set_id": ["d048e52d-7406-4fc1-9a72-c073bafc7439"], "package_ndc": ["57664-606-88", "57664-607-88", "57664-608-88", "57664-609-88"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-195-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-195", "11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0777-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0777", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1752-50", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1752", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0760-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0764", "0527-0765", "0527-0766"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-020-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 20 mg/.4 mL (NDC 82497-020-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "change_date": "01/03/2025", "package_ndc": "0409-1134-05", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1134", "0409-1135"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731517", "1731537", "1731545"], "spl_id": ["a641ae70-f6ba-4f49-b5fc-b2895ef3408f"], "spl_set_id": ["cadc3fdb-8edc-44cd-aaea-89e68aaf9a04"], "package_ndc": ["0409-1134-03", "0409-1134-05", "0409-1135-02"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-03", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated availability: May 2026", "openfda": {"application_number": ["NDA017428"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0004", "0338-0003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["97390588-b679-4caa-b7f3-3d2e11074d0e"], "spl_set_id": ["ef3e79c5-3f58-4b36-a296-64b7d9a651c1"], "package_ndc": ["0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-724-05", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-724", "59651-722", "59651-723"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 59651-724-05)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "0338-0431-03", "generic_name": "Heparin Sodium Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018609"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0431", "0338-0433", "0338-0424", "0338-0428"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["68b37381-6db4-4ac0-ba6b-3204add02665"], "spl_set_id": ["0d929726-76c3-48fc-b4e7-fd06409f9fb3"], "package_ndc": ["0338-0431-03", "0338-0433-04", "0338-0424-18", "0338-0428-12"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/20/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-200-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 200 ug (NDC 72305-200-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-5820-01", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018132"], "brand_name": ["DOPAMINE HYDROCHLORIDE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5820", "0409-9104"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1743938", "1743941"], "spl_id": ["a3fac375-0709-4cc0-84db-b0e5a60b7200"], "spl_set_id": ["1f306ad2-3606-4525-5a8a-ce78f426c1a2"], "package_ndc": ["0409-5820-11", "0409-5820-01", "0409-9104-21", "0409-9104-20"], "unii": ["7L3E358N9L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-161-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078450"], "brand_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-161", "65862-162", "65862-163"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["5842ecc2-874a-481b-8997-afa9d862dc5d"], "spl_set_id": ["50a58159-9572-4445-9859-b392632597da"], "package_ndc": ["65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "63323-970-02", "generic_name": "Benztropine Mesylate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA090233"], "brand_name": ["BENZTROPINE MESYLATE"], "generic_name": ["BENZTROPINE MESYLATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-970"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BENZTROPINE MESYLATE"], "rxcui": ["885205"], "spl_id": ["11222231-55b1-48ee-a8f8-3385f1a2eb36"], "spl_set_id": ["b03bd28e-3b44-41e4-9a7e-28b9d7975245"], "package_ndc": ["63323-970-02"], "unii": ["WMJ8TL7510"]}, "update_date": "01/27/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Benztropine Mesylate, Injection, 1 mg/1 mL (NDC 63323-970-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-075-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-075", "72305-025", "72305-050", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 75 ug (NDC 72305-075-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-02", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-02", "openfda": {"application_number": ["NDA018080"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7930", "0990-7923", "0990-7922"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1077-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020255"], "brand_name": ["DOBUTAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOBUTAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1077", "0338-1073", "0338-1075"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["34c787c1-46f7-4264-951d-c88a34dca533"], "spl_set_id": ["6b17b98b-e06d-42ed-925f-69aa2699dead"], "package_ndc": ["0338-1073-02", "0338-1075-02", "0338-1077-02"], "unii": ["0WR771DJXV"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/08/2026", "update_type": "New", "initial_posting_date": "01/08/2026", "package_ndc": "0006-3516-59", "generic_name": "Imipenem and Cilastatin Injection", "contact_info": "800-672-6372", "related_info": "To be discontinued in approximately Q4 2026.", "openfda": {"application_number": ["NDA050587"], "brand_name": ["PRIMAXIN IV"], "generic_name": ["IMIPENEM AND CILASTATIN SODIUM"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "product_ndc": ["0006-3516", "0006-3514", "0006-3551", "0006-3552"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CILASTATIN SODIUM", "IMIPENEM"], "rxcui": ["1726204", "1726207", "1726214", "1726216"], "spl_id": ["34854f9b-7be0-4bfb-8cd2-40baf206fb80"], "spl_set_id": ["f41d8abd-7792-4918-1b93-bd83ea01955e"], "package_ndc": ["0006-3514-58", "0006-3516-59", "0006-3551-58", "0006-3552-59"], "unii": ["5428WXZ74M", "71OTZ9ZE0A"]}, "update_date": "01/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Primaxin, Injection, 500mg (NDC 0006-3516-59)", "company_name": "Merck Sharp & Dohme Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-025-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 25 ug (NDC 72305-025-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-256-50", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-256", "55150-251", "55150-252", "55150-253", "55150-254", "55150-255"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0535-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 40 mg (NDC 0071-0535-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "72485-508-10", "generic_name": "Etomidate Injection", "contact_info": "908-803-2586", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Armas Pharmaceuticals Inc."], "product_ndc": ["72485-508", "72485-509"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["7444860b-36c1-459d-94ba-d7301d9dc2ca"], "spl_set_id": ["75467058-da52-48fa-8d4e-e1025ec7d461"], "package_ndc": ["72485-508-01", "72485-508-10", "72485-509-01", "72485-509-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3675-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040843"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-3675", "0703-3671", "0703-3678"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["e81074cc-12b4-4ac9-a5bb-749188989b2c"], "spl_set_id": ["346ec9ce-dc98-4a55-b55e-d3af11f2d703"], "package_ndc": ["0703-3671-01", "0703-3675-01", "0703-3678-01"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6126-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May 2026 timeframe.", "openfda": {"application_number": ["ANDA205758"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6126", "0641-6127", "0641-6125"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011"], "spl_id": ["fa18221d-2353-4cf6-a210-fb33ee79d3d9"], "spl_set_id": ["6023606c-150c-40c5-9175-598efe2a56c3"], "package_ndc": ["0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/27/2023", "package_ndc": "45567-0060-2", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "New supply anticipated Q2 2026", "openfda": {"application_number": ["NDA019039"], "brand_name": ["KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE"], "generic_name": ["TECHNETIUM TC99M PYROPHOSPHATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["45567-0060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["TECHNETIUM TC-99M PYROPHOSPHATE"], "spl_id": ["3010b45e-eed1-a5d0-e063-6294a90a40cf"], "spl_set_id": ["1f0cbd23-2fb3-43b7-b8af-7de246151149"], "package_ndc": ["45567-0060-1", "45567-0060-2"], "nui": ["N0000177914", "N0000000205"], "pharm_class_epc": ["Radioactive Diagnostic Agent [EPC]"], "pharm_class_moa": ["Radiopharmaceutical Activity [MoA]"], "unii": ["5L76I61H2B"]}, "update_date": "04/17/2026", "therapeutic_category": ["Medical Imaging"], "dosage_form": "Injection", "presentation": "CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "63323-519-10", "generic_name": "Heparin Sodium Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA212441"], "brand_name": ["HEPARIN SODIUM"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-519"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["3bbbe74a-1246-41a6-9fc3-ca0230529b40"], "spl_set_id": ["25b0ba06-3274-4a3f-8c39-42d13764ecdf"], "package_ndc": ["63323-519-02", "63323-519-77", "63323-519-01", "63323-519-10"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/23/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-163-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-163", "42858-161", "42858-162", "42858-164", "42858-165", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/09/2025", "update_type": "New", "initial_posting_date": "06/09/2025", "package_ndc": "66215-101-03", "generic_name": "Bosentan Tablet", "contact_info": "800-526-7736", "openfda": {"application_number": ["NDA021290"], "brand_name": ["TRACLEER"], "generic_name": ["BOSENTAN"], "manufacturer_name": ["Actelion Pharmaceuticals US, Inc."], "product_ndc": ["66215-101", "66215-102", "66215-232"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["BOSENTAN"], "rxcui": ["349253", "352066", "656659", "656660", "1989081", "1989085"], "spl_id": ["f52a8c9c-529d-4bd8-9bfb-d91161935c20"], "spl_set_id": ["749e42fb-2fe0-45dd-9268-b43bb3f4081c"], "package_ndc": ["66215-101-06", "66215-101-03", "66215-102-06", "66215-102-03", "66215-232-14", "66215-232-56"], "unii": ["Q326023R30"]}, "update_date": "06/09/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Tracleer, Tablet, 62.5 mg (NDC 66215-101-03)", "company_name": "Actelion Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/02/2025", "update_type": "New", "initial_posting_date": "12/02/2025", "package_ndc": "0085-4331-01", "generic_name": "Posaconazole Injection", "contact_info": "800-672-6372", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA205596"], "brand_name": ["NOXAFIL"], "generic_name": ["POSACONAZOLE"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "product_ndc": ["0085-4331", "0085-1328", "0085-4324", "0085-2224"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["POSACONAZOLE"], "rxcui": ["665019", "665022", "1482908", "1482912", "1492043", "1492047", "2558603", "2558607"], "spl_id": ["56740f7d-3b29-4786-b5c7-eea6c0f14400"], "spl_set_id": ["b073b082-7b57-4423-8c06-4fd4263d6f84"], "package_ndc": ["0085-1328-01", "0085-4324-02", "0085-4331-01", "0085-2224-01", "0085-2224-02"], "nui": ["N0000175487", "M0002083"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "unii": ["6TK1G07BHZ"]}, "update_date": "12/02/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01)", "company_name": "Merck Sharp & Dohme Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "66794-230-42", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "855-273-0154", "availability": "Available", "related_info": "Marketed by Piramal Critical Care Inc.: 800-414-1901", "openfda": {"application_number": ["ANDA202126"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Piramal Critical Care Inc"], "product_ndc": ["66794-230"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["3f76a806-297b-184b-e063-6394a90a7404"], "spl_set_id": ["b93a71ed-0f9e-1ff9-e053-2995a90a789d"], "package_ndc": ["66794-230-02", "66794-230-42"], "unii": ["1018WH7F9I"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "59310-822-06", "generic_name": "Fluticasone Propionate; Salmeterol Xinafoate Powder", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA208799"], "brand_name": ["AIRDUO RESPICLICK"], "generic_name": ["FLUTICASONE PROPIONATE AND SALMETEROL"], "manufacturer_name": ["Teva Respiratory, LLC"], "product_ndc": ["59310-822", "59310-805", "59310-812"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE"], "rxcui": ["1918194", "1918199", "1918203", "1918205", "1918209", "1918211"], "spl_id": ["b597bc2d-bf1e-4f9b-826a-b3e39ed56545"], "spl_set_id": ["9c122b91-a11f-49ca-80bb-3eec5112db87"], "package_ndc": ["59310-805-06", "59310-805-08", "59310-812-06", "59310-812-08", "59310-822-06", "59310-822-08"], "unii": ["6EW8Q962A5", "O2GMZ0LF5W"]}, "update_date": "06/13/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Powder", "presentation": "AirDuo RespiClick, Powder, 232 ug; 14 ug (NDC 59310-822-06)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8891-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8893", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/08/2025", "update_type": "New", "initial_posting_date": "08/08/2025", "package_ndc": "57665-101-41", "generic_name": "Amphotericin B Injection", "contact_info": "800-447-0169", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Abelcet, Injection, 5 mg/1 mL; 3.4 mg/1 mL; 1.5 mg/1 mL (NDC 57665-101-41)", "company_name": "Leadiant Biosciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "54288-165-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Estimated recovery: end of August 2026; Distributed by BPI Labs, LLC", "openfda": {"application_number": ["ANDA207324"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["BPI Labs LLC"], "product_ndc": ["54288-165", "54288-166", "54288-167", "54288-164"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["c0a7463c-d90f-4060-a54e-6a4888e8af0e"], "spl_set_id": ["5484d2f0-0cc2-4bba-8f26-c7f6539a9606"], "package_ndc": ["54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3213-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3213", "0093-0832", "0093-3212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0264-4500-00", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "related_info": "On allocation", "openfda": {"application_number": ["ANDA091112"], "brand_name": ["PLENAMINE"], "generic_name": ["LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-4500"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "spl_id": ["905f7c55-bf0d-4150-90ef-e8f1a5455bc1"], "spl_set_id": ["a3244d1a-45b0-4e4c-bd96-f0632d761a1f"], "package_ndc": ["0264-4500-00", "0264-4500-05"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Plenamine, Injection, 0.15 (NDC 0264-4500-00)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/14/2016", "package_ndc": "63323-489-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "69097-004-67", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-247-5287", "resolved_note": "Available", "openfda": {"application_number": ["ANDA214050"], "brand_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Cipla USA Inc."], "product_ndc": ["69097-004"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["238755"], "spl_id": ["44159bea-88a1-49ac-a51e-1c27dc89d9ff"], "spl_set_id": ["451d6d04-b7d9-47d9-ba71-43cc5b9b3054"], "package_ndc": ["69097-004-67"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Pulmonary/Allergy", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Hydrocortisone Sodium Succinate, Injection, 100 mg/ Vial (NDC 69097-004-67)", "company_name": "Cipla Limited", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0990-6139-22", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "Allocated to Contracted Customers Only. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6139-22", "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-88", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA074086"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["e71e9520-871b-479d-9652-1857fceca863", "5d6b1dfe-d679-4aea-97a6-3d074a202afe"], "spl_set_id": ["dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58"], "package_ndc": ["0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/16/2025", "update_type": "New", "initial_posting_date": "07/16/2025", "package_ndc": "0008-4117-01", "generic_name": "Ethionamide Tablet", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.\nSupply expected to exhaust September 2025", "update_date": "07/16/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Trecator, Tablet, 250 mg (NDC 0008-4117-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "70370-5025-1", "generic_name": "Crinecerfont Capsule", "contact_info": "858-617-7600", "related_info": "Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).", "openfda": {"application_number": ["NDA218808"], "brand_name": ["CRENESSITY"], "generic_name": ["CRINECERFONT"], "manufacturer_name": ["Neurocrine Biosciences, Inc."], "product_ndc": ["70370-5025", "70370-5050", "70370-5100", "70370-5250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CRINECERFONT"], "rxcui": ["2701391", "2701397", "2701399", "2701401", "2701403", "2701405", "2701409", "2701413"], "spl_id": ["f5cc43fd-6e18-4a06-8c9f-bd80ea847e83"], "spl_set_id": ["fd3a6fbd-9137-428a-ba46-df6606f07d28"], "package_ndc": ["70370-5025-1", "70370-5050-1", "70370-5100-1", "70370-5250-1"], "nui": ["N0000194151", "N0000194152"], "pharm_class_epc": ["Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]"], "pharm_class_moa": ["Corticotropin-releasing Factor Type 1 Receptor Antagonists [MoA]"], "unii": ["MFT24BX55I"]}, "update_date": "04/28/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Crenessity, Capsule, 25 mg (NDC 70370-5025-1)", "company_name": "Neurocrine Biosciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-601-04", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": {"application_number": ["NDA206628"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["WG Critical Care, LLC"], "product_ndc": ["44567-601", "44567-600", "44567-602", "44567-603"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909", "1788947"], "spl_id": ["e6fa3e27-b374-49b6-a678-a5954f5beae8"], "spl_set_id": ["0d2710f2-ee47-4114-ab5c-8dca74cdcb8d"], "package_ndc": ["44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)", "company_name": "HQ Specialty Pharma", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-194-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-194", "11534-190", "11534-191", "11534-192", "11534-193", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "63323-750-20", "generic_name": "Oxaliplatin Injection", "contact_info": "847-550-2300", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA078811"], "brand_name": ["OXALIPLATIN"], "generic_name": ["OXALIPLATIN"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-750"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["OXALIPLATIN"], "rxcui": ["1736776", "1736781"], "spl_id": ["504bf43e-4c28-4375-a6f4-285b2357f7f7"], "spl_set_id": ["e12e2850-4980-48de-af58-15e559fb921f"], "package_ndc": ["63323-750-10", "63323-750-20"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["04ZR38536J"]}, "update_date": "02/25/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/10/2025", "update_type": "New", "initial_posting_date": "10/10/2025", "package_ndc": "0781-3518-76", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214657"], "brand_name": ["PEMETREXED"], "generic_name": ["PEMETREXED DISODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3518", "0781-3519", "0781-3520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PEMETREXED DISODIUM"], "rxcui": ["2602363", "2602365", "2602366"], "spl_id": ["764ab64b-c642-4314-83a9-efee79fe83a3"], "spl_set_id": ["7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3"], "package_ndc": ["0781-3518-76", "0781-3519-90", "0781-3520-91"], "unii": ["2PKU919BA9"]}, "update_date": "10/10/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Pemetrexed Disodium, Injection, 100 mg/4 mL (NDC 0781-3518-76)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7875-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7875", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5111-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4282-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088294"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4282", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2868", "0781-2859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-420-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA040802"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-420", "67457-423", "67457-422", "67457-421"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["dd5c82b6-a194-462c-9626-34a9b410cfea"], "spl_set_id": ["dff598e8-e662-411f-978d-4ba3fb8ef7db"], "package_ndc": ["67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0409-2026-01", "generic_name": "Docetaxel Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA022234"], "brand_name": ["DOCETAXEL"], "generic_name": ["DOCETAXEL ANHYDROUS"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2026", "0409-0016"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOCETAXEL ANHYDROUS"], "rxcui": ["1093280", "1860619"], "spl_id": ["8156a5f8-7002-479d-a08d-3c68f92c1396"], "spl_set_id": ["00c61d11-d6b7-4618-b6f6-2592dbcc8af7"], "package_ndc": ["0409-2026-01", "0409-0016-01"], "nui": ["N0000175085", "N0000175592"], "pharm_class_pe": ["Microtubule Inhibition [PE]"], "pharm_class_epc": ["Microtubule Inhibitor [EPC]"], "unii": ["699121PHCA"]}, "update_date": "06/24/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus®  (NDC 0409-2026-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0143-9254-25", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the August 2026 timeframe.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA207707"], "brand_name": ["DOPAMINE HYDROCHLORIDE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9254", "0143-9252", "0143-9253", "0143-9255"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1743938", "1743941", "1743950", "1743953"], "spl_id": ["67349236-e8e3-45ec-a76d-2a0a150d8d59"], "spl_set_id": ["0e499952-46c7-4172-8c70-186312e240a3"], "package_ndc": ["0143-9252-01", "0143-9252-25", "0143-9253-01", "0143-9253-25", "0143-9254-01", "0143-9254-25", "0143-9255-01", "0143-9255-25"], "unii": ["7L3E358N9L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0181-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA200795"], "brand_name": ["GEMCITABINE"], "generic_name": ["GEMCITABINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0181", "0409-0183", "0409-0182"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["GEMCITABINE HYDROCHLORIDE"], "rxcui": ["1720960", "1720975", "1720977"], "spl_id": ["3a284abb-8c57-47dc-a138-5a6e6ab92b05", "9c9d382b-8f9a-4fbe-a231-44d73ec83b61"], "spl_set_id": ["dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"], "package_ndc": ["0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25"], "unii": ["U347PV74IL"]}, "update_date": "09/11/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial  NovaPlus (NDC 0409-0181-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-05", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2634"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["50886ad5-eeca-4fe7-beb0-01305f92c65d"], "spl_set_id": ["3832ede8-d3fc-455d-ecab-3b77be5869f5"], "package_ndc": ["0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-61", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4312", "0002-4491"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-61)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7768-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210050"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7768", "0093-7766", "0093-7767", "0093-7769"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["aa521933-950a-441b-9146-93e479a4dde7"], "spl_set_id": ["e3bca36b-29ed-4a2b-a1be-a57b6af805f6"], "package_ndc": ["0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "03/02/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2018", "package_ndc": "73293-0001-2", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "intbiz@huons.com", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA212821"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Huons Co., Ltd."], "product_ndc": ["73293-0001", "73293-0004", "73293-0005", "73293-0003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1737566", "1737761"], "spl_id": ["4711fd53-dad3-f117-e063-6394a90a8d3d"], "spl_set_id": ["8ec2d256-fc4f-44f6-bee2-eef2bf3bf580"], "package_ndc": ["73293-0004-1", "73293-0004-2", "73293-0005-1", "73293-0005-2", "73293-0001-1", "73293-0001-2", "73293-0003-1", "73293-0003-2"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)", "company_name": "Huons Co., Ltd. (South Korea)", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-028-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-028", "65162-023", "65162-024", "65162-025", "65162-026", "65162-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2023", "package_ndc": "0143-9872-10", "generic_name": "Propranolol Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077760"], "brand_name": ["PROPRANOLOL HYDROCHLORIDE"], "generic_name": ["PROPRANOLOL HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9872"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PROPRANOLOL HYDROCHLORIDE"], "rxcui": ["856443"], "spl_id": ["4432e36f-bed0-4e42-87aa-1330d1725963"], "spl_set_id": ["91f2ff1d-68d8-4e83-a2db-618f0410ead7"], "package_ndc": ["0143-9872-01", "0143-9872-10"], "unii": ["F8A3652H1V"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "67457-228-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA079199"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["b65fbcab-781e-4706-a60b-a8eb4aeae0c1"], "spl_set_id": ["f58803b0-f173-4997-b2f8-0f415b94dacf"], "package_ndc": ["67457-228-00", "67457-228-05", "67457-228-99", "67457-228-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43066-557-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA208532"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["43066-557", "43066-555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["d0910ea1-c3e1-44f8-b8b5-1f39ffd43290"], "spl_set_id": ["aea9a3ad-c244-42be-9cd3-5df83fe2b522"], "package_ndc": ["43066-555-24", "43066-557-12"], "unii": ["1018WH7F9I"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-483-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-483", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE BITARTRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-072-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 OR CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-072", "13107-068", "13107-069", "13107-070", "13107-071", "13107-073", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6858-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6858", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-565-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-565", "47781-562", "47781-563", "47781-564", "47781-566", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1891-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1891", "0409-1890", "0409-1892", "0409-1893", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-206-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care Renal Therapies Group, LLC"], "product_ndc": ["49230-206", "49230-209", "49230-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["44506bb0-e5f3-2a05-e063-6294a90ab2c9", "43cd31e0-97ed-1eeb-e063-6294a90a0b3d"], "spl_set_id": ["bbc5b820-4973-11e2-a192-0002a5d5c51b", "c29bdfa0-4976-11e2-939b-0002a5d5c51b"], "package_ndc": ["49230-206-20", "49230-206-30", "49230-206-32", "49230-206-50", "49230-206-60", "49230-206-62", "49230-206-52", "49230-209-23", "49230-209-30", "49230-209-32", "49230-209-50", "49230-209-60", "49230-209-62", "49230-209-52", "49230-212-23", "49230-212-30", "49230-212-32", "49230-212-50", "49230-212-60", "49230-212-62", "49230-212-52", "49230-206-92", "49230-206-94", "49230-206-95", "49230-209-92", "49230-209-94", "49230-209-95", "49230-212-92", "49230-212-94", "49230-212-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-206-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2021", "package_ndc": "67457-445-60", "generic_name": "Rifampin Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA065421"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-445"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["RIFAMPIN"], "rxcui": ["312821"], "spl_id": ["f1107e3c-754b-407d-9d66-23f545c0c692"], "spl_set_id": ["8be91604-d7cd-4f2b-997d-e3364e4092e5"], "package_ndc": ["67457-445-60"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5555-02", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA202981"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868469"], "spl_id": ["e3a44e63-8594-40b6-a3fa-d135b3149661", "bcb3a2dc-1a3f-4ac7-8ea2-426f0771c246"], "spl_set_id": ["0c24b592-4bc8-456f-acac-9c9525844a06", "ea9f4498-0d43-4043-8dd1-f22537841c21"], "package_ndc": ["0409-5555-11", "0409-5555-01", "0409-5555-12", "0409-5555-02"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1165-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070585"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1165", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-600-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2026", "openfda": {"application_number": ["ANDA077059"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-600", "61703-360", "61703-150", "61703-262"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["5aa72c15-8033-4559-b257-373371b18958"], "spl_set_id": ["47677091-fd20-49af-933c-c9dd2be21de9"], "package_ndc": ["61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-137-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-137", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 137 ug (NDC 72305-137-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-105-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-105", "59417-101", "59417-102", "59417-103", "59417-104", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 50 mg (NDC 59417-105-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1893-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1893", "0409-1890", "0409-1891", "0409-1892", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-5534-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-3613-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071810"], "brand_name": ["BUPIVACAINE SPINAL"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3613"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBARACHNOID"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724784"], "spl_id": ["7a09a90d-26da-42bd-bb54-2d2102eb8c1c"], "spl_set_id": ["7a8d2539-4422-4312-0298-207ef1a2948e"], "package_ndc": ["0409-3613-11", "0409-3613-01"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/19/2025", "update_type": "New", "initial_posting_date": "08/19/2025", "package_ndc": "0093-7355-98", "generic_name": "Finasteride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076511"], "brand_name": ["FINASTERIDE"], "generic_name": ["FINASTERIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7355"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FINASTERIDE"], "rxcui": ["310346"], "spl_id": ["4c152e0f-55b3-4357-b983-897ecaf878af"], "spl_set_id": ["77589cc3-c440-4695-800c-82a0e5128a6c"], "package_ndc": ["0093-7355-56", "0093-7355-98", "0093-7355-05"], "nui": ["N0000175836", "N0000000126"], "pharm_class_epc": ["5-alpha Reductase Inhibitor [EPC]"], "pharm_class_moa": ["5-alpha Reductase Inhibitors [MoA]"], "unii": ["57GNO57U7G"]}, "update_date": "08/19/2025", "therapeutic_category": ["Urology"], "dosage_form": "Tablet", "presentation": "Finasteride, Tablet, 5 mg (NDC 0093-7355-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-150-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-150", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 150 ug (NDC 72305-150-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4277-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088327"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4277", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "23155-601-42", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA090850"], "brand_name": ["MIDAZOLAM HYDROCHLORIDE"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-601"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311702"], "spl_id": ["e20feff9-3aca-4bc1-a5c3-44fff8a9459c"], "spl_set_id": ["843cc25e-45ea-4372-ae34-843f805fa869"], "package_ndc": ["23155-601-31", "23155-601-41", "23155-601-32", "23155-601-42"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1582-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1582", "0409-1559", "0409-1560", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1582-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "83831-142-50", "generic_name": "Carboplatin Injection", "contact_info": "877-595-7337; customerservice@avyxa.com", "availability": "Available", "openfda": {"application_number": ["NDA219921"], "brand_name": ["KYXATA"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Avyxa Pharma, LLC"], "product_ndc": ["83831-142", "83831-140", "83831-141"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195", "2721602"], "spl_id": ["5c711945-70be-42f4-b153-e1459dd9929c"], "spl_set_id": ["f91c48da-68d1-4aa7-89b8-d84a3e8b629b"], "package_ndc": ["83831-140-02", "83831-141-08", "83831-142-50"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/15/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)", "company_name": "Avyxa Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "10147-1700-3", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020083"], "brand_name": ["ITRACONAZOLE"], "generic_name": ["ITRACONAZOLE"], "manufacturer_name": ["Patriot Pharmaceuticals"], "product_ndc": ["10147-1700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ITRACONAZOLE"], "rxcui": ["311204"], "spl_id": ["2cca3625-96e8-34cf-e063-6294a90ac975"], "spl_set_id": ["6242b7ad-eaa0-a524-b6e0-ec33e63407db"], "package_ndc": ["10147-1700-3", "10147-1700-7"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]"], "unii": ["304NUG5GF4"]}, "update_date": "02/27/2026", "therapeutic_category": ["Anti-Infective", "Other"], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 10147-1700-3)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6251-10", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": {"application_number": ["ANDA213561"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6251"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190776"], "spl_id": ["f5ca4281-8c89-4efc-80b1-2fbcf61c7c55"], "spl_set_id": ["4c15d3cc-7888-4c82-b3f8-a5d93c5523df"], "package_ndc": ["0641-6251-10"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6060-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6060", "0641-6057", "0641-6059", "0641-6056", "0641-6061", "0641-6063"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-127-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207934"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-127", "49884-119", "49884-125", "49884-128"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["b474c768-50e2-44da-accf-f1bd3d49ab20"], "spl_set_id": ["45d54974-3fc4-4237-a2fa-3158ca1a8105"], "package_ndc": ["49884-119-52", "49884-119-91", "49884-125-52", "49884-125-91", "49884-127-52", "49884-127-91", "49884-128-52", "49884-128-91"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "01/06/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 7.5 mg (NDC 49884-127-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-08", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4491", "0002-4312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-08)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0375-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0375", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0374"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3569-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3569", "0480-3565", "0480-3566", "0480-3567", "0480-3568", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1749-10", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1749", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-722-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-722", "59651-723", "59651-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 59651-722-01)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-196-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-196", "11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-195"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72572-160-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Distributed by Civica", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Civica, Inc."], "product_ndc": ["72572-160", "72572-161"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["380f0c88-03f8-4cfa-8823-4766c2f7700c"], "spl_set_id": ["98002094-f065-4b5f-963f-2c34b5241316"], "package_ndc": ["72572-160-01", "72572-160-10", "72572-161-01", "72572-161-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0013-05", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0013", "0009-0825", "0009-0011", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-117-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-117", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-117-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-117", "57844-105", "57844-110", "57844-112", "57844-115", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1178-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA021171"], "brand_name": ["DEMEROL"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1178", "0409-1181", "0409-1176", "0409-1179", "0409-1180", "0409-1362", "0409-1418"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192"], "spl_id": ["c1704eaf-f0a8-4ba3-89a1-2836ba7e5ee6"], "spl_set_id": ["b31d1308-28c3-43f4-e0a6-2f3ed76b8975"], "package_ndc": ["0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01"], "unii": ["N8E7F7Q170"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-63", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3288-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3288", "0781-3289", "0781-3290"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a"], "spl_set_id": ["231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca"], "package_ndc": ["0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0409-0016-01", "generic_name": "Docetaxel Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA022234"], "brand_name": ["DOCETAXEL"], "generic_name": ["DOCETAXEL ANHYDROUS"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0016", "0409-2026"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOCETAXEL ANHYDROUS"], "rxcui": ["1093280", "1860619"], "spl_id": ["8156a5f8-7002-479d-a08d-3c68f92c1396"], "spl_set_id": ["00c61d11-d6b7-4618-b6f6-2592dbcc8af7"], "package_ndc": ["0409-2026-01", "0409-0016-01"], "nui": ["N0000175085", "N0000175592"], "pharm_class_pe": ["Microtubule Inhibition [PE]"], "pharm_class_epc": ["Microtubule Inhibitor [EPC]"], "unii": ["699121PHCA"]}, "update_date": "06/24/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus®  (NDC 0409-0016-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "71225-126-06", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-566-2505", "availability": "Available", "openfda": {"application_number": ["ANDA212791"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Slayback Pharma LLC"], "product_ndc": ["71225-126"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["027725dc-e468-446c-b702-ab0f8a9e3be5"], "spl_set_id": ["e5d28ed8-e427-4850-81aa-98702d3b6a5d"], "package_ndc": ["71225-126-02", "71225-126-05", "71225-126-03", "71225-126-06", "71225-126-01", "71225-126-04"], "unii": ["1018WH7F9I"]}, "update_date": "09/17/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)", "company_name": "Slayback Pharma", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-7517-16", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019445"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7517", "0409-6648"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["727517", "1795514"], "spl_id": ["2f05a8f1-4651-405c-a66b-8e96a46c1db8"], "spl_set_id": ["4ed365da-4e62-4329-c1b9-c197ab4fb6e1"], "package_ndc": ["0409-7517-66", "0409-7517-16", "0409-6648-16", "0409-6648-02"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-603-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-603", "43547-602", "43547-604", "43547-605", "43547-606", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0591-2925-30", "generic_name": "Testosterone Gel; Gel, Metered", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "06/16/2025", "therapeutic_category": ["Urology"], "dosage_form": "Gel; Gel, Metered", "presentation": "Testosterone, Gel; Gel, Metered, 16.2 mg/1 g (NDC 0591-2925-30)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-467-57", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-467", "63323-465", "63323-460", "63323-464", "63323-466", "63323-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177"], "spl_id": ["2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-30", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA084916"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1116927", "1812194"], "spl_id": ["a832bff9-0bb3-4350-abb5-d57b9417070c", "9dd90418-e564-4bc5-9077-506a1c2c1bce"], "spl_set_id": ["2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e"], "package_ndc": ["63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-28", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-05", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-503-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-503", "64850-500", "64850-501", "64850-502", "64850-504", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-201-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088586"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-201", "63323-202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1737757"], "spl_id": ["d19c26f4-1214-40f7-9680-43c885613306"], "spl_set_id": ["cddb2b22-fce3-8967-6e54-dca3df5ac4b3"], "package_ndc": ["63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02"], "unii": ["V13007Z41A"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-086-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-086", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-568-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-568", "47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-567"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-124-40", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-124", "61703-161"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["6bb8643f-6ab4-4e1c-bcf9-b82e8cf18910"], "spl_set_id": ["bd287e89-32f9-4396-95fa-4b562869f476"], "package_ndc": ["61703-124-40", "61703-161-02", "61703-161-05"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7510", "0264-7520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0517-1001-25", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-645-1706", "availability": "Available", "openfda": {"application_number": ["ANDA216120"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["American Regent, Inc."], "product_ndc": ["0517-1001", "0517-1004"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190795", "1666781"], "spl_id": ["1c500ed9-94a9-472c-bfb7-50e1fcfc31fb"], "spl_set_id": ["6fee1727-52b7-4f73-ab45-ef47d6a1c5bb"], "package_ndc": ["0517-1004-01", "0517-1004-25", "0517-1001-01", "0517-1001-25"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)", "company_name": "American Regent, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9043-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071167"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9043", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2859", "0781-2868"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-00", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7520", "0264-7510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "55150-314-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA211930"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-314", "55150-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["25c5133c-ee17-4be0-88a3-d0231e38f5a0"], "spl_set_id": ["a0cbcdb5-f657-49f7-8f86-cc5959d69db0"], "package_ndc": ["55150-313-25", "55150-313-01", "55150-314-25", "55150-314-01"], "unii": ["43502P7F0P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2851-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA200881"], "brand_name": ["GUANFACINE"], "generic_name": ["GUANFACINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2851", "0228-2850", "0228-2853", "0228-2855"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GUANFACINE HYDROCHLORIDE"], "rxcui": ["862006", "862013", "862019", "862025"], "spl_id": ["b9040df2-42e8-404d-9b90-331dd3efc38c"], "spl_set_id": ["3a171942-37af-430d-8b9d-bb678ca2be4b"], "package_ndc": ["0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11"], "unii": ["PML56A160O"]}, "update_date": "11/13/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 2 mg (NDC 0228-2851-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-0040-10", "generic_name": "Ketamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074549"], "brand_name": ["KETAMINE HYDROCHLORIDE"], "generic_name": ["KETAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0040"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETAMINE HYDROCHLORIDE"], "rxcui": ["238083"], "spl_id": ["aa1e5788-73a9-4b95-99da-17eb252f8702"], "spl_set_id": ["390f2db8-0fcd-4648-b584-9effa084be27"], "package_ndc": ["0409-0040-05", "0409-0040-10"], "unii": ["O18YUO0I83"]}, "update_date": "11/07/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-431-08", "generic_name": "Docetaxel Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-483-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-483", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE BITARTRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-070-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-070", "13107-068", "13107-069", "13107-071", "13107-072", "13107-073", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-112-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-112", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 112 ug (NDC 72305-112-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "47335-326-88", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-818-4555", "resolved_note": "Available", "openfda": {"application_number": ["ANDA090356"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["b0c2b60a-dc96-483b-933e-2fed58b64372"], "spl_set_id": ["0f30f885-d0cd-4fa6-a8e0-142f08a56792"], "package_ndc": ["47335-326-83", "47335-326-88", "47335-326-08", "47335-326-18"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-06", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-06)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070583"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596"], "spl_id": ["fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-493-91", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE MPF"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-493", "63323-492", "63323-496"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764"], "spl_id": ["fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df"], "spl_set_id": ["d5e0d06f-ba1e-44d4-aa89-39d6c146dc23"], "package_ndc": ["63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97"], "unii": ["EC2CNF7XFP"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/30/2026", "update_type": "New", "initial_posting_date": "01/30/2026", "package_ndc": "57664-656-88", "generic_name": "Pindolol Tablet", "contact_info": "800-818-4555", "related_info": "Discontinuation of the manufacture of the drug; Expiry date of last distributed batch October 2026", "openfda": {"application_number": ["ANDA074063"], "brand_name": ["PINDOLOL"], "generic_name": ["PINDOLOL"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-656", "57664-655"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PINDOLOL"], "rxcui": ["198104", "198105"], "spl_id": ["4d3c89dd-e947-5f23-e063-6294a90aeb1f"], "spl_set_id": ["b331a73f-bf7b-4442-8901-36d016530279"], "package_ndc": ["57664-656-88", "57664-655-88"], "nui": ["N0000000161", "N0000175556"], "pharm_class_moa": ["Adrenergic beta-Antagonists [MoA]"], "pharm_class_epc": ["beta-Adrenergic Blocker [EPC]"], "unii": ["BJ4HF6IU1D"]}, "update_date": "01/30/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pindolol, Tablet, 10 mg (NDC 57664-656-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/26/2025", "update_type": "New", "initial_posting_date": "09/26/2025", "package_ndc": "25021-230-05", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA090675"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-230"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["beff4b0b-e884-4134-ba9e-290020a94add"], "spl_set_id": ["caab50e6-0dad-4ddd-9a6c-96cc2b87aee7"], "package_ndc": ["25021-230-02", "25021-230-05"], "unii": ["042LAQ1IIS"]}, "update_date": "09/26/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6052-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA080445"], "brand_name": ["MEPERIDINE HYDROCHLORIDE"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6052", "0641-6053", "0641-6054"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["861476", "1665685", "1665697"], "spl_id": ["9566d54d-7343-4695-94ff-8b5f2d384c81"], "spl_set_id": ["e0e998da-f056-4fce-be8e-ed60cf3b461b"], "package_ndc": ["0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25"], "unii": ["N8E7F7Q170"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-11", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-288", "63323-286", "63323-287", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-468-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "3, 4, 5, 7 & 8 month expiry available upon request. Check wholesaler for inventory", "openfda": {"application_number": ["ANDA070966"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-468", "63323-472", "63323-463", "63323-461"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1867594", "1867596", "1867618", "1867620", "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810"], "spl_id": ["b671015d-f620-4930-a890-5e27a40ae42f", "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["b671015d-f620-4930-a890-5e27a40ae42f", "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-468-08", "63323-468-38", "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-02", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA089646"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-602-85", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-602", "60951-700", "60951-712", "60951-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-133-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-133", "72205-132", "72205-134", "72205-135", "72205-136", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0641-6147-10", "generic_name": "Sterile Water Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA206369"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["081540ac-58cf-437f-ba1b-86d5264ec3dc"], "spl_set_id": ["78ef7ad3-451d-43d0-a9b6-5cf0aadca003"], "package_ndc": ["0641-6147-01", "0641-6147-10", "0641-6147-25"], "unii": ["059QF0KO0R"]}, "update_date": "05/12/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-15", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-851", "63323-852", "63323-853", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "76045-010-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release June 2026.  Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["DILAUDID"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-010", "76045-009", "76045-121"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370"], "spl_id": ["97bfcafb-2037-47dc-a0ae-f7b8007c47df"], "spl_set_id": ["9eebd88a-5632-460f-b7b6-26c8a180540d"], "package_ndc": ["76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-2066-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA040078"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2066"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737761"], "spl_id": ["55b04269-e58a-4df8-a18c-4643c2e1433a"], "spl_set_id": ["9c18eaf1-4a0b-4916-70b2-88a827494711"], "package_ndc": ["0409-2066-10", "0409-2066-05"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-562-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-454-36", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-454", "61314-473", "61314-476", "61314-509", "61314-517", "61314-531"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ADALIMUMAB"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-102-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-102", "59417-101", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 20 mg (NDC 59417-102-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3475-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3475", "0009-3073"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6085-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PHENERGAN"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6085", "0641-6084"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992462", "992858", "992876"], "spl_id": ["7d6e64fc-bbf2-4ea9-b866-8115c448e687"], "spl_set_id": ["481866da-a712-48a5-853f-8e84aacaab6d"], "package_ndc": ["0641-6084-01", "0641-6084-25", "0641-6085-01", "0641-6085-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-472-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070554"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-472", "63323-463", "63323-461", "63323-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620"], "spl_id": ["cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-341-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-341", "42806-339", "42806-343", "42806-344", "42806-345"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-04", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016694"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0023", "0338-0017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0303-1", "generic_name": "Riluzole Oral Suspension", "contact_info": "610-937-6172", "availability": "Unavailable", "related_info": "EacNext release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing", "openfda": {"application_number": ["NDA209080"], "brand_name": ["TIGLUTIK"], "generic_name": ["RILUZOLE"], "manufacturer_name": ["EDW PHARMA, INC"], "product_ndc": ["70726-0303"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RILUZOLE"], "rxcui": ["2058147", "2059266"], "spl_id": ["4746e22f-8ca7-9149-e063-6294a90aea8d"], "spl_set_id": ["75d68f19-4208-109e-e053-2991aa0ac857"], "package_ndc": ["70726-0303-2", "70726-0303-1"], "nui": ["N0000175740", "M0483511"], "pharm_class_epc": ["Benzothiazole [EPC]"], "pharm_class_cs": ["Benzothiazoles [CS]"], "unii": ["7LJ087RS6F"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Suspension", "presentation": "Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9042-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071165"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9042", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-579-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-579", "23155-578", "23155-580", "23155-581", "23155-582", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 25 mg (NDC 23155-579-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0013-06", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0013", "0009-0825", "0009-0011", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8885-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8885", "0406-8891", "0406-8884", "0406-8892", "0406-8893", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2415-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": {"application_number": ["NDA021514"], "brand_name": ["METHYLPHENIDATE TRANSDERMAL SYSTEM"], "generic_name": ["METHYLPHENIDATE"], "manufacturer_name": ["PADAGIS US LLC"], "product_ndc": ["0574-2415", "0574-2410", "0574-2420", "0574-2430"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["METHYLPHENIDATE"], "rxcui": ["753436", "753438", "753440", "753441"], "spl_id": ["b743ef45-2fc0-4086-8a02-6078e6a09eaa"], "spl_set_id": ["7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb"], "package_ndc": ["0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65"], "nui": ["N0000175739", "N0000175729"], "pharm_class_epc": ["Central Nervous System Stimulant [EPC]"], "pharm_class_pe": ["Central Nervous System Stimulation [PE]"], "unii": ["207ZZ9QZ49"]}, "update_date": "05/07/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-02", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0280", "0009-0274", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-610-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": {"application_number": ["NDA017533"], "brand_name": ["KLONOPIN"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["H2-Pharma, LLC"], "product_ndc": ["61269-610", "61269-605", "61269-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529", "206157", "206159", "206160"], "spl_id": ["63cfdab9-fb3d-4c2b-bf88-8ba841dba839"], "spl_set_id": ["cfa0d79a-843c-4b88-95a1-e9511d649ca1"], "package_ndc": ["61269-605-10", "61269-610-10", "61269-620-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, 1 mg (NDC 61269-610-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43066-555-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA208532"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["43066-555", "43066-557"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["d0910ea1-c3e1-44f8-b8b5-1f39ffd43290"], "spl_set_id": ["aea9a3ad-c244-42be-9cd3-5df83fe2b522"], "package_ndc": ["43066-555-24", "43066-557-12"], "unii": ["1018WH7F9I"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5112-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5112", "0406-5111", "0406-5113", "0406-5114", "0406-5115", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "76329-3302-1", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "800-423-4136", "availability": "Limited Availability", "related_info": "Avaiable on allocation", "openfda": {"application_number": ["ANDA203451"], "brand_name": ["DEXTROSE MONOHYDRATE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-3302"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["727517"], "spl_id": ["45b366a9-6c0c-4643-9951-4ff880b29c83"], "spl_set_id": ["fcc7ac79-cd70-4f03-a4de-f051f9ca1f7d"], "package_ndc": ["76329-3302-1"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "0641-6254-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA217812"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6254"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897745"], "spl_id": ["ba25ec4f-3b81-4960-bf74-6a1e4c6be45c"], "spl_set_id": ["c729424e-e483-4bf8-b86c-ce56636dcffa"], "package_ndc": ["0641-6254-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-50", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018801"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4887"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["055437a7-5be5-414a-a97a-946e2730fe12"], "spl_set_id": ["2b9ea23a-f9e9-48a8-25b7-519e3bbd6828"], "package_ndc": ["0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0066-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0066", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0078", "0338-0062", "0338-0074", "0338-0070", "0338-0082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["66eb82f8-6755-42aa-b20c-192a640e8068"], "spl_set_id": ["36e9478c-5df0-4b47-b97d-de3626d7cb29"], "package_ndc": ["0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "83634-302-10", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Avenacy Inc."], "product_ndc": ["83634-302"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1b3f2803-b618-4447-b5ac-cd2bdc7de3e8"], "spl_set_id": ["7d0db0f7-bf4f-4b0b-9359-2a838626e04b"], "package_ndc": ["83634-302-42", "83634-302-02", "83634-302-43", "83634-302-04", "83634-302-41", "83634-302-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 83634-302-10)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3814-12", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA073509"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3814", "0409-3815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1728783", "1728800"], "spl_id": ["0a2ba20b-448f-4412-9899-b82040ebfa7d"], "spl_set_id": ["1d181906-f3ec-4222-1883-e61577a3122e"], "package_ndc": ["0409-3814-11", "0409-3814-12", "0409-3815-11", "0409-3815-12"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070553", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-463-57", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["ANDA070968"], "brand_name": ["SENSORCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-463", "63323-472", "63323-461", "63323-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620"], "spl_id": ["cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-6146-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": {"application_number": ["ANDA084282"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6146", "0641-0367", "0641-6145"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["02bf3273-f0c8-448c-9f74-eb009fee9299"], "spl_set_id": ["0277cc0a-2fd4-4605-a310-b613be84ee26"], "package_ndc": ["0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/12/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3212-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3212", "0093-0832", "0093-3213"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-488-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0280", "0009-0274", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1638-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1638", "0409-1660", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-09", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-09", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0093-7679-02", "generic_name": "Ethinyl Estradiol; Etonogestrel Ring", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA204305"], "brand_name": ["ETONOGESTREL AND ETHINYL ESTRADIOL"], "generic_name": ["ETONOGESTREL AND ETHINYL ESTRADIOL"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7679"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["VAGINAL"], "substance_name": ["ETHINYL ESTRADIOL", "ETONOGESTREL"], "rxcui": ["1367436"], "spl_id": ["d0827dbf-9df5-4438-a0c2-92d7d593e71c"], "spl_set_id": ["a8cc104a-d522-49ad-af54-2f312b829b61"], "package_ndc": ["0093-7679-01", "0093-7679-02"], "nui": ["N0000175825", "N0000000100", "M0447349", "N0000175602"], "pharm_class_epc": ["Estrogen [EPC]", "Progestin [EPC]"], "pharm_class_moa": ["Estrogen Receptor Agonists [MoA]"], "pharm_class_cs": ["Progesterone Congeners [CS]"], "unii": ["423D2T571U", "304GTH6RNH"]}, "update_date": "06/16/2025", "therapeutic_category": ["Reproductive"], "dosage_form": "Ring", "presentation": "Ethinyl Estradiol; Etonogestrel, Ring, .015 mg/1 d; .12 mg/1 d (NDC 0093-7679-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0372-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0372", "0054-0660", "0054-0370", "0054-0371", "0054-0373", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-722-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-722", "71288-721", "71288-724", "71288-725", "71288-727", "71288-728"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-251-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-251", "55150-252", "55150-254", "55150-255", "55150-253", "55150-256"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4663-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4663", "0527-4661", "0527-4662", "0527-4664", "0527-4665", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-06", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA090108"], "brand_name": ["CLINDAMYCIN"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["1737244", "1737578", "1737581"], "spl_id": ["4662502b-ce7c-4278-854d-cf8632ac9b83"], "spl_set_id": ["7a6967b3-5563-4bed-9eee-d400f800e799"], "package_ndc": ["25021-115-02", "25021-115-04", "25021-115-06"], "unii": ["EH6D7113I8"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-723-99", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-723", "59651-722", "59651-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 59651-723-99)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-03", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-03", "openfda": {"application_number": ["NDA018080"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7930", "0990-7923", "0990-7922"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1007-03", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA019615"], "brand_name": ["DOPAMINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1007", "0338-1005", "0338-1009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1292887", "1743869", "1743871", "1743877", "1743879"], "spl_id": ["edc9a091-4cb5-4ec7-b6f9-44d2d588bab9"], "spl_set_id": ["cb97d4a0-89ed-407c-a763-209386b6f75c"], "package_ndc": ["0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02"], "unii": ["7L3E358N9L"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-087-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-087", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "0074-9036-30", "generic_name": "Paricalcitol Capsule", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021606"], "brand_name": ["ZEMPLAR"], "generic_name": ["PARICALCITOL"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-9036", "0074-4314", "0074-4317", "0074-9037"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PARICALCITOL"], "rxcui": ["577315", "577317", "606854", "606859"], "spl_id": ["ed8862d9-4037-4a30-9be6-42f2613c34cd"], "spl_set_id": ["1b27c026-2d60-47b4-2a9c-ded1818f21b5"], "package_ndc": ["0074-4314-30", "0074-4317-30", "0074-4317-73", "0074-9036-30", "0074-9037-30"], "nui": ["M0007651", "N0000175907", "N0000175849"], "pharm_class_cs": ["Ergocalciferols [CS]"], "pharm_class_epc": ["Vitamin D2 Analog [EPC]", "Vitamin D Analog [EPC]"], "unii": ["6702D36OG5"]}, "update_date": "10/07/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Zemplar, Capsule, 1 ug (NDC 0074-9036-30)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-728-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-728", "71288-721", "71288-722", "71288-724", "71288-725", "71288-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-04", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA075880"], "brand_name": ["PREMASOL - SULFITE-FREE (AMINO ACID)"], "generic_name": ["LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1130", "0338-1131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "CYSTEINE HYDROCHLORIDE", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801395", "801398", "801403", "801405"], "spl_id": ["c874a813-b145-4f7f-833e-97d6c4dd727c"], "spl_set_id": ["9afdcc3e-0d06-47f4-86ca-40da48b2b02b"], "package_ndc": ["0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "ZT934N0X4W", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "61958-1401-1", "generic_name": "Cobicistat Tablet", "contact_info": "800-445-3235", "related_info": "Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons.", "openfda": {"application_number": ["NDA203094"], "brand_name": ["TYBOST"], "generic_name": ["COBICISTAT"], "manufacturer_name": ["Gilead Sciences, Inc."], "product_ndc": ["61958-1401", "61958-1402"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["COBICISTAT"], "rxcui": ["1551993", "1551999", "2719618", "2719620"], "spl_id": ["169d8571-3b28-4b3b-8def-18316f1297f3"], "spl_set_id": ["3784c35c-e87f-410c-900b-8fd6313c6010"], "package_ndc": ["61958-1401-1", "61958-1402-1"], "nui": ["N0000190114", "N0000191001", "N0000185503", "N0000182137", "N0000190107", "N0000190108", "N0000190113", "N0000191423"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]"], "pharm_class_epc": ["Cytochrome P450 3A Inhibitor [EPC]"], "unii": ["LW2E03M5PG"]}, "update_date": "10/07/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Tybost, Tablet, 150 mg (NDC 61958-1401-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-566-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-566", "47781-562", "47781-563", "47781-564", "47781-565", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "21586-012-02", "generic_name": "Cefotaxime Sodium Powder, for Solution", "related_info_link": "https://www.fda.gov/media/152896/download", "contact_info": "800-881-3550", "availability": "Available", "openfda": {"brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME INJECTION"], "manufacturer_name": ["SteriMax Inc."], "product_ndc": ["21586-012", "21586-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["1656313", "1656318"], "spl_id": ["425c90b3-5006-427e-95f6-93ee7918fb8b"], "spl_set_id": ["8efe3bd0-c43a-2bd6-e053-2a95a90a92fa"], "package_ndc": ["21586-011-01", "21586-011-02", "21586-012-01", "21586-012-02"], "unii": ["258J72S7TZ"]}, "update_date": "04/30/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)", "company_name": "SteriMax, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "83634-302-04", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Avenacy Inc."], "product_ndc": ["83634-302"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1b3f2803-b618-4447-b5ac-cd2bdc7de3e8"], "spl_set_id": ["7d0db0f7-bf4f-4b0b-9359-2a838626e04b"], "package_ndc": ["83634-302-42", "83634-302-02", "83634-302-43", "83634-302-04", "83634-302-41", "83634-302-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL; 4mL vial (NDC 83634-302-04)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-164-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-164", "42858-161", "42858-162", "42858-163", "42858-165", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5544-05", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018877"], "brand_name": ["ALLOPURINOL"], "generic_name": ["ALLOPURINOL"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5544", "0591-5543"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ALLOPURINOL"], "spl_id": ["f7e04d88-1d9b-47e6-a9ad-deb08af3c098"], "spl_set_id": ["a80fe56f-8d03-423f-8e2a-7ec8c9e5045b"], "package_ndc": ["0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05"], "nui": ["N0000175698", "N0000000206"], "pharm_class_epc": ["Xanthine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Xanthine Oxidase Inhibitors [MoA]"], "unii": ["63CZ7GJN5I"]}, "update_date": "02/19/2026", "therapeutic_category": ["Oncology", "Renal", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 300 mg (NDC 0591-5544-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0761-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0761", "0527-0760", "0527-0762", "0527-0763", "0527-0764", "0527-0765", "0527-0766"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-556-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-20", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088400"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-185"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["42c6c812-706a-425b-b8cb-931006e40484"], "spl_set_id": ["e71c6c83-d518-496c-b2ab-efd5987e4783"], "package_ndc": ["63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/23/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-04", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018931"], "brand_name": ["TRAVASOL"], "generic_name": ["LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0644"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801644", "801648"], "spl_id": ["e0279078-016d-48fd-8de1-c894422b33ff"], "spl_set_id": ["8543b5be-0f43-4891-9e56-d7c39fe839b5"], "package_ndc": ["0338-0644-03", "0338-0644-04", "0338-0644-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "JNJ23Q2COM", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-154", "72888-152", "72888-153"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-05)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "69918-501-05", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Spray", "presentation": "Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6856-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6856", "0378-6854", "0378-6855", "0378-6857", "0378-6858", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3568-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3568", "0480-3565", "0480-3566", "0480-3567", "0480-3569", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-00", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Information pending", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-153", "72888-152", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-00)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-463-16", "generic_name": "Docetaxel Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-205-03", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA217501"], "brand_name": ["HYDRALAZINE HYDROCHLORIDE"], "generic_name": ["HYDRALAZINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-205"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDRALAZINE HYDROCHLORIDE"], "rxcui": ["966571"], "spl_id": ["2926d221-0ca5-4379-ac53-773051ec5c79"], "spl_set_id": ["f3c806a4-b971-421c-bcb9-9979c6d7aaec"], "package_ndc": ["71288-205-01", "71288-205-02"], "unii": ["FD171B778Y"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-202-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088586"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-202", "63323-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1737757"], "spl_id": ["d19c26f4-1214-40f7-9680-43c885613306"], "spl_set_id": ["cddb2b22-fce3-8967-6e54-dca3df5ac4b3"], "package_ndc": ["63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02"], "unii": ["V13007Z41A"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "0228-2837-11", "generic_name": "Pilocarpine Hydrochloride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA020237"], "brand_name": ["PILOCARPINE HYDROCHLORIDE"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2837", "0228-2801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "rxcui": ["1000913", "1001004"], "spl_id": ["7db72b88-d664-4f26-901c-46c901b20d80"], "spl_set_id": ["610022b7-7dc9-405a-a580-104657f43bdf"], "package_ndc": ["0228-2801-11", "0228-2837-11"], "unii": ["0WW6D218XJ"]}, "update_date": "09/19/2025", "therapeutic_category": ["Other"], "dosage_form": "Tablet", "presentation": "Salagen, Tablet, 7.5 mg (NDC 0228-2837-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "0409-3382-21", "generic_name": "Sufentanil Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA074534"], "brand_name": ["SUFENTANIL CITRATE"], "generic_name": ["SUFENTANIL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3382"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRAVENOUS"], "substance_name": ["SUFENTANIL CITRATE"], "rxcui": ["1809097", "1809102", "1809104"], "spl_id": ["30ae65dc-5065-4eb9-880a-db8dcd2f5bb8"], "spl_set_id": ["20293943-46ff-4345-1aa4-929b4e017a25"], "package_ndc": ["0409-3382-11", "0409-3382-21", "0409-3382-12", "0409-3382-22", "0409-3382-15", "0409-3382-25"], "unii": ["S9ZFX8403R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/04/2025", "update_type": "New", "initial_posting_date": "09/04/2025", "package_ndc": "0378-3458-23", "generic_name": "Azelastine Hydrochloride; Fluticasone Propionate Nasal Spray", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA202236"], "brand_name": ["AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE"], "generic_name": ["AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-3458"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["NASAL"], "substance_name": ["AZELASTINE HYDROCHLORIDE", "FLUTICASONE PROPIONATE"], "rxcui": ["1797847"], "spl_id": ["6e1e173a-2d01-4e67-8361-dd30604bc8aa"], "spl_set_id": ["7b5cc5a0-0d47-46b5-b5fb-eb9cc248ae9e"], "package_ndc": ["0378-3458-23"], "unii": ["0L591QR10I", "O2GMZ0LF5W"]}, "update_date": "09/04/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Nasal Spray", "presentation": "Azelastine Hydrochloride; Fluticasone Propionate, Nasal Spray, 137 ug; 50 ug (NDC 0378-3458-23)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1388-1", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "877-835-5472", "availability": "Available", "openfda": {"application_number": ["ANDA207551"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1388", "70121-1389"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["795f643f-855c-4ba4-9bad-a96334c1a2fb"], "spl_set_id": ["eb1ba463-ab42-4f49-9ebe-3ad5af108326"], "package_ndc": ["70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7"], "unii": ["1018WH7F9I"]}, "update_date": "02/09/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6043-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA075772"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6043", "0641-6042", "0641-6041"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["25d6c438-45d2-4162-91c2-b5caa0f86bf3"], "spl_set_id": ["0c2c75c9-ed7b-46a8-9543-429bf2d8f090"], "package_ndc": ["0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-135-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-135", "72205-132", "72205-133", "72205-134", "72205-136", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-726-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA076772"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-726", "62037-725", "62037-734", "62037-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "spl_id": ["24aa9277-3773-489d-8459-f9215140c53f"], "spl_set_id": ["85ef422d-af27-4126-9841-6892af1871d6"], "package_ndc": ["62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"presentation": "Adipex-P, Tablet, 37.5 mg (NDC 57844-140-56)", "discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "57844-140-56", "generic_name": "Phentermine Hydrochloride Tablet", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "update_date": "06/13/2025", "therapeutic_category": ["Other"], "status": "To Be Discontinued", "dosage_form": "Tablet", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0304-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/185611/download?attachment", "contact_info": "610-937-6172", "availability": "Available", "openfda": {"brand_name": ["TEGLUTIK"], "generic_name": ["RILUZOLE"], "manufacturer_name": ["EDW PHARMA, INC"], "product_ndc": ["70726-0304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RILUZOLE"], "rxcui": ["2058147", "2675565"], "spl_id": ["4746bd79-5116-423c-e063-6394a90a17e1"], "spl_set_id": ["0f2b5cfc-a23d-699a-e063-6394a90a67d1"], "package_ndc": ["70726-0304-1"], "nui": ["N0000175740", "M0483511"], "pharm_class_epc": ["Benzothiazole [EPC]"], "pharm_class_cs": ["Benzothiazoles [CS]"], "unii": ["7LJ087RS6F"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9042-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071165"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9042", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-701-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-701", "60951-602", "60951-700", "60951-712"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-580-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-580", "23155-578", "23155-579", "23155-581", "23155-582", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 50 mg (NDC 23155-580-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-3724-32", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA020201"], "brand_name": ["DOBUTAMINE IN DEXTROSE"], "generic_name": ["DOBUTAMINE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3724", "0409-2347", "0409-2346", "0409-0025", "0409-0151", "0409-1100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["1c7cc97c-e244-4a4b-a4a1-8b70ca812107"], "spl_set_id": ["9943a961-3b50-4847-8a84-d8414ce38daa"], "package_ndc": ["0409-2347-31", "0409-2347-32", "0409-2346-31", "0409-2346-32", "0409-3724-11", "0409-3724-32", "0409-0025-01", "0409-0025-10", "0409-0151-01", "0409-0151-10", "0409-1100-01", "0409-1100-10"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-010-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 10 mg/.4 mL (NDC 82497-010-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-8072-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020646"], "brand_name": ["TIAGABINE HYDROCHLORIDE"], "generic_name": ["TIAGABINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8072", "0093-5030", "0093-5031", "0093-8076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TIAGABINE HYDROCHLORIDE"], "rxcui": ["1299903", "1299909", "1299911", "1299917"], "spl_id": ["2a8d7987-54ae-45d7-8224-361dac37e0a4"], "spl_set_id": ["953ef3cc-e3cb-480f-b9ea-256520fd62b8"], "package_ndc": ["0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56"], "unii": ["DQH6T6D8OY"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-461-57", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["ANDA070967"], "brand_name": ["SENSORCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-461", "63323-472", "63323-463", "63323-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620"], "spl_id": ["cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/13/2025", "update_type": "New", "initial_posting_date": "08/13/2025", "package_ndc": "66658-230-01", "generic_name": "Palivizumab Injection", "contact_info": "866-773-5274", "related_info": "Discontinuation of the manufacture of the drug. Product expected to be available through September 2026.", "openfda": {"application_number": ["BLA103770"], "brand_name": ["SYNAGIS"], "generic_name": ["PALIVIZUMAB"], "manufacturer_name": ["Swedish Orphan Biovitrum AB (publ)"], "product_ndc": ["66658-230", "66658-231"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PALIVIZUMAB"], "rxcui": ["1657341", "1657343", "1657361", "1657362"], "spl_id": ["48e6af70-cd93-3f1d-e063-6394a90a8104"], "spl_set_id": ["3a0096c7-8139-44cd-bba4-520ab05c2cb2"], "package_ndc": ["66658-231-01", "66658-230-01"], "nui": ["M0001357", "N0000175615", "N0000175623"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "pharm_class_moa": ["Fusion Protein Inhibitors [MoA]"], "pharm_class_epc": ["Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]"], "unii": ["DQ448MW7KS"]}, "update_date": "08/13/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01)", "company_name": "Swedish Orphan Biovitrum AB", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0480-7270-10", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077793"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-7270"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904481"], "spl_id": ["95e8c960-5096-43a9-8807-89cdf404a214"], "spl_set_id": ["f66cb1c1-5ff1-4b0b-89d0-8ecaee26b0b8"], "package_ndc": ["0480-7270-98", "0480-7270-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "72607-100-00", "generic_name": "Tazemetostat Hydrobromide Tablet", "contact_info": "(855)-463-5127", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA211723"], "brand_name": ["TAZVERIK"], "generic_name": ["TAZEMETOSTAT"], "manufacturer_name": ["Epizyme, Inc."], "product_ndc": ["72607-100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TAZEMETOSTAT HYDROBROMIDE"], "rxcui": ["2274384", "2274390"], "spl_id": ["c4bd8d8a-22c1-4911-a9b4-7368582d8e5d"], "spl_set_id": ["7db07b5f-4e22-467c-9c0a-f830b08dbb1d"], "package_ndc": ["72607-100-00"], "unii": ["6P89T5M073"]}, "update_date": "03/27/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Tazverik, Tablet, 200 mg (NDC 72607-100-00)", "company_name": "Epizyme, Inc. (An Ipsen Company)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-007-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 4% 10X5ML)  is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-551-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-551", "64850-550", "64850-552", "64850-553", "64850-554", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-163-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078450"], "brand_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-163", "65862-161", "65862-162"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["5842ecc2-874a-481b-8997-afa9d862dc5d"], "spl_set_id": ["50a58159-9572-4445-9859-b392632597da"], "package_ndc": ["65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "65219-447-20", "generic_name": "Etomidate Injection", "contact_info": "800-551-7176", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi 800-551-7176", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-447", "65219-445"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["30488a7e-ea9e-4a27-95a9-a07149c50282"], "spl_set_id": ["d07efb9e-5264-461d-96d8-e11fa71c5751"], "package_ndc": ["65219-445-01", "65219-445-10", "65219-447-02", "65219-447-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/mL (NDC 65219-447-20)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "55150-313-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA211930"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-313", "55150-314"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["25c5133c-ee17-4be0-88a3-d0231e38f5a0"], "spl_set_id": ["a0cbcdb5-f657-49f7-8f86-cc5959d69db0"], "package_ndc": ["55150-313-25", "55150-313-01", "55150-314-25", "55150-314-01"], "unii": ["43502P7F0P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-120-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-120", "57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2021", "package_ndc": "63323-351-20", "generic_name": "Rifampin Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA091181"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-351"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["RIFAMPIN"], "rxcui": ["312821"], "spl_id": ["60eb9c46-3c34-455b-a740-c03884565072"], "spl_set_id": ["a1f9f1e2-dfc0-4d31-a13b-b656d897b791"], "package_ndc": ["63323-351-20"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Rifampin, Injection, 600 mg (NDC 63323-351-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "67457-228-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA079199"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["b65fbcab-781e-4706-a60b-a8eb4aeae0c1"], "spl_set_id": ["f58803b0-f173-4997-b2f8-0f415b94dacf"], "package_ndc": ["67457-228-00", "67457-228-05", "67457-228-99", "67457-228-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-813-28", "generic_name": "Ivabradine Solution", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA209964"], "brand_name": ["CORLANOR"], "generic_name": ["IVABRADINE"], "manufacturer_name": ["Amgen Inc"], "product_ndc": ["55513-813", "55513-800", "55513-810"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IVABRADINE HYDROCHLORIDE"], "rxcui": ["1649485", "1649491", "1649493", "1649495", "2168592", "2168596"], "spl_id": ["8ab000cd-0258-489a-b1bb-4cc1ca359d6c"], "spl_set_id": ["92018a65-38f6-45f7-91d4-a34921b81d0d"], "package_ndc": ["55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28"], "unii": ["TP19837BZK"]}, "update_date": "03/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Solution", "presentation": "Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28)", "company_name": "Amgen Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-13", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-137-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-137", "16729-136", "16729-138"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 16729-137-16)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-412-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": {"application_number": ["ANDA205823"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Solco Healthcare US, LLC"], "product_ndc": ["43547-412", "43547-410", "43547-411", "43547-413"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["b8f1731a-cbac-4f64-a8d4-320b80b335e1"], "spl_set_id": ["cd46691d-5593-4a9f-a937-999c6803e312"], "package_ndc": ["43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0338-0411-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018461"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0411", "0338-0409"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e9121a0-25dd-46ba-a2b7-6f71fc3ff9cd"], "spl_set_id": ["f21512ea-c7c3-4766-b976-b2c0b5616bf0"], "package_ndc": ["0338-0409-03", "0338-0409-02", "0338-0411-02"], "unii": ["V13007Z41A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-154", "72888-152", "72888-153"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-30)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-31", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4310-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023", "update_date": "04/28/2023", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 1 mg (NDC 0069-4310-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-5095-06", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-581-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-581", "23155-578", "23155-579", "23155-580", "23155-582", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 75 mg (NDC 23155-581-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "63323-122-50", "generic_name": "Methotrexate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["ANDA040266"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-122"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["311625"], "spl_id": ["3d21237a-ef53-4592-bf06-0c739696203d"], "spl_set_id": ["ec476b11-0b3c-4139-b1eb-a3daa76bc271"], "package_ndc": ["63323-122-50"], "unii": ["3IG1E710ZN"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0527-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 5 mg (NDC 0071-0527-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-422-54", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA040803"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-422", "67457-423", "67457-421", "67457-420"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["dd5c82b6-a194-462c-9626-34a9b410cfea"], "spl_set_id": ["dff598e8-e662-411f-978d-4ba3fb8ef7db"], "package_ndc": ["67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-462-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-462", "65219-456", "65219-464", "65219-458", "65219-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "10147-0570-1", "generic_name": "Etravirine Tablet", "contact_info": "800-526-7736", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA022187"], "brand_name": ["ETRAVIRINE"], "generic_name": ["ETRAVIRINE"], "manufacturer_name": ["Patriot Pharmaceuticals"], "product_ndc": ["10147-0570", "10147-0571"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ETRAVIRINE"], "rxcui": ["754761", "1052658"], "spl_id": ["31cddc7a-0154-c49a-e063-6394a90a1a49"], "spl_set_id": ["50ca19cb-0f43-4d7b-8c9e-8b3aaded0546"], "package_ndc": ["10147-0570-1", "10147-0571-1"], "nui": ["N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000185504", "N0000182140", "N0000185503"], "pharm_class_epc": ["Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "unii": ["0C50HW4FO1"]}, "update_date": "04/28/2026", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Etravirine, Tablet, 100 mg (NDC 10147-0570-1)", "company_name": "Janssen Research and Development", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-604-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-604", "43547-602", "43547-603", "43547-605", "43547-606", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/24/2019", "package_ndc": "48102-053-05", "generic_name": "Echothiophate Iodide Ophthalmic Solution", "contact_info": "516-277-1449", "availability": "Available", "related_info": "Available through limited distribution by Walgreens Specialty Pharmacy.", "openfda": {"application_number": ["NDA011963"], "brand_name": ["PHOSPHOLINE IODIDE"], "generic_name": ["ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION"], "manufacturer_name": ["Fera Pharmaceuticals, LLC"], "product_ndc": ["48102-053"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "rxcui": ["205739", "310049"], "spl_id": ["66abcfcf-b16e-4181-b1db-96bfba0ab95e"], "spl_set_id": ["8afc8951-db76-4f27-8752-7c0d6aa47244"], "package_ndc": ["48102-053-05", "48102-054-05", "48102-055-05"]}, "update_date": "09/17/2025", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)", "company_name": "Fera Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/27/2023", "package_ndc": "69945-094-20", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "888-744-1414", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA017538"], "brand_name": ["TECHNESCAN PYP"], "generic_name": ["TECHNETIUM TC 99M PYROPHOSPHATE"], "manufacturer_name": ["Curium US LLC"], "product_ndc": ["69945-094"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM PYROPHOSPHATE", "STANNOUS CHLORIDE"], "spl_id": ["45358120-83e7-a04b-e063-6394a90af91e"], "spl_set_id": ["304b63f4-a32e-4700-805d-5bc9f27e7d6a"], "package_ndc": ["69945-094-01", "69945-094-20"], "unii": ["O352864B8Z", "1BQV3749L5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Medical Imaging"], "dosage_form": "Injection", "presentation": "Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)", "company_name": "Curium US LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-725-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-725", "71288-721", "71288-722", "71288-724", "71288-727", "71288-728"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "0781-8017-31", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021192"], "brand_name": ["FLUVASTATIN SODIUM ER"], "generic_name": ["FLUVASTATIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-8017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUVASTATIN SODIUM"], "rxcui": ["360507"], "spl_id": ["37375ca6-3a81-4d10-9b39-9aee948e51a4"], "spl_set_id": ["5ab4296c-87c2-4c64-b218-d620eef51310"], "package_ndc": ["0781-8017-31", "0781-8017-01"], "unii": ["PYF7O1FV7F"]}, "update_date": "01/27/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4278-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088328"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4278", "0409-4713", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "83831-141-08", "generic_name": "Carboplatin Injection", "contact_info": "877-595-7337; customerservice@avyxa.com", "availability": "Available", "openfda": {"application_number": ["NDA219921"], "brand_name": ["KYXATA"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Avyxa Pharma, LLC"], "product_ndc": ["83831-141", "83831-140", "83831-142"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195", "2721602"], "spl_id": ["5c711945-70be-42f4-b153-e1459dd9929c"], "spl_set_id": ["f91c48da-68d1-4aa7-89b8-d84a3e8b629b"], "package_ndc": ["83831-140-02", "83831-141-08", "83831-142-50"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/15/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)", "company_name": "Avyxa Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6029-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6029", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6030", "0641-6247", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2855-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA200881"], "brand_name": ["GUANFACINE"], "generic_name": ["GUANFACINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2855", "0228-2850", "0228-2851", "0228-2853"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GUANFACINE HYDROCHLORIDE"], "rxcui": ["862006", "862013", "862019", "862025"], "spl_id": ["b9040df2-42e8-404d-9b90-331dd3efc38c"], "spl_set_id": ["3a171942-37af-430d-8b9d-bb678ca2be4b"], "package_ndc": ["0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11"], "unii": ["PML56A160O"]}, "update_date": "11/13/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 4 mg (NDC 0228-2855-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-162-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-162", "42858-161", "42858-163", "42858-164", "42858-165", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6084-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "This presentation is temporarily on backorder.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PHENERGAN"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6084", "0641-6085"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992462", "992858", "992876"], "spl_id": ["7d6e64fc-bbf2-4ea9-b866-8115c448e687"], "spl_set_id": ["481866da-a712-48a5-853f-8e84aacaab6d"], "package_ndc": ["0641-6084-01", "0641-6084-25", "0641-6085-01", "0641-6085-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3183-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: June 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089651"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3183", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3182", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "71288-563-84", "generic_name": "Liraglutide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA218115"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-563"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["c4f6adef-1b2a-4e7c-b7a9-b19d4ed1df36"], "spl_set_id": ["0efc3a89-211a-4496-baab-e8265e07de2b"], "package_ndc": ["71288-563-84", "71288-563-85"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "08/19/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-403-15", "generic_name": "Insulin Degludec Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Degludec 3 mL U-100 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA203314"], "brand_name": ["INSULIN DEGLUDEC"], "generic_name": ["INSULIN DEGLUDEC"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-403", "73070-503", "73070-400"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN DEGLUDEC"], "rxcui": ["1670011", "1670021", "2107520"], "spl_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "spl_set_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "package_ndc": ["73070-403-15", "73070-503-15", "73070-400-11"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["54Q18076QB"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Degludec, Injection, 3 mL Insulin Degludec 100 units/mL (U-100) FlexTouch® (NDC 73070-403-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1573-1", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Limited Availability", "related_info": "Currently Inventory available 4 to 6 weeks as per current demand. Next supply: week of 02/09/2026", "openfda": {"application_number": ["ANDA210043"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1573", "70121-1574"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743855"], "spl_id": ["af4215ff-94ca-44f8-8506-3024e738cd13"], "spl_set_id": ["d944240d-2c19-46ba-ad4f-3fbee7b8629c"], "package_ndc": ["70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5"], "unii": ["43502P7F0P"]}, "update_date": "02/09/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-027-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-027", "65162-023", "65162-024", "65162-025", "65162-026", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3476-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": {"application_number": ["ANDA206812"], "brand_name": ["FONDAPARINUX SODIUM"], "generic_name": ["FONDAPARINUX SODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3476", "0781-3443", "0781-3454", "0781-3465"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FONDAPARINUX SODIUM"], "rxcui": ["861356", "861360", "861363", "861365"], "spl_id": ["3d5a4b69-462b-7e51-e063-6294a90a0721"], "spl_set_id": ["baa50757-a927-4d56-a933-5d7798fe6ab0"], "package_ndc": ["0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95"], "unii": ["X0Q6N9USOZ"]}, "update_date": "09/29/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "68094-909-50", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Precision Dose Inc."], "product_ndc": ["68094-909"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["efc0724d-4c6e-4974-928c-fd50774f5980"], "spl_set_id": ["b09b4b5e-795a-48e7-b7cc-2e29f41c5660"], "package_ndc": ["68094-909-30", "68094-909-50"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-50)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-99", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018801"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4887"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["055437a7-5be5-414a-a97a-946e2730fe12"], "spl_set_id": ["2b9ea23a-f9e9-48a8-25b7-519e3bbd6828"], "package_ndc": ["0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-04", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated availability: May 2026", "openfda": {"application_number": ["NDA017428"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0004", "0338-0003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["97390588-b679-4caa-b7f3-3d2e11074d0e"], "spl_set_id": ["ef3e79c5-3f58-4b36-a296-64b7d9a651c1"], "package_ndc": ["0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-582-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-582", "23155-578", "23155-579", "23155-580", "23155-581", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 100 mg (NDC 23155-582-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5093-11", "generic_name": "Ceftazidime Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA064032"], "brand_name": ["TAZICEF"], "generic_name": ["CEFTAZIDIME"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5093", "0409-5092"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CEFTAZIDIME"], "rxcui": ["1659283", "1659287", "1659292", "1659294"], "spl_id": ["3f749ee0-db14-4ed0-9056-d545a38bbe3b"], "spl_set_id": ["9b73979c-c95a-4433-0a9d-f9cea3cb557f"], "package_ndc": ["0409-5092-11", "0409-5092-16", "0409-5093-14", "0409-5093-11"], "unii": ["9M416Z9QNR"]}, "update_date": "11/14/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Tazicef, Injection, 2 g (NDC 0409-5093-11)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018931"], "brand_name": ["TRAVASOL"], "generic_name": ["LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0644"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801644", "801648"], "spl_id": ["e0279078-016d-48fd-8de1-c894422b33ff"], "spl_set_id": ["8543b5be-0f43-4891-9e56-d7c39fe839b5"], "package_ndc": ["0338-0644-03", "0338-0644-04", "0338-0644-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "JNJ23Q2COM", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-603-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": {"application_number": ["NDA206628"], "brand_name": ["DEXMEDETOMIDINE IN DEXTROSE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["WG Critical Care, LLC"], "product_ndc": ["44567-603", "44567-600", "44567-601", "44567-602"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909", "1788947"], "spl_id": ["e6fa3e27-b374-49b6-a678-a5954f5beae8"], "spl_set_id": ["0d2710f2-ee47-4114-ab5c-8dca74cdcb8d"], "package_ndc": ["44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)", "company_name": "HQ Specialty Pharma", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-501-43", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070017"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-501", "16729-500", "16729-502"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1cfab300-d796-6a68-e063-6394a90a73f9"], "spl_set_id": ["f6f64972-714c-4ee9-8a5e-9ffcab41a73b"], "package_ndc": ["16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1890-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1890", "0409-1891", "0409-1892", "0409-1893", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0409-1060-01", "generic_name": "Pemetrexed Ditromethamine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "07/17/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Pemetrexed Ditromethamine, Injection, 100 mg Single Dose Vial (NDC 0409-1060-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6054-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA080445"], "brand_name": ["MEPERIDINE HYDROCHLORIDE"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6054", "0641-6053", "0641-6052"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["861476", "1665685", "1665697"], "spl_id": ["9566d54d-7343-4695-94ff-8b5f2d384c81"], "spl_set_id": ["e0e998da-f056-4fce-be8e-ed60cf3b461b"], "package_ndc": ["0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25"], "unii": ["N8E7F7Q170"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-111-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "25021-321-10", "generic_name": "Bumetanide Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Product in transit, expected to arrive last week of April 2026", "openfda": {"application_number": ["ANDA074441"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-321"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["befc1cf3-b71c-4228-bc42-3495b1d4b00d"], "spl_set_id": ["c38a404d-a919-4a2c-9fbb-d0655dee9516"], "package_ndc": ["25021-321-04", "25021-321-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0078-0379-05", "generic_name": "Amlodipine Besylate; Benazepril Hydrochloride Capsule", "contact_info": "888-669-6682", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA020364"], "brand_name": ["LOTREL"], "generic_name": ["AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "product_ndc": ["0078-0379", "0078-0405", "0078-0406", "0078-0364"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMLODIPINE BESYLATE", "BENAZEPRIL HYDROCHLORIDE"], "rxcui": ["898342", "898344", "898346", "898348", "898353", "898355", "898356", "898358"], "spl_id": ["b9db75d9-9d1e-4b2d-9876-5f5520feaecc"], "spl_set_id": ["94ae6054-b7ae-4212-a567-4f803af8f2c7"], "package_ndc": ["0078-0405-05", "0078-0406-05", "0078-0364-05", "0078-0379-05"], "unii": ["864V2Q084H", "N1SN99T69T"]}, "update_date": "06/24/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Lotrel, Capsule, 10 mg; 40 mg (NDC 0078-0379-05)", "company_name": "Novartis Pharmaceuticals Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-808-11", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA212086"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-808", "63323-810"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["2474267", "2474269"], "spl_id": ["a47a3a31-e293-49d5-b6bc-950303525a64"], "spl_set_id": ["0c10e465-4117-48ba-a454-23ccb7a3fcc7"], "package_ndc": ["63323-808-01", "63323-808-11", "63323-810-00", "63323-810-20"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1389-7", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Inventory available 4 to 8 weeks as per current demand. Next supply: week of 2/23/2026", "openfda": {"application_number": ["ANDA207551"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1389", "70121-1388"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["795f643f-855c-4ba4-9bad-a96334c1a2fb"], "spl_set_id": ["eb1ba463-ab42-4f49-9ebe-3ad5af108326"], "package_ndc": ["70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7"], "unii": ["1018WH7F9I"]}, "update_date": "02/09/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-20", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7520", "0264-7510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-282-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA202747"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["36000-282", "36000-063", "36000-064", "36000-065", "36000-283", "36000-284"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53"], "spl_set_id": ["c71371a7-75c5-45b8-b762-8d782d4c71bc"], "package_ndc": ["36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3365-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3365", "0409-2552", "0409-3356", "0409-2540", "0409-1283", "0409-1312", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "897756", "897757", "897758", "1724276", "1724383", "1724644"], "spl_id": ["a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/20/2025", "update_type": "New", "initial_posting_date": "10/20/2025", "package_ndc": "0781-3315-70", "generic_name": "Oxaliplatin Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078817"], "brand_name": ["OXALIPLATIN"], "generic_name": ["OXALIPLATIN"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3315", "0781-3317"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["OXALIPLATIN"], "rxcui": ["1736776", "1736781"], "spl_id": ["f3766495-fce3-461c-8c95-e890f5e3383f"], "spl_set_id": ["ab162009-6f84-4d56-ab56-5e84409ec814"], "package_ndc": ["0781-3315-70", "0781-3317-80"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["04ZR38536J"]}, "update_date": "10/20/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3315-70)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0025-1381-31", "generic_name": "Oxaprozin Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "07/17/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Daypro, Tablet, 600 mg (NDC 0025-1381-31)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-23", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2022", "package_ndc": "0487-9901-30", "generic_name": "Albuterol Sulfate Solution", "contact_info": "800-443-4313", "availability": "Available", "related_info": "Albuterol 0.5% is in stock, though demand remains high; additional supply can be produced as needed.", "openfda": {"application_number": ["ANDA075664"], "brand_name": ["ALBUTEROL SULFATE"], "generic_name": ["ALBUTEROL SULFATE"], "manufacturer_name": ["Nephron Pharmaceuticals Corporation"], "product_ndc": ["0487-9901"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["ALBUTEROL SULFATE"], "rxcui": ["245314"], "spl_id": ["30dbae21-c906-0624-e063-6394a90a299c"], "spl_set_id": ["ecc00500-58b8-491f-80df-dc6c89a08cae"], "package_ndc": ["0487-9901-30", "0487-9901-02"], "unii": ["021SEF3731"]}, "update_date": "05/15/2026", "therapeutic_category": ["Pulmonary/Allergy", "Pediatric"], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)", "company_name": "Nephron Pharmaceuticals Corporation", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0555-9131-67", "generic_name": "Drospirenone; Ethinyl Estradiol Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA021098"], "brand_name": ["OCELLA"], "generic_name": ["DROSPIRENONE AND ETHINYL ESTRADIOL"], "manufacturer_name": ["TEVA PHARMACEUTICALS USA, INC."], "product_ndc": ["0555-9131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["284207", "748797", "748800", "801185"], "spl_id": ["7aced6b3-f763-4234-9b64-2ffdae162347"], "spl_set_id": ["0d729f4d-2fa3-47f6-8a1f-d8cfea4cff37"], "package_ndc": ["0555-9131-79", "0555-9131-67"]}, "update_date": "06/13/2025", "therapeutic_category": ["Reproductive"], "dosage_form": "Tablet", "presentation": "Yasmin, Tablet, Kit (NDC 0555-9131-67)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-03", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089644"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5114-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5114", "0406-5111", "0406-5112", "0406-5113", "0406-5115", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075154"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-411", "63323-412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-088-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-088", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9408-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA061395"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9408", "0781-9401", "0781-9402", "0781-9407", "0781-9404"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["308207", "1721473", "1721474", "1721475", "1721476"], "spl_id": ["a3ddae6c-ac4c-425f-82b0-eb388d92bc0e"], "spl_set_id": ["b371e1a5-1fef-4df2-8940-c4fc02b9e2f0"], "package_ndc": ["0781-9401-78", "0781-9401-95", "0781-9402-78", "0781-9402-95", "0781-9407-78", "0781-9407-95", "0781-9404-85", "0781-9404-95", "0781-9408-80", "0781-9408-95"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8235-99", "generic_name": "Insulin Lispro-aabc Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["BLA761109"], "brand_name": ["LYUMJEV TEMPO PEN"], "generic_name": ["INSULIN LISPRO-AABC"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8235", "0002-7728", "0002-7726", "0002-8207", "0002-8351", "0002-8228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN LISPRO"], "rxcui": ["2380231", "2380236", "2380248", "2380250", "2380254", "2380256", "2380259", "2380260", "2380265", "2380266", "2380267", "2380268"], "spl_id": ["567d0b77-239e-4a05-9d84-8364e0e1ef7a"], "spl_set_id": ["c5a056e2-b568-4ca6-9ed8-79c010942d00"], "package_ndc": ["0002-7728-01", "0002-7728-99", "0002-7726-01", "0002-7726-05", "0002-8207-01", "0002-8207-05", "0002-8207-61", "0002-8351-01", "0002-8351-05", "0002-8235-01", "0002-8235-05", "0002-8235-99", "0002-8228-01", "0002-8228-27"], "nui": ["N0000004931", "N0000175453"], "pharm_class_cs": ["Insulin [Chemical/Ingredient]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["GFX7QIS1II"]}, "update_date": "10/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1574-1", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Currently Inventory available 4 to 8 Weeks as per current demand. Next supply: week of 03/16/2026", "openfda": {"application_number": ["ANDA210043"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1574", "70121-1573"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743855"], "spl_id": ["af4215ff-94ca-44f8-8506-3024e738cd13"], "spl_set_id": ["d944240d-2c19-46ba-ad4f-3fbee7b8629c"], "package_ndc": ["70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5"], "unii": ["43502P7F0P"]}, "update_date": "02/09/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "84383-110-01", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/192256/download", "contact_info": "Mark Cuban Cost Plus Drug Company: 682-428-8081", "availability": "Available", "openfda": {"brand_name": ["LENTOCILIN"], "generic_name": ["PENICILLIN G BENZATHIN"], "manufacturer_name": ["LABORATRIOS ATRAL, S.A."], "product_ndc": ["84383-110"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PENICILLIN G BENZATHINE"], "rxcui": ["2671687", "2684991"], "spl_id": ["1a4e5124-618c-ce44-e063-6394a90a43e3"], "spl_set_id": ["1a4e5124-618b-ce44-e063-6394a90a43e3"], "package_ndc": ["84383-110-01"], "unii": ["RIT82F58GK"]}, "update_date": "04/30/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)", "company_name": "Laboratorios Atral", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-652-82", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-652", "25021-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3454-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": {"application_number": ["ANDA206812"], "brand_name": ["FONDAPARINUX SODIUM"], "generic_name": ["FONDAPARINUX SODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3454", "0781-3443", "0781-3465", "0781-3476"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FONDAPARINUX SODIUM"], "rxcui": ["861356", "861360", "861363", "861365"], "spl_id": ["3d5a4b69-462b-7e51-e063-6294a90a0721"], "spl_set_id": ["baa50757-a927-4d56-a933-5d7798fe6ab0"], "package_ndc": ["0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95"], "unii": ["X0Q6N9USOZ"]}, "update_date": "09/29/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0338-0069-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA209900"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0069", "0338-0072", "0338-0076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2da4dd8a-1b18-481d-b733-9c031d9ea7e3"], "spl_set_id": ["4b58836d-9d58-4539-9691-9e11c505ef2a"], "package_ndc": ["0338-0069-10", "0338-0072-25", "0338-0076-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-339-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-339", "42806-341", "42806-343", "42806-344", "42806-345"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-7202-98", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7202", "0093-0771", "0093-7201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "55150-296-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "62135-242-60", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "845-268-5000 Ext. 510", "resolved_note": "Available", "openfda": {"application_number": ["ANDA207905"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-242"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["1adc57cf-70f9-75b9-e063-6294a90a0de0"], "spl_set_id": ["adb7c4dc-221a-4d91-9687-0d78913a92ad"], "package_ndc": ["62135-242-30", "62135-242-60", "62135-242-90"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 62135-242-60)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "51759-523-21", "generic_name": "Adalimumab-ryvk Kit", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["BLA761299"], "brand_name": ["SIMLANDI"], "generic_name": ["ADALIMUMAB-RYVK"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["51759-523", "51759-402", "51759-386", "51759-412", "51759-274"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["797544", "2677780", "2677787", "2688819", "2688823", "2688826", "2688827", "2688828", "2688829", "2706644", "2706645"], "spl_id": ["90174eed-a6f4-4153-92a1-623aadbcdc24"], "spl_set_id": ["12f609c9-2088-bb05-e063-6394a90a9ecc"], "package_ndc": ["51759-402-02", "51759-402-17", "51759-513-21", "65517-0002-1", "51759-386-22", "51759-497-31", "51759-412-22", "51759-624-31", "51759-523-21", "51759-634-31", "51759-274-17"]}, "update_date": "11/13/2025", "therapeutic_category": ["Rheumatology"], "presentation": "Simlandi, Kit, Kit (NDC 51759-523-21)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/24/2017", "package_ndc": "63323-083-05", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA206688"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-083", "63323-089"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868469", "1868486"], "spl_id": ["9def795c-abcf-483c-8b1d-e4374666efb2"], "spl_set_id": ["0ab55004-bb63-436d-ad77-cd3796905370"], "package_ndc": ["63323-083-03", "63323-083-05", "63323-089-25", "63323-089-50"], "unii": ["8MDF5V39QO"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6056-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6056", "0641-6057", "0641-6059", "0641-6061", "0641-6063", "0641-6060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-06", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Check Wholesaler for Availability; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb"], "spl_set_id": ["abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f"], "package_ndc": ["0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5165-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5165", "0603-5166", "0603-5167", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"presentation": "Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)", "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0409-7620-59", "generic_name": "Heparin Sodium Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Hematology"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-10", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088400"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-185"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["42c6c812-706a-425b-b8cb-931006e40484"], "spl_set_id": ["e71c6c83-d518-496c-b2ab-efd5987e4783"], "package_ndc": ["63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/23/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-345-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-345", "42806-339", "42806-341", "42806-343", "42806-344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-711-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["NDA216117"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-711", "13811-700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2605796", "2605798"], "spl_id": ["ba649db4-df0d-4587-8370-3f866e66e54b"], "spl_set_id": ["dd8d7b6e-c23d-4e16-bb53-959e9127ebc6"], "package_ndc": ["13811-711-30", "13811-700-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "25021-661-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA090850"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-661"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311702"], "spl_id": ["002ea282-09ba-4d79-8bd1-94c9859f442b"], "spl_set_id": ["880cac48-5c0f-49a9-8aef-3c9770bf5d84"], "package_ndc": ["25021-661-10"], "unii": ["W7TTW573JJ"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-01", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-01)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-22", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: September 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-339"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0ddf4411-7138-412a-908a-fadf22bdfb79"], "spl_set_id": ["c3ae9880-44bb-4f4e-93d8-8a5e21708a30"], "package_ndc": ["61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-1495-35", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-1495", "0641-1496"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992858"], "spl_id": ["80a400d2-d293-4180-bfa7-7a8ce0734bc5"], "spl_set_id": ["13d9e59d-eadb-41d5-9f47-9c11a6efb31c"], "package_ndc": ["0641-1495-31", "0641-1495-35", "0641-1496-31", "0641-1496-35"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "16729-483-03", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA212868"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Accord Healthcare, Inc.,"], "product_ndc": ["16729-483", "16729-484"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["4082a1cf-1e1b-6f40-e063-6294a90aec06"], "spl_set_id": ["c82cb295-ffce-47d6-97ad-a8aa723f4e4f"], "package_ndc": ["16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-014-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability June 2026", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-014", "72516-016", "72516-015", "72516-013", "72516-012", "72516-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/21/2025", "update_type": "New", "initial_posting_date": "10/21/2025", "package_ndc": "0591-5590-01", "generic_name": "Tranylcypromine Sulfate Tablet", "contact_info": "800-545-8800", "related_info": "Supply is expected to be depleted by 12/31/2025.", "openfda": {"application_number": ["NDA012342"], "brand_name": ["TRANYLCYPROMINE SULFATE"], "generic_name": ["TRANYLCYPROMINE SULFATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5590"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TRANYLCYPROMINE SULFATE"], "rxcui": ["313447"], "spl_id": ["e42c8b23-863e-4370-a3b1-b71526b12ee5"], "spl_set_id": ["6a0b609b-0625-4c26-91a1-59ee3ece3ddf"], "package_ndc": ["0591-5590-01"], "unii": ["7ZAT6ES870"]}, "update_date": "10/21/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Parnate, Tablet, 10 mg (NDC 0591-5590-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2347-32", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA020201"], "brand_name": ["DOBUTAMINE IN DEXTROSE"], "generic_name": ["DOBUTAMINE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2347", "0409-2346", "0409-3724", "0409-0025", "0409-0151", "0409-1100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["1c7cc97c-e244-4a4b-a4a1-8b70ca812107"], "spl_set_id": ["9943a961-3b50-4847-8a84-d8414ce38daa"], "package_ndc": ["0409-2347-31", "0409-2347-32", "0409-2346-31", "0409-2346-32", "0409-3724-11", "0409-3724-32", "0409-0025-01", "0409-0025-10", "0409-0151-01", "0409-0151-10", "0409-1100-01", "0409-1100-10"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-175-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-175", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 175 ug (NDC 72305-175-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0049-3190-01", "generic_name": "Voriconazole Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021267"], "brand_name": ["VFEND"], "generic_name": ["VORICONAZOLE"], "manufacturer_name": ["Roerig"], "product_ndc": ["0049-3190", "0049-3170", "0049-3180", "0049-3160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VORICONAZOLE"], "rxcui": ["351209", "352220", "349434", "349435", "352218", "352219", "465355", "546624"], "spl_id": ["8b24199e-0319-4538-a971-19d5ac52fd35", "cf9f1b2e-eeb4-48bb-9f1a-c2b8d94dfbea"], "spl_set_id": ["dac26bcd-7a59-401f-9f66-a0649767cece", "ce3ef5cf-3087-4d92-9d94-9eb8287228db"], "package_ndc": ["0049-3190-01", "0049-3170-30", "0049-3180-30", "0049-3190-28", "0049-3160-44"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000182140", "N0000185504"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]"], "unii": ["JFU09I87TR"]}, "update_date": "10/16/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Vfend, Injection, 10 mg/1 mL (NDC 0049-3190-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "69238-1627-6", "generic_name": "Dapsone Gel", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA212701"], "brand_name": ["DAPSONE"], "generic_name": ["DASPONE"], "manufacturer_name": ["Amneal Pharmaceuticals NY LLC"], "product_ndc": ["69238-1627"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DAPSONE"], "rxcui": ["1741905"], "spl_id": ["0622cdcc-1196-4a2f-8c85-6f34f0f97f9d"], "spl_set_id": ["fba0b181-077a-4667-bde1-cf9592f120c2"], "package_ndc": ["69238-1627-6", "69238-1627-9"], "nui": ["N0000175881", "M0020791"], "pharm_class_epc": ["Sulfone [EPC]"], "pharm_class_cs": ["Sulfones [CS]"], "unii": ["8W5C518302"]}, "update_date": "03/27/2026", "therapeutic_category": ["Dermatology"], "dosage_form": "Gel", "presentation": "Dapsone, Gel, 7.5% (NDC 69238-1627-6)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-162-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA075784"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-162", "63323-161"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4"], "spl_set_id": ["ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c"], "package_ndc": ["63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4282-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088294"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4282", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-001-01", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 59212-001-01)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "25021-701-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-701", "25021-700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["cb23332a-48fa-458b-93ab-c4eef189a051"], "spl_set_id": ["62591551-a644-4b2c-a0de-982e906fabc3"], "package_ndc": ["25021-700-01", "25021-701-01", "25021-701-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/20/2026", "update_type": "New", "initial_posting_date": "04/20/2026", "package_ndc": "0378-1134-01", "generic_name": "Ketorolac Tromethamine Tablet", "contact_info": "877-446-3679", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074761"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-1134"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["834022"], "spl_id": ["a2e96323-5726-45ce-9e73-f143f122b06b"], "spl_set_id": ["2837a082-3a34-6f81-5e43-45a70295686b"], "package_ndc": ["0378-1134-01"], "unii": ["4EVE5946BQ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Ketorolac Tromethamine, Tablet, 10 mg (NDC 0378-1134-01)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4904-34", "generic_name": "Lidocaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-567-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-567", "47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075154", "ANDA208878"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-412", "63323-411"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552", "cca4b16a-900d-4c74-86f5-bb9e5587a02a"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc", "09daf48f-1d44-4b7b-bb53-bd5635b93ca6"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10", "63323-412-00"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "51224-206-50", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["TAGI Pharma Inc."], "product_ndc": ["51224-206"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["75a00517-674b-4e87-b37b-598486aedf03"], "spl_set_id": ["60276f5c-657a-4b60-bcd0-44234903d7e0"], "package_ndc": ["51224-206-30", "51224-206-50"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-50)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-587-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": {"application_number": ["NDA021121"], "brand_name": ["CONCERTA"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-587", "50458-585", "50458-588", "50458-586"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212"], "spl_id": ["64d7c1e1-e7ed-4d74-a44d-13b4da64af9a"], "spl_set_id": ["1a88218c-5b18-4220-8f56-526de1a276cd"], "package_ndc": ["50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6020-10", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["NDA018565"], "brand_name": ["DURAMORPH"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6020", "0641-6019"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892473", "892489", "1728783", "1728800"], "spl_id": ["aa74af85-7068-4254-9a79-c7f3792044a6"], "spl_set_id": ["ebb18761-e5c4-4238-bb84-f9549f500210"], "package_ndc": ["0641-6020-01", "0641-6020-10", "0641-6019-01", "0641-6019-10"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "25357-025-03", "generic_name": "Riboflavin 5-phosphate  Ophthalmic Solution", "contact_info": "949-367-9600", "related_info": "Discontinuing manufacture of the product as of June 2026.", "openfda": {"application_number": ["NDA203324"], "brand_name": ["PHOTREXA CROSS-LINKING KIT"], "generic_name": ["RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC"], "manufacturer_name": ["Glaukos Corporation"], "product_ndc": ["25357-025"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["1925825", "1925830"], "spl_id": ["26dc098f-5920-43c2-aa95-5d1953734523"], "spl_set_id": ["f82cfe92-1a24-11e3-8ffd-0800200c9a66"], "package_ndc": ["25357-025-03"]}, "update_date": "01/20/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03)", "company_name": "Glaukos Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/03/2025", "package_ndc": "0574-4022-35", "generic_name": "Bacitracin Ophthalmic Ointment", "contact_info": "866-634-9120", "availability": "Unavailable", "related_info": "Shortage is estimated for 20 months", "update_date": "02/04/2026", "therapeutic_category": ["Anti-Infective", "Ophthalmology"], "dosage_form": "Ophthalmic Ointment", "presentation": "Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)", "company_name": "Padagis US LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2022", "package_ndc": "64980-642-03", "generic_name": "Albuterol Sulfate Solution", "contact_info": "201-961-9000", "availability": "Available", "openfda": {"application_number": ["ANDA075664"], "brand_name": ["ALBUTEROL SULFATE"], "generic_name": ["ALBUTEROL SULFATE"], "manufacturer_name": ["Rising Pharma Holdings, Inc."], "product_ndc": ["64980-642"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["ALBUTEROL SULFATE"], "rxcui": ["245314"], "spl_id": ["33015e7c-a4d2-ecac-e063-6394a90aae00"], "spl_set_id": ["3236f82c-14e9-dfd4-e063-6294a90ac43d"], "package_ndc": ["64980-642-03"], "unii": ["021SEF3731"]}, "update_date": "01/14/2026", "therapeutic_category": ["Pediatric", "Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)", "company_name": "Rising Pharma Holdings, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-385-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0480-3667-22", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "related_info": "Distributed by Teva", "openfda": {"application_number": ["NDA022341"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0480-3667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["57c9f463-a1b8-4efa-8982-40175cf6cf4f"], "spl_set_id": ["14bf9812-14ee-46ce-93b1-686e4906cbbc"], "package_ndc": ["0480-3667-19", "0480-3667-22", "0480-3667-20"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)", "company_name": "Novo Nordisk, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5167-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5167", "0603-5165", "0603-5166", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0971-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0003-3641-11", "generic_name": "Atazanavir Sulfate; Cobicistat Tablet", "contact_info": "800-332-2056", "related_info": "The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.", "openfda": {"application_number": ["NDA206353"], "brand_name": ["EVOTAZ"], "generic_name": ["ATAZANAVIR AND COBICISTAT"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "product_ndc": ["0003-3641"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ATAZANAVIR SULFATE", "COBICISTAT"], "rxcui": ["1601654", "1601660"], "spl_id": ["fa642c67-5a9e-4136-a141-64e1236f6a0f"], "spl_set_id": ["83db29d7-5d85-49d6-8cb6-740473365cf8"], "package_ndc": ["0003-3641-11"], "nui": ["N0000190114", "N0000191001", "N0000185503", "N0000182137", "N0000190107", "N0000190108", "N0000190113", "N0000191423"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]"], "pharm_class_epc": ["Cytochrome P450 3A Inhibitor [EPC]"], "unii": ["4MT4VIE29P", "LW2E03M5PG"]}, "update_date": "11/03/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "49230-300-10", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "800-323-5188", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078177"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care Renal Therapies Group, LLC"], "product_ndc": ["49230-300"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807639"], "spl_id": ["4e559356-726d-a8d7-e063-6294a90aea68"], "spl_set_id": ["af5cdf1a-19f4-11e2-892e-0800200c9a66"], "package_ndc": ["49230-300-10"], "unii": ["451W47IQ8X"]}, "update_date": "06/10/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 49230-300-10)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0113-03", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-0113", "0703-0110", "0703-0018"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["c32108cc-7b73-4921-9f9e-54b3d60c1c6e"], "spl_set_id": ["f0b78db9-a38c-41bb-8233-5e93f7f18c5c"], "package_ndc": ["0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride Injection, USP CII, Injection, 10 mg/1 mL (NDC 0703-0113-03)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2420-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": {"application_number": ["NDA021514"], "brand_name": ["METHYLPHENIDATE TRANSDERMAL SYSTEM"], "generic_name": ["METHYLPHENIDATE"], "manufacturer_name": ["PADAGIS US LLC"], "product_ndc": ["0574-2420", "0574-2410", "0574-2415", "0574-2430"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["METHYLPHENIDATE"], "rxcui": ["753436", "753438", "753440", "753441"], "spl_id": ["b743ef45-2fc0-4086-8a02-6078e6a09eaa"], "spl_set_id": ["7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb"], "package_ndc": ["0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65"], "nui": ["N0000175739", "N0000175729"], "pharm_class_epc": ["Central Nervous System Stimulant [EPC]"], "pharm_class_pe": ["Central Nervous System Stimulation [PE]"], "unii": ["207ZZ9QZ49"]}, "update_date": "05/07/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-5323-10", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-5323", "0832-5322"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953"], "spl_id": ["39e726b1-eab8-fcf4-e063-6394a90a950a"], "spl_set_id": ["616f0de7-8843-44a1-8fa6-274d889286aa"], "package_ndc": ["0832-5322-11", "0832-5322-10", "0832-5323-11", "0832-5323-10"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-10)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "54288-166-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC", "openfda": {"application_number": ["ANDA207324"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["BPI Labs LLC"], "product_ndc": ["54288-166", "54288-165", "54288-167", "54288-164"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["c0a7463c-d90f-4060-a54e-6a4888e8af0e"], "spl_set_id": ["5484d2f0-0cc2-4bba-8f26-c7f6539a9606"], "package_ndc": ["54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "63323-340-20", "generic_name": "Cefepime Hydrochloride Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA065441"], "brand_name": ["CEFEPIME"], "generic_name": ["CEFEPIME"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-340", "63323-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CEFEPIME HYDROCHLORIDE"], "rxcui": ["1665088", "1665093"], "spl_id": ["8c2fbf43-34bd-49d1-bda8-a2191c8bc54b"], "spl_set_id": ["5e1695e0-1310-4cd8-a5da-ad1a7dcd1792"], "package_ndc": ["63323-326-21", "63323-326-20", "63323-340-21", "63323-340-20"], "unii": ["I8X1O0607P"]}, "update_date": "02/10/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cefepime Hydrochloride, Injection, 2 g (NDC 63323-340-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "67457-903-20", "generic_name": "Etomidate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA201044"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-903", "67457-902"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["25fc0aef-d4b3-4b33-897c-81cc7cdae470"], "spl_set_id": ["461e34d1-b862-4a02-9727-548c907aac48"], "package_ndc": ["67457-902-00", "67457-902-10", "67457-903-00", "67457-903-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-01", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9046-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071170"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9046", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "53746-468-19", "generic_name": "Clindamycin Palmitate Hydrochloride Injection", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203513"], "brand_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE (PEDIATRIC)"], "generic_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals of New York LLC"], "product_ndc": ["53746-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE"], "rxcui": ["562266"], "spl_id": ["b9016023-7843-48e3-8ff6-2e5a70aa5daf"], "spl_set_id": ["faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"], "package_ndc": ["53746-468-19"], "unii": ["VN9A8JM7M7"]}, "update_date": "03/26/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9594-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019830"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9594", "0264-9598"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e352802-107c-4f90-babe-4f69c7dc892e"], "spl_set_id": ["7dff29d9-522d-40eb-a9d9-42377912d640"], "package_ndc": ["0264-9598-20", "0264-9594-20", "0264-9594-10"], "unii": ["EC2CNF7XFP", "LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0660-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-506-01", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA040491"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-506", "63323-516"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1812079"], "spl_id": ["9320abbb-bfd8-4df2-9269-3a52736c190f", "d85ab902-ae65-452d-b929-905b93131b15"], "spl_set_id": ["cca2c160-9188-48e8-9505-49a52388dcb7", "7cbd9005-7df2-47ee-adb3-7244c1c69bc3"], "package_ndc": ["63323-506-00", "63323-506-01", "63323-506-03", "63323-506-13", "63323-516-01", "63323-516-10", "63323-506-41", "63323-506-16"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3671-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040843"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-3671", "0703-3675", "0703-3678"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["e81074cc-12b4-4ac9-a5bb-749188989b2c"], "spl_set_id": ["346ec9ce-dc98-4a55-b55e-d3af11f2d703"], "package_ndc": ["0703-3671-01", "0703-3675-01", "0703-3678-01"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-063-59", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-063", "65862-062", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-59)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "65219-632-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-632"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355"], "spl_id": ["7203f32f-2e48-4924-b882-d4f3863ae952"], "spl_set_id": ["da4a7675-97bf-4d2a-9fdc-c1b4b2999126"], "package_ndc": ["65219-632-02", "65219-632-10", "65219-632-04", "65219-632-20"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1162-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070584"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1162", "0409-1159", "0409-1160", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-13", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-13", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0110-03", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-0110", "0703-0113", "0703-0018"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["c32108cc-7b73-4921-9f9e-54b3d60c1c6e"], "spl_set_id": ["f0b78db9-a38c-41bb-8233-5e93f7f18c5c"], "package_ndc": ["0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Regulatory delay", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-800-60", "generic_name": "Ivabradine Hydrochloride Tablet", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA206143"], "brand_name": ["CORLANOR"], "generic_name": ["IVABRADINE"], "manufacturer_name": ["Amgen Inc"], "product_ndc": ["55513-800", "55513-810", "55513-813"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IVABRADINE HYDROCHLORIDE"], "rxcui": ["1649485", "1649491", "1649493", "1649495", "2168592", "2168596"], "spl_id": ["8ab000cd-0258-489a-b1bb-4cc1ca359d6c"], "spl_set_id": ["92018a65-38f6-45f7-91d4-a34921b81d0d"], "package_ndc": ["55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28"], "unii": ["TP19837BZK"]}, "update_date": "03/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60)", "company_name": "Amgen Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0641-6262-01", "generic_name": "Sodium Acetate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the May 2026 timeframe.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA216920"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6262", "0641-6263"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["777b7564-f07b-401a-a042-0cd512ae3b25"], "spl_set_id": ["7ee23a1c-bc99-4ff6-b2e7-d2aa42744553"], "package_ndc": ["0641-6262-01", "0641-6263-01", "0641-6263-10"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-10", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018801"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4887"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["055437a7-5be5-414a-a97a-946e2730fe12"], "spl_set_id": ["2b9ea23a-f9e9-48a8-25b7-519e3bbd6828"], "package_ndc": ["0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-5031-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020646"], "brand_name": ["TIAGABINE HYDROCHLORIDE"], "generic_name": ["TIAGABINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5031", "0093-5030", "0093-8072", "0093-8076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TIAGABINE HYDROCHLORIDE"], "rxcui": ["1299903", "1299909", "1299911", "1299917"], "spl_id": ["2a8d7987-54ae-45d7-8224-361dac37e0a4"], "spl_set_id": ["953ef3cc-e3cb-480f-b9ea-256520fd62b8"], "package_ndc": ["0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56"], "unii": ["DQH6T6D8OY"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-6", "generic_name": "Carboplatin Injection", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Available", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.)", "openfda": {"application_number": ["ANDA077861"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-6282"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0e68e276-b0df-4f03-e063-6394a90a22b9"], "spl_set_id": ["1c275825-0275-4c73-b650-e4c1519f13b8"], "package_ndc": ["60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)", "company_name": "Teyro Labs", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/19/2025", "update_type": "New", "initial_posting_date": "08/19/2025", "package_ndc": "0093-7355-56", "generic_name": "Finasteride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076511"], "brand_name": ["FINASTERIDE"], "generic_name": ["FINASTERIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7355"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FINASTERIDE"], "rxcui": ["310346"], "spl_id": ["4c152e0f-55b3-4357-b983-897ecaf878af"], "spl_set_id": ["77589cc3-c440-4695-800c-82a0e5128a6c"], "package_ndc": ["0093-7355-56", "0093-7355-98", "0093-7355-05"], "nui": ["N0000175836", "N0000000126"], "pharm_class_epc": ["5-alpha Reductase Inhibitor [EPC]"], "pharm_class_moa": ["5-alpha Reductase Inhibitors [MoA]"], "unii": ["57GNO57U7G"]}, "update_date": "08/19/2025", "therapeutic_category": ["Urology"], "dosage_form": "Tablet", "presentation": "Finasteride, Tablet, 5 mg (NDC 0093-7355-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "71357-002-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": {"application_number": ["ANDA214805"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["MILLA PHARMACEUTICALS INC."], "product_ndc": ["71357-002"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["1859490"], "spl_id": ["2bdf8f55-9a63-bff7-e063-6394a90aafd0"], "spl_set_id": ["1ea04916-78e5-4651-e063-6394a90ac4be"], "package_ndc": ["71357-002-01", "71357-002-10"], "unii": ["4550K0SC9B"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)", "company_name": "Milla Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "72205-102-07", "generic_name": "Bumetanide Injection", "contact_info": "Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA215364"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-102", "72205-101"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "spl_set_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "package_ndc": ["72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/02/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)", "company_name": "MSN Laboratories Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/03/2018", "package_ndc": "76329-8261-1", "generic_name": "Lorazepam Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": {"application_number": ["ANDA076150"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-8261"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100"], "spl_id": ["b85a6695-55b9-4780-a803-33f8f2464138"], "spl_set_id": ["7dda070d-7809-46c4-8592-eb4e4c509707"], "package_ndc": ["76329-8261-1"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1574-5", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Currently Inventory available 2 to 4 Weeks as per current demand. Next supply: week of 02/09/2026", "openfda": {"application_number": ["ANDA210043"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1574", "70121-1573"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743855"], "spl_id": ["af4215ff-94ca-44f8-8506-3024e738cd13"], "spl_set_id": ["d944240d-2c19-46ba-ad4f-3fbee7b8629c"], "package_ndc": ["70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5"], "unii": ["43502P7F0P"]}, "update_date": "02/09/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5167-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5167", "0603-5165", "0603-5166", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-558-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077690"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-558", "68180-556", "68180-557", "68180-554", "68180-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["a9598a21-6f99-4c86-ace6-b5638da2bec8"], "spl_set_id": ["8ded0773-3aec-4e89-9836-d22a5a84abf0"], "package_ndc": ["68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/27/2021", "package_ndc": "82667-800-01", "generic_name": "Triamcinolone Acetonide Injection", "contact_info": "(615) 733-4734", "availability": "Limited Availability", "related_info": "Estimated duration: 12 months", "openfda": {"application_number": ["NDA022048"], "brand_name": ["TRIESENCE"], "generic_name": ["TRIAMCINOLONE ACETONIDE"], "manufacturer_name": ["Harrow Eye, LLC"], "product_ndc": ["82667-800"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["TRIAMCINOLONE ACETONIDE"], "rxcui": ["1086259", "1792144"], "spl_id": ["42679191-e5c2-90c6-e063-6294a90a93ed"], "spl_set_id": ["2267978c-72ad-9229-e063-6394a90a09d0"], "package_ndc": ["82667-800-01"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["F446C597KA"]}, "update_date": "05/08/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Injection", "presentation": "Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)", "company_name": "Harrow Eye, LLC", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-7", "generic_name": "Carboplatin Injection", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Available", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.)", "openfda": {"application_number": ["ANDA077861"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-6282"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0e68e276-b0df-4f03-e063-6394a90a22b9"], "spl_set_id": ["1c275825-0275-4c73-b650-e4c1519f13b8"], "package_ndc": ["60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)", "company_name": "Teyro Labs", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-138-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-138", "16729-136", "16729-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 16729-138-16)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1660-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-4060-12", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Limited Availability", "related_info": "Estimated shortage duration TBD", "openfda": {"application_number": ["NDA022341"], "brand_name": ["VICTOZA"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Novo Nordisk"], "product_ndc": ["0169-4060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122", "897126"], "spl_id": ["0d10d10e-0fe0-47ee-b9da-628e34907e98"], "spl_set_id": ["5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"], "package_ndc": ["0169-4060-13", "0169-4060-12", "0169-4060-90", "0169-4060-97", "0169-4060-98", "0169-4060-99"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)", "company_name": "Novo Nordisk, Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5166-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5166", "0603-5165", "0603-5167", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-05", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075604"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-720", "62037-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["1801294", "1801298"], "spl_id": ["01fbdb24-0987-40f6-a920-f36349f6ba61"], "spl_set_id": ["db002ae3-f54c-40a4-9cb4-e5681bf426e3"], "package_ndc": ["62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10"], "unii": ["660YQ98I10"]}, "update_date": "11/21/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/04/2025", "update_type": "New", "initial_posting_date": "06/04/2025", "package_ndc": "0003-3631-12", "generic_name": "Atazanavir Sulfate Capsule", "contact_info": "1-800-332-2056; for Medical Inquiries (1-800-321-1335)", "related_info": "Permanent discontinuation", "openfda": {"application_number": ["NDA021567"], "brand_name": ["REYATAZ"], "generic_name": ["ATAZANAVIR"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "product_ndc": ["0003-3631", "0003-3624", "0003-3622", "0003-3638"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ATAZANAVIR SULFATE"], "rxcui": ["402093", "402094", "402246", "402247", "664741", "664743", "1598985", "1598989"], "spl_id": ["510c2d51-4943-401c-a008-ea22f61c6938"], "spl_set_id": ["165cff62-b284-4a27-a65d-9ec8a5bfcdd8"], "package_ndc": ["0003-3624-12", "0003-3631-12", "0003-3622-12", "0003-3638-10"], "unii": ["4MT4VIE29P"]}, "update_date": "06/04/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Capsule", "presentation": "Reyataz, Capsule, 200 mg (NDC 0003-3631-12)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3982-60", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3982", "0591-3983", "0591-3984", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 50 mg (NDC 0591-3982-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "0093-0832-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: June 2026", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0832", "0093-3212", "0093-3213"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "76204-025-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Limited Availability", "related_info": "No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300", "openfda": {"application_number": ["ANDA209264"], "brand_name": ["CROMOLYN SODIUM ORAL SOLUTION (CONCENTRATE)"], "generic_name": ["CROMOLYN SODIUM ORAL SOLUTION (CONCENTRATE)"], "manufacturer_name": ["Ritedose Pharmaceuticals, LLC"], "product_ndc": ["76204-025"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261"], "spl_id": ["459fa806-53ad-d48e-e063-6394a90af72b"], "spl_set_id": ["d208df15-c823-6e0d-e053-2a95a90ad1be"], "package_ndc": ["76204-025-08", "76204-025-96"], "unii": ["Q2WXR1I0PK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)", "company_name": "Ailex Pharmaceuticals", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-10", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7520", "0264-7510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-382-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/11/2024", "package_ndc": "0990-7120-07", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7120-07", "openfda": {"application_number": ["NDA019893"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["237656"], "spl_id": ["2221fdbf-4b3f-4296-80bc-96c446156fff"], "spl_set_id": ["cdf35d11-fbc8-4f8e-85a8-33220312c0b4"], "package_ndc": ["0990-7120-07"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-050-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-050", "57664-047", "57664-046", "57664-048", "57664-049", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0775-26", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Available", "openfda": {"application_number": ["NDA050441"], "brand_name": ["CLEOCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0775", "0009-0870", "0009-0902", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582", "205964", "309335", "309336", "309339", "685574"], "spl_id": ["dd9fa453-a2ca-4a53-b39b-c59a44a888aa"], "spl_set_id": ["05a75685-0af5-407c-ac57-e380c882b49d"], "package_ndc": ["0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01"], "unii": ["EH6D7113I8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-382-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1283-37", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1283", "0409-1312", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2305-17", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075857"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2305", "0409-2308", "0409-0001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666800", "1666814", "1666823", "1666798"], "spl_id": ["b303a281-6633-47d5-bf29-5e9055e26da6", "74093865-864a-49e8-99b9-c985fe72afb2"], "spl_set_id": ["b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240"], "package_ndc": ["0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-63", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "0037-0678-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(800) 796-9526", "availability": "Available", "openfda": {"application_number": ["NDA020479"], "brand_name": ["GASTROCROM"], "generic_name": ["CROMOLYN SODIUM"], "manufacturer_name": ["Viatris Specialty LLC"], "product_ndc": ["0037-0678"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261", "831269"], "spl_id": ["15aec235-80e7-4d95-b48c-bbca69b4b04d"], "spl_set_id": ["00623958-a8fe-47d1-a0d2-0aa4e2f7966e"], "package_ndc": ["0037-0678-08", "0037-0678-96"], "unii": ["Q2WXR1I0PK"]}, "update_date": "05/05/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)", "company_name": "Mylan Specialty, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "0053-6871-00", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Spray", "presentation": "Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "70436-203-80", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "Slate Run Pharmaceuticals, LLC: 844-529-8988", "availability": "Available", "related_info": "Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988", "openfda": {"application_number": ["ANDA216131"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Slate Run Pharmaceuticals"], "product_ndc": ["70436-203"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["49562559-8e19-fb8a-e063-6394a90a0966"], "spl_set_id": ["ee09a55f-9992-48bb-b8d6-1184bd548536"], "package_ndc": ["70436-203-80", "70436-203-82"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)", "company_name": "Hainan Poly Pharm. Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "25021-655-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA090696"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-655"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666798"], "spl_id": ["943346c0-d98e-4ac2-a1a2-75427decf2fc"], "spl_set_id": ["e22611dd-1830-40af-9139-7cdb07f5a426"], "package_ndc": ["25021-655-02"], "unii": ["W7TTW573JJ"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5316-15", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5316", "0245-5315"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-15)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "59572-102-01", "generic_name": "Azacitidine Injection", "contact_info": "1-888-423-5436", "availability": "Available", "openfda": {"application_number": ["NDA050794"], "brand_name": ["VIDAZA"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Celgene Corporation"], "product_ndc": ["59572-102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246", "545206"], "spl_id": ["8cba79e2-11fa-4eb9-87e7-827ca781fbf3"], "spl_set_id": ["3495a71a-cc04-4776-851f-f185956f32af"], "package_ndc": ["59572-102-01"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Vidaza, Injection, 100 mg (NDC 59572-102-01)", "company_name": "Bristol Myers Squibb Co.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0225-02", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050162"], "brand_name": ["CLEOCIN HYDROCHLORIDE"], "generic_name": ["CLINDAMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0225", "0009-0331", "0009-0395"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN HYDROCHLORIDE"], "rxcui": ["197518", "284215", "309329", "748746", "748748", "748750"], "spl_id": ["51cea3cd-28cf-455e-ba27-5a0d8e052858"], "spl_set_id": ["df9a2a41-b132-4f43-8940-b2d773b1369a"], "package_ndc": ["0009-0331-02", "0009-0225-02", "0009-0395-14"], "unii": ["T20OQ1YN1W"]}, "update_date": "02/25/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-26", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-0771-10", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0771", "0093-7201", "0093-7202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-6145-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA084282"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6145", "0641-0367", "0641-6146"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["02bf3273-f0c8-448c-9f74-eb009fee9299"], "spl_set_id": ["0277cc0a-2fd4-4605-a310-b613be84ee26"], "package_ndc": ["0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/12/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7809-22", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018826"], "brand_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7809", "0409-7810", "0409-0042", "0409-1858"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "spl_id": ["188ce800-ff3a-4b22-9a95-2273c3bc99ae"], "spl_set_id": ["08f23f6e-150d-45ea-098e-f2edf64c21a1"], "package_ndc": ["0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12"], "unii": ["7L3E358N9L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7769-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210050"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7769", "0093-7766", "0093-7767", "0093-7768"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["aa521933-950a-441b-9146-93e479a4dde7"], "spl_set_id": ["e3bca36b-29ed-4a2b-a1be-a57b6af805f6"], "package_ndc": ["0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "03/02/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 10 mg (NDC 0093-7769-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-04", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9575-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA080407"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9575", "0143-9579", "0143-9578", "0143-9577", "0143-9576", "0143-9172", "0143-9173"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["e9b92d4d-8944-4235-8d77-3218f82f00a9"], "spl_set_id": ["5523fdfe-69fd-49a5-b51f-73e2223d49a9"], "package_ndc": ["0143-9579-01", "0143-9579-25", "0143-9578-01", "0143-9578-10", "0143-9577-01", "0143-9577-10", "0143-9576-01", "0143-9576-25", "0143-9575-01", "0143-9575-10", "0143-9172-01", "0143-9172-10", "0143-9173-01", "0143-9173-10"], "unii": ["V13007Z41A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-025-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-025", "65162-023", "65162-024", "65162-026", "65162-027", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-061-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-061", "70069-062", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/09/2025", "update_type": "New", "initial_posting_date": "06/09/2025", "package_ndc": "66215-102-03", "generic_name": "Bosentan Tablet", "contact_info": "800-526-7736", "openfda": {"application_number": ["NDA021290"], "brand_name": ["TRACLEER"], "generic_name": ["BOSENTAN"], "manufacturer_name": ["Actelion Pharmaceuticals US, Inc."], "product_ndc": ["66215-102", "66215-101", "66215-232"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["BOSENTAN"], "rxcui": ["349253", "352066", "656659", "656660", "1989081", "1989085"], "spl_id": ["f52a8c9c-529d-4bd8-9bfb-d91161935c20"], "spl_set_id": ["749e42fb-2fe0-45dd-9268-b43bb3f4081c"], "package_ndc": ["66215-101-06", "66215-101-03", "66215-102-06", "66215-102-03", "66215-232-14", "66215-232-56"], "unii": ["Q326023R30"]}, "update_date": "06/09/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Tracleer, Tablet, 125 mg (NDC 66215-102-03)", "company_name": "Actelion Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "59676-570-01", "generic_name": "Etravirine Tablet", "contact_info": "800-526-7736", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA022187"], "brand_name": ["INTELENCE"], "generic_name": ["ETRAVIRINE"], "manufacturer_name": ["Janssen Products LP"], "product_ndc": ["59676-570", "59676-571", "59676-572"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ETRAVIRINE"], "rxcui": ["754761", "758555", "1052658", "1052660", "1250721", "1250723"], "spl_id": ["02fc6f4f-330d-b32e-e063-6294a90a028a"], "spl_set_id": ["6a9cbc29-9f15-4b24-8d86-206b82887f3d"], "package_ndc": ["59676-570-01", "59676-571-01", "59676-572-01"], "nui": ["N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000185504", "N0000182140", "N0000185503"], "pharm_class_epc": ["Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "unii": ["0C50HW4FO1"]}, "update_date": "04/28/2026", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Intelence, Tablet, 100 mg (NDC 59676-570-01)", "company_name": "Janssen Research and Development", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "0025-1031-31", "generic_name": "Spironolactone Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA012151"], "brand_name": ["ALDACTONE"], "generic_name": ["SPIRONOLACTONE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0025-1031", "0025-1001", "0025-1041"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["SPIRONOLACTONE"], "rxcui": ["198222", "198223", "200817", "200820", "200825", "313096"], "spl_id": ["22946678-dcad-4518-9bc6-cbdf51a38c16"], "spl_set_id": ["0fed2822-3a03-4b64-9857-c682fcd462bc"], "package_ndc": ["0025-1001-31", "0025-1041-31", "0025-1031-31"], "nui": ["N0000175557", "N0000011310"], "pharm_class_epc": ["Aldosterone Antagonist [EPC]"], "pharm_class_moa": ["Aldosterone Antagonists [MoA]"], "unii": ["27O7W4T232"]}, "update_date": "12/10/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Aldactone, Tablet, 100 mg (NDC 0025-1031-31)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "16729-484-90", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA212868"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Accord Healthcare, Inc.,"], "product_ndc": ["16729-484", "16729-483"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["4082a1cf-1e1b-6f40-e063-6294a90aec06"], "spl_set_id": ["c82cb295-ffce-47d6-97ad-a8aa723f4e4f"], "package_ndc": ["16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-152", "72888-153", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-01)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "76045-121-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release June 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["DILAUDID"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-121", "76045-009", "76045-010"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370"], "spl_id": ["97bfcafb-2037-47dc-a0ae-f7b8007c47df"], "spl_set_id": ["9eebd88a-5632-460f-b7b6-26c8a180540d"], "package_ndc": ["76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3678-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA040843"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-3678", "0703-3671", "0703-3675"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["e81074cc-12b4-4ac9-a5bb-749188989b2c"], "spl_set_id": ["346ec9ce-dc98-4a55-b55e-d3af11f2d703"], "package_ndc": ["0703-3671-01", "0703-3675-01", "0703-3678-01"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-212-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care de Mexico, S.A. de C.V."], "product_ndc": ["46163-212", "46163-209", "46163-206"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["444fd7c1-1ed5-25c7-e063-6394a90a3bfe"], "spl_set_id": ["a98facd6-9daa-4d37-8209-63a0599dbfaa"], "package_ndc": ["46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-485-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076803"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-485", "62135-484", "62135-486", "62135-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["09cd5cb9-4fdf-f133-e063-6294a90af691"], "spl_set_id": ["dbc43dbd-94aa-40e2-a9ea-766110cc8687"], "package_ndc": ["62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90"], "unii": ["33067B3N2M"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4928-34", "generic_name": "Calcium Chloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Cardiovascular", "Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/24/2025", "update_type": "New", "initial_posting_date": "07/24/2025", "package_ndc": "0049-0178-08", "generic_name": "Glipizide Tablet, Extended Release", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020329"], "brand_name": ["GLUCOTROL XL"], "generic_name": ["GLIPIZIDE"], "manufacturer_name": ["Roerig"], "product_ndc": ["0049-0178", "0049-0170", "0049-0174"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLIPIZIDE"], "rxcui": ["310489", "314006", "315107", "865568", "865571", "865573"], "spl_id": ["ce46d6b5-eab4-4630-8480-f13885be938e"], "spl_set_id": ["eed99b60-d043-4249-9b2a-f05e46fb588d"], "package_ndc": ["0049-0170-01", "0049-0174-02", "0049-0174-03", "0049-0178-07", "0049-0178-08"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["X7WDT95N5C"]}, "update_date": "07/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glucatrol XL, Tablet, Extended Release, 10 mg tablets; bottle of 500 (NDC 0049-0178-08)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-01", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1749-29", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1749", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-02", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA090108"], "brand_name": ["CLINDAMYCIN"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["1737244", "1737578", "1737581"], "spl_id": ["4662502b-ce7c-4278-854d-cf8632ac9b83"], "spl_set_id": ["7a6967b3-5563-4bed-9eee-d400f800e799"], "package_ndc": ["25021-115-02", "25021-115-04", "25021-115-06"], "unii": ["EH6D7113I8"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/06/2018", "package_ndc": "72266-118-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["FOSUN PHARMA USA INC"], "product_ndc": ["72266-118", "72266-234", "72266-119"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["228ec94a-f777-f61b-e063-6394a90a21a5"], "spl_set_id": ["1aae6a4d-0909-4672-aa26-e3f2d8c4d413"], "package_ndc": ["72266-234-01", "72266-234-25", "72266-118-01", "72266-118-25", "72266-119-01", "72266-119-25"], "unii": ["4EVE5946BQ"]}, "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-046-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-046", "57664-047", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-448-60", "generic_name": "Carboplatin Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "0641-6047-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6047", "0641-6044", "0641-6046", "0641-6045"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100", "238101", "1665188", "1665326"], "spl_id": ["7c73dbc6-2623-4443-9b05-97dec7a0be2e"], "spl_set_id": ["e9b54e42-04cf-4c62-90e1-36f7b31a4e81"], "package_ndc": ["0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0409-0332-20", "generic_name": "Bleomycin Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA065031"], "brand_name": ["BLEOMYCIN"], "generic_name": ["BLEOMYCIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0332", "0409-0323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAPLEURAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["BLEOMYCIN SULFATE"], "rxcui": ["1726673", "1726676"], "spl_id": ["d9e9c332-1b3f-469c-83b8-41e15183e635"], "spl_set_id": ["e629ba5a-4e08-4249-9551-af6dbd98a7e4"], "package_ndc": ["0409-0323-20", "0409-0332-20"], "unii": ["7DP3NTV15T"]}, "update_date": "06/13/2025", "therapeutic_category": ["Hematology", "Oncology", "Pediatric"], "dosage_form": "Injection", "presentation": "Bleomycin Sulfate, Injection, 15 [USP'U] (NDC 0409-0332-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-556-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-556", "64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4248-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA077269"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4248", "0703-4244", "0703-4246", "0703-4239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c"], "spl_set_id": ["f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37"], "package_ndc": ["0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4713-32", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA080408"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-37", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-1323-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA040302"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1323", "0409-4903", "0409-4904", "0409-9137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1012066", "1012068"], "spl_id": ["b386f7fc-ec89-4d73-aba6-2019a9cb1d4a"], "spl_set_id": ["ad1ef0a8-88db-4648-c098-d009eaeb4e5b"], "package_ndc": ["0409-4903-11", "0409-4903-34", "0409-4904-11", "0409-4904-34", "0409-1323-15", "0409-1323-05", "0409-9137-11", "0409-9137-05"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "72205-101-07", "generic_name": "Bumetanide Injection", "contact_info": "Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA215364"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-101", "72205-102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "spl_set_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "package_ndc": ["72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/02/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)", "company_name": "MSN Laboratories Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-801-01", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-801", "42806-799"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 42806-801-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-0109-10", "generic_name": "Carbamazepine Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA070541"], "brand_name": ["CARBAMAZEPINE"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0109", "0093-0778"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["308973", "308979"], "spl_id": ["042aa2c6-95ff-410a-abcf-a8ee79fa96d8"], "spl_set_id": ["bfd63965-56e6-4af7-b7ef-45a5105d4d35"], "package_ndc": ["0093-0109-01", "0093-0109-10", "0093-0778-01"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "06/10/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Epitol, Tablet, 200 mg (NDC 0093-0109-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-712-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-712", "60951-602", "60951-700", "60951-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0143-9144-02", "generic_name": "Liraglutide Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": {"application_number": ["ANDA215503"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9144"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["5088d0a8-f7aa-476c-8cc1-149955781409"], "spl_set_id": ["2100ec49-57b2-4330-ab5f-057ce9b7e4d0"], "package_ndc": ["0143-9144-01", "0143-9144-03", "0143-9144-02"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/27/2025", "update_type": "New", "initial_posting_date": "06/27/2025", "package_ndc": "0591-3713-05", "generic_name": "Ezetimibe Tablet", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the product", "openfda": {"application_number": ["ANDA200831"], "brand_name": ["EZETIMIBE"], "generic_name": ["EZETIMIBE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3713"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EZETIMIBE"], "rxcui": ["349556"], "spl_id": ["24aaf5ca-08e0-4db8-9734-cf2a606f8e57"], "spl_set_id": ["f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba"], "package_ndc": ["0591-3713-30", "0591-3713-19", "0591-3713-05"], "nui": ["N0000008553", "N0000175911"], "pharm_class_pe": ["Decreased Cholesterol Absorption [PE]"], "pharm_class_epc": ["Dietary Cholesterol Absorption Inhibitor [EPC]"], "unii": ["EOR26LQQ24"]}, "update_date": "06/27/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Ezetimibe, Tablet, 10 mg (NDC 0591-3713-05)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4741-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4741", "60505-4739", "60505-4740", "60505-4742", "60505-4743", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9507-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the May 2026 timeframe.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9507", "0143-9506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["98560882-bfdf-404e-ab8b-3ee2a6875830"], "spl_set_id": ["75bf0494-7cb9-4e8a-8edd-af62f035d236"], "package_ndc": ["0143-9506-01", "0143-9506-10", "0143-9507-01", "0143-9507-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-27", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-162-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-162", "55150-161", "55150-163", "55150-164", "55150-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4662-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4662", "0527-4661", "0527-4663", "0527-4664", "0527-4665", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)", "company_name": "Lannett Company, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-585-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": {"application_number": ["NDA021121"], "brand_name": ["CONCERTA"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-585", "50458-588", "50458-586", "50458-587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212"], "spl_id": ["64d7c1e1-e7ed-4d74-a44d-13b4da64af9a"], "spl_set_id": ["1a88218c-5b18-4220-8f56-526de1a276cd"], "package_ndc": ["50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-02", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "6, 7 & 9 month expiry available upon request. Check wholesaler for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1304-31", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1304", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1283", "0409-1312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "897756", "897757", "897758", "1724276", "1724383", "1724644"], "spl_id": ["a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6040-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.", "openfda": {"application_number": ["NDA018565"], "brand_name": ["INFUMORPH 500"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6040", "0641-6039"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892652", "1731522", "1731998", "1731999"], "spl_id": ["b1c060cb-5c5b-495f-90b5-044e04f2a3f2"], "spl_set_id": ["db9ac9e3-d761-4a99-9f34-4946ebe8f255"], "package_ndc": ["0641-6039-01", "0641-6040-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-036-05", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["NDA020630"], "brand_name": ["ULTIVA"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["72078-036", "72078-034", "72078-035"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729581", "1729584", "1729586", "1729710", "1729712"], "spl_id": ["594087a1-25f2-4f68-aea6-ad7df40559ab"], "spl_set_id": ["8b4c8696-e23e-4c51-a4d2-babab5bd945a"], "package_ndc": ["72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05"], "unii": ["5V444H5WIC"]}, "update_date": "05/05/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 5 mg (NDC 72078-036-05)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3565-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3565", "0480-3566", "0480-3567", "0480-3568", "0480-3569", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-723-52", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216039"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-723", "71288-726"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["0949c302-51ce-4fc9-8b99-1df94e693718"], "spl_set_id": ["fe340f98-a0f3-446e-b281-47fd91c1e537"], "package_ndc": ["71288-723-52", "71288-726-52"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-104-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA203242"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-104", "76045-105", "76045-107", "76045-209"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860113", "860114", "860115"], "spl_id": ["0dab642d-7fcf-4301-8ac9-10e64a040c6b"], "spl_set_id": ["3d88cbe6-5230-47aa-80af-0c41283d1f00"], "package_ndc": ["76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-012-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability June 2026", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-012", "72516-016", "72516-015", "72516-014", "72516-013", "72516-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/22/2026", "update_type": "New", "initial_posting_date": "04/22/2026", "package_ndc": "0069-0187-21", "generic_name": "Palbociclib Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet \nNDC 0069-0284-03 will continue to be manufactured.", "openfda": {"application_number": ["NDA207103"], "brand_name": ["IBRANCE"], "generic_name": ["PALBOCICLIB"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-0187", "0069-0188", "0069-0189"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PALBOCICLIB"], "rxcui": ["1601380", "1601386", "1601388", "1601390", "1601392", "1601394"], "spl_id": ["fb858b80-8bd4-43a6-8871-9819a35ca03f"], "spl_set_id": ["e0e6412f-50b4-4fd4-9364-62818d121a07"], "package_ndc": ["0069-0187-21", "0069-0188-21", "0069-0189-21"], "nui": ["N0000175605", "N0000175082", "N0000190114"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["G9ZF61LE7G"]}, "update_date": "04/22/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Capsule", "presentation": "Ibrance, Capsule, 75 mg (NDC 0069-0187-21)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/16/2026", "package_ndc": "72336-032-01", "generic_name": "Isocarboxazid Tablet", "contact_info": "833.627.0070", "availability": "Unavailable", "related_info": "Target availability: May 2026; Delay in shipping of the drug", "openfda": {"application_number": ["NDA011961"], "brand_name": ["MARPLAN"], "generic_name": ["ISOCARBOXAZID"], "manufacturer_name": ["Lifsa Drugs LLC"], "product_ndc": ["72336-032"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ISOCARBOXAZID"], "rxcui": ["104837", "201708"], "spl_id": ["97745d9b-c2a6-45e3-9e1e-7fabec4681fb"], "spl_set_id": ["95fde749-44ad-4668-86c4-0ff17bca0074"], "package_ndc": ["72336-032-01"], "nui": ["N0000175744", "N0000000184"], "pharm_class_epc": ["Monoamine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Monoamine Oxidase Inhibitors [MoA]"], "unii": ["34237V843T"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)", "company_name": "Lifsa Drugs LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-4596-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4596", "0409-0155"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718907", "1718909", "1718910"], "spl_id": ["58e27ec5-ccde-46c9-afd3-2509e6b55e4e"], "spl_set_id": ["92b7ddaa-e45a-4b64-a802-bb5df8771dd6"], "package_ndc": ["0409-4596-01", "0409-4596-20", "0409-0155-01", "0409-0155-02"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0143-9250-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA204679"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9250", "0143-9251"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["76957fea-9b26-42a6-ad71-c8752142a08b"], "spl_set_id": ["d3a172a5-01ab-47d8-92ac-a8539b1d4dc4"], "package_ndc": ["0143-9250-01", "0143-9250-10", "0143-9251-01", "0143-9251-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9553-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["NDA208083"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9553", "0338-9545", "0338-9549"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b0a47c5e-911b-4b12-a0d1-a4425f173eec"], "spl_set_id": ["44fa506b-90ac-42de-831b-5f3f1a500fc0"], "package_ndc": ["0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-136-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-136", "16729-137", "16729-138"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 16729-136-16)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "76045-106-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA203129"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-106"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1812095"], "spl_id": ["f5934e17-4553-425b-b1bf-140cba479c36"], "spl_set_id": ["88d25d19-acff-477b-86c8-9797782045b8"], "package_ndc": ["76045-106-10"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-25", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-003-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X10ML) is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "70069-753-25", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": {"application_number": ["ANDA217792"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-753", "70069-752"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["2b24af95-6f20-4945-bf8c-742f1d6f2721"], "spl_set_id": ["bcaab86f-20f0-4482-8d73-e29b36dced58"], "package_ndc": ["70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3495-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": {"application_number": ["ANDA209065"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3495", "0781-3493", "0781-3494"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["fdf227d9-008e-60f8-e053-6294a90af5c4"], "spl_set_id": ["809e8f77-390f-4cc8-8c8a-4f67a249c9df"], "package_ndc": ["0781-3493-95", "0781-3494-95", "0781-3495-95"], "unii": ["1018WH7F9I"]}, "update_date": "04/06/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-4902-34", "generic_name": "Dextrose Monohydrate 50% Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%20Monohydrate%2050per%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "65219-445-10", "generic_name": "Etomidate Injection", "contact_info": "800-551-7176", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-445", "65219-447"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["446487f1-002e-41d3-846a-67570e797171", "30488a7e-ea9e-4a27-95a9-a07149c50282"], "spl_set_id": ["f38fad46-f2dd-4692-a2a9-a13d0a717bf8", "d07efb9e-5264-461d-96d8-e11fa71c5751"], "package_ndc": ["65219-445-12", "65219-445-22", "65219-445-01", "65219-445-10", "65219-447-02", "65219-447-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 65219-445-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "59310-812-06", "generic_name": "Fluticasone Propionate; Salmeterol Xinafoate Powder", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA208799"], "brand_name": ["AIRDUO RESPICLICK"], "generic_name": ["FLUTICASONE PROPIONATE AND SALMETEROL"], "manufacturer_name": ["Teva Respiratory, LLC"], "product_ndc": ["59310-812", "59310-805", "59310-822"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE"], "rxcui": ["1918194", "1918199", "1918203", "1918205", "1918209", "1918211"], "spl_id": ["b597bc2d-bf1e-4f9b-826a-b3e39ed56545"], "spl_set_id": ["9c122b91-a11f-49ca-80bb-3eec5112db87"], "package_ndc": ["59310-805-06", "59310-805-08", "59310-812-06", "59310-812-08", "59310-822-06", "59310-822-08"], "unii": ["6EW8Q962A5", "O2GMZ0LF5W"]}, "update_date": "06/13/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Powder", "presentation": "AirDuo RespiClick, Powder, 113 ug; 14 ug (NDC 59310-812-06)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4380-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023", "update_date": "04/28/2023", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 5 mg (NDC 0069-4380-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "68180-659-07", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA090034"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-659", "68180-658"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["5ed1edac-e11e-4f87-b390-e770a69a9b37"], "spl_set_id": ["b56004f0-f23d-47f6-80c7-39884fccbccc"], "package_ndc": ["68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 68180-659-07)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "65219-632-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-632"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355"], "spl_id": ["7203f32f-2e48-4924-b882-d4f3863ae952"], "spl_set_id": ["da4a7675-97bf-4d2a-9fdc-c1b4b2999126"], "package_ndc": ["65219-632-02", "65219-632-10", "65219-632-04", "65219-632-20"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5001-5", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": {"application_number": ["ANDA211091"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Exela Pharma Sciences, LLC"], "product_ndc": ["51754-5001", "51754-5011", "51754-5002", "51754-5012"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["807284", "1868486", "1923484", "2198792"], "spl_id": ["4da0ba66-756d-4b4d-8018-81ca16578ef1"], "spl_set_id": ["e9698a4f-1a95-4f28-a945-e8009d1d6dd4"], "package_ndc": ["51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4"], "unii": ["8MDF5V39QO"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/31/2018", "package_ndc": "65219-572-10", "generic_name": "Bumetanide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA216434"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-572", "65219-570"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["aaff61c4-203b-4905-9138-0f98959ad013"], "spl_set_id": ["a007f3aa-3977-4be3-a9a2-db3d458bca58"], "package_ndc": ["65219-570-01", "65219-570-04", "65219-572-01", "65219-572-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-465-57", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-465", "63323-467", "63323-460", "63323-464", "63323-466", "63323-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177"], "spl_id": ["2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1162-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070584"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1162", "0409-1159", "0409-1160", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-02", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/04/2025", "update_type": "New", "initial_posting_date": "06/04/2025", "package_ndc": "0003-3622-12", "generic_name": "Atazanavir Sulfate Capsule", "contact_info": "1-800-332-2056; for Medical Inquiries (1-800-321-1335)", "related_info": "Permanent discontinuation", "openfda": {"application_number": ["NDA021567"], "brand_name": ["REYATAZ"], "generic_name": ["ATAZANAVIR"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "product_ndc": ["0003-3622", "0003-3624", "0003-3631", "0003-3638"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ATAZANAVIR SULFATE"], "rxcui": ["402093", "402094", "402246", "402247", "664741", "664743", "1598985", "1598989"], "spl_id": ["510c2d51-4943-401c-a008-ea22f61c6938"], "spl_set_id": ["165cff62-b284-4a27-a65d-9ec8a5bfcdd8"], "package_ndc": ["0003-3624-12", "0003-3631-12", "0003-3622-12", "0003-3638-10"], "unii": ["4MT4VIE29P"]}, "update_date": "06/04/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Capsule", "presentation": "Reyataz, Capsule, 300 mg (NDC 0003-3622-12)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/26/2025", "update_type": "New", "initial_posting_date": "06/26/2025", "package_ndc": "0093-5537-56", "generic_name": "Eszopiclone Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA091169"], "brand_name": ["ESZOPICLONE"], "generic_name": ["ESZOPICLONE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5537", "0093-5538", "0093-5539"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ESZOPICLONE"], "rxcui": ["485440", "485442", "485465"], "spl_id": ["efcf4106-ac0a-4f8b-bcd0-743e45e66924"], "spl_set_id": ["2435e2f1-bc52-488f-80e9-f1758e354aae"], "package_ndc": ["0093-5537-56", "0093-5538-01", "0093-5539-01"], "unii": ["UZX80K71OE"]}, "update_date": "06/26/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Eszopiclone, Tablet, 1 mg (NDC 0093-5537-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0591-0347-05", "generic_name": "Hydrochlorothiazide Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["NDA020504"], "brand_name": ["HYDROCHLOROTHIAZIDE"], "generic_name": ["HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-0347"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE"], "rxcui": ["199903"], "spl_id": ["b062bc7e-af92-4648-aed1-e02568313e21"], "spl_set_id": ["a3eb7294-f913-434b-896c-da028bfebc73"], "package_ndc": ["0591-0347-01", "0591-0347-05"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["0J48LPH2TH"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Microzide, Capsule, 12.5 mg (NDC 0591-0347-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075154", "ANDA208878"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-412", "63323-411"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552", "cca4b16a-900d-4c74-86f5-bb9e5587a02a"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc", "09daf48f-1d44-4b7b-bb53-bd5635b93ca6"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10", "63323-412-00"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0502-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA020512"], "brand_name": ["CLINISOL"], "generic_name": ["LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0502"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["800584", "800588"], "spl_id": ["7eab93b5-5590-4381-8674-113a05edeff0"], "spl_set_id": ["65ffc962-7538-41ea-9afb-4af5fbce4c5b"], "package_ndc": ["0338-0502-03", "0338-0502-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-200-11", "generic_name": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA021172"], "brand_name": ["INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-200", "73070-203"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["351297", "847191"], "spl_id": ["ec67820c-4008-4894-b933-34b28704221d"], "spl_set_id": ["fc94baa4-3606-48bc-a781-9617ab6960ef"], "package_ndc": ["73070-200-11", "73070-203-10", "73070-203-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injectable Suspension", "presentation": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-702-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA050141"], "brand_name": ["BICILLIN L-A"], "generic_name": ["PENICILLIN G BENZATHINE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["60793-702", "60793-700", "60793-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PENICILLIN G BENZATHINE"], "rxcui": ["731564", "731566", "731567", "731568", "731570", "731571"], "spl_id": ["4b3694af-9d77-487f-8838-b75aec6636da"], "spl_set_id": ["012d46f1-d0a0-4676-a879-cd320297ab16"], "package_ndc": ["60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10"], "unii": ["RIT82F58GK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-5323-11", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-5323", "0832-5322"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953"], "spl_id": ["39e726b1-eab8-fcf4-e063-6394a90a950a"], "spl_set_id": ["616f0de7-8843-44a1-8fa6-274d889286aa"], "package_ndc": ["0832-5322-11", "0832-5322-10", "0832-5323-11", "0832-5323-10"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-55", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-55", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-50", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release June 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0018-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-0018", "0703-0110", "0703-0113"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["c32108cc-7b73-4921-9f9e-54b3d60c1c6e"], "spl_set_id": ["f0b78db9-a38c-41bb-8233-5e93f7f18c5c"], "package_ndc": ["0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-2800-15", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "openfda": {"application_number": ["NDA206321"], "brand_name": ["SAXENDA"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Novo Nordisk"], "product_ndc": ["0169-2800"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["1598268", "2735350"], "spl_id": ["eba7f5c9-44d0-4549-ae94-daa2c5181646"], "spl_set_id": ["3946d389-0926-4f77-a708-0acb8153b143"], "package_ndc": ["0169-2800-15", "0169-2800-90", "0169-2800-97"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)", "company_name": "Novo Nordisk, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-550-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-51", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0280", "0009-0274", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "43066-019-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-019", "43066-015", "43066-023", "43066-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734084", "1734207", "1734475", "1734483"], "spl_id": ["a8d08579-825f-40d9-b1e3-e47b73765ae6"], "spl_set_id": ["781d4b7f-7556-4695-8d48-7772d7a0d8e9"], "package_ndc": ["43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10"], "unii": ["V910P86109"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "0025-1001-31", "generic_name": "Spironolactone Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA012151"], "brand_name": ["ALDACTONE"], "generic_name": ["SPIRONOLACTONE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0025-1001", "0025-1041", "0025-1031"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["SPIRONOLACTONE"], "rxcui": ["198222", "198223", "200817", "200820", "200825", "313096"], "spl_id": ["22946678-dcad-4518-9bc6-cbdf51a38c16"], "spl_set_id": ["0fed2822-3a03-4b64-9857-c682fcd462bc"], "package_ndc": ["0025-1001-31", "0025-1041-31", "0025-1031-31"], "nui": ["N0000175557", "N0000011310"], "pharm_class_epc": ["Aldosterone Antagonist [EPC]"], "pharm_class_moa": ["Aldosterone Antagonists [MoA]"], "unii": ["27O7W4T232"]}, "update_date": "12/10/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Aldactone, Tablet, 25 mg (NDC 0025-1001-31)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "68001-573-41", "generic_name": "Decitabine Injection", "contact_info": "866-321-5031", "related_info": "Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210984"], "brand_name": ["DECITABINE"], "generic_name": ["DECITABINE"], "manufacturer_name": ["BluePoint Laboratories"], "product_ndc": ["68001-573"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DECITABINE"], "rxcui": ["636631"], "spl_id": ["fc96fe77-06cc-dc04-e053-6394a90a99da"], "spl_set_id": ["6c6ab831-6234-4803-8a01-5c51ec3b0716"], "package_ndc": ["68001-573-41"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["776B62CQ27"]}, "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Decitabine, Injection, 50 mg (NDC 68001-573-41)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-408-25", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-408", "61703-350"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"], "spl_set_id": ["0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab"], "package_ndc": ["61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-209-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care Renal Therapies Group, LLC"], "product_ndc": ["49230-209", "49230-206", "49230-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["44506bb0-e5f3-2a05-e063-6294a90ab2c9", "43cd31e0-97ed-1eeb-e063-6294a90a0b3d"], "spl_set_id": ["bbc5b820-4973-11e2-a192-0002a5d5c51b", "c29bdfa0-4976-11e2-939b-0002a5d5c51b"], "package_ndc": ["49230-206-20", "49230-206-30", "49230-206-32", "49230-206-50", "49230-206-60", "49230-206-62", "49230-206-52", "49230-209-23", "49230-209-30", "49230-209-32", "49230-209-50", "49230-209-60", "49230-209-62", "49230-209-52", "49230-212-23", "49230-212-30", "49230-212-32", "49230-212-50", "49230-212-60", "49230-212-62", "49230-212-52", "49230-206-92", "49230-206-94", "49230-206-95", "49230-209-92", "49230-209-94", "49230-209-95", "49230-212-92", "49230-212-94", "49230-212-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0172-5241-60", "generic_name": "Anagrelide Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/19/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Capsule", "presentation": "Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0527-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 5 mg (NDC 0071-0527-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-82", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-671", "25021-652"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "61570-072-01", "generic_name": "Esterified Estrogens Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/29/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Menest, Tablet, .3 mg (NDC 61570-072-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70860-701-04", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Athenex is not active, supplying through Sagent NDC 25021-701-02", "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-04)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-118-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-118", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3073", "0009-3475"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "04/22/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-0929-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-0929", "0641-0928"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992858"], "spl_id": ["9f14d3f5-ad01-44b5-a2b7-16ed5f501f87"], "spl_set_id": ["4bf3912c-8339-401e-9711-dad6acf15f11"], "package_ndc": ["0641-0928-21", "0641-0928-25", "0641-0929-21", "0641-0929-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9549-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["NDA208083"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9549", "0338-9545", "0338-9553"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b0a47c5e-911b-4b12-a0d1-a4425f173eec"], "spl_set_id": ["44fa506b-90ac-42de-831b-5f3f1a500fc0"], "package_ndc": ["0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6025-10", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-016-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability June 2026", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-016", "72516-015", "72516-014", "72516-013", "72516-012", "72516-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-401-02", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA206935"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Ingenus Pharmaceuticals, LLC"], "product_ndc": ["50742-401", "50742-402"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["3c841594-8a93-4728-b184-0f4bfac73390"], "spl_set_id": ["d04f2471-3085-4fc8-a657-bb3918d48e6e"], "package_ndc": ["50742-401-02", "50742-402-05"], "unii": ["042LAQ1IIS"]}, "update_date": "02/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/14/2018", "package_ndc": "65282-1605-1", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "978-657-0889 ext. 5231", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA208017"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "manufacturer_name": ["Spectra Medical Devices, LLC"], "product_ndc": ["65282-1605"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737566"], "spl_id": ["447bfde4-fff3-32a6-e063-6394a90a667e"], "spl_set_id": ["e8ba012a-08a9-4f67-9f88-3284377e80be"], "package_ndc": ["65282-1605-1"], "unii": ["EC2CNF7XFP"]}, "update_date": "05/15/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)", "company_name": "Spectra Medical Devices, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-002-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X5ML)  is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-701-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA050141"], "brand_name": ["BICILLIN L-A"], "generic_name": ["PENICILLIN G BENZATHINE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["60793-701", "60793-700", "60793-702"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PENICILLIN G BENZATHINE"], "rxcui": ["731564", "731566", "731567", "731568", "731570", "731571"], "spl_id": ["4b3694af-9d77-487f-8838-b75aec6636da"], "spl_set_id": ["012d46f1-d0a0-4676-a879-cd320297ab16"], "package_ndc": ["60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10"], "unii": ["RIT82F58GK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6083-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "This presentation is temporarily on backorder.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PHENERGAN"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6083", "0641-6082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992462", "992858", "992876"], "spl_id": ["a64f0625-8d56-4994-8908-13614ca7b09f"], "spl_set_id": ["6f7e47cc-f823-4336-8107-f980e3049617"], "package_ndc": ["0641-6082-01", "0641-6082-25", "0641-6083-01", "0641-6083-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070583"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596"], "spl_id": ["fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1582-29", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1582", "0409-1559", "0409-1560", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1582-29)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-20", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release June 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)", "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-1502-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "company_name": "Lannett Company, Inc.", "contact_info": "844-834-0530", "availability": "Available", "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "status": "Current", "dosage_form": "Tablet", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-4060-13", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Limited Availability", "related_info": "Estimated shortage duration TBD", "openfda": {"application_number": ["NDA022341"], "brand_name": ["VICTOZA"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Novo Nordisk"], "product_ndc": ["0169-4060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122", "897126"], "spl_id": ["0d10d10e-0fe0-47ee-b9da-628e34907e98"], "spl_set_id": ["5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"], "package_ndc": ["0169-4060-13", "0169-4060-12", "0169-4060-90", "0169-4060-97", "0169-4060-98", "0169-4060-99"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)", "company_name": "Novo Nordisk, Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "0406-1170-01", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-325-8888", "resolved_note": "Available", "openfda": {"application_number": ["ANDA076264"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-1170"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["9ed13551-325e-4b82-a266-72fc89ed27dc"], "spl_set_id": ["06ff2d5a-e62b-4fa4-bbdb-01938535bc65"], "package_ndc": ["0406-1170-03", "0406-1170-01"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-01)", "company_name": "SpecGx LLC", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "07/28/2025", "update_type": "New", "initial_posting_date": "07/28/2025", "package_ndc": "0049-3170-30", "generic_name": "Voriconazole Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021266"], "brand_name": ["VFEND"], "generic_name": ["VORICONAZOLE"], "manufacturer_name": ["Roerig"], "product_ndc": ["0049-3170", "0049-3180", "0049-3190", "0049-3160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VORICONAZOLE"], "rxcui": ["349434", "349435", "351209", "352218", "352219", "352220", "465355", "546624"], "spl_id": ["cf9f1b2e-eeb4-48bb-9f1a-c2b8d94dfbea"], "spl_set_id": ["ce3ef5cf-3087-4d92-9d94-9eb8287228db"], "package_ndc": ["0049-3170-30", "0049-3180-30", "0049-3190-28", "0049-3160-44"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000182140", "N0000185504"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]"], "unii": ["JFU09I87TR"]}, "update_date": "07/28/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Vfend, Tablet, 50 mg (NDC 0049-3170-30)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3213-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3213", "0093-0832", "0093-3212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-02", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-062-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-062", "70069-061", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-460-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-460", "63323-465", "63323-467", "63323-464", "63323-466", "63323-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177"], "spl_id": ["2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-105-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "65219-434-20", "generic_name": "Piperacillin and Tazobactam Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203719"], "brand_name": ["PIPERACILLIN AND TAZOBACTAM"], "generic_name": ["PIPERACILLIN AND TAZOBACTAM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-434", "65219-436", "65219-259"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PIPERACILLIN SODIUM", "TAZOBACTAM SODIUM"], "rxcui": ["1659131", "1659137", "1659149"], "spl_id": ["76af03be-bc73-40f9-bde0-31fe9c359ca2"], "spl_set_id": ["a798faf5-cd97-4e35-a700-94c372978c46"], "package_ndc": ["65219-434-02", "65219-434-20", "65219-436-02", "65219-436-20", "65219-259-05", "65219-259-45"], "unii": ["UXA545ABTT", "M98T69Q7HP"]}, "update_date": "01/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7838-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7838", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-02", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1180-69", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Shortage per Manufacturer: Manufacturing Delay", "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "68180-659-06", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA090034"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-659", "68180-658"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["5ed1edac-e11e-4f87-b390-e770a69a9b37"], "spl_set_id": ["b56004f0-f23d-47f6-80c7-39884fccbccc"], "package_ndc": ["68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 68180-659-06)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "63323-089-50", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206688"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-089", "63323-083"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868469", "1868486"], "spl_id": ["9def795c-abcf-483c-8b1d-e4374666efb2"], "spl_set_id": ["0ab55004-bb63-436d-ad77-cd3796905370"], "package_ndc": ["63323-083-03", "63323-083-05", "63323-089-25", "63323-089-50"], "unii": ["8MDF5V39QO"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/27/2023", "package_ndc": "45567-0060-1", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "New supply anticipated Q2 2026", "openfda": {"application_number": ["NDA019039"], "brand_name": ["KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE"], "generic_name": ["TECHNETIUM TC99M PYROPHOSPHATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["45567-0060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["TECHNETIUM TC-99M PYROPHOSPHATE"], "spl_id": ["3010b45e-eed1-a5d0-e063-6294a90a40cf"], "spl_set_id": ["1f0cbd23-2fb3-43b7-b8af-7de246151149"], "package_ndc": ["45567-0060-1", "45567-0060-2"], "nui": ["N0000177914", "N0000000205"], "pharm_class_epc": ["Radioactive Diagnostic Agent [EPC]"], "pharm_class_moa": ["Radiopharmaceutical Activity [MoA]"], "unii": ["5L76I61H2B"]}, "update_date": "04/17/2026", "therapeutic_category": ["Medical Imaging"], "dosage_form": "Injection", "presentation": "CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/31/2018", "package_ndc": "65219-570-04", "generic_name": "Bumetanide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA216434"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-570", "65219-572"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["aaff61c4-203b-4905-9138-0f98959ad013"], "spl_set_id": ["a007f3aa-3977-4be3-a9a2-db3d458bca58"], "package_ndc": ["65219-570-01", "65219-570-04", "65219-572-01", "65219-572-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1454-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1454", "0409-3301", "0409-1174", "0409-2815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["8d48de06-361f-418b-bfec-8ef85f94d5bc"], "spl_set_id": ["4419162d-81d4-49bd-96de-1729440bdb74"], "package_ndc": ["0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0126-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "63323-519-77", "generic_name": "Heparin Sodium Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA212441"], "brand_name": ["HEPARIN SODIUM"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-519"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["3bbbe74a-1246-41a6-9fc3-ca0230529b40"], "spl_set_id": ["25b0ba06-3274-4a3f-8c39-42d13764ecdf"], "package_ndc": ["63323-519-02", "63323-519-77", "63323-519-01", "63323-519-10"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/23/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-74", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE AQUA"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0521"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["0bc2d27e-e0d0-4c85-a5e1-808c625b6f93"], "spl_set_id": ["c85dc235-3f42-4361-9bd2-1aaff798ad75"], "package_ndc": ["0574-0521-04", "0574-0521-08", "0574-0521-25", "0574-0521-74", "0574-0521-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "16729-081-01", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "866-941-7875, option 2", "resolved_note": "Available", "openfda": {"application_number": ["ANDA091205"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-081"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["424db74c-6c0f-1eb3-e063-6294a90a7db8"], "spl_set_id": ["49aa3d6d-2270-4615-aafa-b440859ab870"], "package_ndc": ["16729-081-10", "16729-081-01", "16729-081-16", "16729-081-17"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-01)", "company_name": "Accord Healthcare Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-487-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076803"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-487", "62135-484", "62135-485", "62135-486"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["09cd5cb9-4fdf-f133-e063-6294a90af691"], "spl_set_id": ["dbc43dbd-94aa-40e2-a9ea-766110cc8687"], "package_ndc": ["62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90"], "unii": ["33067B3N2M"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5813-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA090866"], "brand_name": ["VALSARTAN"], "generic_name": ["VALSARTAN"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-5813", "0378-5807", "0378-5814", "0378-5815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VALSARTAN"], "rxcui": ["349199", "349200", "349201", "349483"], "spl_id": ["a5384d58-48c7-494a-a8a8-c296b316bd91"], "spl_set_id": ["73e01dc6-7dd4-421a-a4f6-137e75f69f9a"], "package_ndc": ["0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77"], "nui": ["N0000000070", "N0000175561"], "pharm_class_moa": ["Angiotensin 2 Receptor Antagonists [MoA]"], "pharm_class_epc": ["Angiotensin 2 Receptor Blocker [EPC]"], "unii": ["80M03YXJ7I"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 80 mg (NDC 0378-5813-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-172-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020712"], "brand_name": ["CARBATROL"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["54092-172", "54092-171", "54092-173"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["200131", "200133", "308977", "313931", "388311", "404742"], "spl_id": ["39171a32-c78d-4130-be53-638e19cf2261"], "spl_set_id": ["bc03e499-5bac-4293-bff4-6864153a624d"], "package_ndc": ["54092-171-12", "54092-172-12", "54092-173-12"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "12/19/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-4073-04", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-407", "43547-406", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-421-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA201072"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-421"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["56e0af34-aeb5-4b37-8c61-2e90b2c8ca6c"], "spl_set_id": ["c1b8eb58-596b-481d-beb6-ba9d2237abf4"], "package_ndc": ["63323-421-01", "63323-421-02"], "unii": ["1018WH7F9I"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-112-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-112", "70010-111", "70010-113", "70010-114", "70010-115", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-0152-24", "generic_name": "Metronidazole Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Labeler: Hospira Inc.", "openfda": {"application_number": ["ANDA206191"], "brand_name": ["METRONIDAZOLE"], "generic_name": ["METRONIDAZOLE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0152"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["METRONIDAZOLE"], "rxcui": ["311683"], "spl_id": ["1489f8a8-873f-465f-ac91-980848a8d4a2"], "spl_set_id": ["49360d6f-c8b3-420e-af75-154cf7b05255"], "package_ndc": ["0409-0152-01", "0409-0152-24"], "nui": ["N0000175435", "M0014907"], "pharm_class_epc": ["Nitroimidazole Antimicrobial [EPC]"], "pharm_class_cs": ["Nitroimidazoles [CS]"], "unii": ["140QMO216E"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)", "company_name": "InfoRLife SA", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-111-14", "generic_name": "Nilutamide Tablet", "contact_info": "847-283-7921", "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Nilandron, Tablet, 150 mg (NDC 59212-111-14)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-600-04", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": {"application_number": ["NDA206628"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["WG Critical Care, LLC"], "product_ndc": ["44567-600", "44567-601", "44567-602", "44567-603"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909", "1788947"], "spl_id": ["e6fa3e27-b374-49b6-a678-a5954f5beae8"], "spl_set_id": ["0d2710f2-ee47-4114-ab5c-8dca74cdcb8d"], "package_ndc": ["44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)", "company_name": "HQ Specialty Pharma", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-03", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3796-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA074802"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3796", "0409-3793", "0409-3795"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["572e3ce2-a27c-4a65-9593-84666518ddca"], "spl_set_id": ["8accbb78-fc64-45d5-69b0-35c23a1d2a2e"], "package_ndc": ["0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "16729-277-35", "generic_name": "Methotrexate Sodium Injection", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA040716"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-277"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["2bae3cfe-7aa0-c14c-e063-6294a90a19f4"], "spl_set_id": ["dd035a9f-cd40-4314-b9d8-2294b8a924e2"], "package_ndc": ["16729-277-30", "16729-277-03", "16729-277-35"], "nui": ["N0000175584", "N0000000111"], "pharm_class_epc": ["Folate Analog Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Folic Acid Metabolism Inhibitors [MoA]"], "unii": ["YL5FZ2Y5U1"]}, "update_date": "05/01/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-062-01", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-062", "65862-063", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-01)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "76045-005-11", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi, USA LLC", "Fresenius Kabi USA, LLC"], "product_ndc": ["76045-005", "76045-004", "76045-006", "76045-007", "76045-008"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "894914", "998212", "998213", "1442790"], "spl_id": ["286bce70-23cd-4d5b-989b-230d6cdd5a91", "e064585d-2d2d-41cd-a0f1-43494ce4775b"], "spl_set_id": ["1f53de80-efc8-4930-b3e3-fba0d026af05", "b62ee1ef-db55-417a-a02e-b103890f9c4b"], "package_ndc": ["76045-004-01", "76045-004-11", "76045-005-01", "76045-005-11", "76045-006-01", "76045-006-11", "76045-007-01", "76045-007-11", "76045-008-01", "76045-008-11", "76045-004-02", "76045-004-12", "76045-005-02", "76045-005-12", "76045-006-02", "76045-006-12", "76045-007-00", "76045-007-10", "76045-008-00", "76045-008-10"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6082-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PHENERGAN"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6082", "0641-6083"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992462", "992858", "992876"], "spl_id": ["a64f0625-8d56-4994-8908-13614ca7b09f"], "spl_set_id": ["6f7e47cc-f823-4336-8107-f980e3049617"], "package_ndc": ["0641-6082-01", "0641-6082-25", "0641-6083-01", "0641-6083-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-3112-23", "generic_name": "Hydrochlorothiazide; Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 12.5 mg; 10 mg (NDC 0071-3112-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "63323-172-60", "generic_name": "Carboplatin Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release April 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA077266"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-172"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["3a1dd588-13b0-4d58-8d46-3a25a4fc6b40"], "spl_set_id": ["b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6"], "package_ndc": ["63323-172-60"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0591-0347-01", "generic_name": "Hydrochlorothiazide Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["NDA020504"], "brand_name": ["HYDROCHLOROTHIAZIDE"], "generic_name": ["HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-0347"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE"], "rxcui": ["199903"], "spl_id": ["b062bc7e-af92-4648-aed1-e02568313e21"], "spl_set_id": ["a3eb7294-f913-434b-896c-da028bfebc73"], "package_ndc": ["0591-0347-01", "0591-0347-05"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["0J48LPH2TH"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Microzide, Capsule, 12.5 mg (NDC 0591-0347-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "76045-009-06", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release April 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["DILAUDID"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-009", "76045-010", "76045-121"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370"], "spl_id": ["97bfcafb-2037-47dc-a0ae-f7b8007c47df"], "spl_set_id": ["9eebd88a-5632-460f-b7b6-26c8a180540d"], "package_ndc": ["76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-105-20", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA203242"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-105", "76045-104", "76045-107", "76045-209"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860113", "860114", "860115"], "spl_id": ["0dab642d-7fcf-4301-8ac9-10e64a040c6b"], "spl_set_id": ["3d88cbe6-5230-47aa-80af-0c41283d1f00"], "package_ndc": ["76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-92", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2868", "0781-2859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0591-2682-01", "generic_name": "Potassium Citrate Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue.", "openfda": {"application_number": ["ANDA209758"], "brand_name": ["POTASSIUM CITRATE"], "generic_name": ["POTASSIUM CITRATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2682", "0591-2729", "0591-2742"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CITRATE"], "rxcui": ["199376", "199381", "898490"], "spl_id": ["309b143e-7142-4a21-859e-715ba61e82f7"], "spl_set_id": ["ac173781-486b-461c-97ae-8b5c69e20792"], "package_ndc": ["0591-2682-01", "0591-2729-01", "0591-2742-01"], "unii": ["EE90ONI6FF"]}, "update_date": "07/17/2025", "therapeutic_category": ["Renal"], "dosage_form": "Tablet", "presentation": "Potassium Citrate, Tablet, Extended Release, 5 meq (NDC 0591-2682-01)", "company_name": "Watson Pharma Private Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "64253-020-30", "generic_name": "Sterile Water Injection", "contact_info": "630-682-4600", "availability": "Available", "openfda": {"application_number": ["ANDA211188"], "brand_name": ["STERILE WATER"], "generic_name": ["STERILE WATER FOR INJECTION"], "manufacturer_name": ["Medefil, Inc."], "product_ndc": ["64253-020"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["2b39b41d-419a-dab8-e063-6394a90a319a"], "spl_set_id": ["99e99a50-82d5-aff6-e053-2a95a90a8c56"], "package_ndc": ["64253-020-21", "64253-020-23", "64253-020-30", "64253-020-35", "64253-020-52", "64253-020-25", "64253-020-91"], "unii": ["059QF0KO0R"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)", "company_name": "Medefil, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "16729-525-08", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1761-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018692"], "brand_name": ["MARCAINE SPINAL"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1761"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBARACHNOID"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724784", "1724792"], "spl_id": ["f3862f77-3621-4730-923e-9efbfa18e03f"], "spl_set_id": ["9679cc05-2f8a-4e88-53b5-6e9122c8b8c0"], "package_ndc": ["0409-1761-19", "0409-1761-02", "0409-1761-18", "0409-1761-62", "0409-1761-05", "0409-1761-10"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9310-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Novaplus label", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9310", "0143-9311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["c15bd8c1-34e3-40f2-b31a-634136fe197c"], "spl_set_id": ["4312e3c3-34de-4cb3-8abd-c24d24a4bea1"], "package_ndc": ["0143-9310-01", "0143-9310-10", "0143-9311-01", "0143-9311-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6002-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["ATIVAN"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6002", "0641-6003", "0641-6001", "0641-6000"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327"], "spl_id": ["209b0091-c890-4f69-a693-d0594c2606fe"], "spl_set_id": ["5fc0e987-61c9-40c4-b0d5-fcea07c8733e"], "package_ndc": ["0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/30/2025", "update_type": "New", "initial_posting_date": "09/30/2025", "package_ndc": "0004-0801-85", "generic_name": "Oseltamivir Phosphate Capsule", "contact_info": "800-551-2231", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "09/30/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Capsule", "presentation": "Tamiflu, Capsule, 45 mg (NDC 0004-0801-85)", "company_name": "Genentech, Inc", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/03/2021", "package_ndc": "0409-3977-03", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: September 2026; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018802"], "brand_name": ["BACTERIOSTATIC WATER"], "generic_name": ["BACTERIOSTATIC WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3977", "0409-1093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["e421caa9-6011-4cdf-a16c-6fe96d8b958a"], "spl_set_id": ["87d6e9dc-fe3b-4593-ac9a-d7493d1959c7"], "package_ndc": ["0409-3977-01", "0409-3977-03", "0409-1093-14", "0409-1093-04"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-288", "63323-286", "63323-287", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/13/2017", "package_ndc": "83301-0080-2", "generic_name": "Bumetanide Injection", "contact_info": "800-673-9839", "availability": "Available", "openfda": {"application_number": ["ANDA219116"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Mullan Pharmaceutical Inc."], "product_ndc": ["83301-0080", "83301-0081"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["4c241a3e-649b-4414-e063-6294a90a3a32"], "spl_set_id": ["b7cd724b-817b-4b45-8133-1ebf505867e7"], "package_ndc": ["83301-0080-1", "83301-0080-2", "83301-0081-1", "83301-0081-2"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)", "company_name": "Mullan Pharmaceutical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-23", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9545-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["NDA208083"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9545", "0338-9549", "0338-9553"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b0a47c5e-911b-4b12-a0d1-a4425f173eec"], "spl_set_id": ["44fa506b-90ac-42de-831b-5f3f1a500fc0"], "package_ndc": ["0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0472-0803-04", "generic_name": "Desonide Lotion", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA072354"], "brand_name": ["DESONIDE"], "generic_name": ["DESONIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-0803", "0472-0804"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DESONIDE"], "rxcui": ["197572", "349351"], "spl_id": ["f3953b9e-138f-4d86-8eea-0fc03c3c2747"], "spl_set_id": ["ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99"], "package_ndc": ["0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["J280872D1O"]}, "update_date": "09/18/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Lotion", "presentation": "Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-04)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7853-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7853", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-385-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0480-3667-20", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "related_info": "Distributed by Teva", "openfda": {"application_number": ["NDA022341"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0480-3667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["57c9f463-a1b8-4efa-8982-40175cf6cf4f"], "spl_set_id": ["14bf9812-14ee-46ce-93b1-686e4906cbbc"], "package_ndc": ["0480-3667-19", "0480-3667-22", "0480-3667-20"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)", "company_name": "Novo Nordisk, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-083-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-083", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0264-2101-10", "generic_name": "Sterile Water Irrigant", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA016734"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-2101"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["969bdf41-6565-42fb-8ac1-8661a928cc22"], "spl_set_id": ["f4284eb6-e553-46d4-90d8-efc80a90a480"], "package_ndc": ["0264-2101-00", "0264-2101-10", "0264-2101-50", "0264-2101-70"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-726-52", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216039"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-726", "71288-723"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["0949c302-51ce-4fc9-8b99-1df94e693718"], "spl_set_id": ["fe340f98-a0f3-446e-b281-47fd91c1e537"], "package_ndc": ["71288-723-52", "71288-726-52"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0143-9252-25", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA207707"], "brand_name": ["DOPAMINE HYDROCHLORIDE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9252", "0143-9253", "0143-9254", "0143-9255"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1743938", "1743941", "1743950", "1743953"], "spl_id": ["67349236-e8e3-45ec-a76d-2a0a150d8d59"], "spl_set_id": ["0e499952-46c7-4172-8c70-186312e240a3"], "package_ndc": ["0143-9252-01", "0143-9252-25", "0143-9253-01", "0143-9253-25", "0143-9254-01", "0143-9254-25", "0143-9255-01", "0143-9255-25"], "unii": ["7L3E358N9L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "55150-324-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA212174"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-324", "55150-322", "55150-323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9bb2ffa4-0891-4197-a970-90b178bbfad9"], "spl_set_id": ["421aa6d5-623b-4dc2-abd5-bb9e7765bf37"], "package_ndc": ["55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2634"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["50886ad5-eeca-4fe7-beb0-01305f92c65d"], "spl_set_id": ["3832ede8-d3fc-455d-ecab-3b77be5869f5"], "package_ndc": ["0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-100-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 100 ug (NDC 72305-100-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-580-20", "generic_name": "Atropine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA209260"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-580"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190776"], "spl_id": ["8039a2a4-4c0a-4062-9ca5-78137ba74082"], "spl_set_id": ["310c8a74-ea24-4357-8099-81e394b1634e"], "package_ndc": ["63323-580-20"], "unii": ["03J5ZE7KA5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-10", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1918", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-103-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-103", "59417-101", "59417-102", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 30 mg (NDC 59417-103-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/30/2026", "update_type": "New", "initial_posting_date": "01/30/2026", "package_ndc": "57664-655-88", "generic_name": "Pindolol Tablet", "contact_info": "800-818-4555", "related_info": "Discontinuation of the manufacture of the drug; Expiry date of last distributed batch January 2027", "openfda": {"application_number": ["ANDA074063"], "brand_name": ["PINDOLOL"], "generic_name": ["PINDOLOL"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-655", "57664-656"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PINDOLOL"], "rxcui": ["198104", "198105"], "spl_id": ["4d3c89dd-e947-5f23-e063-6294a90aeb1f"], "spl_set_id": ["b331a73f-bf7b-4442-8901-36d016530279"], "package_ndc": ["57664-656-88", "57664-655-88"], "nui": ["N0000000161", "N0000175556"], "pharm_class_moa": ["Adrenergic beta-Antagonists [MoA]"], "pharm_class_epc": ["beta-Adrenergic Blocker [EPC]"], "unii": ["BJ4HF6IU1D"]}, "update_date": "01/30/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pindolol, Tablet, 5 mg (NDC 57664-655-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1075-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020255"], "brand_name": ["DOBUTAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOBUTAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1075", "0338-1073", "0338-1077"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["34c787c1-46f7-4264-951d-c88a34dca533"], "spl_set_id": ["6b17b98b-e06d-42ed-925f-69aa2699dead"], "package_ndc": ["0338-1073-02", "0338-1075-02", "0338-1077-02"], "unii": ["0WR771DJXV"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0370-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0370", "0054-0660", "0054-0371", "0054-0372", "0054-0373", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "3, 4, 5, 7 & 8 month expiry available upon request. Check wholesaler for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-061-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-061", "70069-062", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-0155-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0155", "0409-4596"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718907", "1718909", "1718910"], "spl_id": ["58e27ec5-ccde-46c9-afd3-2509e6b55e4e"], "spl_set_id": ["92b7ddaa-e45a-4b64-a802-bb5df8771dd6"], "package_ndc": ["0409-4596-01", "0409-4596-20", "0409-0155-01", "0409-0155-02"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-438-10", "generic_name": "Arsenic Trioxide Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA209315"], "brand_name": ["ARSENIC TRIOXIDE"], "generic_name": ["ARSENIC TRIOXIDE"], "manufacturer_name": ["Ingenus Pharmaceuticals, LLC"], "product_ndc": ["50742-438"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ARSENIC TRIOXIDE"], "rxcui": ["829926"], "spl_id": ["b3030683-7cb9-4143-abbd-d3894313e83d"], "spl_set_id": ["c99b01b4-67ff-4793-8375-fe3a21c6c9be"], "package_ndc": ["50742-438-10"], "unii": ["S7V92P67HO"]}, "update_date": "02/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-01", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA074086"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["e71e9520-871b-479d-9652-1857fceca863", "5d6b1dfe-d679-4aea-97a6-3d074a202afe"], "spl_set_id": ["dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58"], "package_ndc": ["0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-66", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA019465"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7101", "0409-7132"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807547", "1807631", "1807632", "1807633"], "spl_id": ["f233e72c-072d-4a43-857a-f4d5791e1a73"], "spl_set_id": ["a2a964f7-c3ec-4dfb-e3a0-6d8136a80397"], "package_ndc": ["0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02"], "unii": ["451W47IQ8X"]}, "update_date": "12/03/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 50 mL  ADD-Vantage® Flexible Container (NDC 0409-7101-66)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-444-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA217472"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-444", "65219-442", "65219-695", "65219-697"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["2720024", "2720026"], "spl_id": ["31c4c874-3d24-4c86-a301-ee9faf0b5c00"], "spl_set_id": ["9a622308-7bda-4ca0-9de5-d6b3b4be3384"], "package_ndc": ["65219-442-02", "65219-442-05", "65219-444-04", "65219-444-10", "65219-695-01", "65219-695-05", "65219-697-01", "65219-697-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5017-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA063076"], "brand_name": ["VANCOMYCIN HYDROCHLORIDE"], "generic_name": ["VANCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5017", "0409-6509"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VANCOMYCIN HYDROCHLORIDE"], "rxcui": ["239209", "313572"], "spl_id": ["818f60e1-7062-4ed0-9839-7cab15866330"], "spl_set_id": ["b01aaa02-8f1d-4b57-96a5-337503428af1"], "package_ndc": ["0409-6509-49", "0409-5017-01"], "unii": ["71WO621TJD"]}, "update_date": "11/14/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"presentation": "Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1559-30", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "73293-0002-2", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "+82-2-854-4700 or via email intbiz@huons.com", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA212822"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Huons Co., Ltd."], "product_ndc": ["73293-0002"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBARACHNOID"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724784"], "spl_id": ["2e641a0d-4d42-e7cd-e063-6394a90a47d4"], "spl_set_id": ["2dc693df-3218-4a90-b3f7-21e80966a851"], "package_ndc": ["73293-0002-1", "73293-0002-2"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)", "company_name": "Huons Co., Ltd", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/03/2023", "package_ndc": "81665-104-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Available", "related_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195", "openfda": {"application_number": ["ANDA209264"], "brand_name": ["CROMOLYN SODIUM"], "generic_name": ["CROMOLYN SODIUM"], "manufacturer_name": ["Omnivium Pharmaceuticals LLC"], "product_ndc": ["81665-104"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261"], "spl_id": ["fd09b0f1-907c-4d4d-a693-9756efd60f20"], "spl_set_id": ["a742664b-265e-49f9-9744-d04e1fb620ae"], "package_ndc": ["81665-104-96"], "unii": ["Q2WXR1I0PK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)", "company_name": "Ailex Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/11/2024", "package_ndc": "0990-7918-19", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7918-19", "openfda": {"application_number": ["NDA018561"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7918", "0990-7935", "0990-7936", "0990-7937", "0990-8004"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["237649", "237650", "237656", "242694", "1795518"], "spl_id": ["6785bd83-c705-41a5-a19c-906f03f380e3"], "spl_set_id": ["b5cb7a5a-bbe8-4217-a82e-da818f7771c9"], "package_ndc": ["0990-7918-19", "0990-7935-19", "0990-7936-19", "0990-7937-19", "0990-8004-15"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72266-146-10", "generic_name": "Etomidate Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": {"application_number": ["ANDA209058"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE INJECTION"], "manufacturer_name": ["Fosun Pharma USA Inc"], "product_ndc": ["72266-146", "72266-147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["2b365133-b609-3285-e063-6394a90a69a6"], "spl_set_id": ["8b6c54d8-3f3f-4290-841c-976bea01086f"], "package_ndc": ["72266-146-01", "72266-146-10", "72266-147-01", "72266-147-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "0409-4264-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: March 2027; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4264", "0409-1283", "0409-1312", "0409-1805"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4667-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4667", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4666"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "25021-687-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Estimated recovery: June 2026", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-687"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["1d066c67-eac2-494a-ad10-ba7e9c60b0e9"], "spl_set_id": ["01825411-be08-4402-b101-cb546291c972"], "package_ndc": ["25021-687-05", "25021-687-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-104-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-104", "59417-101", "59417-102", "59417-103", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 40 mg (NDC 59417-104-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-075-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-075", "72305-025", "72305-050", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 75 ug (NDC 72305-075-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "67457-893-08", "generic_name": "Busulfan Injection", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA208536"], "brand_name": ["BUSULFAN"], "generic_name": ["BUSULFAN"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-893"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["BUSULFAN"], "rxcui": ["253113"], "spl_id": ["2ddd71e8-c2bd-4ee9-bef3-14891809fa28"], "spl_set_id": ["9955aced-ac32-43e6-b39a-c6c023a50dc3"], "package_ndc": ["67457-893-00", "67457-893-08"], "nui": ["N0000000236", "N0000175558"], "pharm_class_moa": ["Alkylating Activity [MoA]"], "pharm_class_epc": ["Alkylating Drug [EPC]"], "unii": ["G1LN9045DK"]}, "update_date": "10/24/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08)", "company_name": "Mylan Institutional, a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-9664-40", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020179"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9664", "0338-9666"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616"], "spl_id": ["bfc4224a-2fc9-4137-b4c6-9d2d6d948413"], "spl_set_id": ["bfc4224a-2fc9-4137-b4c6-9d2d6d948413"], "package_ndc": ["0338-9664-40", "0338-9666-35"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3567-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3567", "0480-3565", "0480-3566", "0480-3568", "0480-3569", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/06/2023", "change_date": "12/15/2025", "package_ndc": "0338-1047-02", "generic_name": "Nitroglycerin Injection", "contact_info": "Baxter Healthcare 888-229-0001", "resolved_note": "Available", "openfda": {"application_number": ["NDA019970"], "brand_name": ["NITROGLYCERIN IN DEXTROSE"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1047", "0338-1049", "0338-1051"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["312004", "1868494", "1868562"], "spl_id": ["b89cb9ff-d275-465b-b70b-d8e2e9406435"], "spl_set_id": ["457a026c-ebce-4701-9deb-2d7652759a99"], "package_ndc": ["0338-1047-02", "0338-1049-02", "0338-1051-02"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "12/15/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Nitroglycerin in Dextrose 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)", "company_name": "Baxter Healthcare", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "16571-600-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(201) 961-9000 or contact@risingpharma.com", "availability": "Limited Availability", "related_info": "Limited Availability", "openfda": {"application_number": ["ANDA202583"], "brand_name": ["CROMOLYN SODIUM"], "generic_name": ["CROMOLYN SODIUM"], "manufacturer_name": ["Rising Pharma Holdings, Inc."], "product_ndc": ["16571-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261"], "spl_id": ["ca2c72ae-db00-4694-9fd0-d4b6b45f8108"], "spl_set_id": ["61c9cb85-129e-4490-b5f7-357307fcecbf"], "package_ndc": ["16571-600-96"], "unii": ["Q2WXR1I0PK"]}, "update_date": "03/02/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)", "company_name": "Rising Pharma Holdings, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3564-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "related_info": "-", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3564", "0480-3565", "0480-3566", "0480-3567", "0480-3568", "0480-3569", "0480-3570"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-801-30", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-801", "42806-799"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 42806-801-30)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "72143-321-30", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug. Manufactured for JG Pharma", "openfda": {"application_number": ["NDA018738"], "brand_name": ["SULCONAZOLE NITRATE"], "generic_name": ["SULCONAZOLE NITRATE"], "manufacturer_name": ["JG Pharma Inc."], "product_ndc": ["72143-321"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["SULCONAZOLE NITRATE"], "rxcui": ["313125"], "spl_id": ["fc60cb89-7eba-463c-91b9-1b21cd8637a5"], "spl_set_id": ["cf6f4340-940c-4a61-b675-456e3297d810"], "package_ndc": ["72143-321-30"], "unii": ["1T89100D5U"]}, "update_date": "05/08/2026", "therapeutic_category": ["Dermatology"], "dosage_form": "Solution", "presentation": "Sulconazole Nitrate, Solution, 30 mL (NDC 72143-321-30)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2850-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA200881"], "brand_name": ["GUANFACINE"], "generic_name": ["GUANFACINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2850", "0228-2851", "0228-2853", "0228-2855"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GUANFACINE HYDROCHLORIDE"], "rxcui": ["862006", "862013", "862019", "862025"], "spl_id": ["b9040df2-42e8-404d-9b90-331dd3efc38c"], "spl_set_id": ["3a171942-37af-430d-8b9d-bb678ca2be4b"], "package_ndc": ["0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11"], "unii": ["PML56A160O"]}, "update_date": "11/13/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 1 mg (NDC 0228-2850-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2596-03", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075293"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2596", "0409-2587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["6c075a2d-b68b-41a7-aa0c-bcf9894e3f76"], "spl_set_id": ["affecd4d-1f78-4bbe-5a8d-86849bbdc520"], "package_ndc": ["0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5315-15", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5315", "0245-5316"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-15)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-578-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-578", "23155-579", "23155-580", "23155-581", "23155-582", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 10 mg (NDC 23155-578-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0011-03", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0011", "0009-0825", "0009-0013", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3793-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2027", "openfda": {"application_number": ["ANDA074802"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3793", "0409-3795", "0409-3796"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["572e3ce2-a27c-4a65-9593-84666518ddca"], "spl_set_id": ["8accbb78-fc64-45d5-69b0-35c23a1d2a2e"], "package_ndc": ["0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1362-01", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Shortage per Manufacturer: Manufacturing Delay", "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "0074-9037-30", "generic_name": "Paricalcitol Capsule", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021606"], "brand_name": ["ZEMPLAR"], "generic_name": ["PARICALCITOL"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-9037", "0074-4314", "0074-4317", "0074-9036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PARICALCITOL"], "rxcui": ["577315", "577317", "606854", "606859"], "spl_id": ["ed8862d9-4037-4a30-9be6-42f2613c34cd"], "spl_set_id": ["1b27c026-2d60-47b4-2a9c-ded1818f21b5"], "package_ndc": ["0074-4314-30", "0074-4317-30", "0074-4317-73", "0074-9036-30", "0074-9037-30"], "nui": ["M0007651", "N0000175907", "N0000175849"], "pharm_class_cs": ["Ergocalciferols [CS]"], "pharm_class_epc": ["Vitamin D2 Analog [EPC]", "Vitamin D Analog [EPC]"], "unii": ["6702D36OG5"]}, "update_date": "10/07/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Zemplar, Capsule, 2 ug (NDC 0074-9037-30)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/30/2020", "package_ndc": "0143-9785-10", "generic_name": "Valproate Sodium Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA078523"], "brand_name": ["VALPROATE SODIUM"], "generic_name": ["VALPROATE SODIUM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9785"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VALPROATE SODIUM"], "rxcui": ["1099648"], "spl_id": ["0610e50d-6447-4a0e-bc36-dc0bffa95c7d"], "spl_set_id": ["bcf57b31-4811-4104-82b3-46fb91a53ee0"], "package_ndc": ["0143-9785-01", "0143-9785-10"], "unii": ["5VOM6GYJ0D"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "63323-516-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA040572"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-516", "63323-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1812079"], "spl_id": ["9320abbb-bfd8-4df2-9269-3a52736c190f"], "spl_set_id": ["cca2c160-9188-48e8-9505-49a52388dcb7"], "package_ndc": ["63323-506-00", "63323-506-01", "63323-506-03", "63323-506-13", "63323-516-01", "63323-516-10"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA208129"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["27411591-44a1-44c4-89c3-dd8c2687f0e2"], "spl_set_id": ["4d5d2294-89a0-4b6f-aa00-d39a0393b6a8"], "package_ndc": ["63323-671-02", "63323-671-20", "63323-671-05", "63323-671-50", "63323-671-01", "63323-671-00"], "unii": ["1018WH7F9I"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-20", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-487-37", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-073-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-073", "13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "63323-426-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA078651"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-426"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["d6e2ff8d-838d-4c27-8e73-230548b09d63", "3f4d5e11-2c14-4406-8954-04dba2fc65ff"], "spl_set_id": ["f1933332-1ae0-4dc1-be4c-694849e6c9f9", "fb9524b2-c353-4747-8954-7ca2529eabb2"], "package_ndc": ["63323-426-02", "63323-426-05", "63323-426-01", "63323-426-10", "63323-426-12", "63323-426-15"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-7299-73", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["1859490"], "spl_id": ["013001c4-5584-4d8c-8bf6-917d2a919aa4", "10c75a24-9542-431a-84f8-44611bc916df"], "spl_set_id": ["ce9a7469-c4ba-4f60-8f7a-47ef0974316e", "c91ede49-c7cc-47b7-0f93-e6841dd5916a"], "package_ndc": ["0409-7299-45", "0409-7299-25", "0409-7299-83", "0409-7299-73"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5544-01", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018877"], "brand_name": ["ALLOPURINOL"], "generic_name": ["ALLOPURINOL"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5544", "0591-5543"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ALLOPURINOL"], "spl_id": ["f7e04d88-1d9b-47e6-a9ad-deb08af3c098"], "spl_set_id": ["a80fe56f-8d03-423f-8e2a-7ec8c9e5045b"], "package_ndc": ["0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05"], "nui": ["N0000175698", "N0000000206"], "pharm_class_epc": ["Xanthine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Xanthine Oxidase Inhibitors [MoA]"], "unii": ["63CZ7GJN5I"]}, "update_date": "02/19/2026", "therapeutic_category": ["Oncology", "Renal", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 300 mg (NDC 0591-5544-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-31", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA206775"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-295"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["35cf6068-f31a-211b-e063-6294a90a6b53"], "spl_set_id": ["48aa7ef3-9f44-2a08-e054-00144ff88e88"], "package_ndc": ["16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9598-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019830"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9598", "0264-9594"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e352802-107c-4f90-babe-4f69c7dc892e"], "spl_set_id": ["7dff29d9-522d-40eb-a9d9-42377912d640"], "package_ndc": ["0264-9598-20", "0264-9594-20", "0264-9594-10"], "unii": ["EC2CNF7XFP", "LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-668-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076374"], "brand_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-668", "62135-667", "62135-669"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["0c3f4504-d57e-aa79-e063-6294a90ad5b8"], "spl_set_id": ["2eae533f-d0af-47e8-a1f2-94bc8cc89b5a"], "package_ndc": ["62135-667-90", "62135-668-90", "62135-669-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "0641-6007-10", "generic_name": "Bumetanide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA079196"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6007", "0641-6008"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["99d2fc38-7e1e-4209-aa57-089794eda8a6"], "spl_set_id": ["681b5e9d-e2c7-4f29-aaad-e06d4a528c11"], "package_ndc": ["0641-6007-01", "0641-6007-10", "0641-6008-01", "0641-6008-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-153", "72888-152", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-30)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-187-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Available", "related_info": "Please check wholesalers for inventory", "openfda": {"application_number": ["ANDA208266"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["42023-187", "42023-146", "42023-186"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710", "1718906", "1718909"], "spl_id": ["54174211-6684-4fb9-a605-be12b94e2948"], "spl_set_id": ["1ee59985-4c1d-48f7-b8f9-5584c2d55e08"], "package_ndc": ["42023-146-25", "42023-186-20", "42023-187-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)", "company_name": "Par Health, USA LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-386-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3795-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: June 2027", "openfda": {"application_number": ["ANDA074802"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3795", "0409-3793", "0409-3796"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["572e3ce2-a27c-4a65-9593-84666518ddca"], "spl_set_id": ["8accbb78-fc64-45d5-69b0-35c23a1d2a2e"], "package_ndc": ["0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0832-0274-11", "generic_name": "Morphine Sulfate Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210610"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0274", "0832-0273"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892582", "892672"], "spl_id": ["46a682fc-0430-5a66-e063-6294a90a6179"], "spl_set_id": ["5ceb3205-2f8d-4ba3-9f27-dc328bab4fa1"], "package_ndc": ["0832-0273-11", "0832-0274-11"], "unii": ["X3P646A2J0"]}, "update_date": "12/22/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1596-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1596", "0409-1660", "0409-1638", "0409-1434", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "63481-025-09", "generic_name": "Frovatriptan Succinate Tablet", "contact_info": "800-828-9393", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/24/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Frova, Tablet, 2.5 mg (NDC 63481-025-09)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0264-9872-00", "generic_name": "Heparin Sodium Injection", "contact_info": "800-227-2862", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA019953"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9872"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["48e17807-e73d-4ea2-81bc-901355903aa7"], "spl_set_id": ["a3041c04-0ea8-4d36-81ce-c5091c906316"], "package_ndc": ["0264-9872-10", "0264-9872-00"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/20/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)", "company_name": "B. Braun Medical Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-618-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202725"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL HYDROCHLORIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-618", "65862-617", "65862-619", "65862-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["5263abd5-ce46-4918-9bb0-9632861bcbc9"], "spl_set_id": ["93e6e668-5306-4f26-81d8-cbc3a7a5e787"], "package_ndc": ["65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78"], "unii": ["33067B3N2M"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0480-5795-08", "generic_name": "Cetrorelix Acetate Injection", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA215737"], "brand_name": ["CETRORELIX"], "generic_name": ["CETRORELIX ACETATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-5795"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "rxcui": ["283402"], "spl_id": ["f8c62e7c-4615-463b-af59-b820a9e3b911"], "spl_set_id": ["f91c971b-89d7-4306-966d-8ecc1afc16d1"], "package_ndc": ["0480-5795-08", "0480-3583-01", "0480-3584-21"]}, "update_date": "11/13/2025", "therapeutic_category": ["Reproductive"], "dosage_form": "Injection", "presentation": "Cetrorelix Acetate, Injection, Kit (NDC 0480-5795-08)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0990-7172-17", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7172-17", "openfda": {"application_number": ["NDA020015"], "brand_name": ["AMINOSYN II"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7172", "0990-7171"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ACETYL L-TYROSINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "VALINE"], "rxcui": ["800188", "800192", "800237", "800241"], "spl_id": ["ea005122-3350-4609-83ad-9d093f25162f"], "spl_set_id": ["5b426208-f090-4650-86c3-89040ba45c2d"], "package_ndc": ["0990-7172-17", "0990-7171-17"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["2ZD004190S", "94ZLA3W45F", "3KX376GY7L", "DA8G610ZO5", "HG18B9YRS7", "TE7660XO1C", "8DUH1N11BX", "4QD397987E", "GMW67QNF9C", "AE28F7PNPL", "47E5O17Y3R", "30KYC7MIAI", "TTL6G7LIWZ", "OF5P57N2ZX", "452VLY9402", "04Y7590D77", "9DLQ4CIU6V"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA089644"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0409-6695-01", "generic_name": "Etomidate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018227"], "brand_name": ["AMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6695"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008", "1654009", "1654011"], "spl_id": ["b59f4852-2843-4a8f-a597-306ebddb259a"], "spl_set_id": ["b7ed5bf8-ba75-44dc-8f81-96b4ad5766be"], "package_ndc": ["0409-6695-11", "0409-6695-01", "0409-6695-12", "0409-6695-02"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0825-01", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0825", "0009-0011", "0009-0013", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-6637-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202494"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6637", "0409-4916"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["727995", "792582"], "spl_id": ["f79ec8cb-b6a3-4ffb-bccf-d39f59d65621"], "spl_set_id": ["ea20a5eb-641e-48cd-bcfa-74c04c45dfda"], "package_ndc": ["0409-4916-24", "0409-4916-14", "0409-6637-24", "0409-6637-14"], "unii": ["8MDF5V39QO"]}, "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0264-1933-10", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "related_info": "On allocation", "openfda": {"application_number": ["NDA019018"], "brand_name": ["TROPHAMINE"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, CYSTEINE HYDROCHLORIDE, HISTIDINE, TYROSINE, N-ACETYL-TYROSINE, ALANINE, ARGININE, PROLINE, SERINE, GLYCINE, ASPARTIC ACID, GLUTAMIC ACID, AND TAURINE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-1933"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ACETYL L-TYROSINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "CYSTEINE HYDROCHLORIDE", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["800611", "1189640"], "spl_id": ["07f53291-419d-4d14-ad81-26f00dc0c474"], "spl_set_id": ["cb6d23ff-3ec5-445a-acbe-f88fd57949bf"], "package_ndc": ["0264-1933-10"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["DA8G610ZO5", "OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "ZT934N0X4W", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-607-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-607", "43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-0771-98", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0771", "0093-7201", "0093-7202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "43066-013-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA091115"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-013", "43066-007"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["9e0317de-2d78-4fd8-8926-4c7b476f3ed4"], "spl_set_id": ["31e15c3f-aefa-4379-b684-7707744fe40d"], "package_ndc": ["43066-007-10", "43066-013-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-8076-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020646"], "brand_name": ["TIAGABINE HYDROCHLORIDE"], "generic_name": ["TIAGABINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8076", "0093-5030", "0093-5031", "0093-8072"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TIAGABINE HYDROCHLORIDE"], "rxcui": ["1299903", "1299909", "1299911", "1299917"], "spl_id": ["2a8d7987-54ae-45d7-8224-361dac37e0a4"], "spl_set_id": ["953ef3cc-e3cb-480f-b9ea-256520fd62b8"], "package_ndc": ["0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56"], "unii": ["DQH6T6D8OY"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-166-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-166", "42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4743-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4743", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0274-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0274", "0009-0280", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-062-99", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-062", "65862-063", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-99)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0264-4500-05", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "related_info": "On allocation", "openfda": {"application_number": ["ANDA091112"], "brand_name": ["PLENAMINE"], "generic_name": ["LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-4500"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "spl_id": ["905f7c55-bf0d-4150-90ef-e8f1a5455bc1"], "spl_set_id": ["a3244d1a-45b0-4e4c-bd96-f0632d761a1f"], "package_ndc": ["0264-4500-00", "0264-4500-05"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Plenamine, Injection, 0.15 (NDC 0264-4500-05)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-03", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-03", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/08/2026", "update_type": "New", "initial_posting_date": "04/08/2026", "package_ndc": "63323-972-10", "generic_name": "Fosaprepitant Dimeglumine Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA206197"], "brand_name": ["FOSAPREPITANT"], "generic_name": ["FOSAPREPITANT"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-972"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FOSAPREPITANT DIMEGLUMINE"], "rxcui": ["1731077"], "spl_id": ["864bb02f-d50d-4ae2-ad9c-82bb1e9aed2c"], "spl_set_id": ["ffee61d1-c1c6-4224-871c-ab7ff6cd01e5"], "package_ndc": ["63323-972-10"], "unii": ["D35FM8T64X"]}, "update_date": "04/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-069-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-069", "13107-068", "13107-070", "13107-071", "13107-072", "13107-073", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/29/2025", "update_type": "New", "initial_posting_date": "10/29/2025", "package_ndc": "63323-850-74", "generic_name": "Moxifloxacin Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA205572"], "brand_name": ["MOXIFLOXACIN"], "generic_name": ["MOXIFLOXACIN HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-850"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MOXIFLOXACIN HYDROCHLORIDE"], "rxcui": ["351156"], "spl_id": ["4070f637-059f-4e3d-8cf3-e5256a46ff3e"], "spl_set_id": ["a4e28b09-714b-46e7-b4e6-0163cad78fc5"], "package_ndc": ["63323-850-74", "63323-850-04"], "unii": ["C53598599T"]}, "update_date": "10/29/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5168-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5168", "0603-5165", "0603-5166", "0603-5167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3985-60", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 400 mg (NDC 0591-3985-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-620-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": {"application_number": ["NDA017533"], "brand_name": ["KLONOPIN"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["H2-Pharma, LLC"], "product_ndc": ["61269-620", "61269-605", "61269-610"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529", "206157", "206159", "206160"], "spl_id": ["63cfdab9-fb3d-4c2b-bf88-8ba841dba839"], "spl_set_id": ["cfa0d79a-843c-4b88-95a1-e9511d649ca1"], "package_ndc": ["61269-605-10", "61269-610-10", "61269-620-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, 2 mg (NDC 61269-620-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "change_date": "12/19/2024", "package_ndc": "0409-3177-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089635"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3177", "0409-1209", "0409-3178", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-084-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-084", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-560-10", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-560", "62037-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "63459-920-59", "generic_name": "Tbo-filgrastim Injection", "contact_info": "800-545-8800", "openfda": {"application_number": ["BLA125294"], "brand_name": ["GRANIX"], "generic_name": ["TBO-FILGRASTIM"], "manufacturer_name": ["Cephalon, LLC"], "product_ndc": ["63459-920", "63459-910", "63459-912", "63459-918"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FILGRASTIM"], "rxcui": ["1433768", "1433771", "1442681", "1442683", "2101456", "2101459", "2101464", "2101465"], "spl_id": ["063f36a7-6f99-40fa-af02-8a5183c51e99"], "spl_set_id": ["df918ec2-0907-443f-a52a-b72866959644"], "package_ndc": ["63459-910-01", "63459-910-12", "63459-910-11", "63459-910-15", "63459-910-18", "63459-910-17", "63459-910-36", "63459-912-01", "63459-912-12", "63459-912-11", "63459-912-15", "63459-912-18", "63459-912-17", "63459-912-36", "63459-918-53", "63459-918-59", "63459-920-53", "63459-920-59"], "nui": ["M0024696", "N0000009451", "N0000175666"], "pharm_class_cs": ["Granulocyte Colony-Stimulating Factor [CS]"], "pharm_class_pe": ["Increased Myeloid Cell Production [PE]"], "pharm_class_epc": ["Leukocyte Growth Factor [EPC]"], "unii": ["PVI5M0M1GW"]}, "update_date": "06/13/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Granix, Injection, 480 ug/1.6 mL (NDC 63459-920-59)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-360-18", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-360", "61703-150", "61703-262", "61703-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["5aa72c15-8033-4559-b257-373371b18958"], "spl_set_id": ["47677091-fd20-49af-933c-c9dd2be21de9"], "package_ndc": ["61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6247-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6247", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6030", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8214-05", "generic_name": "Insulin Glargine Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["BLA205692"], "brand_name": ["BASAGLAR TEMPO PEN"], "generic_name": ["INSULIN GLARGINE"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8214", "0002-7715"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN GLARGINE"], "rxcui": ["847230", "1736863", "2268064", "2268065"], "spl_id": ["3c2283e6-2844-44d2-a447-579b07e77c27"], "spl_set_id": ["0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae"], "package_ndc": ["0002-7715-01", "0002-7715-59", "0002-7715-63", "0002-8214-01", "0002-8214-05"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["2ZM8CX04RZ"]}, "update_date": "10/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "63323-724-05", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206223"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-724", "63323-723", "63323-725"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["2f27e51f-2b55-47ee-bd4a-001b71c60622"], "spl_set_id": ["d2374b84-81c9-44f9-a4a9-1071281b2531"], "package_ndc": ["63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10"], "unii": ["5V444H5WIC"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "55150-225-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206206"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-225", "55150-226"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["30f618bf-fbbd-4489-acbb-204e8ed78dca"], "spl_set_id": ["116385ea-69fc-4f44-b463-6210291032df"], "package_ndc": ["55150-225-05", "55150-226-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-37", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-37", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-100-11", "generic_name": "Insulin Aspart Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Aspart 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA020986"], "brand_name": ["INSULIN ASPART"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-100", "73070-102", "73070-103"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["311040", "1653196", "1653202"], "spl_id": ["393af9a3-df9a-40b2-a5e6-bfa5434a2552"], "spl_set_id": ["bee5b358-c863-420b-be73-ced2e920c499"], "package_ndc": ["73070-100-11", "73070-102-10", "73070-102-15", "73070-103-10", "73070-103-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Aspart, Injection, 10 mL Insulin Aspart vial (NDC 73070-100-11)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9577-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA080407"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9577", "0143-9579", "0143-9578", "0143-9576", "0143-9575", "0143-9172", "0143-9173"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["e9b92d4d-8944-4235-8d77-3218f82f00a9"], "spl_set_id": ["5523fdfe-69fd-49a5-b51f-73e2223d49a9"], "package_ndc": ["0143-9579-01", "0143-9579-25", "0143-9578-01", "0143-9578-10", "0143-9577-01", "0143-9577-10", "0143-9576-01", "0143-9576-25", "0143-9575-01", "0143-9575-10", "0143-9172-01", "0143-9172-10", "0143-9173-01", "0143-9173-10"], "unii": ["V13007Z41A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-112-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-112", "57844-105", "57844-117", "57844-110", "57844-115", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9404-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA061395"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9404", "0781-9401", "0781-9402", "0781-9407", "0781-9408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["308207", "1721473", "1721474", "1721475", "1721476"], "spl_id": ["a3ddae6c-ac4c-425f-82b0-eb388d92bc0e"], "spl_set_id": ["b371e1a5-1fef-4df2-8940-c4fc02b9e2f0"], "package_ndc": ["0781-9401-78", "0781-9401-95", "0781-9402-78", "0781-9402-95", "0781-9407-78", "0781-9407-95", "0781-9404-85", "0781-9404-95", "0781-9408-80", "0781-9408-95"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4370-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023", "update_date": "04/28/2023", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 2 mg (NDC 0069-4370-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-9666-35", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020179"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9666", "0338-9664"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616"], "spl_id": ["bfc4224a-2fc9-4137-b4c6-9d2d6d948413"], "spl_set_id": ["bfc4224a-2fc9-4137-b4c6-9d2d6d948413"], "package_ndc": ["0338-9664-40", "0338-9666-35"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-22", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-820-10", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA201835"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-820", "25021-821"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["13e1ca54-4fc4-4e93-a52d-c9320865e3cb"], "spl_set_id": ["f98314ea-a4e4-4f78-987b-3e9b45a08bb4"], "package_ndc": ["25021-820-05", "25021-820-10", "25021-821-05"], "unii": ["43502P7F0P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "0338-0433-04", "generic_name": "Heparin Sodium Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["NDA018609"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0433", "0338-0431", "0338-0424", "0338-0428"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["68b37381-6db4-4ac0-ba6b-3204add02665"], "spl_set_id": ["0d929726-76c3-48fc-b4e7-fd06409f9fb3"], "package_ndc": ["0338-0431-03", "0338-0433-04", "0338-0424-18", "0338-0428-12"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/20/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)", "company_name": "Baxter Healthcare", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "16729-081-10", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "866-941-7857, option 2", "resolved_note": "Available", "openfda": {"application_number": ["ANDA091205"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-081"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["424db74c-6c0f-1eb3-e063-6294a90a7db8"], "spl_set_id": ["49aa3d6d-2270-4615-aafa-b440859ab870"], "package_ndc": ["16729-081-10", "16729-081-01", "16729-081-16", "16729-081-17"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-10)", "company_name": "Accord Healthcare Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0172-5240-60", "generic_name": "Anagrelide Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/19/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Capsule", "presentation": "Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "0409-7037-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7037", "0409-3189"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["c96726ef-f1fa-4ebb-ba33-3479c3902a8e"], "spl_set_id": ["c96726ef-f1fa-4ebb-ba33-3479c3902a8e"], "package_ndc": ["0409-3189-05", "0409-3189-10", "0409-7037-01", "0409-7037-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-173-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020712"], "brand_name": ["CARBATROL"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["54092-173", "54092-171", "54092-172"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["200131", "200133", "308977", "313931", "388311", "404742"], "spl_id": ["39171a32-c78d-4130-be53-638e19cf2261"], "spl_set_id": ["bc03e499-5bac-4293-bff4-6864153a624d"], "package_ndc": ["54092-171-12", "54092-172-12", "54092-173-12"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "12/19/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "55150-221-10", "generic_name": "Etomidate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206126"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-221", "55150-222"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["278b160e-cdc4-451e-9405-cb001f443680"], "spl_set_id": ["0820f15a-046b-4185-a2b3-2e4051ee3d82"], "package_ndc": ["55150-221-10", "55150-222-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70860-700-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Athenex is not active, supplying through Sagent NDC  25021-700-01", "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 70860-700-02)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-106-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-106", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 60 mg (NDC 59417-106-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-025-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 25 mg/.4 mL (NDC 82497-025-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0974-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0974", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0973"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-01", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "0338-9555-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA208532"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9555", "0338-9557"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["594e9faa-bc32-42e0-9c0a-8fa9460b1e24"], "spl_set_id": ["8ccb45a7-8290-469c-9644-a4dca967d88f"], "package_ndc": ["0338-9555-24", "0338-9557-12"], "unii": ["1018WH7F9I"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/14/2016", "package_ndc": "63323-487-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/26/2025", "update_type": "New", "initial_posting_date": "06/26/2025", "package_ndc": "0093-5538-01", "generic_name": "Eszopiclone Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA091169"], "brand_name": ["ESZOPICLONE"], "generic_name": ["ESZOPICLONE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5538", "0093-5537", "0093-5539"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ESZOPICLONE"], "rxcui": ["485440", "485442", "485465"], "spl_id": ["efcf4106-ac0a-4f8b-bcd0-743e45e66924"], "spl_set_id": ["2435e2f1-bc52-488f-80e9-f1758e354aae"], "package_ndc": ["0093-5537-56", "0093-5538-01", "0093-5539-01"], "unii": ["UZX80K71OE"]}, "update_date": "06/26/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Eszopiclone, Tablet, 2 mg (NDC 0093-5538-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-737-30", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": {"application_number": ["ANDA072369"], "brand_name": ["FLURAZEPAM HYDROCHLORIDE"], "generic_name": ["FLURAZEPAM HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-737", "62135-736"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLURAZEPAM HYDROCHLORIDE"], "rxcui": ["1298088", "1298091"], "spl_id": ["25893c92-c8f1-567a-e063-6294a90a00d4"], "spl_set_id": ["8f476891-1346-4e8c-ac1b-f8cbdc64f5a1"], "package_ndc": ["62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90"], "unii": ["756RDM536M"]}, "update_date": "02/02/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4740-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4740", "60505-4739", "60505-4741", "60505-4742", "60505-4743", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3566-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3566", "0480-3565", "0480-3567", "0480-3568", "0480-3569", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "68094-909-30", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Precision Dose Inc."], "product_ndc": ["68094-909"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["efc0724d-4c6e-4974-928c-fd50774f5980"], "spl_set_id": ["b09b4b5e-795a-48e7-b7cc-2e29f41c5660"], "package_ndc": ["68094-909-30", "68094-909-50"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-30)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/06/2023", "change_date": "12/15/2025", "package_ndc": "0338-1051-02", "generic_name": "Nitroglycerin Injection", "contact_info": "Baxter Healthcare 888-229-0001", "resolved_note": "Available", "openfda": {"application_number": ["NDA019970"], "brand_name": ["NITROGLYCERIN IN DEXTROSE"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1051", "0338-1047", "0338-1049"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["312004", "1868494", "1868562"], "spl_id": ["b89cb9ff-d275-465b-b70b-d8e2e9406435"], "spl_set_id": ["457a026c-ebce-4701-9deb-2d7652759a99"], "package_ndc": ["0338-1047-02", "0338-1049-02", "0338-1051-02"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "12/15/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Nitroglycerin in Dextrose 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)", "company_name": "Baxter Healthcare", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-4900-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0374-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0374", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/08/2025", "update_type": "New", "initial_posting_date": "07/08/2025", "package_ndc": "0409-1891-23", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1891", "0409-1890", "0409-1892", "0409-1893", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "07/08/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-23)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/06/2023", "change_date": "12/15/2025", "package_ndc": "0517-4810-25", "generic_name": "Nitroglycerin Injection", "contact_info": "800-645-1706", "resolved_note": "Available", "openfda": {"application_number": ["ANDA072034"], "brand_name": ["NITROGLYCERIN"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["American Regent, Inc."], "product_ndc": ["0517-4810"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["237205"], "spl_id": ["ee83c8b9-c31a-4f32-9e9d-0370545204cb"], "spl_set_id": ["8c52cdf6-87be-4719-b105-f08be096d462"], "package_ndc": ["0517-4810-01", "0517-4810-25"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "12/15/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Nitroglycerin, Injection, 5 mg/1 mL (NDC 0517-4810-25)", "company_name": "American Regent, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-051-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-051", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-199-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-199", "55150-195", "55150-196", "55150-197", "55150-198", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "16729-512-43", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA213424"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-512"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190776"], "spl_id": ["275def6c-5b2d-918b-e063-6294a90aa71f"], "spl_set_id": ["f3cb74e9-b4ac-4efe-bd8e-8a71970ee7c7"], "package_ndc": ["16729-512-05", "16729-512-43"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-61", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4491", "0002-4312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-61)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-559-01", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-559", "62037-560"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2023", "package_ndc": "72888-153-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-153", "72888-152", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-01)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0078-0364-05", "generic_name": "Amlodipine Besylate; Benazepril Hydrochloride Capsule", "contact_info": "888-669-6682", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA020364"], "brand_name": ["LOTREL"], "generic_name": ["AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "product_ndc": ["0078-0364", "0078-0405", "0078-0406", "0078-0379"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMLODIPINE BESYLATE", "BENAZEPRIL HYDROCHLORIDE"], "rxcui": ["898342", "898344", "898346", "898348", "898353", "898355", "898356", "898358"], "spl_id": ["b9db75d9-9d1e-4b2d-9876-5f5520feaecc"], "spl_set_id": ["94ae6054-b7ae-4212-a567-4f803af8f2c7"], "package_ndc": ["0078-0405-05", "0078-0406-05", "0078-0364-05", "0078-0379-05"], "unii": ["864V2Q084H", "N1SN99T69T"]}, "update_date": "06/24/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Lotrel, Capsule, 10 mg; 20 mg (NDC 0078-0364-05)", "company_name": "Novartis Pharmaceuticals Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-458-30", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-458", "65219-456", "65219-464", "65219-460", "65219-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/04/2024", "package_ndc": "50633-310-11", "generic_name": "Hydroxocobalamin Injection", "related_info_link": "https://www.fda.gov/media/185400/download", "contact_info": "844-293-0007", "availability": "Limited Availability", "related_info": "Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.", "openfda": {"application_number": ["NDA022041"], "brand_name": ["CYANOKIT"], "generic_name": ["HYDROXOCOBALAMIN"], "manufacturer_name": ["BTG INTERNATIONAL INC."], "product_ndc": ["50633-310"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HYDROXOCOBALAMIN"], "rxcui": ["700496", "700499"], "spl_id": ["9955075c-c059-4b63-b387-e98ef13e60dc"], "spl_set_id": ["d56fcc8d-bd64-46ab-b0c0-2124bd745a6b"], "package_ndc": ["50633-310-11"], "nui": ["N0000175429"], "pharm_class_epc": ["Antidote [EPC]"], "unii": ["Q40X8H422O"]}, "update_date": "10/31/2025", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)", "company_name": "BTG International Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-564-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-193-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-193", "11534-190", "11534-191", "11534-192", "11534-194", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0002-7640-01", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-545-5979", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021462"], "brand_name": ["ALIMTA"], "generic_name": ["PEMETREXED DISODIUM"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-7640", "0002-7623"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PEMETREXED DISODIUM HEPTAHYDRATE"], "rxcui": ["1728072", "1728075", "1728077", "1728079"], "spl_id": ["3af0bc84-13d6-46aa-a4c0-c62410b73bc6"], "spl_set_id": ["f5a860f3-37ec-429c-ae04-9c88d7c55c08"], "package_ndc": ["0002-7640-01", "0002-7623-01"], "unii": ["9T47E4OM16"]}, "update_date": "10/16/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Alimta, Injection, 100 mg/4 mL (NDC 0002-7640-01)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "08/15/2023", "package_ndc": "64850-506-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-506", "64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-505"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0371-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0371", "0054-0660", "0054-0370", "0054-0372", "0054-0373", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-174-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Limited Availability", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 5 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-179", "47781-180"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0185-0842-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA040439"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0185-0842", "0185-0831", "0185-0853", "0185-0864", "0185-2099", "0185-2098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577961"], "spl_id": ["9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd"], "spl_set_id": ["288dafc4-fe6e-4891-832f-511022c87445"], "package_ndc": ["0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-31", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Not available at this time.", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1174-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1174", "0409-1454", "0409-3301", "0409-2815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["8d48de06-361f-418b-bfec-8ef85f94d5bc"], "spl_set_id": ["4419162d-81d4-49bd-96de-1729440bdb74"], "package_ndc": ["0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/27/2025", "update_type": "New", "initial_posting_date": "06/27/2025", "package_ndc": "0591-3713-30", "generic_name": "Ezetimibe Tablet", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the product", "openfda": {"application_number": ["ANDA200831"], "brand_name": ["EZETIMIBE"], "generic_name": ["EZETIMIBE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3713"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EZETIMIBE"], "rxcui": ["349556"], "spl_id": ["24aaf5ca-08e0-4db8-9734-cf2a606f8e57"], "spl_set_id": ["f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba"], "package_ndc": ["0591-3713-30", "0591-3713-19", "0591-3713-05"], "nui": ["N0000008553", "N0000175911"], "pharm_class_pe": ["Decreased Cholesterol Absorption [PE]"], "pharm_class_epc": ["Dietary Cholesterol Absorption Inhibitor [EPC]"], "unii": ["EOR26LQQ24"]}, "update_date": "06/27/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Ezetimibe, Tablet, 10 mg (NDC 0591-3713-30)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62175-313-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA091695"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["62175-313", "62175-310", "62175-311", "62175-312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001564", "2001565", "2001566", "2001568"], "spl_id": ["8b133cd2-e3c6-4742-b402-2393b56ffc93"], "spl_set_id": ["3d1f5aff-5d39-496c-b5ed-7f3c70ec641c"], "package_ndc": ["62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37"], "unii": ["4B3SC438HI"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)", "company_name": "Lannett Company, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-001-02", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 59212-001-02)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3494-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": {"application_number": ["ANDA209065"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3494", "0781-3493", "0781-3495"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["fdf227d9-008e-60f8-e053-6294a90af5c4"], "spl_set_id": ["809e8f77-390f-4cc8-8c8a-4f67a249c9df"], "package_ndc": ["0781-3493-95", "0781-3494-95", "0781-3495-95"], "unii": ["1018WH7F9I"]}, "update_date": "04/06/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL  (NDC 0781-3494-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1073-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020255"], "brand_name": ["DOBUTAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOBUTAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1073", "0338-1075", "0338-1077"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["34c787c1-46f7-4264-951d-c88a34dca533"], "spl_set_id": ["6b17b98b-e06d-42ed-925f-69aa2699dead"], "package_ndc": ["0338-1073-02", "0338-1075-02", "0338-1077-02"], "unii": ["0WR771DJXV"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "25021-701-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-701", "25021-700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["cb23332a-48fa-458b-93ab-c4eef189a051"], "spl_set_id": ["62591551-a644-4b2c-a0de-982e906fabc3"], "package_ndc": ["25021-700-01", "25021-701-01", "25021-701-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-561-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA201791"], "brand_name": ["LAMOTRIGINE EXTENDED RELEASE"], "generic_name": ["LAMOTRIGINE EXTENDED RELEASE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-561", "49884-562", "49884-563", "49884-564", "49884-604", "49884-605"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LAMOTRIGINE"], "rxcui": ["850087", "850091", "900156", "900164", "1098608", "1146690"], "spl_id": ["9c5e0c2a-800e-47e9-a26b-582b98a05957"], "spl_set_id": ["fb59c76a-9b6f-40ea-ac3a-58c3195c4377"], "package_ndc": ["49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05"], "nui": ["N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191"], "pharm_class_epc": ["Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]"], "unii": ["U3H27498KS"]}, "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "64850-300-01", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-300"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["cae1ac14-ab22-42d1-8449-5e36c137b905"], "spl_set_id": ["5f188bdc-2009-43aa-ad32-f06dbfac2642"], "package_ndc": ["64850-300-30", "64850-300-01"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 64850-300-01)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "0023-6150-04", "generic_name": "Progesterone Vaginal Gel", "contact_info": "800-678-1605", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/27/2026", "therapeutic_category": ["Urology"], "dosage_form": "Vaginal Gel", "presentation": "Crinone, Vaginal Gel, 4% (NDC 0023-6150-04)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "45802-580-46", "generic_name": "Scopolamine Transdermal System", "contact_info": "866-634-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078830"], "brand_name": ["SCOPOLAMINE TRANSDERMAL SYSTEM"], "generic_name": ["SCOPOLAMINE TRANSDERMAL SYSTEM"], "manufacturer_name": ["Padagis Israel Pharmaceuticals Ltd"], "product_ndc": ["45802-580"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["SCOPOLAMINE"], "rxcui": ["226552"], "spl_id": ["d334a21d-7546-477f-a66a-f95b2cf523ce"], "spl_set_id": ["cb93bfad-3e37-4a27-92f6-f21703ae7bdf"], "package_ndc": ["45802-580-84", "45802-580-46", "45802-580-62", "45802-580-01"], "nui": ["N0000175574", "N0000175370"], "pharm_class_epc": ["Anticholinergic [EPC]"], "pharm_class_moa": ["Cholinergic Antagonists [MoA]"], "unii": ["DL48G20X8X"]}, "update_date": "11/03/2025", "therapeutic_category": ["Gastroenterology", "Neurology", "Other"], "dosage_form": "Transdermal System", "presentation": "Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-0111-50", "generic_name": "Amantadine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076186"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0111"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849395"], "spl_id": ["45af44df-1a9b-32b6-e063-6394a90acdaf"], "spl_set_id": ["63d9d4aa-5f92-45b0-98d0-d6ec38b727cb"], "package_ndc": ["0832-0111-00", "0832-0111-50", "0832-0111-89", "0832-0111-03"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Tablet", "presentation": "Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-50)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-11", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-406", "43547-407", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-11)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-23", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-23", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-125-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-125", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 125 ug (NDC 72305-125-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6044-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Lots are being manufactured to meet demand", "openfda": {"application_number": ["NDA018140"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6044", "0641-6046", "0641-6045", "0641-6047"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100", "238101", "1665188", "1665326"], "spl_id": ["7c73dbc6-2623-4443-9b05-97dec7a0be2e"], "spl_set_id": ["e9b54e42-04cf-4c62-90e1-36f7b31a4e81"], "package_ndc": ["0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/23/2025", "update_type": "New", "initial_posting_date": "05/23/2025", "package_ndc": "0093-0813-05", "generic_name": "Nortriptyline Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "Permanent discontinuation of specific package size/ SKU for business reasons.", "openfda": {"application_number": ["ANDA074132"], "brand_name": ["NORTRIPTYLINE HYDROCHLORIDE"], "generic_name": ["NORTRIPTYLINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0813", "0093-0810", "0093-0811", "0093-0812"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NORTRIPTYLINE HYDROCHLORIDE"], "rxcui": ["198045", "198046", "198047", "317136"], "spl_id": ["314d74dc-7394-40b9-be81-cb67b6e925a1"], "spl_set_id": ["b58d473a-b19f-4d2a-b1ae-dd398d7a29e1"], "package_ndc": ["0093-0810-01", "0093-0810-05", "0093-0811-01", "0093-0811-05", "0093-0812-01", "0093-0812-05", "0093-0813-01", "0093-0813-05"], "unii": ["00FN6IH15D"]}, "update_date": "05/23/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Nortriptyline Hydrochloride, Capsule, 75 mg (NDC 0093-0813-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-200-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-200", "55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-722-99", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-722", "59651-723", "59651-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 59651-722-99)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-383-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-17", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3475-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3475", "0009-3073"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"presentation": "Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1560-10", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4739-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-137-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-137", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 137 ug (NDC 72305-137-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "55150-322-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; check wholesalers for inventory", "openfda": {"application_number": ["ANDA212174"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-322", "55150-323", "55150-324"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9bb2ffa4-0891-4197-a970-90b178bbfad9"], "spl_set_id": ["421aa6d5-623b-4dc2-abd5-bb9e7765bf37"], "package_ndc": ["55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-047-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 57664-047-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/23/2025", "update_type": "New", "initial_posting_date": "05/23/2025", "package_ndc": "0591-3153-01", "generic_name": "Minocycline Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "Permanent discontinuation of manufacture due to business decision.", "openfda": {"application_number": ["ANDA063065"], "brand_name": ["MINOCYCLINE HYDROCHLORIDE"], "generic_name": ["MINOCYCLINE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3153", "0591-5694", "0591-5695"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["MINOCYCLINE HYDROCHLORIDE"], "rxcui": ["197984", "197985", "314108"], "spl_id": ["2d74faa2-99c4-4f01-adc6-60110d2b24da"], "spl_set_id": ["a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"], "package_ndc": ["0591-5694-60", "0591-5694-01", "0591-3153-01", "0591-5695-50"], "unii": ["0020414E5U"]}, "update_date": "05/23/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Minocycline Hydrochloride, Capsule, 75 mg (NDC 0591-3153-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-9104-20", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018132"], "brand_name": ["DOPAMINE HYDROCHLORIDE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9104", "0409-5820"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1743938", "1743941"], "spl_id": ["a3fac375-0709-4cc0-84db-b0e5a60b7200"], "spl_set_id": ["1f306ad2-3606-4525-5a8a-ce78f426c1a2"], "package_ndc": ["0409-5820-11", "0409-5820-01", "0409-9104-21", "0409-9104-20"], "unii": ["7L3E358N9L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-413-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": {"application_number": ["ANDA205823"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Solco Healthcare US, LLC"], "product_ndc": ["43547-413", "43547-410", "43547-411", "43547-412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["b8f1731a-cbac-4f64-a8d4-320b80b335e1"], "spl_set_id": ["cd46691d-5593-4a9f-a937-999c6803e312"], "package_ndc": ["43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0078-0405-05", "generic_name": "Amlodipine Besylate; Benazepril Hydrochloride Capsule", "contact_info": "888-669-6682", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA020364"], "brand_name": ["LOTREL"], "generic_name": ["AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "product_ndc": ["0078-0405", "0078-0406", "0078-0364", "0078-0379"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMLODIPINE BESYLATE", "BENAZEPRIL HYDROCHLORIDE"], "rxcui": ["898342", "898344", "898346", "898348", "898353", "898355", "898356", "898358"], "spl_id": ["b9db75d9-9d1e-4b2d-9876-5f5520feaecc"], "spl_set_id": ["94ae6054-b7ae-4212-a567-4f803af8f2c7"], "package_ndc": ["0078-0405-05", "0078-0406-05", "0078-0364-05", "0078-0379-05"], "unii": ["864V2Q084H", "N1SN99T69T"]}, "update_date": "06/24/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Lotrel, Capsule, 5 mg; 10 mg (NDC 0078-0405-05)", "company_name": "Novartis Pharmaceuticals Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-397-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "55150-323-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; check wholesalers for inventory", "openfda": {"application_number": ["ANDA212174"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-323", "55150-322", "55150-324"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9bb2ffa4-0891-4197-a970-90b178bbfad9"], "spl_set_id": ["421aa6d5-623b-4dc2-abd5-bb9e7765bf37"], "package_ndc": ["55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-200-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 200 ug (NDC 72305-200-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5012-4", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": {"application_number": ["ANDA211091"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Exela Pharma Sciences, LLC"], "product_ndc": ["51754-5012", "51754-5001", "51754-5011", "51754-5002"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["807284", "1868486", "1923484", "2198792"], "spl_id": ["4da0ba66-756d-4b4d-8018-81ca16578ef1"], "spl_set_id": ["e9698a4f-1a95-4f28-a945-e8009d1d6dd4"], "package_ndc": ["51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4"], "unii": ["8MDF5V39QO"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1896-20", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1896", "0409-2022"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731537", "1731545"], "spl_id": ["6f2d5741-5543-4bea-8d1d-7e4889b634a0"], "spl_set_id": ["ee8057d1-ed12-4e18-9efa-d83504abf612"], "package_ndc": ["0409-1896-20", "0409-2022-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-64", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3298-63", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070433"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-3298", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3294"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FUROSEMIDE"], "rxcui": ["197730", "197731", "197732", "310429", "313988"], "spl_id": ["bc62ddda-7639-4090-99f0-7dd4d13518f3"], "spl_set_id": ["9e493331-dddd-496e-abf8-61747fb67aba"], "package_ndc": ["0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-192-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-192", "11534-190", "11534-191", "11534-193", "11534-194", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0530-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 10 mg (NDC 0071-0530-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/10/2026", "update_type": "New", "initial_posting_date": "04/10/2026", "package_ndc": "69238-2512-9", "generic_name": "Nitrofurantoin Oral Suspension", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA201679"], "brand_name": ["NITROFURANTOIN"], "generic_name": ["NITROFURANTOIN"], "manufacturer_name": ["Amneal Pharmaceuticals NY LLC"], "product_ndc": ["69238-2512"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NITROFURANTOIN"], "rxcui": ["311989"], "spl_id": ["87af7ed1-6ae7-4eaf-ab35-d46d07549450"], "spl_set_id": ["80129dba-5939-4292-bfd0-8d53ba165941"], "package_ndc": ["69238-2512-9"], "nui": ["N0000175494", "M0014892"], "pharm_class_epc": ["Nitrofuran Antibacterial [EPC]"], "pharm_class_cs": ["Nitrofurans [CS]"], "unii": ["927AH8112L"]}, "update_date": "04/10/2026", "therapeutic_category": ["Anti-Infective", "Other"], "dosage_form": "Oral Suspension", "presentation": "Nitrofurantoin, Oral Suspension, 25 mg/5 mL (NDC 69238-2512-9)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/06/2023", "change_date": "12/15/2025", "package_ndc": "0338-1049-02", "generic_name": "Nitroglycerin Injection", "contact_info": "Baxter Healthcare 888-229-0001", "resolved_note": "Available", "openfda": {"application_number": ["NDA019970"], "brand_name": ["NITROGLYCERIN IN DEXTROSE"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1049", "0338-1047", "0338-1051"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["312004", "1868494", "1868562"], "spl_id": ["b89cb9ff-d275-465b-b70b-d8e2e9406435"], "spl_set_id": ["457a026c-ebce-4701-9deb-2d7652759a99"], "package_ndc": ["0338-1047-02", "0338-1049-02", "0338-1051-02"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "12/15/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Nitroglycerin in Dextrose 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)", "company_name": "Baxter Healthcare", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0530-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 10 mg (NDC 0071-0530-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-710-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075604"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-710", "62037-720"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["1801294", "1801298"], "spl_id": ["01fbdb24-0987-40f6-a920-f36349f6ba61"], "spl_set_id": ["db002ae3-f54c-40a4-9cb4-e5681bf426e3"], "package_ndc": ["62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10"], "unii": ["660YQ98I10"]}, "update_date": "11/21/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 10 meq (NDC 62037-710-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "16729-432-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-723-52", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216039"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-723", "71288-726"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["0949c302-51ce-4fc9-8b99-1df94e693718"], "spl_set_id": ["fe340f98-a0f3-446e-b281-47fd91c1e537"], "package_ndc": ["71288-723-52", "71288-726-52"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-48", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-6531-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA062933", "ANDA062912"], "brand_name": ["VANCOMYCIN HYDROCHLORIDE"], "generic_name": ["VANCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6531", "0409-6535", "0409-6534", "0409-6533", "0409-4332", "0409-3515"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VANCOMYCIN HYDROCHLORIDE"], "rxcui": ["1807513", "1807516", "1807518", "2049890"], "spl_id": ["771a44e0-5858-449c-be36-438a9ff52e67", "10032a19-0373-4c42-b785-f3d915614e30"], "spl_set_id": ["2fd9de3f-a95f-451c-a687-d2e1306e53bf", "f2901045-904f-47bd-74a1-c561facd7f25"], "package_ndc": ["0409-6531-11", "0409-6531-01", "0409-6535-11", "0409-6535-01", "0409-6534-11", "0409-6534-01", "0409-6531-12", "0409-6531-02", "0409-6533-11", "0409-6533-01", "0409-6533-21", "0409-4332-11", "0409-4332-01", "0409-3515-11", "0409-3515-01"], "unii": ["71WO621TJD"]}, "update_date": "09/09/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 750 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-6531-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-5030-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020646"], "brand_name": ["TIAGABINE HYDROCHLORIDE"], "generic_name": ["TIAGABINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5030", "0093-5031", "0093-8072", "0093-8076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TIAGABINE HYDROCHLORIDE"], "rxcui": ["1299903", "1299909", "1299911", "1299917"], "spl_id": ["2a8d7987-54ae-45d7-8224-361dac37e0a4"], "spl_set_id": ["953ef3cc-e3cb-480f-b9ea-256520fd62b8"], "package_ndc": ["0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56"], "unii": ["DQH6T6D8OY"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1573-5", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Currently product is under backorder as per current demand. Next supply: week of 02/09/2026", "openfda": {"application_number": ["ANDA210043"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1573", "70121-1574"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743855"], "spl_id": ["af4215ff-94ca-44f8-8506-3024e738cd13"], "spl_set_id": ["d944240d-2c19-46ba-ad4f-3fbee7b8629c"], "package_ndc": ["70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5"], "unii": ["43502P7F0P"]}, "update_date": "02/09/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-452-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-452", "63323-454", "63323-455", "63323-458", "63323-451"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011", "1732136", "2003714"], "spl_id": ["dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc"], "spl_set_id": ["582f42e5-444e-4246-af8c-e7e28097c69a"], "package_ndc": ["63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5543-10", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018832"], "brand_name": ["ALLOPURINOL"], "generic_name": ["ALLOPURINOL"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5543", "0591-5544"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ALLOPURINOL"], "spl_id": ["f7e04d88-1d9b-47e6-a9ad-deb08af3c098"], "spl_set_id": ["a80fe56f-8d03-423f-8e2a-7ec8c9e5045b"], "package_ndc": ["0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05"], "nui": ["N0000175698", "N0000000206"], "pharm_class_epc": ["Xanthine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Xanthine Oxidase Inhibitors [MoA]"], "unii": ["63CZ7GJN5I"]}, "update_date": "02/19/2026", "therapeutic_category": ["Oncology", "Renal", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 100 mg (NDC 0591-5543-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-601-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": {"application_number": ["ANDA214456"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Alembic Pharmaceuticals Inc."], "product_ndc": ["62332-601", "62332-599", "62332-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["9030f496-5021-4454-ac16-dbb376315608"], "spl_set_id": ["419cf756-3c96-4bb8-ae96-6aea5a5f3afd"], "package_ndc": ["62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/15/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-088-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-088", "72305-025", "72305-050", "72305-075", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 88 ug (NDC 72305-088-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/07/2026", "update_type": "New", "initial_posting_date": "05/07/2026", "package_ndc": "63323-574-86", "generic_name": "Icatibant Acetate Injection", "contact_info": "847-550-2300", "related_info": "Discontinuation of the manufacturer of the drug", "openfda": {"application_number": ["ANDA208317"], "brand_name": ["ICATIBANT"], "generic_name": ["ICATIBANT"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-574"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ICATIBANT ACETATE"], "rxcui": ["1148141"], "spl_id": ["d1c9afa7-c4ac-4739-85f1-2ae82440210c"], "spl_set_id": ["52c12c15-c00b-4efc-952d-1425c907706a"], "package_ndc": ["63323-574-01", "63323-574-86", "63323-574-93"], "unii": ["325O8467XK"]}, "update_date": "05/07/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/24/2025", "package_ndc": "82154-0451-4", "generic_name": "Peginterferon alfa-2a Injection", "contact_info": "800-506-8501, email: medinfo.us@pharmaand.com", "availability": "Limited Availability", "related_info": "Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.", "openfda": {"application_number": ["BLA103964"], "brand_name": ["PEGASYS"], "generic_name": ["PEGINTERFERON ALFA-2A"], "manufacturer_name": ["pharmaand GmbH"], "product_ndc": ["82154-0451", "82154-0449"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PEGINTERFERON ALFA-2A"], "rxcui": ["351270", "352297", "731326", "731328"], "spl_id": ["3c18e4a2-193f-ef4e-e063-6394a90a56b2"], "spl_set_id": ["d9290e5b-6d40-2318-e053-2995a90a9916"], "package_ndc": ["82154-0449-1", "82154-0451-4"], "nui": ["N0000175521", "M0025711"], "pharm_class_epc": ["Interferon alpha [EPC]"], "pharm_class_cs": ["Interferon-alpha [CS]"], "unii": ["Q46947FE7K"]}, "update_date": "08/19/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)", "company_name": "pharmaand GmbH (pharma&)", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-136-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-136", "72205-132", "72205-133", "72205-134", "72205-135", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0093-3750-63", "generic_name": "Tobramycin Solution", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210915"], "brand_name": ["TOBRAMYCIN"], "generic_name": ["TOBRAMYCIN"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3750"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["TOBRAMYCIN"], "rxcui": ["1314763"], "spl_id": ["8aa98982-a156-4bc8-8d31-9a39b88808ed"], "spl_set_id": ["d03079d2-5617-4628-92b9-3caa757b22c0"], "package_ndc": ["0093-3750-28", "0093-3750-63"], "nui": ["N0000175477", "M0000946"], "pharm_class_epc": ["Aminoglycoside Antibacterial [EPC]"], "pharm_class_cs": ["Aminoglycosides [CS]"], "unii": ["VZ8RRZ51VK"]}, "update_date": "06/16/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-63)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0703-4094-01", "generic_name": "Palonosetron Hydrochloride Injection", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA090713"], "brand_name": ["PALONOSETRON HYDROCHLORIDE"], "generic_name": ["PALONOSETRON HYDROCHLORIDE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4094"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PALONOSETRON HYDROCHLORIDE"], "rxcui": ["1728055"], "spl_id": ["124fd0ad-cda6-4a00-9355-c4809c039c74"], "spl_set_id": ["911783eb-91a8-4ef4-bd6f-809211e207d6"], "package_ndc": ["0703-4094-01"], "unii": ["23310D4I19"]}, "update_date": "11/14/2025", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-460-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-460", "65219-456", "65219-464", "65219-458", "65219-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0123-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "change_date": "01/02/2025", "package_ndc": "0409-1312-30", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1312", "0409-1283", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0338-1055-48", "generic_name": "Metronidazole Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018657"], "brand_name": ["METRONIDAZOLE"], "generic_name": ["METRONIDAZOLE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1055"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["METRONIDAZOLE"], "rxcui": ["311683"], "spl_id": ["7841a410-43a9-4c79-acee-b831b42da8a8"], "spl_set_id": ["d2112f37-5080-4a19-bcc3-6386b49abe1d"], "package_ndc": ["0338-1055-48"], "nui": ["N0000175435", "M0014907"], "pharm_class_epc": ["Nitroimidazole Antimicrobial [EPC]"], "pharm_class_cs": ["Nitroimidazoles [CS]"], "unii": ["140QMO216E"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-03", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-03)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-085-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-085", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "61570-074-01", "generic_name": "Esterified Estrogens Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/29/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Menest, Tablet, 1.25 mg (NDC 61570-074-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0331-02", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050162"], "brand_name": ["CLEOCIN HYDROCHLORIDE"], "generic_name": ["CLINDAMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0331", "0009-0225", "0009-0395"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN HYDROCHLORIDE"], "rxcui": ["197518", "284215", "309329", "748746", "748748", "748750"], "spl_id": ["51cea3cd-28cf-455e-ba27-5a0d8e052858"], "spl_set_id": ["df9a2a41-b132-4f43-8940-b2d773b1369a"], "package_ndc": ["0009-0331-02", "0009-0225-02", "0009-0395-14"], "unii": ["T20OQ1YN1W"]}, "update_date": "02/25/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-02", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "50458-290-04", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020083"], "brand_name": ["SPORANOX"], "generic_name": ["ITRACONAZOLE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-290"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ITRACONAZOLE"], "rxcui": ["311204", "833164"], "spl_id": ["b5d1c275-8665-4f63-8232-e34a02c998c7"], "spl_set_id": ["a4d555fa-787c-40fb-bb7d-b0d4f7318fd0"], "package_ndc": ["50458-290-01", "50458-290-04", "50458-290-28"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]"], "unii": ["304NUG5GF4"]}, "update_date": "02/27/2026", "therapeutic_category": ["Anti-Infective", "Other"], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 50458-290-04)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-484-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-484", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-049-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-049", "57664-047", "57664-046", "57664-048", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-178-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Unavailable", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 15 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-178", "47781-174", "47781-175", "47781-176", "47781-177", "47781-179", "47781-180"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5534-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3983-01", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3983", "0591-3982", "0591-3984", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 100 mg (NDC 0591-3983-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-125-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207934"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-125", "49884-119", "49884-127", "49884-128"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["b474c768-50e2-44da-accf-f1bd3d49ab20"], "spl_set_id": ["45d54974-3fc4-4237-a2fa-3158ca1a8105"], "package_ndc": ["49884-119-52", "49884-119-91", "49884-125-52", "49884-125-91", "49884-127-52", "49884-127-91", "49884-128-52", "49884-128-91"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "01/06/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 49884-125-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-736-30", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": {"application_number": ["ANDA072368"], "brand_name": ["FLURAZEPAM HYDROCHLORIDE"], "generic_name": ["FLURAZEPAM HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-736", "62135-737"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLURAZEPAM HYDROCHLORIDE"], "rxcui": ["1298088", "1298091"], "spl_id": ["25893c92-c8f1-567a-e063-6294a90a00d4"], "spl_set_id": ["8f476891-1346-4e8c-ac1b-f8cbdc64f5a1"], "package_ndc": ["62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90"], "unii": ["756RDM536M"]}, "update_date": "02/02/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/01/2026", "update_type": "New", "initial_posting_date": "04/01/2026", "package_ndc": "60429-005-12", "generic_name": "Icosapent Ethyl Capsule", "contact_info": "800-706-5575", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {}, "update_date": "04/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Icosapent Ethyl, Capsule, 1 g (NDC 60429-005-12)", "company_name": "Apotex Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6857-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6857", "0378-6854", "0378-6855", "0378-6856", "0378-6858", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-115-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-115", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0306-02", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0306", "0009-0274", "0009-0280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/27/2025", "update_type": "New", "initial_posting_date": "10/27/2025", "package_ndc": "0310-6615-02", "generic_name": "Pramlintide Acetate Injection", "contact_info": "800-236-9933", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA021332"], "brand_name": ["SYMLINPEN"], "generic_name": ["PRAMLINTIDE ACETATE"], "manufacturer_name": ["AstraZeneca Pharmaceuticals LP"], "product_ndc": ["0310-6615", "0310-6627"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PRAMLINTIDE ACETATE"], "rxcui": ["861042", "861043", "861044", "861045"], "spl_id": ["a84753f1-6ac5-4a47-a382-29972938ccaa"], "spl_set_id": ["4aea30ff-eb0d-45c1-b114-3127966328ff"], "package_ndc": ["0310-6615-02", "0310-6627-02"], "unii": ["726I6TE06G"]}, "update_date": "10/27/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02)", "company_name": "AstraZeneca AB", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/16/2022", "package_ndc": "42023-240-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "800-828-9393", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA214297"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Endo USA, Inc."], "product_ndc": ["42023-240", "42023-239", "42023-238"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["9d6bd79b-4885-454e-b127-c5978e501024"], "spl_set_id": ["631f7d3e-5620-4be3-b918-2f0d38a97890"], "package_ndc": ["42023-240-01", "42023-239-01", "42023-238-01"], "unii": ["43502P7F0P"]}, "update_date": "05/01/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)", "company_name": "Par Health, USA LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1007-02", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA019615"], "brand_name": ["DOPAMINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1007", "0338-1005", "0338-1009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1292887", "1743869", "1743871", "1743877", "1743879"], "spl_id": ["edc9a091-4cb5-4ec7-b6f9-44d2d588bab9"], "spl_set_id": ["cb97d4a0-89ed-407c-a763-209386b6f75c"], "package_ndc": ["0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02"], "unii": ["7L3E358N9L"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/21/2026", "update_type": "New", "initial_posting_date": "04/21/2026", "package_ndc": "16729-239-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-941-7875, option 2", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA204023"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["2de0daf8-b7a3-1dca-e063-6394a90a4d0a"], "spl_set_id": ["2b9881f0-4a66-660f-e054-00144ff88e88"], "package_ndc": ["16729-239-30", "16729-239-93"], "unii": ["1018WH7F9I"]}, "update_date": "04/21/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)", "company_name": "Accord Healthcare Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "63323-853-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-853", "63323-851", "63323-852", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0006-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 3 mg (NDC 0378-0006-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "66758-211-31", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021192"], "brand_name": ["LESCOL XL"], "generic_name": ["FLUVASTATIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["66758-211"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUVASTATIN SODIUM"], "rxcui": ["360507", "687048"], "spl_id": ["726ea2db-f1b0-4b73-a515-02157db88a42"], "spl_set_id": ["726ea2db-f1b0-4b73-a515-02157db88a42"], "package_ndc": ["66758-211-01", "66758-211-31"], "unii": ["PYF7O1FV7F"]}, "update_date": "01/27/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-31", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-096-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-096", "68025-088", "68025-089", "68025-095", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "43066-027-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-027", "43066-015", "43066-019", "43066-023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734084", "1734207", "1734475", "1734483"], "spl_id": ["a8d08579-825f-40d9-b1e3-e47b73765ae6"], "spl_set_id": ["781d4b7f-7556-4695-8d48-7772d7a0d8e9"], "package_ndc": ["43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10"], "unii": ["V910P86109"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "71288-115-30", "generic_name": "Azacitidine Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA212128"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["bad343f5-0c12-47de-93e7-9b2af3670b7c"], "spl_set_id": ["97b0917a-03fa-4cc4-91cf-1bed57a988c9"], "package_ndc": ["71288-115-30"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "08/19/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8884-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Available", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8884", "0406-8891", "0406-8892", "0406-8885", "0406-8893", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)", "company_name": "SpecGx LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-5322-10", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-5322", "0832-5323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953"], "spl_id": ["39e726b1-eab8-fcf4-e063-6394a90a950a"], "spl_set_id": ["616f0de7-8843-44a1-8fa6-274d889286aa"], "package_ndc": ["0832-5322-11", "0832-5322-10", "0832-5323-11", "0832-5323-10"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-10)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-50", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: September 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-339"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0ddf4411-7138-412a-908a-fadf22bdfb79"], "spl_set_id": ["c3ae9880-44bb-4f4e-93d8-8a5e21708a30"], "package_ndc": ["61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0551-18", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020179"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-0551"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616"], "spl_id": ["e702be26-651e-4d4a-9d79-4df9f53821c9"], "spl_set_id": ["7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e"], "package_ndc": ["0338-0551-11", "0338-0551-18"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-502-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-502", "64850-500", "64850-501", "64850-503", "64850-504", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-255-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-255", "55150-251", "55150-252", "55150-254", "55150-253", "55150-256"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "39822-0350-2", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA201746"], "brand_name": ["LINCOMYCIN"], "generic_name": ["LINCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-0350", "39822-0353"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCONJUNCTIVAL"], "substance_name": ["LINCOMYCIN HYDROCHLORIDE"], "rxcui": ["239212"], "spl_id": ["df369d62-f1a4-1a53-e053-2995a90abbf9"], "spl_set_id": ["61f4851d-d919-400d-912a-05eb9dca11d4"], "package_ndc": ["39822-0350-1", "39822-0350-2", "39822-0353-6"], "unii": ["M6T05Z2B68"]}, "update_date": "03/26/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-67", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-671", "25021-652"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-1510-32", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA016730"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-1510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616", "1795618"], "spl_id": ["0a144591-6cfa-4aed-a067-c95aebc29057"], "spl_set_id": ["60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5"], "package_ndc": ["0264-1510-36", "0264-1510-31", "0264-1510-32"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-481-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-481", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-483", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE BITARTRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-024-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-024", "65162-023", "65162-025", "65162-026", "65162-027", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0093-4085-63", "generic_name": "Tobramycin Solution", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA091589"], "brand_name": ["TOBRAMYCIN"], "generic_name": ["TOBRAMYCIN"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-4085"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["TOBRAMYCIN"], "rxcui": ["348719"], "spl_id": ["2aeb6242-a55e-4e45-96df-f2d26616e167"], "spl_set_id": ["c5f65e5b-c851-45da-a0e8-215d9a4e6ad3"], "package_ndc": ["0093-4085-63"], "nui": ["N0000175477", "M0000946"], "pharm_class_epc": ["Aminoglycoside Antibacterial [EPC]"], "pharm_class_cs": ["Aminoglycosides [CS]"], "unii": ["VZ8RRZ51VK"]}, "update_date": "06/16/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Tobramycin, Solution, 300 mg/5 mL (NDC 0093-4085-63)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-4911-34", "generic_name": "Atropine Sulfate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-442-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA217472"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-442", "65219-444", "65219-695", "65219-697"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["2720024", "2720026"], "spl_id": ["31c4c874-3d24-4c86-a301-ee9faf0b5c00"], "spl_set_id": ["9a622308-7bda-4ca0-9de5-d6b3b4be3384"], "package_ndc": ["65219-442-02", "65219-442-05", "65219-444-04", "65219-444-10", "65219-695-01", "65219-695-05", "65219-697-01", "65219-697-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-195-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-088-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-088", "72305-025", "72305-050", "72305-075", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 88 ug (NDC 72305-088-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-00", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7510", "0264-7520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-161-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-1496-35", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "This presentation is temporarily on backorder.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-1496", "0641-1495"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992858"], "spl_id": ["80a400d2-d293-4180-bfa7-7a8ce0734bc5"], "spl_set_id": ["13d9e59d-eadb-41d5-9f47-9c11a6efb31c"], "package_ndc": ["0641-1495-31", "0641-1495-35", "0641-1496-31", "0641-1496-35"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5316-11", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5316", "0245-5315"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-3", "generic_name": "Carboplatin Injection", "related_info_link": "https://dps.fda.gov/drugshortages/discontinuations/carboplatin-injection", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Available", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.)", "openfda": {"application_number": ["ANDA077861"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-6282"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0e68e276-b0df-4f03-e063-6394a90a22b9"], "spl_set_id": ["1c275825-0275-4c73-b650-e4c1519f13b8"], "package_ndc": ["60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)", "company_name": "Teyro Labs", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-062-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-062", "70069-061", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-489-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0104-04", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050317"], "brand_name": ["LINCOCIN"], "generic_name": ["LINCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0104", "0009-0555", "0009-0107"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCONJUNCTIVAL"], "substance_name": ["LINCOMYCIN HYDROCHLORIDE"], "rxcui": ["102787", "239212"], "spl_id": ["7e2f3780-88ee-4971-a4ab-3d6cd972c42c"], "spl_set_id": ["c01906fa-2c73-4c13-9765-2fd06628d263"], "package_ndc": ["0009-0555-01", "0009-0104-04", "0009-0107-04"], "unii": ["M6T05Z2B68"]}, "update_date": "02/25/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-608-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-608", "43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-607"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-015-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 15 mg/.4 mL (NDC 82497-015-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-201-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-201", "55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-0109-01", "generic_name": "Carbamazepine Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA070541"], "brand_name": ["CARBAMAZEPINE"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0109", "0093-0778"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["308973", "308979"], "spl_id": ["042aa2c6-95ff-410a-abcf-a8ee79fa96d8"], "spl_set_id": ["bfd63965-56e6-4af7-b7ef-45a5105d4d35"], "package_ndc": ["0093-0109-01", "0093-0109-10", "0093-0778-01"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "06/10/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Epitol, Tablet, 200 mg (NDC 0093-0109-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-504-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-504", "64850-500", "64850-501", "64850-502", "64850-503", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-11", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5115-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5115", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-097-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-097", "68025-088", "68025-089", "68025-095", "68025-096", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0990-7139-36", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "Allocated to Contracted Customers Only. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7139-36", "openfda": {"application_number": ["NDA017513"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7139", "0990-6139", "0990-7973"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["90930d29-6b1a-438c-b719-c5e7484dcad5"], "spl_set_id": ["e3484bc6-ed7f-43ef-9d49-c131a8dff2dd"], "package_ndc": ["0990-6139-22", "0990-6139-03", "0990-7139-09", "0990-7139-36", "0990-7973-05", "0990-7973-07", "0990-7973-08"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-700-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-700", "60951-602", "60951-712", "60951-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "76045-009-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["DILAUDID"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-009", "76045-010", "76045-121"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370"], "spl_id": ["97bfcafb-2037-47dc-a0ae-f7b8007c47df"], "spl_set_id": ["9eebd88a-5632-460f-b7b6-26c8a180540d"], "package_ndc": ["76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "63323-326-20", "generic_name": "Cefepime Hydrochloride Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA065441"], "brand_name": ["CEFEPIME"], "generic_name": ["CEFEPIME"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-326", "63323-340"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFEPIME HYDROCHLORIDE"], "rxcui": ["1665088", "1665093"], "spl_id": ["8c2fbf43-34bd-49d1-bda8-a2191c8bc54b"], "spl_set_id": ["5e1695e0-1310-4cd8-a5da-ad1a7dcd1792"], "package_ndc": ["63323-326-21", "63323-326-20", "63323-340-21", "63323-340-20"], "unii": ["I8X1O0607P"]}, "update_date": "02/10/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cefepime Hydrochloride, Injection, 1 g (NDC 63323-326-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-737-90", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": {"application_number": ["ANDA072369"], "brand_name": ["FLURAZEPAM HYDROCHLORIDE"], "generic_name": ["FLURAZEPAM HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-737", "62135-736"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLURAZEPAM HYDROCHLORIDE"], "rxcui": ["1298088", "1298091"], "spl_id": ["25893c92-c8f1-567a-e063-6294a90a00d4"], "spl_set_id": ["8f476891-1346-4e8c-ac1b-f8cbdc64f5a1"], "package_ndc": ["62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90"], "unii": ["756RDM536M"]}, "update_date": "02/02/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-203-11", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA212803"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-203"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b06d36f6-507c-4b04-b79d-d6370a30a551", "53a09c30-7295-4337-89a4-93d3748d6ea3"], "spl_set_id": ["a2e3c748-28ce-4c50-a182-721912919840", "3aadaca7-3661-4bfe-87f8-6368e4ab6536"], "package_ndc": ["71288-203-02", "71288-203-03", "71288-203-04", "71288-203-05", "71288-203-10", "71288-203-11", "71288-203-91", "71288-203-92", "71288-203-93", "71288-203-94"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2430-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": {"application_number": ["NDA021514"], "brand_name": ["METHYLPHENIDATE TRANSDERMAL SYSTEM"], "generic_name": ["METHYLPHENIDATE"], "manufacturer_name": ["PADAGIS US LLC"], "product_ndc": ["0574-2430", "0574-2410", "0574-2415", "0574-2420"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["METHYLPHENIDATE"], "rxcui": ["753436", "753438", "753440", "753441"], "spl_id": ["b743ef45-2fc0-4086-8a02-6078e6a09eaa"], "spl_set_id": ["7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb"], "package_ndc": ["0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65"], "nui": ["N0000175739", "N0000175729"], "pharm_class_epc": ["Central Nervous System Stimulant [EPC]"], "pharm_class_pe": ["Central Nervous System Stimulation [PE]"], "unii": ["207ZZ9QZ49"]}, "update_date": "05/07/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "0406-1170-03", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-325-8888", "resolved_note": "Available", "openfda": {"application_number": ["ANDA076264"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-1170"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["9ed13551-325e-4b82-a266-72fc89ed27dc"], "spl_set_id": ["06ff2d5a-e62b-4fa4-bbdb-01938535bc65"], "package_ndc": ["0406-1170-03", "0406-1170-01"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-03)", "company_name": "SpecGx LLC", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "69516-010-30", "generic_name": "Obeticholic Acid Tablet", "contact_info": "1-844-782-4278", "related_info": "Business decision. Products will not be available after November 14, 2025.", "update_date": "09/19/2025", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Tablet", "presentation": "Ocaliva, Tablet, 10 mg (NDC 69516-010-30)", "company_name": "Intercept Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-169-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-169", "55150-167", "55150-168", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "71225-126-05", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-566-2505", "availability": "Available", "openfda": {"application_number": ["ANDA212791"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Slayback Pharma LLC"], "product_ndc": ["71225-126"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["027725dc-e468-446c-b702-ab0f8a9e3be5"], "spl_set_id": ["e5d28ed8-e427-4850-81aa-98702d3b6a5d"], "package_ndc": ["71225-126-02", "71225-126-05", "71225-126-03", "71225-126-06", "71225-126-01", "71225-126-04"], "unii": ["1018WH7F9I"]}, "update_date": "09/17/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)", "company_name": "Slayback Pharma", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-02", "generic_name": "Furosemide Injection", "contact_info": "Sagent Pharmaceuticals: 866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6860-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6860", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-821-05", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA201835"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-821", "25021-820"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["13e1ca54-4fc4-4e93-a52d-c9320865e3cb"], "spl_set_id": ["f98314ea-a4e4-4f78-987b-3e9b45a08bb4"], "package_ndc": ["25021-820-05", "25021-820-10", "25021-821-05"], "unii": ["43502P7F0P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "66993-212-38", "generic_name": "Nilutamide Tablet", "contact_info": "847-283-7921", "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Nilandron, Tablet, 150 mg (NDC 66993-212-38)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "0641-6008-10", "generic_name": "Bumetanide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA079196"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6008", "0641-6007"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["99d2fc38-7e1e-4209-aa57-089794eda8a6"], "spl_set_id": ["681b5e9d-e2c7-4f29-aaad-e06d4a528c11"], "package_ndc": ["0641-6007-01", "0641-6007-10", "0641-6008-01", "0641-6008-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-407", "43547-406", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "55150-222-20", "generic_name": "Etomidate Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206126"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-222", "55150-221"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["278b160e-cdc4-451e-9405-cb001f443680"], "spl_set_id": ["0820f15a-046b-4185-a2b3-2e4051ee3d82"], "package_ndc": ["55150-221-10", "55150-222-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"presentation": "Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)", "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0409-7620-03", "generic_name": "Heparin Sodium Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Hematology"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4283-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088295"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4283"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RETROBULBAR", "TOPICAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010844"], "spl_id": ["499e9cfa-ea8d-487c-a8b3-fd7e1917d25f"], "spl_set_id": ["89a4bd73-89f4-4fd7-2c9f-921e1da8f96b"], "package_ndc": ["0409-4283-11", "0409-4283-25", "0409-4283-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "49702-260-55", "generic_name": "Maraviroc Solution", "contact_info": "877-844-8872", "related_info": "The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026.", "openfda": {"application_number": ["NDA208984"], "brand_name": ["SELZENTRY"], "generic_name": ["MARAVIROC"], "manufacturer_name": ["ViiV Healthcare Company"], "product_ndc": ["49702-260", "49702-223", "49702-224"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["728223", "728225", "729201", "729203", "1857921", "1857925"], "spl_id": ["c3a27122-8cd6-4889-a1ef-7ef629c270b3"], "spl_set_id": ["46f30ac5-c96b-429e-976d-8c5ee1c0761b"], "package_ndc": ["49702-223-18", "49702-224-18", "49702-260-55"], "nui": ["N0000175572", "N0000175445"], "pharm_class_epc": ["CCR5 Co-receptor Antagonist [EPC]"], "pharm_class_moa": ["Chemokine Co-receptor 5 Antagonists [MoA]"], "unii": ["MD6P741W8A"]}, "update_date": "01/20/2026", "therapeutic_category": ["Antiviral"], "dosage_form": "Solution", "presentation": "Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton  (NDC 49702-260-55)", "company_name": "ViiV Healthcare Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "71357-009-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA214805"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE INJECTION, USP, 400 MEQ/100 ML"], "manufacturer_name": ["MILLA PHARMACEUTICALS INC."], "product_ndc": ["71357-009", "71357-007", "71357-008"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["237371", "312965"], "spl_id": ["47d8d0e7-6db5-950d-e063-6294a90ab1bf"], "spl_set_id": ["1ea1466d-a492-4056-e063-6394a90a80bf"], "package_ndc": ["71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10"], "unii": ["4550K0SC9B"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)", "company_name": "Milla Pharmaceuticals", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "69489-721-30", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018738"], "brand_name": ["EXELDERM"], "generic_name": ["SULCONAZOLE NITRATE"], "manufacturer_name": ["Journey Medical Corporation"], "product_ndc": ["69489-721"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["SULCONAZOLE NITRATE"], "rxcui": ["208118", "313125"], "spl_id": ["af026933-9a3d-4027-90f6-57fe4349d11e"], "spl_set_id": ["5b73e83e-8d3c-4d96-b4f6-9f854430add8"], "package_ndc": ["69489-721-30", "69489-721-05"], "unii": ["1T89100D5U"]}, "update_date": "05/08/2026", "therapeutic_category": ["Dermatology"], "dosage_form": "Solution", "presentation": "Exelderm, Solution, 1.0% 30 mL (NDC 69489-721-30)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-41", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7809-24", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018826"], "brand_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7809", "0409-7810", "0409-0042", "0409-1858"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "spl_id": ["188ce800-ff3a-4b22-9a95-2273c3bc99ae"], "spl_set_id": ["08f23f6e-150d-45ea-098e-f2edf64c21a1"], "package_ndc": ["0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12"], "unii": ["7L3E358N9L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089646"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0005-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2 mg (NDC 0378-0005-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-10", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "39822-4200-6", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-390-4411", "availability": "Available", "related_info": "Tamarang is the application holder and X-Gen is the distributor/labeler", "openfda": {"application_number": ["ANDA091115"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-4200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["eedcfb07-4e23-3152-e053-2995a90a6e6a"], "spl_set_id": ["b73f192c-2912-4ec3-9b4f-05a58d9b35ba"], "package_ndc": ["39822-4200-1", "39822-4200-2", "39822-4200-5", "39822-4200-6"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "63323-358-10", "generic_name": "Caspofungin Acetate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA206110"], "brand_name": ["CASPOFUNGIN ACETATE"], "generic_name": ["CASPOFUNGIN ACETATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-358", "63323-356"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CASPOFUNGIN ACETATE"], "rxcui": ["828539", "828755"], "spl_id": ["7cdf103b-418f-42a8-bd1b-ebfd8027124a"], "spl_set_id": ["e76d8d83-3691-451c-a32c-d91448c54d16"], "package_ndc": ["63323-356-01", "63323-356-10", "63323-358-01", "63323-358-10"], "unii": ["VUW370O5QE"]}, "update_date": "01/12/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1660-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-736-90", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": {"application_number": ["ANDA072368"], "brand_name": ["FLURAZEPAM HYDROCHLORIDE"], "generic_name": ["FLURAZEPAM HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-736", "62135-737"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLURAZEPAM HYDROCHLORIDE"], "rxcui": ["1298088", "1298091"], "spl_id": ["25893c92-c8f1-567a-e063-6294a90a00d4"], "spl_set_id": ["8f476891-1346-4e8c-ac1b-f8cbdc64f5a1"], "package_ndc": ["62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90"], "unii": ["756RDM536M"]}, "update_date": "02/02/2026", "therapeutic_category": ["Oncology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "50458-290-01", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020083"], "brand_name": ["SPORANOX"], "generic_name": ["ITRACONAZOLE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-290"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ITRACONAZOLE"], "rxcui": ["311204", "833164"], "spl_id": ["b5d1c275-8665-4f63-8232-e34a02c998c7"], "spl_set_id": ["a4d555fa-787c-40fb-bb7d-b0d4f7318fd0"], "package_ndc": ["50458-290-01", "50458-290-04", "50458-290-28"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]"], "unii": ["304NUG5GF4"]}, "update_date": "02/27/2026", "therapeutic_category": ["Anti-Infective", "Other"], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 50458-290-01)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8892-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8892", "0406-8891", "0406-8884", "0406-8885", "0406-8893", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-618-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202725"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL HYDROCHLORIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-618", "65862-617", "65862-619", "65862-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["5263abd5-ce46-4918-9bb0-9632861bcbc9"], "spl_set_id": ["93e6e668-5306-4f26-81d8-cbc3a7a5e787"], "package_ndc": ["65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78"], "unii": ["33067B3N2M"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4911-34", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2)  (NDC 0409-4911-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-26", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb"], "spl_set_id": ["abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f"], "package_ndc": ["0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0990-7171-17", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7171-17", "openfda": {"application_number": ["NDA020041"], "brand_name": ["AMINOSYN II"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7171", "0990-7172"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ACETYL L-TYROSINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "VALINE"], "rxcui": ["800188", "800192", "800237", "800241"], "spl_id": ["ea005122-3350-4609-83ad-9d093f25162f"], "spl_set_id": ["5b426208-f090-4650-86c3-89040ba45c2d"], "package_ndc": ["0990-7172-17", "0990-7171-17"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["2ZD004190S", "94ZLA3W45F", "3KX376GY7L", "DA8G610ZO5", "HG18B9YRS7", "TE7660XO1C", "8DUH1N11BX", "4QD397987E", "GMW67QNF9C", "AE28F7PNPL", "47E5O17Y3R", "30KYC7MIAI", "TTL6G7LIWZ", "OF5P57N2ZX", "452VLY9402", "04Y7590D77", "9DLQ4CIU6V"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-1473-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA075629"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-1473", "0406-1445"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091145", "1091225"], "spl_id": ["7bfd27d5-70ed-440b-949a-140aa3304d4a"], "spl_set_id": ["ed004cf0-eb23-43d2-96dc-20c4ad63824f"], "package_ndc": ["0406-1445-01", "0406-1473-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/13/2025", "update_type": "New", "initial_posting_date": "08/13/2025", "package_ndc": "66658-231-01", "generic_name": "Palivizumab Injection", "contact_info": "866-773-5274", "related_info": "Discontinuation of the manufacture of the drug. Product expected to be available through July 2026.", "openfda": {"application_number": ["BLA103770"], "brand_name": ["SYNAGIS"], "generic_name": ["PALIVIZUMAB"], "manufacturer_name": ["Swedish Orphan Biovitrum AB (publ)"], "product_ndc": ["66658-231", "66658-230"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PALIVIZUMAB"], "rxcui": ["1657341", "1657343", "1657361", "1657362"], "spl_id": ["48e6af70-cd93-3f1d-e063-6394a90a8104"], "spl_set_id": ["3a0096c7-8139-44cd-bba4-520ab05c2cb2"], "package_ndc": ["66658-231-01", "66658-230-01"], "nui": ["M0001357", "N0000175615", "N0000175623"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "pharm_class_moa": ["Fusion Protein Inhibitors [MoA]"], "pharm_class_epc": ["Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]"], "unii": ["DQ448MW7KS"]}, "update_date": "08/13/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)", "company_name": "Swedish Orphan Biovitrum AB", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2017", "package_ndc": "76329-3352-1", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": {"application_number": ["ANDA203449"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-3352"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["792582"], "spl_id": ["74a86dc7-0929-40d0-9661-9f9063a8fd7d"], "spl_set_id": ["77698221-a01d-4568-a7bc-d3d4e982875d"], "package_ndc": ["76329-3352-1"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "72485-201-01", "generic_name": "Azacitidine Injection", "contact_info": "1-732-637-1971", "availability": "Available", "openfda": {"application_number": ["ANDA207518"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Armas Pharmaceuticals Inc."], "product_ndc": ["72485-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["ca345575-17a6-43a3-aa02-3d4bb9d136c5"], "spl_set_id": ["5c0a2d5f-8c34-4c04-8425-7543965cedd4"], "package_ndc": ["72485-201-01"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "02/18/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 72485-201-01)", "company_name": "Armas Pharmaceuticals Inc", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0520-76", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0520"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["2e960a62-b5d8-4fad-a17c-9d07bdbe06d1"], "spl_set_id": ["76e4fe6a-afd4-4f68-b12d-0b094f750615"], "package_ndc": ["0574-0520-04", "0574-0520-08", "0574-0520-74", "0574-0520-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-100-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 100 ug (NDC 72305-100-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "66794-162-02", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-414-1901", "availability": "Available", "openfda": {"application_number": ["ANDA204393"], "brand_name": ["MITIGO"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Piramal Critical Care, Inc."], "product_ndc": ["66794-162", "66794-160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731522", "1731998", "2055307", "2055311"], "spl_id": ["495a6a51-d35d-2b96-e063-6394a90ac5f3"], "spl_set_id": ["728f3d83-9a63-0c1f-e053-2a91aa0ac7db"], "package_ndc": ["66794-160-02", "66794-162-02"], "unii": ["X3P646A2J0"]}, "update_date": "05/07/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)", "company_name": "Piramal Critical Care Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/21/2023", "package_ndc": "39822-5550-6", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "866-390-4411", "availability": "Available", "openfda": {"application_number": ["ANDA040737"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-5550"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992858"], "spl_id": ["0e860109-725f-1c28-e063-6394a90a50ef"], "spl_set_id": ["b6f6698f-f23c-452a-9b38-bbb96ab88ae4"], "package_ndc": ["39822-5550-5", "39822-5550-6"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Other", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-05", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/09/2026", "update_type": "New", "initial_posting_date": "04/09/2026", "package_ndc": "0069-3070-30", "generic_name": "Azithromycin Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050784"], "brand_name": ["ZITHROMAX"], "generic_name": ["AZITHROMYCIN DIHYDRATE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-3070", "0069-3060", "0069-3110", "0069-3120", "0069-3130", "0069-3140", "0069-4061"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AZITHROMYCIN DIHYDRATE"], "rxcui": ["105260", "141963", "211307", "212446", "226827", "248656", "308459", "308460", "749780", "749783", "750149", "750157"], "spl_id": ["e15f2173-8700-4392-96a4-8560772b6f8a"], "spl_set_id": ["db52b91e-79f7-4cc1-9564-f2eee8e31c45"], "package_ndc": ["0069-3060-30", "0069-3060-75", "0069-3060-86", "0069-3070-30", "0069-3070-75", "0069-3110-19", "0069-3120-19", "0069-3130-19", "0069-3140-19", "0069-4061-01", "0069-4061-75", "0069-4061-89"], "unii": ["5FD1131I7S"]}, "update_date": "04/09/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Zithromax, Tablet, 500 mg (NDC 0069-3070-30)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070552", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-025-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 25 ug (NDC 72305-025-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-0136-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA202608"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-0136", "0406-0127", "0406-0154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001565", "2001566", "2001568"], "spl_id": ["7a3a8731-e545-455e-83c3-888f4923e901"], "spl_set_id": ["b1b0f2ff-d9df-42ab-b471-226ecf97e075"], "package_ndc": ["0406-0127-01", "0406-0136-01", "0406-0154-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 36 mg (NDC 0406-0136-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "71288-700-06", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA213453"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-700", "71288-718"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["aad39c88-2e2c-49a6-aa13-de852483661f", "37295b13-65a4-40fa-8d6c-53aeb45e2939"], "spl_set_id": ["b23aa80e-2af2-4a66-92ed-b1c8863be704", "b9abaf64-760d-43e0-8669-a9ca70feab11"], "package_ndc": ["71288-700-91", "71288-700-92", "71288-718-91", "71288-718-92", "71288-700-05", "71288-700-06", "71288-718-10", "71288-718-11"], "unii": ["I65MW4OFHZ"]}, "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "72572-074-24", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "related_info": "Civica Label", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Civica, Inc."], "product_ndc": ["72572-074", "72572-076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336"], "spl_id": ["e40b6e7f-1d37-4d0a-ace3-e5accc461e02"], "spl_set_id": ["80217bd6-2bc4-401c-9345-22532b36a24f"], "package_ndc": ["72572-074-01", "72572-074-24", "72572-076-01", "72572-076-24"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0183-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA200795"], "brand_name": ["GEMCITABINE"], "generic_name": ["GEMCITABINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0183", "0409-0181", "0409-0182"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["GEMCITABINE HYDROCHLORIDE"], "rxcui": ["1720960", "1720975", "1720977"], "spl_id": ["3a284abb-8c57-47dc-a138-5a6e6ab92b05", "9c9d382b-8f9a-4fbe-a231-44d73ec83b61"], "spl_set_id": ["dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"], "package_ndc": ["0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25"], "unii": ["U347PV74IL"]}, "update_date": "09/11/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-064-99", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-064", "65862-062", "65862-063"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-99)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "72205-102-01", "generic_name": "Bumetanide Injection", "contact_info": "Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA215364"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-102", "72205-101"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "spl_set_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "package_ndc": ["72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/02/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)", "company_name": "MSN Laboratories Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "72485-509-10", "generic_name": "Etomidate Injection", "contact_info": "908-803-2586", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Armas Pharmaceuticals Inc."], "product_ndc": ["72485-509", "72485-508"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["7444860b-36c1-459d-94ba-d7301d9dc2ca"], "spl_set_id": ["75467058-da52-48fa-8d4e-e1025ec7d461"], "package_ndc": ["72485-508-01", "72485-508-10", "72485-509-01", "72485-509-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70860-701-03", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Athenex is not active, supplying through Sagent NDC 25021-701-01", "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-03)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-485-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5555-01", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA202981"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868469"], "spl_id": ["e3a44e63-8594-40b6-a3fa-d135b3149661", "bcb3a2dc-1a3f-4ac7-8ea2-426f0771c246"], "spl_set_id": ["0c24b592-4bc8-456f-acac-9c9525844a06", "ea9f4498-0d43-4043-8dd1-f22537841c21"], "package_ndc": ["0409-5555-11", "0409-5555-01", "0409-5555-12", "0409-5555-02"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-249-50", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207183"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-249", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-113-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-113", "70010-111", "70010-112", "70010-114", "70010-115", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "46163-300-10", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "800-323-5188", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078177"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care de Mexico, S.A. de C.V."], "product_ndc": ["46163-300"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807639"], "spl_id": ["4e7bc97a-4d31-b66d-e063-6294a90a294c"], "spl_set_id": ["9a1220fb-6853-45ae-838c-10d8596e1af7"], "package_ndc": ["46163-300-10"], "unii": ["451W47IQ8X"]}, "update_date": "06/10/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 46163-300-10)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-1510-31", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA016730"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-1510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616", "1795618"], "spl_id": ["0a144591-6cfa-4aed-a067-c95aebc29057"], "spl_set_id": ["60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5"], "package_ndc": ["0264-1510-36", "0264-1510-31", "0264-1510-32"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-088-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6059-01", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6059", "0641-6057", "0641-6056", "0641-6061", "0641-6063", "0641-6060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/07/2026", "update_type": "New", "initial_posting_date": "05/07/2026", "package_ndc": "63323-574-93", "generic_name": "Icatibant Acetate Injection", "contact_info": "847-550-2300", "related_info": "Discontinuation of the manufacturer of the drug", "openfda": {"application_number": ["ANDA208317"], "brand_name": ["ICATIBANT"], "generic_name": ["ICATIBANT"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-574"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ICATIBANT ACETATE"], "rxcui": ["1148141"], "spl_id": ["d1c9afa7-c4ac-4739-85f1-2ae82440210c"], "spl_set_id": ["52c12c15-c00b-4efc-952d-1425c907706a"], "package_ndc": ["63323-574-01", "63323-574-86", "63323-574-93"], "unii": ["325O8467XK"]}, "update_date": "05/07/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-198-30", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-198", "55150-195", "55150-196", "55150-197", "55150-199", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/12/2022", "package_ndc": "68118-100-01", "generic_name": "Streptozocin Powder, For Solution", "related_info_link": "https://www.fda.gov/media/187353/download?attachment", "contact_info": "USSZTOrders@esteve.com", "availability": "Available", "openfda": {"brand_name": ["ZANOSAR"], "generic_name": ["STREPTOZOCIN"], "manufacturer_name": ["ESTEVE PHARMACEUTICALS, S.A."], "product_ndc": ["68118-100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["STREPTOZOCIN"], "rxcui": ["207948", "239180"], "spl_id": ["509e4d98-ccef-8a7f-e063-6394a90a5a78"], "spl_set_id": ["f31d3bff-6fc6-c35f-e053-2995a90a596b"], "package_ndc": ["68118-100-01"], "nui": ["N0000000236", "N0000175558"], "pharm_class_moa": ["Alkylating Activity [MoA]"], "pharm_class_epc": ["Alkylating Drug [EPC]"], "unii": ["5W494URQ81"]}, "update_date": "05/06/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Powder, For Solution", "presentation": "Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)", "company_name": "ESTEVE PHARMACEUTICALS, S.A.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1746-30", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1746", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-74", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209448"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-824"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481"], "spl_id": ["0591ab74-99a6-40ee-af96-80bc2ef423dc"], "spl_set_id": ["3b8f2692-4371-4f1a-95af-b41842131fdd"], "package_ndc": ["63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0902-18", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Available", "openfda": {"application_number": ["NDA050441"], "brand_name": ["CLEOCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0902", "0009-0870", "0009-0775", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582", "205964", "309335", "309336", "309339", "685574"], "spl_id": ["dd9fa453-a2ca-4a53-b39b-c59a44a888aa"], "spl_set_id": ["05a75685-0af5-407c-ac57-e380c882b49d"], "package_ndc": ["0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01"], "unii": ["EH6D7113I8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-383-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-41", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-473"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c14acada-333e-43bb-b1cf-81d569e3e918"], "spl_set_id": ["1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec"], "package_ndc": ["23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/07/2026", "update_type": "New", "initial_posting_date": "04/07/2026", "package_ndc": "61958-1701-1", "generic_name": "Idelalisib Tablet", "contact_info": "800-445-3235", "related_info": "Discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA205858"], "brand_name": ["ZYDELIG"], "generic_name": ["IDELALISIB"], "manufacturer_name": ["Gilead Sciences, Inc."], "product_ndc": ["61958-1701", "61958-1702"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IDELALISIB"], "rxcui": ["1544465", "1544471", "1544473", "1544475"], "spl_id": ["ca3e7112-6dfe-403f-af6f-a0051e77d125"], "spl_set_id": ["efbdafa9-d18c-4e85-b4a2-1e620fc74e50"], "package_ndc": ["61958-1701-1", "61958-1702-1"], "nui": ["N0000175605", "N0000175082", "N0000190114"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["YG57I8T5M0"]}, "update_date": "04/07/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Zydelig, Tablet, 100 mg (NDC 61958-1701-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-208-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA017584"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-208"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737761"], "spl_id": ["289524c2-d0be-443d-aedf-39d621f217a5"], "spl_set_id": ["f1b26274-a55e-4321-b96c-ce0df830f205"], "package_ndc": ["63323-208-01", "63323-208-05"], "unii": ["V13007Z41A"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-7201-98", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7201", "0093-0771", "0093-7202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-924-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA212571"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-924", "67457-925"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["b51a1fb0-fcee-4a76-9eaf-91c35813c242"], "spl_set_id": ["f140de5a-f13d-46b4-a742-049c63e474f5"], "package_ndc": ["67457-924-00", "67457-924-50", "67457-925-00", "67457-925-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-175-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-175", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 175 ug (NDC 72305-175-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-606-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-606", "43547-602", "43547-603", "43547-604", "43547-605", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "65219-368-02", "generic_name": "Lorazepam Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA217598"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-368"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["1665188"], "spl_id": ["5cd2d0d8-9639-4e96-aafd-4991ad35fabc", "462a13da-259a-40e7-bd5b-f7f42ae025b7"], "spl_set_id": ["b2487467-a63f-48b5-b0de-3a6ce6672d50", "462a13da-259a-40e7-bd5b-f7f42ae025b7"], "package_ndc": ["65219-368-01", "65219-368-02", "65219-368-14", "65219-368-24"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "04/23/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-31", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Not available at this time.", "openfda": {"application_number": ["ANDA070552", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/01/2025", "update_type": "New", "initial_posting_date": "08/01/2025", "package_ndc": "0591-3916-68", "generic_name": "Clindamycin Phosphate; Benzoyl Peroxide Gel", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the product.", "openfda": {"application_number": ["ANDA205128"], "brand_name": ["CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE"], "generic_name": ["CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3916"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["BENZOYL PEROXIDE", "CLINDAMYCIN PHOSPHATE"], "rxcui": ["885131"], "spl_id": ["c2dcadb5-8ef3-4c6a-af4f-bf201184a6d0"], "spl_set_id": ["87622142-000b-460b-977e-92d6735f5337"], "package_ndc": ["0591-3916-68"], "unii": ["W9WZN9A0GM", "EH6D7113I8"]}, "update_date": "08/01/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Gel", "presentation": "Clindamycin Phosphate; Benzoyl Peroxide, Gel, 25 mg/1 g; 10 mg/1 g (NDC 0591-3916-68)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-8035-05", "generic_name": "Glyburide Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074686"], "brand_name": ["GLYBURIDE"], "generic_name": ["GLYBURIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8035", "0093-8034", "0093-8036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLYBURIDE"], "rxcui": ["310536", "310539", "314000"], "spl_id": ["d734cd0e-df7b-40a2-a511-fc04308a764d"], "spl_set_id": ["e84c0dfc-a4e9-4c89-b6ea-45732eb412f5"], "package_ndc": ["0093-8034-01", "0093-8035-01", "0093-8035-05", "0093-8036-01"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["SX6K58TVWC"]}, "update_date": "06/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/04/2025", "update_type": "New", "initial_posting_date": "08/04/2025", "package_ndc": "45963-614-55", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "800-545-8800", "related_info": "Product not anticipated to be available beyond mid-late September 2025", "openfda": {"application_number": ["ANDA078589"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["45963-614"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["3bbdb61c-9194-416e-9034-5d2b11b5b8ee"], "spl_set_id": ["5e1fdcaa-918f-4cd8-9c7a-4c538d866198"], "package_ndc": ["45963-614-51", "45963-614-55"], "unii": ["042LAQ1IIS"]}, "update_date": "08/04/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-707-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-707", "13811-709", "13811-706", "13811-708", "13811-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3294-46", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070434"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-3294", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3298"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FUROSEMIDE"], "rxcui": ["197730", "197731", "197732", "310429", "313988"], "spl_id": ["bc62ddda-7639-4090-99f0-7dd4d13518f3"], "spl_set_id": ["9e493331-dddd-496e-abf8-61747fb67aba"], "package_ndc": ["0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-095-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-095", "68025-088", "68025-089", "68025-096", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "10122-100-10", "generic_name": "Deferiprone Tablet", "contact_info": "888-466-6505", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "11/07/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Tablet", "presentation": "Ferriprox, Tablet, 500 mg (NDC 10122-100-10)", "company_name": "Chiesi USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "81298-7620-3", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "833-268-5559", "availability": "Available", "openfda": {"application_number": ["ANDA216042"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE INJECTION,"], "manufacturer_name": ["Long Grove Pharmaceuticals, LLC"], "product_ndc": ["81298-7620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868486"], "spl_id": ["1a255946-a137-4e13-8203-65dd80b34872"], "spl_set_id": ["a26d709b-b294-4b02-9a88-7e840f099a33"], "package_ndc": ["81298-7620-1", "81298-7620-3"], "unii": ["8MDF5V39QO"]}, "update_date": "01/05/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)", "company_name": "Long Grove Pharmaceuticals LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/30/2020", "package_ndc": "63323-494-05", "generic_name": "Valproate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Checkwholesalers for inventory", "openfda": {"application_number": ["ANDA076539"], "brand_name": ["VALPROATE SODIUM"], "generic_name": ["VALPROATE SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-494"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VALPROATE SODIUM"], "rxcui": ["1099648"], "spl_id": ["f09a2148-edd9-4918-8359-7554ed263d3a", "fff889dc-6006-43c2-be57-01b2a5724b26"], "spl_set_id": ["3dfb6da1-f66a-4618-9f74-d2d6c16c0b58", "c572ece7-03d3-4c2a-aeb5-61f2023b28ea"], "package_ndc": ["63323-494-41", "63323-494-16", "63323-494-01", "63323-494-05"], "unii": ["5VOM6GYJ0D"]}, "update_date": "04/23/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-262-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-262", "61703-360", "61703-150", "61703-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["5aa72c15-8033-4559-b257-373371b18958"], "spl_set_id": ["47677091-fd20-49af-933c-c9dd2be21de9"], "package_ndc": ["61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0070-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0070", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0078", "0338-0062", "0338-0074", "0338-0066", "0338-0082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["66eb82f8-6755-42aa-b20c-192a640e8068"], "spl_set_id": ["36e9478c-5df0-4b47-b97d-de3626d7cb29"], "package_ndc": ["0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-488-37", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/26/2025", "update_type": "New", "initial_posting_date": "09/26/2025", "package_ndc": "25021-230-02", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA090675"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-230"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["beff4b0b-e884-4134-ba9e-290020a94add"], "spl_set_id": ["caab50e6-0dad-4ddd-9a6c-96cc2b87aee7"], "package_ndc": ["25021-230-02", "25021-230-05"], "unii": ["042LAQ1IIS"]}, "update_date": "09/26/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-722-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-722", "71288-721", "71288-724", "71288-725", "71288-727", "71288-728"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2021", "package_ndc": "71288-505-03", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA204843"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-505"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["74e25a75-2d63-4f39-b6d0-a73392bd1040"], "spl_set_id": ["8fa36783-b94d-4084-8c41-40ee64192074"], "package_ndc": ["71288-505-02", "71288-505-03"], "unii": ["1018WH7F9I"]}, "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6057-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May timeframe.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6057", "0641-6059", "0641-6056", "0641-6061", "0641-6063", "0641-6060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-04", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-04)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-87", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-671", "25021-652"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6004-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA213784"], "brand_name": ["FLUPHENAZINE HYDROCHLORIDE"], "generic_name": ["FLUPHENAZINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories,LLC"], "product_ndc": ["0832-6004", "0832-6003", "0832-6005", "0832-6006"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUPHENAZINE HYDROCHLORIDE"], "rxcui": ["859841", "860918", "865117", "865123"], "spl_id": ["3bb74f82-8872-9829-e063-6294a90aeace"], "spl_set_id": ["f07bb3f1-c68c-441b-9de4-99a219f2500a"], "package_ndc": ["0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11"], "unii": ["ZOU145W1XL"]}, "update_date": "09/18/2025", "therapeutic_category": ["Neurology", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 2.5 mg (NDC 0832-6004-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0306-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/185612/download?attachment", "contact_info": "610-937-6172", "availability": "Available", "openfda": {"brand_name": ["TEGLUTIK"], "generic_name": ["RILUZOLE"], "manufacturer_name": ["EDW PHARMA"], "product_ndc": ["70726-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RILUZOLE"], "rxcui": ["2058147", "2675565"], "spl_id": ["4746bb53-bb35-7aa0-e063-6394a90a647b"], "spl_set_id": ["1a3aeb59-d589-8d12-e063-6394a90a0a3a"], "package_ndc": ["70726-0306-1"], "nui": ["N0000175740", "M0483511"], "pharm_class_epc": ["Benzothiazole [EPC]"], "pharm_class_cs": ["Benzothiazoles [CS]"], "unii": ["7LJ087RS6F"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9045-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071168"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9045", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-31", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Not available at this time.", "openfda": {"application_number": ["ANDA070553", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-03", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA089646"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-04", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA090108"], "brand_name": ["CLINDAMYCIN"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["1737244", "1737578", "1737581"], "spl_id": ["4662502b-ce7c-4278-854d-cf8632ac9b83"], "spl_set_id": ["7a6967b3-5563-4bed-9eee-d400f800e799"], "package_ndc": ["25021-115-02", "25021-115-04", "25021-115-06"], "unii": ["EH6D7113I8"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "63323-032-00", "generic_name": "Sodium Acetate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206687"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-032"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["312965"], "spl_id": ["37c19fc5-c1ce-4ea0-9cba-4cdf32112091"], "spl_set_id": ["d7fabf08-d4e0-4bb5-8416-2e8ffe27c04b"], "package_ndc": ["63323-032-04", "63323-032-00"], "unii": ["4550K0SC9B"]}, "update_date": "04/23/2026", "therapeutic_category": ["Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-0367-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Product will be made available as it is released.", "openfda": {"application_number": ["ANDA087702"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-0367", "0641-6145", "0641-6146"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["02bf3273-f0c8-448c-9f74-eb009fee9299"], "spl_set_id": ["0277cc0a-2fd4-4605-a310-b613be84ee26"], "package_ndc": ["0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/12/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0143-9144-03", "generic_name": "Liraglutide Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": {"application_number": ["ANDA215503"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9144"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["5088d0a8-f7aa-476c-8cc1-149955781409"], "spl_set_id": ["2100ec49-57b2-4330-ab5f-057ce9b7e4d0"], "package_ndc": ["0143-9144-01", "0143-9144-03", "0143-9144-02"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-36", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-36", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-552-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-552", "64850-550", "64850-551", "64850-553", "64850-554", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-725-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA076772"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-725", "62037-734", "62037-726", "62037-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "spl_id": ["24aa9277-3773-489d-8459-f9215140c53f"], "spl_set_id": ["85ef422d-af27-4126-9841-6892af1871d6"], "package_ndc": ["62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/28/2026", "update_type": "New", "initial_posting_date": "01/28/2026", "package_ndc": "0023-6118-03", "generic_name": "Podofilox Topical Gel", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020529"], "brand_name": ["CONDYLOX"], "generic_name": ["PODOFILOX"], "manufacturer_name": ["Allergan, Inc."], "product_ndc": ["0023-6118"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["PODOFILOX"], "rxcui": ["312466", "351750"], "spl_id": ["9f2892be-8330-4fd1-930e-b4d204df4e03"], "spl_set_id": ["032e4bcb-b1ed-4029-b2a6-e92f3bf5cc37"], "package_ndc": ["0023-6118-03"], "nui": ["N0000008732"], "pharm_class_pe": ["Decreased Mitosis [PE]"], "unii": ["L36H50F353"]}, "update_date": "01/28/2026", "therapeutic_category": ["Dermatology", "Other"], "dosage_form": "Topical Gel", "presentation": "Condylox , Topical Gel, 0.5% (NDC 0023-6118-03)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-669-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076374"], "brand_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-669", "62135-667", "62135-668"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["0c3f4504-d57e-aa79-e063-6294a90ad5b8"], "spl_set_id": ["2eae533f-d0af-47e8-a1f2-94bc8cc89b5a"], "package_ndc": ["62135-667-90", "62135-668-90", "62135-669-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-171-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-171", "55150-167", "55150-168", "55150-169", "55150-170", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/06/2026", "update_type": "New", "initial_posting_date": "05/06/2026", "package_ndc": "0409-1208-01", "generic_name": "Cisatracurium Besylate Injection", "contact_info": "844-646-4398", "related_info": "Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203238"], "brand_name": ["CISATRACURIUM BESYLATE"], "generic_name": ["CISATRACURIUM BESYLATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1208", "0409-1098", "0409-1103"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CISATRACURIUM BESYLATE"], "rxcui": ["199211", "199212", "1730194"], "spl_id": ["0ec666c8-db68-4a59-9da4-e0abd8e209c5"], "spl_set_id": ["67908e20-044d-454d-9c51-bf106e817bd0"], "package_ndc": ["0409-1098-12", "0409-1098-02", "0409-1103-11", "0409-1103-01", "0409-1208-11", "0409-1208-01"], "unii": ["80YS8O1MBS"]}, "update_date": "05/06/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-152", "72888-153", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-05)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0127-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-201-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088586"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-201", "63323-202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1737757"], "spl_id": ["d19c26f4-1214-40f7-9680-43c885613306"], "spl_set_id": ["cddb2b22-fce3-8967-6e54-dca3df5ac4b3"], "package_ndc": ["63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02"], "unii": ["V13007Z41A"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-022-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 22.5 mg/.4 mL (NDC 82497-022-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "76045-004-11", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi, USA LLC", "Fresenius Kabi USA, LLC"], "product_ndc": ["76045-004", "76045-005", "76045-006", "76045-007", "76045-008"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "894914", "998212", "998213", "1442790"], "spl_id": ["286bce70-23cd-4d5b-989b-230d6cdd5a91", "e064585d-2d2d-41cd-a0f1-43494ce4775b"], "spl_set_id": ["1f53de80-efc8-4930-b3e3-fba0d026af05", "b62ee1ef-db55-417a-a02e-b103890f9c4b"], "package_ndc": ["76045-004-01", "76045-004-11", "76045-005-01", "76045-005-11", "76045-006-01", "76045-006-11", "76045-007-01", "76045-007-11", "76045-008-01", "76045-008-11", "76045-004-02", "76045-004-12", "76045-005-02", "76045-005-12", "76045-006-02", "76045-006-12", "76045-007-00", "76045-007-10", "76045-008-00", "76045-008-10"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0973-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0973", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-734-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA076772"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-734", "62037-725", "62037-726", "62037-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "spl_id": ["24aa9277-3773-489d-8459-f9215140c53f"], "spl_set_id": ["85ef422d-af27-4126-9841-6892af1871d6"], "package_ndc": ["62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "55150-209-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5117-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5117", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5116"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0185-2099-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Limited Availability, 2 weeks", "related_info": "Low supply of Amphetamine combo 30mg due to packaging delays", "openfda": {"application_number": ["ANDA040439"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0185-2099", "0185-0831", "0185-0842", "0185-0853", "0185-0864", "0185-2098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577961"], "spl_id": ["9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd"], "spl_set_id": ["288dafc4-fe6e-4891-832f-511022c87445"], "package_ndc": ["0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)", "company_name": "Sandoz Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2859", "0781-2868"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-386-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6061-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May 2026 timeframe.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6061", "0641-6057", "0641-6059", "0641-6056", "0641-6063", "0641-6060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-197-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-197", "55150-195", "55150-196", "55150-198", "55150-199", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-50", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088400"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-185"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["42c6c812-706a-425b-b8cb-931006e40484"], "spl_set_id": ["e71c6c83-d518-496c-b2ab-efd5987e4783"], "package_ndc": ["63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/23/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0870-26", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: December 2028", "openfda": {"application_number": ["NDA050441"], "brand_name": ["CLEOCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0870", "0009-0775", "0009-0902", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582", "205964", "309335", "309336", "309339", "685574"], "spl_id": ["dd9fa453-a2ca-4a53-b39b-c59a44a888aa"], "spl_set_id": ["05a75685-0af5-407c-ac57-e380c882b49d"], "package_ndc": ["0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01"], "unii": ["EH6D7113I8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)", "company_name": "Pfizer Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-382-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070552", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-22", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3073", "0009-3475"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-723-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-723", "59651-722", "59651-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 59651-723-01)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "83634-600-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": {"application_number": ["ANDA209065"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Avenacy Inc."], "product_ndc": ["83634-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["3e30e931-4d42-465c-9e4b-cd3137ba5fe2"], "spl_set_id": ["eee6145b-d83f-4596-92d3-733934d8a3a4"], "package_ndc": ["83634-600-41", "83634-600-02"], "unii": ["1018WH7F9I"]}, "update_date": "04/06/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0143-9532-25", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA205046"], "brand_name": ["DEXMEDETOMIDINE HCL"], "generic_name": ["DEXMEDETOMIDINE HCL"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9532"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "spl_id": ["8cb1c4c8-48b4-471f-b443-5f03896a3fb7"], "spl_set_id": ["de6f01a2-9f2d-4c68-9c02-06643704acb1"], "package_ndc": ["0143-9532-01", "0143-9532-25"], "unii": ["1018WH7F9I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-553-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-553", "64850-550", "64850-551", "64850-552", "64850-554", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-557-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "Lupin Pharmaceuticals, Inc.", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077690"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-557", "68180-556", "68180-558", "68180-554", "68180-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["a9598a21-6f99-4c86-ace6-b5638da2bec8"], "spl_set_id": ["8ded0773-3aec-4e89-9836-d22a5a84abf0"], "package_ndc": ["68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA076515"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2234"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["200329"], "spl_id": ["fe6aa833-89e6-4679-a7b8-6600e92c1bed"], "spl_set_id": ["5a09ce48-7139-4fc7-9b6e-439459c8e866"], "package_ndc": ["0781-2234-10", "0781-2234-01", "0781-2234-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-287-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-287", "63323-286", "63323-288", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "65219-445-20", "generic_name": "Etomidate Injection", "contact_info": "800-551-7176", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-445", "65219-447"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["446487f1-002e-41d3-846a-67570e797171", "30488a7e-ea9e-4a27-95a9-a07149c50282"], "spl_set_id": ["f38fad46-f2dd-4692-a2a9-a13d0a717bf8", "d07efb9e-5264-461d-96d8-e11fa71c5751"], "package_ndc": ["65219-445-12", "65219-445-22", "65219-445-01", "65219-445-10", "65219-447-02", "65219-447-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 40 mg/20 mL (NDC 65219-445-20)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4744-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4744", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "23155-600-41", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA090696"], "brand_name": ["MIDAZOLAM HYDROCHLORIDE"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "spl_id": ["0703352c-df9e-40fb-be00-0742a2511a7d"], "spl_set_id": ["8b690f5c-2923-4c34-a8f7-11af5f546b62"], "package_ndc": ["23155-600-31", "23155-600-41"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-25", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb"], "spl_set_id": ["abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f"], "package_ndc": ["0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "76045-211-20", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA203460"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-211", "76045-001", "76045-002", "76045-003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["998211", "1551393", "1551395"], "spl_id": ["ec9c9aee-b95f-4645-bf17-df7f1e3967d3"], "spl_set_id": ["1cc9ba6e-fa1b-405e-9de8-720c567b2a73"], "package_ndc": ["76045-211-00", "76045-211-20", "76045-001-00", "76045-001-20", "76045-002-00", "76045-002-10", "76045-003-00", "76045-003-20"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "64253-400-91", "generic_name": "Atropine Sulfate Injection", "contact_info": "630-682-4600", "availability": "Available", "openfda": {"application_number": ["ANDA214970"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE INJECTION"], "manufacturer_name": ["Medefil, Inc."], "product_ndc": ["64253-400"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546"], "spl_id": ["46a6a31f-46ab-a437-e063-6394a90a4ad0"], "spl_set_id": ["fbfdf718-befe-ad22-e053-6294a90a3715"], "package_ndc": ["64253-400-30", "64253-400-91"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/15/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)", "company_name": "Medefil, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-7299-25", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["1859490"], "spl_id": ["013001c4-5584-4d8c-8bf6-917d2a919aa4", "10c75a24-9542-431a-84f8-44611bc916df"], "spl_set_id": ["ce9a7469-c4ba-4f60-8f7a-47ef0974316e", "c91ede49-c7cc-47b7-0f93-e6841dd5916a"], "package_ndc": ["0409-7299-45", "0409-7299-25", "0409-7299-83", "0409-7299-73"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)", "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-1505-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "company_name": "Lannett Company, Inc.", "contact_info": "844-834-0530", "availability": "Available", "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "status": "Current", "dosage_form": "Tablet", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "68025-095-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-095", "68025-088", "68025-089", "68025-096", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "25021-131-82", "generic_name": "Metronidazole Injection", "contact_info": "866-625-1618", "availability": "Available", "related_info": "Labeler: Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206191"], "brand_name": ["METRONIDAZOLE"], "generic_name": ["METRONIDAZOLE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["METRONIDAZOLE"], "rxcui": ["311683"], "spl_id": ["cad111bb-2009-422a-b16e-87d75ade4e4c"], "spl_set_id": ["d46870f5-e2b1-46bd-8413-4a0a8bcf3175"], "package_ndc": ["25021-131-82"], "nui": ["N0000175435", "M0014907"], "pharm_class_epc": ["Nitroimidazole Antimicrobial [EPC]"], "pharm_class_cs": ["Nitroimidazoles [CS]"], "unii": ["140QMO216E"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/25/2020", "package_ndc": "0088-2102-24", "generic_name": "Rifapentine Tablet, Film Coated", "contact_info": "800-633-1610 Option 7", "availability": "Available", "openfda": {"application_number": ["NDA021024"], "brand_name": ["PRIFTIN"], "generic_name": ["RIFAPENTINE"], "manufacturer_name": ["sanofi-aventis U.S. LLC"], "product_ndc": ["0088-2102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAPENTINE"], "rxcui": ["242671", "261101"], "spl_id": ["83c11919-ca6d-49f5-8f9f-7b8405fcbaec"], "spl_set_id": ["3a64fb70-b85e-43d9-8bcd-7e893f568ae1"], "package_ndc": ["0088-2102-01", "0088-2102-24"], "nui": ["N0000175501", "M0019113"], "pharm_class_epc": ["Rifamycin Antimycobacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["XJM390A33U"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-4916-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5815-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA090866"], "brand_name": ["VALSARTAN"], "generic_name": ["VALSARTAN"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-5815", "0378-5807", "0378-5813", "0378-5814"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VALSARTAN"], "rxcui": ["349199", "349200", "349201", "349483"], "spl_id": ["a5384d58-48c7-494a-a8a8-c296b316bd91"], "spl_set_id": ["73e01dc6-7dd4-421a-a4f6-137e75f69f9a"], "package_ndc": ["0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77"], "nui": ["N0000000070", "N0000175561"], "pharm_class_moa": ["Angiotensin 2 Receptor Antagonists [MoA]"], "pharm_class_epc": ["Angiotensin 2 Receptor Blocker [EPC]"], "unii": ["80M03YXJ7I"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 320 mg (NDC 0378-5815-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "21586-011-02", "generic_name": "Cefotaxime Sodium Powder, for Solution", "related_info_link": "https://www.fda.gov/media/152896/download", "contact_info": "800-881-3550", "availability": "Available", "openfda": {"brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME INJECTION"], "manufacturer_name": ["SteriMax Inc."], "product_ndc": ["21586-011", "21586-012"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["1656313", "1656318"], "spl_id": ["425c90b3-5006-427e-95f6-93ee7918fb8b"], "spl_set_id": ["8efe3bd0-c43a-2bd6-e053-2a95a90a92fa"], "package_ndc": ["21586-011-01", "21586-011-02", "21586-012-01", "21586-012-02"], "unii": ["258J72S7TZ"]}, "update_date": "04/30/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)", "company_name": "SteriMax, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6003-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA213784"], "brand_name": ["FLUPHENAZINE HYDROCHLORIDE"], "generic_name": ["FLUPHENAZINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories,LLC"], "product_ndc": ["0832-6003", "0832-6004", "0832-6005", "0832-6006"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUPHENAZINE HYDROCHLORIDE"], "rxcui": ["859841", "860918", "865117", "865123"], "spl_id": ["3bb74f82-8872-9829-e063-6294a90aeace"], "spl_set_id": ["f07bb3f1-c68c-441b-9de4-99a219f2500a"], "package_ndc": ["0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11"], "unii": ["ZOU145W1XL"]}, "update_date": "09/18/2025", "therapeutic_category": ["Neurology", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 1 mg (NDC 0832-6003-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-136-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-136", "16729-137", "16729-138"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 16729-136-00)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7938-19", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7938-19", "openfda": {"application_number": ["NDA018080"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7938"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477"], "spl_id": ["43f81a41-0a45-45f5-840c-768d768edd3b"], "spl_set_id": ["cb578dba-094c-4787-951d-763d12fd06e1"], "package_ndc": ["0990-7938-19"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-4615-01", "generic_name": "Doxylamine Succinate and Pyridoxine  Hydrochloride Tablet, Delayed Release", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA207825"], "brand_name": ["DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE"], "generic_name": ["DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-4615"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DOXYLAMINE SUCCINATE", "PYRIDOXINE HYDROCHLORIDE"], "rxcui": ["1375948"], "spl_id": ["948c17d8-e019-4e4e-b93b-a775ec327a6d"], "spl_set_id": ["957865a2-efcf-43a6-92a8-f9f980892833"], "package_ndc": ["0378-4615-01"], "unii": ["V9BI9B5YI2", "68Y4CF58BV"]}, "update_date": "01/12/2026", "therapeutic_category": ["Other"], "dosage_form": "Tablet", "presentation": "Doxylamine Succinate and Pyridoxine  Hydrochloride, Tablet, Delayed Release, 10 mg; 10 mg (NDC 0378-4615-01)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "0143-9830-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": {"application_number": ["ANDA040632"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9830"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE"], "rxcui": ["311625"], "spl_id": ["49eb25b2-c59c-4374-a216-076767fe1126"], "spl_set_id": ["b080eb92-fc72-4ce6-a7ab-3f9ce2415526"], "package_ndc": ["0143-9830-01"], "nui": ["N0000175584", "N0000000111"], "pharm_class_epc": ["Folate Analog Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Folic Acid Metabolism Inhibitors [MoA]"], "unii": ["YL5FZ2Y5U1"]}, "update_date": "05/12/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "71357-008-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": {"application_number": ["ANDA214805"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE INJECTION, USP, 200 MEQ/100 ML"], "manufacturer_name": ["MILLA PHARMACEUTICALS INC."], "product_ndc": ["71357-008", "71357-007", "71357-009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["237371", "312965"], "spl_id": ["47d8d0e7-6db5-950d-e063-6294a90ab1bf"], "spl_set_id": ["1ea1466d-a492-4056-e063-6394a90a80bf"], "package_ndc": ["71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10"], "unii": ["4550K0SC9B"]}, "update_date": "05/15/2026", "therapeutic_category": ["Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)", "company_name": "Milla Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "0338-9557-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA208532"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9557", "0338-9555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["594e9faa-bc32-42e0-9c0a-8fa9460b1e24"], "spl_set_id": ["8ccb45a7-8290-469c-9644-a4dca967d88f"], "package_ndc": ["0338-9555-24", "0338-9557-12"], "unii": ["1018WH7F9I"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0551-11", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020179"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-0551"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616"], "spl_id": ["e702be26-651e-4d4a-9d79-4df9f53821c9"], "spl_set_id": ["7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e"], "package_ndc": ["0338-0551-11", "0338-0551-18"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-0111-00", "generic_name": "Amantadine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076186"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0111"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849395"], "spl_id": ["45af44df-1a9b-32b6-e063-6394a90acdaf"], "spl_set_id": ["63d9d4aa-5f92-45b0-98d0-d6ec38b727cb"], "package_ndc": ["0832-0111-00", "0832-0111-50", "0832-0111-89", "0832-0111-03"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Tablet", "presentation": "Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-00)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "0378-4415-01", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "1-844-874-7464", "availability": "Unavailable", "related_info": "Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.", "update_date": "01/14/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)", "company_name": "Rising Pharma Holdings, Inc.", "shortage_reason": "Regulatory delay", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/12/2025", "update_type": "New", "initial_posting_date": "11/12/2025", "package_ndc": "0603-3718-34", "generic_name": "Frovatriptan Succinate Tablet", "contact_info": "800-828-9393", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/12/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Frova, Tablet, 2.5 mg (NDC 0603-3718-34)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-101-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 10 mg (NDC 59417-101-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-455-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-455", "63323-452", "63323-454", "63323-458", "63323-451"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011", "1732136", "2003714"], "spl_id": ["dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc"], "spl_set_id": ["582f42e5-444e-4246-af8c-e7e28097c69a"], "package_ndc": ["63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-035-02", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["NDA020630"], "brand_name": ["ULTIVA"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["72078-035", "72078-034", "72078-036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729581", "1729584", "1729586", "1729710", "1729712"], "spl_id": ["594087a1-25f2-4f68-aea6-ad7df40559ab"], "spl_set_id": ["8b4c8696-e23e-4c51-a4d2-babab5bd945a"], "package_ndc": ["72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05"], "unii": ["5V444H5WIC"]}, "update_date": "05/05/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 2 mg (NDC 72078-035-02)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1434-01", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1434", "0409-1660", "0409-1638", "0409-1596", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-161-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-161", "55150-162", "55150-163", "55150-164", "55150-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-116-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-116", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6045-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6045", "0641-6044", "0641-6046", "0641-6047"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100", "238101", "1665188", "1665326"], "spl_id": ["7c73dbc6-2623-4443-9b05-97dec7a0be2e"], "spl_set_id": ["e9b54e42-04cf-4c62-90e1-36f7b31a4e81"], "package_ndc": ["0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-312-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA091695"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["62175-312", "62175-310", "62175-311", "62175-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001564", "2001565", "2001566", "2001568"], "spl_id": ["8b133cd2-e3c6-4742-b402-2393b56ffc93"], "spl_set_id": ["3d1f5aff-5d39-496c-b5ed-7f3c70ec641c"], "package_ndc": ["62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37"], "unii": ["4B3SC438HI"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)", "company_name": "Lannett Company, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0306-12", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0306", "0009-0274", "0009-0280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/27/2025", "update_type": "New", "initial_posting_date": "10/27/2025", "package_ndc": "0310-6627-02", "generic_name": "Pramlintide Acetate Injection", "contact_info": "800-236-9933", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA021332"], "brand_name": ["SYMLINPEN"], "generic_name": ["PRAMLINTIDE ACETATE"], "manufacturer_name": ["AstraZeneca Pharmaceuticals LP"], "product_ndc": ["0310-6627", "0310-6615"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PRAMLINTIDE ACETATE"], "rxcui": ["861042", "861043", "861044", "861045"], "spl_id": ["a84753f1-6ac5-4a47-a382-29972938ccaa"], "spl_set_id": ["4aea30ff-eb0d-45c1-b114-3127966328ff"], "package_ndc": ["0310-6615-02", "0310-6627-02"], "unii": ["726I6TE06G"]}, "update_date": "10/27/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "SymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02)", "company_name": "AstraZeneca AB", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-35", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1755-50", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1755", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-1209-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA088571"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/04/2025", "update_type": "New", "initial_posting_date": "08/04/2025", "package_ndc": "45963-614-51", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "800-545-8800", "related_info": "Product not anticipated to be available beyond mid-late October 2025", "openfda": {"application_number": ["ANDA078589"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["45963-614"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["3bbdb61c-9194-416e-9034-5d2b11b5b8ee"], "spl_set_id": ["5e1fdcaa-918f-4cd8-9c7a-4c538d866198"], "package_ndc": ["45963-614-51", "45963-614-55"], "unii": ["042LAQ1IIS"]}, "update_date": "08/04/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-709-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-709", "13811-706", "13811-707", "13811-708", "13811-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6125-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May 2026 timeframe.", "openfda": {"application_number": ["ANDA205758"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6125", "0641-6126", "0641-6127"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011"], "spl_id": ["fa18221d-2353-4cf6-a210-fb33ee79d3d9"], "spl_set_id": ["6023606c-150c-40c5-9175-598efe2a56c3"], "package_ndc": ["0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-5322-11", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-5322", "0832-5323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953"], "spl_id": ["39e726b1-eab8-fcf4-e063-6394a90a950a"], "spl_set_id": ["616f0de7-8843-44a1-8fa6-274d889286aa"], "package_ndc": ["0832-5322-11", "0832-5322-10", "0832-5323-11", "0832-5323-10"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-05", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA084916"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1116927", "1812194"], "spl_id": ["a832bff9-0bb3-4350-abb5-d57b9417070c", "9dd90418-e564-4bc5-9077-506a1c2c1bce"], "spl_set_id": ["2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e"], "package_ndc": ["63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-501-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-501", "64850-500", "64850-502", "64850-503", "64850-504", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0591-2679-30", "generic_name": "Lidocaine Patch", "contact_info": "800-545-8800", "related_info": "Discontinuation is for the “NovaPlus” label product only.", "openfda": {"application_number": ["ANDA200675"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2679"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["LIDOCAINE"], "rxcui": ["1745091"], "spl_id": ["e0683309-89ba-4804-887f-12fcaf59a2ca"], "spl_set_id": ["c18799cd-9e11-4196-9ab1-0a2a84585e56"], "package_ndc": ["0591-2679-11", "0591-2679-30"], "nui": ["N0000175682", "M0000897", "N0000175426", "N0000175976"], "pharm_class_epc": ["Amide Local Anesthetic [EPC]", "Antiarrhythmic [EPC]"], "pharm_class_cs": ["Amides [CS]"], "pharm_class_pe": ["Local Anesthesia [PE]"], "unii": ["98PI200987"]}, "update_date": "07/17/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Patch", "presentation": "Lidocaine, Patch, 5% (NDC 0591-2679-30)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "63323-413-10", "generic_name": "Neostigmine Methylsulfate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA203629"], "brand_name": ["NEOSTIGMINE METHYLSULFATE"], "generic_name": ["NEOSTIGMINE METHYLSULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-413", "63323-415"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NEOSTIGMINE METHYLSULFATE"], "rxcui": ["311935", "311936"], "spl_id": ["3abc0611-0e8c-49f9-9678-e4b2fda3d8ed", "1efedce1-b2c3-4652-a289-6ea596b039e2"], "spl_set_id": ["6448229c-e650-47ba-bb00-cba3604502c5", "d0e11e4c-41c3-4874-b567-579db655fba3"], "package_ndc": ["63323-413-01", "63323-413-10", "63323-415-01", "63323-415-10", "63323-413-36", "63323-415-36"], "unii": ["98IMH7M386"]}, "update_date": "01/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9413-92", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA062738"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9413", "0781-9412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["1721475", "1721476"], "spl_id": ["f1afd007-8e8c-40e2-b353-8def35a0ce8b"], "spl_set_id": ["f77db491-31c4-4a7c-a114-0f3244c97090"], "package_ndc": ["0781-9412-15", "0781-9412-92", "0781-9413-15", "0781-9413-92"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "60505-3947-3", "generic_name": "Adefovir Dipivoxil Tablet", "contact_info": "800-706-5575", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA205459"], "brand_name": ["ADEFOVIR DIPIVOXIL"], "generic_name": ["ADEFOVIR DIPIVOXIL"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-3947"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ADEFOVIR DIPIVOXIL"], "rxcui": ["881341"], "spl_id": ["bd0233d0-e141-a321-66a5-4afd09dbabfe"], "spl_set_id": ["08e07fae-3191-b6a3-c894-d3a8cc53923f"], "package_ndc": ["60505-3947-3"], "unii": ["U6Q8Z01514"]}, "update_date": "07/29/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Adefovir Dipivoxil, Tablet, 10 mg (NDC 60505-3947-3)", "company_name": "Apotex Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9935-01", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA065071"], "brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9935"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["309065"], "spl_id": ["e25af43f-54cb-4526-a8a5-6bef0a7939c7"], "spl_set_id": ["ef1a6dc6-bc3d-4f09-8f92-7ff328f56561"], "package_ndc": ["0143-9935-01"], "unii": ["258J72S7TZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-408-41", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-408", "61703-350"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"], "spl_set_id": ["0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab"], "package_ndc": ["61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA075154", "ANDA208878"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-412", "63323-411"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552", "cca4b16a-900d-4c74-86f5-bb9e5587a02a"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc", "09daf48f-1d44-4b7b-bb53-bd5635b93ca6"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10", "63323-412-00"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-20", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018801"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4887"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["055437a7-5be5-414a-a97a-946e2730fe12"], "spl_set_id": ["2b9ea23a-f9e9-48a8-25b7-519e3bbd6828"], "package_ndc": ["0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4933-10", "generic_name": "Epinephrine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Cardiovascular", "Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4742-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4742", "60505-4739", "60505-4740", "60505-4741", "60505-4743", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-700-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA050141"], "brand_name": ["BICILLIN L-A"], "generic_name": ["PENICILLIN G BENZATHINE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["60793-700", "60793-701", "60793-702"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PENICILLIN G BENZATHINE"], "rxcui": ["731564", "731566", "731567", "731568", "731570", "731571"], "spl_id": ["4b3694af-9d77-487f-8838-b75aec6636da"], "spl_set_id": ["012d46f1-d0a0-4676-a879-cd320297ab16"], "package_ndc": ["60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10"], "unii": ["RIT82F58GK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "39822-4200-2", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-390-4411", "availability": "Available", "related_info": "Tamarang is the application holder and X-Gen is the distributor/labeler", "openfda": {"application_number": ["ANDA091115"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-4200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["eedcfb07-4e23-3152-e053-2995a90a6e6a"], "spl_set_id": ["b73f192c-2912-4ec3-9b4f-05a58d9b35ba"], "package_ndc": ["39822-4200-1", "39822-4200-2", "39822-4200-5", "39822-4200-6"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/09/2026", "update_type": "New", "initial_posting_date": "01/09/2026", "package_ndc": "63323-469-01", "generic_name": "Haloperidol Decanoate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074893"], "brand_name": ["HALOPERIDOL DECANOATE"], "generic_name": ["HALOPERIDOL DECANOATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-469", "63323-471"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["HALOPERIDOL DECANOATE"], "rxcui": ["859867", "859871", "1719803", "1719862"], "spl_id": ["86dff2aa-2ab3-42fc-989e-619b13ace573"], "spl_set_id": ["ca9896e0-fb2e-46a4-8700-20d144c14764"], "package_ndc": ["63323-469-01", "63323-469-05", "63323-471-01", "63323-471-05"], "unii": ["AC20PJ4101"]}, "update_date": "01/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Injection", "presentation": "Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-05", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-05)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-726-52", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216039"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-726", "71288-723"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["0949c302-51ce-4fc9-8b99-1df94e693718"], "spl_set_id": ["fe340f98-a0f3-446e-b281-47fd91c1e537"], "package_ndc": ["71288-723-52", "71288-726-52"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-284-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA202747"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["36000-284", "36000-063", "36000-064", "36000-065", "36000-282", "36000-283"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53"], "spl_set_id": ["c71371a7-75c5-45b8-b762-8d782d4c71bc"], "package_ndc": ["36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-493-97", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE MPF"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-493", "63323-492", "63323-496"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764"], "spl_id": ["fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df"], "spl_set_id": ["d5e0d06f-ba1e-44d4-aa89-39d6c146dc23"], "package_ndc": ["63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97"], "unii": ["EC2CNF7XFP"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-089-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-089", "68025-088", "68025-095", "68025-096", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0222-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-00", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3983-05", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3983", "0591-3982", "0591-3984", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 100 mg (NDC 0591-3983-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-180-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Unavailable", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 30 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-180", "47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-179"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-084-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-084", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0591-2729-01", "generic_name": "Potassium Citrate Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue.", "openfda": {"application_number": ["ANDA209758"], "brand_name": ["POTASSIUM CITRATE"], "generic_name": ["POTASSIUM CITRATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2729", "0591-2682", "0591-2742"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CITRATE"], "rxcui": ["199376", "199381", "898490"], "spl_id": ["309b143e-7142-4a21-859e-715ba61e82f7"], "spl_set_id": ["ac173781-486b-461c-97ae-8b5c69e20792"], "package_ndc": ["0591-2682-01", "0591-2729-01", "0591-2742-01"], "unii": ["EE90ONI6FF"]}, "update_date": "07/17/2025", "therapeutic_category": ["Renal"], "dosage_form": "Tablet", "presentation": "Potassium Citrate, Tablet, Extended Release, 10 meq (NDC 0591-2729-01)", "company_name": "Watson Pharma Private Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9392-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA210594"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9392", "0143-9391", "0143-9393"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["5c5e498b-d829-4f78-bcca-466631014767"], "spl_set_id": ["9d289052-1eb6-4ba2-a3ca-d2e542a052ae"], "package_ndc": ["0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10"], "unii": ["5V444H5WIC"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1761-62", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018692"], "brand_name": ["MARCAINE SPINAL"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1761"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBARACHNOID"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724784", "1724792"], "spl_id": ["f3862f77-3621-4730-923e-9efbfa18e03f"], "spl_set_id": ["9679cc05-2f8a-4e88-53b5-6e9122c8b8c0"], "package_ndc": ["0409-1761-19", "0409-1761-02", "0409-1761-18", "0409-1761-62", "0409-1761-05", "0409-1761-10"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3984-01", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3984", "0591-3982", "0591-3983", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 200 mg (NDC 0591-3984-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43598-975-58", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "Distributed by DRL", "availability": "Available", "related_info": "Distributed by DRL", "openfda": {"application_number": ["ANDA209307"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Dr.Reddy's Laboratories Inc"], "product_ndc": ["43598-975", "43598-976"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["5785a11f-7784-4ae0-8029-f50b782eaf4a"], "spl_set_id": ["d174c19d-56f1-4ef4-087c-23c26db8e40b"], "package_ndc": ["43598-976-11", "43598-976-58", "43598-975-11", "43598-975-58"], "unii": ["1018WH7F9I"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-554-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-554", "64850-550", "64850-551", "64850-552", "64850-553", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6053-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA080445"], "brand_name": ["MEPERIDINE HYDROCHLORIDE"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6053", "0641-6054", "0641-6052"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["861476", "1665685", "1665697"], "spl_id": ["9566d54d-7343-4695-94ff-8b5f2d384c81"], "spl_set_id": ["e0e998da-f056-4fce-be8e-ed60cf3b461b"], "package_ndc": ["0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25"], "unii": ["N8E7F7Q170"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "0781-8017-01", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021192"], "brand_name": ["FLUVASTATIN SODIUM ER"], "generic_name": ["FLUVASTATIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-8017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUVASTATIN SODIUM"], "rxcui": ["360507"], "spl_id": ["37375ca6-3a81-4d10-9b39-9aee948e51a4"], "spl_set_id": ["5ab4296c-87c2-4c64-b218-d620eef51310"], "package_ndc": ["0781-8017-31", "0781-8017-01"], "unii": ["PYF7O1FV7F"]}, "update_date": "01/27/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-132-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-132", "72205-133", "72205-134", "72205-135", "72205-136", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3073", "0009-3475"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "04/22/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)", "company_name": "Pfizer Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6019-10", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["NDA018565"], "brand_name": ["DURAMORPH"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6019", "0641-6020"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892473", "892489", "1728783", "1728800"], "spl_id": ["aa74af85-7068-4254-9a79-c7f3792044a6"], "spl_set_id": ["ebb18761-e5c4-4238-bb84-f9549f500210"], "package_ndc": ["0641-6020-01", "0641-6020-10", "0641-6019-01", "0641-6019-10"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-0928-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-0928", "0641-0929"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992858"], "spl_id": ["9f14d3f5-ad01-44b5-a2b7-16ed5f501f87"], "spl_set_id": ["4bf3912c-8339-401e-9711-dad6acf15f11"], "package_ndc": ["0641-0928-21", "0641-0928-25", "0641-0929-21", "0641-0929-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/09/2026", "update_type": "New", "initial_posting_date": "04/09/2026", "package_ndc": "0069-4061-01", "generic_name": "Azithromycin Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050711"], "brand_name": ["ZITHROMAX"], "generic_name": ["AZITHROMYCIN DIHYDRATE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-4061", "0069-3060", "0069-3070", "0069-3110", "0069-3120", "0069-3130", "0069-3140"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AZITHROMYCIN DIHYDRATE"], "rxcui": ["105260", "141963", "211307", "212446", "226827", "248656", "308459", "308460", "749780", "749783", "750149", "750157"], "spl_id": ["e15f2173-8700-4392-96a4-8560772b6f8a"], "spl_set_id": ["db52b91e-79f7-4cc1-9564-f2eee8e31c45"], "package_ndc": ["0069-3060-30", "0069-3060-75", "0069-3060-86", "0069-3070-30", "0069-3070-75", "0069-3110-19", "0069-3120-19", "0069-3130-19", "0069-3140-19", "0069-4061-01", "0069-4061-75", "0069-4061-89"], "unii": ["5FD1131I7S"]}, "update_date": "04/09/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Zithromax, Tablet, 250 mg (NDC 0069-4061-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-09", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-09", "openfda": {"application_number": ["NDA018080"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7930", "0990-7923", "0990-7922"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-102-15", "generic_name": "Insulin Aspart Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Aspart 3 mL PenFill® cartridge will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA020986"], "brand_name": ["INSULIN ASPART"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-102", "73070-100", "73070-103"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["311040", "1653196", "1653202"], "spl_id": ["393af9a3-df9a-40b2-a5e6-bfa5434a2552"], "spl_set_id": ["bee5b358-c863-420b-be73-ced2e920c499"], "package_ndc": ["73070-100-11", "73070-102-10", "73070-102-15", "73070-103-10", "73070-103-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Aspart, Injection, 3 mL Insulin Aspart PenFill® cartridge (NDC 73070-102-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-001-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X2ML) is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-1445-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA075629"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-1445", "0406-1473"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091145", "1091225"], "spl_id": ["7bfd27d5-70ed-440b-949a-140aa3304d4a"], "spl_set_id": ["ed004cf0-eb23-43d2-96dc-20c4ad63824f"], "package_ndc": ["0406-1445-01", "0406-1473-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-454-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-454", "63323-452", "63323-455", "63323-458", "63323-451"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011", "1732136", "2003714"], "spl_id": ["dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc"], "spl_set_id": ["582f42e5-444e-4246-af8c-e7e28097c69a"], "package_ndc": ["63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2868", "0781-2859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-560-05", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-560", "62037-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-01", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-799", "42806-801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "43598-305-62", "generic_name": "Azacitidine Injection", "contact_info": "866-732-3952", "availability": "Available", "related_info": "Available to existing customers", "openfda": {"application_number": ["ANDA201537"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Dr. Reddy's Laboratories Inc."], "product_ndc": ["43598-305"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["35e92030-ae2f-04b2-c3de-69f8c8da6b82"], "spl_set_id": ["71d8d758-86c9-b571-aed1-719654fd4b82"], "package_ndc": ["43598-305-62"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "04/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 43598-305-62)", "company_name": "Dr. Reddy's Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "53746-468-19", "generic_name": "Clindamycin Palmitate Hydrochloride Injection", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203513"], "brand_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE (PEDIATRIC)"], "generic_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals of New York LLC"], "product_ndc": ["53746-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE"], "rxcui": ["562266"], "spl_id": ["b9016023-7843-48e3-8ff6-2e5a70aa5daf"], "spl_set_id": ["faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"], "package_ndc": ["53746-468-19"], "unii": ["VN9A8JM7M7"]}, "update_date": "02/27/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-583-25", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 150 mg (NDC 23155-583-25)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0520-74", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0520"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["2e960a62-b5d8-4fad-a17c-9d07bdbe06d1"], "spl_set_id": ["76e4fe6a-afd4-4f68-b12d-0b094f750615"], "package_ndc": ["0574-0520-04", "0574-0520-08", "0574-0520-74", "0574-0520-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-397-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-503-15", "generic_name": "Insulin Degludec Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Degludec 3 mL U-200 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA203314"], "brand_name": ["INSULIN DEGLUDEC"], "generic_name": ["INSULIN DEGLUDEC"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-503", "73070-403", "73070-400"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN DEGLUDEC"], "rxcui": ["1670011", "1670021", "2107520"], "spl_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "spl_set_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "package_ndc": ["73070-403-15", "73070-503-15", "73070-400-11"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["54Q18076QB"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Degludec, Injection, 3 mL Insulin Degludec 200 units/mL (U-200) FlexTouch® (NDC 73070-503-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-08", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4312", "0002-4491"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-08)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-602-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-602", "60951-700", "60951-712", "60951-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2308-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075857"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2308", "0409-2305", "0409-0001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666800", "1666814", "1666823", "1666798"], "spl_id": ["b303a281-6633-47d5-bf29-5e9055e26da6", "74093865-864a-49e8-99b9-c985fe72afb2"], "spl_set_id": ["b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240"], "package_ndc": ["0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9931-25", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA065072"], "brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9931", "0143-9933", "0143-9930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["309068", "1656313", "1656318"], "spl_id": ["7e0897ec-2275-4438-9cc5-4c951e52ad97"], "spl_set_id": ["ed23b6bc-32c7-4c50-a53d-313ae78e5623"], "package_ndc": ["0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10"], "unii": ["258J72S7TZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "59310-805-06", "generic_name": "Fluticasone Propionate; Salmeterol Xinafoate Powder", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA208799"], "brand_name": ["AIRDUO RESPICLICK"], "generic_name": ["FLUTICASONE PROPIONATE AND SALMETEROL"], "manufacturer_name": ["Teva Respiratory, LLC"], "product_ndc": ["59310-805", "59310-812", "59310-822"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE"], "rxcui": ["1918194", "1918199", "1918203", "1918205", "1918209", "1918211"], "spl_id": ["b597bc2d-bf1e-4f9b-826a-b3e39ed56545"], "spl_set_id": ["9c122b91-a11f-49ca-80bb-3eec5112db87"], "package_ndc": ["59310-805-06", "59310-805-08", "59310-812-06", "59310-812-08", "59310-822-06", "59310-822-08"], "unii": ["6EW8Q962A5", "O2GMZ0LF5W"]}, "update_date": "06/13/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Powder", "presentation": "AirDuo RespiClick, Powder, 55 ug; 14 ug (NDC 59310-805-06)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-851", "63323-852", "63323-853", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4903-34", "generic_name": "Lidocaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9409-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA061395"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9409"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["789980"], "spl_id": ["86e9a3cc-bc65-4d4f-916d-98c916588730"], "spl_set_id": ["5308ddfa-4a5b-4f7b-83ce-9d1b528e050d"], "package_ndc": ["0781-9409-46", "0781-9409-95"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-0167-02", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/12/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-02)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "0264-9872-10", "generic_name": "Heparin Sodium Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019953"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9872"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["48e17807-e73d-4ea2-81bc-901355903aa7"], "spl_set_id": ["a3041c04-0ea8-4d36-81ce-c5091c906316"], "package_ndc": ["0264-9872-10", "0264-9872-00"], "unii": ["ZZ45AB24CA"]}, "update_date": "05/08/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "39822-0355-6", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "03/26/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-190-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-710-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-710", "13811-709", "13811-706", "13811-707", "13811-708"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0591-2742-01", "generic_name": "Potassium Citrate Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue.", "openfda": {"application_number": ["ANDA209758"], "brand_name": ["POTASSIUM CITRATE"], "generic_name": ["POTASSIUM CITRATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2742", "0591-2682", "0591-2729"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CITRATE"], "rxcui": ["199376", "199381", "898490"], "spl_id": ["309b143e-7142-4a21-859e-715ba61e82f7"], "spl_set_id": ["ac173781-486b-461c-97ae-8b5c69e20792"], "package_ndc": ["0591-2682-01", "0591-2729-01", "0591-2742-01"], "unii": ["EE90ONI6FF"]}, "update_date": "07/17/2025", "therapeutic_category": ["Renal"], "dosage_form": "Tablet", "presentation": "Potassium Citrate, Tablet, Extended Release, 15 meq (NDC 0591-2742-01)", "company_name": "Watson Pharma Private Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0223-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-76", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209448"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-824"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481"], "spl_id": ["0591ab74-99a6-40ee-af96-80bc2ef423dc"], "spl_set_id": ["3b8f2692-4371-4f1a-95af-b41842131fdd"], "package_ndc": ["63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/07/2026", "update_type": "New", "initial_posting_date": "04/07/2026", "package_ndc": "61958-1702-1", "generic_name": "Idelalisib Tablet", "contact_info": "800-445-3235", "related_info": "Discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA205858"], "brand_name": ["ZYDELIG"], "generic_name": ["IDELALISIB"], "manufacturer_name": ["Gilead Sciences, Inc."], "product_ndc": ["61958-1702", "61958-1701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IDELALISIB"], "rxcui": ["1544465", "1544471", "1544473", "1544475"], "spl_id": ["ca3e7112-6dfe-403f-af6f-a0051e77d125"], "spl_set_id": ["efbdafa9-d18c-4e85-b4a2-1e620fc74e50"], "package_ndc": ["61958-1701-1", "61958-1702-1"], "nui": ["N0000175605", "N0000175082", "N0000190114"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["YG57I8T5M0"]}, "update_date": "04/07/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Zydelig, Tablet, 150 mg (NDC 61958-1702-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-62", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4491", "0002-4312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-62)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6625-35", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: June 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA202432"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6625"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868486"], "spl_id": ["dcc55d90-d55e-4e1a-9e48-5703cbc74a52", "c39c0ef6-4140-4c6c-91c4-e43d67872b05"], "spl_set_id": ["8664c7ce-707b-4c6c-9ce4-7160b5f877f8", "084f5572-8c1f-4802-b179-ca0cc838fc68"], "package_ndc": ["0409-6625-30", "0409-6625-35", "0409-6625-22", "0409-6625-14"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0972-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0972", "0555-0971", "0555-0775", "0555-0776", "0555-0777", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-30", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-799", "42806-801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-30)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-564-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-564", "47781-562", "47781-563", "47781-565", "47781-566", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "66993-081-69", "generic_name": "Sumatriptan Nasal Spray", "contact_info": "866-525-0688", "related_info": "This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately February 28, 2026.", "openfda": {"application_number": ["NDA020626"], "brand_name": ["SUMATRIPTAN"], "generic_name": ["SUMATRIPTAN"], "manufacturer_name": ["Prasco Laboratories"], "product_ndc": ["66993-081", "66993-082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["NASAL"], "substance_name": ["SUMATRIPTAN"], "rxcui": ["313159", "314227"], "spl_id": ["06b6df24-20eb-4b22-b8e3-591ae1f3518a"], "spl_set_id": ["f63e616b-ae0c-432b-badc-8c45023aa725"], "package_ndc": ["66993-081-69", "66993-082-69"], "nui": ["N0000175763", "N0000175764", "N0000175765"], "pharm_class_moa": ["Serotonin 1b Receptor Agonists [MoA]", "Serotonin 1d Receptor Agonists [MoA]"], "pharm_class_epc": ["Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]"], "unii": ["8R78F6L9VO"]}, "update_date": "09/08/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Nasal Spray", "presentation": "Imitrex, Nasal Spray, 5 mg/100 uL (NDC 66993-081-69)", "company_name": "Prasco Laboratories", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-130-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-130", "57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "0409-3189-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3189", "0409-7037"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["c96726ef-f1fa-4ebb-ba33-3479c3902a8e"], "spl_set_id": ["c96726ef-f1fa-4ebb-ba33-3479c3902a8e"], "package_ndc": ["0409-3189-05", "0409-3189-10", "0409-7037-01", "0409-7037-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA075880"], "brand_name": ["PREMASOL - SULFITE-FREE (AMINO ACID)"], "generic_name": ["LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1130", "0338-1131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "CYSTEINE HYDROCHLORIDE", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801395", "801398", "801403", "801405"], "spl_id": ["c874a813-b145-4f7f-833e-97d6c4dd727c"], "spl_set_id": ["9afdcc3e-0d06-47f4-86ca-40da48b2b02b"], "package_ndc": ["0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "ZT934N0X4W", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "44567-610-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-493-0861", "availability": "Available", "related_info": "Please check wholesalers and distributors for inventory.", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)", "company_name": "WG Critical Care", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/06/2018", "package_ndc": "76329-1912-1", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": {"application_number": ["ANDA202861"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-1912"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "spl_id": ["99799101-d92b-485b-93ec-f2b5a2e5ca26"], "spl_set_id": ["1034467f-d436-4b87-a902-c7e8885daa8a"], "package_ndc": ["76329-1912-0", "76329-1912-1"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-12", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA206775"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-295"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["35cf6068-f31a-211b-e063-6294a90a6b53"], "spl_set_id": ["48aa7ef3-9f44-2a08-e054-00144ff88e88"], "package_ndc": ["16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/11/2024", "package_ndc": "0338-0719-06", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020047"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0719"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["237656"], "spl_id": ["aa64f648-e931-4a99-9b81-791a3827272c"], "spl_set_id": ["0332f34a-7038-47cc-ba59-d55cad6b73ca"], "package_ndc": ["0338-0719-06"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-600-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": {"application_number": ["ANDA214456"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Alembic Pharmaceuticals Inc."], "product_ndc": ["62332-600", "62332-599", "62332-601"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["9030f496-5021-4454-ac16-dbb376315608"], "spl_set_id": ["419cf756-3c96-4bb8-ae96-6aea5a5f3afd"], "package_ndc": ["62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/15/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "61570-075-50", "generic_name": "Esterified Estrogens Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/29/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Menest, Tablet, 2.5 mg (NDC 61570-075-50)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "76329-3390-1", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-423-4136", "availability": "Limited Availability", "related_info": "old NDC 0548-3390-00", "openfda": {"application_number": ["ANDA083173"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-3390"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1012068"], "spl_id": ["3d910bb6-792f-41f3-8b28-b33bcbec5ccb"], "spl_set_id": ["5d3e9984-cef9-46f2-a6c9-3be8b26f45b3"], "package_ndc": ["76329-3390-1"], "unii": ["V13007Z41A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6028-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6028", "0641-6024", "0641-6027", "0641-6025", "0641-6026", "0641-6029", "0641-6030", "0641-6247", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-117-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-117", "70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-116"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-05", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb"], "spl_set_id": ["abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f"], "package_ndc": ["0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-064-39", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-064", "65862-062", "65862-063"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-39)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0409-0323-20", "generic_name": "Bleomycin Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA065031"], "brand_name": ["BLEOMYCIN"], "generic_name": ["BLEOMYCIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0323", "0409-0332"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAPLEURAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["BLEOMYCIN SULFATE"], "rxcui": ["1726673", "1726676"], "spl_id": ["d9e9c332-1b3f-469c-83b8-41e15183e635"], "spl_set_id": ["e629ba5a-4e08-4249-9551-af6dbd98a7e4"], "package_ndc": ["0409-0323-20", "0409-0332-20"], "unii": ["7DP3NTV15T"]}, "update_date": "06/13/2025", "therapeutic_category": ["Hematology", "Oncology", "Pediatric"], "dosage_form": "Injection", "presentation": "Bleomycin Sulfate, Injection, 30 [USP'U] (NDC 0409-0323-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-0127-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA202608"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-0127", "0406-0136", "0406-0154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001565", "2001566", "2001568"], "spl_id": ["7a3a8731-e545-455e-83c3-888f4923e901"], "spl_set_id": ["b1b0f2ff-d9df-42ab-b471-226ecf97e075"], "package_ndc": ["0406-0127-01", "0406-0136-01", "0406-0154-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 27 mg (NDC 0406-0127-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-50", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2634"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["50886ad5-eeca-4fe7-beb0-01305f92c65d"], "spl_set_id": ["3832ede8-d3fc-455d-ecab-3b77be5869f5"], "package_ndc": ["0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-252-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-252", "55150-251", "55150-254", "55150-255", "55150-253", "55150-256"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/03/2023", "package_ndc": "69784-200-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Limited Availability", "related_info": "No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2", "update_date": "05/08/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)", "company_name": "Ailex Pharmaceuticals", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5092-16", "generic_name": "Ceftazidime Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA064032"], "brand_name": ["TAZICEF"], "generic_name": ["CEFTAZIDIME"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5092", "0409-5093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CEFTAZIDIME"], "rxcui": ["1659283", "1659287", "1659292", "1659294"], "spl_id": ["3f749ee0-db14-4ed0-9056-d545a38bbe3b"], "spl_set_id": ["9b73979c-c95a-4433-0a9d-f9cea3cb557f"], "package_ndc": ["0409-5092-11", "0409-5092-16", "0409-5093-14", "0409-5093-11"], "unii": ["9M416Z9QNR"]}, "update_date": "11/14/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Tazicef, Injection, 1 g (NDC 0409-5092-16)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-472-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070554"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-472", "63323-463", "63323-461", "63323-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620"], "spl_id": ["cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-33", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA206775"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-295"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["35cf6068-f31a-211b-e063-6294a90a6b53"], "spl_set_id": ["48aa7ef3-9f44-2a08-e054-00144ff88e88"], "package_ndc": ["16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-137-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-137", "72205-132", "72205-133", "72205-134", "72205-135", "72205-136"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/19/2026", "update_type": "New", "initial_posting_date": "03/19/2026", "package_ndc": "64764-805-30", "generic_name": "Ramelteon Tablet", "contact_info": "877-825-3327", "related_info": "Product is expected to be available through June 2027.", "openfda": {"application_number": ["NDA021782"], "brand_name": ["ROZEREM"], "generic_name": ["RAMELTEON"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["64764-805"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RAMELTEON"], "rxcui": ["577348", "603162"], "spl_id": ["2021e7fb-108a-4783-9a37-8bc05bf28b28"], "spl_set_id": ["9de82310-70e8-47b9-b1fc-6c6848b99455"], "package_ndc": ["64764-805-30", "64764-805-10", "64764-805-22"], "nui": ["N0000175743", "N0000000250"], "pharm_class_epc": ["Melatonin Receptor Agonist [EPC]"], "pharm_class_moa": ["Melatonin Receptor Agonists [MoA]"], "unii": ["901AS54I69"]}, "update_date": "03/19/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Rozerem, Tablet, 8 mg (NDC 64764-805-30)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3814-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA208084"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-3814", "0338-3410", "0338-3612"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["c8906ab2-37d2-4fde-9784-0442bf7b9565"], "spl_set_id": ["78832ac6-04c5-45e0-ae4d-f56d7920dda9"], "package_ndc": ["0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0054-0390-41", "generic_name": "Oxycodone Hydrochloride Oral Solution", "contact_info": "800-631-2174", "related_info": "Hikma has permanently discontinued (NDC 0054-0390-41) for the 15 mL bottle configuration. Hikma will continue to distribute Oxycodone Hydrochloride Oral Solution 5 mg/5 mL in the 500 mL bottle (NDC 0054-0390-63).", "openfda": {"application_number": ["ANDA204037"], "brand_name": ["OXYCODONE HYDROCHLORIDE"], "generic_name": ["OXYCODONE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmceuticals USA Inc."], "product_ndc": ["0054-0390"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049604"], "spl_id": ["47e856d4-de7d-49aa-8671-d1b4a35bad4d"], "spl_set_id": ["d8e87c66-f872-4e1d-9ade-ef11490af63b"], "package_ndc": ["0054-0390-41", "0054-0390-63"], "unii": ["C1ENJ2TE6C"]}, "update_date": "09/11/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Oral Solution", "presentation": "Oxycodone Hydrochloride, Oral Solution, 5 mg/5 mL (NDC 0054-0390-41)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6027-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6027", "0641-6024", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6030", "0641-6247", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-451-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-451", "63323-452", "63323-454", "63323-455", "63323-458"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011", "1732136", "2003714"], "spl_id": ["dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc"], "spl_set_id": ["582f42e5-444e-4246-af8c-e7e28097c69a"], "package_ndc": ["63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-56", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: September 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-339"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0ddf4411-7138-412a-908a-fadf22bdfb79"], "spl_set_id": ["c3ae9880-44bb-4f4e-93d8-8a5e21708a30"], "package_ndc": ["61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-67", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA019465"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7101", "0409-7132"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807547", "1807631", "1807632", "1807633"], "spl_id": ["f233e72c-072d-4a43-857a-f4d5791e1a73"], "spl_set_id": ["a2a964f7-c3ec-4dfb-e3a0-6d8136a80397"], "package_ndc": ["0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02"], "unii": ["451W47IQ8X"]}, "update_date": "12/03/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 100 mL  ADD-Vantage® Flexible Container (NDC 0409-7101-67)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-500-08", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070017"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-500", "16729-501", "16729-502"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1cfab300-d796-6a68-e063-6394a90a73f9"], "spl_set_id": ["f6f64972-714c-4ee9-8a5e-9ffcab41a73b"], "package_ndc": ["16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-212-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care de Mexico, S.A. de C.V."], "product_ndc": ["46163-212", "46163-209", "46163-206"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["444fd7c1-1ed5-25c7-e063-6394a90a3bfe"], "spl_set_id": ["a98facd6-9daa-4d37-8209-63a0599dbfaa"], "package_ndc": ["46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-447-45", "generic_name": "Carboplatin Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0641-6261-01", "generic_name": "Sodium Acetate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA216920"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6261"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["1859490"], "spl_id": ["3493d4c1-4f73-44e8-94bc-7b55fe4fd436"], "spl_set_id": ["8a338072-6f1e-460c-b9ec-59cef4f3f597"], "package_ndc": ["0641-6261-01"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-171-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020712"], "brand_name": ["CARBATROL"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["54092-171", "54092-172", "54092-173"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["200131", "200133", "308977", "313931", "388311", "404742"], "spl_id": ["39171a32-c78d-4130-be53-638e19cf2261"], "spl_set_id": ["bc03e499-5bac-4293-bff4-6864153a624d"], "package_ndc": ["54092-171-12", "54092-172-12", "54092-173-12"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "12/19/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-004-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X2ML)  is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-0167-13", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/12/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-13)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8213-05", "generic_name": "Insulin Lispro Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["BLA020563"], "brand_name": ["HUMALOG TEMPO PEN"], "generic_name": ["INSULIN LISPRO"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8213", "0002-7510", "0002-7533", "0002-8799", "0002-7516", "0002-7714", "0002-0800", "0002-7712", "0002-8208"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN LISPRO"], "rxcui": ["242120", "865098", "1652239", "1652242", "1652639", "1652640", "1652644", "1652646", "1926331", "1926332", "2621571", "2621572"], "spl_id": ["d0a38a0f-9d29-44eb-bfd1-c83cbcba1008"], "spl_set_id": ["c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f"], "package_ndc": ["0002-7510-01", "0002-7510-17", "0002-7510-99", "0002-7533-01", "0002-8799-01", "0002-8799-59", "0002-8799-61", "0002-7516-01", "0002-7516-59", "0002-7516-99", "0002-7714-01", "0002-7714-59", "0002-7714-61", "0002-8213-01", "0002-8213-05", "0002-0800-01", "0002-7712-01", "0002-7712-27", "0002-7712-61", "0002-8208-01", "0002-8208-27"], "nui": ["N0000004931", "N0000175453"], "pharm_class_cs": ["Insulin [Chemical/Ingredient]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["059QF0KO0R", "GFX7QIS1II"]}, "update_date": "10/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-288", "63323-286", "63323-287", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/13/2017", "package_ndc": "83301-0081-2", "generic_name": "Bumetanide Injection", "contact_info": "800-673-9839", "availability": "Limited Availability", "related_info": "Additional lots are currently in the manufacturing process and will be available upon release.", "openfda": {"application_number": ["ANDA219116"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Mullan Pharmaceutical Inc."], "product_ndc": ["83301-0081", "83301-0080"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["4c241a3e-649b-4414-e063-6294a90a3a32"], "spl_set_id": ["b7cd724b-817b-4b45-8133-1ebf505867e7"], "package_ndc": ["83301-0080-1", "83301-0080-2", "83301-0081-1", "83301-0081-2"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)", "company_name": "Mullan Pharmaceutical Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/04/2024", "package_ndc": "0591-2888-30", "generic_name": "Hydroxocobalamin Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: June 2026", "openfda": {"application_number": ["ANDA085998"], "brand_name": ["HYDROXOCOBALAMIN"], "generic_name": ["HYDROXOCOBALAMIN"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2888"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["HYDROXOCOBALAMIN ACETATE"], "rxcui": ["317106"], "spl_id": ["c47477bf-6413-4699-ab77-c5441a9d1557"], "spl_set_id": ["a3087a39-f218-4f16-a1e7-17c39bb2eb69"], "package_ndc": ["0591-2888-30"], "unii": ["S535M27N3Q"]}, "update_date": "05/01/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0373-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0373", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2868", "0781-2859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0535-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 40 mg (NDC 0071-0535-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "47335-932-44", "generic_name": "Vecuronium Bromide Injection", "contact_info": "800-818-4555", "related_info": "The 10 mg presentation remains available.", "openfda": {"application_number": ["ANDA079001"], "brand_name": ["VECURONIUM BROMIDE"], "generic_name": ["VECURONIUM BROMIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-932", "47335-931"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VECURONIUM BROMIDE"], "rxcui": ["859437"], "spl_id": ["82d6bc45-04a5-409a-9223-da1884b2468f"], "spl_set_id": ["a14da3ee-a731-4282-be9d-407473517470"], "package_ndc": ["47335-931-40", "47335-931-44", "47335-932-40", "47335-932-44"], "unii": ["7E4PHP5N1D"]}, "update_date": "09/08/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Vecuronium Bromide, Injection, 20 mg (NDC 47335-932-44)", "company_name": "Sun Pharmaceutical Industries Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6041-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA075772"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6041", "0641-6043", "0641-6042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["25d6c438-45d2-4162-91c2-b5caa0f86bf3"], "spl_set_id": ["0c2c75c9-ed7b-46a8-9543-429bf2d8f090"], "package_ndc": ["0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "0069-3150-83", "generic_name": "Azithromycin Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA050733"], "brand_name": ["ZITHROMAX"], "generic_name": ["AZITHROMYCIN DIHYDRATE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-3150"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AZITHROMYCIN DIHYDRATE"], "rxcui": ["1668238", "1668240"], "spl_id": ["b0eb7eb4-90fe-4add-a327-e8be68165a3b"], "spl_set_id": ["3b631aa1-2d46-40bc-a614-d698301ea4f9"], "package_ndc": ["0069-3150-84", "0069-3150-83"], "unii": ["5FD1131I7S"]}, "update_date": "01/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/28/2025", "update_type": "New", "initial_posting_date": "05/28/2025", "package_ndc": "0472-0804-60", "generic_name": "Desonide Cream", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA019048"], "brand_name": ["DESONIDE"], "generic_name": ["DESONIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-0804", "0472-0803"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DESONIDE"], "rxcui": ["197572", "349351"], "spl_id": ["f3953b9e-138f-4d86-8eea-0fc03c3c2747"], "spl_set_id": ["ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99"], "package_ndc": ["0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["J280872D1O"]}, "update_date": "05/28/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Cream", "presentation": "Desowen, Cream, .5 mg/1 g (NDC 0472-0804-60)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6039-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May 2026 timeframe.", "openfda": {"application_number": ["NDA018565"], "brand_name": ["INFUMORPH 200"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6039", "0641-6040"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892652", "1731522", "1731998", "1731999"], "spl_id": ["b1c060cb-5c5b-495f-90b5-044e04f2a3f2"], "spl_set_id": ["db9ac9e3-d761-4a99-9f34-4946ebe8f255"], "package_ndc": ["0641-6039-01", "0641-6040-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/10/2025", "update_type": "New", "initial_posting_date": "10/10/2025", "package_ndc": "0781-3519-90", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214657"], "brand_name": ["PEMETREXED"], "generic_name": ["PEMETREXED DISODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3519", "0781-3518", "0781-3520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PEMETREXED DISODIUM"], "rxcui": ["2602363", "2602365", "2602366"], "spl_id": ["764ab64b-c642-4314-83a9-efee79fe83a3"], "spl_set_id": ["7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3"], "package_ndc": ["0781-3518-76", "0781-3519-90", "0781-3520-91"], "unii": ["2PKU919BA9"]}, "update_date": "10/10/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Pemetrexed Disodium, Injection, 500 mg/20 mL (NDC 0781-3519-90)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-7201-10", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7201", "0093-0771", "0093-7202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0093-3750-28", "generic_name": "Tobramycin Solution", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210915"], "brand_name": ["TOBRAMYCIN"], "generic_name": ["TOBRAMYCIN"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3750"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["TOBRAMYCIN"], "rxcui": ["1314763"], "spl_id": ["8aa98982-a156-4bc8-8d31-9a39b88808ed"], "spl_set_id": ["d03079d2-5617-4628-92b9-3caa757b22c0"], "package_ndc": ["0093-3750-28", "0093-3750-63"], "nui": ["N0000175477", "M0000946"], "pharm_class_epc": ["Aminoglycoside Antibacterial [EPC]"], "pharm_class_cs": ["Aminoglycosides [CS]"], "unii": ["VZ8RRZ51VK"]}, "update_date": "06/16/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-28)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)", "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7810-22", "generic_name": "Dopamine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6026-05", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-402-05", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA206935"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Ingenus Pharmaceuticals, LLC"], "product_ndc": ["50742-402", "50742-401"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["3c841594-8a93-4728-b184-0f4bfac73390"], "spl_set_id": ["d04f2471-3085-4fc8-a657-bb3918d48e6e"], "package_ndc": ["50742-401-02", "50742-402-05"], "unii": ["042LAQ1IIS"]}, "update_date": "02/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-344-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-344", "42806-339", "42806-341", "42806-343", "42806-345"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "66993-066-02", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 66993-066-02)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "76329-3340-1", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": {"application_number": ["ANDA212461"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-3340"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546"], "spl_id": ["697aa53c-f31f-463a-a752-d2faaad354db"], "spl_set_id": ["b72d0a82-6163-460f-965a-12f6da47370a"], "package_ndc": ["76329-3340-1"], "unii": ["03J5ZE7KA5"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-02", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d"], "spl_set_id": ["3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75"], "package_ndc": ["63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-150-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-150", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 150 ug (NDC 72305-150-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-495-07", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-0154-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA202608"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-0154", "0406-0127", "0406-0136"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001565", "2001566", "2001568"], "spl_id": ["7a3a8731-e545-455e-83c3-888f4923e901"], "spl_set_id": ["b1b0f2ff-d9df-42ab-b471-226ecf97e075"], "package_ndc": ["0406-0127-01", "0406-0136-01", "0406-0154-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 54 mg (NDC 0406-0154-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-115-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-115", "57844-105", "57844-117", "57844-110", "57844-112", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-206-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care de Mexico, S.A. de C.V."], "product_ndc": ["46163-206", "46163-209", "46163-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["444fd7c1-1ed5-25c7-e063-6394a90a3bfe"], "spl_set_id": ["a98facd6-9daa-4d37-8209-63a0599dbfaa"], "package_ndc": ["46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/04/2025", "update_type": "New", "initial_posting_date": "12/04/2025", "package_ndc": "0093-7353-01", "generic_name": "Calcitriol Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug", "openfda": {"application_number": ["ANDA075765"], "brand_name": ["CALCITRIOL"], "generic_name": ["CALCITRIOL"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7353", "0093-7352"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CALCITRIOL"], "rxcui": ["308867", "308868"], "spl_id": ["9e6df585-e3d1-4a89-bc02-8e4b223578c4"], "spl_set_id": ["ec93b667-aad2-4e3a-adc6-952f070a0c0a"], "package_ndc": ["0093-7352-01", "0093-7353-01"], "nui": ["M0004229", "N0000175908"], "pharm_class_cs": ["Cholecalciferol [CS]"], "pharm_class_epc": ["Vitamin D3 Analog [EPC]"], "unii": ["FXC9231JVH"]}, "update_date": "12/04/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Calcitriol, Capsule, .5 ug (NDC 0093-7353-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "72572-076-24", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "related_info": "Civica Label", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Civica, Inc."], "product_ndc": ["72572-076", "72572-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336"], "spl_id": ["e40b6e7f-1d37-4d0a-ace3-e5accc461e02"], "spl_set_id": ["80217bd6-2bc4-401c-9345-22532b36a24f"], "package_ndc": ["72572-074-01", "72572-074-24", "72572-076-01", "72572-076-24"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-406", "43547-407", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "0409-1985-30", "generic_name": "Lorazepam Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA074243"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1985", "0409-1539"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["763028", "763029"], "spl_id": ["e90a536c-421f-4774-8f88-013e18a8163e"], "spl_set_id": ["20140b19-846b-425f-b191-670e17809945"], "package_ndc": ["0409-1539-03", "0409-1539-31", "0409-1985-03", "0409-1985-30"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "44567-611-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-493-0861", "availability": "Available", "related_info": "Please check wholesalers and distributors for inventory.", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)", "company_name": "WG Critical Care", "status": "Current", "source": "drug_shortages"}
{"presentation": "Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1560-29", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "16729-138-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-138", "16729-136", "16729-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 16729-138-00)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-1630-10", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: July 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA021146"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1630", "0409-9630", "0409-4910", "0409-4911"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["ab573c15-9504-48d1-bf4a-d8b8d7ae748a"], "spl_set_id": ["ad8916e7-206e-409e-2582-30d072845dd4"], "package_ndc": ["0409-1630-15", "0409-1630-10", "0409-9630-15", "0409-9630-05", "0409-4910-11", "0409-4910-34", "0409-4911-11", "0409-4911-34"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/06/2026", "update_type": "New", "initial_posting_date": "05/06/2026", "package_ndc": "0409-1103-01", "generic_name": "Cisatracurium Besylate Injection", "contact_info": "844-646-4398", "related_info": "Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203236"], "brand_name": ["CISATRACURIUM BESYLATE"], "generic_name": ["CISATRACURIUM BESYLATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1103", "0409-1098", "0409-1208"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CISATRACURIUM BESYLATE"], "rxcui": ["199211", "199212", "1730194"], "spl_id": ["0ec666c8-db68-4a59-9da4-e0abd8e209c5"], "spl_set_id": ["67908e20-044d-454d-9c51-bf106e817bd0"], "package_ndc": ["0409-1098-12", "0409-1098-02", "0409-1103-11", "0409-1103-01", "0409-1208-11", "0409-1208-01"], "unii": ["80YS8O1MBS"]}, "update_date": "05/06/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/01/2025", "update_type": "New", "initial_posting_date": "07/01/2025", "package_ndc": "64950-217-10", "generic_name": "Isoniazid Tablet", "contact_info": "610-782-9780", "related_info": "Product expected to be available until August 2025.", "openfda": {"application_number": ["ANDA080937"], "brand_name": ["ISONIAZID"], "generic_name": ["ISONIAZID"], "manufacturer_name": ["Genus Lifesciences"], "product_ndc": ["64950-217", "64950-216"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ISONIAZID"], "rxcui": ["197832", "311166"], "spl_id": ["6ea58bc8-a5a8-47a1-81e1-f769924e1502"], "spl_set_id": ["f0b46d1d-2300-457d-a7bd-a88a3f8d2235"], "package_ndc": ["64950-216-10", "64950-217-03", "64950-217-10"], "nui": ["N0000175483"], "pharm_class_epc": ["Antimycobacterial [EPC]"], "unii": ["V83O1VOZ8L"]}, "update_date": "07/01/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Isoniazid, Tablet, 300 mg (NDC 64950-217-10)", "company_name": "Genus Lifesciences", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4276-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088299"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4276", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-165-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-165", "42858-161", "42858-162", "42858-163", "42858-164", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2023", "package_ndc": "63323-604-01", "generic_name": "Propranolol Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075826"], "brand_name": ["PROPRANOLOL"], "generic_name": ["PROPRANOLOL HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-604"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PROPRANOLOL HYDROCHLORIDE"], "rxcui": ["856443"], "spl_id": ["505851c4-b18c-4cd7-805c-4e923cc1fa7e"], "spl_set_id": ["f14ea537-dd5c-4c78-9037-9a85e9e610ef"], "package_ndc": ["63323-604-01"], "unii": ["F8A3652H1V"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/29/2025", "update_type": "New", "initial_posting_date": "12/29/2025", "package_ndc": "69238-2391-1", "generic_name": "Sodium Oxybate Solution", "contact_info": "800-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/29/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Solution", "presentation": "Sodium Oxybate, Solution, .5 g/1 mL (NDC 69238-2391-1)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "64850-300-30", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-300"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["cae1ac14-ab22-42d1-8449-5e36c137b905"], "spl_set_id": ["5f188bdc-2009-43aa-ad32-f06dbfac2642"], "package_ndc": ["64850-300-30", "64850-300-01"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 64850-300-30)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5315-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5315", "0245-5316"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-01)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "54288-167-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC", "openfda": {"application_number": ["ANDA207324"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["BPI Labs LLC"], "product_ndc": ["54288-167", "54288-165", "54288-166", "54288-164"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["c0a7463c-d90f-4060-a54e-6a4888e8af0e"], "spl_set_id": ["5484d2f0-0cc2-4bba-8f26-c7f6539a9606"], "package_ndc": ["54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-0111-03", "generic_name": "Amantadine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076186"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0111"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849395"], "spl_id": ["45af44df-1a9b-32b6-e063-6394a90acdaf"], "spl_set_id": ["63d9d4aa-5f92-45b0-98d0-d6ec38b727cb"], "package_ndc": ["0832-0111-00", "0832-0111-50", "0832-0111-89", "0832-0111-03"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Tablet", "presentation": "Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-03)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9930-10", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA065072"], "brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9930", "0143-9931", "0143-9933"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["309068", "1656313", "1656318"], "spl_id": ["7e0897ec-2275-4438-9cc5-4c951e52ad97"], "spl_set_id": ["ed23b6bc-32c7-4c50-a53d-313ae78e5623"], "package_ndc": ["0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10"], "unii": ["258J72S7TZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-152", "72888-153", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-30)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "0378-4430-01", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "1-844-874-7464", "availability": "Unavailable", "related_info": "Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.", "update_date": "01/14/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)", "company_name": "Rising Pharma Holdings, Inc.", "shortage_reason": "Regulatory delay", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "0409-5160-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5160", "0409-1403"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["f01f9986-43f9-40e8-9506-11bfe78f9242"], "spl_set_id": ["f01f9986-43f9-40e8-9506-11bfe78f9242"], "package_ndc": ["0409-1403-05", "0409-1403-10", "0409-5160-01", "0409-5160-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0016-12", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0016", "0009-0825", "0009-0011", "0009-0013", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-114-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-114", "70010-111", "70010-112", "70010-113", "70010-115", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-107-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-107", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 70 mg (NDC 59417-107-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0776-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0776", "0555-0971", "0555-0775", "0555-0972", "0555-0777", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0832-0273-11", "generic_name": "Morphine Sulfate Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210610"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0273", "0832-0274"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892582", "892672"], "spl_id": ["46a682fc-0430-5a66-e063-6294a90a6179"], "spl_set_id": ["5ceb3205-2f8d-4ba3-9f27-dc328bab4fa1"], "package_ndc": ["0832-0273-11", "0832-0274-11"], "unii": ["X3P646A2J0"]}, "update_date": "12/22/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "54288-164-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC;  Customer service number:  (727) 471-0850 Ext 270", "availability": "Unavailable", "related_info": "Discontinued; Distributed by BPI Labs, LLC", "openfda": {"application_number": ["ANDA207324"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["BPI Labs LLC"], "product_ndc": ["54288-164", "54288-165", "54288-166", "54288-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["c0a7463c-d90f-4060-a54e-6a4888e8af0e"], "spl_set_id": ["5484d2f0-0cc2-4bba-8f26-c7f6539a9606"], "package_ndc": ["54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/09/2026", "update_type": "New", "initial_posting_date": "01/09/2026", "package_ndc": "63323-469-05", "generic_name": "Haloperidol Decanoate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074893"], "brand_name": ["HALOPERIDOL DECANOATE"], "generic_name": ["HALOPERIDOL DECANOATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-469", "63323-471"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["HALOPERIDOL DECANOATE"], "rxcui": ["859867", "859871", "1719803", "1719862"], "spl_id": ["86dff2aa-2ab3-42fc-989e-619b13ace573"], "spl_set_id": ["ca9896e0-fb2e-46a4-8700-20d144c14764"], "package_ndc": ["63323-469-01", "63323-469-05", "63323-471-01", "63323-471-05"], "unii": ["AC20PJ4101"]}, "update_date": "01/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Injection", "presentation": "Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-5212-23", "generic_name": "Hydrochlorothiazide; Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 12.5 mg; 20 mg (NDC 0071-5212-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-162-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075784"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-162", "63323-161"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4"], "spl_set_id": ["ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c"], "package_ndc": ["63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4276-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088299"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4276", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4745-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4745", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4744"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "43066-015-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-015", "43066-019", "43066-023", "43066-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734084", "1734207", "1734475", "1734483"], "spl_id": ["a8d08579-825f-40d9-b1e3-e47b73765ae6"], "spl_set_id": ["781d4b7f-7556-4695-8d48-7772d7a0d8e9"], "package_ndc": ["43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10"], "unii": ["V910P86109"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)", "company_name": "Caplin Steriles, Ltd.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0487-6105-01", "generic_name": "Sterile Water Injection", "contact_info": "800-443-4313", "availability": "Unavailable", "related_info": "Product can be manufactured as requested", "openfda": {"application_number": ["ANDA211222"], "brand_name": ["STERILE WATER"], "generic_name": ["STERILE WATER"], "manufacturer_name": ["Nephron Pharmaceuticals Corporation"], "product_ndc": ["0487-6105"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["39ada97d-53b0-5144-e063-6294a90a91ba"], "spl_set_id": ["bc04a883-babc-87a6-e053-2995a90a3dfd"], "package_ndc": ["0487-6105-01"], "unii": ["059QF0KO0R"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)", "company_name": "Nephron Pharmaceuticals Corporation", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-430-01", "generic_name": "Decitabine Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Decitabine, Injection, 50 mg (NDC 50742-430-01)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "25021-700-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-700", "25021-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["cb23332a-48fa-458b-93ab-c4eef189a051"], "spl_set_id": ["62591551-a644-4b2c-a0de-982e906fabc3"], "package_ndc": ["25021-700-01", "25021-701-01", "25021-701-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-026-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-026", "65162-023", "65162-024", "65162-025", "65162-027", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1181-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021171"], "brand_name": ["DEMEROL"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1181", "0409-1176", "0409-1178", "0409-1179", "0409-1180", "0409-1362", "0409-1418"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192"], "spl_id": ["c1704eaf-f0a8-4ba3-89a1-2836ba7e5ee6"], "spl_set_id": ["b31d1308-28c3-43f4-e0a6-2f3ed76b8975"], "package_ndc": ["0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01"], "unii": ["N8E7F7Q170"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-8035-01", "generic_name": "Glyburide Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074686"], "brand_name": ["GLYBURIDE"], "generic_name": ["GLYBURIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8035", "0093-8034", "0093-8036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLYBURIDE"], "rxcui": ["310536", "310539", "314000"], "spl_id": ["d734cd0e-df7b-40a2-a511-fc04308a764d"], "spl_set_id": ["e84c0dfc-a4e9-4c89-b6ea-45732eb412f5"], "package_ndc": ["0093-8034-01", "0093-8035-01", "0093-8035-05", "0093-8036-01"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["SX6K58TVWC"]}, "update_date": "06/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0062-30", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0062", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0078", "0338-0074", "0338-0066", "0338-0070", "0338-0082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["66eb82f8-6755-42aa-b20c-192a640e8068"], "spl_set_id": ["36e9478c-5df0-4b47-b97d-de3626d7cb29"], "package_ndc": ["0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0591-5553-05", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA062421"], "brand_name": ["DOXYCYCLINE HYCLATE"], "generic_name": ["DOXYCYCLINE HYCLATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5553"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DOXYCYCLINE HYCLATE"], "rxcui": ["1650143"], "spl_id": ["0fb9a3f8-9ebb-4c21-8a73-9f082b39039c"], "spl_set_id": ["a569ba80-ffea-40b2-9fbe-a42810b1fccb"], "package_ndc": ["0591-5553-50", "0591-5553-05"], "unii": ["19XTS3T51U"]}, "update_date": "06/13/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-209-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care Renal Therapies Group, LLC"], "product_ndc": ["49230-209", "49230-206", "49230-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["44506bb0-e5f3-2a05-e063-6294a90ab2c9", "43cd31e0-97ed-1eeb-e063-6294a90a0b3d"], "spl_set_id": ["bbc5b820-4973-11e2-a192-0002a5d5c51b", "c29bdfa0-4976-11e2-939b-0002a5d5c51b"], "package_ndc": ["49230-206-20", "49230-206-30", "49230-206-32", "49230-206-50", "49230-206-60", "49230-206-62", "49230-206-52", "49230-209-23", "49230-209-30", "49230-209-32", "49230-209-50", "49230-209-60", "49230-209-62", "49230-209-52", "49230-212-23", "49230-212-30", "49230-212-32", "49230-212-50", "49230-212-60", "49230-212-62", "49230-212-52", "49230-206-92", "49230-206-94", "49230-206-95", "49230-209-92", "49230-209-94", "49230-209-95", "49230-212-92", "49230-212-94", "49230-212-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3443-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": {"application_number": ["ANDA206812"], "brand_name": ["FONDAPARINUX SODIUM"], "generic_name": ["FONDAPARINUX SODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3443", "0781-3454", "0781-3465", "0781-3476"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FONDAPARINUX SODIUM"], "rxcui": ["861356", "861360", "861363", "861365"], "spl_id": ["3d5a4b69-462b-7e51-e063-6294a90a0721"], "spl_set_id": ["baa50757-a927-4d56-a933-5d7798fe6ab0"], "package_ndc": ["0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95"], "unii": ["X0Q6N9USOZ"]}, "update_date": "09/29/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-068-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-073", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-161-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA075784"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-161", "63323-162"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4"], "spl_set_id": ["ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c"], "package_ndc": ["63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0532-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 20 mg (NDC 0071-0532-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-251-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202881"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-251"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["7c66a6ac-0548-4555-b9d1-077feb277c37"], "spl_set_id": ["ebdfe2e8-30ca-4f18-935a-41bcbbce4937"], "package_ndc": ["67457-251-00", "67457-251-02"], "unii": ["1018WH7F9I"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6003-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["ATIVAN"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6003", "0641-6002", "0641-6001", "0641-6000"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327"], "spl_id": ["209b0091-c890-4f69-a693-d0594c2606fe"], "spl_set_id": ["5fc0e987-61c9-40c4-b0d5-fcea07c8733e"], "package_ndc": ["0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "0228-2801-11", "generic_name": "Pilocarpine Hydrochloride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA020237"], "brand_name": ["PILOCARPINE HYDROCHLORIDE"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2801", "0228-2837"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "rxcui": ["1000913", "1001004"], "spl_id": ["7db72b88-d664-4f26-901c-46c901b20d80"], "spl_set_id": ["610022b7-7dc9-405a-a580-104657f43bdf"], "package_ndc": ["0228-2801-11", "0228-2837-11"], "unii": ["0WW6D218XJ"]}, "update_date": "09/19/2025", "therapeutic_category": ["Other"], "dosage_form": "Tablet", "presentation": "Salagen, Tablet, 5 mg (NDC 0228-2801-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6637-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202494"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6637", "0409-4916"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["727995", "792582"], "spl_id": ["f79ec8cb-b6a3-4ffb-bccf-d39f59d65621"], "spl_set_id": ["ea20a5eb-641e-48cd-bcfa-74c04c45dfda"], "package_ndc": ["0409-4916-24", "0409-4916-14", "0409-6637-24", "0409-6637-14"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0502-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA020512"], "brand_name": ["CLINISOL"], "generic_name": ["LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0502"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["800584", "800588"], "spl_id": ["7eab93b5-5590-4381-8674-113a05edeff0"], "spl_set_id": ["65ffc962-7538-41ea-9afb-4af5fbce4c5b"], "package_ndc": ["0338-0502-03", "0338-0502-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43598-976-58", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "Distributed by DRL", "availability": "Available", "related_info": "Distributed by DRL", "openfda": {"application_number": ["ANDA209307"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Dr.Reddy's Laboratories Inc"], "product_ndc": ["43598-976", "43598-975"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["5785a11f-7784-4ae0-8029-f50b782eaf4a"], "spl_set_id": ["d174c19d-56f1-4ef4-087c-23c26db8e40b"], "package_ndc": ["43598-976-11", "43598-976-58", "43598-975-11", "43598-975-58"], "unii": ["1018WH7F9I"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/27/2025", "update_type": "New", "initial_posting_date": "08/27/2025", "package_ndc": "0409-2344-88", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074086"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["e71e9520-871b-479d-9652-1857fceca863", "5d6b1dfe-d679-4aea-97a6-3d074a202afe"], "spl_set_id": ["dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58"], "package_ndc": ["0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88"], "unii": ["0WR771DJXV"]}, "update_date": "08/27/2025", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-700-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["NDA216117"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-700", "13811-711"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2605796", "2605798"], "spl_id": ["ba649db4-df0d-4587-8370-3f866e66e54b"], "spl_set_id": ["dd8d7b6e-c23d-4e16-bb53-959e9127ebc6"], "package_ndc": ["13811-711-30", "13811-700-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9311-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Novaplus label", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9311", "0143-9310"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["c15bd8c1-34e3-40f2-b31a-634136fe197c"], "spl_set_id": ["4312e3c3-34de-4cb3-8abd-c24d24a4bea1"], "package_ndc": ["0143-9310-01", "0143-9310-10", "0143-9311-01", "0143-9311-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1312-36", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1312", "0409-1283", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-343-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-343", "42806-339", "42806-341", "42806-344", "42806-345"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "43066-007-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA091115"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-007", "43066-013"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["9e0317de-2d78-4fd8-8926-4c7b476f3ed4"], "spl_set_id": ["31e15c3f-aefa-4379-b684-7707744fe40d"], "package_ndc": ["43066-007-10", "43066-013-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0002-8011-27", "generic_name": "Mirikizumab-mrkz Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.", "openfda": {"application_number": ["BLA761279"], "brand_name": ["OMVOH"], "generic_name": ["MIRIKIZUMAB-MRKZ"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8011", "0002-7575", "0002-8870", "0002-7717", "0002-7722", "0002-3116", "0002-1442"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["MIRIKIZUMAB"], "rxcui": ["2668391", "2668398", "2668405", "2668410", "2680728", "2680732", "2703047", "2703048", "2703049", "2703050", "2703051", "2703052", "2703053", "2703054"], "spl_id": ["e1015232-2dfd-4b5d-b1d0-e0302e49c55a"], "spl_set_id": ["472cbe04-263e-433d-9a0f-58c1b50b715a"], "package_ndc": ["0002-7575-01", "0002-8011-01", "0002-8011-27", "0002-8011-61", "0002-8870-01", "0002-8870-27", "0002-7717-11", "0002-7717-61", "0002-3116-01", "0002-7722-11", "0002-1442-01", "0002-3116-11", "0002-3116-61", "0002-1442-11"], "nui": ["N0000192799", "N0000192798"], "pharm_class_epc": ["Interleukin-23 Antagonist [EPC]"], "pharm_class_moa": ["Interleukin-23 Antagonists [MoA]"], "unii": ["Z7HVY03PHP"]}, "update_date": "12/22/2025", "therapeutic_category": ["Gastroenterology", "Other"], "dosage_form": "Injection", "presentation": "Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-034-01", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["NDA020630"], "brand_name": ["ULTIVA"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["72078-034", "72078-035", "72078-036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729581", "1729584", "1729586", "1729710", "1729712"], "spl_id": ["594087a1-25f2-4f68-aea6-ad7df40559ab"], "spl_set_id": ["8b4c8696-e23e-4c51-a4d2-babab5bd945a"], "package_ndc": ["72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05"], "unii": ["5V444H5WIC"]}, "update_date": "05/05/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-421-30", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA040803"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-421", "67457-423", "67457-422", "67457-420"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["dd5c82b6-a194-462c-9626-34a9b410cfea"], "spl_set_id": ["dff598e8-e662-411f-978d-4ba3fb8ef7db"], "package_ndc": ["67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5113-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Unavailable", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5113", "0406-5111", "0406-5112", "0406-5114", "0406-5115", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "70069-752-25", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": {"application_number": ["ANDA217792"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-752", "70069-753"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["2b24af95-6f20-4945-bf8c-742f1d6f2721"], "spl_set_id": ["bcaab86f-20f0-4482-8d73-e29b36dced58"], "package_ndc": ["70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-04", "generic_name": "Furosemide Injection", "contact_info": "Sagent Pharmaceuticals: 866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0011-04", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0011", "0009-0825", "0009-0013", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-495-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0766-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Limited Availability", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0766", "0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0764", "0527-0765"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)", "company_name": "Lannett Company, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0781-3220-92", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA079195"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3220"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["eaf32464-7950-434a-e053-2a95a90aa2dc"], "spl_set_id": ["cb28d869-6510-4402-9462-f6bb25fa0fa8"], "package_ndc": ["0781-3220-70", "0781-3220-92", "0781-3220-75", "0781-3220-95"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "72205-101-01", "generic_name": "Bumetanide Injection", "contact_info": "Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA215364"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-101", "72205-102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "spl_set_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "package_ndc": ["72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/02/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)", "company_name": "MSN Laboratories Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-052-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-052", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4661-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3570-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3570", "0480-3565", "0480-3566", "0480-3567", "0480-3568", "0480-3569", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-310-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA091695"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["62175-310", "62175-311", "62175-312", "62175-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001564", "2001565", "2001566", "2001568"], "spl_id": ["8b133cd2-e3c6-4742-b402-2393b56ffc93"], "spl_set_id": ["3d1f5aff-5d39-496c-b5ed-7f3c70ec641c"], "package_ndc": ["62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37"], "unii": ["4B3SC438HI"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/08/2025", "update_type": "New", "initial_posting_date": "07/08/2025", "package_ndc": "0409-1893-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1893", "0409-1890", "0409-1891", "0409-1892", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "07/08/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3984-05", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3984", "0591-3982", "0591-3983", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 200 mg (NDC 0591-3984-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1005-03", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA019615"], "brand_name": ["DOPAMINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1005", "0338-1007", "0338-1009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1292887", "1743869", "1743871", "1743877", "1743879"], "spl_id": ["edc9a091-4cb5-4ec7-b6f9-44d2d588bab9"], "spl_set_id": ["cb97d4a0-89ed-407c-a763-209386b6f75c"], "package_ndc": ["0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02"], "unii": ["7L3E358N9L"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-02", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: July 2026; Estimated Recovery: September 2026; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089644"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-42", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-473"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c14acada-333e-43bb-b1cf-81d569e3e918"], "spl_set_id": ["1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec"], "package_ndc": ["23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-852-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-852", "63323-851", "63323-853", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "68025-096-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-096", "68025-088", "68025-089", "68025-095", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0078-0406-05", "generic_name": "Amlodipine Besylate; Benazepril Hydrochloride Capsule", "contact_info": "888-669-6682", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA020364"], "brand_name": ["LOTREL"], "generic_name": ["AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "product_ndc": ["0078-0406", "0078-0405", "0078-0364", "0078-0379"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMLODIPINE BESYLATE", "BENAZEPRIL HYDROCHLORIDE"], "rxcui": ["898342", "898344", "898346", "898348", "898353", "898355", "898356", "898358"], "spl_id": ["b9db75d9-9d1e-4b2d-9876-5f5520feaecc"], "spl_set_id": ["94ae6054-b7ae-4212-a567-4f803af8f2c7"], "package_ndc": ["0078-0405-05", "0078-0406-05", "0078-0364-05", "0078-0379-05"], "unii": ["864V2Q084H", "N1SN99T69T"]}, "update_date": "06/24/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Lotrel, Capsule, 5 mg; 20 mg (NDC 0078-0406-05)", "company_name": "Novartis Pharmaceuticals Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6005-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA213784"], "brand_name": ["FLUPHENAZINE HYDROCHLORIDE"], "generic_name": ["FLUPHENAZINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories,LLC"], "product_ndc": ["0832-6005", "0832-6004", "0832-6003", "0832-6006"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUPHENAZINE HYDROCHLORIDE"], "rxcui": ["859841", "860918", "865117", "865123"], "spl_id": ["3bb74f82-8872-9829-e063-6294a90aeace"], "spl_set_id": ["f07bb3f1-c68c-441b-9de4-99a219f2500a"], "package_ndc": ["0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11"], "unii": ["ZOU145W1XL"]}, "update_date": "09/18/2025", "therapeutic_category": ["Neurology", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 5 mg (NDC 0832-6005-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6855-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6855", "0378-6854", "0378-6856", "0378-6857", "0378-6858", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-9137-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA040302"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9137", "0409-4903", "0409-4904", "0409-1323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1012066", "1012068"], "spl_id": ["b386f7fc-ec89-4d73-aba6-2019a9cb1d4a"], "spl_set_id": ["ad1ef0a8-88db-4648-c098-d009eaeb4e5b"], "package_ndc": ["0409-4903-11", "0409-4903-34", "0409-4904-11", "0409-4904-34", "0409-1323-15", "0409-1323-05", "0409-9137-11", "0409-9137-05"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-473-64", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-473", "61314-454", "61314-476", "61314-509", "61314-517", "61314-531"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ADALIMUMAB"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-555-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-555", "64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-383-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/06/2018", "package_ndc": "72266-119-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["FOSUN PHARMA USA INC"], "product_ndc": ["72266-119", "72266-234", "72266-118"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["228ec94a-f777-f61b-e063-6394a90a21a5"], "spl_set_id": ["1aae6a4d-0909-4672-aa26-e3f2d8c4d413"], "package_ndc": ["72266-234-01", "72266-234-25", "72266-118-01", "72266-118-25", "72266-119-01", "72266-119-25"], "unii": ["4EVE5946BQ"]}, "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-18", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "72516-011-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Available", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-011", "72516-016", "72516-015", "72516-014", "72516-013", "72516-012"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)", "company_name": "Oryza Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-50", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-851", "63323-852", "63323-853", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "55150-297-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-7202-10", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7202", "0093-0771", "0093-7201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-604-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA201791"], "brand_name": ["LAMOTRIGINE EXTENDED RELEASE"], "generic_name": ["LAMOTRIGINE EXTENDED RELEASE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-604", "49884-561", "49884-562", "49884-563", "49884-564", "49884-605"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LAMOTRIGINE"], "rxcui": ["850087", "850091", "900156", "900164", "1098608", "1146690"], "spl_id": ["9c5e0c2a-800e-47e9-a26b-582b98a05957"], "spl_set_id": ["fb59c76a-9b6f-40ea-ac3a-58c3195c4377"], "package_ndc": ["49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05"], "nui": ["N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191"], "pharm_class_epc": ["Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]"], "unii": ["U3H27498KS"]}, "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-66", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-671", "25021-652"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-706-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-706", "13811-709", "13811-707", "13811-708", "13811-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0185-0853-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA040439"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0185-0853", "0185-0831", "0185-0842", "0185-0864", "0185-2099", "0185-2098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577961"], "spl_id": ["9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd"], "spl_set_id": ["288dafc4-fe6e-4891-832f-511022c87445"], "package_ndc": ["0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-61", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "0143-9606-01", "generic_name": "Azacitidine Injection", "contact_info": "1-800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA209337"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9606"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["592a688f-2e42-4e91-a3ea-34befe2a4e07"], "spl_set_id": ["ff73515d-bd55-4eb5-992b-d2138c80887e"], "package_ndc": ["0143-9606-01"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/12/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0395-14", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050162"], "brand_name": ["CLEOCIN HYDROCHLORIDE"], "generic_name": ["CLINDAMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0395", "0009-0331", "0009-0225"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN HYDROCHLORIDE"], "rxcui": ["197518", "284215", "309329", "748746", "748748", "748750"], "spl_id": ["51cea3cd-28cf-455e-ba27-5a0d8e052858"], "spl_set_id": ["df9a2a41-b132-4f43-8940-b2d773b1369a"], "package_ndc": ["0009-0331-02", "0009-0225-02", "0009-0395-14"], "unii": ["T20OQ1YN1W"]}, "update_date": "02/25/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/05/2026", "update_type": "New", "initial_posting_date": "01/05/2026", "package_ndc": "0093-2401-01", "generic_name": "Hydroxychloroquine Sulfate Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040081"], "brand_name": ["HYDROXYCHLOROQUINE SULFATE"], "generic_name": ["HYDROXYCHLOROQUINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-2401"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROXYCHLOROQUINE SULFATE"], "rxcui": ["979092"], "spl_id": ["0c6c28a5-e86f-4643-bb22-f7eb5b1f440d"], "spl_set_id": ["5f3e49b2-dc11-40a9-b366-c88e36a471e5"], "package_ndc": ["0093-2401-01"], "unii": ["8Q2869CNVH"]}, "update_date": "01/05/2026", "therapeutic_category": ["Anti-Infective", "Other", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Hydroxychloroquine Sulfate, Tablet, 200 mg (NDC 0093-2401-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-605-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA201791"], "brand_name": ["LAMOTRIGINE EXTENDED RELEASE"], "generic_name": ["LAMOTRIGINE EXTENDED RELEASE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-605", "49884-561", "49884-562", "49884-563", "49884-564", "49884-604"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LAMOTRIGINE"], "rxcui": ["850087", "850091", "900156", "900164", "1098608", "1146690"], "spl_id": ["9c5e0c2a-800e-47e9-a26b-582b98a05957"], "spl_set_id": ["fb59c76a-9b6f-40ea-ac3a-58c3195c4377"], "package_ndc": ["49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05"], "nui": ["N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191"], "pharm_class_epc": ["Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]"], "unii": ["U3H27498KS"]}, "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/17/2023", "change_date": "01/27/2026", "package_ndc": "68308-115-01", "generic_name": "Methamphetamine Hydrochloride Tablet", "contact_info": "866-732-3952", "resolved_note": "Available", "openfda": {"application_number": ["ANDA091189"], "brand_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "generic_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "manufacturer_name": ["Mayne Pharma Commercial LLC"], "product_ndc": ["68308-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "rxcui": ["977860"], "spl_id": ["ffc2cd39-e42b-5821-e053-6394a90a9974"], "spl_set_id": ["f31f580f-1f08-4a0f-b078-0b9e3308f712"], "package_ndc": ["68308-115-01"], "unii": ["997F43Z9CV"]}, "update_date": "01/27/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 68308-115-01)", "company_name": "Dr. Reddy's Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-21", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-288", "63323-286", "63323-287", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-10", "generic_name": "Furosemide Injection", "contact_info": "866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0007-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 0378-0007-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-485-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3815-12", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: June 2026; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA073510"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3815", "0409-3814"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1728783", "1728800"], "spl_id": ["0a2ba20b-448f-4412-9899-b82040ebfa7d"], "spl_set_id": ["1d181906-f3ec-4222-1883-e61577a3122e"], "package_ndc": ["0409-3814-11", "0409-3814-12", "0409-3815-11", "0409-3815-12"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7767-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210050"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7767", "0093-7766", "0093-7768", "0093-7769"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["aa521933-950a-441b-9146-93e479a4dde7"], "spl_set_id": ["e3bca36b-29ed-4a2b-a1be-a57b6af805f6"], "package_ndc": ["0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "03/02/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 0093-7767-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9933-25", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA065072"], "brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9933", "0143-9931", "0143-9930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["309068", "1656313", "1656318"], "spl_id": ["7e0897ec-2275-4438-9cc5-4c951e52ad97"], "spl_set_id": ["ed23b6bc-32c7-4c50-a53d-313ae78e5623"], "package_ndc": ["0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10"], "unii": ["258J72S7TZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0990-4179-05", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-4179-05", "openfda": {"application_number": ["NDA019492"], "brand_name": ["AMINOSYN-PF"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-4179"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["800341", "800345"], "spl_id": ["2d8f2280-bc20-45ba-bdf3-12c055684017"], "spl_set_id": ["46e74ce4-cd7e-437f-bf54-ca9b98eb2663"], "package_ndc": ["0990-4179-05"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-602-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "71288-718-11", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA213453"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-718", "71288-700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["aad39c88-2e2c-49a6-aa13-de852483661f", "37295b13-65a4-40fa-8d6c-53aeb45e2939"], "spl_set_id": ["b23aa80e-2af2-4a66-92ed-b1c8863be704", "b9abaf64-760d-43e0-8669-a9ca70feab11"], "package_ndc": ["71288-700-91", "71288-700-92", "71288-718-91", "71288-718-92", "71288-700-05", "71288-700-06", "71288-718-10", "71288-718-11"], "unii": ["I65MW4OFHZ"]}, "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0781-3220-95", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA079195"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3220"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["eaf32464-7950-434a-e053-2a95a90aa2dc"], "spl_set_id": ["cb28d869-6510-4402-9462-f6bb25fa0fa8"], "package_ndc": ["0781-3220-70", "0781-3220-92", "0781-3220-75", "0781-3220-95"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"presentation": "Adipex-P, Tablet, 37.5 mg (NDC 57844-140-01)", "discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "57844-140-01", "generic_name": "Phentermine Hydrochloride Tablet", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "update_date": "06/13/2025", "therapeutic_category": ["Other"], "status": "To Be Discontinued", "dosage_form": "Tablet", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5316-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5316", "0245-5315"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-01)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "68001-313-56", "generic_name": "Azacitidine Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA208216"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["BluePoint Laboratories"], "product_ndc": ["68001-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["36080e4e-a0fe-ba15-e063-6394a90aed5c"], "spl_set_id": ["5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a"], "package_ndc": ["68001-313-56"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 68001-313-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-6648-02", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019445"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6648", "0409-7517"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["727517", "1795514"], "spl_id": ["2f05a8f1-4651-405c-a66b-8e96a46c1db8"], "spl_set_id": ["4ed365da-4e62-4329-c1b9-c197ab4fb6e1"], "package_ndc": ["0409-7517-66", "0409-7517-16", "0409-6648-16", "0409-6648-02"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-04", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d"], "spl_set_id": ["3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75"], "package_ndc": ["63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-563-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-496-97", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE MPF"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-496", "63323-492", "63323-493"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764"], "spl_id": ["fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df"], "spl_set_id": ["d5e0d06f-ba1e-44d4-aa89-39d6c146dc23"], "package_ndc": ["63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97"], "unii": ["EC2CNF7XFP"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5168-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5168", "0603-5165", "0603-5166", "0603-5167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4910-34", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-167-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2596-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA075293"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2596", "0409-2587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["6c075a2d-b68b-41a7-aa0c-bcf9894e3f76"], "spl_set_id": ["affecd4d-1f78-4bbe-5a8d-86849bbdc520"], "package_ndc": ["0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-728-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-728", "71288-721", "71288-722", "71288-724", "71288-725", "71288-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-411-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": {"application_number": ["ANDA205823"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Solco Healthcare US, LLC"], "product_ndc": ["43547-411", "43547-410", "43547-412", "43547-413"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["b8f1731a-cbac-4f64-a8d4-320b80b335e1"], "spl_set_id": ["cd46691d-5593-4a9f-a937-999c6803e312"], "package_ndc": ["43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-4910-34", "generic_name": "Atropine Sulfate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "55150-386-01", "generic_name": "Carboplatin Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; check wholesalers for inventory", "openfda": {"application_number": ["ANDA205487"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-386", "55150-333", "55150-334", "55150-335"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["6029d051-ee8d-44cc-8dae-b91c3385d4c3", "5abfcb87-bb02-4384-9c9d-7d0e3e809311"], "spl_set_id": ["f5fe9a20-47a5-45b9-ab06-c6158d9b6aca", "5abfcb87-bb02-4384-9c9d-7d0e3e809311"], "package_ndc": ["55150-333-01", "55150-334-01", "55150-335-01", "55150-386-01", "55150-335-00", "55150-386-00"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4246-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA077269"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4246", "0703-4244", "0703-4248", "0703-4239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c"], "spl_set_id": ["f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37"], "package_ndc": ["0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4665-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4665", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-012-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 12.5 mg/.4 mL (NDC 82497-012-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-287-21", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-287", "63323-286", "63323-288", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "55150-304-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA210966"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1812079"], "spl_id": ["5d97a8a3-fd79-4fd1-8a0f-c8cf95d40964"], "spl_set_id": ["29947f67-7868-40af-8ad2-a61f7149b44c"], "package_ndc": ["55150-304-01", "55150-304-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-8036-01", "generic_name": "Glyburide Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074686"], "brand_name": ["GLYBURIDE"], "generic_name": ["GLYBURIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8036", "0093-8034", "0093-8035"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLYBURIDE"], "rxcui": ["310536", "310539", "314000"], "spl_id": ["d734cd0e-df7b-40a2-a511-fc04308a764d"], "spl_set_id": ["e84c0dfc-a4e9-4c89-b6ea-45732eb412f5"], "package_ndc": ["0093-8034-01", "0093-8035-01", "0093-8035-05", "0093-8036-01"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["SX6K58TVWC"]}, "update_date": "06/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glyburide (Micronized), Tablet, 6 mg (NDC 0093-8036-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-103-15", "generic_name": "Insulin Aspart Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Aspart 3 mL FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA020986"], "brand_name": ["INSULIN ASPART"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-103", "73070-100", "73070-102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["311040", "1653196", "1653202"], "spl_id": ["393af9a3-df9a-40b2-a5e6-bfa5434a2552"], "spl_set_id": ["bee5b358-c863-420b-be73-ced2e920c499"], "package_ndc": ["73070-100-11", "73070-102-10", "73070-102-15", "73070-103-10", "73070-103-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Aspart, Injection, 3 mL Insulin Aspart FlexPen® (NDC 73070-103-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2410-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": {"application_number": ["NDA021514"], "brand_name": ["METHYLPHENIDATE TRANSDERMAL SYSTEM"], "generic_name": ["METHYLPHENIDATE"], "manufacturer_name": ["PADAGIS US LLC"], "product_ndc": ["0574-2410", "0574-2415", "0574-2420", "0574-2430"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["METHYLPHENIDATE"], "rxcui": ["753436", "753438", "753440", "753441"], "spl_id": ["b743ef45-2fc0-4086-8a02-6078e6a09eaa"], "spl_set_id": ["7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb"], "package_ndc": ["0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65"], "nui": ["N0000175739", "N0000175729"], "pharm_class_epc": ["Central Nervous System Stimulant [EPC]"], "pharm_class_pe": ["Central Nervous System Stimulation [PE]"], "unii": ["207ZZ9QZ49"]}, "update_date": "05/07/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "23155-601-41", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA090850"], "brand_name": ["MIDAZOLAM HYDROCHLORIDE"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-601"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311702"], "spl_id": ["e20feff9-3aca-4bc1-a5c3-44fff8a9459c"], "spl_set_id": ["843cc25e-45ea-4372-ae34-843f805fa869"], "package_ndc": ["23155-601-31", "23155-601-41", "23155-601-32", "23155-601-42"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-554-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077690"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-554", "68180-556", "68180-557", "68180-558", "68180-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["a9598a21-6f99-4c86-ace6-b5638da2bec8"], "spl_set_id": ["8ded0773-3aec-4e89-9836-d22a5a84abf0"], "package_ndc": ["68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/04/2021", "package_ndc": "59137-570-01", "generic_name": "Triamcinolone Hexacetonide Injection", "related_info_link": "https://www.fda.gov/media/154709/download", "contact_info": "1-855-336-3322 Option 9", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"brand_name": ["HEXATRIONE 2%"], "generic_name": ["TRIAMCINOLONE HEXACETONIDE"], "manufacturer_name": ["Medexus Pharma, Inc."], "product_ndc": ["59137-570"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR"], "substance_name": ["TRIAMCINOLONE HEXACETONIDE"], "rxcui": ["2539176", "2539181"], "spl_id": ["4970c1c8-aa33-7c54-e063-6294a90a6167"], "spl_set_id": ["bc07ae9f-8a74-6bc8-e053-2995a90afc0d"], "package_ndc": ["59137-570-01"], "unii": ["I7GT1U99Y9"]}, "update_date": "04/30/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)", "company_name": "Medexus", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-1015-00", "generic_name": "Amantadine Hydrochloride Capsule", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA070589"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-1015"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849389"], "spl_id": ["398493aa-8a67-10e2-e063-6394a90aef8d"], "spl_set_id": ["5232b933-1df9-43b4-8ac2-61bfa4855e68"], "package_ndc": ["0832-1015-00", "0832-1015-50"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Capsule", "presentation": "Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-00)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "69516-005-30", "generic_name": "Obeticholic Acid Tablet", "contact_info": "1-844-782-4278", "related_info": "Business decision. Products will not be available after November 14, 2025.", "update_date": "09/19/2025", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Tablet", "presentation": "Ocaliva, Tablet, 5 mg (NDC 69516-005-30)", "company_name": "Intercept Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/06/2026", "update_type": "New", "initial_posting_date": "04/06/2026", "package_ndc": "64380-844-06", "generic_name": "Ursodiol Capsule", "contact_info": "877-244-9825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210344"], "brand_name": ["URSODIOL"], "generic_name": ["URSODIOL"], "manufacturer_name": ["Strides Pharma Science Limited"], "product_ndc": ["64380-844"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["URSODIOL"], "rxcui": ["858747"], "spl_id": ["46e8718f-fb37-4590-ad7e-7a55913fddf4"], "spl_set_id": ["9a6c1928-2d52-4d9a-8e83-f71892a7e98d"], "package_ndc": ["64380-844-06", "64380-844-07", "64380-844-04"], "nui": ["N0000175802", "M0002475"], "pharm_class_epc": ["Bile Acid [EPC]"], "pharm_class_cs": ["Bile Acids and Salts [CS]"], "unii": ["724L30Y2QR"]}, "update_date": "04/06/2026", "therapeutic_category": ["Other"], "dosage_form": "Capsule", "presentation": "Ursodiol, Capsule, 300 mg (NDC 64380-844-06)", "company_name": "Strides Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-168-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-168", "55150-167", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0005-01", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0005", "0009-0825", "0009-0011", "0009-0013", "0009-0016"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "change_date": "01/03/2025", "package_ndc": "0641-0121-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0185-2098-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA040439"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0185-2098", "0185-0831", "0185-0842", "0185-0853", "0185-0864", "0185-2099"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577961"], "spl_id": ["9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd"], "spl_set_id": ["288dafc4-fe6e-4891-832f-511022c87445"], "package_ndc": ["0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/11/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0002-8870-27", "generic_name": "Mirikizumab-mrkz Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.", "openfda": {"application_number": ["BLA761279"], "brand_name": ["OMVOH"], "generic_name": ["MIRIKIZUMAB-MRKZ"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8870", "0002-7575", "0002-8011", "0002-7717", "0002-7722", "0002-3116", "0002-1442"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["MIRIKIZUMAB"], "rxcui": ["2668391", "2668398", "2668405", "2668410", "2680728", "2680732", "2703047", "2703048", "2703049", "2703050", "2703051", "2703052", "2703053", "2703054"], "spl_id": ["e1015232-2dfd-4b5d-b1d0-e0302e49c55a"], "spl_set_id": ["472cbe04-263e-433d-9a0f-58c1b50b715a"], "package_ndc": ["0002-7575-01", "0002-8011-01", "0002-8011-27", "0002-8011-61", "0002-8870-01", "0002-8870-27", "0002-7717-11", "0002-7717-61", "0002-3116-01", "0002-7722-11", "0002-1442-01", "0002-3116-11", "0002-3116-61", "0002-1442-11"], "nui": ["N0000192799", "N0000192798"], "pharm_class_epc": ["Interleukin-23 Antagonist [EPC]"], "pharm_class_moa": ["Interleukin-23 Antagonists [MoA]"], "unii": ["Z7HVY03PHP"]}, "update_date": "12/22/2025", "therapeutic_category": ["Gastroenterology", "Other"], "dosage_form": "Injection", "presentation": "Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-65", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0264-2101-00", "generic_name": "Sterile Water Irrigant", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA016734"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-2101"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["969bdf41-6565-42fb-8ac1-8661a928cc22"], "spl_set_id": ["f4284eb6-e553-46d4-90d8-efc80a90a480"], "package_ndc": ["0264-2101-00", "0264-2101-10", "0264-2101-50", "0264-2101-70"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "25021-321-04", "generic_name": "Bumetanide Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Product in transit, expected to arrive last week of April 2026", "openfda": {"application_number": ["ANDA074441"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-321"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["befc1cf3-b71c-4228-bc42-3495b1d4b00d"], "spl_set_id": ["c38a404d-a919-4a2c-9fbb-d0655dee9516"], "package_ndc": ["25021-321-04", "25021-321-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-02", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-02", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-119-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207934"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-119", "49884-125", "49884-127", "49884-128"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["b474c768-50e2-44da-accf-f1bd3d49ab20"], "spl_set_id": ["45d54974-3fc4-4237-a2fa-3158ca1a8105"], "package_ndc": ["49884-119-52", "49884-119-91", "49884-125-52", "49884-125-91", "49884-127-52", "49884-127-91", "49884-128-52", "49884-128-91"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "01/06/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2.5 mg (NDC 49884-119-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-397-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4903-34", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only)  100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/20/2025", "update_type": "New", "initial_posting_date": "10/20/2025", "package_ndc": "0781-3317-80", "generic_name": "Oxaliplatin Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078817"], "brand_name": ["OXALIPLATIN"], "generic_name": ["OXALIPLATIN"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3317", "0781-3315"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["OXALIPLATIN"], "rxcui": ["1736776", "1736781"], "spl_id": ["f3766495-fce3-461c-8c95-e890f5e3383f"], "spl_set_id": ["ab162009-6f84-4d56-ab56-5e84409ec814"], "package_ndc": ["0781-3315-70", "0781-3317-80"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["04ZR38536J"]}, "update_date": "10/20/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-162-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078450"], "brand_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-162", "65862-161", "65862-163"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["5842ecc2-874a-481b-8997-afa9d862dc5d"], "spl_set_id": ["50a58159-9572-4445-9859-b392632597da"], "package_ndc": ["65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2020", "package_ndc": "16729-484-45", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA212868"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Accord Healthcare, Inc.,"], "product_ndc": ["16729-484", "16729-483"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["4082a1cf-1e1b-6f40-e063-6294a90aec06"], "spl_set_id": ["c82cb295-ffce-47d6-97ad-a8aa723f4e4f"], "package_ndc": ["16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3493-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": {"application_number": ["ANDA209065"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3493", "0781-3494", "0781-3495"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["fdf227d9-008e-60f8-e053-6294a90af5c4"], "spl_set_id": ["809e8f77-390f-4cc8-8c8a-4f67a249c9df"], "package_ndc": ["0781-3493-95", "0781-3494-95", "0781-3495-95"], "unii": ["1018WH7F9I"]}, "update_date": "04/06/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL  (NDC 0781-3493-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-505-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-505", "64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "63323-854-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-854", "63323-851", "63323-852", "63323-853"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-454-68", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-454", "61314-473", "61314-476", "61314-509", "61314-517", "61314-531"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ADALIMUMAB"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2020", "package_ndc": "55150-393-01", "generic_name": "Azacitidine Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA215066"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-393"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["e89b9510-86df-4095-b6d3-4eb05b613c4f"], "spl_set_id": ["ecd108bd-bb5f-4b2e-ad91-210fca452e9b"], "package_ndc": ["55150-393-01"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/05/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-605-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-605", "43547-602", "43547-603", "43547-604", "43547-606", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0002-7623-01", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-545-5979", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021462"], "brand_name": ["ALIMTA"], "generic_name": ["PEMETREXED DISODIUM"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-7623", "0002-7640"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PEMETREXED DISODIUM HEPTAHYDRATE"], "rxcui": ["1728072", "1728075", "1728077", "1728079"], "spl_id": ["3af0bc84-13d6-46aa-a4c0-c62410b73bc6"], "spl_set_id": ["f5a860f3-37ec-429c-ae04-9c88d7c55c08"], "package_ndc": ["0002-7640-01", "0002-7623-01"], "unii": ["9T47E4OM16"]}, "update_date": "10/16/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Alimta, Injection, 500 mg/20 mL (NDC 0002-7623-01)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4933-01", "generic_name": "Epinephrine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Cardiovascular", "Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4277-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088327"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4277", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/14/2026", "update_type": "New", "initial_posting_date": "05/14/2026", "package_ndc": "0480-7250-46", "generic_name": "Liraglutide Injection", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA214568"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-7250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["2735350"], "spl_id": ["4df44cd9-cb11-46b6-ba6c-88ff963ec414"], "spl_set_id": ["625ac780-70a9-41e4-a892-bcba0f803f1c"], "package_ndc": ["0480-7250-46"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "05/14/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6859-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6859", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-652-87", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-652", "25021-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA075880"], "brand_name": ["PREMASOL - SULFITE-FREE (AMINO ACID)"], "generic_name": ["LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1130", "0338-1131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "CYSTEINE HYDROCHLORIDE", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801395", "801398", "801403", "801405"], "spl_id": ["c874a813-b145-4f7f-833e-97d6c4dd727c"], "spl_set_id": ["9afdcc3e-0d06-47f4-86ca-40da48b2b02b"], "package_ndc": ["0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "ZT934N0X4W", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/14/2022", "package_ndc": "66220-160-10", "generic_name": "Conivaptan Hydrochloride Injection", "contact_info": "615-255-0068", "availability": "Unavailable", "update_date": "05/11/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)", "company_name": "Cumberland Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "71357-007-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": {"application_number": ["ANDA214805"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["MILLA PHARMACEUTICALS INC."], "product_ndc": ["71357-007", "71357-008", "71357-009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["237371", "312965"], "spl_id": ["47d8d0e7-6db5-950d-e063-6294a90ab1bf"], "spl_set_id": ["1ea1466d-a492-4056-e063-6394a90a80bf"], "package_ndc": ["71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10"], "unii": ["4550K0SC9B"]}, "update_date": "05/15/2026", "therapeutic_category": ["Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)", "company_name": "Milla Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070583"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596"], "spl_id": ["fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3212-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: October 2026", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3212", "0093-0832", "0093-3213"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6030-01", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the May 2026 timeframe.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6030", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6247", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9594-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019830"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9594", "0264-9598"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e352802-107c-4f90-babe-4f69c7dc892e"], "spl_set_id": ["7dff29d9-522d-40eb-a9d9-42377912d640"], "package_ndc": ["0264-9598-20", "0264-9594-20", "0264-9594-10"], "unii": ["EC2CNF7XFP", "LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4279-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088329"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4279", "0409-4713", "0409-4278", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-047-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-047-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6001-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Lots are being manufactured to meet demand", "openfda": {"application_number": ["NDA018140"], "brand_name": ["ATIVAN"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6001", "0641-6003", "0641-6002", "0641-6000"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327"], "spl_id": ["209b0091-c890-4f69-a693-d0594c2606fe"], "spl_set_id": ["5fc0e987-61c9-40c4-b0d5-fcea07c8733e"], "package_ndc": ["0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "63323-123-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["ANDA040263"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-123"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1946772"], "spl_id": ["880c2caa-1b11-45ce-a54e-a3733da367f0"], "spl_set_id": ["b585f621-f6c9-4735-ab61-bd1b401f3df0"], "package_ndc": ["63323-123-10"], "unii": ["3IG1E710ZN"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-196-99", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-196", "55150-195", "55150-197", "55150-198", "55150-199", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1388-8", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Inventory available 2 to 6 weeks as per current demand. Next supply: week of 2/23/2026", "openfda": {"application_number": ["ANDA207551"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1388", "70121-1389"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["795f643f-855c-4ba4-9bad-a96334c1a2fb"], "spl_set_id": ["eb1ba463-ab42-4f49-9ebe-3ad5af108326"], "package_ndc": ["70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7"], "unii": ["1018WH7F9I"]}, "update_date": "02/09/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6006-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA213784"], "brand_name": ["FLUPHENAZINE HYDROCHLORIDE"], "generic_name": ["FLUPHENAZINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories,LLC"], "product_ndc": ["0832-6006", "0832-6004", "0832-6003", "0832-6005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUPHENAZINE HYDROCHLORIDE"], "rxcui": ["859841", "860918", "865117", "865123"], "spl_id": ["3bb74f82-8872-9829-e063-6294a90aeace"], "spl_set_id": ["f07bb3f1-c68c-441b-9de4-99a219f2500a"], "package_ndc": ["0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11"], "unii": ["ZOU145W1XL"]}, "update_date": "09/18/2025", "therapeutic_category": ["Neurology", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 10 mg (NDC 0832-6006-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-502-43", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070017"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-502", "16729-500", "16729-501"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1cfab300-d796-6a68-e063-6394a90a73f9"], "spl_set_id": ["f6f64972-714c-4ee9-8a5e-9ffcab41a73b"], "package_ndc": ["16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-283-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA202747"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["36000-283", "36000-063", "36000-064", "36000-065", "36000-282", "36000-284"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53"], "spl_set_id": ["c71371a7-75c5-45b8-b762-8d782d4c71bc"], "package_ndc": ["36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/08/2025", "update_type": "New", "initial_posting_date": "07/08/2025", "package_ndc": "0409-1892-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/08/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/14/2026", "update_type": "New", "initial_posting_date": "04/14/2026", "package_ndc": "58914-301-80", "generic_name": "Nitroglycerin Ointment", "contact_info": "800-678-1605", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021359"], "brand_name": ["RECTIV"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["Allergan, Inc."], "product_ndc": ["58914-301"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RECTAL"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["1114466", "1114470"], "spl_id": ["a2f0ef5a-c3b6-4330-9b33-131369431ddd"], "spl_set_id": ["603aa9ed-54c4-4a35-ade4-690fa44850e4"], "package_ndc": ["58914-301-80", "58914-301-85"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "04/14/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Ointment", "presentation": "Rectiv, Ointment, 0.4% (NDC 58914-301-80)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-75", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209448"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-824"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481"], "spl_id": ["0591ab74-99a6-40ee-af96-80bc2ef423dc"], "spl_set_id": ["3b8f2692-4371-4f1a-95af-b41842131fdd"], "package_ndc": ["63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "New", "initial_posting_date": "08/27/2025", "package_ndc": "0409-7809-24", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018826"], "brand_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7809", "0409-7810", "0409-0042", "0409-1858"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "spl_id": ["188ce800-ff3a-4b22-9a95-2273c3bc99ae"], "spl_set_id": ["08f23f6e-150d-45ea-098e-f2edf64c21a1"], "package_ndc": ["0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12"], "unii": ["7L3E358N9L"]}, "update_date": "08/27/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-203-05", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA212803"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-203"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b06d36f6-507c-4b04-b79d-d6370a30a551", "53a09c30-7295-4337-89a4-93d3748d6ea3"], "spl_set_id": ["a2e3c748-28ce-4c50-a182-721912919840", "3aadaca7-3661-4bfe-87f8-6368e4ab6536"], "package_ndc": ["71288-203-02", "71288-203-03", "71288-203-04", "71288-203-05", "71288-203-10", "71288-203-11", "71288-203-91", "71288-203-92", "71288-203-93", "71288-203-94"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-098-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-098", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2859", "0781-2868"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0532-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 20 mg (NDC 0071-0532-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-667-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076374"], "brand_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-667", "62135-668", "62135-669"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["0c3f4504-d57e-aa79-e063-6294a90ad5b8"], "spl_set_id": ["2eae533f-d0af-47e8-a1f2-94bc8cc89b5a"], "package_ndc": ["62135-667-90", "62135-668-90", "62135-669-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-02", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated availability: May 2026", "openfda": {"application_number": ["NDA017428"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0004", "0338-0003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["97390588-b679-4caa-b7f3-3d2e11074d0e"], "spl_set_id": ["ef3e79c5-3f58-4b36-a296-64b7d9a651c1"], "package_ndc": ["0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "76045-109-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209192"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-109", "76045-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["2099700"], "spl_id": ["6fd9ed0e-dddc-4e73-9442-49da54685f7b"], "spl_set_id": ["4dd55929-fe0a-4884-ae0d-6f9435920eb7"], "package_ndc": ["76045-109-01", "76045-109-10", "76045-212-00", "76045-212-10"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-109-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-3301-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3301", "0409-1454", "0409-1174", "0409-2815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["8d48de06-361f-418b-bfec-8ef85f94d5bc"], "spl_set_id": ["4419162d-81d4-49bd-96de-1729440bdb74"], "package_ndc": ["0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-386-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-10", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d"], "spl_set_id": ["3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75"], "package_ndc": ["63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "change_date": "01/02/2025", "package_ndc": "0409-1283-31", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1283", "0409-1312", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-203-15", "generic_name": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin aspart protamine and insulin aspart FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA021172"], "brand_name": ["INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-203", "73070-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["351297", "847191"], "spl_id": ["ec67820c-4008-4894-b933-34b28704221d"], "spl_set_id": ["fc94baa4-3606-48bc-a781-9617ab6960ef"], "package_ndc": ["73070-200-11", "73070-203-10", "73070-203-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injectable Suspension", "presentation": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 3 mL vial Insulin aspart protamine and insulin aspart Mix 70/30 FlexPen® (NDC 73070-203-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-586-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": {"application_number": ["NDA021121"], "brand_name": ["CONCERTA"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-586", "50458-585", "50458-588", "50458-587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212"], "spl_id": ["64d7c1e1-e7ed-4d74-a44d-13b4da64af9a"], "spl_set_id": ["1a88218c-5b18-4220-8f56-526de1a276cd"], "package_ndc": ["50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "63323-750-10", "generic_name": "Oxaliplatin Injection", "contact_info": "847-550-2300", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA078811"], "brand_name": ["OXALIPLATIN"], "generic_name": ["OXALIPLATIN"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-750"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["OXALIPLATIN"], "rxcui": ["1736776", "1736781"], "spl_id": ["504bf43e-4c28-4375-a6f4-285b2357f7f7"], "spl_set_id": ["e12e2850-4980-48de-af58-15e559fb921f"], "package_ndc": ["63323-750-10", "63323-750-20"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["04ZR38536J"]}, "update_date": "02/25/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/13/2026", "update_type": "New", "initial_posting_date": "03/13/2026", "package_ndc": "65219-284-12", "generic_name": "Plerixafor Injection", "contact_info": "888-391-6300 www.fresenius-kabi.com", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["NDA022311"], "brand_name": ["PLERIXAFOR"], "generic_name": ["PLERIXAFOR"], "manufacturer_name": ["Fresenius Kabi Usa, LLC"], "product_ndc": ["65219-284"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PLERIXAFOR"], "rxcui": ["828700"], "spl_id": ["ba468eca-fb47-497b-8aed-a1576249ea6a"], "spl_set_id": ["5d670cb4-163e-498c-b5fa-c193ea9d55c0"], "package_ndc": ["65219-284-12"], "nui": ["N0000178326", "N0000178324"], "pharm_class_epc": ["Hematopoietic Stem Cell Mobilizer [EPC]"], "pharm_class_pe": ["Increased Hematopoietic Stem Cell Mobilization [PE]"], "unii": ["S915P5499N"]}, "update_date": "03/13/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6024-10", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "66794-228-41", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-414-1901", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA210437"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM"], "manufacturer_name": ["Piramal Critical Care Inc"], "product_ndc": ["66794-228", "66794-229"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["3f9e12e4-d3c5-fba6-e063-6294a90a7fd6"], "spl_set_id": ["98255b70-51f9-8d16-e053-2995a90a8f97"], "package_ndc": ["66794-229-02", "66794-229-41", "66794-228-02", "66794-228-41"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)", "company_name": "Piramal Critical Care Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-456-60", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholealers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-456", "65219-464", "65219-458", "65219-460", "65219-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-52", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0280", "0009-0274", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-12", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA075154"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-411", "63323-412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA076515"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2234"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["200329"], "spl_id": ["fe6aa833-89e6-4679-a7b8-6600e92c1bed"], "spl_set_id": ["5a09ce48-7139-4fc7-9b6e-439459c8e866"], "package_ndc": ["0781-2234-10", "0781-2234-01", "0781-2234-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-620-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202725"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL HYDROCHLORIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-620", "65862-617", "65862-618", "65862-619"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["5263abd5-ce46-4918-9bb0-9632861bcbc9"], "spl_set_id": ["93e6e668-5306-4f26-81d8-cbc3a7a5e787"], "package_ndc": ["65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78"], "unii": ["33067B3N2M"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "65649-311-12", "generic_name": "Chlorothiazide Oral Suspension", "contact_info": "800-321-4576", "openfda": {"application_number": ["NDA011870"], "brand_name": ["DIURIL"], "generic_name": ["CHLOROTHIAZIDE"], "manufacturer_name": ["Salix Pharmaceuticals, Inc"], "product_ndc": ["65649-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CHLOROTHIAZIDE"], "rxcui": ["213439", "309198"], "spl_id": ["e311f727-9882-4c42-bd5b-e8e38ee54466"], "spl_set_id": ["bd936e35-1af8-42da-bcc0-f22489d68574"], "package_ndc": ["65649-311-12"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["77W477J15H"]}, "update_date": "02/10/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Oral Suspension", "presentation": "Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12)", "company_name": "Salix Pharmaceuticals, a division of Bausch Health US, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-563-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-563", "47781-562", "47781-564", "47781-565", "47781-566", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5011-4", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": {"application_number": ["ANDA211091"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Exela Pharma Sciences, LLC"], "product_ndc": ["51754-5011", "51754-5001", "51754-5002", "51754-5012"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["807284", "1868486", "1923484", "2198792"], "spl_id": ["4da0ba66-756d-4b4d-8018-81ca16578ef1"], "spl_set_id": ["e9698a4f-1a95-4f28-a945-e8009d1d6dd4"], "package_ndc": ["51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4"], "unii": ["8MDF5V39QO"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-074-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 OR CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-074", "13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-073"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2305-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026", "openfda": {"application_number": ["ANDA075857"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2305", "0409-2308", "0409-0001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666800", "1666814", "1666823", "1666798"], "spl_id": ["b303a281-6633-47d5-bf29-5e9055e26da6", "74093865-864a-49e8-99b9-c985fe72afb2"], "spl_set_id": ["b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240"], "package_ndc": ["0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/08/2025", "update_type": "New", "initial_posting_date": "07/08/2025", "package_ndc": "0004-0802-85", "generic_name": "Oseltamivir Phosphate Capsule", "contact_info": "800-551-2231", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021087"], "brand_name": ["TAMIFLU"], "generic_name": ["OSELTAMIVIR PHOSPHATE"], "manufacturer_name": ["Genentech, Inc."], "product_ndc": ["0004-0802", "0004-0801", "0004-0800", "0004-0822"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OSELTAMIVIR PHOSPHATE"], "rxcui": ["261315", "312122", "728109", "728111", "728113", "728115", "1115698", "1115700"], "spl_id": ["94a312ac-c47a-4437-8dd3-6bcd7e08e42c"], "spl_set_id": ["ee3c9555-60f2-4f82-a760-11983c86e97b"], "package_ndc": ["0004-0802-85", "0004-0801-85", "0004-0800-85", "0004-0800-07", "0004-0800-08", "0004-0822-05"], "unii": ["4A3O49NGEZ"]}, "update_date": "07/08/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Capsule", "presentation": "Tamiflu, Capsule, 30 mg (NDC 0004-0802-85)", "company_name": "Genentech, Inc", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9393-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA210594"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9393", "0143-9391", "0143-9392"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["5c5e498b-d829-4f78-bcca-466631014767"], "spl_set_id": ["9d289052-1eb6-4ba2-a3ca-d2e542a052ae"], "package_ndc": ["0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10"], "unii": ["5V444H5WIC"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-178-76", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209689"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-178"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["WATER"], "spl_id": ["d40f0ff2-4abf-4030-b4e1-2b85ad7448a0"], "spl_set_id": ["b45e9f1d-9c48-4b46-8541-d846b89540df"], "package_ndc": ["63323-178-76"], "unii": ["059QF0KO0R"]}, "update_date": "04/23/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-0144-11", "generic_name": "Azithromycin Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA065500"], "brand_name": ["AZITHROMYCIN"], "generic_name": ["AZITHROMYCIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0144"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AZITHROMYCIN MONOHYDRATE"], "rxcui": ["1668238"], "spl_id": ["0daee3b8-efec-4ff2-aedf-87035563373f"], "spl_set_id": ["d2f4907f-b952-403b-229e-cc5b8327a773"], "package_ndc": ["0409-0144-21", "0409-0144-11"], "unii": ["JTE4MNN1MD"]}, "update_date": "09/09/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Azithromycin, Injection, 500 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-0144-11)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1389-1", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "openfda": {"application_number": ["ANDA207551"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1389", "70121-1388"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["795f643f-855c-4ba4-9bad-a96334c1a2fb"], "spl_set_id": ["eb1ba463-ab42-4f49-9ebe-3ad5af108326"], "package_ndc": ["70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7"], "unii": ["1018WH7F9I"]}, "update_date": "02/09/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "67457-902-10", "generic_name": "Etomidate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA201044"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-902", "67457-903"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["25fc0aef-d4b3-4b33-897c-81cc7cdae470"], "spl_set_id": ["461e34d1-b862-4a02-9727-548c907aac48"], "package_ndc": ["67457-902-00", "67457-902-10", "67457-903-00", "67457-903-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-165-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-165", "55150-161", "55150-162", "55150-163", "55150-164"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/13/2022", "package_ndc": "47335-993-01", "generic_name": "Metronidazole Injection", "contact_info": "Distributed by Sun Pharma", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA212435"], "brand_name": ["METRONIDAZOLE"], "generic_name": ["METRONIDAZOLE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-993"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["METRONIDAZOLE"], "rxcui": ["311683"], "spl_id": ["9549fa19-5d89-4ad8-82ac-5d023072b126"], "spl_set_id": ["7187779a-1f4c-4607-af53-4119e324aad5"], "package_ndc": ["47335-993-01"], "nui": ["N0000175435", "M0014907"], "pharm_class_epc": ["Nitroimidazole Antimicrobial [EPC]"], "pharm_class_cs": ["Nitroimidazoles [CS]"], "unii": ["140QMO216E"]}, "update_date": "04/27/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "51224-206-30", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["TAGI Pharma Inc."], "product_ndc": ["51224-206"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["75a00517-674b-4e87-b37b-598486aedf03"], "spl_set_id": ["60276f5c-657a-4b60-bcd0-44234903d7e0"], "package_ndc": ["51224-206-30", "51224-206-50"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-30)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5165-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5165", "0603-5166", "0603-5167", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1176-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA021171"], "brand_name": ["DEMEROL"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1176", "0409-1181", "0409-1178", "0409-1179", "0409-1180", "0409-1362", "0409-1418"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192"], "spl_id": ["c1704eaf-f0a8-4ba3-89a1-2836ba7e5ee6"], "spl_set_id": ["b31d1308-28c3-43f4-e0a6-2f3ed76b8975"], "package_ndc": ["0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01"], "unii": ["N8E7F7Q170"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/08/2026", "update_type": "New", "initial_posting_date": "04/08/2026", "package_ndc": "0006-3066-03", "generic_name": "Aprepitant Oral Powder for Suspension", "contact_info": "800-672-6372", "related_info": "To be discontinued in approximately November 2026.", "openfda": {"application_number": ["NDA207865"], "brand_name": ["EMEND"], "generic_name": ["APREPITANT"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "product_ndc": ["0006-3066", "0006-0461", "0006-0462", "0006-3862", "0006-0464"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["APREPITANT"], "rxcui": ["403810", "403811", "404465", "404466", "644088", "644278", "754508", "754509", "1729308", "1729311"], "spl_id": ["428f7828-6d1c-438b-a17d-b4af0700c740"], "spl_set_id": ["696f9e80-9cae-403b-de9e-078343ce4713"], "package_ndc": ["0006-0461-02", "0006-0461-01", "0006-0461-06", "0006-0461-12", "0006-0462-01", "0006-0462-06", "0006-3862-03", "0006-3862-13", "0006-0464-01", "0006-0464-10", "0006-0464-05", "0006-3066-01", "0006-3066-03"], "nui": ["N0000010262", "N0000175786", "N0000182141", "N0000185507", "N0000185506"], "pharm_class_moa": ["Neurokinin 1 Antagonists [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 3A4 Inducers [MoA]"], "pharm_class_epc": ["Substance P/Neurokinin-1 Receptor Antagonist [EPC]"], "unii": ["1NF15YR6UY"]}, "update_date": "04/08/2026", "therapeutic_category": ["Gastroenterology"], "presentation": "Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03)", "company_name": "Merck Sharp & Dohme LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6625-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA202432"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6625"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868486"], "spl_id": ["dcc55d90-d55e-4e1a-9e48-5703cbc74a52", "c39c0ef6-4140-4c6c-91c4-e43d67872b05"], "spl_set_id": ["8664c7ce-707b-4c6c-9ce4-7160b5f877f8", "084f5572-8c1f-4802-b179-ca0cc838fc68"], "package_ndc": ["0409-6625-30", "0409-6625-35", "0409-6625-22", "0409-6625-14"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/22/2026", "update_type": "New", "initial_posting_date": "04/22/2026", "package_ndc": "0069-0188-21", "generic_name": "Palbociclib Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.", "openfda": {"application_number": ["NDA207103"], "brand_name": ["IBRANCE"], "generic_name": ["PALBOCICLIB"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-0188", "0069-0187", "0069-0189"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PALBOCICLIB"], "rxcui": ["1601380", "1601386", "1601388", "1601390", "1601392", "1601394"], "spl_id": ["fb858b80-8bd4-43a6-8871-9819a35ca03f"], "spl_set_id": ["e0e6412f-50b4-4fd4-9364-62818d121a07"], "package_ndc": ["0069-0187-21", "0069-0188-21", "0069-0189-21"], "nui": ["N0000175605", "N0000175082", "N0000190114"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["G9ZF61LE7G"]}, "update_date": "04/22/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Capsule", "presentation": "Ibrance, Capsule, 100 mg (NDC 0069-0188-21)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-02", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA019465"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7101", "0409-7132"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807547", "1807631", "1807632", "1807633"], "spl_id": ["f233e72c-072d-4a43-857a-f4d5791e1a73"], "spl_set_id": ["a2a964f7-c3ec-4dfb-e3a0-6d8136a80397"], "package_ndc": ["0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02"], "unii": ["451W47IQ8X"]}, "update_date": "12/03/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 250 mL  ADD-Vantage® Flexible Container (NDC 0409-7101-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "61570-073-01", "generic_name": "Esterified Estrogens Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/29/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Menest, Tablet, .625 mg (NDC 61570-073-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-120-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-120", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-01", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA084916"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1116927", "1812194"], "spl_id": ["a832bff9-0bb3-4350-abb5-d57b9417070c", "9dd90418-e564-4bc5-9077-506a1c2c1bce"], "spl_set_id": ["2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e"], "package_ndc": ["63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-00", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA208129"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["27411591-44a1-44c4-89c3-dd8c2687f0e2"], "spl_set_id": ["4d5d2294-89a0-4b6f-aa00-d39a0393b6a8"], "package_ndc": ["63323-671-02", "63323-671-20", "63323-671-05", "63323-671-50", "63323-671-01", "63323-671-00"], "unii": ["1018WH7F9I"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-468-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "6, 7 & 8 month expiry available upon request. Check wholesaler for inventory", "openfda": {"application_number": ["ANDA070966"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-468", "63323-472", "63323-463", "63323-461"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1867594", "1867596", "1867618", "1867620", "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810"], "spl_id": ["b671015d-f620-4930-a890-5e27a40ae42f", "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["b671015d-f620-4930-a890-5e27a40ae42f", "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-468-08", "63323-468-38", "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-8034-01", "generic_name": "Glyburide Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074686"], "brand_name": ["GLYBURIDE"], "generic_name": ["GLYBURIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8034", "0093-8035", "0093-8036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLYBURIDE"], "rxcui": ["310536", "310539", "314000"], "spl_id": ["d734cd0e-df7b-40a2-a511-fc04308a764d"], "spl_set_id": ["e84c0dfc-a4e9-4c89-b6ea-45732eb412f5"], "package_ndc": ["0093-8034-01", "0093-8035-01", "0093-8035-05", "0093-8036-01"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["SX6K58TVWC"]}, "update_date": "06/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glyburide (Micronized), Tablet, 1.5 mg (NDC 0093-8034-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0338-0409-03", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018461"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0409", "0338-0411"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e9121a0-25dd-46ba-a2b7-6f71fc3ff9cd"], "spl_set_id": ["f21512ea-c7c3-4766-b976-b2c0b5616bf0"], "package_ndc": ["0338-0409-03", "0338-0409-02", "0338-0411-02"], "unii": ["V13007Z41A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1179-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA021171"], "brand_name": ["DEMEROL"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1179", "0409-1181", "0409-1176", "0409-1178", "0409-1180", "0409-1362", "0409-1418"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192"], "spl_id": ["c1704eaf-f0a8-4ba3-89a1-2836ba7e5ee6"], "spl_set_id": ["b31d1308-28c3-43f4-e0a6-2f3ed76b8975"], "package_ndc": ["0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01"], "unii": ["N8E7F7Q170"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-063-01", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-063", "65862-062", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-01)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-005-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X5ML)  is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-110-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-110", "57844-105", "57844-117", "57844-112", "57844-115", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "68180-658-06", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA090034"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-658", "68180-659"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["5ed1edac-e11e-4f87-b390-e770a69a9b37"], "spl_set_id": ["b56004f0-f23d-47f6-80c7-39884fccbccc"], "package_ndc": ["68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 68180-658-06)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-065-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesaler for inventory.", "openfda": {"application_number": ["ANDA078651"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-065"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["68f8f5e7-46a8-47f9-a622-6339df1a3d1b"], "spl_set_id": ["209a654d-f92d-4242-bfef-2dcc90a30d3f"], "package_ndc": ["65219-065-02", "65219-065-05"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1746-10", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1746", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-2815-01", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2815", "0409-1454", "0409-3301", "0409-1174"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["8d48de06-361f-418b-bfec-8ef85f94d5bc"], "spl_set_id": ["4419162d-81d4-49bd-96de-1729440bdb74"], "package_ndc": ["0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-500-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018931"], "brand_name": ["TRAVASOL"], "generic_name": ["LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0644"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801644", "801648"], "spl_id": ["e0279078-016d-48fd-8de1-c894422b33ff"], "spl_set_id": ["8543b5be-0f43-4891-9e56-d7c39fe839b5"], "package_ndc": ["0338-0644-03", "0338-0644-04", "0338-0644-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "JNJ23Q2COM", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-00", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Information pending", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-152", "72888-153", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-00)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2308-01", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075857"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2308", "0409-2305", "0409-0001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666800", "1666814", "1666823", "1666798"], "spl_id": ["b303a281-6633-47d5-bf29-5e9055e26da6", "74093865-864a-49e8-99b9-c985fe72afb2"], "spl_set_id": ["b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240"], "package_ndc": ["0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "63323-723-03", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release April 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA206223"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-723", "63323-724", "63323-725"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["406a07e3-a3f8-4fef-901e-021d00743c40", "2f27e51f-2b55-47ee-bd4a-001b71c60622"], "spl_set_id": ["5b8025d2-3424-477b-9cff-3990a98c2a65", "d2374b84-81c9-44f9-a4a9-1071281b2531"], "package_ndc": ["63323-723-04", "63323-723-06", "63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10"], "unii": ["5V444H5WIC"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-34", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA206775"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-295"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["35cf6068-f31a-211b-e063-6294a90a6b53"], "spl_set_id": ["48aa7ef3-9f44-2a08-e054-00144ff88e88"], "package_ndc": ["16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0499-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020849"], "brand_name": ["PROSOL"], "generic_name": ["VALINE, LYSINE, HISTIDINE, ISOLEUCINE, LEUCINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0499"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801133", "801136"], "spl_id": ["ee240b46-c2a9-42e0-8750-a5a554becea3"], "spl_set_id": ["cc2ace81-5881-43f1-ba94-41b674adc2fc"], "package_ndc": ["0338-0499-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2853-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA200881"], "brand_name": ["GUANFACINE"], "generic_name": ["GUANFACINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2853", "0228-2850", "0228-2851", "0228-2855"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GUANFACINE HYDROCHLORIDE"], "rxcui": ["862006", "862013", "862019", "862025"], "spl_id": ["b9040df2-42e8-404d-9b90-331dd3efc38c"], "spl_set_id": ["3a171942-37af-430d-8b9d-bb678ca2be4b"], "package_ndc": ["0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11"], "unii": ["PML56A160O"]}, "update_date": "11/13/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 3 mg (NDC 0228-2853-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7510", "0264-7520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0409-1805-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1805", "0409-1283", "0409-1312", "0409-4264"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3294-50", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070434"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-3294", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3298"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FUROSEMIDE"], "rxcui": ["197730", "197731", "197732", "310429", "313988"], "spl_id": ["bc62ddda-7639-4090-99f0-7dd4d13518f3"], "spl_set_id": ["9e493331-dddd-496e-abf8-61747fb67aba"], "package_ndc": ["0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-115-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-115", "70010-111", "70010-112", "70010-113", "70010-114", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6854-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-017-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 17.5 mg/.4 mL (NDC 82497-017-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-607-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "openfda": {"application_number": ["ANDA205135"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-607", "57664-606", "57664-608", "57664-609"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210"], "spl_id": ["509cf8be-4306-9755-e063-6294a90ab425"], "spl_set_id": ["d048e52d-7406-4fc1-9a72-c073bafc7439"], "package_ndc": ["57664-606-88", "57664-607-88", "57664-608-88", "57664-609-88"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-023-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-023", "65162-024", "65162-025", "65162-026", "65162-027", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/17/2021", "package_ndc": "0068-0597-01", "generic_name": "Rifampin Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Rifampin%20Injection&st=d", "contact_info": "800-633-1610", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050627"], "brand_name": ["RIFADIN IV"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Sanofi-Aventis U.S. LLC"], "product_ndc": ["0068-0597"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["RIFAMPIN"], "rxcui": ["207436", "312821"], "spl_id": ["d5ee3f24-779e-4fd0-ba26-e870acbd1111"], "spl_set_id": ["036ab68e-5085-4edc-bd83-784b43d64eab"], "package_ndc": ["0068-0597-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)", "company_name": "Sanofi-Aventis U.S. LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "72516-013-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Available", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-013", "72516-016", "72516-015", "72516-014", "72516-012", "72516-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)", "company_name": "Oryza Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-31", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0305-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/177206/download", "contact_info": "610-937-6172", "availability": "Available", "openfda": {"brand_name": ["TEGLUTIK"], "generic_name": ["RILUZOLE"], "manufacturer_name": ["EDW PHARMA"], "product_ndc": ["70726-0305"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RILUZOLE"], "rxcui": ["2058147", "2675565"], "spl_id": ["4746c4d8-402a-0390-e063-6294a90a7fc2"], "spl_set_id": ["125fdd37-02f7-a610-e063-6294a90a009d"], "package_ndc": ["70726-0305-1"], "nui": ["N0000175740", "M0483511"], "pharm_class_epc": ["Benzothiazole [EPC]"], "pharm_class_cs": ["Benzothiazoles [CS]"], "unii": ["7LJ087RS6F"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "68025-097-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-097", "68025-088", "68025-089", "68025-095", "68025-096", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1587-50", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1587", "0409-1559", "0409-1560", "0409-1582", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1587-50)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1005-02", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA019615"], "brand_name": ["DOPAMINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1005", "0338-1007", "0338-1009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1292887", "1743869", "1743871", "1743877", "1743879"], "spl_id": ["edc9a091-4cb5-4ec7-b6f9-44d2d588bab9"], "spl_set_id": ["cb97d4a0-89ed-407c-a763-209386b6f75c"], "package_ndc": ["0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02"], "unii": ["7L3E358N9L"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0143-9251-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA204679"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9251", "0143-9250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["76957fea-9b26-42a6-ad71-c8752142a08b"], "spl_set_id": ["d3a172a5-01ab-47d8-92ac-a8539b1d4dc4"], "package_ndc": ["0143-9250-01", "0143-9250-10", "0143-9251-01", "0143-9251-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-559-05", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-559", "62037-560"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1160-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070590"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1160", "0409-1159", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/19/2025", "update_type": "New", "initial_posting_date": "08/19/2025", "package_ndc": "0093-7355-05", "generic_name": "Finasteride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076511"], "brand_name": ["FINASTERIDE"], "generic_name": ["FINASTERIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7355"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FINASTERIDE"], "rxcui": ["310346"], "spl_id": ["4c152e0f-55b3-4357-b983-897ecaf878af"], "spl_set_id": ["77589cc3-c440-4695-800c-82a0e5128a6c"], "package_ndc": ["0093-7355-56", "0093-7355-98", "0093-7355-05"], "nui": ["N0000175836", "N0000000126"], "pharm_class_epc": ["5-alpha Reductase Inhibitor [EPC]"], "pharm_class_moa": ["5-alpha Reductase Inhibitors [MoA]"], "unii": ["57GNO57U7G"]}, "update_date": "08/19/2025", "therapeutic_category": ["Urology"], "dosage_form": "Tablet", "presentation": "Finasteride, Tablet, 5 mg (NDC 0093-7355-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "66794-160-02", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-414-1901", "availability": "Available", "openfda": {"application_number": ["ANDA204393"], "brand_name": ["MITIGO"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Piramal Critical Care, Inc."], "product_ndc": ["66794-160", "66794-162"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731522", "1731998", "2055307", "2055311"], "spl_id": ["495a6a51-d35d-2b96-e063-6394a90ac5f3"], "spl_set_id": ["728f3d83-9a63-0c1f-e053-2a91aa0ac7db"], "package_ndc": ["66794-160-02", "66794-162-02"], "unii": ["X3P646A2J0"]}, "update_date": "05/07/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)", "company_name": "Piramal Critical Care Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-119-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-119", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-725-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-725", "71288-721", "71288-722", "71288-724", "71288-727", "71288-728"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-44", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-473"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c14acada-333e-43bb-b1cf-81d569e3e918"], "spl_set_id": ["1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec"], "package_ndc": ["23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9594-25", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA084625"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9594", "0143-9595"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737566", "1737761"], "spl_id": ["a7da0a25-5efb-48fa-9063-f7c0423f820f"], "spl_set_id": ["1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1"], "package_ndc": ["0143-9595-01", "0143-9595-25", "0143-9594-01", "0143-9594-25"], "unii": ["V13007Z41A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA076515"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2234"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["200329"], "spl_id": ["fe6aa833-89e6-4679-a7b8-6600e92c1bed"], "spl_set_id": ["5a09ce48-7139-4fc7-9b6e-439459c8e866"], "package_ndc": ["0781-2234-10", "0781-2234-01", "0781-2234-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0990-7139-09", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "Allocated to Contracted Customers Only. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7139-09", "openfda": {"application_number": ["NDA017513"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7139", "0990-6139", "0990-7973"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["90930d29-6b1a-438c-b719-c5e7484dcad5"], "spl_set_id": ["e3484bc6-ed7f-43ef-9d49-c131a8dff2dd"], "package_ndc": ["0990-6139-22", "0990-6139-03", "0990-7139-09", "0990-7139-36", "0990-7973-05", "0990-7973-07", "0990-7973-08"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-186-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Available", "related_info": "Please check wholesalers for inventory", "openfda": {"application_number": ["ANDA208266"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["42023-186", "42023-146", "42023-187"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710", "1718906", "1718909"], "spl_id": ["54174211-6684-4fb9-a605-be12b94e2948"], "spl_set_id": ["1ee59985-4c1d-48f7-b8f9-5584c2d55e08"], "package_ndc": ["42023-146-25", "42023-186-20", "42023-187-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)", "company_name": "Par Health, USA LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2346-32", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA020201"], "brand_name": ["DOBUTAMINE IN DEXTROSE"], "generic_name": ["DOBUTAMINE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2346", "0409-2347", "0409-3724", "0409-0025", "0409-0151", "0409-1100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["1c7cc97c-e244-4a4b-a4a1-8b70ca812107"], "spl_set_id": ["9943a961-3b50-4847-8a84-d8414ce38daa"], "package_ndc": ["0409-2347-31", "0409-2347-32", "0409-2346-31", "0409-2346-32", "0409-3724-11", "0409-3724-32", "0409-0025-01", "0409-0025-10", "0409-0151-01", "0409-0151-10", "0409-1100-01", "0409-1100-10"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-562-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-063-99", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-063", "65862-062", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-99)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-484-60", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076803"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-484", "62135-485", "62135-486", "62135-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["09cd5cb9-4fdf-f133-e063-6294a90af691"], "spl_set_id": ["dbc43dbd-94aa-40e2-a9ea-766110cc8687"], "package_ndc": ["62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90"], "unii": ["33067B3N2M"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "0071-0737-20", "generic_name": "Gemfibrozil Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA018422"], "brand_name": ["LOPID"], "generic_name": ["GEMFIBROZIL"], "manufacturer_name": ["Parke-Davis Div of Pfizer Inc"], "product_ndc": ["0071-0737"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GEMFIBROZIL"], "rxcui": ["205751", "310459"], "spl_id": ["e23c4bc1-151b-469a-a7a6-99c13bb666ce"], "spl_set_id": ["c48855b7-215e-453b-b3b1-a0f9dee7221f"], "package_ndc": ["0071-0737-20", "0071-0737-30"], "nui": ["N0000175596", "N0000175375", "M0543661"], "pharm_class_epc": ["Peroxisome Proliferator Receptor alpha Agonist [EPC]"], "pharm_class_moa": ["Peroxisome Proliferator-activated Receptor alpha Agonists [MoA]"], "pharm_class_cs": ["Fibric Acids [CS]"], "unii": ["Q8X02027X3"]}, "update_date": "02/10/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Lopid, Tablet, 600 mg (NDC 0071-0737-20)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-810-60", "generic_name": "Ivabradine Hydrochloride Tablet", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA206143"], "brand_name": ["CORLANOR"], "generic_name": ["IVABRADINE"], "manufacturer_name": ["Amgen Inc"], "product_ndc": ["55513-810", "55513-800", "55513-813"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IVABRADINE HYDROCHLORIDE"], "rxcui": ["1649485", "1649491", "1649493", "1649495", "2168592", "2168596"], "spl_id": ["8ab000cd-0258-489a-b1bb-4cc1ca359d6c"], "spl_set_id": ["92018a65-38f6-45f7-91d4-a34921b81d0d"], "package_ndc": ["55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28"], "unii": ["TP19837BZK"]}, "update_date": "03/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60)", "company_name": "Amgen Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-125-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-125", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 125 ug (NDC 72305-125-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "16729-277-30", "generic_name": "Methotrexate Sodium Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: 30 days", "openfda": {"application_number": ["ANDA040716"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-277"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["2bae3cfe-7aa0-c14c-e063-6294a90a19f4"], "spl_set_id": ["dd035a9f-cd40-4314-b9d8-2294b8a924e2"], "package_ndc": ["16729-277-30", "16729-277-03", "16729-277-35"], "nui": ["N0000175584", "N0000000111"], "pharm_class_epc": ["Folate Analog Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Folic Acid Metabolism Inhibitors [MoA]"], "unii": ["YL5FZ2Y5U1"]}, "update_date": "05/01/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-609-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "openfda": {"application_number": ["ANDA205135"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-609", "57664-606", "57664-607", "57664-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210"], "spl_id": ["509cf8be-4306-9755-e063-6294a90ab425"], "spl_set_id": ["d048e52d-7406-4fc1-9a72-c073bafc7439"], "package_ndc": ["57664-606-88", "57664-607-88", "57664-608-88", "57664-609-88"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-60", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-799", "42806-801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-60)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/21/2018", "package_ndc": "84898-911-02", "generic_name": "Sodium Chloride 0.9% Injection", "related_info_link": "https://www.fda.gov/media/183850/download", "contact_info": "855-826-4885", "availability": "Available", "related_info": "Call to Order 855-826-4885", "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sodium Chloride, Injection, 9 g/1000 mL (NDC 84898-911-02)", "company_name": "Sichuan Kelun Pharmaceutical Co., Ltd", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2587-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075293"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2587", "0409-2596"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["6c075a2d-b68b-41a7-aa0c-bcf9894e3f76"], "spl_set_id": ["affecd4d-1f78-4bbe-5a8d-86849bbdc520"], "package_ndc": ["0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "71288-563-85", "generic_name": "Liraglutide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA218115"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-563"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["c4f6adef-1b2a-4e7c-b7a9-b19d4ed1df36"], "spl_set_id": ["0efc3a89-211a-4496-baab-e8265e07de2b"], "package_ndc": ["71288-563-84", "71288-563-85"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "08/19/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "63481-627-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-107-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA203242"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-107", "76045-104", "76045-105", "76045-209"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860113", "860114", "860115"], "spl_id": ["0dab642d-7fcf-4301-8ac9-10e64a040c6b"], "spl_set_id": ["3d88cbe6-5230-47aa-80af-0c41283d1f00"], "package_ndc": ["76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-350-38", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-350", "61703-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"], "spl_set_id": ["0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab"], "package_ndc": ["61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "39822-5525-3", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "866-390-4411", "availability": "Available", "openfda": {"application_number": ["ANDA040737"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-5525"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460"], "spl_id": ["0e3526e1-38be-1d89-e063-6294a90a775d"], "spl_set_id": ["1d02d52b-84bb-4e81-b352-125029eb39f6"], "package_ndc": ["39822-5525-2", "39822-5525-3"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Other", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-608-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "openfda": {"application_number": ["ANDA205135"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-608", "57664-606", "57664-607", "57664-609"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210"], "spl_id": ["509cf8be-4306-9755-e063-6294a90ab425"], "spl_set_id": ["d048e52d-7406-4fc1-9a72-c073bafc7439"], "package_ndc": ["57664-606-88", "57664-607-88", "57664-608-88", "57664-609-88"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0409-1061-01", "generic_name": "Pemetrexed Ditromethamine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "07/17/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Pemetrexed Ditromethamine, Injection, 500 mg Single Dose Vial (NDC 0409-1061-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-602-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": {"application_number": ["NDA206628"], "brand_name": ["DEXMEDETOMIDINE IN DEXTROSE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["WG Critical Care, LLC"], "product_ndc": ["44567-602", "44567-600", "44567-601", "44567-603"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909", "1788947"], "spl_id": ["e6fa3e27-b374-49b6-a678-a5954f5beae8"], "spl_set_id": ["0d2710f2-ee47-4114-ab5c-8dca74cdcb8d"], "package_ndc": ["44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)", "company_name": "HQ Specialty Pharma", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-560-90", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-560", "62037-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-90)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4900-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/19/2026", "update_type": "New", "initial_posting_date": "03/19/2026", "package_ndc": "64764-805-10", "generic_name": "Ramelteon Tablet", "contact_info": "877-825-3327", "related_info": "Product is expected to be available through February 2027.", "openfda": {"application_number": ["NDA021782"], "brand_name": ["ROZEREM"], "generic_name": ["RAMELTEON"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["64764-805"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RAMELTEON"], "rxcui": ["577348", "603162"], "spl_id": ["2021e7fb-108a-4783-9a37-8bc05bf28b28"], "spl_set_id": ["9de82310-70e8-47b9-b1fc-6c6848b99455"], "package_ndc": ["64764-805-30", "64764-805-10", "64764-805-22"], "nui": ["N0000175743", "N0000000250"], "pharm_class_epc": ["Melatonin Receptor Agonist [EPC]"], "pharm_class_moa": ["Melatonin Receptor Agonists [MoA]"], "unii": ["901AS54I69"]}, "update_date": "03/19/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Rozerem, Tablet, 8 mg (NDC 64764-805-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3290-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3290", "0781-3288", "0781-3289"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a"], "spl_set_id": ["231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca"], "package_ndc": ["0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/18/2020", "package_ndc": "63323-771-39", "generic_name": "Azacitidine Injection", "contact_info": "1-888-386-1300", "availability": "Available", "related_info": "Check wholesaler inventory", "openfda": {"application_number": ["ANDA207518"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-771"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["4becda8d-8042-4cf1-bef3-c0ec3c23eebe"], "spl_set_id": ["3b594aba-e798-4105-b801-0b0d970747c1"], "package_ndc": ["63323-771-39"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3612-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA208084"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-3612", "0338-3410", "0338-3814"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["c8906ab2-37d2-4fde-9784-0442bf7b9565"], "spl_set_id": ["78832ac6-04c5-45e0-ae4d-f56d7920dda9"], "package_ndc": ["0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-153", "72888-152", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-05)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-423-12", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA040803"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-423", "67457-422", "67457-421", "67457-420"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["dd5c82b6-a194-462c-9626-34a9b410cfea"], "spl_set_id": ["dff598e8-e662-411f-978d-4ba3fb8ef7db"], "package_ndc": ["67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6000-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["ATIVAN"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6000", "0641-6003", "0641-6002", "0641-6001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327"], "spl_id": ["209b0091-c890-4f69-a693-d0594c2606fe"], "spl_set_id": ["5fc0e987-61c9-40c4-b0d5-fcea07c8733e"], "package_ndc": ["0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0517-1004-25", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-645-1706", "availability": "Available", "openfda": {"application_number": ["ANDA216120"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["American Regent, Inc."], "product_ndc": ["0517-1004", "0517-1001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190795", "1666781"], "spl_id": ["1c500ed9-94a9-472c-bfb7-50e1fcfc31fb"], "spl_set_id": ["6fee1727-52b7-4f73-ab45-ef47d6a1c5bb"], "package_ndc": ["0517-1004-01", "0517-1004-25", "0517-1001-01", "0517-1001-25"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)", "company_name": "American Regent, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-0832-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0832", "0093-3212", "0093-3213"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "55566-2500-0", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Spray", "presentation": "Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/05/2026", "update_type": "New", "initial_posting_date": "01/05/2026", "package_ndc": "0409-4350-03", "generic_name": "Diltiazem Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075853"], "brand_name": ["DILTIAZEM HYDROCHLORIDE"], "generic_name": ["DILTIAZEM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4350", "0409-1171"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DILTIAZEM HYDROCHLORIDE"], "rxcui": ["1791230", "1791240"], "spl_id": ["18648c0d-5f60-4195-92f0-1dffc1452d4c"], "spl_set_id": ["bba03666-ff4f-4bf6-fa92-78e1ec2d9073"], "package_ndc": ["0409-1171-11", "0409-1171-01", "0409-1171-12", "0409-1171-02", "0409-4350-13", "0409-4350-03"], "unii": ["OLH94387TE"]}, "update_date": "01/05/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-4350-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6046-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6046", "0641-6044", "0641-6045", "0641-6047"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100", "238101", "1665188", "1665326"], "spl_id": ["7c73dbc6-2623-4443-9b05-97dec7a0be2e"], "spl_set_id": ["e9b54e42-04cf-4c62-90e1-36f7b31a4e81"], "package_ndc": ["0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/20/2023", "package_ndc": "0527-4666-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4666", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "55150-226-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206206"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-226", "55150-225"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["30f618bf-fbbd-4489-acbb-204e8ed78dca"], "spl_set_id": ["116385ea-69fc-4f44-b463-6210291032df"], "package_ndc": ["55150-225-05", "55150-226-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070553", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-134-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-134", "72205-132", "72205-133", "72205-135", "72205-136", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-146-25", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Available", "related_info": "Please check wholesalers for inventory", "openfda": {"application_number": ["ANDA203972"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["42023-146", "42023-186", "42023-187"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710", "1718906", "1718909"], "spl_id": ["54174211-6684-4fb9-a605-be12b94e2948"], "spl_set_id": ["1ee59985-4c1d-48f7-b8f9-5584c2d55e08"], "package_ndc": ["42023-146-25", "42023-186-20", "42023-187-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)", "company_name": "Par Health, USA LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-172-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-172", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-464-50", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-464", "65219-456", "65219-458", "65219-460", "65219-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "0143-9519-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA089340"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9519", "0143-9518", "0143-9517", "0143-9516"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE"], "rxcui": ["1655959", "1655960", "1655967", "1655968"], "spl_id": ["3046ff78-3565-46d1-a88b-283e5ff6e7c3"], "spl_set_id": ["3989d30d-56e5-4e8d-9379-c30fecc894f2"], "package_ndc": ["0143-9519-10", "0143-9518-01", "0143-9517-01", "0143-9516-01"], "nui": ["N0000175584", "N0000000111"], "pharm_class_epc": ["Folate Analog Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Folic Acid Metabolism Inhibitors [MoA]"], "unii": ["YL5FZ2Y5U1"]}, "update_date": "05/12/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "47335-326-18", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-818-4555", "resolved_note": "Available", "openfda": {"application_number": ["ANDA090356"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["b0c2b60a-dc96-483b-933e-2fed58b64372"], "spl_set_id": ["0f30f885-d0cd-4fa6-a8e0-142f08a56792"], "package_ndc": ["47335-326-83", "47335-326-88", "47335-326-08", "47335-326-18"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-18)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-617-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202725"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL HYDROCHLORIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-617", "65862-618", "65862-619", "65862-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["5263abd5-ce46-4918-9bb0-9632861bcbc9"], "spl_set_id": ["93e6e668-5306-4f26-81d8-cbc3a7a5e787"], "package_ndc": ["65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78"], "unii": ["33067B3N2M"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0009-0017-58", "generic_name": "Triazolam Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA017892"], "brand_name": ["HALCION"], "generic_name": ["TRIAZOLAM"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TRIAZOLAM"], "rxcui": ["198318", "208681"], "spl_id": ["632e2836-1da3-4c6d-a954-e452580587e2"], "spl_set_id": ["a0da0dba-a56d-486b-a45b-e8a7cdfbeac6"], "package_ndc": ["0009-0017-55", "0009-0017-58"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["1HM943223R"]}, "update_date": "09/29/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Halcion, Tablet, .25 mg (NDC 0009-0017-58)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-1015-50", "generic_name": "Amantadine Hydrochloride Capsule", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA070589"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-1015"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849389"], "spl_id": ["398493aa-8a67-10e2-e063-6394a90aef8d"], "spl_set_id": ["5232b933-1df9-43b4-8ac2-61bfa4855e68"], "package_ndc": ["0832-1015-00", "0832-1015-50"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Capsule", "presentation": "Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-50)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"presentation": "Zovia 1/50E-28, Tablet, Kit (NDC 0093-8073-16)", "discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-8073-16", "generic_name": "Ethinyl Estradiol; Ethinyl Diacetate Tablet", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "update_date": "06/13/2025", "therapeutic_category": ["Reproductive"], "status": "To Be Discontinued", "dosage_form": "Tablet", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0763-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0763", "0527-0760", "0527-0761", "0527-0762", "0527-0764", "0527-0765", "0527-0766"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8893-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8893", "0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-04", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"presentation": "Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1559-10", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-250-50", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207183"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-250", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-925-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA212571"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-925", "67457-924"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["b51a1fb0-fcee-4a76-9eaf-91c35813c242"], "spl_set_id": ["f140de5a-f13d-46b4-a742-049c63e474f5"], "package_ndc": ["67457-924-00", "67457-924-50", "67457-925-00", "67457-925-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/11/2024", "package_ndc": "0264-7387-50", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7387"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE"], "rxcui": ["237656"], "spl_id": ["200c4b9e-283a-4dea-b33a-9bb4936b2b99"], "spl_set_id": ["8ccb10fe-75a5-440b-8cd4-b11f4e98f7b0"], "package_ndc": ["0264-7387-50"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0338-0072-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA209900"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0072", "0338-0069", "0338-0076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2da4dd8a-1b18-481d-b733-9c031d9ea7e3"], "spl_set_id": ["4b58836d-9d58-4539-9691-9e11c505ef2a"], "package_ndc": ["0338-0069-10", "0338-0072-25", "0338-0076-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-0090-01", "generic_name": "Carbamazepine Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA070541"], "brand_name": ["EPITOL"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0090"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["211817", "308979"], "spl_id": ["5c31da75-fc21-4ab2-9487-64169767ebd0"], "spl_set_id": ["32bbe864-7374-44da-8c6e-e733f0648243"], "package_ndc": ["0093-0090-01"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "06/10/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Epitol, Tablet, 200 mg (NDC 0093-0090-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-050-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-050", "72305-025", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 50 ug (NDC 72305-050-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "47335-326-08", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-818-4555", "resolved_note": "Available", "openfda": {"application_number": ["ANDA090356"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["b0c2b60a-dc96-483b-933e-2fed58b64372"], "spl_set_id": ["0f30f885-d0cd-4fa6-a8e0-142f08a56792"], "package_ndc": ["47335-326-83", "47335-326-88", "47335-326-08", "47335-326-18"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-08)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "80789-117-50", "generic_name": "Vigabatrin Oral Solution", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/16/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Solution", "presentation": "Vigpoder, Oral Solution, 50 mg/1 mL (NDC 80789-117-50)", "company_name": "Pyros Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-605-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": {"application_number": ["NDA017533"], "brand_name": ["KLONOPIN"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["H2-Pharma, LLC"], "product_ndc": ["61269-605", "61269-610", "61269-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529", "206157", "206159", "206160"], "spl_id": ["63cfdab9-fb3d-4c2b-bf88-8ba841dba839"], "spl_set_id": ["cfa0d79a-843c-4b88-95a1-e9511d649ca1"], "package_ndc": ["61269-605-10", "61269-610-10", "61269-620-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, .5 mg (NDC 61269-605-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/26/2025", "update_type": "New", "initial_posting_date": "06/26/2025", "package_ndc": "0093-5539-01", "generic_name": "Eszopiclone Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA091169"], "brand_name": ["ESZOPICLONE"], "generic_name": ["ESZOPICLONE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5539", "0093-5537", "0093-5538"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ESZOPICLONE"], "rxcui": ["485440", "485442", "485465"], "spl_id": ["efcf4106-ac0a-4f8b-bcd0-743e45e66924"], "spl_set_id": ["2435e2f1-bc52-488f-80e9-f1758e354aae"], "package_ndc": ["0093-5537-56", "0093-5538-01", "0093-5539-01"], "unii": ["UZX80K71OE"]}, "update_date": "06/26/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Eszopiclone, Tablet, 3 mg (NDC 0093-5539-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/11/2024", "package_ndc": "42858-167-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-167", "42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-166"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA075154"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-411", "63323-412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/23/2026", "update_type": "New", "initial_posting_date": "03/23/2026", "package_ndc": "39822-3050-2", "generic_name": "Pentamidine Isethionate Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA206982"], "brand_name": ["PENTAMIDINE ISETHIONATE"], "generic_name": ["PENTAMIDINE ISETHIONATE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-3050"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PENTAMIDINE ISETHIONATE"], "rxcui": ["861601"], "spl_id": ["0fcb7bdf-013e-a77c-e063-6394a90ad20f"], "spl_set_id": ["860c799c-5199-4f0c-b21b-9910273474d9"], "package_ndc": ["39822-3050-2"], "unii": ["V2P3K60DA2"]}, "update_date": "03/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Pentamidine Isethionate, Injection, 300 mg/3 mL (NDC 39822-3050-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0169-7703-21", "generic_name": "Somatropin Injection", "contact_info": "833-493-4689", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["BLA021148"], "brand_name": ["NORDITROPIN"], "generic_name": ["SOMATROPIN"], "manufacturer_name": ["Novo Nordisk"], "product_ndc": ["0169-7703", "0169-7704", "0169-7705", "0169-7708"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["SOMATROPIN"], "rxcui": ["847243", "847245", "847247", "847348", "849850", "849851", "1736262", "1736329"], "spl_id": ["b67c2419-4feb-4ce1-b97e-88760a8e1aee"], "spl_set_id": ["1058e17c-9261-459c-a3e6-fae38d196c14"], "package_ndc": ["0169-7704-21", "0169-7704-92", "0169-7705-21", "0169-7705-92", "0169-7708-21", "0169-7708-92", "0169-7703-11", "0169-7703-91", "0169-7703-21", "0169-7703-92"], "nui": ["N0000175606", "M0028842"], "pharm_class_epc": ["Recombinant Human Growth Hormone [EPC]"], "pharm_class_cs": ["Human Growth Hormone [CS]"], "unii": ["NQX9KB6PCL"]}, "update_date": "11/14/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0764-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0764", "0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0765", "0527-0766"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-708-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-708", "13811-709", "13811-706", "13811-707", "13811-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-517-36", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-517", "61314-454", "61314-473", "61314-476", "61314-509", "61314-531"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, Kit (NDC 61314-517-36)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0480-7270-98", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077793"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-7270"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904481"], "spl_id": ["95e8c960-5096-43a9-8807-89cdf404a214"], "spl_set_id": ["f66cb1c1-5ff1-4b0b-89d0-8ecaee26b0b8"], "package_ndc": ["0480-7270-98", "0480-7270-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-05", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-799", "42806-801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-05)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "66794-229-41", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-414-1901", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA210437"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM"], "manufacturer_name": ["Piramal Critical Care Inc"], "product_ndc": ["66794-229", "66794-228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["3f9e12e4-d3c5-fba6-e063-6294a90a7fd6"], "spl_set_id": ["98255b70-51f9-8d16-e053-2995a90a8f97"], "package_ndc": ["66794-229-02", "66794-229-41", "66794-228-02", "66794-228-41"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)", "company_name": "Piramal Critical Care Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3289-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Unavailable", "related_info": "Estimated full recovery: August 2026", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3289", "0781-3288", "0781-3290"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a"], "spl_set_id": ["231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca"], "package_ndc": ["0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)", "company_name": "Sandoz Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/17/2023", "change_date": "01/27/2026", "package_ndc": "0054-0389-25", "generic_name": "Methamphetamine Hydrochloride Tablet", "contact_info": "800-631-2174", "resolved_note": "Available", "openfda": {"application_number": ["ANDA203846"], "brand_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "generic_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0389"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHAMPHETAMINE HYDROCHLORIDE"], "rxcui": ["977860"], "spl_id": ["9f3c9287-0615-4d2e-823d-673b33586e06"], "spl_set_id": ["90c02ac6-e5e2-4c97-8c68-81e4e389a195"], "package_ndc": ["0054-0389-25"], "unii": ["997F43Z9CV"]}, "update_date": "01/27/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 0054-0389-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-191-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-191", "11534-190", "11534-192", "11534-193", "11534-194", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-588-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": {"application_number": ["NDA021121"], "brand_name": ["CONCERTA"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-588", "50458-585", "50458-586", "50458-587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212"], "spl_id": ["64d7c1e1-e7ed-4d74-a44d-13b4da64af9a"], "spl_set_id": ["1a88218c-5b18-4220-8f56-526de1a276cd"], "package_ndc": ["50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0472-0803-02", "generic_name": "Desonide Lotion", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA072354"], "brand_name": ["DESONIDE"], "generic_name": ["DESONIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-0803", "0472-0804"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DESONIDE"], "rxcui": ["197572", "349351"], "spl_id": ["f3953b9e-138f-4d86-8eea-0fc03c3c2747"], "spl_set_id": ["ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99"], "package_ndc": ["0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["J280872D1O"]}, "update_date": "09/18/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Lotion", "presentation": "Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-02)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-385-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9391-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA210594"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9391", "0143-9392", "0143-9393"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["5c5e498b-d829-4f78-bcca-466631014767"], "spl_set_id": ["9d289052-1eb6-4ba2-a3ca-d2e542a052ae"], "package_ndc": ["0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10"], "unii": ["5V444H5WIC"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/04/2025", "update_type": "New", "initial_posting_date": "12/04/2025", "package_ndc": "0093-7352-01", "generic_name": "Calcitriol Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug", "openfda": {"application_number": ["ANDA075765"], "brand_name": ["CALCITRIOL"], "generic_name": ["CALCITRIOL"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7352", "0093-7353"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CALCITRIOL"], "rxcui": ["308867", "308868"], "spl_id": ["9e6df585-e3d1-4a89-bc02-8e4b223578c4"], "spl_set_id": ["ec93b667-aad2-4e3a-adc6-952f070a0c0a"], "package_ndc": ["0093-7352-01", "0093-7353-01"], "nui": ["M0004229", "N0000175908"], "pharm_class_cs": ["Cholecalciferol [CS]"], "pharm_class_epc": ["Vitamin D3 Analog [EPC]"], "unii": ["FXC9231JVH"]}, "update_date": "12/04/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Calcitriol, Capsule, .25 ug (NDC 0093-7352-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-150-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-150", "61703-360", "61703-262", "61703-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["5aa72c15-8033-4559-b257-373371b18958"], "spl_set_id": ["47677091-fd20-49af-933c-c9dd2be21de9"], "package_ndc": ["61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8235-05", "generic_name": "Insulin Lispro-aabc Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["BLA761109"], "brand_name": ["LYUMJEV TEMPO PEN"], "generic_name": ["INSULIN LISPRO-AABC"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8235", "0002-7728", "0002-7726", "0002-8207", "0002-8351", "0002-8228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN LISPRO"], "rxcui": ["2380231", "2380236", "2380248", "2380250", "2380254", "2380256", "2380259", "2380260", "2380265", "2380266", "2380267", "2380268"], "spl_id": ["567d0b77-239e-4a05-9d84-8364e0e1ef7a"], "spl_set_id": ["c5a056e2-b568-4ca6-9ed8-79c010942d00"], "package_ndc": ["0002-7728-01", "0002-7728-99", "0002-7726-01", "0002-7726-05", "0002-8207-01", "0002-8207-05", "0002-8207-61", "0002-8351-01", "0002-8351-05", "0002-8235-01", "0002-8235-05", "0002-8235-99", "0002-8228-01", "0002-8228-27"], "nui": ["N0000004931", "N0000175453"], "pharm_class_cs": ["Insulin [Chemical/Ingredient]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["GFX7QIS1II"]}, "update_date": "10/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-112-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-112", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 112 ug (NDC 72305-112-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-254-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-254", "55150-251", "55150-252", "55150-255", "55150-253", "55150-256"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-491-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE MPF"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-491", "63323-492", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-350-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-350", "61703-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"], "spl_set_id": ["0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab"], "package_ndc": ["61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "0409-1403-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1403", "0409-5160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["f01f9986-43f9-40e8-9506-11bfe78f9242"], "spl_set_id": ["f01f9986-43f9-40e8-9506-11bfe78f9242"], "package_ndc": ["0409-1403-05", "0409-1403-10", "0409-5160-01", "0409-5160-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4916-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-61", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "83634-302-02", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Avenacy Inc."], "product_ndc": ["83634-302"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1b3f2803-b618-4447-b5ac-cd2bdc7de3e8"], "spl_set_id": ["7d0db0f7-bf4f-4b0b-9359-2a838626e04b"], "package_ndc": ["83634-302-42", "83634-302-02", "83634-302-43", "83634-302-04", "83634-302-41", "83634-302-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL; 2mL vial (NDC 83634-302-02)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-820-05", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Estimated availability: May 2026", "openfda": {"application_number": ["ANDA201835"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-820", "25021-821"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["13e1ca54-4fc4-4e93-a52d-c9320865e3cb"], "spl_set_id": ["f98314ea-a4e4-4f78-987b-3e9b45a08bb4"], "package_ndc": ["25021-820-05", "25021-820-10", "25021-821-05"], "unii": ["43502P7F0P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-410-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": {"application_number": ["ANDA205823"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Solco Healthcare US, LLC"], "product_ndc": ["43547-410", "43547-411", "43547-412", "43547-413"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["b8f1731a-cbac-4f64-a8d4-320b80b335e1"], "spl_set_id": ["cd46691d-5593-4a9f-a937-999c6803e312"], "package_ndc": ["43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/20/2026", "update_type": "New", "initial_posting_date": "04/20/2026", "package_ndc": "0068-0597-01", "generic_name": "Rifampin Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050627"], "brand_name": ["RIFADIN IV"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Sanofi-Aventis U.S. LLC"], "product_ndc": ["0068-0597"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["RIFAMPIN"], "rxcui": ["207436", "312821"], "spl_id": ["d5ee3f24-779e-4fd0-ba26-e870acbd1111"], "spl_set_id": ["036ab68e-5085-4edc-bd83-784b43d64eab"], "package_ndc": ["0068-0597-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5814-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA090866"], "brand_name": ["VALSARTAN"], "generic_name": ["VALSARTAN"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-5814", "0378-5807", "0378-5813", "0378-5815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VALSARTAN"], "rxcui": ["349199", "349200", "349201", "349483"], "spl_id": ["a5384d58-48c7-494a-a8a8-c296b316bd91"], "spl_set_id": ["73e01dc6-7dd4-421a-a4f6-137e75f69f9a"], "package_ndc": ["0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77"], "nui": ["N0000000070", "N0000175561"], "pharm_class_moa": ["Angiotensin 2 Receptor Antagonists [MoA]"], "pharm_class_epc": ["Angiotensin 2 Receptor Blocker [EPC]"], "unii": ["80M03YXJ7I"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 160 mg (NDC 0378-5814-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2022", "package_ndc": "76204-027-01", "generic_name": "Albuterol Sulfate Solution", "contact_info": "803-806-3300", "availability": "Available", "openfda": {"application_number": ["ANDA218386"], "brand_name": ["ALBUTEROL SULFATE INHALATION SOLUTION, 0.5%"], "generic_name": ["ALBUTEROL SULFATE"], "manufacturer_name": ["Ritedose Pharmaceuticals, LLC"], "product_ndc": ["76204-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["ALBUTEROL SULFATE"], "rxcui": ["245314"], "spl_id": ["4e7f86ab-55bc-c123-e063-6394a90abd8d"], "spl_set_id": ["fdb4ac5a-bf0d-4896-89f7-1828c081b79e"], "package_ndc": ["76204-027-11", "76204-027-01"], "unii": ["021SEF3731"]}, "update_date": "05/04/2026", "therapeutic_category": ["Pediatric", "Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)", "company_name": "Ritedose Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "55150-335-01", "generic_name": "Carboplatin Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; check wholesalers for inventory", "openfda": {"application_number": ["ANDA205487"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-335", "55150-333", "55150-334", "55150-386"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["6029d051-ee8d-44cc-8dae-b91c3385d4c3", "5abfcb87-bb02-4384-9c9d-7d0e3e809311"], "spl_set_id": ["f5fe9a20-47a5-45b9-ab06-c6158d9b6aca", "5abfcb87-bb02-4384-9c9d-7d0e3e809311"], "package_ndc": ["55150-333-01", "55150-334-01", "55150-335-01", "55150-386-01", "55150-335-00", "55150-386-00"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4244-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA077269"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4244", "0703-4246", "0703-4248", "0703-4239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c"], "spl_set_id": ["f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37"], "package_ndc": ["0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-11", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-407", "43547-406", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-11)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4902-34", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0591-5553-50", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA062421"], "brand_name": ["DOXYCYCLINE HYCLATE"], "generic_name": ["DOXYCYCLINE HYCLATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5553"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DOXYCYCLINE HYCLATE"], "rxcui": ["1650143"], "spl_id": ["0fb9a3f8-9ebb-4c21-8a73-9f082b39039c"], "spl_set_id": ["a569ba80-ffea-40b2-9fbe-a42810b1fccb"], "package_ndc": ["0591-5553-50", "0591-5553-05"], "unii": ["19XTS3T51U"]}, "update_date": "06/13/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0338-0431-03", "generic_name": "Heparin Sodium Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018609"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0431", "0338-0433", "0338-0424", "0338-0428"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["68b37381-6db4-4ac0-ba6b-3204add02665"], "spl_set_id": ["0d929726-76c3-48fc-b4e7-fd06409f9fb3"], "package_ndc": ["0338-0431-03", "0338-0433-04", "0338-0424-18", "0338-0428-12"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/20/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/04/2025", "update_type": "New", "initial_posting_date": "06/04/2025", "package_ndc": "0003-3638-10", "generic_name": "Atazanavir Sulfate Oral Powder", "contact_info": "1-800-332-2056; for Medical Inquiries (1-800-321-1335)", "related_info": "Permanent discontinuation", "openfda": {"application_number": ["NDA206352"], "brand_name": ["REYATAZ"], "generic_name": ["ATAZANAVIR"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "product_ndc": ["0003-3638", "0003-3624", "0003-3631", "0003-3622"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ATAZANAVIR SULFATE"], "rxcui": ["402093", "402094", "402246", "402247", "664741", "664743", "1598985", "1598989"], "spl_id": ["510c2d51-4943-401c-a008-ea22f61c6938"], "spl_set_id": ["165cff62-b284-4a27-a65d-9ec8a5bfcdd8"], "package_ndc": ["0003-3624-12", "0003-3631-12", "0003-3622-12", "0003-3638-10"], "unii": ["4MT4VIE29P"]}, "update_date": "06/04/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Oral Powder", "presentation": "Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "0409-9633-05", "generic_name": "Verapamil Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075136"], "brand_name": ["VERAPAMIL HYDROCHLORIDE"], "generic_name": ["VERAPAMIL HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9633", "0409-1144", "0409-4011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VERAPAMIL HYDROCHLORIDE"], "spl_id": ["fec5ce65-a6c8-4945-9f22-47b00be775ba"], "spl_set_id": ["1c993365-1b62-4524-e781-d307f28f63bc"], "package_ndc": ["0409-1144-62", "0409-1144-02", "0409-1144-65", "0409-1144-05", "0409-4011-61", "0409-4011-01", "0409-9633-65", "0409-9633-05"], "unii": ["V3888OEY5R"]}, "update_date": "11/21/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-38", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-176-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Unavailable", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 10 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-176", "47781-174", "47781-175", "47781-177", "47781-178", "47781-179", "47781-180"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-6535-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA062933"], "brand_name": ["VANCOMYCIN HYDROCHLORIDE"], "generic_name": ["VANCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6535", "0409-6531", "0409-6534"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VANCOMYCIN HYDROCHLORIDE"], "rxcui": ["1807513", "1807516", "1807518"], "spl_id": ["771a44e0-5858-449c-be36-438a9ff52e67"], "spl_set_id": ["2fd9de3f-a95f-451c-a687-d2e1306e53bf"], "package_ndc": ["0409-6531-11", "0409-6531-01", "0409-6535-11", "0409-6535-01", "0409-6534-11", "0409-6534-01"], "unii": ["71WO621TJD"]}, "update_date": "09/09/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 1 g Single Dose ADD-Vantage® Glass Vial (NDC 0409-6535-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9506-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9506", "0143-9507"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["98560882-bfdf-404e-ab8b-3ee2a6875830"], "spl_set_id": ["75bf0494-7cb9-4e8a-8edd-af62f035d236"], "package_ndc": ["0143-9506-01", "0143-9506-10", "0143-9507-01", "0143-9507-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-179-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Unavailable", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 20 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-179", "47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-180"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "47335-326-83", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-818-4555", "resolved_note": "Available", "openfda": {"application_number": ["ANDA090356"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["b0c2b60a-dc96-483b-933e-2fed58b64372"], "spl_set_id": ["0f30f885-d0cd-4fa6-a8e0-142f08a56792"], "package_ndc": ["47335-326-83", "47335-326-88", "47335-326-08", "47335-326-18"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-83)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-18", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: September 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-339"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0ddf4411-7138-412a-908a-fadf22bdfb79"], "spl_set_id": ["c3ae9880-44bb-4f4e-93d8-8a5e21708a30"], "package_ndc": ["61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/03/2023", "package_ndc": "42571-132-52", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(908) 484-7410", "availability": "Available", "openfda": {"application_number": ["ANDA202745"], "brand_name": ["CROMOLYN SODIUM"], "generic_name": ["CROMOLYN SODIUM"], "manufacturer_name": ["Micro Labs Limited"], "product_ndc": ["42571-132"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261"], "spl_id": ["22ffea9c-cd39-22dd-e063-6394a90aae4b"], "spl_set_id": ["93f80edb-3b38-423e-8cd6-5b5cb4393ec2"], "package_ndc": ["42571-132-21", "42571-132-52"], "unii": ["Q2WXR1I0PK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)", "company_name": "Micro Labs LTD", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "60505-0815-0", "generic_name": "Desmopressin Acetate Spray", "contact_info": "800-706-5575", "availability": "Available", "openfda": {"application_number": ["ANDA076703"], "brand_name": ["DESMOPRESSIN ACETATE"], "generic_name": ["DESMOPRESSIN ACETATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-0815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["NASAL"], "substance_name": ["DESMOPRESSIN ACETATE"], "rxcui": ["849506"], "spl_id": ["f90935bd-bb23-2f9c-3271-8508e92d45c4"], "spl_set_id": ["1ac423b8-27a6-4cef-4a82-c50bf81b4f49"], "package_ndc": ["60505-0815-0"], "unii": ["XB13HYU18U"]}, "update_date": "05/08/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Spray", "presentation": "Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)", "company_name": "Apotex Corp.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/01/2026", "update_type": "New", "initial_posting_date": "04/01/2026", "package_ndc": "61474-9711-1", "generic_name": "Icosapent Ethyl Capsule", "contact_info": "800-706-5575", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Icosapent Ethyl, Capsule, 1 g (NDC 61474-9711-1)", "company_name": "Apotex Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6042-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA075772"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6042", "0641-6043", "0641-6041"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["25d6c438-45d2-4162-91c2-b5caa0f86bf3"], "spl_set_id": ["0c2c75c9-ed7b-46a8-9543-429bf2d8f090"], "package_ndc": ["0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-163-30", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-163", "55150-161", "55150-162", "55150-164", "55150-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0220-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-128-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/06/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 10 mg (NDC 49884-128-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-164-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-164", "55150-161", "55150-162", "55150-163", "55150-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5116-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5116", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9630-05", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021146"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9630", "0409-1630", "0409-4910", "0409-4911"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["ab573c15-9504-48d1-bf4a-d8b8d7ae748a"], "spl_set_id": ["ad8916e7-206e-409e-2582-30d072845dd4"], "package_ndc": ["0409-1630-15", "0409-1630-10", "0409-9630-15", "0409-9630-05", "0409-4910-11", "0409-4910-34", "0409-4911-11", "0409-4911-34"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4275-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA088325"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4275", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4664-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4664", "0527-4661", "0527-4662", "0527-4663", "0527-4665", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "63323-725-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206223"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-725", "63323-723", "63323-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["2f27e51f-2b55-47ee-bd4a-001b71c60622"], "spl_set_id": ["d2374b84-81c9-44f9-a4a9-1071281b2531"], "package_ndc": ["63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10"], "unii": ["5V444H5WIC"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "69489-721-05", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018738"], "brand_name": ["EXELDERM"], "generic_name": ["SULCONAZOLE NITRATE"], "manufacturer_name": ["Journey Medical Corporation"], "product_ndc": ["69489-721"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["SULCONAZOLE NITRATE"], "rxcui": ["208118", "313125"], "spl_id": ["af026933-9a3d-4027-90f6-57fe4349d11e"], "spl_set_id": ["5b73e83e-8d3c-4d96-b4f6-9f854430add8"], "package_ndc": ["69489-721-30", "69489-721-05"], "unii": ["1T89100D5U"]}, "update_date": "05/08/2026", "therapeutic_category": ["Dermatology"], "dosage_form": "Solution", "presentation": "Exelderm, Solution, 1.0% 5 mL (NDC 69489-721-05)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-724-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-724", "59651-722", "59651-723"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 59651-724-01)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3181-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089645"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3181", "0409-1209", "0409-3177", "0409-3178", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-050-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-050", "72305-025", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 50 ug (NDC 72305-050-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-531-64", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-531", "61314-454", "61314-473", "61314-476", "61314-509", "61314-517"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, Kit (NDC 61314-531-64)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075604"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-720", "62037-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["1801294", "1801298"], "spl_id": ["01fbdb24-0987-40f6-a920-f36349f6ba61"], "spl_set_id": ["db002ae3-f54c-40a4-9cb4-e5681bf426e3"], "package_ndc": ["62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10"], "unii": ["660YQ98I10"]}, "update_date": "11/21/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9045-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071168"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9045", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4776-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA080408"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4776", "0409-4713", "0409-4278", "0409-4279", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-159-74", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA203040"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-159", "55150-158", "55150-160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737566", "1737568", "1737757"], "spl_id": ["cc439f66-fdd6-41f9-8a08-3f623898f20c"], "spl_set_id": ["5524cbfd-d6e6-42eb-aaa5-22495e0a86b6"], "package_ndc": ["55150-158-72", "55150-159-74", "55150-160-72"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)", "company_name": "Eugia US LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8894-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8894", "0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8893"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5315-11", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5315", "0245-5316"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "43066-023-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Limited supply; Check wholesalers for inventory; Marketed by Baxter", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-023", "43066-015", "43066-019", "43066-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734084", "1734207", "1734475", "1734483"], "spl_id": ["a8d08579-825f-40d9-b1e3-e47b73765ae6"], "spl_set_id": ["781d4b7f-7556-4695-8d48-7772d7a0d8e9"], "package_ndc": ["43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10"], "unii": ["V910P86109"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)", "company_name": "Caplin Steriles, Ltd.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0990-6139-03", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "Allocated to Contracted Customers Only. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6139-03", "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-170-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-170", "55150-167", "55150-168", "55150-169", "55150-171", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0990-4178-03", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-4178-03", "openfda": {"application_number": ["NDA019398"], "brand_name": ["AMINOSYN-PF"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-4178"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["831426", "831430"], "spl_id": ["488d78ac-3cd2-4593-8968-2992fe59bb49"], "spl_set_id": ["2d212e10-7e08-4aeb-b63f-dcc927897769"], "package_ndc": ["0990-4178-03"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0409-6695-02", "generic_name": "Etomidate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018227"], "brand_name": ["AMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6695"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008", "1654009", "1654011"], "spl_id": ["b59f4852-2843-4a8f-a597-306ebddb259a"], "spl_set_id": ["b7ed5bf8-ba75-44dc-8f81-96b4ad5766be"], "package_ndc": ["0409-6695-11", "0409-6695-01", "0409-6695-12", "0409-6695-02"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1418-01", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Shortage per Manufacturer: Manufacturing Delay", "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-064-01", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-064", "65862-062", "65862-063"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-01)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6127-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA205758"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6127", "0641-6126", "0641-6125"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011"], "spl_id": ["fa18221d-2353-4cf6-a210-fb33ee79d3d9"], "spl_set_id": ["6023606c-150c-40c5-9175-598efe2a56c3"], "package_ndc": ["0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/24/2025", "package_ndc": "82154-0449-1", "generic_name": "Peginterferon alfa-2a Injection", "contact_info": "800-506-8501, email: medinfo.us@pharmaand.com", "availability": "Limited Availability", "related_info": "Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.", "openfda": {"application_number": ["BLA103964"], "brand_name": ["PEGASYS"], "generic_name": ["PEGINTERFERON ALFA-2A"], "manufacturer_name": ["pharmaand GmbH"], "product_ndc": ["82154-0449", "82154-0451"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PEGINTERFERON ALFA-2A"], "rxcui": ["351270", "352297", "731326", "731328"], "spl_id": ["3c18e4a2-193f-ef4e-e063-6394a90a56b2"], "spl_set_id": ["d9290e5b-6d40-2318-e053-2995a90a9916"], "package_ndc": ["82154-0449-1", "82154-0451-4"], "nui": ["N0000175521", "M0025711"], "pharm_class_epc": ["Interferon alpha [EPC]"], "pharm_class_cs": ["Interferon-alpha [CS]"], "unii": ["Q46947FE7K"]}, "update_date": "08/19/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)", "company_name": "pharmaand GmbH (pharma&)", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0025-0325-01", "generic_name": "Adalimumab-afzb Injection", "contact_info": "800-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["BLA761118"], "brand_name": ["ABRILADA"], "generic_name": ["ADALIMUMAB-AFZB"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0025-0325", "0025-0328", "0025-0333", "0025-0347", "0025-0319"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["797544", "2668064", "2668071", "2668074", "2668078", "2668095", "2668096", "2668105", "2668106", "2668109", "2668113"], "spl_id": ["0989d777-c225-46a6-854e-01bdf4f19679"], "spl_set_id": ["5ef1c7cf-466f-495e-8d13-82e2ddfa7a4f"], "package_ndc": ["0025-0325-01", "0025-0325-02", "0025-0318-01", "0069-1111-01", "0025-0328-01", "0025-0328-02", "0025-0317-01", "0025-0333-02", "0025-0329-01", "0025-0347-02", "0025-0331-01", "0025-0319-01"]}, "update_date": "10/09/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Abrilada, Injection, Kit (NDC 0025-0325-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1163-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070597"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1163", "0409-1159", "0409-1160", "0409-1162", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-1", "generic_name": "Carboplatin Injection", "related_info_link": "https://dps.fda.gov/drugshortages/discontinuations/carboplatin-injection", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Available", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.)", "openfda": {"application_number": ["ANDA077861"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-6282"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0e68e276-b0df-4f03-e063-6394a90a22b9"], "spl_set_id": ["1c275825-0275-4c73-b650-e4c1519f13b8"], "package_ndc": ["60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)", "company_name": "Teyro Labs", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-3051-02", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA208129"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["27411591-44a1-44c4-89c3-dd8c2687f0e2"], "spl_set_id": ["4d5d2294-89a0-4b6f-aa00-d39a0393b6a8"], "package_ndc": ["63323-671-02", "63323-671-20", "63323-671-05", "63323-671-50", "63323-671-01", "63323-671-00"], "unii": ["1018WH7F9I"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "16729-526-08", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/28/2025", "update_type": "New", "initial_posting_date": "05/28/2025", "package_ndc": "0472-0804-15", "generic_name": "Desonide Cream", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA019048"], "brand_name": ["DESONIDE"], "generic_name": ["DESONIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-0804", "0472-0803"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DESONIDE"], "rxcui": ["197572", "349351"], "spl_id": ["f3953b9e-138f-4d86-8eea-0fc03c3c2747"], "spl_set_id": ["ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99"], "package_ndc": ["0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["J280872D1O"]}, "update_date": "05/28/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Cream", "presentation": "Desowen, Cream, .5 mg/1 g (NDC 0472-0804-15)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7766-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210050"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7766", "0093-7767", "0093-7768", "0093-7769"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["aa521933-950a-441b-9146-93e479a4dde7"], "spl_set_id": ["e3bca36b-29ed-4a2b-a1be-a57b6af805f6"], "package_ndc": ["0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "03/02/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9595-25", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA084625"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9595", "0143-9594"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737566", "1737761"], "spl_id": ["a7da0a25-5efb-48fa-9063-f7c0423f820f"], "spl_set_id": ["1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1"], "package_ndc": ["0143-9595-01", "0143-9595-25", "0143-9594-01", "0143-9594-25"], "unii": ["V13007Z41A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-408-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-408", "43547-406", "43547-407"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 43547-408-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0069-1975-40", "generic_name": "Tafamidis Meglumine Capsule", "contact_info": "800-879-3477", "related_info": "Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025.", "openfda": {"application_number": ["NDA211996"], "brand_name": ["VYNDAQEL"], "generic_name": ["TAFAMIDIS MEGLUMINE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-1975", "0069-8730"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TAFAMIDIS MEGLUMINE"], "spl_id": ["67f1031d-c298-4cf9-9051-bb8f99e56442"], "spl_set_id": ["1b4121ee-a733-4456-a917-be2603477839"], "package_ndc": ["0069-1975-12", "0069-1975-40", "0069-8730-01", "0069-8730-30"], "unii": ["8FG9H9D31J", "ZU7CF08A1A"]}, "update_date": "09/29/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-1975-40)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72266-147-10", "generic_name": "Etomidate Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": {"application_number": ["ANDA209058"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE INJECTION"], "manufacturer_name": ["Fosun Pharma USA Inc"], "product_ndc": ["72266-147", "72266-146"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["2b365133-b609-3285-e063-6394a90a69a6"], "spl_set_id": ["8b6c54d8-3f3f-4290-841c-976bea01086f"], "package_ndc": ["72266-146-01", "72266-146-10", "72266-147-01", "72266-147-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0472-1030-16", "generic_name": "Homatropine Methylbromide and Hydrocodone Bitartrate Syrup", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA088017"], "brand_name": ["HYDROMET"], "generic_name": ["HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-1030"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HOMATROPINE METHYLBROMIDE", "HYDROCODONE BITARTRATE"], "rxcui": ["992668", "992675"], "spl_id": ["7937f983-1f1c-475b-ab10-76a582d1bedd"], "spl_set_id": ["a324c912-a3ef-4296-b9a8-b0fec687eb06"], "package_ndc": ["0472-1030-16"], "unii": ["68JRS2HC1C", "NO70W886KK"]}, "update_date": "09/11/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Syrup", "presentation": "Hydromet, Syrup, 1.5 mg/5 mL; 5 mg/5 mL (NDC 0472-1030-16)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-727-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA076655"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-727", "62037-725", "62037-734", "62037-726"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "spl_id": ["24aa9277-3773-489d-8459-f9215140c53f"], "spl_set_id": ["85ef422d-af27-4126-9841-6892af1871d6"], "package_ndc": ["62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/21/2020", "package_ndc": "16729-306-10", "generic_name": "Azacitidine Injection", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA207475"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["28604daf-46a3-ef6c-e063-6394a90a4b27"], "spl_set_id": ["70140e11-33f1-2240-e053-2991aa0a0480"], "package_ndc": ["16729-306-10"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 16729-306-10)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1165-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070585"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1165", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-61", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-61", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "16729-239-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexmedetomidine%20Hydrochloride%20Injection&st=d", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA204023"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["2de0daf8-b7a3-1dca-e063-6394a90a4d0a"], "spl_set_id": ["2b9881f0-4a66-660f-e054-00144ff88e88"], "package_ndc": ["16729-239-30", "16729-239-93"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-400-11", "generic_name": "Insulin Degludec Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Degludec 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA203314"], "brand_name": ["INSULIN DEGLUDEC"], "generic_name": ["INSULIN DEGLUDEC"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-400", "73070-403", "73070-503"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN DEGLUDEC"], "rxcui": ["1670011", "1670021", "2107520"], "spl_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "spl_set_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "package_ndc": ["73070-403-15", "73070-503-15", "73070-400-11"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["54Q18076QB"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Degludec, Injection, 10 mL Insulin Degludec vial (NDC 73070-400-11)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-76", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE AQUA"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0521"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["0bc2d27e-e0d0-4c85-a5e1-808c625b6f93"], "spl_set_id": ["c85dc235-3f42-4361-9bd2-1aaff798ad75"], "package_ndc": ["0574-0521-04", "0574-0521-08", "0574-0521-25", "0574-0521-74", "0574-0521-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-154", "72888-152", "72888-153"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-01)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA074086"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["e71e9520-871b-479d-9652-1857fceca863", "5d6b1dfe-d679-4aea-97a6-3d074a202afe"], "spl_set_id": ["dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58"], "package_ndc": ["0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-31", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4713-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA080408"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9412-92", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA062738"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9412", "0781-9413"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["1721475", "1721476"], "spl_id": ["f1afd007-8e8c-40e2-b353-8def35a0ce8b"], "spl_set_id": ["f77db491-31c4-4a7c-a114-0f3244c97090"], "package_ndc": ["0781-9412-15", "0781-9412-92", "0781-9413-15", "0781-9413-92"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/17/2025", "update_type": "New", "initial_posting_date": "11/17/2025", "package_ndc": "78206-170-01", "generic_name": "Montelukast Sodium Tablet, Chewable", "contact_info": "844-674-3200", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020830"], "brand_name": ["SINGULAIR"], "generic_name": ["MONTELUKAST SODIUM"], "manufacturer_name": ["Organon LLC"], "product_ndc": ["78206-170", "78206-171", "78206-173", "78206-172"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["MONTELUKAST SODIUM"], "rxcui": ["153892", "153893", "200224", "242438", "261367", "311759", "351246", "404406"], "spl_id": ["57a12189-3bb3-4a5d-b5fe-fc57db87c134"], "spl_set_id": ["482dcc92-b47f-4ea6-854a-f5ac2aea7842"], "package_ndc": ["78206-171-01", "78206-170-01", "78206-173-01", "78206-172-01", "78206-172-02"], "unii": ["U1O3J18SFL"]}, "update_date": "11/17/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Tablet, Chewable", "presentation": "Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01)", "company_name": "Organon", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5807-93", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA090866"], "brand_name": ["VALSARTAN"], "generic_name": ["VALSARTAN"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-5807", "0378-5813", "0378-5814", "0378-5815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VALSARTAN"], "rxcui": ["349199", "349200", "349201", "349483"], "spl_id": ["a5384d58-48c7-494a-a8a8-c296b316bd91"], "spl_set_id": ["73e01dc6-7dd4-421a-a4f6-137e75f69f9a"], "package_ndc": ["0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77"], "nui": ["N0000000070", "N0000175561"], "pharm_class_moa": ["Angiotensin 2 Receptor Antagonists [MoA]"], "pharm_class_epc": ["Angiotensin 2 Receptor Blocker [EPC]"], "unii": ["80M03YXJ7I"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 40 mg (NDC 0378-5807-93)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3410-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA208084"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-3410", "0338-3612", "0338-3814"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["c8906ab2-37d2-4fde-9784-0442bf7b9565"], "spl_set_id": ["78832ac6-04c5-45e0-ae4d-f56d7920dda9"], "package_ndc": ["0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-137-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-137", "16729-136", "16729-138"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 16729-137-00)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72572-161-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Distributed by Civica", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Civica, Inc."], "product_ndc": ["72572-161", "72572-160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["380f0c88-03f8-4cfa-8823-4766c2f7700c"], "spl_set_id": ["98002094-f065-4b5f-963f-2c34b5241316"], "package_ndc": ["72572-160-01", "72572-160-10", "72572-161-01", "72572-161-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-02", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016694"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0023", "0338-0017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-408-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-408", "43547-406", "43547-407"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 43547-408-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-560-01", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-560", "62037-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-599-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": {"application_number": ["ANDA214456"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Alembic Pharmaceuticals Inc."], "product_ndc": ["62332-599", "62332-600", "62332-601"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["9030f496-5021-4454-ac16-dbb376315608"], "spl_set_id": ["419cf756-3c96-4bb8-ae96-6aea5a5f3afd"], "package_ndc": ["62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/15/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "63323-426-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA078651"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-426"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["d6e2ff8d-838d-4c27-8e73-230548b09d63", "3f4d5e11-2c14-4406-8954-04dba2fc65ff"], "spl_set_id": ["f1933332-1ae0-4dc1-be4c-694849e6c9f9", "fb9524b2-c353-4747-8954-7ca2529eabb2"], "package_ndc": ["63323-426-02", "63323-426-05", "63323-426-01", "63323-426-10", "63323-426-12", "63323-426-15"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/27/2025", "update_type": "New", "initial_posting_date": "06/27/2025", "package_ndc": "0591-3713-19", "generic_name": "Ezetimibe Tablet", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the product", "openfda": {"application_number": ["ANDA200831"], "brand_name": ["EZETIMIBE"], "generic_name": ["EZETIMIBE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3713"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EZETIMIBE"], "rxcui": ["349556"], "spl_id": ["24aaf5ca-08e0-4db8-9734-cf2a606f8e57"], "spl_set_id": ["f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba"], "package_ndc": ["0591-3713-30", "0591-3713-19", "0591-3713-05"], "nui": ["N0000008553", "N0000175911"], "pharm_class_pe": ["Decreased Cholesterol Absorption [PE]"], "pharm_class_epc": ["Dietary Cholesterol Absorption Inhibitor [EPC]"], "unii": ["EOR26LQQ24"]}, "update_date": "06/27/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Ezetimibe, Tablet, 10 mg (NDC 0591-3713-19)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-116-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-116", "70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-03", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016694"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0023", "0338-0017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-006-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X10ML) is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/17/2025", "update_type": "New", "initial_posting_date": "10/17/2025", "package_ndc": "0006-3074-02", "generic_name": "Elbasvir; Grazoprevir Tablet", "contact_info": "800-672-6372", "related_info": "To be discontinued December 1, 2025", "openfda": {"application_number": ["NDA208261"], "brand_name": ["ZEPATIER"], "generic_name": ["ELBASVIR AND GRAZOPREVIR"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "product_ndc": ["0006-3074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ELBASVIR", "GRAZOPREVIR ANHYDROUS"], "rxcui": ["1734636", "1734642"], "spl_id": ["227ae348-5f6f-44d8-a6dc-103e63d28102"], "spl_set_id": ["164dc02a-9180-426a-b8b5-04ab39d2bbd4"], "package_ndc": ["0006-3074-01", "0006-3074-02"], "nui": ["N0000191256", "N0000190113", "N0000182638", "N0000182639", "N0000190114"], "pharm_class_epc": ["Hepatitis C Virus NS5A Inhibitor [EPC]", "Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]"], "pharm_class_moa": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "HCV NS3/4A Protease Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["632L571YDK", "8YE81R1X1J"]}, "update_date": "10/17/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Zepatier, Tablet, 50 mg; 100 mg (NDC 0006-3074-02)", "company_name": "Merck Sharp & Dohme LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3465-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": {"application_number": ["ANDA206812"], "brand_name": ["FONDAPARINUX SODIUM"], "generic_name": ["FONDAPARINUX SODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3465", "0781-3443", "0781-3454", "0781-3476"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FONDAPARINUX SODIUM"], "rxcui": ["861356", "861360", "861363", "861365"], "spl_id": ["3d5a4b69-462b-7e51-e063-6294a90a0721"], "spl_set_id": ["baa50757-a927-4d56-a933-5d7798fe6ab0"], "package_ndc": ["0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95"], "unii": ["X0Q6N9USOZ"]}, "update_date": "09/29/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/01/2025", "update_type": "New", "initial_posting_date": "07/01/2025", "package_ndc": "64950-217-03", "generic_name": "Isoniazid Tablet", "contact_info": "610-782-9780", "related_info": "Product expected to be available until August 2025.", "openfda": {"application_number": ["ANDA080937"], "brand_name": ["ISONIAZID"], "generic_name": ["ISONIAZID"], "manufacturer_name": ["Genus Lifesciences"], "product_ndc": ["64950-217", "64950-216"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ISONIAZID"], "rxcui": ["197832", "311166"], "spl_id": ["6ea58bc8-a5a8-47a1-81e1-f769924e1502"], "spl_set_id": ["f0b46d1d-2300-457d-a7bd-a88a3f8d2235"], "package_ndc": ["64950-216-10", "64950-217-03", "64950-217-10"], "nui": ["N0000175483"], "pharm_class_epc": ["Antimycobacterial [EPC]"], "unii": ["V83O1VOZ8L"]}, "update_date": "07/01/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Isoniazid, Tablet, 300 mg (NDC 64950-217-03)", "company_name": "Genus Lifesciences", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-23", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3073", "0009-3475"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-486-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076803"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-486", "62135-484", "62135-485", "62135-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["09cd5cb9-4fdf-f133-e063-6294a90af691"], "spl_set_id": ["dbc43dbd-94aa-40e2-a9ea-766110cc8687"], "package_ndc": ["62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90"], "unii": ["33067B3N2M"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0775-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0775", "0555-0971", "0555-0972", "0555-0776", "0555-0777", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5543-01", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018832"], "brand_name": ["ALLOPURINOL"], "generic_name": ["ALLOPURINOL"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5543", "0591-5544"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ALLOPURINOL"], "spl_id": ["f7e04d88-1d9b-47e6-a9ad-deb08af3c098"], "spl_set_id": ["a80fe56f-8d03-423f-8e2a-7ec8c9e5045b"], "package_ndc": ["0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05"], "nui": ["N0000175698", "N0000000206"], "pharm_class_epc": ["Xanthine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Xanthine Oxidase Inhibitors [MoA]"], "unii": ["63CZ7GJN5I"]}, "update_date": "02/19/2026", "therapeutic_category": ["Oncology", "Renal", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 100 mg (NDC 0591-5543-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "70069-021-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207442"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-021"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1812079"], "spl_id": ["73618326-ff56-4a30-9d6d-6b019b61c2cd"], "spl_set_id": ["799028e2-c0e4-494f-89ff-1b786babc34a"], "package_ndc": ["70069-021-01", "70069-021-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "66993-082-69", "generic_name": "Sumatriptan Nasal Spray", "contact_info": "866-525-0688", "related_info": "This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately March 16, 2026.", "openfda": {"application_number": ["NDA020626"], "brand_name": ["SUMATRIPTAN"], "generic_name": ["SUMATRIPTAN"], "manufacturer_name": ["Prasco Laboratories"], "product_ndc": ["66993-082", "66993-081"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["NASAL"], "substance_name": ["SUMATRIPTAN"], "rxcui": ["313159", "314227"], "spl_id": ["06b6df24-20eb-4b22-b8e3-591ae1f3518a"], "spl_set_id": ["f63e616b-ae0c-432b-badc-8c45023aa725"], "package_ndc": ["66993-081-69", "66993-082-69"], "nui": ["N0000175763", "N0000175764", "N0000175765"], "pharm_class_moa": ["Serotonin 1b Receptor Agonists [MoA]", "Serotonin 1d Receptor Agonists [MoA]"], "pharm_class_epc": ["Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]"], "unii": ["8R78F6L9VO"]}, "update_date": "09/08/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Nasal Spray", "presentation": "Imitrex, Nasal Spray, 20 mg/100 uL (NDC 66993-082-69)", "company_name": "Prasco Laboratories", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-406", "43547-407", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0182-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA200795"], "brand_name": ["GEMCITABINE"], "generic_name": ["GEMCITABINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0182", "0409-0181", "0409-0183"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["GEMCITABINE HYDROCHLORIDE"], "rxcui": ["1720960", "1720975", "1720977"], "spl_id": ["3a284abb-8c57-47dc-a138-5a6e6ab92b05", "9c9d382b-8f9a-4fbe-a231-44d73ec83b61"], "spl_set_id": ["dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"], "package_ndc": ["0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25"], "unii": ["U347PV74IL"]}, "update_date": "09/11/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-25", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE AQUA"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0521"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["0bc2d27e-e0d0-4c85-a5e1-808c625b6f93"], "spl_set_id": ["c85dc235-3f42-4361-9bd2-1aaff798ad75"], "package_ndc": ["0574-0521-04", "0574-0521-08", "0574-0521-25", "0574-0521-74", "0574-0521-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-62", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4312", "0002-4491"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-62)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4904-34", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "68025-098-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-098", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5166-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5166", "0603-5165", "0603-5167", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-10", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075604"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-720", "62037-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["1801294", "1801298"], "spl_id": ["01fbdb24-0987-40f6-a920-f36349f6ba61"], "spl_set_id": ["db002ae3-f54c-40a4-9cb4-e5681bf426e3"], "package_ndc": ["62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10"], "unii": ["660YQ98I10"]}, "update_date": "11/21/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/12/2022", "package_ndc": "0703-4636-01", "generic_name": "Streptozocin Powder, For Solution", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Powder, For Solution", "presentation": "Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4239-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA077269"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4239", "0703-4244", "0703-4246", "0703-4248"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c"], "spl_set_id": ["f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37"], "package_ndc": ["0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-311-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA091695"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["62175-311", "62175-310", "62175-312", "62175-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001564", "2001565", "2001566", "2001568"], "spl_id": ["8b133cd2-e3c6-4742-b402-2393b56ffc93"], "spl_set_id": ["3d1f5aff-5d39-496c-b5ed-7f3c70ec641c"], "package_ndc": ["62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37"], "unii": ["4B3SC438HI"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-606-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "openfda": {"application_number": ["ANDA205135"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-606", "57664-607", "57664-608", "57664-609"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210"], "spl_id": ["509cf8be-4306-9755-e063-6294a90ab425"], "spl_set_id": ["d048e52d-7406-4fc1-9a72-c073bafc7439"], "package_ndc": ["57664-606-88", "57664-607-88", "57664-608-88", "57664-609-88"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-195-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-195", "11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0777-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0777", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1752-50", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1752", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0760-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0764", "0527-0765", "0527-0766"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-020-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 20 mg/.4 mL (NDC 82497-020-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "change_date": "01/03/2025", "package_ndc": "0409-1134-05", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1134", "0409-1135"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731517", "1731537", "1731545"], "spl_id": ["a641ae70-f6ba-4f49-b5fc-b2895ef3408f"], "spl_set_id": ["cadc3fdb-8edc-44cd-aaea-89e68aaf9a04"], "package_ndc": ["0409-1134-03", "0409-1134-05", "0409-1135-02"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-03", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated availability: May 2026", "openfda": {"application_number": ["NDA017428"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0004", "0338-0003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["97390588-b679-4caa-b7f3-3d2e11074d0e"], "spl_set_id": ["ef3e79c5-3f58-4b36-a296-64b7d9a651c1"], "package_ndc": ["0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-724-05", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-724", "59651-722", "59651-723"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 59651-724-05)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "0338-0431-03", "generic_name": "Heparin Sodium Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018609"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0431", "0338-0433", "0338-0424", "0338-0428"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["68b37381-6db4-4ac0-ba6b-3204add02665"], "spl_set_id": ["0d929726-76c3-48fc-b4e7-fd06409f9fb3"], "package_ndc": ["0338-0431-03", "0338-0433-04", "0338-0424-18", "0338-0428-12"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/20/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-200-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 200 ug (NDC 72305-200-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-5820-01", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018132"], "brand_name": ["DOPAMINE HYDROCHLORIDE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5820", "0409-9104"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1743938", "1743941"], "spl_id": ["a3fac375-0709-4cc0-84db-b0e5a60b7200"], "spl_set_id": ["1f306ad2-3606-4525-5a8a-ce78f426c1a2"], "package_ndc": ["0409-5820-11", "0409-5820-01", "0409-9104-21", "0409-9104-20"], "unii": ["7L3E358N9L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-161-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078450"], "brand_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-161", "65862-162", "65862-163"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["5842ecc2-874a-481b-8997-afa9d862dc5d"], "spl_set_id": ["50a58159-9572-4445-9859-b392632597da"], "package_ndc": ["65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "63323-970-02", "generic_name": "Benztropine Mesylate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA090233"], "brand_name": ["BENZTROPINE MESYLATE"], "generic_name": ["BENZTROPINE MESYLATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-970"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BENZTROPINE MESYLATE"], "rxcui": ["885205"], "spl_id": ["11222231-55b1-48ee-a8f8-3385f1a2eb36"], "spl_set_id": ["b03bd28e-3b44-41e4-9a7e-28b9d7975245"], "package_ndc": ["63323-970-02"], "unii": ["WMJ8TL7510"]}, "update_date": "01/27/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Benztropine Mesylate, Injection, 1 mg/1 mL (NDC 63323-970-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-075-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-075", "72305-025", "72305-050", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 75 ug (NDC 72305-075-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-02", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-02", "openfda": {"application_number": ["NDA018080"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7930", "0990-7923", "0990-7922"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1077-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020255"], "brand_name": ["DOBUTAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOBUTAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1077", "0338-1073", "0338-1075"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["34c787c1-46f7-4264-951d-c88a34dca533"], "spl_set_id": ["6b17b98b-e06d-42ed-925f-69aa2699dead"], "package_ndc": ["0338-1073-02", "0338-1075-02", "0338-1077-02"], "unii": ["0WR771DJXV"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/08/2026", "update_type": "New", "initial_posting_date": "01/08/2026", "package_ndc": "0006-3516-59", "generic_name": "Imipenem and Cilastatin Injection", "contact_info": "800-672-6372", "related_info": "To be discontinued in approximately Q4 2026.", "openfda": {"application_number": ["NDA050587"], "brand_name": ["PRIMAXIN IV"], "generic_name": ["IMIPENEM AND CILASTATIN SODIUM"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "product_ndc": ["0006-3516", "0006-3514", "0006-3551", "0006-3552"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CILASTATIN SODIUM", "IMIPENEM"], "rxcui": ["1726204", "1726207", "1726214", "1726216"], "spl_id": ["34854f9b-7be0-4bfb-8cd2-40baf206fb80"], "spl_set_id": ["f41d8abd-7792-4918-1b93-bd83ea01955e"], "package_ndc": ["0006-3514-58", "0006-3516-59", "0006-3551-58", "0006-3552-59"], "unii": ["5428WXZ74M", "71OTZ9ZE0A"]}, "update_date": "01/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Primaxin, Injection, 500mg (NDC 0006-3516-59)", "company_name": "Merck Sharp & Dohme Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-025-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 25 ug (NDC 72305-025-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-256-50", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-256", "55150-251", "55150-252", "55150-253", "55150-254", "55150-255"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0535-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 40 mg (NDC 0071-0535-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "72485-508-10", "generic_name": "Etomidate Injection", "contact_info": "908-803-2586", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Armas Pharmaceuticals Inc."], "product_ndc": ["72485-508", "72485-509"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["7444860b-36c1-459d-94ba-d7301d9dc2ca"], "spl_set_id": ["75467058-da52-48fa-8d4e-e1025ec7d461"], "package_ndc": ["72485-508-01", "72485-508-10", "72485-509-01", "72485-509-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3675-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040843"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-3675", "0703-3671", "0703-3678"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["e81074cc-12b4-4ac9-a5bb-749188989b2c"], "spl_set_id": ["346ec9ce-dc98-4a55-b55e-d3af11f2d703"], "package_ndc": ["0703-3671-01", "0703-3675-01", "0703-3678-01"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6126-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.  Additional lots will be available in the May 2026 timeframe.", "openfda": {"application_number": ["ANDA205758"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6126", "0641-6127", "0641-6125"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011"], "spl_id": ["fa18221d-2353-4cf6-a210-fb33ee79d3d9"], "spl_set_id": ["6023606c-150c-40c5-9175-598efe2a56c3"], "package_ndc": ["0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/27/2023", "package_ndc": "45567-0060-2", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "New supply anticipated Q2 2026", "openfda": {"application_number": ["NDA019039"], "brand_name": ["KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE"], "generic_name": ["TECHNETIUM TC99M PYROPHOSPHATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["45567-0060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["TECHNETIUM TC-99M PYROPHOSPHATE"], "spl_id": ["3010b45e-eed1-a5d0-e063-6294a90a40cf"], "spl_set_id": ["1f0cbd23-2fb3-43b7-b8af-7de246151149"], "package_ndc": ["45567-0060-1", "45567-0060-2"], "nui": ["N0000177914", "N0000000205"], "pharm_class_epc": ["Radioactive Diagnostic Agent [EPC]"], "pharm_class_moa": ["Radiopharmaceutical Activity [MoA]"], "unii": ["5L76I61H2B"]}, "update_date": "04/17/2026", "therapeutic_category": ["Medical Imaging"], "dosage_form": "Injection", "presentation": "CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "63323-519-10", "generic_name": "Heparin Sodium Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA212441"], "brand_name": ["HEPARIN SODIUM"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-519"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["3bbbe74a-1246-41a6-9fc3-ca0230529b40"], "spl_set_id": ["25b0ba06-3274-4a3f-8c39-42d13764ecdf"], "package_ndc": ["63323-519-02", "63323-519-77", "63323-519-01", "63323-519-10"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/23/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-163-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-163", "42858-161", "42858-162", "42858-164", "42858-165", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/09/2025", "update_type": "New", "initial_posting_date": "06/09/2025", "package_ndc": "66215-101-03", "generic_name": "Bosentan Tablet", "contact_info": "800-526-7736", "openfda": {"application_number": ["NDA021290"], "brand_name": ["TRACLEER"], "generic_name": ["BOSENTAN"], "manufacturer_name": ["Actelion Pharmaceuticals US, Inc."], "product_ndc": ["66215-101", "66215-102", "66215-232"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["BOSENTAN"], "rxcui": ["349253", "352066", "656659", "656660", "1989081", "1989085"], "spl_id": ["f52a8c9c-529d-4bd8-9bfb-d91161935c20"], "spl_set_id": ["749e42fb-2fe0-45dd-9268-b43bb3f4081c"], "package_ndc": ["66215-101-06", "66215-101-03", "66215-102-06", "66215-102-03", "66215-232-14", "66215-232-56"], "unii": ["Q326023R30"]}, "update_date": "06/09/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Tracleer, Tablet, 62.5 mg (NDC 66215-101-03)", "company_name": "Actelion Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/02/2025", "update_type": "New", "initial_posting_date": "12/02/2025", "package_ndc": "0085-4331-01", "generic_name": "Posaconazole Injection", "contact_info": "800-672-6372", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA205596"], "brand_name": ["NOXAFIL"], "generic_name": ["POSACONAZOLE"], "manufacturer_name": ["Merck Sharp & Dohme LLC"], "product_ndc": ["0085-4331", "0085-1328", "0085-4324", "0085-2224"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["POSACONAZOLE"], "rxcui": ["665019", "665022", "1482908", "1482912", "1492043", "1492047", "2558603", "2558607"], "spl_id": ["56740f7d-3b29-4786-b5c7-eea6c0f14400"], "spl_set_id": ["b073b082-7b57-4423-8c06-4fd4263d6f84"], "package_ndc": ["0085-1328-01", "0085-4324-02", "0085-4331-01", "0085-2224-01", "0085-2224-02"], "nui": ["N0000175487", "M0002083"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "unii": ["6TK1G07BHZ"]}, "update_date": "12/02/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01)", "company_name": "Merck Sharp & Dohme Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "66794-230-42", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "855-273-0154", "availability": "Available", "related_info": "Marketed by Piramal Critical Care Inc.: 800-414-1901", "openfda": {"application_number": ["ANDA202126"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Piramal Critical Care Inc"], "product_ndc": ["66794-230"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["3f76a806-297b-184b-e063-6394a90a7404"], "spl_set_id": ["b93a71ed-0f9e-1ff9-e053-2995a90a789d"], "package_ndc": ["66794-230-02", "66794-230-42"], "unii": ["1018WH7F9I"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "59310-822-06", "generic_name": "Fluticasone Propionate; Salmeterol Xinafoate Powder", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA208799"], "brand_name": ["AIRDUO RESPICLICK"], "generic_name": ["FLUTICASONE PROPIONATE AND SALMETEROL"], "manufacturer_name": ["Teva Respiratory, LLC"], "product_ndc": ["59310-822", "59310-805", "59310-812"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE"], "rxcui": ["1918194", "1918199", "1918203", "1918205", "1918209", "1918211"], "spl_id": ["b597bc2d-bf1e-4f9b-826a-b3e39ed56545"], "spl_set_id": ["9c122b91-a11f-49ca-80bb-3eec5112db87"], "package_ndc": ["59310-805-06", "59310-805-08", "59310-812-06", "59310-812-08", "59310-822-06", "59310-822-08"], "unii": ["6EW8Q962A5", "O2GMZ0LF5W"]}, "update_date": "06/13/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Powder", "presentation": "AirDuo RespiClick, Powder, 232 ug; 14 ug (NDC 59310-822-06)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8891-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8893", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/08/2025", "update_type": "New", "initial_posting_date": "08/08/2025", "package_ndc": "57665-101-41", "generic_name": "Amphotericin B Injection", "contact_info": "800-447-0169", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Abelcet, Injection, 5 mg/1 mL; 3.4 mg/1 mL; 1.5 mg/1 mL (NDC 57665-101-41)", "company_name": "Leadiant Biosciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "54288-165-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Estimated recovery: end of August 2026; Distributed by BPI Labs, LLC", "openfda": {"application_number": ["ANDA207324"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["BPI Labs LLC"], "product_ndc": ["54288-165", "54288-166", "54288-167", "54288-164"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["c0a7463c-d90f-4060-a54e-6a4888e8af0e"], "spl_set_id": ["5484d2f0-0cc2-4bba-8f26-c7f6539a9606"], "package_ndc": ["54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3213-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3213", "0093-0832", "0093-3212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0264-4500-00", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "related_info": "On allocation", "openfda": {"application_number": ["ANDA091112"], "brand_name": ["PLENAMINE"], "generic_name": ["LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-4500"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "spl_id": ["905f7c55-bf0d-4150-90ef-e8f1a5455bc1"], "spl_set_id": ["a3244d1a-45b0-4e4c-bd96-f0632d761a1f"], "package_ndc": ["0264-4500-00", "0264-4500-05"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Plenamine, Injection, 0.15 (NDC 0264-4500-00)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/14/2016", "package_ndc": "63323-489-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "69097-004-67", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-247-5287", "resolved_note": "Available", "openfda": {"application_number": ["ANDA214050"], "brand_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Cipla USA Inc."], "product_ndc": ["69097-004"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["238755"], "spl_id": ["44159bea-88a1-49ac-a51e-1c27dc89d9ff"], "spl_set_id": ["451d6d04-b7d9-47d9-ba71-43cc5b9b3054"], "package_ndc": ["69097-004-67"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Pulmonary/Allergy", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Hydrocortisone Sodium Succinate, Injection, 100 mg/ Vial (NDC 69097-004-67)", "company_name": "Cipla Limited", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0990-6139-22", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "Allocated to Contracted Customers Only. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-6139-22", "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-88", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA074086"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["e71e9520-871b-479d-9652-1857fceca863", "5d6b1dfe-d679-4aea-97a6-3d074a202afe"], "spl_set_id": ["dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58"], "package_ndc": ["0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/16/2025", "update_type": "New", "initial_posting_date": "07/16/2025", "package_ndc": "0008-4117-01", "generic_name": "Ethionamide Tablet", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.\nSupply expected to exhaust September 2025", "update_date": "07/16/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Trecator, Tablet, 250 mg (NDC 0008-4117-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "70370-5025-1", "generic_name": "Crinecerfont Capsule", "contact_info": "858-617-7600", "related_info": "Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).", "openfda": {"application_number": ["NDA218808"], "brand_name": ["CRENESSITY"], "generic_name": ["CRINECERFONT"], "manufacturer_name": ["Neurocrine Biosciences, Inc."], "product_ndc": ["70370-5025", "70370-5050", "70370-5100", "70370-5250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CRINECERFONT"], "rxcui": ["2701391", "2701397", "2701399", "2701401", "2701403", "2701405", "2701409", "2701413"], "spl_id": ["f5cc43fd-6e18-4a06-8c9f-bd80ea847e83"], "spl_set_id": ["fd3a6fbd-9137-428a-ba46-df6606f07d28"], "package_ndc": ["70370-5025-1", "70370-5050-1", "70370-5100-1", "70370-5250-1"], "nui": ["N0000194151", "N0000194152"], "pharm_class_epc": ["Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC]"], "pharm_class_moa": ["Corticotropin-releasing Factor Type 1 Receptor Antagonists [MoA]"], "unii": ["MFT24BX55I"]}, "update_date": "04/28/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Crenessity, Capsule, 25 mg (NDC 70370-5025-1)", "company_name": "Neurocrine Biosciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-601-04", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": {"application_number": ["NDA206628"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["WG Critical Care, LLC"], "product_ndc": ["44567-601", "44567-600", "44567-602", "44567-603"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909", "1788947"], "spl_id": ["e6fa3e27-b374-49b6-a678-a5954f5beae8"], "spl_set_id": ["0d2710f2-ee47-4114-ab5c-8dca74cdcb8d"], "package_ndc": ["44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)", "company_name": "HQ Specialty Pharma", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-194-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-194", "11534-190", "11534-191", "11534-192", "11534-193", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "63323-750-20", "generic_name": "Oxaliplatin Injection", "contact_info": "847-550-2300", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA078811"], "brand_name": ["OXALIPLATIN"], "generic_name": ["OXALIPLATIN"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-750"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["OXALIPLATIN"], "rxcui": ["1736776", "1736781"], "spl_id": ["504bf43e-4c28-4375-a6f4-285b2357f7f7"], "spl_set_id": ["e12e2850-4980-48de-af58-15e559fb921f"], "package_ndc": ["63323-750-10", "63323-750-20"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["04ZR38536J"]}, "update_date": "02/25/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/10/2025", "update_type": "New", "initial_posting_date": "10/10/2025", "package_ndc": "0781-3518-76", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214657"], "brand_name": ["PEMETREXED"], "generic_name": ["PEMETREXED DISODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3518", "0781-3519", "0781-3520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PEMETREXED DISODIUM"], "rxcui": ["2602363", "2602365", "2602366"], "spl_id": ["764ab64b-c642-4314-83a9-efee79fe83a3"], "spl_set_id": ["7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3"], "package_ndc": ["0781-3518-76", "0781-3519-90", "0781-3520-91"], "unii": ["2PKU919BA9"]}, "update_date": "10/10/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Pemetrexed Disodium, Injection, 100 mg/4 mL (NDC 0781-3518-76)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7875-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7875", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5111-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4282-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088294"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4282", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2868", "0781-2859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-420-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA040802"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-420", "67457-423", "67457-422", "67457-421"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["dd5c82b6-a194-462c-9626-34a9b410cfea"], "spl_set_id": ["dff598e8-e662-411f-978d-4ba3fb8ef7db"], "package_ndc": ["67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0409-2026-01", "generic_name": "Docetaxel Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA022234"], "brand_name": ["DOCETAXEL"], "generic_name": ["DOCETAXEL ANHYDROUS"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2026", "0409-0016"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOCETAXEL ANHYDROUS"], "rxcui": ["1093280", "1860619"], "spl_id": ["8156a5f8-7002-479d-a08d-3c68f92c1396"], "spl_set_id": ["00c61d11-d6b7-4618-b6f6-2592dbcc8af7"], "package_ndc": ["0409-2026-01", "0409-0016-01"], "nui": ["N0000175085", "N0000175592"], "pharm_class_pe": ["Microtubule Inhibition [PE]"], "pharm_class_epc": ["Microtubule Inhibitor [EPC]"], "unii": ["699121PHCA"]}, "update_date": "06/24/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus®  (NDC 0409-2026-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0143-9254-25", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the August 2026 timeframe.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA207707"], "brand_name": ["DOPAMINE HYDROCHLORIDE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9254", "0143-9252", "0143-9253", "0143-9255"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1743938", "1743941", "1743950", "1743953"], "spl_id": ["67349236-e8e3-45ec-a76d-2a0a150d8d59"], "spl_set_id": ["0e499952-46c7-4172-8c70-186312e240a3"], "package_ndc": ["0143-9252-01", "0143-9252-25", "0143-9253-01", "0143-9253-25", "0143-9254-01", "0143-9254-25", "0143-9255-01", "0143-9255-25"], "unii": ["7L3E358N9L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0181-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA200795"], "brand_name": ["GEMCITABINE"], "generic_name": ["GEMCITABINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0181", "0409-0183", "0409-0182"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["GEMCITABINE HYDROCHLORIDE"], "rxcui": ["1720960", "1720975", "1720977"], "spl_id": ["3a284abb-8c57-47dc-a138-5a6e6ab92b05", "9c9d382b-8f9a-4fbe-a231-44d73ec83b61"], "spl_set_id": ["dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"], "package_ndc": ["0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25"], "unii": ["U347PV74IL"]}, "update_date": "09/11/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial  NovaPlus (NDC 0409-0181-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-05", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2634"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["50886ad5-eeca-4fe7-beb0-01305f92c65d"], "spl_set_id": ["3832ede8-d3fc-455d-ecab-3b77be5869f5"], "package_ndc": ["0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-61", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4312", "0002-4491"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-61)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7768-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210050"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7768", "0093-7766", "0093-7767", "0093-7769"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["aa521933-950a-441b-9146-93e479a4dde7"], "spl_set_id": ["e3bca36b-29ed-4a2b-a1be-a57b6af805f6"], "package_ndc": ["0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "03/02/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2018", "package_ndc": "73293-0001-2", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "intbiz@huons.com", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA212821"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Huons Co., Ltd."], "product_ndc": ["73293-0001", "73293-0004", "73293-0005", "73293-0003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1737566", "1737761"], "spl_id": ["4711fd53-dad3-f117-e063-6394a90a8d3d"], "spl_set_id": ["8ec2d256-fc4f-44f6-bee2-eef2bf3bf580"], "package_ndc": ["73293-0004-1", "73293-0004-2", "73293-0005-1", "73293-0005-2", "73293-0001-1", "73293-0001-2", "73293-0003-1", "73293-0003-2"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)", "company_name": "Huons Co., Ltd. (South Korea)", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-028-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-028", "65162-023", "65162-024", "65162-025", "65162-026", "65162-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2023", "package_ndc": "0143-9872-10", "generic_name": "Propranolol Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077760"], "brand_name": ["PROPRANOLOL HYDROCHLORIDE"], "generic_name": ["PROPRANOLOL HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9872"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PROPRANOLOL HYDROCHLORIDE"], "rxcui": ["856443"], "spl_id": ["4432e36f-bed0-4e42-87aa-1330d1725963"], "spl_set_id": ["91f2ff1d-68d8-4e83-a2db-618f0410ead7"], "package_ndc": ["0143-9872-01", "0143-9872-10"], "unii": ["F8A3652H1V"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "67457-228-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA079199"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["b65fbcab-781e-4706-a60b-a8eb4aeae0c1"], "spl_set_id": ["f58803b0-f173-4997-b2f8-0f415b94dacf"], "package_ndc": ["67457-228-00", "67457-228-05", "67457-228-99", "67457-228-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43066-557-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA208532"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["43066-557", "43066-555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["d0910ea1-c3e1-44f8-b8b5-1f39ffd43290"], "spl_set_id": ["aea9a3ad-c244-42be-9cd3-5df83fe2b522"], "package_ndc": ["43066-555-24", "43066-557-12"], "unii": ["1018WH7F9I"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-483-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-483", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE BITARTRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-072-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 OR CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-072", "13107-068", "13107-069", "13107-070", "13107-071", "13107-073", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6858-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6858", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-565-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-565", "47781-562", "47781-563", "47781-564", "47781-566", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1891-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1891", "0409-1890", "0409-1892", "0409-1893", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-206-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care Renal Therapies Group, LLC"], "product_ndc": ["49230-206", "49230-209", "49230-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["44506bb0-e5f3-2a05-e063-6294a90ab2c9", "43cd31e0-97ed-1eeb-e063-6294a90a0b3d"], "spl_set_id": ["bbc5b820-4973-11e2-a192-0002a5d5c51b", "c29bdfa0-4976-11e2-939b-0002a5d5c51b"], "package_ndc": ["49230-206-20", "49230-206-30", "49230-206-32", "49230-206-50", "49230-206-60", "49230-206-62", "49230-206-52", "49230-209-23", "49230-209-30", "49230-209-32", "49230-209-50", "49230-209-60", "49230-209-62", "49230-209-52", "49230-212-23", "49230-212-30", "49230-212-32", "49230-212-50", "49230-212-60", "49230-212-62", "49230-212-52", "49230-206-92", "49230-206-94", "49230-206-95", "49230-209-92", "49230-209-94", "49230-209-95", "49230-212-92", "49230-212-94", "49230-212-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-206-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2021", "package_ndc": "67457-445-60", "generic_name": "Rifampin Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA065421"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-445"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["RIFAMPIN"], "rxcui": ["312821"], "spl_id": ["f1107e3c-754b-407d-9d66-23f545c0c692"], "spl_set_id": ["8be91604-d7cd-4f2b-997d-e3364e4092e5"], "package_ndc": ["67457-445-60"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5555-02", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA202981"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868469"], "spl_id": ["e3a44e63-8594-40b6-a3fa-d135b3149661", "bcb3a2dc-1a3f-4ac7-8ea2-426f0771c246"], "spl_set_id": ["0c24b592-4bc8-456f-acac-9c9525844a06", "ea9f4498-0d43-4043-8dd1-f22537841c21"], "package_ndc": ["0409-5555-11", "0409-5555-01", "0409-5555-12", "0409-5555-02"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1165-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070585"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1165", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-600-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2026", "openfda": {"application_number": ["ANDA077059"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-600", "61703-360", "61703-150", "61703-262"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["5aa72c15-8033-4559-b257-373371b18958"], "spl_set_id": ["47677091-fd20-49af-933c-c9dd2be21de9"], "package_ndc": ["61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-137-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-137", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 137 ug (NDC 72305-137-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-105-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-105", "59417-101", "59417-102", "59417-103", "59417-104", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 50 mg (NDC 59417-105-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1893-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1893", "0409-1890", "0409-1891", "0409-1892", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-5534-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-3613-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071810"], "brand_name": ["BUPIVACAINE SPINAL"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3613"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBARACHNOID"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724784"], "spl_id": ["7a09a90d-26da-42bd-bb54-2d2102eb8c1c"], "spl_set_id": ["7a8d2539-4422-4312-0298-207ef1a2948e"], "package_ndc": ["0409-3613-11", "0409-3613-01"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/19/2025", "update_type": "New", "initial_posting_date": "08/19/2025", "package_ndc": "0093-7355-98", "generic_name": "Finasteride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076511"], "brand_name": ["FINASTERIDE"], "generic_name": ["FINASTERIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7355"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FINASTERIDE"], "rxcui": ["310346"], "spl_id": ["4c152e0f-55b3-4357-b983-897ecaf878af"], "spl_set_id": ["77589cc3-c440-4695-800c-82a0e5128a6c"], "package_ndc": ["0093-7355-56", "0093-7355-98", "0093-7355-05"], "nui": ["N0000175836", "N0000000126"], "pharm_class_epc": ["5-alpha Reductase Inhibitor [EPC]"], "pharm_class_moa": ["5-alpha Reductase Inhibitors [MoA]"], "unii": ["57GNO57U7G"]}, "update_date": "08/19/2025", "therapeutic_category": ["Urology"], "dosage_form": "Tablet", "presentation": "Finasteride, Tablet, 5 mg (NDC 0093-7355-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-150-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-150", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 150 ug (NDC 72305-150-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4277-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088327"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4277", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "23155-601-42", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA090850"], "brand_name": ["MIDAZOLAM HYDROCHLORIDE"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-601"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311702"], "spl_id": ["e20feff9-3aca-4bc1-a5c3-44fff8a9459c"], "spl_set_id": ["843cc25e-45ea-4372-ae34-843f805fa869"], "package_ndc": ["23155-601-31", "23155-601-41", "23155-601-32", "23155-601-42"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1582-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1582", "0409-1559", "0409-1560", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1582-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "83831-142-50", "generic_name": "Carboplatin Injection", "contact_info": "877-595-7337; customerservice@avyxa.com", "availability": "Available", "openfda": {"application_number": ["NDA219921"], "brand_name": ["KYXATA"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Avyxa Pharma, LLC"], "product_ndc": ["83831-142", "83831-140", "83831-141"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195", "2721602"], "spl_id": ["5c711945-70be-42f4-b153-e1459dd9929c"], "spl_set_id": ["f91c48da-68d1-4aa7-89b8-d84a3e8b629b"], "package_ndc": ["83831-140-02", "83831-141-08", "83831-142-50"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/15/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)", "company_name": "Avyxa Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "10147-1700-3", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020083"], "brand_name": ["ITRACONAZOLE"], "generic_name": ["ITRACONAZOLE"], "manufacturer_name": ["Patriot Pharmaceuticals"], "product_ndc": ["10147-1700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ITRACONAZOLE"], "rxcui": ["311204"], "spl_id": ["2cca3625-96e8-34cf-e063-6294a90ac975"], "spl_set_id": ["6242b7ad-eaa0-a524-b6e0-ec33e63407db"], "package_ndc": ["10147-1700-3", "10147-1700-7"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]"], "unii": ["304NUG5GF4"]}, "update_date": "02/27/2026", "therapeutic_category": ["Anti-Infective", "Other"], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 10147-1700-3)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6251-10", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": {"application_number": ["ANDA213561"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6251"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190776"], "spl_id": ["f5ca4281-8c89-4efc-80b1-2fbcf61c7c55"], "spl_set_id": ["4c15d3cc-7888-4c82-b3f8-a5d93c5523df"], "package_ndc": ["0641-6251-10"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6060-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6060", "0641-6057", "0641-6059", "0641-6056", "0641-6061", "0641-6063"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-127-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207934"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-127", "49884-119", "49884-125", "49884-128"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["b474c768-50e2-44da-accf-f1bd3d49ab20"], "spl_set_id": ["45d54974-3fc4-4237-a2fa-3158ca1a8105"], "package_ndc": ["49884-119-52", "49884-119-91", "49884-125-52", "49884-125-91", "49884-127-52", "49884-127-91", "49884-128-52", "49884-128-91"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "01/06/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 7.5 mg (NDC 49884-127-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-08", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4491", "0002-4312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-08)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0375-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0375", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0374"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3569-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3569", "0480-3565", "0480-3566", "0480-3567", "0480-3568", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1749-10", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1749", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-722-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-722", "59651-723", "59651-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 59651-722-01)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-196-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-196", "11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-195"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72572-160-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Distributed by Civica", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Civica, Inc."], "product_ndc": ["72572-160", "72572-161"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["380f0c88-03f8-4cfa-8823-4766c2f7700c"], "spl_set_id": ["98002094-f065-4b5f-963f-2c34b5241316"], "package_ndc": ["72572-160-01", "72572-160-10", "72572-161-01", "72572-161-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0013-05", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0013", "0009-0825", "0009-0011", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-117-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-117", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-117-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-117", "57844-105", "57844-110", "57844-112", "57844-115", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1178-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA021171"], "brand_name": ["DEMEROL"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1178", "0409-1181", "0409-1176", "0409-1179", "0409-1180", "0409-1362", "0409-1418"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192"], "spl_id": ["c1704eaf-f0a8-4ba3-89a1-2836ba7e5ee6"], "spl_set_id": ["b31d1308-28c3-43f4-e0a6-2f3ed76b8975"], "package_ndc": ["0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01"], "unii": ["N8E7F7Q170"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-63", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3288-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3288", "0781-3289", "0781-3290"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a"], "spl_set_id": ["231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca"], "package_ndc": ["0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0409-0016-01", "generic_name": "Docetaxel Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA022234"], "brand_name": ["DOCETAXEL"], "generic_name": ["DOCETAXEL ANHYDROUS"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0016", "0409-2026"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOCETAXEL ANHYDROUS"], "rxcui": ["1093280", "1860619"], "spl_id": ["8156a5f8-7002-479d-a08d-3c68f92c1396"], "spl_set_id": ["00c61d11-d6b7-4618-b6f6-2592dbcc8af7"], "package_ndc": ["0409-2026-01", "0409-0016-01"], "nui": ["N0000175085", "N0000175592"], "pharm_class_pe": ["Microtubule Inhibition [PE]"], "pharm_class_epc": ["Microtubule Inhibitor [EPC]"], "unii": ["699121PHCA"]}, "update_date": "06/24/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus®  (NDC 0409-0016-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "71225-126-06", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-566-2505", "availability": "Available", "openfda": {"application_number": ["ANDA212791"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Slayback Pharma LLC"], "product_ndc": ["71225-126"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["027725dc-e468-446c-b702-ab0f8a9e3be5"], "spl_set_id": ["e5d28ed8-e427-4850-81aa-98702d3b6a5d"], "package_ndc": ["71225-126-02", "71225-126-05", "71225-126-03", "71225-126-06", "71225-126-01", "71225-126-04"], "unii": ["1018WH7F9I"]}, "update_date": "09/17/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)", "company_name": "Slayback Pharma", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-7517-16", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019445"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7517", "0409-6648"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["727517", "1795514"], "spl_id": ["2f05a8f1-4651-405c-a66b-8e96a46c1db8"], "spl_set_id": ["4ed365da-4e62-4329-c1b9-c197ab4fb6e1"], "package_ndc": ["0409-7517-66", "0409-7517-16", "0409-6648-16", "0409-6648-02"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-603-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-603", "43547-602", "43547-604", "43547-605", "43547-606", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0591-2925-30", "generic_name": "Testosterone Gel; Gel, Metered", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "06/16/2025", "therapeutic_category": ["Urology"], "dosage_form": "Gel; Gel, Metered", "presentation": "Testosterone, Gel; Gel, Metered, 16.2 mg/1 g (NDC 0591-2925-30)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-467-57", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-467", "63323-465", "63323-460", "63323-464", "63323-466", "63323-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177"], "spl_id": ["2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-30", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA084916"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1116927", "1812194"], "spl_id": ["a832bff9-0bb3-4350-abb5-d57b9417070c", "9dd90418-e564-4bc5-9077-506a1c2c1bce"], "spl_set_id": ["2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e"], "package_ndc": ["63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-28", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-05", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-503-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-503", "64850-500", "64850-501", "64850-502", "64850-504", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-201-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088586"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-201", "63323-202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1737757"], "spl_id": ["d19c26f4-1214-40f7-9680-43c885613306"], "spl_set_id": ["cddb2b22-fce3-8967-6e54-dca3df5ac4b3"], "package_ndc": ["63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02"], "unii": ["V13007Z41A"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-086-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-086", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-568-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-568", "47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-567"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-124-40", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-124", "61703-161"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["6bb8643f-6ab4-4e1c-bcf9-b82e8cf18910"], "spl_set_id": ["bd287e89-32f9-4396-95fa-4b562869f476"], "package_ndc": ["61703-124-40", "61703-161-02", "61703-161-05"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7510", "0264-7520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0517-1001-25", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-645-1706", "availability": "Available", "openfda": {"application_number": ["ANDA216120"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["American Regent, Inc."], "product_ndc": ["0517-1001", "0517-1004"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190795", "1666781"], "spl_id": ["1c500ed9-94a9-472c-bfb7-50e1fcfc31fb"], "spl_set_id": ["6fee1727-52b7-4f73-ab45-ef47d6a1c5bb"], "package_ndc": ["0517-1004-01", "0517-1004-25", "0517-1001-01", "0517-1001-25"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)", "company_name": "American Regent, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9043-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071167"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9043", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2859", "0781-2868"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-00", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7520", "0264-7510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "55150-314-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA211930"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-314", "55150-313"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["25c5133c-ee17-4be0-88a3-d0231e38f5a0"], "spl_set_id": ["a0cbcdb5-f657-49f7-8f86-cc5959d69db0"], "package_ndc": ["55150-313-25", "55150-313-01", "55150-314-25", "55150-314-01"], "unii": ["43502P7F0P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2851-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA200881"], "brand_name": ["GUANFACINE"], "generic_name": ["GUANFACINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2851", "0228-2850", "0228-2853", "0228-2855"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GUANFACINE HYDROCHLORIDE"], "rxcui": ["862006", "862013", "862019", "862025"], "spl_id": ["b9040df2-42e8-404d-9b90-331dd3efc38c"], "spl_set_id": ["3a171942-37af-430d-8b9d-bb678ca2be4b"], "package_ndc": ["0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11"], "unii": ["PML56A160O"]}, "update_date": "11/13/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 2 mg (NDC 0228-2851-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-0040-10", "generic_name": "Ketamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074549"], "brand_name": ["KETAMINE HYDROCHLORIDE"], "generic_name": ["KETAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0040"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETAMINE HYDROCHLORIDE"], "rxcui": ["238083"], "spl_id": ["aa1e5788-73a9-4b95-99da-17eb252f8702"], "spl_set_id": ["390f2db8-0fcd-4648-b584-9effa084be27"], "package_ndc": ["0409-0040-05", "0409-0040-10"], "unii": ["O18YUO0I83"]}, "update_date": "11/07/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-431-08", "generic_name": "Docetaxel Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-483-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-483", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE BITARTRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-070-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-070", "13107-068", "13107-069", "13107-071", "13107-072", "13107-073", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-112-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-112", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 112 ug (NDC 72305-112-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "47335-326-88", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-818-4555", "resolved_note": "Available", "openfda": {"application_number": ["ANDA090356"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["47335-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["b0c2b60a-dc96-483b-933e-2fed58b64372"], "spl_set_id": ["0f30f885-d0cd-4fa6-a8e0-142f08a56792"], "package_ndc": ["47335-326-83", "47335-326-88", "47335-326-08", "47335-326-18"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-06", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-06)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070583"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596"], "spl_id": ["fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-493-91", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE MPF"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-493", "63323-492", "63323-496"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764"], "spl_id": ["fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df"], "spl_set_id": ["d5e0d06f-ba1e-44d4-aa89-39d6c146dc23"], "package_ndc": ["63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97"], "unii": ["EC2CNF7XFP"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/30/2026", "update_type": "New", "initial_posting_date": "01/30/2026", "package_ndc": "57664-656-88", "generic_name": "Pindolol Tablet", "contact_info": "800-818-4555", "related_info": "Discontinuation of the manufacture of the drug; Expiry date of last distributed batch October 2026", "openfda": {"application_number": ["ANDA074063"], "brand_name": ["PINDOLOL"], "generic_name": ["PINDOLOL"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-656", "57664-655"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PINDOLOL"], "rxcui": ["198104", "198105"], "spl_id": ["4d3c89dd-e947-5f23-e063-6294a90aeb1f"], "spl_set_id": ["b331a73f-bf7b-4442-8901-36d016530279"], "package_ndc": ["57664-656-88", "57664-655-88"], "nui": ["N0000000161", "N0000175556"], "pharm_class_moa": ["Adrenergic beta-Antagonists [MoA]"], "pharm_class_epc": ["beta-Adrenergic Blocker [EPC]"], "unii": ["BJ4HF6IU1D"]}, "update_date": "01/30/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pindolol, Tablet, 10 mg (NDC 57664-656-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/26/2025", "update_type": "New", "initial_posting_date": "09/26/2025", "package_ndc": "25021-230-05", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA090675"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-230"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["beff4b0b-e884-4134-ba9e-290020a94add"], "spl_set_id": ["caab50e6-0dad-4ddd-9a6c-96cc2b87aee7"], "package_ndc": ["25021-230-02", "25021-230-05"], "unii": ["042LAQ1IIS"]}, "update_date": "09/26/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6052-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA080445"], "brand_name": ["MEPERIDINE HYDROCHLORIDE"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6052", "0641-6053", "0641-6054"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["861476", "1665685", "1665697"], "spl_id": ["9566d54d-7343-4695-94ff-8b5f2d384c81"], "spl_set_id": ["e0e998da-f056-4fce-be8e-ed60cf3b461b"], "package_ndc": ["0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25"], "unii": ["N8E7F7Q170"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-11", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-288", "63323-286", "63323-287", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-468-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "3, 4, 5, 7 & 8 month expiry available upon request. Check wholesaler for inventory", "openfda": {"application_number": ["ANDA070966"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-468", "63323-472", "63323-463", "63323-461"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1867594", "1867596", "1867618", "1867620", "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810"], "spl_id": ["b671015d-f620-4930-a890-5e27a40ae42f", "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["b671015d-f620-4930-a890-5e27a40ae42f", "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-468-08", "63323-468-38", "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-02", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA089646"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-602-85", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-602", "60951-700", "60951-712", "60951-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-133-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-133", "72205-132", "72205-134", "72205-135", "72205-136", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0641-6147-10", "generic_name": "Sterile Water Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA206369"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["081540ac-58cf-437f-ba1b-86d5264ec3dc"], "spl_set_id": ["78ef7ad3-451d-43d0-a9b6-5cf0aadca003"], "package_ndc": ["0641-6147-01", "0641-6147-10", "0641-6147-25"], "unii": ["059QF0KO0R"]}, "update_date": "05/12/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-15", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-851", "63323-852", "63323-853", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "76045-010-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release June 2026.  Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["DILAUDID"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-010", "76045-009", "76045-121"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370"], "spl_id": ["97bfcafb-2037-47dc-a0ae-f7b8007c47df"], "spl_set_id": ["9eebd88a-5632-460f-b7b6-26c8a180540d"], "package_ndc": ["76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-2066-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA040078"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2066"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737761"], "spl_id": ["55b04269-e58a-4df8-a18c-4643c2e1433a"], "spl_set_id": ["9c18eaf1-4a0b-4916-70b2-88a827494711"], "package_ndc": ["0409-2066-10", "0409-2066-05"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-562-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-454-36", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "openfda": {"application_number": ["BLA761071"], "brand_name": ["HYRIMOZ"], "generic_name": ["ADALIMUMAB-ADAZ"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["61314-454", "61314-473", "61314-476", "61314-509", "61314-517", "61314-531"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ADALIMUMAB"], "rxcui": ["2641644", "2641650", "2641653", "2641654", "2641655", "2641658", "2641660", "2641661", "2641662", "2641663", "2641664", "2641665", "2641666", "2641667", "2641668", "2641669", "2641670", "2641671", "2641672", "2641673"], "spl_id": ["af358c91-4472-4fb1-87ba-001d67f2b4f8"], "spl_set_id": ["1ac7d061-3380-468c-b077-c05f8dfbc829"], "package_ndc": ["61314-454-20", "61314-454-36", "61314-454-68", "61314-473-64", "61314-473-20", "61314-473-92", "61314-476-64", "61314-509-64", "61314-517-36", "61314-531-64"], "nui": ["N0000175610", "N0000175451", "M0001357"], "pharm_class_epc": ["Tumor Necrosis Factor Blocker [EPC]"], "pharm_class_moa": ["Tumor Necrosis Factor Receptor Blocking Activity [MoA]"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "unii": ["FYS6T7F842"]}, "update_date": "01/13/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-102-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-102", "59417-101", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 20 mg (NDC 59417-102-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3475-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3475", "0009-3073"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6085-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PHENERGAN"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6085", "0641-6084"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992462", "992858", "992876"], "spl_id": ["7d6e64fc-bbf2-4ea9-b866-8115c448e687"], "spl_set_id": ["481866da-a712-48a5-853f-8e84aacaab6d"], "package_ndc": ["0641-6084-01", "0641-6084-25", "0641-6085-01", "0641-6085-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-472-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070554"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-472", "63323-463", "63323-461", "63323-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620"], "spl_id": ["cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-341-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-341", "42806-339", "42806-343", "42806-344", "42806-345"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-04", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016694"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0023", "0338-0017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0303-1", "generic_name": "Riluzole Oral Suspension", "contact_info": "610-937-6172", "availability": "Unavailable", "related_info": "EacNext release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing", "openfda": {"application_number": ["NDA209080"], "brand_name": ["TIGLUTIK"], "generic_name": ["RILUZOLE"], "manufacturer_name": ["EDW PHARMA, INC"], "product_ndc": ["70726-0303"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RILUZOLE"], "rxcui": ["2058147", "2059266"], "spl_id": ["4746e22f-8ca7-9149-e063-6294a90aea8d"], "spl_set_id": ["75d68f19-4208-109e-e053-2991aa0ac857"], "package_ndc": ["70726-0303-2", "70726-0303-1"], "nui": ["N0000175740", "M0483511"], "pharm_class_epc": ["Benzothiazole [EPC]"], "pharm_class_cs": ["Benzothiazoles [CS]"], "unii": ["7LJ087RS6F"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Suspension", "presentation": "Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9042-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071165"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9042", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-579-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-579", "23155-578", "23155-580", "23155-581", "23155-582", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 25 mg (NDC 23155-579-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0013-06", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0013", "0009-0825", "0009-0011", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8885-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8885", "0406-8891", "0406-8884", "0406-8892", "0406-8893", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2415-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": {"application_number": ["NDA021514"], "brand_name": ["METHYLPHENIDATE TRANSDERMAL SYSTEM"], "generic_name": ["METHYLPHENIDATE"], "manufacturer_name": ["PADAGIS US LLC"], "product_ndc": ["0574-2415", "0574-2410", "0574-2420", "0574-2430"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["METHYLPHENIDATE"], "rxcui": ["753436", "753438", "753440", "753441"], "spl_id": ["b743ef45-2fc0-4086-8a02-6078e6a09eaa"], "spl_set_id": ["7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb"], "package_ndc": ["0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65"], "nui": ["N0000175739", "N0000175729"], "pharm_class_epc": ["Central Nervous System Stimulant [EPC]"], "pharm_class_pe": ["Central Nervous System Stimulation [PE]"], "unii": ["207ZZ9QZ49"]}, "update_date": "05/07/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-02", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0280", "0009-0274", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-610-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": {"application_number": ["NDA017533"], "brand_name": ["KLONOPIN"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["H2-Pharma, LLC"], "product_ndc": ["61269-610", "61269-605", "61269-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529", "206157", "206159", "206160"], "spl_id": ["63cfdab9-fb3d-4c2b-bf88-8ba841dba839"], "spl_set_id": ["cfa0d79a-843c-4b88-95a1-e9511d649ca1"], "package_ndc": ["61269-605-10", "61269-610-10", "61269-620-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, 1 mg (NDC 61269-610-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43066-555-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA208532"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["43066-555", "43066-557"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["d0910ea1-c3e1-44f8-b8b5-1f39ffd43290"], "spl_set_id": ["aea9a3ad-c244-42be-9cd3-5df83fe2b522"], "package_ndc": ["43066-555-24", "43066-557-12"], "unii": ["1018WH7F9I"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5112-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5112", "0406-5111", "0406-5113", "0406-5114", "0406-5115", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "76329-3302-1", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "800-423-4136", "availability": "Limited Availability", "related_info": "Avaiable on allocation", "openfda": {"application_number": ["ANDA203451"], "brand_name": ["DEXTROSE MONOHYDRATE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-3302"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["727517"], "spl_id": ["45b366a9-6c0c-4643-9951-4ff880b29c83"], "spl_set_id": ["fcc7ac79-cd70-4f03-a4de-f051f9ca1f7d"], "package_ndc": ["76329-3302-1"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "0641-6254-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA217812"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6254"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897745"], "spl_id": ["ba25ec4f-3b81-4960-bf74-6a1e4c6be45c"], "spl_set_id": ["c729424e-e483-4bf8-b86c-ce56636dcffa"], "package_ndc": ["0641-6254-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-50", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018801"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4887"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["055437a7-5be5-414a-a97a-946e2730fe12"], "spl_set_id": ["2b9ea23a-f9e9-48a8-25b7-519e3bbd6828"], "package_ndc": ["0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0066-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0066", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0078", "0338-0062", "0338-0074", "0338-0070", "0338-0082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["66eb82f8-6755-42aa-b20c-192a640e8068"], "spl_set_id": ["36e9478c-5df0-4b47-b97d-de3626d7cb29"], "package_ndc": ["0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "83634-302-10", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Avenacy Inc."], "product_ndc": ["83634-302"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1b3f2803-b618-4447-b5ac-cd2bdc7de3e8"], "spl_set_id": ["7d0db0f7-bf4f-4b0b-9359-2a838626e04b"], "package_ndc": ["83634-302-42", "83634-302-02", "83634-302-43", "83634-302-04", "83634-302-41", "83634-302-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 83634-302-10)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3814-12", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA073509"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3814", "0409-3815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1728783", "1728800"], "spl_id": ["0a2ba20b-448f-4412-9899-b82040ebfa7d"], "spl_set_id": ["1d181906-f3ec-4222-1883-e61577a3122e"], "package_ndc": ["0409-3814-11", "0409-3814-12", "0409-3815-11", "0409-3815-12"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070553", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-463-57", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["ANDA070968"], "brand_name": ["SENSORCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-463", "63323-472", "63323-461", "63323-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620"], "spl_id": ["cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-6146-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": {"application_number": ["ANDA084282"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6146", "0641-0367", "0641-6145"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["02bf3273-f0c8-448c-9f74-eb009fee9299"], "spl_set_id": ["0277cc0a-2fd4-4605-a310-b613be84ee26"], "package_ndc": ["0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/12/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3212-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3212", "0093-0832", "0093-3213"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-488-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0280", "0009-0274", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1638-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1638", "0409-1660", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-09", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-09", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0093-7679-02", "generic_name": "Ethinyl Estradiol; Etonogestrel Ring", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA204305"], "brand_name": ["ETONOGESTREL AND ETHINYL ESTRADIOL"], "generic_name": ["ETONOGESTREL AND ETHINYL ESTRADIOL"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7679"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["VAGINAL"], "substance_name": ["ETHINYL ESTRADIOL", "ETONOGESTREL"], "rxcui": ["1367436"], "spl_id": ["d0827dbf-9df5-4438-a0c2-92d7d593e71c"], "spl_set_id": ["a8cc104a-d522-49ad-af54-2f312b829b61"], "package_ndc": ["0093-7679-01", "0093-7679-02"], "nui": ["N0000175825", "N0000000100", "M0447349", "N0000175602"], "pharm_class_epc": ["Estrogen [EPC]", "Progestin [EPC]"], "pharm_class_moa": ["Estrogen Receptor Agonists [MoA]"], "pharm_class_cs": ["Progesterone Congeners [CS]"], "unii": ["423D2T571U", "304GTH6RNH"]}, "update_date": "06/16/2025", "therapeutic_category": ["Reproductive"], "dosage_form": "Ring", "presentation": "Ethinyl Estradiol; Etonogestrel, Ring, .015 mg/1 d; .12 mg/1 d (NDC 0093-7679-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0372-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0372", "0054-0660", "0054-0370", "0054-0371", "0054-0373", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-722-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-722", "71288-721", "71288-724", "71288-725", "71288-727", "71288-728"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-251-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-251", "55150-252", "55150-254", "55150-255", "55150-253", "55150-256"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4663-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4663", "0527-4661", "0527-4662", "0527-4664", "0527-4665", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-06", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA090108"], "brand_name": ["CLINDAMYCIN"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["1737244", "1737578", "1737581"], "spl_id": ["4662502b-ce7c-4278-854d-cf8632ac9b83"], "spl_set_id": ["7a6967b3-5563-4bed-9eee-d400f800e799"], "package_ndc": ["25021-115-02", "25021-115-04", "25021-115-06"], "unii": ["EH6D7113I8"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-723-99", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-723", "59651-722", "59651-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 59651-723-99)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-03", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7930-03", "openfda": {"application_number": ["NDA018080"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7930", "0990-7923", "0990-7922"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1007-03", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA019615"], "brand_name": ["DOPAMINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1007", "0338-1005", "0338-1009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1292887", "1743869", "1743871", "1743877", "1743879"], "spl_id": ["edc9a091-4cb5-4ec7-b6f9-44d2d588bab9"], "spl_set_id": ["cb97d4a0-89ed-407c-a763-209386b6f75c"], "package_ndc": ["0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02"], "unii": ["7L3E358N9L"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-087-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-087", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "0074-9036-30", "generic_name": "Paricalcitol Capsule", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021606"], "brand_name": ["ZEMPLAR"], "generic_name": ["PARICALCITOL"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-9036", "0074-4314", "0074-4317", "0074-9037"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PARICALCITOL"], "rxcui": ["577315", "577317", "606854", "606859"], "spl_id": ["ed8862d9-4037-4a30-9be6-42f2613c34cd"], "spl_set_id": ["1b27c026-2d60-47b4-2a9c-ded1818f21b5"], "package_ndc": ["0074-4314-30", "0074-4317-30", "0074-4317-73", "0074-9036-30", "0074-9037-30"], "nui": ["M0007651", "N0000175907", "N0000175849"], "pharm_class_cs": ["Ergocalciferols [CS]"], "pharm_class_epc": ["Vitamin D2 Analog [EPC]", "Vitamin D Analog [EPC]"], "unii": ["6702D36OG5"]}, "update_date": "10/07/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Zemplar, Capsule, 1 ug (NDC 0074-9036-30)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-728-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-728", "71288-721", "71288-722", "71288-724", "71288-725", "71288-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-04", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA075880"], "brand_name": ["PREMASOL - SULFITE-FREE (AMINO ACID)"], "generic_name": ["LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1130", "0338-1131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "CYSTEINE HYDROCHLORIDE", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801395", "801398", "801403", "801405"], "spl_id": ["c874a813-b145-4f7f-833e-97d6c4dd727c"], "spl_set_id": ["9afdcc3e-0d06-47f4-86ca-40da48b2b02b"], "package_ndc": ["0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "ZT934N0X4W", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "61958-1401-1", "generic_name": "Cobicistat Tablet", "contact_info": "800-445-3235", "related_info": "Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons.", "openfda": {"application_number": ["NDA203094"], "brand_name": ["TYBOST"], "generic_name": ["COBICISTAT"], "manufacturer_name": ["Gilead Sciences, Inc."], "product_ndc": ["61958-1401", "61958-1402"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["COBICISTAT"], "rxcui": ["1551993", "1551999", "2719618", "2719620"], "spl_id": ["169d8571-3b28-4b3b-8def-18316f1297f3"], "spl_set_id": ["3784c35c-e87f-410c-900b-8fd6313c6010"], "package_ndc": ["61958-1401-1", "61958-1402-1"], "nui": ["N0000190114", "N0000191001", "N0000185503", "N0000182137", "N0000190107", "N0000190108", "N0000190113", "N0000191423"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]"], "pharm_class_epc": ["Cytochrome P450 3A Inhibitor [EPC]"], "unii": ["LW2E03M5PG"]}, "update_date": "10/07/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Tybost, Tablet, 150 mg (NDC 61958-1401-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-566-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-566", "47781-562", "47781-563", "47781-564", "47781-565", "47781-567", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "21586-012-02", "generic_name": "Cefotaxime Sodium Powder, for Solution", "related_info_link": "https://www.fda.gov/media/152896/download", "contact_info": "800-881-3550", "availability": "Available", "openfda": {"brand_name": ["CEFOTAXIME"], "generic_name": ["CEFOTAXIME INJECTION"], "manufacturer_name": ["SteriMax Inc."], "product_ndc": ["21586-012", "21586-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFOTAXIME SODIUM"], "rxcui": ["1656313", "1656318"], "spl_id": ["425c90b3-5006-427e-95f6-93ee7918fb8b"], "spl_set_id": ["8efe3bd0-c43a-2bd6-e053-2a95a90a92fa"], "package_ndc": ["21586-011-01", "21586-011-02", "21586-012-01", "21586-012-02"], "unii": ["258J72S7TZ"]}, "update_date": "04/30/2026", "therapeutic_category": ["Anti-Infective", "Pediatric"], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)", "company_name": "SteriMax, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "83634-302-04", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Avenacy Inc."], "product_ndc": ["83634-302"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1b3f2803-b618-4447-b5ac-cd2bdc7de3e8"], "spl_set_id": ["7d0db0f7-bf4f-4b0b-9359-2a838626e04b"], "package_ndc": ["83634-302-42", "83634-302-02", "83634-302-43", "83634-302-04", "83634-302-41", "83634-302-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL; 4mL vial (NDC 83634-302-04)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-164-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-164", "42858-161", "42858-162", "42858-163", "42858-165", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5544-05", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018877"], "brand_name": ["ALLOPURINOL"], "generic_name": ["ALLOPURINOL"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5544", "0591-5543"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ALLOPURINOL"], "spl_id": ["f7e04d88-1d9b-47e6-a9ad-deb08af3c098"], "spl_set_id": ["a80fe56f-8d03-423f-8e2a-7ec8c9e5045b"], "package_ndc": ["0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05"], "nui": ["N0000175698", "N0000000206"], "pharm_class_epc": ["Xanthine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Xanthine Oxidase Inhibitors [MoA]"], "unii": ["63CZ7GJN5I"]}, "update_date": "02/19/2026", "therapeutic_category": ["Oncology", "Renal", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 300 mg (NDC 0591-5544-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0761-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215565"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-0761", "0527-0760", "0527-0762", "0527-0763", "0527-0764", "0527-0765", "0527-0766"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["e0804f43-4685-4017-b839-3212d1167362"], "spl_set_id": ["f92497b5-baea-4760-b615-45a0b6184402"], "package_ndc": ["0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-556-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-20", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088400"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-185"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["42c6c812-706a-425b-b8cb-931006e40484"], "spl_set_id": ["e71c6c83-d518-496c-b2ab-efd5987e4783"], "package_ndc": ["63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/23/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-04", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018931"], "brand_name": ["TRAVASOL"], "generic_name": ["LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0644"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801644", "801648"], "spl_id": ["e0279078-016d-48fd-8de1-c894422b33ff"], "spl_set_id": ["8543b5be-0f43-4891-9e56-d7c39fe839b5"], "package_ndc": ["0338-0644-03", "0338-0644-04", "0338-0644-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "JNJ23Q2COM", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-154", "72888-152", "72888-153"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-05)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "69918-501-05", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Spray", "presentation": "Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6856-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6856", "0378-6854", "0378-6855", "0378-6857", "0378-6858", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3568-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3568", "0480-3565", "0480-3566", "0480-3567", "0480-3569", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-00", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Information pending", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-153", "72888-152", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-00)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-463-16", "generic_name": "Docetaxel Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-205-03", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA217501"], "brand_name": ["HYDRALAZINE HYDROCHLORIDE"], "generic_name": ["HYDRALAZINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-205"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDRALAZINE HYDROCHLORIDE"], "rxcui": ["966571"], "spl_id": ["2926d221-0ca5-4379-ac53-773051ec5c79"], "spl_set_id": ["f3c806a4-b971-421c-bcb9-9979c6d7aaec"], "package_ndc": ["71288-205-01", "71288-205-02"], "unii": ["FD171B778Y"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-202-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088586"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-202", "63323-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1737757"], "spl_id": ["d19c26f4-1214-40f7-9680-43c885613306"], "spl_set_id": ["cddb2b22-fce3-8967-6e54-dca3df5ac4b3"], "package_ndc": ["63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02"], "unii": ["V13007Z41A"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "0228-2837-11", "generic_name": "Pilocarpine Hydrochloride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA020237"], "brand_name": ["PILOCARPINE HYDROCHLORIDE"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2837", "0228-2801"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "rxcui": ["1000913", "1001004"], "spl_id": ["7db72b88-d664-4f26-901c-46c901b20d80"], "spl_set_id": ["610022b7-7dc9-405a-a580-104657f43bdf"], "package_ndc": ["0228-2801-11", "0228-2837-11"], "unii": ["0WW6D218XJ"]}, "update_date": "09/19/2025", "therapeutic_category": ["Other"], "dosage_form": "Tablet", "presentation": "Salagen, Tablet, 7.5 mg (NDC 0228-2837-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "0409-3382-21", "generic_name": "Sufentanil Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA074534"], "brand_name": ["SUFENTANIL CITRATE"], "generic_name": ["SUFENTANIL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3382"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRAVENOUS"], "substance_name": ["SUFENTANIL CITRATE"], "rxcui": ["1809097", "1809102", "1809104"], "spl_id": ["30ae65dc-5065-4eb9-880a-db8dcd2f5bb8"], "spl_set_id": ["20293943-46ff-4345-1aa4-929b4e017a25"], "package_ndc": ["0409-3382-11", "0409-3382-21", "0409-3382-12", "0409-3382-22", "0409-3382-15", "0409-3382-25"], "unii": ["S9ZFX8403R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/04/2025", "update_type": "New", "initial_posting_date": "09/04/2025", "package_ndc": "0378-3458-23", "generic_name": "Azelastine Hydrochloride; Fluticasone Propionate Nasal Spray", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA202236"], "brand_name": ["AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE"], "generic_name": ["AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-3458"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["NASAL"], "substance_name": ["AZELASTINE HYDROCHLORIDE", "FLUTICASONE PROPIONATE"], "rxcui": ["1797847"], "spl_id": ["6e1e173a-2d01-4e67-8361-dd30604bc8aa"], "spl_set_id": ["7b5cc5a0-0d47-46b5-b5fb-eb9cc248ae9e"], "package_ndc": ["0378-3458-23"], "unii": ["0L591QR10I", "O2GMZ0LF5W"]}, "update_date": "09/04/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Nasal Spray", "presentation": "Azelastine Hydrochloride; Fluticasone Propionate, Nasal Spray, 137 ug; 50 ug (NDC 0378-3458-23)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1388-1", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "877-835-5472", "availability": "Available", "openfda": {"application_number": ["ANDA207551"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1388", "70121-1389"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["795f643f-855c-4ba4-9bad-a96334c1a2fb"], "spl_set_id": ["eb1ba463-ab42-4f49-9ebe-3ad5af108326"], "package_ndc": ["70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7"], "unii": ["1018WH7F9I"]}, "update_date": "02/09/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6043-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA075772"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6043", "0641-6042", "0641-6041"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["25d6c438-45d2-4162-91c2-b5caa0f86bf3"], "spl_set_id": ["0c2c75c9-ed7b-46a8-9543-429bf2d8f090"], "package_ndc": ["0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-135-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-135", "72205-132", "72205-133", "72205-134", "72205-136", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-726-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA076772"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-726", "62037-725", "62037-734", "62037-727"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "spl_id": ["24aa9277-3773-489d-8459-f9215140c53f"], "spl_set_id": ["85ef422d-af27-4126-9841-6892af1871d6"], "package_ndc": ["62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"presentation": "Adipex-P, Tablet, 37.5 mg (NDC 57844-140-56)", "discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "57844-140-56", "generic_name": "Phentermine Hydrochloride Tablet", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "update_date": "06/13/2025", "therapeutic_category": ["Other"], "status": "To Be Discontinued", "dosage_form": "Tablet", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0304-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/185611/download?attachment", "contact_info": "610-937-6172", "availability": "Available", "openfda": {"brand_name": ["TEGLUTIK"], "generic_name": ["RILUZOLE"], "manufacturer_name": ["EDW PHARMA, INC"], "product_ndc": ["70726-0304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RILUZOLE"], "rxcui": ["2058147", "2675565"], "spl_id": ["4746bd79-5116-423c-e063-6394a90a17e1"], "spl_set_id": ["0f2b5cfc-a23d-699a-e063-6394a90a67d1"], "package_ndc": ["70726-0304-1"], "nui": ["N0000175740", "M0483511"], "pharm_class_epc": ["Benzothiazole [EPC]"], "pharm_class_cs": ["Benzothiazoles [CS]"], "unii": ["7LJ087RS6F"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9042-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071165"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9042", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-701-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-701", "60951-602", "60951-700", "60951-712"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-580-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-580", "23155-578", "23155-579", "23155-581", "23155-582", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 50 mg (NDC 23155-580-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-3724-32", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA020201"], "brand_name": ["DOBUTAMINE IN DEXTROSE"], "generic_name": ["DOBUTAMINE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3724", "0409-2347", "0409-2346", "0409-0025", "0409-0151", "0409-1100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["1c7cc97c-e244-4a4b-a4a1-8b70ca812107"], "spl_set_id": ["9943a961-3b50-4847-8a84-d8414ce38daa"], "package_ndc": ["0409-2347-31", "0409-2347-32", "0409-2346-31", "0409-2346-32", "0409-3724-11", "0409-3724-32", "0409-0025-01", "0409-0025-10", "0409-0151-01", "0409-0151-10", "0409-1100-01", "0409-1100-10"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-010-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 10 mg/.4 mL (NDC 82497-010-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-8072-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020646"], "brand_name": ["TIAGABINE HYDROCHLORIDE"], "generic_name": ["TIAGABINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8072", "0093-5030", "0093-5031", "0093-8076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TIAGABINE HYDROCHLORIDE"], "rxcui": ["1299903", "1299909", "1299911", "1299917"], "spl_id": ["2a8d7987-54ae-45d7-8224-361dac37e0a4"], "spl_set_id": ["953ef3cc-e3cb-480f-b9ea-256520fd62b8"], "package_ndc": ["0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56"], "unii": ["DQH6T6D8OY"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-461-57", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["ANDA070967"], "brand_name": ["SENSORCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-461", "63323-472", "63323-463", "63323-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620"], "spl_id": ["cc1f6507-eb3e-4398-a1d3-0c56a2099e6b"], "spl_set_id": ["bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb"], "package_ndc": ["63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/13/2025", "update_type": "New", "initial_posting_date": "08/13/2025", "package_ndc": "66658-230-01", "generic_name": "Palivizumab Injection", "contact_info": "866-773-5274", "related_info": "Discontinuation of the manufacture of the drug. Product expected to be available through September 2026.", "openfda": {"application_number": ["BLA103770"], "brand_name": ["SYNAGIS"], "generic_name": ["PALIVIZUMAB"], "manufacturer_name": ["Swedish Orphan Biovitrum AB (publ)"], "product_ndc": ["66658-230", "66658-231"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PALIVIZUMAB"], "rxcui": ["1657341", "1657343", "1657361", "1657362"], "spl_id": ["48e6af70-cd93-3f1d-e063-6394a90a8104"], "spl_set_id": ["3a0096c7-8139-44cd-bba4-520ab05c2cb2"], "package_ndc": ["66658-231-01", "66658-230-01"], "nui": ["M0001357", "N0000175615", "N0000175623"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "pharm_class_moa": ["Fusion Protein Inhibitors [MoA]"], "pharm_class_epc": ["Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]"], "unii": ["DQ448MW7KS"]}, "update_date": "08/13/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01)", "company_name": "Swedish Orphan Biovitrum AB", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0480-7270-10", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077793"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-7270"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904481"], "spl_id": ["95e8c960-5096-43a9-8807-89cdf404a214"], "spl_set_id": ["f66cb1c1-5ff1-4b0b-89d0-8ecaee26b0b8"], "package_ndc": ["0480-7270-98", "0480-7270-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "72607-100-00", "generic_name": "Tazemetostat Hydrobromide Tablet", "contact_info": "(855)-463-5127", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA211723"], "brand_name": ["TAZVERIK"], "generic_name": ["TAZEMETOSTAT"], "manufacturer_name": ["Epizyme, Inc."], "product_ndc": ["72607-100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TAZEMETOSTAT HYDROBROMIDE"], "rxcui": ["2274384", "2274390"], "spl_id": ["c4bd8d8a-22c1-4911-a9b4-7368582d8e5d"], "spl_set_id": ["7db07b5f-4e22-467c-9c0a-f830b08dbb1d"], "package_ndc": ["72607-100-00"], "unii": ["6P89T5M073"]}, "update_date": "03/27/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Tazverik, Tablet, 200 mg (NDC 72607-100-00)", "company_name": "Epizyme, Inc. (An Ipsen Company)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-007-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 4% 10X5ML)  is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-551-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-551", "64850-550", "64850-552", "64850-553", "64850-554", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-163-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078450"], "brand_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-163", "65862-161", "65862-162"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["5842ecc2-874a-481b-8997-afa9d862dc5d"], "spl_set_id": ["50a58159-9572-4445-9859-b392632597da"], "package_ndc": ["65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "65219-447-20", "generic_name": "Etomidate Injection", "contact_info": "800-551-7176", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi 800-551-7176", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-447", "65219-445"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["30488a7e-ea9e-4a27-95a9-a07149c50282"], "spl_set_id": ["d07efb9e-5264-461d-96d8-e11fa71c5751"], "package_ndc": ["65219-445-01", "65219-445-10", "65219-447-02", "65219-447-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/mL (NDC 65219-447-20)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "55150-313-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA211930"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-313", "55150-314"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["25c5133c-ee17-4be0-88a3-d0231e38f5a0"], "spl_set_id": ["a0cbcdb5-f657-49f7-8f86-cc5959d69db0"], "package_ndc": ["55150-313-25", "55150-313-01", "55150-314-25", "55150-314-01"], "unii": ["43502P7F0P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-120-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-120", "57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/17/2021", "package_ndc": "63323-351-20", "generic_name": "Rifampin Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA091181"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-351"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["RIFAMPIN"], "rxcui": ["312821"], "spl_id": ["60eb9c46-3c34-455b-a740-c03884565072"], "spl_set_id": ["a1f9f1e2-dfc0-4d31-a13b-b656d897b791"], "package_ndc": ["63323-351-20"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Rifampin, Injection, 600 mg (NDC 63323-351-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "67457-228-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA079199"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["b65fbcab-781e-4706-a60b-a8eb4aeae0c1"], "spl_set_id": ["f58803b0-f173-4997-b2f8-0f415b94dacf"], "package_ndc": ["67457-228-00", "67457-228-05", "67457-228-99", "67457-228-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-813-28", "generic_name": "Ivabradine Solution", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA209964"], "brand_name": ["CORLANOR"], "generic_name": ["IVABRADINE"], "manufacturer_name": ["Amgen Inc"], "product_ndc": ["55513-813", "55513-800", "55513-810"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IVABRADINE HYDROCHLORIDE"], "rxcui": ["1649485", "1649491", "1649493", "1649495", "2168592", "2168596"], "spl_id": ["8ab000cd-0258-489a-b1bb-4cc1ca359d6c"], "spl_set_id": ["92018a65-38f6-45f7-91d4-a34921b81d0d"], "package_ndc": ["55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28"], "unii": ["TP19837BZK"]}, "update_date": "03/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Solution", "presentation": "Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28)", "company_name": "Amgen Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-13", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-137-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-137", "16729-136", "16729-138"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 16729-137-16)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-412-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": {"application_number": ["ANDA205823"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Solco Healthcare US, LLC"], "product_ndc": ["43547-412", "43547-410", "43547-411", "43547-413"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["b8f1731a-cbac-4f64-a8d4-320b80b335e1"], "spl_set_id": ["cd46691d-5593-4a9f-a937-999c6803e312"], "package_ndc": ["43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0338-0411-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018461"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0411", "0338-0409"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e9121a0-25dd-46ba-a2b7-6f71fc3ff9cd"], "spl_set_id": ["f21512ea-c7c3-4766-b976-b2c0b5616bf0"], "package_ndc": ["0338-0409-03", "0338-0409-02", "0338-0411-02"], "unii": ["V13007Z41A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-154", "72888-152", "72888-153"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-30)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-31", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4310-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023", "update_date": "04/28/2023", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 1 mg (NDC 0069-4310-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-5095-06", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-581-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-581", "23155-578", "23155-579", "23155-580", "23155-582", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 75 mg (NDC 23155-581-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "63323-122-50", "generic_name": "Methotrexate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["ANDA040266"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-122"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["311625"], "spl_id": ["3d21237a-ef53-4592-bf06-0c739696203d"], "spl_set_id": ["ec476b11-0b3c-4139-b1eb-a3daa76bc271"], "package_ndc": ["63323-122-50"], "unii": ["3IG1E710ZN"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0527-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 5 mg (NDC 0071-0527-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-422-54", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA040803"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-422", "67457-423", "67457-421", "67457-420"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["dd5c82b6-a194-462c-9626-34a9b410cfea"], "spl_set_id": ["dff598e8-e662-411f-978d-4ba3fb8ef7db"], "package_ndc": ["67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10"], "unii": ["AI9376Y64P"]}, "update_date": "05/05/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-462-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-462", "65219-456", "65219-464", "65219-458", "65219-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "10147-0570-1", "generic_name": "Etravirine Tablet", "contact_info": "800-526-7736", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA022187"], "brand_name": ["ETRAVIRINE"], "generic_name": ["ETRAVIRINE"], "manufacturer_name": ["Patriot Pharmaceuticals"], "product_ndc": ["10147-0570", "10147-0571"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ETRAVIRINE"], "rxcui": ["754761", "1052658"], "spl_id": ["31cddc7a-0154-c49a-e063-6394a90a1a49"], "spl_set_id": ["50ca19cb-0f43-4d7b-8c9e-8b3aaded0546"], "package_ndc": ["10147-0570-1", "10147-0571-1"], "nui": ["N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000185504", "N0000182140", "N0000185503"], "pharm_class_epc": ["Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "unii": ["0C50HW4FO1"]}, "update_date": "04/28/2026", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Etravirine, Tablet, 100 mg (NDC 10147-0570-1)", "company_name": "Janssen Research and Development", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-604-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-604", "43547-602", "43547-603", "43547-605", "43547-606", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/24/2019", "package_ndc": "48102-053-05", "generic_name": "Echothiophate Iodide Ophthalmic Solution", "contact_info": "516-277-1449", "availability": "Available", "related_info": "Available through limited distribution by Walgreens Specialty Pharmacy.", "openfda": {"application_number": ["NDA011963"], "brand_name": ["PHOSPHOLINE IODIDE"], "generic_name": ["ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION"], "manufacturer_name": ["Fera Pharmaceuticals, LLC"], "product_ndc": ["48102-053"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "rxcui": ["205739", "310049"], "spl_id": ["66abcfcf-b16e-4181-b1db-96bfba0ab95e"], "spl_set_id": ["8afc8951-db76-4f27-8752-7c0d6aa47244"], "package_ndc": ["48102-053-05", "48102-054-05", "48102-055-05"]}, "update_date": "09/17/2025", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)", "company_name": "Fera Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/27/2023", "package_ndc": "69945-094-20", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "888-744-1414", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA017538"], "brand_name": ["TECHNESCAN PYP"], "generic_name": ["TECHNETIUM TC 99M PYROPHOSPHATE"], "manufacturer_name": ["Curium US LLC"], "product_ndc": ["69945-094"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM PYROPHOSPHATE", "STANNOUS CHLORIDE"], "spl_id": ["45358120-83e7-a04b-e063-6394a90af91e"], "spl_set_id": ["304b63f4-a32e-4700-805d-5bc9f27e7d6a"], "package_ndc": ["69945-094-01", "69945-094-20"], "unii": ["O352864B8Z", "1BQV3749L5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Medical Imaging"], "dosage_form": "Injection", "presentation": "Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)", "company_name": "Curium US LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-725-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-725", "71288-721", "71288-722", "71288-724", "71288-727", "71288-728"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "0781-8017-31", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021192"], "brand_name": ["FLUVASTATIN SODIUM ER"], "generic_name": ["FLUVASTATIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-8017"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUVASTATIN SODIUM"], "rxcui": ["360507"], "spl_id": ["37375ca6-3a81-4d10-9b39-9aee948e51a4"], "spl_set_id": ["5ab4296c-87c2-4c64-b218-d620eef51310"], "package_ndc": ["0781-8017-31", "0781-8017-01"], "unii": ["PYF7O1FV7F"]}, "update_date": "01/27/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4278-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088328"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4278", "0409-4713", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "83831-141-08", "generic_name": "Carboplatin Injection", "contact_info": "877-595-7337; customerservice@avyxa.com", "availability": "Available", "openfda": {"application_number": ["NDA219921"], "brand_name": ["KYXATA"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Avyxa Pharma, LLC"], "product_ndc": ["83831-141", "83831-140", "83831-142"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195", "2721602"], "spl_id": ["5c711945-70be-42f4-b153-e1459dd9929c"], "spl_set_id": ["f91c48da-68d1-4aa7-89b8-d84a3e8b629b"], "package_ndc": ["83831-140-02", "83831-141-08", "83831-142-50"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/15/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)", "company_name": "Avyxa Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6029-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6029", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6030", "0641-6247", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2855-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA200881"], "brand_name": ["GUANFACINE"], "generic_name": ["GUANFACINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2855", "0228-2850", "0228-2851", "0228-2853"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GUANFACINE HYDROCHLORIDE"], "rxcui": ["862006", "862013", "862019", "862025"], "spl_id": ["b9040df2-42e8-404d-9b90-331dd3efc38c"], "spl_set_id": ["3a171942-37af-430d-8b9d-bb678ca2be4b"], "package_ndc": ["0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11"], "unii": ["PML56A160O"]}, "update_date": "11/13/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 4 mg (NDC 0228-2855-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-162-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-162", "42858-161", "42858-163", "42858-164", "42858-165", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6084-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "This presentation is temporarily on backorder.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PHENERGAN"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6084", "0641-6085"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992462", "992858", "992876"], "spl_id": ["7d6e64fc-bbf2-4ea9-b866-8115c448e687"], "spl_set_id": ["481866da-a712-48a5-853f-8e84aacaab6d"], "package_ndc": ["0641-6084-01", "0641-6084-25", "0641-6085-01", "0641-6085-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3183-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: June 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089651"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3183", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3182", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "71288-563-84", "generic_name": "Liraglutide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA218115"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-563"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["c4f6adef-1b2a-4e7c-b7a9-b19d4ed1df36"], "spl_set_id": ["0efc3a89-211a-4496-baab-e8265e07de2b"], "package_ndc": ["71288-563-84", "71288-563-85"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "08/19/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-403-15", "generic_name": "Insulin Degludec Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Degludec 3 mL U-100 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA203314"], "brand_name": ["INSULIN DEGLUDEC"], "generic_name": ["INSULIN DEGLUDEC"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-403", "73070-503", "73070-400"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN DEGLUDEC"], "rxcui": ["1670011", "1670021", "2107520"], "spl_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "spl_set_id": ["c1be283d-4b1d-4996-b2a7-4488dbff3037"], "package_ndc": ["73070-403-15", "73070-503-15", "73070-400-11"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["54Q18076QB"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Degludec, Injection, 3 mL Insulin Degludec 100 units/mL (U-100) FlexTouch® (NDC 73070-403-15)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1573-1", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Limited Availability", "related_info": "Currently Inventory available 4 to 6 weeks as per current demand. Next supply: week of 02/09/2026", "openfda": {"application_number": ["ANDA210043"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1573", "70121-1574"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743855"], "spl_id": ["af4215ff-94ca-44f8-8506-3024e738cd13"], "spl_set_id": ["d944240d-2c19-46ba-ad4f-3fbee7b8629c"], "package_ndc": ["70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5"], "unii": ["43502P7F0P"]}, "update_date": "02/09/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-027-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-027", "65162-023", "65162-024", "65162-025", "65162-026", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3476-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": {"application_number": ["ANDA206812"], "brand_name": ["FONDAPARINUX SODIUM"], "generic_name": ["FONDAPARINUX SODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3476", "0781-3443", "0781-3454", "0781-3465"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FONDAPARINUX SODIUM"], "rxcui": ["861356", "861360", "861363", "861365"], "spl_id": ["3d5a4b69-462b-7e51-e063-6294a90a0721"], "spl_set_id": ["baa50757-a927-4d56-a933-5d7798fe6ab0"], "package_ndc": ["0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95"], "unii": ["X0Q6N9USOZ"]}, "update_date": "09/29/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "68094-909-50", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Precision Dose Inc."], "product_ndc": ["68094-909"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["efc0724d-4c6e-4974-928c-fd50774f5980"], "spl_set_id": ["b09b4b5e-795a-48e7-b7cc-2e29f41c5660"], "package_ndc": ["68094-909-30", "68094-909-50"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-50)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-99", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018801"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4887"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["055437a7-5be5-414a-a97a-946e2730fe12"], "spl_set_id": ["2b9ea23a-f9e9-48a8-25b7-519e3bbd6828"], "package_ndc": ["0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-04", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated availability: May 2026", "openfda": {"application_number": ["NDA017428"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0004", "0338-0003"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["97390588-b679-4caa-b7f3-3d2e11074d0e"], "spl_set_id": ["ef3e79c5-3f58-4b36-a296-64b7d9a651c1"], "package_ndc": ["0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-582-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-582", "23155-578", "23155-579", "23155-580", "23155-581", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 100 mg (NDC 23155-582-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5093-11", "generic_name": "Ceftazidime Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA064032"], "brand_name": ["TAZICEF"], "generic_name": ["CEFTAZIDIME"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5093", "0409-5092"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CEFTAZIDIME"], "rxcui": ["1659283", "1659287", "1659292", "1659294"], "spl_id": ["3f749ee0-db14-4ed0-9056-d545a38bbe3b"], "spl_set_id": ["9b73979c-c95a-4433-0a9d-f9cea3cb557f"], "package_ndc": ["0409-5092-11", "0409-5092-16", "0409-5093-14", "0409-5093-11"], "unii": ["9M416Z9QNR"]}, "update_date": "11/14/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Tazicef, Injection, 2 g (NDC 0409-5093-11)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018931"], "brand_name": ["TRAVASOL"], "generic_name": ["LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0644"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["801644", "801648"], "spl_id": ["e0279078-016d-48fd-8de1-c894422b33ff"], "spl_set_id": ["8543b5be-0f43-4891-9e56-d7c39fe839b5"], "package_ndc": ["0338-0644-03", "0338-0644-04", "0338-0644-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "JNJ23Q2COM", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-603-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": {"application_number": ["NDA206628"], "brand_name": ["DEXMEDETOMIDINE IN DEXTROSE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["WG Critical Care, LLC"], "product_ndc": ["44567-603", "44567-600", "44567-601", "44567-602"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909", "1788947"], "spl_id": ["e6fa3e27-b374-49b6-a678-a5954f5beae8"], "spl_set_id": ["0d2710f2-ee47-4114-ab5c-8dca74cdcb8d"], "package_ndc": ["44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)", "company_name": "HQ Specialty Pharma", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-501-43", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070017"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-501", "16729-500", "16729-502"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["1cfab300-d796-6a68-e063-6394a90a73f9"], "spl_set_id": ["f6f64972-714c-4ee9-8a5e-9ffcab41a73b"], "package_ndc": ["16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1890-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1890", "0409-1891", "0409-1892", "0409-1893", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0409-1060-01", "generic_name": "Pemetrexed Ditromethamine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "07/17/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Pemetrexed Ditromethamine, Injection, 100 mg Single Dose Vial (NDC 0409-1060-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6054-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA080445"], "brand_name": ["MEPERIDINE HYDROCHLORIDE"], "generic_name": ["MEPERIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6054", "0641-6053", "0641-6052"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["MEPERIDINE HYDROCHLORIDE"], "rxcui": ["861476", "1665685", "1665697"], "spl_id": ["9566d54d-7343-4695-94ff-8b5f2d384c81"], "spl_set_id": ["e0e998da-f056-4fce-be8e-ed60cf3b461b"], "package_ndc": ["0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25"], "unii": ["N8E7F7Q170"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-111-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "25021-321-10", "generic_name": "Bumetanide Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Product in transit, expected to arrive last week of April 2026", "openfda": {"application_number": ["ANDA074441"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-321"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["befc1cf3-b71c-4228-bc42-3495b1d4b00d"], "spl_set_id": ["c38a404d-a919-4a2c-9fbb-d0655dee9516"], "package_ndc": ["25021-321-04", "25021-321-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0078-0379-05", "generic_name": "Amlodipine Besylate; Benazepril Hydrochloride Capsule", "contact_info": "888-669-6682", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA020364"], "brand_name": ["LOTREL"], "generic_name": ["AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "product_ndc": ["0078-0379", "0078-0405", "0078-0406", "0078-0364"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMLODIPINE BESYLATE", "BENAZEPRIL HYDROCHLORIDE"], "rxcui": ["898342", "898344", "898346", "898348", "898353", "898355", "898356", "898358"], "spl_id": ["b9db75d9-9d1e-4b2d-9876-5f5520feaecc"], "spl_set_id": ["94ae6054-b7ae-4212-a567-4f803af8f2c7"], "package_ndc": ["0078-0405-05", "0078-0406-05", "0078-0364-05", "0078-0379-05"], "unii": ["864V2Q084H", "N1SN99T69T"]}, "update_date": "06/24/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Lotrel, Capsule, 10 mg; 40 mg (NDC 0078-0379-05)", "company_name": "Novartis Pharmaceuticals Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-808-11", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA212086"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-808", "63323-810"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["2474267", "2474269"], "spl_id": ["a47a3a31-e293-49d5-b6bc-950303525a64"], "spl_set_id": ["0c10e465-4117-48ba-a454-23ccb7a3fcc7"], "package_ndc": ["63323-808-01", "63323-808-11", "63323-810-00", "63323-810-20"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1389-7", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Inventory available 4 to 8 weeks as per current demand. Next supply: week of 2/23/2026", "openfda": {"application_number": ["ANDA207551"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1389", "70121-1388"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["795f643f-855c-4ba4-9bad-a96334c1a2fb"], "spl_set_id": ["eb1ba463-ab42-4f49-9ebe-3ad5af108326"], "package_ndc": ["70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7"], "unii": ["1018WH7F9I"]}, "update_date": "02/09/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-20", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7520", "0264-7510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-282-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA202747"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["36000-282", "36000-063", "36000-064", "36000-065", "36000-283", "36000-284"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53"], "spl_set_id": ["c71371a7-75c5-45b8-b762-8d782d4c71bc"], "package_ndc": ["36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3365-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3365", "0409-2552", "0409-3356", "0409-2540", "0409-1283", "0409-1312", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "897756", "897757", "897758", "1724276", "1724383", "1724644"], "spl_id": ["a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/20/2025", "update_type": "New", "initial_posting_date": "10/20/2025", "package_ndc": "0781-3315-70", "generic_name": "Oxaliplatin Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078817"], "brand_name": ["OXALIPLATIN"], "generic_name": ["OXALIPLATIN"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-3315", "0781-3317"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["OXALIPLATIN"], "rxcui": ["1736776", "1736781"], "spl_id": ["f3766495-fce3-461c-8c95-e890f5e3383f"], "spl_set_id": ["ab162009-6f84-4d56-ab56-5e84409ec814"], "package_ndc": ["0781-3315-70", "0781-3317-80"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["04ZR38536J"]}, "update_date": "10/20/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3315-70)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0025-1381-31", "generic_name": "Oxaprozin Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "07/17/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Daypro, Tablet, 600 mg (NDC 0025-1381-31)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-23", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2022", "package_ndc": "0487-9901-30", "generic_name": "Albuterol Sulfate Solution", "contact_info": "800-443-4313", "availability": "Available", "related_info": "Albuterol 0.5% is in stock, though demand remains high; additional supply can be produced as needed.", "openfda": {"application_number": ["ANDA075664"], "brand_name": ["ALBUTEROL SULFATE"], "generic_name": ["ALBUTEROL SULFATE"], "manufacturer_name": ["Nephron Pharmaceuticals Corporation"], "product_ndc": ["0487-9901"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["ALBUTEROL SULFATE"], "rxcui": ["245314"], "spl_id": ["30dbae21-c906-0624-e063-6394a90a299c"], "spl_set_id": ["ecc00500-58b8-491f-80df-dc6c89a08cae"], "package_ndc": ["0487-9901-30", "0487-9901-02"], "unii": ["021SEF3731"]}, "update_date": "05/15/2026", "therapeutic_category": ["Pulmonary/Allergy", "Pediatric"], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)", "company_name": "Nephron Pharmaceuticals Corporation", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0555-9131-67", "generic_name": "Drospirenone; Ethinyl Estradiol Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA021098"], "brand_name": ["OCELLA"], "generic_name": ["DROSPIRENONE AND ETHINYL ESTRADIOL"], "manufacturer_name": ["TEVA PHARMACEUTICALS USA, INC."], "product_ndc": ["0555-9131"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["284207", "748797", "748800", "801185"], "spl_id": ["7aced6b3-f763-4234-9b64-2ffdae162347"], "spl_set_id": ["0d729f4d-2fa3-47f6-8a1f-d8cfea4cff37"], "package_ndc": ["0555-9131-79", "0555-9131-67"]}, "update_date": "06/13/2025", "therapeutic_category": ["Reproductive"], "dosage_form": "Tablet", "presentation": "Yasmin, Tablet, Kit (NDC 0555-9131-67)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-03", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089644"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5114-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5114", "0406-5111", "0406-5112", "0406-5113", "0406-5115", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075154"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-411", "63323-412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-088-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-088", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9408-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA061395"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9408", "0781-9401", "0781-9402", "0781-9407", "0781-9404"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["308207", "1721473", "1721474", "1721475", "1721476"], "spl_id": ["a3ddae6c-ac4c-425f-82b0-eb388d92bc0e"], "spl_set_id": ["b371e1a5-1fef-4df2-8940-c4fc02b9e2f0"], "package_ndc": ["0781-9401-78", "0781-9401-95", "0781-9402-78", "0781-9402-95", "0781-9407-78", "0781-9407-95", "0781-9404-85", "0781-9404-95", "0781-9408-80", "0781-9408-95"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8235-99", "generic_name": "Insulin Lispro-aabc Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["BLA761109"], "brand_name": ["LYUMJEV TEMPO PEN"], "generic_name": ["INSULIN LISPRO-AABC"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8235", "0002-7728", "0002-7726", "0002-8207", "0002-8351", "0002-8228"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN LISPRO"], "rxcui": ["2380231", "2380236", "2380248", "2380250", "2380254", "2380256", "2380259", "2380260", "2380265", "2380266", "2380267", "2380268"], "spl_id": ["567d0b77-239e-4a05-9d84-8364e0e1ef7a"], "spl_set_id": ["c5a056e2-b568-4ca6-9ed8-79c010942d00"], "package_ndc": ["0002-7728-01", "0002-7728-99", "0002-7726-01", "0002-7726-05", "0002-8207-01", "0002-8207-05", "0002-8207-61", "0002-8351-01", "0002-8351-05", "0002-8235-01", "0002-8235-05", "0002-8235-99", "0002-8228-01", "0002-8228-27"], "nui": ["N0000004931", "N0000175453"], "pharm_class_cs": ["Insulin [Chemical/Ingredient]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["GFX7QIS1II"]}, "update_date": "10/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1574-1", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Currently Inventory available 4 to 8 Weeks as per current demand. Next supply: week of 03/16/2026", "openfda": {"application_number": ["ANDA210043"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1574", "70121-1573"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743855"], "spl_id": ["af4215ff-94ca-44f8-8506-3024e738cd13"], "spl_set_id": ["d944240d-2c19-46ba-ad4f-3fbee7b8629c"], "package_ndc": ["70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5"], "unii": ["43502P7F0P"]}, "update_date": "02/09/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "84383-110-01", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/192256/download", "contact_info": "Mark Cuban Cost Plus Drug Company: 682-428-8081", "availability": "Available", "openfda": {"brand_name": ["LENTOCILIN"], "generic_name": ["PENICILLIN G BENZATHIN"], "manufacturer_name": ["LABORATRIOS ATRAL, S.A."], "product_ndc": ["84383-110"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PENICILLIN G BENZATHINE"], "rxcui": ["2671687", "2684991"], "spl_id": ["1a4e5124-618c-ce44-e063-6394a90a43e3"], "spl_set_id": ["1a4e5124-618b-ce44-e063-6394a90a43e3"], "package_ndc": ["84383-110-01"], "unii": ["RIT82F58GK"]}, "update_date": "04/30/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)", "company_name": "Laboratorios Atral", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-652-82", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-652", "25021-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3454-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": {"application_number": ["ANDA206812"], "brand_name": ["FONDAPARINUX SODIUM"], "generic_name": ["FONDAPARINUX SODIUM"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3454", "0781-3443", "0781-3465", "0781-3476"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FONDAPARINUX SODIUM"], "rxcui": ["861356", "861360", "861363", "861365"], "spl_id": ["3d5a4b69-462b-7e51-e063-6294a90a0721"], "spl_set_id": ["baa50757-a927-4d56-a933-5d7798fe6ab0"], "package_ndc": ["0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95"], "unii": ["X0Q6N9USOZ"]}, "update_date": "09/29/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0338-0069-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA209900"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0069", "0338-0072", "0338-0076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2da4dd8a-1b18-481d-b733-9c031d9ea7e3"], "spl_set_id": ["4b58836d-9d58-4539-9691-9e11c505ef2a"], "package_ndc": ["0338-0069-10", "0338-0072-25", "0338-0076-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-339-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-339", "42806-341", "42806-343", "42806-344", "42806-345"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-7202-98", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7202", "0093-0771", "0093-7201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "55150-296-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "62135-242-60", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "845-268-5000 Ext. 510", "resolved_note": "Available", "openfda": {"application_number": ["ANDA207905"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-242"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["1adc57cf-70f9-75b9-e063-6294a90a0de0"], "spl_set_id": ["adb7c4dc-221a-4d91-9687-0d78913a92ad"], "package_ndc": ["62135-242-30", "62135-242-60", "62135-242-90"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 62135-242-60)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "51759-523-21", "generic_name": "Adalimumab-ryvk Kit", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["BLA761299"], "brand_name": ["SIMLANDI"], "generic_name": ["ADALIMUMAB-RYVK"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["51759-523", "51759-402", "51759-386", "51759-412", "51759-274"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["797544", "2677780", "2677787", "2688819", "2688823", "2688826", "2688827", "2688828", "2688829", "2706644", "2706645"], "spl_id": ["90174eed-a6f4-4153-92a1-623aadbcdc24"], "spl_set_id": ["12f609c9-2088-bb05-e063-6394a90a9ecc"], "package_ndc": ["51759-402-02", "51759-402-17", "51759-513-21", "65517-0002-1", "51759-386-22", "51759-497-31", "51759-412-22", "51759-624-31", "51759-523-21", "51759-634-31", "51759-274-17"]}, "update_date": "11/13/2025", "therapeutic_category": ["Rheumatology"], "presentation": "Simlandi, Kit, Kit (NDC 51759-523-21)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/24/2017", "package_ndc": "63323-083-05", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA206688"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-083", "63323-089"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868469", "1868486"], "spl_id": ["9def795c-abcf-483c-8b1d-e4374666efb2"], "spl_set_id": ["0ab55004-bb63-436d-ad77-cd3796905370"], "package_ndc": ["63323-083-03", "63323-083-05", "63323-089-25", "63323-089-50"], "unii": ["8MDF5V39QO"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6056-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6056", "0641-6057", "0641-6059", "0641-6061", "0641-6063", "0641-6060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-06", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Check Wholesaler for Availability; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb"], "spl_set_id": ["abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f"], "package_ndc": ["0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5165-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5165", "0603-5166", "0603-5167", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"presentation": "Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)", "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0409-7620-59", "generic_name": "Heparin Sodium Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Hematology"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-10", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA088400"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-185"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["42c6c812-706a-425b-b8cb-931006e40484"], "spl_set_id": ["e71c6c83-d518-496c-b2ab-efd5987e4783"], "package_ndc": ["63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05"], "unii": ["059QF0KO0R"]}, "update_date": "04/23/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-345-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA040444"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Epic Pharma, LLC"], "product_ndc": ["42806-345", "42806-339", "42806-341", "42806-343", "42806-344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961"], "spl_id": ["f11301e2-3b5d-468d-b44c-45839e7e5dfb"], "spl_set_id": ["1757e132-061d-4773-89ed-fdc77f69008f"], "package_ndc": ["42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-711-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["NDA216117"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-711", "13811-700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2605796", "2605798"], "spl_id": ["ba649db4-df0d-4587-8370-3f866e66e54b"], "spl_set_id": ["dd8d7b6e-c23d-4e16-bb53-959e9127ebc6"], "package_ndc": ["13811-711-30", "13811-700-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "25021-661-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA090850"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-661"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311702"], "spl_id": ["002ea282-09ba-4d79-8bd1-94c9859f442b"], "spl_set_id": ["880cac48-5c0f-49a9-8aef-3c9770bf5d84"], "package_ndc": ["25021-661-10"], "unii": ["W7TTW573JJ"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-01", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-01)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-22", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: September 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-339"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0ddf4411-7138-412a-908a-fadf22bdfb79"], "spl_set_id": ["c3ae9880-44bb-4f4e-93d8-8a5e21708a30"], "package_ndc": ["61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-1495-35", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-1495", "0641-1496"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992858"], "spl_id": ["80a400d2-d293-4180-bfa7-7a8ce0734bc5"], "spl_set_id": ["13d9e59d-eadb-41d5-9f47-9c11a6efb31c"], "package_ndc": ["0641-1495-31", "0641-1495-35", "0641-1496-31", "0641-1496-35"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "16729-483-03", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA212868"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Accord Healthcare, Inc.,"], "product_ndc": ["16729-483", "16729-484"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["4082a1cf-1e1b-6f40-e063-6294a90aec06"], "spl_set_id": ["c82cb295-ffce-47d6-97ad-a8aa723f4e4f"], "package_ndc": ["16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-014-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability June 2026", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-014", "72516-016", "72516-015", "72516-013", "72516-012", "72516-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/21/2025", "update_type": "New", "initial_posting_date": "10/21/2025", "package_ndc": "0591-5590-01", "generic_name": "Tranylcypromine Sulfate Tablet", "contact_info": "800-545-8800", "related_info": "Supply is expected to be depleted by 12/31/2025.", "openfda": {"application_number": ["NDA012342"], "brand_name": ["TRANYLCYPROMINE SULFATE"], "generic_name": ["TRANYLCYPROMINE SULFATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5590"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TRANYLCYPROMINE SULFATE"], "rxcui": ["313447"], "spl_id": ["e42c8b23-863e-4370-a3b1-b71526b12ee5"], "spl_set_id": ["6a0b609b-0625-4c26-91a1-59ee3ece3ddf"], "package_ndc": ["0591-5590-01"], "unii": ["7ZAT6ES870"]}, "update_date": "10/21/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Parnate, Tablet, 10 mg (NDC 0591-5590-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2347-32", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA020201"], "brand_name": ["DOBUTAMINE IN DEXTROSE"], "generic_name": ["DOBUTAMINE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2347", "0409-2346", "0409-3724", "0409-0025", "0409-0151", "0409-1100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["1c7cc97c-e244-4a4b-a4a1-8b70ca812107"], "spl_set_id": ["9943a961-3b50-4847-8a84-d8414ce38daa"], "package_ndc": ["0409-2347-31", "0409-2347-32", "0409-2346-31", "0409-2346-32", "0409-3724-11", "0409-3724-32", "0409-0025-01", "0409-0025-10", "0409-0151-01", "0409-0151-10", "0409-1100-01", "0409-1100-10"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-175-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-175", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 175 ug (NDC 72305-175-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0049-3190-01", "generic_name": "Voriconazole Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021267"], "brand_name": ["VFEND"], "generic_name": ["VORICONAZOLE"], "manufacturer_name": ["Roerig"], "product_ndc": ["0049-3190", "0049-3170", "0049-3180", "0049-3160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VORICONAZOLE"], "rxcui": ["351209", "352220", "349434", "349435", "352218", "352219", "465355", "546624"], "spl_id": ["8b24199e-0319-4538-a971-19d5ac52fd35", "cf9f1b2e-eeb4-48bb-9f1a-c2b8d94dfbea"], "spl_set_id": ["dac26bcd-7a59-401f-9f66-a0649767cece", "ce3ef5cf-3087-4d92-9d94-9eb8287228db"], "package_ndc": ["0049-3190-01", "0049-3170-30", "0049-3180-30", "0049-3190-28", "0049-3160-44"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000182140", "N0000185504"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]"], "unii": ["JFU09I87TR"]}, "update_date": "10/16/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Vfend, Injection, 10 mg/1 mL (NDC 0049-3190-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "69238-1627-6", "generic_name": "Dapsone Gel", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA212701"], "brand_name": ["DAPSONE"], "generic_name": ["DASPONE"], "manufacturer_name": ["Amneal Pharmaceuticals NY LLC"], "product_ndc": ["69238-1627"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DAPSONE"], "rxcui": ["1741905"], "spl_id": ["0622cdcc-1196-4a2f-8c85-6f34f0f97f9d"], "spl_set_id": ["fba0b181-077a-4667-bde1-cf9592f120c2"], "package_ndc": ["69238-1627-6", "69238-1627-9"], "nui": ["N0000175881", "M0020791"], "pharm_class_epc": ["Sulfone [EPC]"], "pharm_class_cs": ["Sulfones [CS]"], "unii": ["8W5C518302"]}, "update_date": "03/27/2026", "therapeutic_category": ["Dermatology"], "dosage_form": "Gel", "presentation": "Dapsone, Gel, 7.5% (NDC 69238-1627-6)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-162-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA075784"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-162", "63323-161"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4"], "spl_set_id": ["ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c"], "package_ndc": ["63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4282-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088294"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4282", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-001-01", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 59212-001-01)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "25021-701-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-701", "25021-700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["cb23332a-48fa-458b-93ab-c4eef189a051"], "spl_set_id": ["62591551-a644-4b2c-a0de-982e906fabc3"], "package_ndc": ["25021-700-01", "25021-701-01", "25021-701-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/20/2026", "update_type": "New", "initial_posting_date": "04/20/2026", "package_ndc": "0378-1134-01", "generic_name": "Ketorolac Tromethamine Tablet", "contact_info": "877-446-3679", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074761"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-1134"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["834022"], "spl_id": ["a2e96323-5726-45ce-9e73-f143f122b06b"], "spl_set_id": ["2837a082-3a34-6f81-5e43-45a70295686b"], "package_ndc": ["0378-1134-01"], "unii": ["4EVE5946BQ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Ketorolac Tromethamine, Tablet, 10 mg (NDC 0378-1134-01)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4904-34", "generic_name": "Lidocaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "47781-567-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": {"application_number": ["ANDA214547"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-567", "47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-568"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["567bb281-4098-07f8-9503-92299dc1c4c6"], "spl_set_id": ["7f2dd6ee-3363-c87c-9693-ed838942556c"], "package_ndc": ["47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)", "company_name": "Alvogen", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075154", "ANDA208878"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-412", "63323-411"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552", "cca4b16a-900d-4c74-86f5-bb9e5587a02a"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc", "09daf48f-1d44-4b7b-bb53-bd5635b93ca6"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10", "63323-412-00"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "51224-206-50", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["TAGI Pharma Inc."], "product_ndc": ["51224-206"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["75a00517-674b-4e87-b37b-598486aedf03"], "spl_set_id": ["60276f5c-657a-4b60-bcd0-44234903d7e0"], "package_ndc": ["51224-206-30", "51224-206-50"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-50)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-587-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": {"application_number": ["NDA021121"], "brand_name": ["CONCERTA"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-587", "50458-585", "50458-588", "50458-586"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212"], "spl_id": ["64d7c1e1-e7ed-4d74-a44d-13b4da64af9a"], "spl_set_id": ["1a88218c-5b18-4220-8f56-526de1a276cd"], "package_ndc": ["50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6020-10", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["NDA018565"], "brand_name": ["DURAMORPH"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6020", "0641-6019"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892473", "892489", "1728783", "1728800"], "spl_id": ["aa74af85-7068-4254-9a79-c7f3792044a6"], "spl_set_id": ["ebb18761-e5c4-4238-bb84-f9549f500210"], "package_ndc": ["0641-6020-01", "0641-6020-10", "0641-6019-01", "0641-6019-10"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "25357-025-03", "generic_name": "Riboflavin 5-phosphate  Ophthalmic Solution", "contact_info": "949-367-9600", "related_info": "Discontinuing manufacture of the product as of June 2026.", "openfda": {"application_number": ["NDA203324"], "brand_name": ["PHOTREXA CROSS-LINKING KIT"], "generic_name": ["RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC"], "manufacturer_name": ["Glaukos Corporation"], "product_ndc": ["25357-025"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["1925825", "1925830"], "spl_id": ["26dc098f-5920-43c2-aa95-5d1953734523"], "spl_set_id": ["f82cfe92-1a24-11e3-8ffd-0800200c9a66"], "package_ndc": ["25357-025-03"]}, "update_date": "01/20/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03)", "company_name": "Glaukos Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/03/2025", "package_ndc": "0574-4022-35", "generic_name": "Bacitracin Ophthalmic Ointment", "contact_info": "866-634-9120", "availability": "Unavailable", "related_info": "Shortage is estimated for 20 months", "update_date": "02/04/2026", "therapeutic_category": ["Anti-Infective", "Ophthalmology"], "dosage_form": "Ophthalmic Ointment", "presentation": "Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)", "company_name": "Padagis US LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2022", "package_ndc": "64980-642-03", "generic_name": "Albuterol Sulfate Solution", "contact_info": "201-961-9000", "availability": "Available", "openfda": {"application_number": ["ANDA075664"], "brand_name": ["ALBUTEROL SULFATE"], "generic_name": ["ALBUTEROL SULFATE"], "manufacturer_name": ["Rising Pharma Holdings, Inc."], "product_ndc": ["64980-642"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["ALBUTEROL SULFATE"], "rxcui": ["245314"], "spl_id": ["33015e7c-a4d2-ecac-e063-6394a90aae00"], "spl_set_id": ["3236f82c-14e9-dfd4-e063-6294a90ac43d"], "package_ndc": ["64980-642-03"], "unii": ["021SEF3731"]}, "update_date": "01/14/2026", "therapeutic_category": ["Pediatric", "Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)", "company_name": "Rising Pharma Holdings, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-385-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0480-3667-22", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "related_info": "Distributed by Teva", "openfda": {"application_number": ["NDA022341"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0480-3667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["57c9f463-a1b8-4efa-8982-40175cf6cf4f"], "spl_set_id": ["14bf9812-14ee-46ce-93b1-686e4906cbbc"], "package_ndc": ["0480-3667-19", "0480-3667-22", "0480-3667-20"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)", "company_name": "Novo Nordisk, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5167-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5167", "0603-5165", "0603-5166", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0971-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0973", "0555-0974"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0003-3641-11", "generic_name": "Atazanavir Sulfate; Cobicistat Tablet", "contact_info": "800-332-2056", "related_info": "The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.", "openfda": {"application_number": ["NDA206353"], "brand_name": ["EVOTAZ"], "generic_name": ["ATAZANAVIR AND COBICISTAT"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "product_ndc": ["0003-3641"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ATAZANAVIR SULFATE", "COBICISTAT"], "rxcui": ["1601654", "1601660"], "spl_id": ["fa642c67-5a9e-4136-a141-64e1236f6a0f"], "spl_set_id": ["83db29d7-5d85-49d6-8cb6-740473365cf8"], "package_ndc": ["0003-3641-11"], "nui": ["N0000190114", "N0000191001", "N0000185503", "N0000182137", "N0000190107", "N0000190108", "N0000190113", "N0000191423"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]"], "pharm_class_epc": ["Cytochrome P450 3A Inhibitor [EPC]"], "unii": ["4MT4VIE29P", "LW2E03M5PG"]}, "update_date": "11/03/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "49230-300-10", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "800-323-5188", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078177"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care Renal Therapies Group, LLC"], "product_ndc": ["49230-300"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807639"], "spl_id": ["4e559356-726d-a8d7-e063-6294a90aea68"], "spl_set_id": ["af5cdf1a-19f4-11e2-892e-0800200c9a66"], "package_ndc": ["49230-300-10"], "unii": ["451W47IQ8X"]}, "update_date": "06/10/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 49230-300-10)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0113-03", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-0113", "0703-0110", "0703-0018"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["c32108cc-7b73-4921-9f9e-54b3d60c1c6e"], "spl_set_id": ["f0b78db9-a38c-41bb-8233-5e93f7f18c5c"], "package_ndc": ["0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride Injection, USP CII, Injection, 10 mg/1 mL (NDC 0703-0113-03)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2420-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": {"application_number": ["NDA021514"], "brand_name": ["METHYLPHENIDATE TRANSDERMAL SYSTEM"], "generic_name": ["METHYLPHENIDATE"], "manufacturer_name": ["PADAGIS US LLC"], "product_ndc": ["0574-2420", "0574-2410", "0574-2415", "0574-2430"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["METHYLPHENIDATE"], "rxcui": ["753436", "753438", "753440", "753441"], "spl_id": ["b743ef45-2fc0-4086-8a02-6078e6a09eaa"], "spl_set_id": ["7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb"], "package_ndc": ["0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65"], "nui": ["N0000175739", "N0000175729"], "pharm_class_epc": ["Central Nervous System Stimulant [EPC]"], "pharm_class_pe": ["Central Nervous System Stimulation [PE]"], "unii": ["207ZZ9QZ49"]}, "update_date": "05/07/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-5323-10", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-5323", "0832-5322"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953"], "spl_id": ["39e726b1-eab8-fcf4-e063-6394a90a950a"], "spl_set_id": ["616f0de7-8843-44a1-8fa6-274d889286aa"], "package_ndc": ["0832-5322-11", "0832-5322-10", "0832-5323-11", "0832-5323-10"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-10)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "54288-166-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC", "openfda": {"application_number": ["ANDA207324"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["BPI Labs LLC"], "product_ndc": ["54288-166", "54288-165", "54288-167", "54288-164"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["c0a7463c-d90f-4060-a54e-6a4888e8af0e"], "spl_set_id": ["5484d2f0-0cc2-4bba-8f26-c7f6539a9606"], "package_ndc": ["54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "63323-340-20", "generic_name": "Cefepime Hydrochloride Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA065441"], "brand_name": ["CEFEPIME"], "generic_name": ["CEFEPIME"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-340", "63323-326"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CEFEPIME HYDROCHLORIDE"], "rxcui": ["1665088", "1665093"], "spl_id": ["8c2fbf43-34bd-49d1-bda8-a2191c8bc54b"], "spl_set_id": ["5e1695e0-1310-4cd8-a5da-ad1a7dcd1792"], "package_ndc": ["63323-326-21", "63323-326-20", "63323-340-21", "63323-340-20"], "unii": ["I8X1O0607P"]}, "update_date": "02/10/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cefepime Hydrochloride, Injection, 2 g (NDC 63323-340-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "67457-903-20", "generic_name": "Etomidate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA201044"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-903", "67457-902"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["25fc0aef-d4b3-4b33-897c-81cc7cdae470"], "spl_set_id": ["461e34d1-b862-4a02-9727-548c907aac48"], "package_ndc": ["67457-902-00", "67457-902-10", "67457-903-00", "67457-903-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-01", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9046-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA071170"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9046", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "53746-468-19", "generic_name": "Clindamycin Palmitate Hydrochloride Injection", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203513"], "brand_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE (PEDIATRIC)"], "generic_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE"], "manufacturer_name": ["Amneal Pharmaceuticals of New York LLC"], "product_ndc": ["53746-468"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN PALMITATE HYDROCHLORIDE"], "rxcui": ["562266"], "spl_id": ["b9016023-7843-48e3-8ff6-2e5a70aa5daf"], "spl_set_id": ["faf67eb8-1fd7-4b2c-a55b-24ba664c0dce"], "package_ndc": ["53746-468-19"], "unii": ["VN9A8JM7M7"]}, "update_date": "03/26/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9594-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019830"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9594", "0264-9598"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e352802-107c-4f90-babe-4f69c7dc892e"], "spl_set_id": ["7dff29d9-522d-40eb-a9d9-42377912d640"], "package_ndc": ["0264-9598-20", "0264-9594-20", "0264-9594-10"], "unii": ["EC2CNF7XFP", "LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0660-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-506-01", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA040491"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-506", "63323-516"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1812079"], "spl_id": ["9320abbb-bfd8-4df2-9269-3a52736c190f", "d85ab902-ae65-452d-b929-905b93131b15"], "spl_set_id": ["cca2c160-9188-48e8-9505-49a52388dcb7", "7cbd9005-7df2-47ee-adb3-7244c1c69bc3"], "package_ndc": ["63323-506-00", "63323-506-01", "63323-506-03", "63323-506-13", "63323-516-01", "63323-516-10", "63323-506-41", "63323-506-16"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3671-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040843"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-3671", "0703-3675", "0703-3678"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["e81074cc-12b4-4ac9-a5bb-749188989b2c"], "spl_set_id": ["346ec9ce-dc98-4a55-b55e-d3af11f2d703"], "package_ndc": ["0703-3671-01", "0703-3675-01", "0703-3678-01"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-063-59", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-063", "65862-062", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-59)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "65219-632-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-632"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355"], "spl_id": ["7203f32f-2e48-4924-b882-d4f3863ae952"], "spl_set_id": ["da4a7675-97bf-4d2a-9fdc-c1b4b2999126"], "package_ndc": ["65219-632-02", "65219-632-10", "65219-632-04", "65219-632-20"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1162-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070584"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1162", "0409-1159", "0409-1160", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-13", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-13", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0110-03", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-0110", "0703-0113", "0703-0018"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["c32108cc-7b73-4921-9f9e-54b3d60c1c6e"], "spl_set_id": ["f0b78db9-a38c-41bb-8233-5e93f7f18c5c"], "package_ndc": ["0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Regulatory delay", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-800-60", "generic_name": "Ivabradine Hydrochloride Tablet", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA206143"], "brand_name": ["CORLANOR"], "generic_name": ["IVABRADINE"], "manufacturer_name": ["Amgen Inc"], "product_ndc": ["55513-800", "55513-810", "55513-813"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IVABRADINE HYDROCHLORIDE"], "rxcui": ["1649485", "1649491", "1649493", "1649495", "2168592", "2168596"], "spl_id": ["8ab000cd-0258-489a-b1bb-4cc1ca359d6c"], "spl_set_id": ["92018a65-38f6-45f7-91d4-a34921b81d0d"], "package_ndc": ["55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28"], "unii": ["TP19837BZK"]}, "update_date": "03/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60)", "company_name": "Amgen Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0641-6262-01", "generic_name": "Sodium Acetate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the May 2026 timeframe.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA216920"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6262", "0641-6263"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["777b7564-f07b-401a-a042-0cd512ae3b25"], "spl_set_id": ["7ee23a1c-bc99-4ff6-b2e7-d2aa42744553"], "package_ndc": ["0641-6262-01", "0641-6263-01", "0641-6263-10"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-10", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018801"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4887"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["055437a7-5be5-414a-a97a-946e2730fe12"], "spl_set_id": ["2b9ea23a-f9e9-48a8-25b7-519e3bbd6828"], "package_ndc": ["0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-5031-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020646"], "brand_name": ["TIAGABINE HYDROCHLORIDE"], "generic_name": ["TIAGABINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5031", "0093-5030", "0093-8072", "0093-8076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TIAGABINE HYDROCHLORIDE"], "rxcui": ["1299903", "1299909", "1299911", "1299917"], "spl_id": ["2a8d7987-54ae-45d7-8224-361dac37e0a4"], "spl_set_id": ["953ef3cc-e3cb-480f-b9ea-256520fd62b8"], "package_ndc": ["0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56"], "unii": ["DQH6T6D8OY"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-6", "generic_name": "Carboplatin Injection", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Available", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.)", "openfda": {"application_number": ["ANDA077861"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-6282"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0e68e276-b0df-4f03-e063-6394a90a22b9"], "spl_set_id": ["1c275825-0275-4c73-b650-e4c1519f13b8"], "package_ndc": ["60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)", "company_name": "Teyro Labs", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/19/2025", "update_type": "New", "initial_posting_date": "08/19/2025", "package_ndc": "0093-7355-56", "generic_name": "Finasteride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076511"], "brand_name": ["FINASTERIDE"], "generic_name": ["FINASTERIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7355"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FINASTERIDE"], "rxcui": ["310346"], "spl_id": ["4c152e0f-55b3-4357-b983-897ecaf878af"], "spl_set_id": ["77589cc3-c440-4695-800c-82a0e5128a6c"], "package_ndc": ["0093-7355-56", "0093-7355-98", "0093-7355-05"], "nui": ["N0000175836", "N0000000126"], "pharm_class_epc": ["5-alpha Reductase Inhibitor [EPC]"], "pharm_class_moa": ["5-alpha Reductase Inhibitors [MoA]"], "unii": ["57GNO57U7G"]}, "update_date": "08/19/2025", "therapeutic_category": ["Urology"], "dosage_form": "Tablet", "presentation": "Finasteride, Tablet, 5 mg (NDC 0093-7355-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "71357-002-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": {"application_number": ["ANDA214805"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["MILLA PHARMACEUTICALS INC."], "product_ndc": ["71357-002"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["1859490"], "spl_id": ["2bdf8f55-9a63-bff7-e063-6394a90aafd0"], "spl_set_id": ["1ea04916-78e5-4651-e063-6394a90ac4be"], "package_ndc": ["71357-002-01", "71357-002-10"], "unii": ["4550K0SC9B"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)", "company_name": "Milla Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "72205-102-07", "generic_name": "Bumetanide Injection", "contact_info": "Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA215364"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-102", "72205-101"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "spl_set_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "package_ndc": ["72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/02/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)", "company_name": "MSN Laboratories Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/03/2018", "package_ndc": "76329-8261-1", "generic_name": "Lorazepam Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": {"application_number": ["ANDA076150"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-8261"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100"], "spl_id": ["b85a6695-55b9-4780-a803-33f8f2464138"], "spl_set_id": ["7dda070d-7809-46c4-8592-eb4e4c509707"], "package_ndc": ["76329-8261-1"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1574-5", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Currently Inventory available 2 to 4 Weeks as per current demand. Next supply: week of 02/09/2026", "openfda": {"application_number": ["ANDA210043"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1574", "70121-1573"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743855"], "spl_id": ["af4215ff-94ca-44f8-8506-3024e738cd13"], "spl_set_id": ["d944240d-2c19-46ba-ad4f-3fbee7b8629c"], "package_ndc": ["70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5"], "unii": ["43502P7F0P"]}, "update_date": "02/09/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5167-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5167", "0603-5165", "0603-5166", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-558-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA077690"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-558", "68180-556", "68180-557", "68180-554", "68180-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["a9598a21-6f99-4c86-ace6-b5638da2bec8"], "spl_set_id": ["8ded0773-3aec-4e89-9836-d22a5a84abf0"], "package_ndc": ["68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/27/2021", "package_ndc": "82667-800-01", "generic_name": "Triamcinolone Acetonide Injection", "contact_info": "(615) 733-4734", "availability": "Limited Availability", "related_info": "Estimated duration: 12 months", "openfda": {"application_number": ["NDA022048"], "brand_name": ["TRIESENCE"], "generic_name": ["TRIAMCINOLONE ACETONIDE"], "manufacturer_name": ["Harrow Eye, LLC"], "product_ndc": ["82667-800"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["TRIAMCINOLONE ACETONIDE"], "rxcui": ["1086259", "1792144"], "spl_id": ["42679191-e5c2-90c6-e063-6294a90a93ed"], "spl_set_id": ["2267978c-72ad-9229-e063-6394a90a09d0"], "package_ndc": ["82667-800-01"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["F446C597KA"]}, "update_date": "05/08/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Injection", "presentation": "Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)", "company_name": "Harrow Eye, LLC", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-7", "generic_name": "Carboplatin Injection", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Available", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.)", "openfda": {"application_number": ["ANDA077861"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-6282"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0e68e276-b0df-4f03-e063-6394a90a22b9"], "spl_set_id": ["1c275825-0275-4c73-b650-e4c1519f13b8"], "package_ndc": ["60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)", "company_name": "Teyro Labs", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-138-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-138", "16729-136", "16729-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 16729-138-16)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1660-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-4060-12", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Limited Availability", "related_info": "Estimated shortage duration TBD", "openfda": {"application_number": ["NDA022341"], "brand_name": ["VICTOZA"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Novo Nordisk"], "product_ndc": ["0169-4060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122", "897126"], "spl_id": ["0d10d10e-0fe0-47ee-b9da-628e34907e98"], "spl_set_id": ["5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"], "package_ndc": ["0169-4060-13", "0169-4060-12", "0169-4060-90", "0169-4060-97", "0169-4060-98", "0169-4060-99"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)", "company_name": "Novo Nordisk, Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5166-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5166", "0603-5165", "0603-5167", "0603-5168"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-05", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075604"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-720", "62037-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["1801294", "1801298"], "spl_id": ["01fbdb24-0987-40f6-a920-f36349f6ba61"], "spl_set_id": ["db002ae3-f54c-40a4-9cb4-e5681bf426e3"], "package_ndc": ["62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10"], "unii": ["660YQ98I10"]}, "update_date": "11/21/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/04/2025", "update_type": "New", "initial_posting_date": "06/04/2025", "package_ndc": "0003-3631-12", "generic_name": "Atazanavir Sulfate Capsule", "contact_info": "1-800-332-2056; for Medical Inquiries (1-800-321-1335)", "related_info": "Permanent discontinuation", "openfda": {"application_number": ["NDA021567"], "brand_name": ["REYATAZ"], "generic_name": ["ATAZANAVIR"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "product_ndc": ["0003-3631", "0003-3624", "0003-3622", "0003-3638"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ATAZANAVIR SULFATE"], "rxcui": ["402093", "402094", "402246", "402247", "664741", "664743", "1598985", "1598989"], "spl_id": ["510c2d51-4943-401c-a008-ea22f61c6938"], "spl_set_id": ["165cff62-b284-4a27-a65d-9ec8a5bfcdd8"], "package_ndc": ["0003-3624-12", "0003-3631-12", "0003-3622-12", "0003-3638-10"], "unii": ["4MT4VIE29P"]}, "update_date": "06/04/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Capsule", "presentation": "Reyataz, Capsule, 200 mg (NDC 0003-3631-12)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3982-60", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3982", "0591-3983", "0591-3984", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 50 mg (NDC 0591-3982-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "0093-0832-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: June 2026", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0832", "0093-3212", "0093-3213"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "76204-025-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Limited Availability", "related_info": "No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300", "openfda": {"application_number": ["ANDA209264"], "brand_name": ["CROMOLYN SODIUM ORAL SOLUTION (CONCENTRATE)"], "generic_name": ["CROMOLYN SODIUM ORAL SOLUTION (CONCENTRATE)"], "manufacturer_name": ["Ritedose Pharmaceuticals, LLC"], "product_ndc": ["76204-025"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261"], "spl_id": ["459fa806-53ad-d48e-e063-6394a90af72b"], "spl_set_id": ["d208df15-c823-6e0d-e053-2a95a90ad1be"], "package_ndc": ["76204-025-08", "76204-025-96"], "unii": ["Q2WXR1I0PK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)", "company_name": "Ailex Pharmaceuticals", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-10", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7520", "0264-7510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-382-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/11/2024", "package_ndc": "0990-7120-07", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7120-07", "openfda": {"application_number": ["NDA019893"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["237656"], "spl_id": ["2221fdbf-4b3f-4296-80bc-96c446156fff"], "spl_set_id": ["cdf35d11-fbc8-4f8e-85a8-33220312c0b4"], "package_ndc": ["0990-7120-07"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-050-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-050", "57664-047", "57664-046", "57664-048", "57664-049", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0775-26", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Available", "openfda": {"application_number": ["NDA050441"], "brand_name": ["CLEOCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0775", "0009-0870", "0009-0902", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582", "205964", "309335", "309336", "309339", "685574"], "spl_id": ["dd9fa453-a2ca-4a53-b39b-c59a44a888aa"], "spl_set_id": ["05a75685-0af5-407c-ac57-e380c882b49d"], "package_ndc": ["0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01"], "unii": ["EH6D7113I8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-382-90", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-90)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1283-37", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1283", "0409-1312", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2305-17", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075857"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2305", "0409-2308", "0409-0001"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666800", "1666814", "1666823", "1666798"], "spl_id": ["b303a281-6633-47d5-bf29-5e9055e26da6", "74093865-864a-49e8-99b9-c985fe72afb2"], "spl_set_id": ["b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240"], "package_ndc": ["0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-63", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "0037-0678-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(800) 796-9526", "availability": "Available", "openfda": {"application_number": ["NDA020479"], "brand_name": ["GASTROCROM"], "generic_name": ["CROMOLYN SODIUM"], "manufacturer_name": ["Viatris Specialty LLC"], "product_ndc": ["0037-0678"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261", "831269"], "spl_id": ["15aec235-80e7-4d95-b48c-bbca69b4b04d"], "spl_set_id": ["00623958-a8fe-47d1-a0d2-0aa4e2f7966e"], "package_ndc": ["0037-0678-08", "0037-0678-96"], "unii": ["Q2WXR1I0PK"]}, "update_date": "05/05/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)", "company_name": "Mylan Specialty, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "0053-6871-00", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Spray", "presentation": "Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "70436-203-80", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "Slate Run Pharmaceuticals, LLC: 844-529-8988", "availability": "Available", "related_info": "Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988", "openfda": {"application_number": ["ANDA216131"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Slate Run Pharmaceuticals"], "product_ndc": ["70436-203"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["49562559-8e19-fb8a-e063-6394a90a0966"], "spl_set_id": ["ee09a55f-9992-48bb-b8d6-1184bd548536"], "package_ndc": ["70436-203-80", "70436-203-82"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)", "company_name": "Hainan Poly Pharm. Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "25021-655-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA090696"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-655"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["1666798"], "spl_id": ["943346c0-d98e-4ac2-a1a2-75427decf2fc"], "spl_set_id": ["e22611dd-1830-40af-9139-7cdb07f5a426"], "package_ndc": ["25021-655-02"], "unii": ["W7TTW573JJ"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5316-15", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5316", "0245-5315"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-15)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "59572-102-01", "generic_name": "Azacitidine Injection", "contact_info": "1-888-423-5436", "availability": "Available", "openfda": {"application_number": ["NDA050794"], "brand_name": ["VIDAZA"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Celgene Corporation"], "product_ndc": ["59572-102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246", "545206"], "spl_id": ["8cba79e2-11fa-4eb9-87e7-827ca781fbf3"], "spl_set_id": ["3495a71a-cc04-4776-851f-f185956f32af"], "package_ndc": ["59572-102-01"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Vidaza, Injection, 100 mg (NDC 59572-102-01)", "company_name": "Bristol Myers Squibb Co.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0225-02", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050162"], "brand_name": ["CLEOCIN HYDROCHLORIDE"], "generic_name": ["CLINDAMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0225", "0009-0331", "0009-0395"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN HYDROCHLORIDE"], "rxcui": ["197518", "284215", "309329", "748746", "748748", "748750"], "spl_id": ["51cea3cd-28cf-455e-ba27-5a0d8e052858"], "spl_set_id": ["df9a2a41-b132-4f43-8940-b2d773b1369a"], "package_ndc": ["0009-0331-02", "0009-0225-02", "0009-0395-14"], "unii": ["T20OQ1YN1W"]}, "update_date": "02/25/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-26", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-0771-10", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0771", "0093-7201", "0093-7202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-6145-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA084282"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6145", "0641-0367", "0641-6146"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1116927", "1812194"], "spl_id": ["02bf3273-f0c8-448c-9f74-eb009fee9299"], "spl_set_id": ["0277cc0a-2fd4-4605-a310-b613be84ee26"], "package_ndc": ["0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25"], "unii": ["AI9376Y64P"]}, "update_date": "05/12/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7809-22", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018826"], "brand_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7809", "0409-7810", "0409-0042", "0409-1858"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "spl_id": ["188ce800-ff3a-4b22-9a95-2273c3bc99ae"], "spl_set_id": ["08f23f6e-150d-45ea-098e-f2edf64c21a1"], "package_ndc": ["0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12"], "unii": ["7L3E358N9L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7769-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210050"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7769", "0093-7766", "0093-7767", "0093-7768"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["aa521933-950a-441b-9146-93e479a4dde7"], "spl_set_id": ["e3bca36b-29ed-4a2b-a1be-a57b6af805f6"], "package_ndc": ["0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "03/02/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 10 mg (NDC 0093-7769-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-04", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9575-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA080407"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9575", "0143-9579", "0143-9578", "0143-9577", "0143-9576", "0143-9172", "0143-9173"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["e9b92d4d-8944-4235-8d77-3218f82f00a9"], "spl_set_id": ["5523fdfe-69fd-49a5-b51f-73e2223d49a9"], "package_ndc": ["0143-9579-01", "0143-9579-25", "0143-9578-01", "0143-9578-10", "0143-9577-01", "0143-9577-10", "0143-9576-01", "0143-9576-25", "0143-9575-01", "0143-9575-10", "0143-9172-01", "0143-9172-10", "0143-9173-01", "0143-9173-10"], "unii": ["V13007Z41A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-025-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-025", "65162-023", "65162-024", "65162-026", "65162-027", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-061-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-061", "70069-062", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/09/2025", "update_type": "New", "initial_posting_date": "06/09/2025", "package_ndc": "66215-102-03", "generic_name": "Bosentan Tablet", "contact_info": "800-526-7736", "openfda": {"application_number": ["NDA021290"], "brand_name": ["TRACLEER"], "generic_name": ["BOSENTAN"], "manufacturer_name": ["Actelion Pharmaceuticals US, Inc."], "product_ndc": ["66215-102", "66215-101", "66215-232"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["BOSENTAN"], "rxcui": ["349253", "352066", "656659", "656660", "1989081", "1989085"], "spl_id": ["f52a8c9c-529d-4bd8-9bfb-d91161935c20"], "spl_set_id": ["749e42fb-2fe0-45dd-9268-b43bb3f4081c"], "package_ndc": ["66215-101-06", "66215-101-03", "66215-102-06", "66215-102-03", "66215-232-14", "66215-232-56"], "unii": ["Q326023R30"]}, "update_date": "06/09/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Tracleer, Tablet, 125 mg (NDC 66215-102-03)", "company_name": "Actelion Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "59676-570-01", "generic_name": "Etravirine Tablet", "contact_info": "800-526-7736", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA022187"], "brand_name": ["INTELENCE"], "generic_name": ["ETRAVIRINE"], "manufacturer_name": ["Janssen Products LP"], "product_ndc": ["59676-570", "59676-571", "59676-572"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ETRAVIRINE"], "rxcui": ["754761", "758555", "1052658", "1052660", "1250721", "1250723"], "spl_id": ["02fc6f4f-330d-b32e-e063-6294a90a028a"], "spl_set_id": ["6a9cbc29-9f15-4b24-8d86-206b82887f3d"], "package_ndc": ["59676-570-01", "59676-571-01", "59676-572-01"], "nui": ["N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000185504", "N0000182140", "N0000185503"], "pharm_class_epc": ["Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "unii": ["0C50HW4FO1"]}, "update_date": "04/28/2026", "therapeutic_category": ["Antiviral"], "dosage_form": "Tablet", "presentation": "Intelence, Tablet, 100 mg (NDC 59676-570-01)", "company_name": "Janssen Research and Development", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "0025-1031-31", "generic_name": "Spironolactone Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA012151"], "brand_name": ["ALDACTONE"], "generic_name": ["SPIRONOLACTONE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0025-1031", "0025-1001", "0025-1041"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["SPIRONOLACTONE"], "rxcui": ["198222", "198223", "200817", "200820", "200825", "313096"], "spl_id": ["22946678-dcad-4518-9bc6-cbdf51a38c16"], "spl_set_id": ["0fed2822-3a03-4b64-9857-c682fcd462bc"], "package_ndc": ["0025-1001-31", "0025-1041-31", "0025-1031-31"], "nui": ["N0000175557", "N0000011310"], "pharm_class_epc": ["Aldosterone Antagonist [EPC]"], "pharm_class_moa": ["Aldosterone Antagonists [MoA]"], "unii": ["27O7W4T232"]}, "update_date": "12/10/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Aldactone, Tablet, 100 mg (NDC 0025-1031-31)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "16729-484-90", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA212868"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Accord Healthcare, Inc.,"], "product_ndc": ["16729-484", "16729-483"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190546", "1190551", "1190552"], "spl_id": ["4082a1cf-1e1b-6f40-e063-6294a90aec06"], "spl_set_id": ["c82cb295-ffce-47d6-97ad-a8aa723f4e4f"], "package_ndc": ["16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-152", "72888-153", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-01)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "76045-121-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release June 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["DILAUDID"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-121", "76045-009", "76045-010"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370"], "spl_id": ["97bfcafb-2037-47dc-a0ae-f7b8007c47df"], "spl_set_id": ["9eebd88a-5632-460f-b7b6-26c8a180540d"], "package_ndc": ["76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3678-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA040843"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-3678", "0703-3671", "0703-3675"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["e81074cc-12b4-4ac9-a5bb-749188989b2c"], "spl_set_id": ["346ec9ce-dc98-4a55-b55e-d3af11f2d703"], "package_ndc": ["0703-3671-01", "0703-3675-01", "0703-3678-01"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-212-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care de Mexico, S.A. de C.V."], "product_ndc": ["46163-212", "46163-209", "46163-206"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["444fd7c1-1ed5-25c7-e063-6394a90a3bfe"], "spl_set_id": ["a98facd6-9daa-4d37-8209-63a0599dbfaa"], "package_ndc": ["46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-485-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076803"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-485", "62135-484", "62135-486", "62135-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["09cd5cb9-4fdf-f133-e063-6294a90af691"], "spl_set_id": ["dbc43dbd-94aa-40e2-a9ea-766110cc8687"], "package_ndc": ["62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90"], "unii": ["33067B3N2M"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4928-34", "generic_name": "Calcium Chloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Cardiovascular", "Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/24/2025", "update_type": "New", "initial_posting_date": "07/24/2025", "package_ndc": "0049-0178-08", "generic_name": "Glipizide Tablet, Extended Release", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020329"], "brand_name": ["GLUCOTROL XL"], "generic_name": ["GLIPIZIDE"], "manufacturer_name": ["Roerig"], "product_ndc": ["0049-0178", "0049-0170", "0049-0174"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLIPIZIDE"], "rxcui": ["310489", "314006", "315107", "865568", "865571", "865573"], "spl_id": ["ce46d6b5-eab4-4630-8480-f13885be938e"], "spl_set_id": ["eed99b60-d043-4249-9b2a-f05e46fb588d"], "package_ndc": ["0049-0170-01", "0049-0174-02", "0049-0174-03", "0049-0178-07", "0049-0178-08"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["X7WDT95N5C"]}, "update_date": "07/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glucatrol XL, Tablet, Extended Release, 10 mg tablets; bottle of 500 (NDC 0049-0178-08)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-01", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1749-29", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1749", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-02", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA090108"], "brand_name": ["CLINDAMYCIN"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["1737244", "1737578", "1737581"], "spl_id": ["4662502b-ce7c-4278-854d-cf8632ac9b83"], "spl_set_id": ["7a6967b3-5563-4bed-9eee-d400f800e799"], "package_ndc": ["25021-115-02", "25021-115-04", "25021-115-06"], "unii": ["EH6D7113I8"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/06/2018", "package_ndc": "72266-118-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["FOSUN PHARMA USA INC"], "product_ndc": ["72266-118", "72266-234", "72266-119"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["228ec94a-f777-f61b-e063-6394a90a21a5"], "spl_set_id": ["1aae6a4d-0909-4672-aa26-e3f2d8c4d413"], "package_ndc": ["72266-234-01", "72266-234-25", "72266-118-01", "72266-118-25", "72266-119-01", "72266-119-25"], "unii": ["4EVE5946BQ"]}, "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-046-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-046", "57664-047", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-448-60", "generic_name": "Carboplatin Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "0641-6047-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6047", "0641-6044", "0641-6046", "0641-6045"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100", "238101", "1665188", "1665326"], "spl_id": ["7c73dbc6-2623-4443-9b05-97dec7a0be2e"], "spl_set_id": ["e9b54e42-04cf-4c62-90e1-36f7b31a4e81"], "package_ndc": ["0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0409-0332-20", "generic_name": "Bleomycin Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA065031"], "brand_name": ["BLEOMYCIN"], "generic_name": ["BLEOMYCIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0332", "0409-0323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAPLEURAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["BLEOMYCIN SULFATE"], "rxcui": ["1726673", "1726676"], "spl_id": ["d9e9c332-1b3f-469c-83b8-41e15183e635"], "spl_set_id": ["e629ba5a-4e08-4249-9551-af6dbd98a7e4"], "package_ndc": ["0409-0323-20", "0409-0332-20"], "unii": ["7DP3NTV15T"]}, "update_date": "06/13/2025", "therapeutic_category": ["Hematology", "Oncology", "Pediatric"], "dosage_form": "Injection", "presentation": "Bleomycin Sulfate, Injection, 15 [USP'U] (NDC 0409-0332-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-556-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-556", "64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4248-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA077269"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4248", "0703-4244", "0703-4246", "0703-4239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c"], "spl_set_id": ["f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37"], "package_ndc": ["0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4713-32", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA080408"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763"], "spl_id": ["78818553-f818-42a1-81b9-e5a5a5da5a27"], "spl_set_id": ["3b2dd84e-cee8-4e58-d494-395a65a353a0"], "package_ndc": ["0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-37", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-1323-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA040302"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1323", "0409-4903", "0409-4904", "0409-9137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1012066", "1012068"], "spl_id": ["b386f7fc-ec89-4d73-aba6-2019a9cb1d4a"], "spl_set_id": ["ad1ef0a8-88db-4648-c098-d009eaeb4e5b"], "package_ndc": ["0409-4903-11", "0409-4903-34", "0409-4904-11", "0409-4904-34", "0409-1323-15", "0409-1323-05", "0409-9137-11", "0409-9137-05"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "72205-101-07", "generic_name": "Bumetanide Injection", "contact_info": "Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA215364"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-101", "72205-102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "spl_set_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "package_ndc": ["72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/02/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)", "company_name": "MSN Laboratories Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-801-01", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-801", "42806-799"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 42806-801-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-0109-10", "generic_name": "Carbamazepine Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA070541"], "brand_name": ["CARBAMAZEPINE"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0109", "0093-0778"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["308973", "308979"], "spl_id": ["042aa2c6-95ff-410a-abcf-a8ee79fa96d8"], "spl_set_id": ["bfd63965-56e6-4af7-b7ef-45a5105d4d35"], "package_ndc": ["0093-0109-01", "0093-0109-10", "0093-0778-01"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "06/10/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Epitol, Tablet, 200 mg (NDC 0093-0109-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-712-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-712", "60951-602", "60951-700", "60951-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0143-9144-02", "generic_name": "Liraglutide Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": {"application_number": ["ANDA215503"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9144"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["5088d0a8-f7aa-476c-8cc1-149955781409"], "spl_set_id": ["2100ec49-57b2-4330-ab5f-057ce9b7e4d0"], "package_ndc": ["0143-9144-01", "0143-9144-03", "0143-9144-02"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/27/2025", "update_type": "New", "initial_posting_date": "06/27/2025", "package_ndc": "0591-3713-05", "generic_name": "Ezetimibe Tablet", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the product", "openfda": {"application_number": ["ANDA200831"], "brand_name": ["EZETIMIBE"], "generic_name": ["EZETIMIBE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3713"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EZETIMIBE"], "rxcui": ["349556"], "spl_id": ["24aaf5ca-08e0-4db8-9734-cf2a606f8e57"], "spl_set_id": ["f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba"], "package_ndc": ["0591-3713-30", "0591-3713-19", "0591-3713-05"], "nui": ["N0000008553", "N0000175911"], "pharm_class_pe": ["Decreased Cholesterol Absorption [PE]"], "pharm_class_epc": ["Dietary Cholesterol Absorption Inhibitor [EPC]"], "unii": ["EOR26LQQ24"]}, "update_date": "06/27/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Ezetimibe, Tablet, 10 mg (NDC 0591-3713-05)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4741-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4741", "60505-4739", "60505-4740", "60505-4742", "60505-4743", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9507-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the May 2026 timeframe.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9507", "0143-9506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["98560882-bfdf-404e-ab8b-3ee2a6875830"], "spl_set_id": ["75bf0494-7cb9-4e8a-8edd-af62f035d236"], "package_ndc": ["0143-9506-01", "0143-9506-10", "0143-9507-01", "0143-9507-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-27", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-162-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA203082"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-162", "55150-161", "55150-163", "55150-164", "55150-165"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737562", "1737566", "1737568", "1737757", "1737761"], "spl_id": ["bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154"], "spl_set_id": ["9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee"], "package_ndc": ["55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4662-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4662", "0527-4661", "0527-4663", "0527-4664", "0527-4665", "0527-4666", "0527-4667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)", "company_name": "Lannett Company, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-585-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": {"application_number": ["NDA021121"], "brand_name": ["CONCERTA"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-585", "50458-588", "50458-586", "50458-587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212"], "spl_id": ["64d7c1e1-e7ed-4d74-a44d-13b4da64af9a"], "spl_set_id": ["1a88218c-5b18-4220-8f56-526de1a276cd"], "package_ndc": ["50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01"], "unii": ["4B3SC438HI"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-02", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "6, 7 & 9 month expiry available upon request. Check wholesaler for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1304-31", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1304", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1283", "0409-1312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "897756", "897757", "897758", "1724276", "1724383", "1724644"], "spl_id": ["a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6040-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder.", "openfda": {"application_number": ["NDA018565"], "brand_name": ["INFUMORPH 500"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6040", "0641-6039"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892652", "1731522", "1731998", "1731999"], "spl_id": ["b1c060cb-5c5b-495f-90b5-044e04f2a3f2"], "spl_set_id": ["db9ac9e3-d761-4a99-9f34-4946ebe8f255"], "package_ndc": ["0641-6039-01", "0641-6040-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-036-05", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["NDA020630"], "brand_name": ["ULTIVA"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["72078-036", "72078-034", "72078-035"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729581", "1729584", "1729586", "1729710", "1729712"], "spl_id": ["594087a1-25f2-4f68-aea6-ad7df40559ab"], "spl_set_id": ["8b4c8696-e23e-4c51-a4d2-babab5bd945a"], "package_ndc": ["72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05"], "unii": ["5V444H5WIC"]}, "update_date": "05/05/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 5 mg (NDC 72078-036-05)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3565-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3565", "0480-3566", "0480-3567", "0480-3568", "0480-3569", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-723-52", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216039"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-723", "71288-726"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["0949c302-51ce-4fc9-8b99-1df94e693718"], "spl_set_id": ["fe340f98-a0f3-446e-b281-47fd91c1e537"], "package_ndc": ["71288-723-52", "71288-726-52"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-104-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA203242"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-104", "76045-105", "76045-107", "76045-209"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860113", "860114", "860115"], "spl_id": ["0dab642d-7fcf-4301-8ac9-10e64a040c6b"], "spl_set_id": ["3d88cbe6-5230-47aa-80af-0c41283d1f00"], "package_ndc": ["76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-012-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability June 2026", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-012", "72516-016", "72516-015", "72516-014", "72516-013", "72516-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/22/2026", "update_type": "New", "initial_posting_date": "04/22/2026", "package_ndc": "0069-0187-21", "generic_name": "Palbociclib Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet \nNDC 0069-0284-03 will continue to be manufactured.", "openfda": {"application_number": ["NDA207103"], "brand_name": ["IBRANCE"], "generic_name": ["PALBOCICLIB"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-0187", "0069-0188", "0069-0189"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PALBOCICLIB"], "rxcui": ["1601380", "1601386", "1601388", "1601390", "1601392", "1601394"], "spl_id": ["fb858b80-8bd4-43a6-8871-9819a35ca03f"], "spl_set_id": ["e0e6412f-50b4-4fd4-9364-62818d121a07"], "package_ndc": ["0069-0187-21", "0069-0188-21", "0069-0189-21"], "nui": ["N0000175605", "N0000175082", "N0000190114"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["G9ZF61LE7G"]}, "update_date": "04/22/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Capsule", "presentation": "Ibrance, Capsule, 75 mg (NDC 0069-0187-21)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/16/2026", "package_ndc": "72336-032-01", "generic_name": "Isocarboxazid Tablet", "contact_info": "833.627.0070", "availability": "Unavailable", "related_info": "Target availability: May 2026; Delay in shipping of the drug", "openfda": {"application_number": ["NDA011961"], "brand_name": ["MARPLAN"], "generic_name": ["ISOCARBOXAZID"], "manufacturer_name": ["Lifsa Drugs LLC"], "product_ndc": ["72336-032"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ISOCARBOXAZID"], "rxcui": ["104837", "201708"], "spl_id": ["97745d9b-c2a6-45e3-9e1e-7fabec4681fb"], "spl_set_id": ["95fde749-44ad-4668-86c4-0ff17bca0074"], "package_ndc": ["72336-032-01"], "nui": ["N0000175744", "N0000000184"], "pharm_class_epc": ["Monoamine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Monoamine Oxidase Inhibitors [MoA]"], "unii": ["34237V843T"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)", "company_name": "Lifsa Drugs LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-4596-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4596", "0409-0155"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718907", "1718909", "1718910"], "spl_id": ["58e27ec5-ccde-46c9-afd3-2509e6b55e4e"], "spl_set_id": ["92b7ddaa-e45a-4b64-a802-bb5df8771dd6"], "package_ndc": ["0409-4596-01", "0409-4596-20", "0409-0155-01", "0409-0155-02"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0143-9250-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA204679"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9250", "0143-9251"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["76957fea-9b26-42a6-ad71-c8752142a08b"], "spl_set_id": ["d3a172a5-01ab-47d8-92ac-a8539b1d4dc4"], "package_ndc": ["0143-9250-01", "0143-9250-10", "0143-9251-01", "0143-9251-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9553-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["NDA208083"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9553", "0338-9545", "0338-9549"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b0a47c5e-911b-4b12-a0d1-a4425f173eec"], "spl_set_id": ["44fa506b-90ac-42de-831b-5f3f1a500fc0"], "package_ndc": ["0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-136-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA077147"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-136", "16729-137", "16729-138"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["0e1e7f41-f78b-27cf-e063-6394a90a1ae0"], "spl_set_id": ["ebc11109-e7bf-452d-b675-4b3236d54164"], "package_ndc": ["16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 16729-136-16)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "76045-106-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA203129"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-106"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["1812095"], "spl_id": ["f5934e17-4553-425b-b1bf-140cba479c36"], "spl_set_id": ["88d25d19-acff-477b-86c8-9797782045b8"], "package_ndc": ["76045-106-10"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-25", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-003-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X10ML) is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "70069-753-25", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": {"application_number": ["ANDA217792"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-753", "70069-752"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["2b24af95-6f20-4945-bf8c-742f1d6f2721"], "spl_set_id": ["bcaab86f-20f0-4482-8d73-e29b36dced58"], "package_ndc": ["70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3495-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": {"application_number": ["ANDA209065"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3495", "0781-3493", "0781-3494"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["fdf227d9-008e-60f8-e053-6294a90af5c4"], "spl_set_id": ["809e8f77-390f-4cc8-8c8a-4f67a249c9df"], "package_ndc": ["0781-3493-95", "0781-3494-95", "0781-3495-95"], "unii": ["1018WH7F9I"]}, "update_date": "04/06/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-4902-34", "generic_name": "Dextrose Monohydrate 50% Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%20Monohydrate%2050per%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "65219-445-10", "generic_name": "Etomidate Injection", "contact_info": "800-551-7176", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-445", "65219-447"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["446487f1-002e-41d3-846a-67570e797171", "30488a7e-ea9e-4a27-95a9-a07149c50282"], "spl_set_id": ["f38fad46-f2dd-4692-a2a9-a13d0a717bf8", "d07efb9e-5264-461d-96d8-e11fa71c5751"], "package_ndc": ["65219-445-12", "65219-445-22", "65219-445-01", "65219-445-10", "65219-447-02", "65219-447-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 65219-445-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "59310-812-06", "generic_name": "Fluticasone Propionate; Salmeterol Xinafoate Powder", "contact_info": "800-545-8800", "openfda": {"application_number": ["NDA208799"], "brand_name": ["AIRDUO RESPICLICK"], "generic_name": ["FLUTICASONE PROPIONATE AND SALMETEROL"], "manufacturer_name": ["Teva Respiratory, LLC"], "product_ndc": ["59310-812", "59310-805", "59310-822"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE"], "rxcui": ["1918194", "1918199", "1918203", "1918205", "1918209", "1918211"], "spl_id": ["b597bc2d-bf1e-4f9b-826a-b3e39ed56545"], "spl_set_id": ["9c122b91-a11f-49ca-80bb-3eec5112db87"], "package_ndc": ["59310-805-06", "59310-805-08", "59310-812-06", "59310-812-08", "59310-822-06", "59310-822-08"], "unii": ["6EW8Q962A5", "O2GMZ0LF5W"]}, "update_date": "06/13/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Powder", "presentation": "AirDuo RespiClick, Powder, 113 ug; 14 ug (NDC 59310-812-06)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4380-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023", "update_date": "04/28/2023", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 5 mg (NDC 0069-4380-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "68180-659-07", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA090034"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-659", "68180-658"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["5ed1edac-e11e-4f87-b390-e770a69a9b37"], "spl_set_id": ["b56004f0-f23d-47f6-80c7-39884fccbccc"], "package_ndc": ["68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 68180-659-07)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "65219-632-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-632"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355"], "spl_id": ["7203f32f-2e48-4924-b882-d4f3863ae952"], "spl_set_id": ["da4a7675-97bf-4d2a-9fdc-c1b4b2999126"], "package_ndc": ["65219-632-02", "65219-632-10", "65219-632-04", "65219-632-20"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5001-5", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": {"application_number": ["ANDA211091"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Exela Pharma Sciences, LLC"], "product_ndc": ["51754-5001", "51754-5011", "51754-5002", "51754-5012"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["807284", "1868486", "1923484", "2198792"], "spl_id": ["4da0ba66-756d-4b4d-8018-81ca16578ef1"], "spl_set_id": ["e9698a4f-1a95-4f28-a945-e8009d1d6dd4"], "package_ndc": ["51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4"], "unii": ["8MDF5V39QO"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/31/2018", "package_ndc": "65219-572-10", "generic_name": "Bumetanide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA216434"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-572", "65219-570"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["aaff61c4-203b-4905-9138-0f98959ad013"], "spl_set_id": ["a007f3aa-3977-4be3-a9a2-db3d458bca58"], "package_ndc": ["65219-570-01", "65219-570-04", "65219-572-01", "65219-572-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-465-57", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-465", "63323-467", "63323-460", "63323-464", "63323-466", "63323-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177"], "spl_id": ["2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1162-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070584"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1162", "0409-1159", "0409-1160", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596"], "spl_id": ["6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-02", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/04/2025", "update_type": "New", "initial_posting_date": "06/04/2025", "package_ndc": "0003-3622-12", "generic_name": "Atazanavir Sulfate Capsule", "contact_info": "1-800-332-2056; for Medical Inquiries (1-800-321-1335)", "related_info": "Permanent discontinuation", "openfda": {"application_number": ["NDA021567"], "brand_name": ["REYATAZ"], "generic_name": ["ATAZANAVIR"], "manufacturer_name": ["E.R. Squibb & Sons, L.L.C."], "product_ndc": ["0003-3622", "0003-3624", "0003-3631", "0003-3638"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ATAZANAVIR SULFATE"], "rxcui": ["402093", "402094", "402246", "402247", "664741", "664743", "1598985", "1598989"], "spl_id": ["510c2d51-4943-401c-a008-ea22f61c6938"], "spl_set_id": ["165cff62-b284-4a27-a65d-9ec8a5bfcdd8"], "package_ndc": ["0003-3624-12", "0003-3631-12", "0003-3622-12", "0003-3638-10"], "unii": ["4MT4VIE29P"]}, "update_date": "06/04/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Capsule", "presentation": "Reyataz, Capsule, 300 mg (NDC 0003-3622-12)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/26/2025", "update_type": "New", "initial_posting_date": "06/26/2025", "package_ndc": "0093-5537-56", "generic_name": "Eszopiclone Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA091169"], "brand_name": ["ESZOPICLONE"], "generic_name": ["ESZOPICLONE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5537", "0093-5538", "0093-5539"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ESZOPICLONE"], "rxcui": ["485440", "485442", "485465"], "spl_id": ["efcf4106-ac0a-4f8b-bcd0-743e45e66924"], "spl_set_id": ["2435e2f1-bc52-488f-80e9-f1758e354aae"], "package_ndc": ["0093-5537-56", "0093-5538-01", "0093-5539-01"], "unii": ["UZX80K71OE"]}, "update_date": "06/26/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Eszopiclone, Tablet, 1 mg (NDC 0093-5537-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0591-0347-05", "generic_name": "Hydrochlorothiazide Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["NDA020504"], "brand_name": ["HYDROCHLOROTHIAZIDE"], "generic_name": ["HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-0347"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE"], "rxcui": ["199903"], "spl_id": ["b062bc7e-af92-4648-aed1-e02568313e21"], "spl_set_id": ["a3eb7294-f913-434b-896c-da028bfebc73"], "package_ndc": ["0591-0347-01", "0591-0347-05"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["0J48LPH2TH"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Microzide, Capsule, 12.5 mg (NDC 0591-0347-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA075154", "ANDA208878"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-412", "63323-411"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["9814447b-a93e-42ad-b57e-5db0a5b7f552", "cca4b16a-900d-4c74-86f5-bb9e5587a02a"], "spl_set_id": ["a91ce254-14a3-4cbf-8ab8-5da252aa3fdc", "09daf48f-1d44-4b7b-bb53-bd5635b93ca6"], "package_ndc": ["63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10", "63323-412-00"], "unii": ["W7TTW573JJ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0502-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA020512"], "brand_name": ["CLINISOL"], "generic_name": ["LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0502"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["800584", "800588"], "spl_id": ["7eab93b5-5590-4381-8674-113a05edeff0"], "spl_set_id": ["65ffc962-7538-41ea-9afb-4af5fbce4c5b"], "package_ndc": ["0338-0502-03", "0338-0502-06"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-200-11", "generic_name": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA021172"], "brand_name": ["INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-200", "73070-203"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["351297", "847191"], "spl_id": ["ec67820c-4008-4894-b933-34b28704221d"], "spl_set_id": ["fc94baa4-3606-48bc-a781-9617ab6960ef"], "package_ndc": ["73070-200-11", "73070-203-10", "73070-203-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injectable Suspension", "presentation": "Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-702-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA050141"], "brand_name": ["BICILLIN L-A"], "generic_name": ["PENICILLIN G BENZATHINE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["60793-702", "60793-700", "60793-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PENICILLIN G BENZATHINE"], "rxcui": ["731564", "731566", "731567", "731568", "731570", "731571"], "spl_id": ["4b3694af-9d77-487f-8838-b75aec6636da"], "spl_set_id": ["012d46f1-d0a0-4676-a879-cd320297ab16"], "package_ndc": ["60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10"], "unii": ["RIT82F58GK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-5323-11", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-5323", "0832-5322"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953"], "spl_id": ["39e726b1-eab8-fcf4-e063-6394a90a950a"], "spl_set_id": ["616f0de7-8843-44a1-8fa6-274d889286aa"], "package_ndc": ["0832-5322-11", "0832-5322-10", "0832-5323-11", "0832-5323-10"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-55", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-55", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-50", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release June 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0018-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-0018", "0703-0110", "0703-0113"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["c32108cc-7b73-4921-9f9e-54b3d60c1c6e"], "spl_set_id": ["f0b78db9-a38c-41bb-8233-5e93f7f18c5c"], "package_ndc": ["0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-2800-15", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "openfda": {"application_number": ["NDA206321"], "brand_name": ["SAXENDA"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Novo Nordisk"], "product_ndc": ["0169-2800"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["1598268", "2735350"], "spl_id": ["eba7f5c9-44d0-4549-ae94-daa2c5181646"], "spl_set_id": ["3946d389-0926-4f77-a708-0acb8153b143"], "package_ndc": ["0169-2800-15", "0169-2800-90", "0169-2800-97"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)", "company_name": "Novo Nordisk, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-550-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA218604"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-555", "64850-556"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["81cfbfd5-71c0-4c39-bcf3-2eae9fbd48fa"], "spl_set_id": ["0e024b69-567c-4b40-9c3e-a2daec34256c"], "package_ndc": ["64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-51", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0280", "0009-0274", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "43066-019-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-019", "43066-015", "43066-023", "43066-027"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734084", "1734207", "1734475", "1734483"], "spl_id": ["a8d08579-825f-40d9-b1e3-e47b73765ae6"], "spl_set_id": ["781d4b7f-7556-4695-8d48-7772d7a0d8e9"], "package_ndc": ["43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10"], "unii": ["V910P86109"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "0025-1001-31", "generic_name": "Spironolactone Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA012151"], "brand_name": ["ALDACTONE"], "generic_name": ["SPIRONOLACTONE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0025-1001", "0025-1041", "0025-1031"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["SPIRONOLACTONE"], "rxcui": ["198222", "198223", "200817", "200820", "200825", "313096"], "spl_id": ["22946678-dcad-4518-9bc6-cbdf51a38c16"], "spl_set_id": ["0fed2822-3a03-4b64-9857-c682fcd462bc"], "package_ndc": ["0025-1001-31", "0025-1041-31", "0025-1031-31"], "nui": ["N0000175557", "N0000011310"], "pharm_class_epc": ["Aldosterone Antagonist [EPC]"], "pharm_class_moa": ["Aldosterone Antagonists [MoA]"], "unii": ["27O7W4T232"]}, "update_date": "12/10/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Aldactone, Tablet, 25 mg (NDC 0025-1001-31)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "68001-573-41", "generic_name": "Decitabine Injection", "contact_info": "866-321-5031", "related_info": "Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210984"], "brand_name": ["DECITABINE"], "generic_name": ["DECITABINE"], "manufacturer_name": ["BluePoint Laboratories"], "product_ndc": ["68001-573"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DECITABINE"], "rxcui": ["636631"], "spl_id": ["fc96fe77-06cc-dc04-e053-6394a90a99da"], "spl_set_id": ["6c6ab831-6234-4803-8a01-5c51ec3b0716"], "package_ndc": ["68001-573-41"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["776B62CQ27"]}, "update_date": "02/20/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Decitabine, Injection, 50 mg (NDC 68001-573-41)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-408-25", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011719"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-408", "61703-350"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["METHOTREXATE SODIUM"], "rxcui": ["1655956", "1946772"], "spl_id": ["95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a"], "spl_set_id": ["0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab"], "package_ndc": ["61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25"], "unii": ["3IG1E710ZN"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-209-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": {"application_number": ["NDA020171"], "brand_name": ["DELFLEX"], "generic_name": ["DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care Renal Therapies Group, LLC"], "product_ndc": ["49230-209", "49230-206", "49230-212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAPERITONEAL"], "substance_name": ["CALCIUM CHLORIDE", "DEXTROSE MONOHYDRATE", "MAGNESIUM CHLORIDE", "SODIUM CHLORIDE", "SODIUM LACTATE"], "spl_id": ["44506bb0-e5f3-2a05-e063-6294a90ab2c9", "43cd31e0-97ed-1eeb-e063-6294a90a0b3d"], "spl_set_id": ["bbc5b820-4973-11e2-a192-0002a5d5c51b", "c29bdfa0-4976-11e2-939b-0002a5d5c51b"], "package_ndc": ["49230-206-20", "49230-206-30", "49230-206-32", "49230-206-50", "49230-206-60", "49230-206-62", "49230-206-52", "49230-209-23", "49230-209-30", "49230-209-32", "49230-209-50", "49230-209-60", "49230-209-62", "49230-209-52", "49230-212-23", "49230-212-30", "49230-212-32", "49230-212-50", "49230-212-60", "49230-212-62", "49230-212-52", "49230-206-92", "49230-206-94", "49230-206-95", "49230-209-92", "49230-209-94", "49230-209-95", "49230-212-92", "49230-212-94", "49230-212-95"], "unii": ["02F3473H9O", "LX22YL083G", "M4I0D6VV5M", "TU7HW0W0QT", "451W47IQ8X"]}, "update_date": "03/10/2026", "therapeutic_category": ["Renal"], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0172-5241-60", "generic_name": "Anagrelide Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/19/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Capsule", "presentation": "Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0527-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 5 mg (NDC 0071-0527-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-82", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-671", "25021-652"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "61570-072-01", "generic_name": "Esterified Estrogens Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/29/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Menest, Tablet, .3 mg (NDC 61570-072-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70860-701-04", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Athenex is not active, supplying through Sagent NDC 25021-701-02", "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-04)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-118-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-118", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: June 2026; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3073", "0009-3475"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "04/22/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-0929-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-0929", "0641-0928"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992858"], "spl_id": ["9f14d3f5-ad01-44b5-a2b7-16ed5f501f87"], "spl_set_id": ["4bf3912c-8339-401e-9711-dad6acf15f11"], "package_ndc": ["0641-0928-21", "0641-0928-25", "0641-0929-21", "0641-0929-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9549-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["NDA208083"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9549", "0338-9545", "0338-9553"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b0a47c5e-911b-4b12-a0d1-a4425f173eec"], "spl_set_id": ["44fa506b-90ac-42de-831b-5f3f1a500fc0"], "package_ndc": ["0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6025-10", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-016-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability June 2026", "openfda": {"application_number": ["ANDA210293"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Oryza Pharmaceuticals Inc."], "product_ndc": ["72516-016", "72516-015", "72516-014", "72516-013", "72516-012", "72516-011"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["39fb17a2-617d-37dc-e063-6394a90a1be3"], "spl_set_id": ["acd27181-a3f3-4c38-85d8-029a4a82e7c2"], "package_ndc": ["72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-401-02", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA206935"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Ingenus Pharmaceuticals, LLC"], "product_ndc": ["50742-401", "50742-402"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["3c841594-8a93-4728-b184-0f4bfac73390"], "spl_set_id": ["d04f2471-3085-4fc8-a657-bb3918d48e6e"], "package_ndc": ["50742-401-02", "50742-402-05"], "unii": ["042LAQ1IIS"]}, "update_date": "02/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/14/2018", "package_ndc": "65282-1605-1", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "978-657-0889 ext. 5231", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA208017"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "manufacturer_name": ["Spectra Medical Devices, LLC"], "product_ndc": ["65282-1605"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737566"], "spl_id": ["447bfde4-fff3-32a6-e063-6394a90a667e"], "spl_set_id": ["e8ba012a-08a9-4f67-9f88-3284377e80be"], "package_ndc": ["65282-1605-1"], "unii": ["EC2CNF7XFP"]}, "update_date": "05/15/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)", "company_name": "Spectra Medical Devices, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "83090-002-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-425-3131, SinteticaCS@eversana.com", "availability": "Available", "related_info": "Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X5ML)  is Preservative free.", "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)", "company_name": "Sintetica US", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-701-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA050141"], "brand_name": ["BICILLIN L-A"], "generic_name": ["PENICILLIN G BENZATHINE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["60793-701", "60793-700", "60793-702"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PENICILLIN G BENZATHINE"], "rxcui": ["731564", "731566", "731567", "731568", "731570", "731571"], "spl_id": ["4b3694af-9d77-487f-8838-b75aec6636da"], "spl_set_id": ["012d46f1-d0a0-4676-a879-cd320297ab16"], "package_ndc": ["60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10"], "unii": ["RIT82F58GK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6083-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "This presentation is temporarily on backorder.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PHENERGAN"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6083", "0641-6082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992462", "992858", "992876"], "spl_id": ["a64f0625-8d56-4994-8908-13614ca7b09f"], "spl_set_id": ["6f7e47cc-f823-4336-8107-f980e3049617"], "package_ndc": ["0641-6082-01", "0641-6082-25", "0641-6083-01", "0641-6083-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA070583"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596"], "spl_id": ["fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364"], "spl_set_id": ["bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6"], "package_ndc": ["0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1582-29", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1582", "0409-1559", "0409-1560", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1582-29)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-20", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release June 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA210762"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-806"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270"], "spl_id": ["341b092a-1f6f-40f1-98f2-9346bf2e1242"], "spl_set_id": ["38d0c14a-a0c1-44cc-a939-0304eb8037d6"], "package_ndc": ["63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50"], "unii": ["MUN5LYG46H"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)", "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-1502-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "company_name": "Lannett Company, Inc.", "contact_info": "844-834-0530", "availability": "Available", "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "status": "Current", "dosage_form": "Tablet", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-4060-13", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Limited Availability", "related_info": "Estimated shortage duration TBD", "openfda": {"application_number": ["NDA022341"], "brand_name": ["VICTOZA"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Novo Nordisk"], "product_ndc": ["0169-4060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122", "897126"], "spl_id": ["0d10d10e-0fe0-47ee-b9da-628e34907e98"], "spl_set_id": ["5a9ef4ea-c76a-4d34-a604-27c5b505f5a4"], "package_ndc": ["0169-4060-13", "0169-4060-12", "0169-4060-90", "0169-4060-97", "0169-4060-98", "0169-4060-99"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)", "company_name": "Novo Nordisk, Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "0406-1170-01", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-325-8888", "resolved_note": "Available", "openfda": {"application_number": ["ANDA076264"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-1170"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["9ed13551-325e-4b82-a266-72fc89ed27dc"], "spl_set_id": ["06ff2d5a-e62b-4fa4-bbdb-01938535bc65"], "package_ndc": ["0406-1170-03", "0406-1170-01"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-01)", "company_name": "SpecGx LLC", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "07/28/2025", "update_type": "New", "initial_posting_date": "07/28/2025", "package_ndc": "0049-3170-30", "generic_name": "Voriconazole Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021266"], "brand_name": ["VFEND"], "generic_name": ["VORICONAZOLE"], "manufacturer_name": ["Roerig"], "product_ndc": ["0049-3170", "0049-3180", "0049-3190", "0049-3160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VORICONAZOLE"], "rxcui": ["349434", "349435", "351209", "352218", "352219", "352220", "465355", "546624"], "spl_id": ["cf9f1b2e-eeb4-48bb-9f1a-c2b8d94dfbea"], "spl_set_id": ["ce3ef5cf-3087-4d92-9d94-9eb8287228db"], "package_ndc": ["0049-3170-30", "0049-3180-30", "0049-3190-28", "0049-3160-44"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000182140", "N0000185504"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]"], "unii": ["JFU09I87TR"]}, "update_date": "07/28/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Vfend, Tablet, 50 mg (NDC 0049-3170-30)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3213-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA074569"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3213", "0093-0832", "0093-3212"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["d6abe4e3-7699-4ead-95f4-739a961b23ad"], "spl_set_id": ["8069b1a0-7c06-4252-b44e-e2eef065d9b8"], "package_ndc": ["0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/01/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-02", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-062-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-062", "70069-061", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-460-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-460", "63323-465", "63323-467", "63323-464", "63323-466", "63323-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "RETROBULBAR"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177"], "spl_id": ["2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-105-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "65219-434-20", "generic_name": "Piperacillin and Tazobactam Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA203719"], "brand_name": ["PIPERACILLIN AND TAZOBACTAM"], "generic_name": ["PIPERACILLIN AND TAZOBACTAM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-434", "65219-436", "65219-259"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PIPERACILLIN SODIUM", "TAZOBACTAM SODIUM"], "rxcui": ["1659131", "1659137", "1659149"], "spl_id": ["76af03be-bc73-40f9-bde0-31fe9c359ca2"], "spl_set_id": ["a798faf5-cd97-4e35-a700-94c372978c46"], "package_ndc": ["65219-434-02", "65219-434-20", "65219-436-02", "65219-436-20", "65219-259-05", "65219-259-45"], "unii": ["UXA545ABTT", "M98T69Q7HP"]}, "update_date": "01/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7838-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7838", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-02", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1180-69", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Shortage per Manufacturer: Manufacturing Delay", "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "68180-659-06", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA090034"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["Lupin Pharmaceuticals, Inc."], "product_ndc": ["68180-659", "68180-658"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["5ed1edac-e11e-4f87-b390-e770a69a9b37"], "spl_set_id": ["b56004f0-f23d-47f6-80c7-39884fccbccc"], "package_ndc": ["68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/29/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 68180-659-06)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "63323-089-50", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206688"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-089", "63323-083"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868469", "1868486"], "spl_id": ["9def795c-abcf-483c-8b1d-e4374666efb2"], "spl_set_id": ["0ab55004-bb63-436d-ad77-cd3796905370"], "package_ndc": ["63323-083-03", "63323-083-05", "63323-089-25", "63323-089-50"], "unii": ["8MDF5V39QO"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/27/2023", "package_ndc": "45567-0060-1", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "New supply anticipated Q2 2026", "openfda": {"application_number": ["NDA019039"], "brand_name": ["KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE"], "generic_name": ["TECHNETIUM TC99M PYROPHOSPHATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["45567-0060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["TECHNETIUM TC-99M PYROPHOSPHATE"], "spl_id": ["3010b45e-eed1-a5d0-e063-6294a90a40cf"], "spl_set_id": ["1f0cbd23-2fb3-43b7-b8af-7de246151149"], "package_ndc": ["45567-0060-1", "45567-0060-2"], "nui": ["N0000177914", "N0000000205"], "pharm_class_epc": ["Radioactive Diagnostic Agent [EPC]"], "pharm_class_moa": ["Radiopharmaceutical Activity [MoA]"], "unii": ["5L76I61H2B"]}, "update_date": "04/17/2026", "therapeutic_category": ["Medical Imaging"], "dosage_form": "Injection", "presentation": "CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/31/2018", "package_ndc": "65219-570-04", "generic_name": "Bumetanide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA216434"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-570", "65219-572"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["aaff61c4-203b-4905-9138-0f98959ad013"], "spl_set_id": ["a007f3aa-3977-4be3-a9a2-db3d458bca58"], "package_ndc": ["65219-570-01", "65219-570-04", "65219-572-01", "65219-572-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1454-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1454", "0409-3301", "0409-1174", "0409-2815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["8d48de06-361f-418b-bfec-8ef85f94d5bc"], "spl_set_id": ["4419162d-81d4-49bd-96de-1729440bdb74"], "package_ndc": ["0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0126-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "63323-519-77", "generic_name": "Heparin Sodium Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA212441"], "brand_name": ["HEPARIN SODIUM"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-519"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["3bbbe74a-1246-41a6-9fc3-ca0230529b40"], "spl_set_id": ["25b0ba06-3274-4a3f-8c39-42d13764ecdf"], "package_ndc": ["63323-519-02", "63323-519-77", "63323-519-01", "63323-519-10"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/23/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-74", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE AQUA"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0521"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["0bc2d27e-e0d0-4c85-a5e1-808c625b6f93"], "spl_set_id": ["c85dc235-3f42-4361-9bd2-1aaff798ad75"], "package_ndc": ["0574-0521-04", "0574-0521-08", "0574-0521-25", "0574-0521-74", "0574-0521-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "16729-081-01", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "866-941-7875, option 2", "resolved_note": "Available", "openfda": {"application_number": ["ANDA091205"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-081"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["424db74c-6c0f-1eb3-e063-6294a90a7db8"], "spl_set_id": ["49aa3d6d-2270-4615-aafa-b440859ab870"], "package_ndc": ["16729-081-10", "16729-081-01", "16729-081-16", "16729-081-17"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-01)", "company_name": "Accord Healthcare Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-487-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076803"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-487", "62135-484", "62135-485", "62135-486"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["09cd5cb9-4fdf-f133-e063-6294a90af691"], "spl_set_id": ["dbc43dbd-94aa-40e2-a9ea-766110cc8687"], "package_ndc": ["62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90"], "unii": ["33067B3N2M"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5813-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA090866"], "brand_name": ["VALSARTAN"], "generic_name": ["VALSARTAN"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-5813", "0378-5807", "0378-5814", "0378-5815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["VALSARTAN"], "rxcui": ["349199", "349200", "349201", "349483"], "spl_id": ["a5384d58-48c7-494a-a8a8-c296b316bd91"], "spl_set_id": ["73e01dc6-7dd4-421a-a4f6-137e75f69f9a"], "package_ndc": ["0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77"], "nui": ["N0000000070", "N0000175561"], "pharm_class_moa": ["Angiotensin 2 Receptor Antagonists [MoA]"], "pharm_class_epc": ["Angiotensin 2 Receptor Blocker [EPC]"], "unii": ["80M03YXJ7I"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 80 mg (NDC 0378-5813-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-172-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020712"], "brand_name": ["CARBATROL"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["54092-172", "54092-171", "54092-173"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["200131", "200133", "308977", "313931", "388311", "404742"], "spl_id": ["39171a32-c78d-4130-be53-638e19cf2261"], "spl_set_id": ["bc03e499-5bac-4293-bff4-6864153a624d"], "package_ndc": ["54092-171-12", "54092-172-12", "54092-173-12"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "12/19/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-4073-04", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-407", "43547-406", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-421-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA201072"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-421"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["56e0af34-aeb5-4b37-8c61-2e90b2c8ca6c"], "spl_set_id": ["c1b8eb58-596b-481d-beb6-ba9d2237abf4"], "package_ndc": ["63323-421-01", "63323-421-02"], "unii": ["1018WH7F9I"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-112-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-112", "70010-111", "70010-113", "70010-114", "70010-115", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-0152-24", "generic_name": "Metronidazole Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Labeler: Hospira Inc.", "openfda": {"application_number": ["ANDA206191"], "brand_name": ["METRONIDAZOLE"], "generic_name": ["METRONIDAZOLE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0152"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["METRONIDAZOLE"], "rxcui": ["311683"], "spl_id": ["1489f8a8-873f-465f-ac91-980848a8d4a2"], "spl_set_id": ["49360d6f-c8b3-420e-af75-154cf7b05255"], "package_ndc": ["0409-0152-01", "0409-0152-24"], "nui": ["N0000175435", "M0014907"], "pharm_class_epc": ["Nitroimidazole Antimicrobial [EPC]"], "pharm_class_cs": ["Nitroimidazoles [CS]"], "unii": ["140QMO216E"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)", "company_name": "InfoRLife SA", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-111-14", "generic_name": "Nilutamide Tablet", "contact_info": "847-283-7921", "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Nilandron, Tablet, 150 mg (NDC 59212-111-14)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-600-04", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": {"application_number": ["NDA206628"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["WG Critical Care, LLC"], "product_ndc": ["44567-600", "44567-601", "44567-602", "44567-603"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909", "1788947"], "spl_id": ["e6fa3e27-b374-49b6-a678-a5954f5beae8"], "spl_set_id": ["0d2710f2-ee47-4114-ab5c-8dca74cdcb8d"], "package_ndc": ["44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)", "company_name": "HQ Specialty Pharma", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-03", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3796-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA074802"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3796", "0409-3793", "0409-3795"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["572e3ce2-a27c-4a65-9593-84666518ddca"], "spl_set_id": ["8accbb78-fc64-45d5-69b0-35c23a1d2a2e"], "package_ndc": ["0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "16729-277-35", "generic_name": "Methotrexate Sodium Injection", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": {"application_number": ["ANDA040716"], "brand_name": ["METHOTREXATE"], "generic_name": ["METHOTREXATE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-277"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS"], "substance_name": ["METHOTREXATE"], "rxcui": ["1655956", "1655959", "1655960"], "spl_id": ["2bae3cfe-7aa0-c14c-e063-6294a90a19f4"], "spl_set_id": ["dd035a9f-cd40-4314-b9d8-2294b8a924e2"], "package_ndc": ["16729-277-30", "16729-277-03", "16729-277-35"], "nui": ["N0000175584", "N0000000111"], "pharm_class_epc": ["Folate Analog Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Folic Acid Metabolism Inhibitors [MoA]"], "unii": ["YL5FZ2Y5U1"]}, "update_date": "05/01/2026", "therapeutic_category": ["Rheumatology", "Oncology"], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)", "company_name": "Accord Healthcare Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-062-01", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-062", "65862-063", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-01)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "76045-005-11", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi, USA LLC", "Fresenius Kabi USA, LLC"], "product_ndc": ["76045-005", "76045-004", "76045-006", "76045-007", "76045-008"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "894914", "998212", "998213", "1442790"], "spl_id": ["286bce70-23cd-4d5b-989b-230d6cdd5a91", "e064585d-2d2d-41cd-a0f1-43494ce4775b"], "spl_set_id": ["1f53de80-efc8-4930-b3e3-fba0d026af05", "b62ee1ef-db55-417a-a02e-b103890f9c4b"], "package_ndc": ["76045-004-01", "76045-004-11", "76045-005-01", "76045-005-11", "76045-006-01", "76045-006-11", "76045-007-01", "76045-007-11", "76045-008-01", "76045-008-11", "76045-004-02", "76045-004-12", "76045-005-02", "76045-005-12", "76045-006-02", "76045-006-12", "76045-007-00", "76045-007-10", "76045-008-00", "76045-008-10"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6082-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PHENERGAN"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6082", "0641-6083"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992462", "992858", "992876"], "spl_id": ["a64f0625-8d56-4994-8908-13614ca7b09f"], "spl_set_id": ["6f7e47cc-f823-4336-8107-f980e3049617"], "package_ndc": ["0641-6082-01", "0641-6082-25", "0641-6083-01", "0641-6083-25"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-3112-23", "generic_name": "Hydrochlorothiazide; Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 12.5 mg; 10 mg (NDC 0071-3112-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "63323-172-60", "generic_name": "Carboplatin Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release April 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA077266"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-172"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["3a1dd588-13b0-4d58-8d46-3a25a4fc6b40"], "spl_set_id": ["b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6"], "package_ndc": ["63323-172-60"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0591-0347-01", "generic_name": "Hydrochlorothiazide Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["NDA020504"], "brand_name": ["HYDROCHLOROTHIAZIDE"], "generic_name": ["HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-0347"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE"], "rxcui": ["199903"], "spl_id": ["b062bc7e-af92-4648-aed1-e02568313e21"], "spl_set_id": ["a3eb7294-f913-434b-896c-da028bfebc73"], "package_ndc": ["0591-0347-01", "0591-0347-05"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["0J48LPH2TH"]}, "update_date": "11/19/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Microzide, Capsule, 12.5 mg (NDC 0591-0347-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "76045-009-06", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release April 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["DILAUDID"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-009", "76045-010", "76045-121"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370"], "spl_id": ["97bfcafb-2037-47dc-a0ae-f7b8007c47df"], "spl_set_id": ["9eebd88a-5632-460f-b7b6-26c8a180540d"], "package_ndc": ["76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-105-20", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA203242"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-105", "76045-104", "76045-107", "76045-209"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860113", "860114", "860115"], "spl_id": ["0dab642d-7fcf-4301-8ac9-10e64a040c6b"], "spl_set_id": ["3d88cbe6-5230-47aa-80af-0c41283d1f00"], "package_ndc": ["76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-92", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075757"], "brand_name": ["OMEPRAZOLE"], "generic_name": ["OMEPRAZOLE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-2868", "0781-2859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["OMEPRAZOLE"], "rxcui": ["198051", "199119"], "spl_id": ["b182f298-e28f-434b-b6f1-ecfac29d495e"], "spl_set_id": ["516170d4-4913-4577-a2d2-f5c52d1e79c6"], "package_ndc": ["0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31"], "nui": ["N0000175525", "N0000000147", "N0000182140"], "pharm_class_epc": ["Proton Pump Inhibitor [EPC]"], "pharm_class_moa": ["Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]"], "unii": ["KG60484QX9"]}, "update_date": "10/09/2025", "therapeutic_category": ["Gastroenterology"], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/17/2025", "update_type": "New", "initial_posting_date": "07/17/2025", "package_ndc": "0591-2682-01", "generic_name": "Potassium Citrate Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue.", "openfda": {"application_number": ["ANDA209758"], "brand_name": ["POTASSIUM CITRATE"], "generic_name": ["POTASSIUM CITRATE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-2682", "0591-2729", "0591-2742"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CITRATE"], "rxcui": ["199376", "199381", "898490"], "spl_id": ["309b143e-7142-4a21-859e-715ba61e82f7"], "spl_set_id": ["ac173781-486b-461c-97ae-8b5c69e20792"], "package_ndc": ["0591-2682-01", "0591-2729-01", "0591-2742-01"], "unii": ["EE90ONI6FF"]}, "update_date": "07/17/2025", "therapeutic_category": ["Renal"], "dosage_form": "Tablet", "presentation": "Potassium Citrate, Tablet, Extended Release, 5 meq (NDC 0591-2682-01)", "company_name": "Watson Pharma Private Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "64253-020-30", "generic_name": "Sterile Water Injection", "contact_info": "630-682-4600", "availability": "Available", "openfda": {"application_number": ["ANDA211188"], "brand_name": ["STERILE WATER"], "generic_name": ["STERILE WATER FOR INJECTION"], "manufacturer_name": ["Medefil, Inc."], "product_ndc": ["64253-020"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["2b39b41d-419a-dab8-e063-6394a90a319a"], "spl_set_id": ["99e99a50-82d5-aff6-e053-2a95a90a8c56"], "package_ndc": ["64253-020-21", "64253-020-23", "64253-020-30", "64253-020-35", "64253-020-52", "64253-020-25", "64253-020-91"], "unii": ["059QF0KO0R"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)", "company_name": "Medefil, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "16729-525-08", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1761-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018692"], "brand_name": ["MARCAINE SPINAL"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1761"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBARACHNOID"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724784", "1724792"], "spl_id": ["f3862f77-3621-4730-923e-9efbfa18e03f"], "spl_set_id": ["9679cc05-2f8a-4e88-53b5-6e9122c8b8c0"], "package_ndc": ["0409-1761-19", "0409-1761-02", "0409-1761-18", "0409-1761-62", "0409-1761-05", "0409-1761-10"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9310-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Novaplus label", "openfda": {"application_number": ["ANDA202354"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9310", "0143-9311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["c15bd8c1-34e3-40f2-b31a-634136fe197c"], "spl_set_id": ["4312e3c3-34de-4cb3-8abd-c24d24a4bea1"], "package_ndc": ["0143-9310-01", "0143-9310-10", "0143-9311-01", "0143-9311-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6002-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA018140"], "brand_name": ["ATIVAN"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6002", "0641-6003", "0641-6001", "0641-6000"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327"], "spl_id": ["209b0091-c890-4f69-a693-d0594c2606fe"], "spl_set_id": ["5fc0e987-61c9-40c4-b0d5-fcea07c8733e"], "package_ndc": ["0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/30/2025", "update_type": "New", "initial_posting_date": "09/30/2025", "package_ndc": "0004-0801-85", "generic_name": "Oseltamivir Phosphate Capsule", "contact_info": "800-551-2231", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "09/30/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Capsule", "presentation": "Tamiflu, Capsule, 45 mg (NDC 0004-0801-85)", "company_name": "Genentech, Inc", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/03/2021", "package_ndc": "0409-3977-03", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: September 2026; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018802"], "brand_name": ["BACTERIOSTATIC WATER"], "generic_name": ["BACTERIOSTATIC WATER"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3977", "0409-1093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["WATER"], "spl_id": ["e421caa9-6011-4cdf-a16c-6fe96d8b958a"], "spl_set_id": ["87d6e9dc-fe3b-4593-ac9a-d7493d1959c7"], "package_ndc": ["0409-3977-01", "0409-3977-03", "0409-1093-14", "0409-1093-04"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-288", "63323-286", "63323-287", "63323-285"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484"], "spl_id": ["cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce"], "spl_set_id": ["23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f"], "package_ndc": ["63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/13/2017", "package_ndc": "83301-0080-2", "generic_name": "Bumetanide Injection", "contact_info": "800-673-9839", "availability": "Available", "openfda": {"application_number": ["ANDA219116"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Mullan Pharmaceutical Inc."], "product_ndc": ["83301-0080", "83301-0081"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["4c241a3e-649b-4414-e063-6294a90a3a32"], "spl_set_id": ["b7cd724b-817b-4b45-8133-1ebf505867e7"], "package_ndc": ["83301-0080-1", "83301-0080-2", "83301-0081-1", "83301-0081-2"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)", "company_name": "Mullan Pharmaceutical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-23", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-286", "63323-285", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9545-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["NDA208083"], "brand_name": ["CLINDAMYCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9545", "0338-9549", "0338-9553"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["309335", "309336", "309339"], "spl_id": ["b0a47c5e-911b-4b12-a0d1-a4425f173eec"], "spl_set_id": ["44fa506b-90ac-42de-831b-5f3f1a500fc0"], "package_ndc": ["0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24"], "unii": ["EH6D7113I8"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0472-0803-04", "generic_name": "Desonide Lotion", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA072354"], "brand_name": ["DESONIDE"], "generic_name": ["DESONIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0472-0803", "0472-0804"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["DESONIDE"], "rxcui": ["197572", "349351"], "spl_id": ["f3953b9e-138f-4d86-8eea-0fc03c3c2747"], "spl_set_id": ["ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99"], "package_ndc": ["0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04"], "nui": ["N0000175576", "N0000175450"], "pharm_class_epc": ["Corticosteroid [EPC]"], "pharm_class_moa": ["Corticosteroid Hormone Receptor Agonists [MoA]"], "unii": ["J280872D1O"]}, "update_date": "09/18/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Lotion", "presentation": "Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-04)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7853-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7853", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-385-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0480-3667-20", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "related_info": "Distributed by Teva", "openfda": {"application_number": ["NDA022341"], "brand_name": ["LIRAGLUTIDE"], "generic_name": ["LIRAGLUTIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0480-3667"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["LIRAGLUTIDE"], "rxcui": ["897122"], "spl_id": ["57c9f463-a1b8-4efa-8982-40175cf6cf4f"], "spl_set_id": ["14bf9812-14ee-46ce-93b1-686e4906cbbc"], "package_ndc": ["0480-3667-19", "0480-3667-22", "0480-3667-20"], "nui": ["N0000178480", "M0160181", "N0000020058"], "pharm_class_epc": ["GLP-1 Receptor Agonist [EPC]"], "pharm_class_cs": ["Glucagon-Like Peptide 1 [CS]"], "pharm_class_moa": ["Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"], "unii": ["839I73S42A"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)", "company_name": "Novo Nordisk, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-083-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-083", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0264-2101-10", "generic_name": "Sterile Water Irrigant", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA016734"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-2101"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["969bdf41-6565-42fb-8ac1-8661a928cc22"], "spl_set_id": ["f4284eb6-e553-46d4-90d8-efc80a90a480"], "package_ndc": ["0264-2101-00", "0264-2101-10", "0264-2101-50", "0264-2101-70"], "unii": ["059QF0KO0R"]}, "update_date": "04/20/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-726-52", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216039"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-726", "71288-723"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["0949c302-51ce-4fc9-8b99-1df94e693718"], "spl_set_id": ["fe340f98-a0f3-446e-b281-47fd91c1e537"], "package_ndc": ["71288-723-52", "71288-726-52"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0143-9252-25", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA207707"], "brand_name": ["DOPAMINE HYDROCHLORIDE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9252", "0143-9253", "0143-9254", "0143-9255"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1743938", "1743941", "1743950", "1743953"], "spl_id": ["67349236-e8e3-45ec-a76d-2a0a150d8d59"], "spl_set_id": ["0e499952-46c7-4172-8c70-186312e240a3"], "package_ndc": ["0143-9252-01", "0143-9252-25", "0143-9253-01", "0143-9253-25", "0143-9254-01", "0143-9254-25", "0143-9255-01", "0143-9255-25"], "unii": ["7L3E358N9L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "55150-324-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA212174"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-324", "55150-322", "55150-323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9bb2ffa4-0891-4197-a970-90b178bbfad9"], "spl_set_id": ["421aa6d5-623b-4dc2-abd5-bb9e7765bf37"], "package_ndc": ["55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA078591"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2634"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["1724338", "1724340", "1724341"], "spl_id": ["50886ad5-eeca-4fe7-beb0-01305f92c65d"], "spl_set_id": ["3832ede8-d3fc-455d-ecab-3b77be5869f5"], "package_ndc": ["0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-100-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 100 ug (NDC 72305-100-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-580-20", "generic_name": "Atropine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA209260"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-580"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190776"], "spl_id": ["8039a2a4-4c0a-4062-9ca5-78137ba74082"], "spl_set_id": ["310c8a74-ea24-4357-8099-81e394b1634e"], "package_ndc": ["63323-580-20"], "unii": ["03J5ZE7KA5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-10", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1918", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-103-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-103", "59417-101", "59417-102", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 30 mg (NDC 59417-103-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/30/2026", "update_type": "New", "initial_posting_date": "01/30/2026", "package_ndc": "57664-655-88", "generic_name": "Pindolol Tablet", "contact_info": "800-818-4555", "related_info": "Discontinuation of the manufacture of the drug; Expiry date of last distributed batch January 2027", "openfda": {"application_number": ["ANDA074063"], "brand_name": ["PINDOLOL"], "generic_name": ["PINDOLOL"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-655", "57664-656"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PINDOLOL"], "rxcui": ["198104", "198105"], "spl_id": ["4d3c89dd-e947-5f23-e063-6294a90aeb1f"], "spl_set_id": ["b331a73f-bf7b-4442-8901-36d016530279"], "package_ndc": ["57664-656-88", "57664-655-88"], "nui": ["N0000000161", "N0000175556"], "pharm_class_moa": ["Adrenergic beta-Antagonists [MoA]"], "pharm_class_epc": ["beta-Adrenergic Blocker [EPC]"], "unii": ["BJ4HF6IU1D"]}, "update_date": "01/30/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pindolol, Tablet, 5 mg (NDC 57664-655-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1075-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020255"], "brand_name": ["DOBUTAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOBUTAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1075", "0338-1073", "0338-1077"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["34c787c1-46f7-4264-951d-c88a34dca533"], "spl_set_id": ["6b17b98b-e06d-42ed-925f-69aa2699dead"], "package_ndc": ["0338-1073-02", "0338-1075-02", "0338-1077-02"], "unii": ["0WR771DJXV"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0370-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0370", "0054-0660", "0054-0371", "0054-0372", "0054-0373", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "3, 4, 5, 7 & 8 month expiry available upon request. Check wholesaler for inventory", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-061-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-061", "70069-062", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-0155-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0155", "0409-4596"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718907", "1718909", "1718910"], "spl_id": ["58e27ec5-ccde-46c9-afd3-2509e6b55e4e"], "spl_set_id": ["92b7ddaa-e45a-4b64-a802-bb5df8771dd6"], "package_ndc": ["0409-4596-01", "0409-4596-20", "0409-0155-01", "0409-0155-02"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-438-10", "generic_name": "Arsenic Trioxide Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA209315"], "brand_name": ["ARSENIC TRIOXIDE"], "generic_name": ["ARSENIC TRIOXIDE"], "manufacturer_name": ["Ingenus Pharmaceuticals, LLC"], "product_ndc": ["50742-438"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ARSENIC TRIOXIDE"], "rxcui": ["829926"], "spl_id": ["b3030683-7cb9-4143-abbd-d3894313e83d"], "spl_set_id": ["c99b01b4-67ff-4793-8375-fe3a21c6c9be"], "package_ndc": ["50742-438-10"], "unii": ["S7V92P67HO"]}, "update_date": "02/24/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-01", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA074086"], "brand_name": ["DOBUTAMINE"], "generic_name": ["DOBUTAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2344"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["1812168"], "spl_id": ["e71e9520-871b-479d-9652-1857fceca863", "5d6b1dfe-d679-4aea-97a6-3d074a202afe"], "spl_set_id": ["dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58"], "package_ndc": ["0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88"], "unii": ["0WR771DJXV"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-66", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA019465"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7101", "0409-7132"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807547", "1807631", "1807632", "1807633"], "spl_id": ["f233e72c-072d-4a43-857a-f4d5791e1a73"], "spl_set_id": ["a2a964f7-c3ec-4dfb-e3a0-6d8136a80397"], "package_ndc": ["0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02"], "unii": ["451W47IQ8X"]}, "update_date": "12/03/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 50 mL  ADD-Vantage® Flexible Container (NDC 0409-7101-66)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-444-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA217472"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-444", "65219-442", "65219-695", "65219-697"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["2720024", "2720026"], "spl_id": ["31c4c874-3d24-4c86-a301-ee9faf0b5c00"], "spl_set_id": ["9a622308-7bda-4ca0-9de5-d6b3b4be3384"], "package_ndc": ["65219-442-02", "65219-442-05", "65219-444-04", "65219-444-10", "65219-695-01", "65219-695-05", "65219-697-01", "65219-697-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5017-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA063076"], "brand_name": ["VANCOMYCIN HYDROCHLORIDE"], "generic_name": ["VANCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5017", "0409-6509"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VANCOMYCIN HYDROCHLORIDE"], "rxcui": ["239209", "313572"], "spl_id": ["818f60e1-7062-4ed0-9839-7cab15866330"], "spl_set_id": ["b01aaa02-8f1d-4b57-96a5-337503428af1"], "package_ndc": ["0409-6509-49", "0409-5017-01"], "unii": ["71WO621TJD"]}, "update_date": "11/14/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"presentation": "Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1559-30", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "73293-0002-2", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "+82-2-854-4700 or via email intbiz@huons.com", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA212822"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Huons Co., Ltd."], "product_ndc": ["73293-0002"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBARACHNOID"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724784"], "spl_id": ["2e641a0d-4d42-e7cd-e063-6394a90a47d4"], "spl_set_id": ["2dc693df-3218-4a90-b3f7-21e80966a851"], "package_ndc": ["73293-0002-1", "73293-0002-2"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)", "company_name": "Huons Co., Ltd", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/03/2023", "package_ndc": "81665-104-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Available", "related_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195", "openfda": {"application_number": ["ANDA209264"], "brand_name": ["CROMOLYN SODIUM"], "generic_name": ["CROMOLYN SODIUM"], "manufacturer_name": ["Omnivium Pharmaceuticals LLC"], "product_ndc": ["81665-104"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261"], "spl_id": ["fd09b0f1-907c-4d4d-a693-9756efd60f20"], "spl_set_id": ["a742664b-265e-49f9-9744-d04e1fb620ae"], "package_ndc": ["81665-104-96"], "unii": ["Q2WXR1I0PK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)", "company_name": "Ailex Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/11/2024", "package_ndc": "0990-7918-19", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7918-19", "openfda": {"application_number": ["NDA018561"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7918", "0990-7935", "0990-7936", "0990-7937", "0990-8004"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["237649", "237650", "237656", "242694", "1795518"], "spl_id": ["6785bd83-c705-41a5-a19c-906f03f380e3"], "spl_set_id": ["b5cb7a5a-bbe8-4217-a82e-da818f7771c9"], "package_ndc": ["0990-7918-19", "0990-7935-19", "0990-7936-19", "0990-7937-19", "0990-8004-15"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72266-146-10", "generic_name": "Etomidate Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": {"application_number": ["ANDA209058"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE INJECTION"], "manufacturer_name": ["Fosun Pharma USA Inc"], "product_ndc": ["72266-146", "72266-147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["2b365133-b609-3285-e063-6394a90a69a6"], "spl_set_id": ["8b6c54d8-3f3f-4290-841c-976bea01086f"], "package_ndc": ["72266-146-01", "72266-146-10", "72266-147-01", "72266-147-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/24/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "0409-4264-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2026; Estimated Recovery: March 2027; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4264", "0409-1283", "0409-1312", "0409-1805"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4667-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": {"application_number": ["ANDA215802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["0527-4667", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4666"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["cb49954d-0f9d-4471-bc86-0c926473c00b"], "spl_set_id": ["2cedb4c2-1e40-4bc4-b9f4-127150c4afbd"], "package_ndc": ["0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37"], "unii": ["SJT761GEGS"]}, "update_date": "05/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)", "company_name": "Lannett Company, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "25021-687-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Estimated recovery: June 2026", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-687"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["1d066c67-eac2-494a-ad10-ba7e9c60b0e9"], "spl_set_id": ["01825411-be08-4402-b101-cb546291c972"], "package_ndc": ["25021-687-05", "25021-687-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-104-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-104", "59417-101", "59417-102", "59417-103", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 40 mg (NDC 59417-104-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-075-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-075", "72305-025", "72305-050", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 75 ug (NDC 72305-075-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "67457-893-08", "generic_name": "Busulfan Injection", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA208536"], "brand_name": ["BUSULFAN"], "generic_name": ["BUSULFAN"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-893"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["BUSULFAN"], "rxcui": ["253113"], "spl_id": ["2ddd71e8-c2bd-4ee9-bef3-14891809fa28"], "spl_set_id": ["9955aced-ac32-43e6-b39a-c6c023a50dc3"], "package_ndc": ["67457-893-00", "67457-893-08"], "nui": ["N0000000236", "N0000175558"], "pharm_class_moa": ["Alkylating Activity [MoA]"], "pharm_class_epc": ["Alkylating Drug [EPC]"], "unii": ["G1LN9045DK"]}, "update_date": "10/24/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08)", "company_name": "Mylan Institutional, a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-9664-40", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020179"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9664", "0338-9666"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616"], "spl_id": ["bfc4224a-2fc9-4137-b4c6-9d2d6d948413"], "spl_set_id": ["bfc4224a-2fc9-4137-b4c6-9d2d6d948413"], "package_ndc": ["0338-9664-40", "0338-9666-35"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3567-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3567", "0480-3565", "0480-3566", "0480-3568", "0480-3569", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/06/2023", "change_date": "12/15/2025", "package_ndc": "0338-1047-02", "generic_name": "Nitroglycerin Injection", "contact_info": "Baxter Healthcare 888-229-0001", "resolved_note": "Available", "openfda": {"application_number": ["NDA019970"], "brand_name": ["NITROGLYCERIN IN DEXTROSE"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1047", "0338-1049", "0338-1051"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["312004", "1868494", "1868562"], "spl_id": ["b89cb9ff-d275-465b-b70b-d8e2e9406435"], "spl_set_id": ["457a026c-ebce-4701-9deb-2d7652759a99"], "package_ndc": ["0338-1047-02", "0338-1049-02", "0338-1051-02"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "12/15/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Nitroglycerin in Dextrose 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)", "company_name": "Baxter Healthcare", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "16571-600-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(201) 961-9000 or contact@risingpharma.com", "availability": "Limited Availability", "related_info": "Limited Availability", "openfda": {"application_number": ["ANDA202583"], "brand_name": ["CROMOLYN SODIUM"], "generic_name": ["CROMOLYN SODIUM"], "manufacturer_name": ["Rising Pharma Holdings, Inc."], "product_ndc": ["16571-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CROMOLYN SODIUM"], "rxcui": ["831261"], "spl_id": ["ca2c72ae-db00-4694-9fd0-d4b6b45f8108"], "spl_set_id": ["61c9cb85-129e-4490-b5f7-357307fcecbf"], "package_ndc": ["16571-600-96"], "unii": ["Q2WXR1I0PK"]}, "update_date": "03/02/2026", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)", "company_name": "Rising Pharma Holdings, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3564-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "related_info": "-", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3564", "0480-3565", "0480-3566", "0480-3567", "0480-3568", "0480-3569", "0480-3570"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-801-30", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": {"application_number": ["ANDA064150"], "brand_name": ["RIFAMPIN"], "generic_name": ["RIFAMPIN"], "manufacturer_name": ["EPIC PHARMA, LLC"], "product_ndc": ["42806-801", "42806-799"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["RIFAMPIN"], "rxcui": ["198201", "198202"], "spl_id": ["a4ac02e8-68ac-4e79-8ca5-0939dd002c87"], "spl_set_id": ["0391f1e1-70d4-4b15-8b58-055bb6a385b8"], "package_ndc": ["42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05"], "nui": ["N0000175500", "M0019113"], "pharm_class_epc": ["Rifamycin Antibacterial [EPC]"], "pharm_class_cs": ["Rifamycins [CS]"], "unii": ["VJT6J7R4TR"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 42806-801-30)", "company_name": "Epic Pharma, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "72143-321-30", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug. Manufactured for JG Pharma", "openfda": {"application_number": ["NDA018738"], "brand_name": ["SULCONAZOLE NITRATE"], "generic_name": ["SULCONAZOLE NITRATE"], "manufacturer_name": ["JG Pharma Inc."], "product_ndc": ["72143-321"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["SULCONAZOLE NITRATE"], "rxcui": ["313125"], "spl_id": ["fc60cb89-7eba-463c-91b9-1b21cd8637a5"], "spl_set_id": ["cf6f4340-940c-4a61-b675-456e3297d810"], "package_ndc": ["72143-321-30"], "unii": ["1T89100D5U"]}, "update_date": "05/08/2026", "therapeutic_category": ["Dermatology"], "dosage_form": "Solution", "presentation": "Sulconazole Nitrate, Solution, 30 mL (NDC 72143-321-30)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2850-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA200881"], "brand_name": ["GUANFACINE"], "generic_name": ["GUANFACINE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0228-2850", "0228-2851", "0228-2853", "0228-2855"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GUANFACINE HYDROCHLORIDE"], "rxcui": ["862006", "862013", "862019", "862025"], "spl_id": ["b9040df2-42e8-404d-9b90-331dd3efc38c"], "spl_set_id": ["3a171942-37af-430d-8b9d-bb678ca2be4b"], "package_ndc": ["0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11"], "unii": ["PML56A160O"]}, "update_date": "11/13/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 1 mg (NDC 0228-2850-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2596-03", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA075293"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-2596", "0409-2587"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["6c075a2d-b68b-41a7-aa0c-bcf9894e3f76"], "spl_set_id": ["affecd4d-1f78-4bbe-5a8d-86849bbdc520"], "package_ndc": ["0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05"], "unii": ["W7TTW573JJ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5315-15", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5315", "0245-5316"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-15)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/12/2025", "update_type": "New", "initial_posting_date": "08/12/2025", "package_ndc": "23155-578-01", "generic_name": "Desipramine Hydrochloride Tablet", "contact_info": "855-228-9470", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207433"], "brand_name": ["DESIPRAMINE HYDROCHLORIDE"], "generic_name": ["DESIPRAMINE HYDROCHLORIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-578", "23155-579", "23155-580", "23155-581", "23155-582", "23155-583"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["DESIPRAMINE HYDROCHLORIDE"], "rxcui": ["1099288", "1099292", "1099296", "1099300", "1099304", "1099316"], "spl_id": ["49984729-ddde-44ed-927b-8a4ba65cefa0"], "spl_set_id": ["ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0"], "package_ndc": ["23155-578-01", "23155-579-01", "23155-580-01", "23155-581-01", "23155-582-01", "23155-583-25"], "unii": ["1Y58DO4MY1"]}, "update_date": "08/12/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Desipramine Hydrochloride, Tablet, 10 mg (NDC 23155-578-01)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0011-03", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0011", "0009-0825", "0009-0013", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3793-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2027", "openfda": {"application_number": ["ANDA074802"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3793", "0409-3795", "0409-3796"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["572e3ce2-a27c-4a65-9593-84666518ddca"], "spl_set_id": ["8accbb78-fc64-45d5-69b0-35c23a1d2a2e"], "package_ndc": ["0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1362-01", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Shortage per Manufacturer: Manufacturing Delay", "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "0074-9037-30", "generic_name": "Paricalcitol Capsule", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021606"], "brand_name": ["ZEMPLAR"], "generic_name": ["PARICALCITOL"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-9037", "0074-4314", "0074-4317", "0074-9036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PARICALCITOL"], "rxcui": ["577315", "577317", "606854", "606859"], "spl_id": ["ed8862d9-4037-4a30-9be6-42f2613c34cd"], "spl_set_id": ["1b27c026-2d60-47b4-2a9c-ded1818f21b5"], "package_ndc": ["0074-4314-30", "0074-4317-30", "0074-4317-73", "0074-9036-30", "0074-9037-30"], "nui": ["M0007651", "N0000175907", "N0000175849"], "pharm_class_cs": ["Ergocalciferols [CS]"], "pharm_class_epc": ["Vitamin D2 Analog [EPC]", "Vitamin D Analog [EPC]"], "unii": ["6702D36OG5"]}, "update_date": "10/07/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Capsule", "presentation": "Zemplar, Capsule, 2 ug (NDC 0074-9037-30)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/30/2020", "package_ndc": "0143-9785-10", "generic_name": "Valproate Sodium Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA078523"], "brand_name": ["VALPROATE SODIUM"], "generic_name": ["VALPROATE SODIUM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9785"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VALPROATE SODIUM"], "rxcui": ["1099648"], "spl_id": ["0610e50d-6447-4a0e-bc36-dc0bffa95c7d"], "spl_set_id": ["bcf57b31-4811-4104-82b3-46fb91a53ee0"], "package_ndc": ["0143-9785-01", "0143-9785-10"], "unii": ["5VOM6GYJ0D"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "63323-516-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["ANDA040572"], "brand_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "generic_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-516", "63323-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["DEXAMETHASONE SODIUM PHOSPHATE"], "rxcui": ["309696", "1812079"], "spl_id": ["9320abbb-bfd8-4df2-9269-3a52736c190f"], "spl_set_id": ["cca2c160-9188-48e8-9505-49a52388dcb7"], "package_ndc": ["63323-506-00", "63323-506-01", "63323-506-03", "63323-506-13", "63323-516-01", "63323-516-10"], "unii": ["AI9376Y64P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology"], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["ANDA208129"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-671"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["27411591-44a1-44c4-89c3-dd8c2687f0e2"], "spl_set_id": ["4d5d2294-89a0-4b6f-aa00-d39a0393b6a8"], "package_ndc": ["63323-671-02", "63323-671-20", "63323-671-05", "63323-671-50", "63323-671-01", "63323-671-00"], "unii": ["1018WH7F9I"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-20", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-487-37", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-073-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-073", "13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "63323-426-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA078651"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-426"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["d6e2ff8d-838d-4c27-8e73-230548b09d63", "3f4d5e11-2c14-4406-8954-04dba2fc65ff"], "spl_set_id": ["f1933332-1ae0-4dc1-be4c-694849e6c9f9", "fb9524b2-c353-4747-8954-7ca2529eabb2"], "package_ndc": ["63323-426-02", "63323-426-05", "63323-426-01", "63323-426-10", "63323-426-12", "63323-426-15"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-7299-73", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["1859490"], "spl_id": ["013001c4-5584-4d8c-8bf6-917d2a919aa4", "10c75a24-9542-431a-84f8-44611bc916df"], "spl_set_id": ["ce9a7469-c4ba-4f60-8f7a-47ef0974316e", "c91ede49-c7cc-47b7-0f93-e6841dd5916a"], "package_ndc": ["0409-7299-45", "0409-7299-25", "0409-7299-83", "0409-7299-73"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5544-01", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018877"], "brand_name": ["ALLOPURINOL"], "generic_name": ["ALLOPURINOL"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5544", "0591-5543"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ALLOPURINOL"], "spl_id": ["f7e04d88-1d9b-47e6-a9ad-deb08af3c098"], "spl_set_id": ["a80fe56f-8d03-423f-8e2a-7ec8c9e5045b"], "package_ndc": ["0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05"], "nui": ["N0000175698", "N0000000206"], "pharm_class_epc": ["Xanthine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Xanthine Oxidase Inhibitors [MoA]"], "unii": ["63CZ7GJN5I"]}, "update_date": "02/19/2026", "therapeutic_category": ["Oncology", "Renal", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 300 mg (NDC 0591-5544-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-31", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA206775"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-295"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["35cf6068-f31a-211b-e063-6294a90a6b53"], "spl_set_id": ["48aa7ef3-9f44-2a08-e054-00144ff88e88"], "package_ndc": ["16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9598-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019830"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9598", "0264-9594"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1737723", "1737742", "1737744"], "spl_id": ["9e352802-107c-4f90-babe-4f69c7dc892e"], "spl_set_id": ["7dff29d9-522d-40eb-a9d9-42377912d640"], "package_ndc": ["0264-9598-20", "0264-9594-20", "0264-9594-10"], "unii": ["EC2CNF7XFP", "LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-668-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA076374"], "brand_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "generic_name": ["QUINAPRIL AND HYDROCHLOROTHIAZIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-668", "62135-667", "62135-669"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["HYDROCHLOROTHIAZIDE", "QUINAPRIL HYDROCHLORIDE"], "rxcui": ["310796", "310797", "310809"], "spl_id": ["0c3f4504-d57e-aa79-e063-6294a90ad5b8"], "spl_set_id": ["2eae533f-d0af-47e8-a1f2-94bc8cc89b5a"], "package_ndc": ["62135-667-90", "62135-668-90", "62135-669-90"], "nui": ["N0000175359", "N0000175419", "M0471776"], "pharm_class_pe": ["Increased Diuresis [PE]"], "pharm_class_epc": ["Thiazide Diuretic [EPC]"], "pharm_class_cs": ["Thiazides [CS]"], "unii": ["33067B3N2M", "0J48LPH2TH"]}, "update_date": "04/24/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "0641-6007-10", "generic_name": "Bumetanide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA079196"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6007", "0641-6008"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["99d2fc38-7e1e-4209-aa57-089794eda8a6"], "spl_set_id": ["681b5e9d-e2c7-4f29-aaad-e06d4a528c11"], "package_ndc": ["0641-6007-01", "0641-6007-10", "0641-6008-01", "0641-6008-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-153", "72888-152", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-30)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-187-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Available", "related_info": "Please check wholesalers for inventory", "openfda": {"application_number": ["ANDA208266"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["42023-187", "42023-146", "42023-186"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710", "1718906", "1718909"], "spl_id": ["54174211-6684-4fb9-a605-be12b94e2948"], "spl_set_id": ["1ee59985-4c1d-48f7-b8f9-5584c2d55e08"], "package_ndc": ["42023-146-25", "42023-186-20", "42023-187-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)", "company_name": "Par Health, USA LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-386-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3795-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: June 2027", "openfda": {"application_number": ["ANDA074802"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3795", "0409-3793", "0409-3796"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["572e3ce2-a27c-4a65-9593-84666518ddca"], "spl_set_id": ["8accbb78-fc64-45d5-69b0-35c23a1d2a2e"], "package_ndc": ["0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0832-0274-11", "generic_name": "Morphine Sulfate Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210610"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0274", "0832-0273"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["892582", "892672"], "spl_id": ["46a682fc-0430-5a66-e063-6294a90a6179"], "spl_set_id": ["5ceb3205-2f8d-4ba3-9f27-dc328bab4fa1"], "package_ndc": ["0832-0273-11", "0832-0274-11"], "unii": ["X3P646A2J0"]}, "update_date": "12/22/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1596-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1596", "0409-1660", "0409-1638", "0409-1434", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "63481-025-09", "generic_name": "Frovatriptan Succinate Tablet", "contact_info": "800-828-9393", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/24/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Frova, Tablet, 2.5 mg (NDC 63481-025-09)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0264-9872-00", "generic_name": "Heparin Sodium Injection", "contact_info": "800-227-2862", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA019953"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-9872"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["48e17807-e73d-4ea2-81bc-901355903aa7"], "spl_set_id": ["a3041c04-0ea8-4d36-81ce-c5091c906316"], "package_ndc": ["0264-9872-10", "0264-9872-00"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/20/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)", "company_name": "B. Braun Medical Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-618-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202725"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL HYDROCHLORIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-618", "65862-617", "65862-619", "65862-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["5263abd5-ce46-4918-9bb0-9632861bcbc9"], "spl_set_id": ["93e6e668-5306-4f26-81d8-cbc3a7a5e787"], "package_ndc": ["65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78"], "unii": ["33067B3N2M"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0480-5795-08", "generic_name": "Cetrorelix Acetate Injection", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA215737"], "brand_name": ["CETRORELIX"], "generic_name": ["CETRORELIX ACETATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-5795"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "rxcui": ["283402"], "spl_id": ["f8c62e7c-4615-463b-af59-b820a9e3b911"], "spl_set_id": ["f91c971b-89d7-4306-966d-8ecc1afc16d1"], "package_ndc": ["0480-5795-08", "0480-3583-01", "0480-3584-21"]}, "update_date": "11/13/2025", "therapeutic_category": ["Reproductive"], "dosage_form": "Injection", "presentation": "Cetrorelix Acetate, Injection, Kit (NDC 0480-5795-08)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0990-7172-17", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7172-17", "openfda": {"application_number": ["NDA020015"], "brand_name": ["AMINOSYN II"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7172", "0990-7171"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ACETYL L-TYROSINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "VALINE"], "rxcui": ["800188", "800192", "800237", "800241"], "spl_id": ["ea005122-3350-4609-83ad-9d093f25162f"], "spl_set_id": ["5b426208-f090-4650-86c3-89040ba45c2d"], "package_ndc": ["0990-7172-17", "0990-7171-17"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["2ZD004190S", "94ZLA3W45F", "3KX376GY7L", "DA8G610ZO5", "HG18B9YRS7", "TE7660XO1C", "8DUH1N11BX", "4QD397987E", "GMW67QNF9C", "AE28F7PNPL", "47E5O17Y3R", "30KYC7MIAI", "TTL6G7LIWZ", "OF5P57N2ZX", "452VLY9402", "04Y7590D77", "9DLQ4CIU6V"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA089644"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0409-6695-01", "generic_name": "Etomidate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018227"], "brand_name": ["AMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6695"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008", "1654009", "1654011"], "spl_id": ["b59f4852-2843-4a8f-a597-306ebddb259a"], "spl_set_id": ["b7ed5bf8-ba75-44dc-8f81-96b4ad5766be"], "package_ndc": ["0409-6695-11", "0409-6695-01", "0409-6695-12", "0409-6695-02"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0825-01", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": {"application_number": ["NDA009866"], "brand_name": ["SOLU-CORTEF"], "generic_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0825", "0009-0011", "0009-0013", "0009-0016", "0009-0005"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["HYDROCORTISONE SODIUM SUCCINATE"], "rxcui": ["105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596"], "spl_id": ["8512044a-4a54-4634-bb97-9e20126adc61"], "spl_set_id": ["65eefd58-b166-4d71-ade6-45c8fdf86922"], "package_ndc": ["0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01"], "unii": ["50LQB69S1Z"]}, "update_date": "02/24/2026", "therapeutic_category": ["Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology"], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-6637-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202494"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6637", "0409-4916"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["727995", "792582"], "spl_id": ["f79ec8cb-b6a3-4ffb-bccf-d39f59d65621"], "spl_set_id": ["ea20a5eb-641e-48cd-bcfa-74c04c45dfda"], "package_ndc": ["0409-4916-24", "0409-4916-14", "0409-6637-24", "0409-6637-14"], "unii": ["8MDF5V39QO"]}, "update_date": "11/07/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0264-1933-10", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "related_info": "On allocation", "openfda": {"application_number": ["NDA019018"], "brand_name": ["TROPHAMINE"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, CYSTEINE HYDROCHLORIDE, HISTIDINE, TYROSINE, N-ACETYL-TYROSINE, ALANINE, ARGININE, PROLINE, SERINE, GLYCINE, ASPARTIC ACID, GLUTAMIC ACID, AND TAURINE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-1933"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ACETYL L-TYROSINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "CYSTEINE HYDROCHLORIDE", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "TAURINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "rxcui": ["800611", "1189640"], "spl_id": ["07f53291-419d-4d14-ad81-26f00dc0c474"], "spl_set_id": ["cb6d23ff-3ec5-445a-acbe-f88fd57949bf"], "package_ndc": ["0264-1933-10"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["DA8G610ZO5", "OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "ZT934N0X4W", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-607-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-607", "43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-0771-98", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0771", "0093-7201", "0093-7202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "43066-013-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["ANDA091115"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-013", "43066-007"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["9e0317de-2d78-4fd8-8926-4c7b476f3ed4"], "spl_set_id": ["31e15c3f-aefa-4379-b684-7707744fe40d"], "package_ndc": ["43066-007-10", "43066-013-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-8076-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020646"], "brand_name": ["TIAGABINE HYDROCHLORIDE"], "generic_name": ["TIAGABINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8076", "0093-5030", "0093-5031", "0093-8072"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TIAGABINE HYDROCHLORIDE"], "rxcui": ["1299903", "1299909", "1299911", "1299917"], "spl_id": ["2a8d7987-54ae-45d7-8224-361dac37e0a4"], "spl_set_id": ["953ef3cc-e3cb-480f-b9ea-256520fd62b8"], "package_ndc": ["0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56"], "unii": ["DQH6T6D8OY"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-166-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-166", "42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4743-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4743", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0274-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0274", "0009-0280", "0009-0306"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-062-99", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-062", "65862-063", "65862-064"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-99)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0264-4500-05", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "related_info": "On allocation", "openfda": {"application_number": ["ANDA091112"], "brand_name": ["PLENAMINE"], "generic_name": ["LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-4500"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "TYROSINE", "VALINE"], "spl_id": ["905f7c55-bf0d-4150-90ef-e8f1a5455bc1"], "spl_set_id": ["a3244d1a-45b0-4e4c-bd96-f0632d761a1f"], "package_ndc": ["0264-4500-00", "0264-4500-05"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "9DLQ4CIU6V", "452VLY9402", "2ZD004190S", "8DUH1N11BX", "42HK56048U", "HG18B9YRS7"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Plenamine, Injection, 0.15 (NDC 0264-4500-05)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-03", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7922-03", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7922", "0990-7923", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/08/2026", "update_type": "New", "initial_posting_date": "04/08/2026", "package_ndc": "63323-972-10", "generic_name": "Fosaprepitant Dimeglumine Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA206197"], "brand_name": ["FOSAPREPITANT"], "generic_name": ["FOSAPREPITANT"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-972"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FOSAPREPITANT DIMEGLUMINE"], "rxcui": ["1731077"], "spl_id": ["864bb02f-d50d-4ae2-ad9c-82bb1e9aed2c"], "spl_set_id": ["ffee61d1-c1c6-4224-871c-ab7ff6cd01e5"], "package_ndc": ["63323-972-10"], "unii": ["D35FM8T64X"]}, "update_date": "04/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "13107-069-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability October 2026", "openfda": {"application_number": ["ANDA202424"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Aurolife Pharma, LLC"], "product_ndc": ["13107-069", "13107-068", "13107-070", "13107-071", "13107-072", "13107-073", "13107-074"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["5962d880-9f18-4a57-8c95-ca0ec1e86f44"], "spl_set_id": ["a582d57f-d191-4ca5-b105-585b2d8a0e3e"], "package_ndc": ["13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/29/2025", "update_type": "New", "initial_posting_date": "10/29/2025", "package_ndc": "63323-850-74", "generic_name": "Moxifloxacin Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA205572"], "brand_name": ["MOXIFLOXACIN"], "generic_name": ["MOXIFLOXACIN HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-850"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MOXIFLOXACIN HYDROCHLORIDE"], "rxcui": ["351156"], "spl_id": ["4070f637-059f-4e3d-8cf3-e5256a46ff3e"], "spl_set_id": ["a4e28b09-714b-46e7-b4e6-0163cad78fc5"], "package_ndc": ["63323-850-74", "63323-850-04"], "unii": ["C53598599T"]}, "update_date": "10/29/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5168-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"brand_name": ["PHENOBARBITAL"], "generic_name": ["PHENOBARBITAL"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["0603-5168", "0603-5165", "0603-5166", "0603-5167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PHENOBARBITAL"], "rxcui": ["198086", "199164", "199167", "199168"], "spl_id": ["f8c5136e-e35c-4425-8d49-b7f92c827b42"], "spl_set_id": ["069b92ce-0061-4724-8c25-08d8596770a2"], "package_ndc": ["0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32"], "unii": ["YQE403BP4D"]}, "update_date": "10/31/2025", "therapeutic_category": ["Analgesia/Addiction", "Neurology", "Other"], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3985-60", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 400 mg (NDC 0591-3985-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-620-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": {"application_number": ["NDA017533"], "brand_name": ["KLONOPIN"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["H2-Pharma, LLC"], "product_ndc": ["61269-620", "61269-605", "61269-610"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529", "206157", "206159", "206160"], "spl_id": ["63cfdab9-fb3d-4c2b-bf88-8ba841dba839"], "spl_set_id": ["cfa0d79a-843c-4b88-95a1-e9511d649ca1"], "package_ndc": ["61269-605-10", "61269-610-10", "61269-620-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, 2 mg (NDC 61269-620-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "change_date": "12/19/2024", "package_ndc": "0409-3177-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089635"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3177", "0409-1209", "0409-3178", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-084-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-084", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-560-10", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-560", "62037-559"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "63459-920-59", "generic_name": "Tbo-filgrastim Injection", "contact_info": "800-545-8800", "openfda": {"application_number": ["BLA125294"], "brand_name": ["GRANIX"], "generic_name": ["TBO-FILGRASTIM"], "manufacturer_name": ["Cephalon, LLC"], "product_ndc": ["63459-920", "63459-910", "63459-912", "63459-918"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["FILGRASTIM"], "rxcui": ["1433768", "1433771", "1442681", "1442683", "2101456", "2101459", "2101464", "2101465"], "spl_id": ["063f36a7-6f99-40fa-af02-8a5183c51e99"], "spl_set_id": ["df918ec2-0907-443f-a52a-b72866959644"], "package_ndc": ["63459-910-01", "63459-910-12", "63459-910-11", "63459-910-15", "63459-910-18", "63459-910-17", "63459-910-36", "63459-912-01", "63459-912-12", "63459-912-11", "63459-912-15", "63459-912-18", "63459-912-17", "63459-912-36", "63459-918-53", "63459-918-59", "63459-920-53", "63459-920-59"], "nui": ["M0024696", "N0000009451", "N0000175666"], "pharm_class_cs": ["Granulocyte Colony-Stimulating Factor [CS]"], "pharm_class_pe": ["Increased Myeloid Cell Production [PE]"], "pharm_class_epc": ["Leukocyte Growth Factor [EPC]"], "unii": ["PVI5M0M1GW"]}, "update_date": "06/13/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Granix, Injection, 480 ug/1.6 mL (NDC 63459-920-59)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-360-18", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-360", "61703-150", "61703-262", "61703-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["5aa72c15-8033-4559-b257-373371b18958"], "spl_set_id": ["47677091-fd20-49af-933c-c9dd2be21de9"], "package_ndc": ["61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6247-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["NDA019101"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6247", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6030", "0641-6248", "0641-6249"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337"], "spl_id": ["546a047c-1faf-4751-9e48-079e4c35b6fa"], "spl_set_id": ["ce5db1c2-feb1-4ad2-847a-d02e865bd47e"], "package_ndc": ["0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10"], "unii": ["MUN5LYG46H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8214-05", "generic_name": "Insulin Glargine Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["BLA205692"], "brand_name": ["BASAGLAR TEMPO PEN"], "generic_name": ["INSULIN GLARGINE"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-8214", "0002-7715"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["INSULIN GLARGINE"], "rxcui": ["847230", "1736863", "2268064", "2268065"], "spl_id": ["3c2283e6-2844-44d2-a447-579b07e77c27"], "spl_set_id": ["0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae"], "package_ndc": ["0002-7715-01", "0002-7715-59", "0002-7715-63", "0002-8214-01", "0002-8214-05"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["2ZM8CX04RZ"]}, "update_date": "10/24/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "63323-724-05", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206223"], "brand_name": ["REMIFENTANIL HYDROCHLORIDE"], "generic_name": ["REMIFENTANIL HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-724", "63323-723", "63323-725"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["REMIFENTANIL HYDROCHLORIDE"], "rxcui": ["1729578", "1729584", "1729710"], "spl_id": ["2f27e51f-2b55-47ee-bd4a-001b71c60622"], "spl_set_id": ["d2374b84-81c9-44f9-a4a9-1071281b2531"], "package_ndc": ["63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10"], "unii": ["5V444H5WIC"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "55150-225-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206206"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-225", "55150-226"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["30f618bf-fbbd-4489-acbb-204e8ed78dca"], "spl_set_id": ["116385ea-69fc-4f44-b463-6210291032df"], "package_ndc": ["55150-225-05", "55150-226-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-37", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-37", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/21/2025", "update_type": "New", "initial_posting_date": "07/21/2025", "package_ndc": "73070-100-11", "generic_name": "Insulin Aspart Injection", "contact_info": "609-987-5800", "related_info": "Unbranded Insulin Aspart 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.", "openfda": {"application_number": ["BLA020986"], "brand_name": ["INSULIN ASPART"], "generic_name": ["INSULIN ASPART"], "manufacturer_name": ["Novo Nordisk Pharma, Inc."], "product_ndc": ["73070-100", "73070-102", "73070-103"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["INSULIN ASPART"], "rxcui": ["311040", "1653196", "1653202"], "spl_id": ["393af9a3-df9a-40b2-a5e6-bfa5434a2552"], "spl_set_id": ["bee5b358-c863-420b-be73-ced2e920c499"], "package_ndc": ["73070-100-11", "73070-102-10", "73070-102-15", "73070-103-10", "73070-103-15"], "nui": ["M0011417", "N0000175453"], "pharm_class_cs": ["Insulin [CS]"], "pharm_class_epc": ["Insulin Analog [EPC]"], "unii": ["D933668QVX"]}, "update_date": "07/21/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Insulin Aspart, Injection, 10 mL Insulin Aspart vial (NDC 73070-100-11)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9577-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA080407"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0143-9577", "0143-9579", "0143-9578", "0143-9576", "0143-9575", "0143-9172", "0143-9173"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["e9b92d4d-8944-4235-8d77-3218f82f00a9"], "spl_set_id": ["5523fdfe-69fd-49a5-b51f-73e2223d49a9"], "package_ndc": ["0143-9579-01", "0143-9579-25", "0143-9578-01", "0143-9578-10", "0143-9577-01", "0143-9577-10", "0143-9576-01", "0143-9576-25", "0143-9575-01", "0143-9575-10", "0143-9172-01", "0143-9172-10", "0143-9173-01", "0143-9173-10"], "unii": ["V13007Z41A"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-112-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["ADDERALL"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["57844-112", "57844-105", "57844-117", "57844-110", "57844-115", "57844-120", "57844-130"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147"], "spl_id": ["79af1dc6-c7cf-41b1-a750-e9b47c2187ff"], "spl_set_id": ["f22635fe-821d-4cde-aa12-419f8b53db81"], "package_ndc": ["57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9404-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": {"application_number": ["ANDA061395"], "brand_name": ["AMPICILLIN"], "generic_name": ["AMPICILLIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0781-9404", "0781-9401", "0781-9402", "0781-9407", "0781-9408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["AMPICILLIN SODIUM"], "rxcui": ["308207", "1721473", "1721474", "1721475", "1721476"], "spl_id": ["a3ddae6c-ac4c-425f-82b0-eb388d92bc0e"], "spl_set_id": ["b371e1a5-1fef-4df2-8940-c4fc02b9e2f0"], "package_ndc": ["0781-9401-78", "0781-9401-95", "0781-9402-78", "0781-9402-95", "0781-9407-78", "0781-9407-95", "0781-9404-85", "0781-9404-95", "0781-9408-80", "0781-9408-95"], "unii": ["JFN36L5S8K"]}, "update_date": "12/08/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4370-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023", "update_date": "04/28/2023", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 2 mg (NDC 0069-4370-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-9666-35", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020179"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9666", "0338-9664"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616"], "spl_id": ["bfc4224a-2fc9-4137-b4c6-9d2d6d948413"], "spl_set_id": ["bfc4224a-2fc9-4137-b4c6-9d2d6d948413"], "package_ndc": ["0338-9664-40", "0338-9666-35"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-22", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-820-10", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA201835"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-820", "25021-821"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["13e1ca54-4fc4-4e93-a52d-c9320865e3cb"], "spl_set_id": ["f98314ea-a4e4-4f78-987b-3e9b45a08bb4"], "package_ndc": ["25021-820-05", "25021-820-10", "25021-821-05"], "unii": ["43502P7F0P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "0338-0433-04", "generic_name": "Heparin Sodium Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["NDA018609"], "brand_name": ["HEPARIN SODIUM IN SODIUM CHLORIDE"], "generic_name": ["HEPARIN SODIUM"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0433", "0338-0431", "0338-0424", "0338-0428"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HEPARIN SODIUM"], "rxcui": ["1658690", "1658692"], "spl_id": ["68b37381-6db4-4ac0-ba6b-3204add02665"], "spl_set_id": ["0d929726-76c3-48fc-b4e7-fd06409f9fb3"], "package_ndc": ["0338-0431-03", "0338-0433-04", "0338-0424-18", "0338-0428-12"], "unii": ["ZZ45AB24CA"]}, "update_date": "04/20/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)", "company_name": "Baxter Healthcare", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "16729-081-10", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "866-941-7857, option 2", "resolved_note": "Available", "openfda": {"application_number": ["ANDA091205"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Accord Healthcare, Inc."], "product_ndc": ["16729-081"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["424db74c-6c0f-1eb3-e063-6294a90a7db8"], "spl_set_id": ["49aa3d6d-2270-4615-aafa-b440859ab870"], "package_ndc": ["16729-081-10", "16729-081-01", "16729-081-16", "16729-081-17"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-10)", "company_name": "Accord Healthcare Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0172-5240-60", "generic_name": "Anagrelide Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/19/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Capsule", "presentation": "Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "0409-7037-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA205656"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7037", "0409-3189"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["c96726ef-f1fa-4ebb-ba33-3479c3902a8e"], "spl_set_id": ["c96726ef-f1fa-4ebb-ba33-3479c3902a8e"], "package_ndc": ["0409-3189-05", "0409-3189-10", "0409-7037-01", "0409-7037-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-173-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020712"], "brand_name": ["CARBATROL"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["54092-173", "54092-171", "54092-172"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["200131", "200133", "308977", "313931", "388311", "404742"], "spl_id": ["39171a32-c78d-4130-be53-638e19cf2261"], "spl_set_id": ["bc03e499-5bac-4293-bff4-6864153a624d"], "package_ndc": ["54092-171-12", "54092-172-12", "54092-173-12"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "12/19/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "55150-221-10", "generic_name": "Etomidate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206126"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-221", "55150-222"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["278b160e-cdc4-451e-9405-cb001f443680"], "spl_set_id": ["0820f15a-046b-4185-a2b3-2e4051ee3d82"], "package_ndc": ["55150-221-10", "55150-222-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70860-700-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Athenex is not active, supplying through Sagent NDC  25021-700-01", "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 70860-700-02)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-106-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA021977"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-106", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 60 mg (NDC 59417-106-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-025-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 25 mg/.4 mL (NDC 82497-025-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0974-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA040422"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0555-0974", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0973"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["88468f3d-7d03-4cee-aabf-3abc8c9b5e38"], "spl_set_id": ["cffbbb15-d776-41ae-a8a6-687f2c07bfa4"], "package_ndc": ["0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-01", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "0338-9555-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: May 2026", "openfda": {"application_number": ["ANDA208532"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-9555", "0338-9557"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["594e9faa-bc32-42e0-9c0a-8fa9460b1e24"], "spl_set_id": ["8ccb45a7-8290-469c-9644-a4dca967d88f"], "package_ndc": ["0338-9555-24", "0338-9557-12"], "unii": ["1018WH7F9I"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/14/2016", "package_ndc": "63323-487-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/26/2025", "update_type": "New", "initial_posting_date": "06/26/2025", "package_ndc": "0093-5538-01", "generic_name": "Eszopiclone Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA091169"], "brand_name": ["ESZOPICLONE"], "generic_name": ["ESZOPICLONE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5538", "0093-5537", "0093-5539"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ESZOPICLONE"], "rxcui": ["485440", "485442", "485465"], "spl_id": ["efcf4106-ac0a-4f8b-bcd0-743e45e66924"], "spl_set_id": ["2435e2f1-bc52-488f-80e9-f1758e354aae"], "package_ndc": ["0093-5537-56", "0093-5538-01", "0093-5539-01"], "unii": ["UZX80K71OE"]}, "update_date": "06/26/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Eszopiclone, Tablet, 2 mg (NDC 0093-5538-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-737-30", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": {"application_number": ["ANDA072369"], "brand_name": ["FLURAZEPAM HYDROCHLORIDE"], "generic_name": ["FLURAZEPAM HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-737", "62135-736"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLURAZEPAM HYDROCHLORIDE"], "rxcui": ["1298088", "1298091"], "spl_id": ["25893c92-c8f1-567a-e063-6294a90a00d4"], "spl_set_id": ["8f476891-1346-4e8c-ac1b-f8cbdc64f5a1"], "package_ndc": ["62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90"], "unii": ["756RDM536M"]}, "update_date": "02/02/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4740-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4740", "60505-4739", "60505-4741", "60505-4742", "60505-4743", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3566-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-545-8800", "availability": "Available", "openfda": {"application_number": ["ANDA202802"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Teva Pharmaceuticals, Inc."], "product_ndc": ["0480-3566", "0480-3565", "0480-3567", "0480-3568", "0480-3569", "0480-3570", "0480-3564"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["ded5754b-2e33-48b2-95cb-fb9457ea95c6"], "spl_set_id": ["c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc"], "package_ndc": ["0480-3565-01", "0480-3566-01", "0480-3567-01", "0480-3568-01", "0480-3569-01", "0480-3570-01", "0480-3564-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/01/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "68094-909-30", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Precision Dose Inc."], "product_ndc": ["68094-909"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["efc0724d-4c6e-4974-928c-fd50774f5980"], "spl_set_id": ["b09b4b5e-795a-48e7-b7cc-2e29f41c5660"], "package_ndc": ["68094-909-30", "68094-909-50"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-30)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/06/2023", "change_date": "12/15/2025", "package_ndc": "0338-1051-02", "generic_name": "Nitroglycerin Injection", "contact_info": "Baxter Healthcare 888-229-0001", "resolved_note": "Available", "openfda": {"application_number": ["NDA019970"], "brand_name": ["NITROGLYCERIN IN DEXTROSE"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1051", "0338-1047", "0338-1049"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["312004", "1868494", "1868562"], "spl_id": ["b89cb9ff-d275-465b-b70b-d8e2e9406435"], "spl_set_id": ["457a026c-ebce-4701-9deb-2d7652759a99"], "package_ndc": ["0338-1047-02", "0338-1049-02", "0338-1051-02"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "12/15/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Nitroglycerin in Dextrose 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)", "company_name": "Baxter Healthcare", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-4900-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0374-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0374", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/08/2025", "update_type": "New", "initial_posting_date": "07/08/2025", "package_ndc": "0409-1891-23", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1891", "0409-1890", "0409-1892", "0409-1893", "0409-1894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["894912", "998212", "998213", "1729197", "1731995", "1732014"], "spl_id": ["56671cfe-7548-442e-a2b5-ffebebf65ade"], "spl_set_id": ["be420e8b-bcb0-49b5-bb4d-1df8b9959809"], "package_ndc": ["0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01"], "unii": ["X3P646A2J0"]}, "update_date": "07/08/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-23)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/06/2023", "change_date": "12/15/2025", "package_ndc": "0517-4810-25", "generic_name": "Nitroglycerin Injection", "contact_info": "800-645-1706", "resolved_note": "Available", "openfda": {"application_number": ["ANDA072034"], "brand_name": ["NITROGLYCERIN"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["American Regent, Inc."], "product_ndc": ["0517-4810"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["237205"], "spl_id": ["ee83c8b9-c31a-4f32-9e9d-0370545204cb"], "spl_set_id": ["8c52cdf6-87be-4719-b105-f08be096d462"], "package_ndc": ["0517-4810-01", "0517-4810-25"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "12/15/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Nitroglycerin, Injection, 5 mg/1 mL (NDC 0517-4810-25)", "company_name": "American Regent, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-051-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-051", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-199-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-199", "55150-195", "55150-196", "55150-197", "55150-198", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "16729-512-43", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA213424"], "brand_name": ["ATROPINE SULFATE"], "generic_name": ["ATROPINE SULFATE"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-512"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["ATROPINE SULFATE"], "rxcui": ["1190776"], "spl_id": ["275def6c-5b2d-918b-e063-6294a90aa71f"], "spl_set_id": ["f3cb74e9-b4ac-4efe-bd8e-8a71970ee7c7"], "package_ndc": ["16729-512-05", "16729-512-43"], "unii": ["03J5ZE7KA5"]}, "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-61", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": {"application_number": ["NDA211280"], "brand_name": ["REYVOW"], "generic_name": ["LASMIDITAN"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-4491", "0002-4312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LASMIDITAN"], "rxcui": ["2256937", "2256943", "2256945", "2256947"], "spl_id": ["75a13e98-3736-4256-8277-6c05bcaddcf5"], "spl_set_id": ["aea3358c-ff41-4490-9e6d-c7bf7b3de13f"], "package_ndc": ["0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62"], "unii": ["760I9WM792"]}, "update_date": "11/03/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-61)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/19/2025", "update_type": "New", "initial_posting_date": "05/19/2025", "package_ndc": "62037-559-01", "generic_name": "Potassium Chloride Capsule, Extended Release", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA077419"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-559", "62037-560"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312504", "315183"], "spl_id": ["57df625b-891f-4826-a64b-46db5e64378e"], "spl_set_id": ["ed5baaf6-270b-4dd3-b100-36030c0098fc"], "package_ndc": ["62037-559-01", "62037-559-05", "62037-560-90", "62037-560-01", "62037-560-05", "62037-560-10"], "unii": ["660YQ98I10"]}, "update_date": "05/19/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Capsule, Extended Release", "presentation": "Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2023", "package_ndc": "72888-153-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": {"application_number": ["ANDA075468"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Advagen Pharma Ltd"], "product_ndc": ["72888-153", "72888-152", "72888-154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["36cf156e-5980-a21b-e063-6294a90ab3a0"], "spl_set_id": ["30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec"], "package_ndc": ["72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "01/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-01)", "company_name": "Rubicon Research Private Limited", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0078-0364-05", "generic_name": "Amlodipine Besylate; Benazepril Hydrochloride Capsule", "contact_info": "888-669-6682", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA020364"], "brand_name": ["LOTREL"], "generic_name": ["AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "product_ndc": ["0078-0364", "0078-0405", "0078-0406", "0078-0379"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMLODIPINE BESYLATE", "BENAZEPRIL HYDROCHLORIDE"], "rxcui": ["898342", "898344", "898346", "898348", "898353", "898355", "898356", "898358"], "spl_id": ["b9db75d9-9d1e-4b2d-9876-5f5520feaecc"], "spl_set_id": ["94ae6054-b7ae-4212-a567-4f803af8f2c7"], "package_ndc": ["0078-0405-05", "0078-0406-05", "0078-0364-05", "0078-0379-05"], "unii": ["864V2Q084H", "N1SN99T69T"]}, "update_date": "06/24/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Lotrel, Capsule, 10 mg; 20 mg (NDC 0078-0364-05)", "company_name": "Novartis Pharmaceuticals Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-458-30", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-458", "65219-456", "65219-464", "65219-460", "65219-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/04/2024", "package_ndc": "50633-310-11", "generic_name": "Hydroxocobalamin Injection", "related_info_link": "https://www.fda.gov/media/185400/download", "contact_info": "844-293-0007", "availability": "Limited Availability", "related_info": "Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.", "openfda": {"application_number": ["NDA022041"], "brand_name": ["CYANOKIT"], "generic_name": ["HYDROXOCOBALAMIN"], "manufacturer_name": ["BTG INTERNATIONAL INC."], "product_ndc": ["50633-310"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["HYDROXOCOBALAMIN"], "rxcui": ["700496", "700499"], "spl_id": ["9955075c-c059-4b63-b387-e98ef13e60dc"], "spl_set_id": ["d56fcc8d-bd64-46ab-b0c0-2124bd745a6b"], "package_ndc": ["50633-310-11"], "nui": ["N0000175429"], "pharm_class_epc": ["Antidote [EPC]"], "unii": ["Q40X8H422O"]}, "update_date": "10/31/2025", "therapeutic_category": ["Other"], "dosage_form": "Injection", "presentation": "Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)", "company_name": "BTG International Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-564-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-193-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-193", "11534-190", "11534-191", "11534-192", "11534-194", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0002-7640-01", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-545-5979", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021462"], "brand_name": ["ALIMTA"], "generic_name": ["PEMETREXED DISODIUM"], "manufacturer_name": ["Eli Lilly and Company"], "product_ndc": ["0002-7640", "0002-7623"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PEMETREXED DISODIUM HEPTAHYDRATE"], "rxcui": ["1728072", "1728075", "1728077", "1728079"], "spl_id": ["3af0bc84-13d6-46aa-a4c0-c62410b73bc6"], "spl_set_id": ["f5a860f3-37ec-429c-ae04-9c88d7c55c08"], "package_ndc": ["0002-7640-01", "0002-7623-01"], "unii": ["9T47E4OM16"]}, "update_date": "10/16/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Alimta, Injection, 100 mg/4 mL (NDC 0002-7640-01)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "08/15/2023", "package_ndc": "64850-506-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-506", "64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-505"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0371-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": {"application_number": ["ANDA202827"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-0371", "0054-0660", "0054-0370", "0054-0372", "0054-0373", "0054-0374", "0054-0375"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["54a99322-a206-447c-b820-9e1b7e525816"], "spl_set_id": ["6740a621-9bec-4178-a4fc-a3fc89f34e0a"], "package_ndc": ["0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25"], "unii": ["SJT761GEGS"]}, "update_date": "05/12/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-174-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Limited Availability", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 5 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-179", "47781-180"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0185-0842-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": {"application_number": ["ANDA040439"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["0185-0842", "0185-0831", "0185-0853", "0185-0864", "0185-2099", "0185-2098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577961"], "spl_id": ["9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd"], "spl_set_id": ["288dafc4-fe6e-4891-832f-511022c87445"], "package_ndc": ["0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-31", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Not available at this time.", "openfda": {"application_number": ["NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1174-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1174", "0409-1454", "0409-3301", "0409-2815"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["8d48de06-361f-418b-bfec-8ef85f94d5bc"], "spl_set_id": ["4419162d-81d4-49bd-96de-1729440bdb74"], "package_ndc": ["0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/27/2025", "update_type": "New", "initial_posting_date": "06/27/2025", "package_ndc": "0591-3713-30", "generic_name": "Ezetimibe Tablet", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the product", "openfda": {"application_number": ["ANDA200831"], "brand_name": ["EZETIMIBE"], "generic_name": ["EZETIMIBE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3713"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EZETIMIBE"], "rxcui": ["349556"], "spl_id": ["24aaf5ca-08e0-4db8-9734-cf2a606f8e57"], "spl_set_id": ["f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba"], "package_ndc": ["0591-3713-30", "0591-3713-19", "0591-3713-05"], "nui": ["N0000008553", "N0000175911"], "pharm_class_pe": ["Decreased Cholesterol Absorption [PE]"], "pharm_class_epc": ["Dietary Cholesterol Absorption Inhibitor [EPC]"], "unii": ["EOR26LQQ24"]}, "update_date": "06/27/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Ezetimibe, Tablet, 10 mg (NDC 0591-3713-30)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62175-313-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA091695"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Lannett Company, Inc."], "product_ndc": ["62175-313", "62175-310", "62175-311", "62175-312"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001564", "2001565", "2001566", "2001568"], "spl_id": ["8b133cd2-e3c6-4742-b402-2393b56ffc93"], "spl_set_id": ["3d1f5aff-5d39-496c-b5ed-7f3c70ec641c"], "package_ndc": ["62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37"], "unii": ["4B3SC438HI"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)", "company_name": "Lannett Company, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-001-02", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 59212-001-02)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3494-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": {"application_number": ["ANDA209065"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE"], "manufacturer_name": ["Sandoz Inc."], "product_ndc": ["0781-3494", "0781-3493", "0781-3495"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["fdf227d9-008e-60f8-e053-6294a90af5c4"], "spl_set_id": ["809e8f77-390f-4cc8-8c8a-4f67a249c9df"], "package_ndc": ["0781-3493-95", "0781-3494-95", "0781-3495-95"], "unii": ["1018WH7F9I"]}, "update_date": "04/06/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL  (NDC 0781-3494-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1073-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020255"], "brand_name": ["DOBUTAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOBUTAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1073", "0338-1075", "0338-1077"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOBUTAMINE HYDROCHLORIDE"], "rxcui": ["309985", "309986", "309987"], "spl_id": ["34c787c1-46f7-4264-951d-c88a34dca533"], "spl_set_id": ["6b17b98b-e06d-42ed-925f-69aa2699dead"], "package_ndc": ["0338-1073-02", "0338-1075-02", "0338-1077-02"], "unii": ["0WR771DJXV"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular", "Pediatric", "Renal"], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "25021-701-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA204216"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-701", "25021-700"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["cb23332a-48fa-458b-93ab-c4eef189a051"], "spl_set_id": ["62591551-a644-4b2c-a0de-982e906fabc3"], "package_ndc": ["25021-700-01", "25021-701-01", "25021-701-02"], "unii": ["4EVE5946BQ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-561-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA201791"], "brand_name": ["LAMOTRIGINE EXTENDED RELEASE"], "generic_name": ["LAMOTRIGINE EXTENDED RELEASE"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-561", "49884-562", "49884-563", "49884-564", "49884-604", "49884-605"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LAMOTRIGINE"], "rxcui": ["850087", "850091", "900156", "900164", "1098608", "1146690"], "spl_id": ["9c5e0c2a-800e-47e9-a26b-582b98a05957"], "spl_set_id": ["fb59c76a-9b6f-40ea-ac3a-58c3195c4377"], "package_ndc": ["49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05"], "nui": ["N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191"], "pharm_class_epc": ["Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_moa": ["Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]"], "unii": ["U3H27498KS"]}, "update_date": "04/29/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "64850-300-01", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "888-852-6657", "resolved_note": "Available", "openfda": {"application_number": ["ANDA075274"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-300"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["cae1ac14-ab22-42d1-8449-5e36c137b905"], "spl_set_id": ["5f188bdc-2009-43aa-ad32-f06dbfac2642"], "package_ndc": ["64850-300-30", "64850-300-01"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 64850-300-01)", "company_name": "Elite Laboratories, Inc.", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "0023-6150-04", "generic_name": "Progesterone Vaginal Gel", "contact_info": "800-678-1605", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/27/2026", "therapeutic_category": ["Urology"], "dosage_form": "Vaginal Gel", "presentation": "Crinone, Vaginal Gel, 4% (NDC 0023-6150-04)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "45802-580-46", "generic_name": "Scopolamine Transdermal System", "contact_info": "866-634-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078830"], "brand_name": ["SCOPOLAMINE TRANSDERMAL SYSTEM"], "generic_name": ["SCOPOLAMINE TRANSDERMAL SYSTEM"], "manufacturer_name": ["Padagis Israel Pharmaceuticals Ltd"], "product_ndc": ["45802-580"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["SCOPOLAMINE"], "rxcui": ["226552"], "spl_id": ["d334a21d-7546-477f-a66a-f95b2cf523ce"], "spl_set_id": ["cb93bfad-3e37-4a27-92f6-f21703ae7bdf"], "package_ndc": ["45802-580-84", "45802-580-46", "45802-580-62", "45802-580-01"], "nui": ["N0000175574", "N0000175370"], "pharm_class_epc": ["Anticholinergic [EPC]"], "pharm_class_moa": ["Cholinergic Antagonists [MoA]"], "unii": ["DL48G20X8X"]}, "update_date": "11/03/2025", "therapeutic_category": ["Gastroenterology", "Neurology", "Other"], "dosage_form": "Transdermal System", "presentation": "Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-0111-50", "generic_name": "Amantadine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["ANDA076186"], "brand_name": ["AMANTADINE HYDROCHLORIDE"], "generic_name": ["AMANTADINE HYDROCHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-0111"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMANTADINE HYDROCHLORIDE"], "rxcui": ["849395"], "spl_id": ["45af44df-1a9b-32b6-e063-6394a90acdaf"], "spl_set_id": ["63d9d4aa-5f92-45b0-98d0-d6ec38b727cb"], "package_ndc": ["0832-0111-00", "0832-0111-50", "0832-0111-89", "0832-0111-03"], "unii": ["M6Q1EO9TD0"]}, "update_date": "07/23/2025", "therapeutic_category": ["Antiviral", "Neurology"], "dosage_form": "Tablet", "presentation": "Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-50)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-11", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-406", "43547-407", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-11)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-23", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "On Allocation. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7923-23", "openfda": {"application_number": ["NDA016367"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["ICU Medical, Inc."], "product_ndc": ["0990-7923", "0990-7922", "0990-7930"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621"], "spl_id": ["ea5b9574-2321-442f-b550-3ac4f10dcaf8"], "spl_set_id": ["8b25b7e0-703e-4b43-a4eb-52863511602d"], "package_ndc": ["0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09"], "unii": ["LX22YL083G"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-125-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-125", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 125 ug (NDC 72305-125-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6044-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Lots are being manufactured to meet demand", "openfda": {"application_number": ["NDA018140"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6044", "0641-6046", "0641-6045", "0641-6047"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["238100", "238101", "1665188", "1665326"], "spl_id": ["7c73dbc6-2623-4443-9b05-97dec7a0be2e"], "spl_set_id": ["e9b54e42-04cf-4c62-90e1-36f7b31a4e81"], "package_ndc": ["0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "05/12/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/23/2025", "update_type": "New", "initial_posting_date": "05/23/2025", "package_ndc": "0093-0813-05", "generic_name": "Nortriptyline Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "Permanent discontinuation of specific package size/ SKU for business reasons.", "openfda": {"application_number": ["ANDA074132"], "brand_name": ["NORTRIPTYLINE HYDROCHLORIDE"], "generic_name": ["NORTRIPTYLINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0813", "0093-0810", "0093-0811", "0093-0812"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NORTRIPTYLINE HYDROCHLORIDE"], "rxcui": ["198045", "198046", "198047", "317136"], "spl_id": ["314d74dc-7394-40b9-be81-cb67b6e925a1"], "spl_set_id": ["b58d473a-b19f-4d2a-b1ae-dd398d7a29e1"], "package_ndc": ["0093-0810-01", "0093-0810-05", "0093-0811-01", "0093-0811-05", "0093-0812-01", "0093-0812-05", "0093-0813-01", "0093-0813-05"], "unii": ["00FN6IH15D"]}, "update_date": "05/23/2025", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Nortriptyline Hydrochloride, Capsule, 75 mg (NDC 0093-0813-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-200-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-200", "55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "59651-722-99", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": {"application_number": ["ANDA075150"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["59651-722", "59651-723", "59651-724"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "spl_set_id": ["b1582eb7-af35-45d5-a52e-0e380d08527d"], "package_ndc": ["59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 59651-722-99)", "company_name": "Aurobindo Pharma USA", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-383-30", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-30)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-17", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3475-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-3475", "0009-3073"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743781", "1743855", "1743856"], "spl_id": ["742fcec7-8db3-4cc6-b276-42587a993810"], "spl_set_id": ["9a7b3837-e038-48bf-97e9-78ad463760dc"], "package_ndc": ["0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"presentation": "Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1560-10", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4739-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Next resupply: TBD", "openfda": {"application_number": ["ANDA216944"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4744", "60505-4745"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["2eec36cd-6063-fea0-d6dd-b7a5c8df186b"], "spl_set_id": ["ecad4442-a644-18e3-6ff2-fdbac45eec47"], "package_ndc": ["60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)", "company_name": "Apotex Corp.", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-137-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-137", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 137 ug (NDC 72305-137-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "55150-322-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; check wholesalers for inventory", "openfda": {"application_number": ["ANDA212174"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-322", "55150-323", "55150-324"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9bb2ffa4-0891-4197-a970-90b178bbfad9"], "spl_set_id": ["421aa6d5-623b-4dc2-abd5-bb9e7765bf37"], "package_ndc": ["55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-047-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 57664-047-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/23/2025", "update_type": "New", "initial_posting_date": "05/23/2025", "package_ndc": "0591-3153-01", "generic_name": "Minocycline Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "Permanent discontinuation of manufacture due to business decision.", "openfda": {"application_number": ["ANDA063065"], "brand_name": ["MINOCYCLINE HYDROCHLORIDE"], "generic_name": ["MINOCYCLINE HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3153", "0591-5694", "0591-5695"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["MINOCYCLINE HYDROCHLORIDE"], "rxcui": ["197984", "197985", "314108"], "spl_id": ["2d74faa2-99c4-4f01-adc6-60110d2b24da"], "spl_set_id": ["a5fc4d50-50b2-46e0-b722-4c6b2ec47d06"], "package_ndc": ["0591-5694-60", "0591-5694-01", "0591-3153-01", "0591-5695-50"], "unii": ["0020414E5U"]}, "update_date": "05/23/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Minocycline Hydrochloride, Capsule, 75 mg (NDC 0591-3153-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-9104-20", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018132"], "brand_name": ["DOPAMINE HYDROCHLORIDE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9104", "0409-5820"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1743938", "1743941"], "spl_id": ["a3fac375-0709-4cc0-84db-b0e5a60b7200"], "spl_set_id": ["1f306ad2-3606-4525-5a8a-ce78f426c1a2"], "package_ndc": ["0409-5820-11", "0409-5820-01", "0409-9104-21", "0409-9104-20"], "unii": ["7L3E358N9L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-413-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": {"application_number": ["ANDA205823"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL"], "manufacturer_name": ["Solco Healthcare US, LLC"], "product_ndc": ["43547-413", "43547-410", "43547-411", "43547-412"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["b8f1731a-cbac-4f64-a8d4-320b80b335e1"], "spl_set_id": ["cd46691d-5593-4a9f-a937-999c6803e312"], "package_ndc": ["43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09"], "unii": ["33067B3N2M"]}, "update_date": "04/29/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/24/2025", "update_type": "New", "initial_posting_date": "06/24/2025", "package_ndc": "0078-0405-05", "generic_name": "Amlodipine Besylate; Benazepril Hydrochloride Capsule", "contact_info": "888-669-6682", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA020364"], "brand_name": ["LOTREL"], "generic_name": ["AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE"], "manufacturer_name": ["Novartis Pharmaceuticals Corporation"], "product_ndc": ["0078-0405", "0078-0406", "0078-0364", "0078-0379"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMLODIPINE BESYLATE", "BENAZEPRIL HYDROCHLORIDE"], "rxcui": ["898342", "898344", "898346", "898348", "898353", "898355", "898356", "898358"], "spl_id": ["b9db75d9-9d1e-4b2d-9876-5f5520feaecc"], "spl_set_id": ["94ae6054-b7ae-4212-a567-4f803af8f2c7"], "package_ndc": ["0078-0405-05", "0078-0406-05", "0078-0364-05", "0078-0379-05"], "unii": ["864V2Q084H", "N1SN99T69T"]}, "update_date": "06/24/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Lotrel, Capsule, 5 mg; 10 mg (NDC 0078-0405-05)", "company_name": "Novartis Pharmaceuticals Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-397-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "55150-323-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; check wholesalers for inventory", "openfda": {"application_number": ["ANDA212174"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-323", "55150-322", "55150-324"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["9bb2ffa4-0891-4197-a970-90b178bbfad9"], "spl_set_id": ["421aa6d5-623b-4dc2-abd5-bb9e7765bf37"], "package_ndc": ["55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/05/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-200-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 200 ug (NDC 72305-200-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5012-4", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": {"application_number": ["ANDA211091"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Exela Pharma Sciences, LLC"], "product_ndc": ["51754-5012", "51754-5001", "51754-5011", "51754-5002"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["807284", "1868486", "1923484", "2198792"], "spl_id": ["4da0ba66-756d-4b4d-8018-81ca16578ef1"], "spl_set_id": ["e9698a4f-1a95-4f28-a945-e8009d1d6dd4"], "package_ndc": ["51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4"], "unii": ["8MDF5V39QO"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1896-20", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA202515"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1896", "0409-2022"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731537", "1731545"], "spl_id": ["6f2d5741-5543-4bea-8d1d-7e4889b634a0"], "spl_set_id": ["ee8057d1-ed12-4e18-9efa-d83504abf612"], "package_ndc": ["0409-1896-20", "0409-2022-01"], "unii": ["X3P646A2J0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-64", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": {"application_number": ["NDA020533"], "brand_name": ["NAROPIN"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-285", "63323-286", "63323-287", "63323-288"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091"], "spl_id": ["324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c"], "spl_set_id": ["dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6"], "package_ndc": ["63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95"], "unii": ["V910P86109"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3298-63", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070433"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-3298", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3294"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FUROSEMIDE"], "rxcui": ["197730", "197731", "197732", "310429", "313988"], "spl_id": ["bc62ddda-7639-4090-99f0-7dd4d13518f3"], "spl_set_id": ["9e493331-dddd-496e-abf8-61747fb67aba"], "package_ndc": ["0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-192-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": {"application_number": ["ANDA209799"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SUNRISE PHARMACEUTICAL, INC."], "product_ndc": ["11534-192", "11534-190", "11534-191", "11534-193", "11534-194", "11534-195", "11534-196"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["86a00bec-51eb-4d73-a945-b1937970b29a"], "spl_set_id": ["ac102599-3a5b-4154-899e-6ff262be7ff7"], "package_ndc": ["11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/15/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0530-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: TBD", "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 10 mg (NDC 0071-0530-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/10/2026", "update_type": "New", "initial_posting_date": "04/10/2026", "package_ndc": "69238-2512-9", "generic_name": "Nitrofurantoin Oral Suspension", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA201679"], "brand_name": ["NITROFURANTOIN"], "generic_name": ["NITROFURANTOIN"], "manufacturer_name": ["Amneal Pharmaceuticals NY LLC"], "product_ndc": ["69238-2512"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NITROFURANTOIN"], "rxcui": ["311989"], "spl_id": ["87af7ed1-6ae7-4eaf-ab35-d46d07549450"], "spl_set_id": ["80129dba-5939-4292-bfd0-8d53ba165941"], "package_ndc": ["69238-2512-9"], "nui": ["N0000175494", "M0014892"], "pharm_class_epc": ["Nitrofuran Antibacterial [EPC]"], "pharm_class_cs": ["Nitrofurans [CS]"], "unii": ["927AH8112L"]}, "update_date": "04/10/2026", "therapeutic_category": ["Anti-Infective", "Other"], "dosage_form": "Oral Suspension", "presentation": "Nitrofurantoin, Oral Suspension, 25 mg/5 mL (NDC 69238-2512-9)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/06/2023", "change_date": "12/15/2025", "package_ndc": "0338-1049-02", "generic_name": "Nitroglycerin Injection", "contact_info": "Baxter Healthcare 888-229-0001", "resolved_note": "Available", "openfda": {"application_number": ["NDA019970"], "brand_name": ["NITROGLYCERIN IN DEXTROSE"], "generic_name": ["NITROGLYCERIN"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-1049", "0338-1047", "0338-1051"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["NITROGLYCERIN"], "rxcui": ["312004", "1868494", "1868562"], "spl_id": ["b89cb9ff-d275-465b-b70b-d8e2e9406435"], "spl_set_id": ["457a026c-ebce-4701-9deb-2d7652759a99"], "package_ndc": ["0338-1047-02", "0338-1049-02", "0338-1051-02"], "nui": ["N0000175415", "M0014874", "N0000009909"], "pharm_class_epc": ["Nitrate Vasodilator [EPC]"], "pharm_class_cs": ["Nitrates [CS]"], "pharm_class_pe": ["Vasodilation [PE]"], "unii": ["G59M7S0WS3"]}, "update_date": "12/15/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Nitroglycerin in Dextrose 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)", "company_name": "Baxter Healthcare", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0530-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 10 mg (NDC 0071-0530-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-710-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA075604"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["62037-710", "62037-720"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["1801294", "1801298"], "spl_id": ["01fbdb24-0987-40f6-a920-f36349f6ba61"], "spl_set_id": ["db002ae3-f54c-40a4-9cb4-e5681bf426e3"], "package_ndc": ["62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10"], "unii": ["660YQ98I10"]}, "update_date": "11/21/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 10 meq (NDC 62037-710-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "16729-432-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/01/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-723-52", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA216039"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-723", "71288-726"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404"], "spl_id": ["0949c302-51ce-4fc9-8b99-1df94e693718"], "spl_set_id": ["fe340f98-a0f3-446e-b281-47fd91c1e537"], "package_ndc": ["71288-723-52", "71288-726-52"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-48", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-6531-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA062933", "ANDA062912"], "brand_name": ["VANCOMYCIN HYDROCHLORIDE"], "generic_name": ["VANCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6531", "0409-6535", "0409-6534", "0409-6533", "0409-4332", "0409-3515"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VANCOMYCIN HYDROCHLORIDE"], "rxcui": ["1807513", "1807516", "1807518", "2049890"], "spl_id": ["771a44e0-5858-449c-be36-438a9ff52e67", "10032a19-0373-4c42-b785-f3d915614e30"], "spl_set_id": ["2fd9de3f-a95f-451c-a687-d2e1306e53bf", "f2901045-904f-47bd-74a1-c561facd7f25"], "package_ndc": ["0409-6531-11", "0409-6531-01", "0409-6535-11", "0409-6535-01", "0409-6534-11", "0409-6534-01", "0409-6531-12", "0409-6531-02", "0409-6533-11", "0409-6533-01", "0409-6533-21", "0409-4332-11", "0409-4332-01", "0409-3515-11", "0409-3515-01"], "unii": ["71WO621TJD"]}, "update_date": "09/09/2025", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 750 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-6531-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-5030-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020646"], "brand_name": ["TIAGABINE HYDROCHLORIDE"], "generic_name": ["TIAGABINE HYDROCHLORIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-5030", "0093-5031", "0093-8072", "0093-8076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["TIAGABINE HYDROCHLORIDE"], "rxcui": ["1299903", "1299909", "1299911", "1299917"], "spl_id": ["2a8d7987-54ae-45d7-8224-361dac37e0a4"], "spl_set_id": ["953ef3cc-e3cb-480f-b9ea-256520fd62b8"], "package_ndc": ["0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56"], "unii": ["DQH6T6D8OY"]}, "update_date": "04/15/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1573-5", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Currently product is under backorder as per current demand. Next supply: week of 02/09/2026", "openfda": {"application_number": ["ANDA210043"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["70121-1573", "70121-1574"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1743779", "1743855"], "spl_id": ["af4215ff-94ca-44f8-8506-3024e738cd13"], "spl_set_id": ["d944240d-2c19-46ba-ad4f-3fbee7b8629c"], "package_ndc": ["70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5"], "unii": ["43502P7F0P"]}, "update_date": "02/09/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)", "company_name": "Amneal Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-452-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA204223"], "brand_name": ["MORPHINE SULFATE"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-452", "63323-454", "63323-455", "63323-458", "63323-451"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731993", "1732006", "1732011", "1732136", "2003714"], "spl_id": ["dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc"], "spl_set_id": ["582f42e5-444e-4246-af8c-e7e28097c69a"], "package_ndc": ["63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01"], "unii": ["X3P646A2J0"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5543-10", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018832"], "brand_name": ["ALLOPURINOL"], "generic_name": ["ALLOPURINOL"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-5543", "0591-5544"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ALLOPURINOL"], "spl_id": ["f7e04d88-1d9b-47e6-a9ad-deb08af3c098"], "spl_set_id": ["a80fe56f-8d03-423f-8e2a-7ec8c9e5045b"], "package_ndc": ["0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05"], "nui": ["N0000175698", "N0000000206"], "pharm_class_epc": ["Xanthine Oxidase Inhibitor [EPC]"], "pharm_class_moa": ["Xanthine Oxidase Inhibitors [MoA]"], "unii": ["63CZ7GJN5I"]}, "update_date": "02/19/2026", "therapeutic_category": ["Oncology", "Renal", "Rheumatology"], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 100 mg (NDC 0591-5543-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-601-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": {"application_number": ["ANDA214456"], "brand_name": ["KETOROLAC TROMETHAMINE"], "generic_name": ["KETOROLAC TROMETHAMINE"], "manufacturer_name": ["Alembic Pharmaceuticals Inc."], "product_ndc": ["62332-601", "62332-599", "62332-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["KETOROLAC TROMETHAMINE"], "rxcui": ["860092", "1665459", "1665461"], "spl_id": ["9030f496-5021-4454-ac16-dbb376315608"], "spl_set_id": ["419cf756-3c96-4bb8-ae96-6aea5a5f3afd"], "package_ndc": ["62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25"], "unii": ["4EVE5946BQ"]}, "update_date": "05/15/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-088-30", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-088", "72305-025", "72305-050", "72305-075", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 88 ug (NDC 72305-088-30)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "05/07/2026", "update_type": "New", "initial_posting_date": "05/07/2026", "package_ndc": "63323-574-86", "generic_name": "Icatibant Acetate Injection", "contact_info": "847-550-2300", "related_info": "Discontinuation of the manufacturer of the drug", "openfda": {"application_number": ["ANDA208317"], "brand_name": ["ICATIBANT"], "generic_name": ["ICATIBANT"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-574"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ICATIBANT ACETATE"], "rxcui": ["1148141"], "spl_id": ["d1c9afa7-c4ac-4739-85f1-2ae82440210c"], "spl_set_id": ["52c12c15-c00b-4efc-952d-1425c907706a"], "package_ndc": ["63323-574-01", "63323-574-86", "63323-574-93"], "unii": ["325O8467XK"]}, "update_date": "05/07/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/24/2025", "package_ndc": "82154-0451-4", "generic_name": "Peginterferon alfa-2a Injection", "contact_info": "800-506-8501, email: medinfo.us@pharmaand.com", "availability": "Limited Availability", "related_info": "Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.", "openfda": {"application_number": ["BLA103964"], "brand_name": ["PEGASYS"], "generic_name": ["PEGINTERFERON ALFA-2A"], "manufacturer_name": ["pharmaand GmbH"], "product_ndc": ["82154-0451", "82154-0449"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PEGINTERFERON ALFA-2A"], "rxcui": ["351270", "352297", "731326", "731328"], "spl_id": ["3c18e4a2-193f-ef4e-e063-6394a90a56b2"], "spl_set_id": ["d9290e5b-6d40-2318-e053-2995a90a9916"], "package_ndc": ["82154-0449-1", "82154-0451-4"], "nui": ["N0000175521", "M0025711"], "pharm_class_epc": ["Interferon alpha [EPC]"], "pharm_class_cs": ["Interferon-alpha [CS]"], "unii": ["Q46947FE7K"]}, "update_date": "08/19/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)", "company_name": "pharmaand GmbH (pharma&)", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "72205-136-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Limited supply from Manufacturers", "openfda": {"application_number": ["ANDA218306"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-136", "72205-132", "72205-133", "72205-134", "72205-135", "72205-137"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "spl_set_id": ["a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811"], "package_ndc": ["72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91"], "unii": ["SJT761GEGS"]}, "update_date": "04/02/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)", "company_name": "Novadoz Pharmaceuticals LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0093-3750-63", "generic_name": "Tobramycin Solution", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA210915"], "brand_name": ["TOBRAMYCIN"], "generic_name": ["TOBRAMYCIN"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-3750"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["TOBRAMYCIN"], "rxcui": ["1314763"], "spl_id": ["8aa98982-a156-4bc8-8d31-9a39b88808ed"], "spl_set_id": ["d03079d2-5617-4628-92b9-3caa757b22c0"], "package_ndc": ["0093-3750-28", "0093-3750-63"], "nui": ["N0000175477", "M0000946"], "pharm_class_epc": ["Aminoglycoside Antibacterial [EPC]"], "pharm_class_cs": ["Aminoglycosides [CS]"], "unii": ["VZ8RRZ51VK"]}, "update_date": "06/16/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-63)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0703-4094-01", "generic_name": "Palonosetron Hydrochloride Injection", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA090713"], "brand_name": ["PALONOSETRON HYDROCHLORIDE"], "generic_name": ["PALONOSETRON HYDROCHLORIDE"], "manufacturer_name": ["Teva Parenteral Medicines, Inc."], "product_ndc": ["0703-4094"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["PALONOSETRON HYDROCHLORIDE"], "rxcui": ["1728055"], "spl_id": ["124fd0ad-cda6-4a00-9355-c4809c039c74"], "spl_set_id": ["911783eb-91a8-4ef4-bd6f-809211e207d6"], "package_ndc": ["0703-4094-01"], "unii": ["23310D4I19"]}, "update_date": "11/14/2025", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-460-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207449"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["FRESENIUS KABI USA, LLC"], "product_ndc": ["65219-460", "65219-456", "65219-464", "65219-458", "65219-462"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["efc3b0c9-518a-47db-bb3e-ebdfd4646e9b"], "spl_set_id": ["576a22d8-5f2f-497e-80ad-1842ca74bb53"], "package_ndc": ["65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0123-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "change_date": "01/02/2025", "package_ndc": "0409-1312-30", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA200403"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1312", "0409-1283", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276"], "spl_id": ["766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08"], "spl_set_id": ["f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b"], "package_ndc": ["0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31"], "unii": ["L960UP2KRW"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0338-1055-48", "generic_name": "Metronidazole Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA018657"], "brand_name": ["METRONIDAZOLE"], "generic_name": ["METRONIDAZOLE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1055"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["METRONIDAZOLE"], "rxcui": ["311683"], "spl_id": ["7841a410-43a9-4c79-acee-b831b42da8a8"], "spl_set_id": ["d2112f37-5080-4a19-bcc3-6386b49abe1d"], "package_ndc": ["0338-1055-48"], "nui": ["N0000175435", "M0014907"], "pharm_class_epc": ["Nitroimidazole Antimicrobial [EPC]"], "pharm_class_cs": ["Nitroimidazoles [CS]"], "unii": ["140QMO216E"]}, "update_date": "04/20/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-03", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA214028"], "brand_name": ["VUITY"], "generic_name": ["PILOCARPINE HYDROCHLORIDE"], "manufacturer_name": ["AbbVie Inc."], "product_ndc": ["0074-7098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["OPHTHALMIC"], "substance_name": ["PILOCARPINE HYDROCHLORIDE"], "spl_id": ["ed4cf150-c4b6-4d26-9326-e3a3490de489"], "spl_set_id": ["8d806897-8a2a-4518-8c68-0ec3b778de50"], "package_ndc": ["0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06"], "unii": ["0WW6D218XJ"]}, "update_date": "03/24/2026", "therapeutic_category": ["Ophthalmology"], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-03)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-085-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214134"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-085", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/29/2025", "update_type": "New", "initial_posting_date": "07/29/2025", "package_ndc": "61570-074-01", "generic_name": "Esterified Estrogens Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/29/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Menest, Tablet, 1.25 mg (NDC 61570-074-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0331-02", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050162"], "brand_name": ["CLEOCIN HYDROCHLORIDE"], "generic_name": ["CLINDAMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0331", "0009-0225", "0009-0395"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLINDAMYCIN HYDROCHLORIDE"], "rxcui": ["197518", "284215", "309329", "748746", "748748", "748750"], "spl_id": ["51cea3cd-28cf-455e-ba27-5a0d8e052858"], "spl_set_id": ["df9a2a41-b132-4f43-8940-b2d773b1369a"], "package_ndc": ["0009-0331-02", "0009-0225-02", "0009-0395-14"], "unii": ["T20OQ1YN1W"]}, "update_date": "02/25/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-02", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "50458-290-04", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020083"], "brand_name": ["SPORANOX"], "generic_name": ["ITRACONAZOLE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-290"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ITRACONAZOLE"], "rxcui": ["311204", "833164"], "spl_id": ["b5d1c275-8665-4f63-8232-e34a02c998c7"], "spl_set_id": ["a4d555fa-787c-40fb-bb7d-b0d4f7318fd0"], "package_ndc": ["50458-290-01", "50458-290-04", "50458-290-28"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]"], "unii": ["304NUG5GF4"]}, "update_date": "02/27/2026", "therapeutic_category": ["Anti-Infective", "Other"], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 50458-290-04)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-484-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-484", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-049-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Available", "openfda": {"application_number": ["ANDA214484"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Sun Pharmaceutical Industries, Inc."], "product_ndc": ["57664-049", "57664-047", "57664-046", "57664-048", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468"], "spl_id": ["0b77417a-5789-8818-e063-6294a90ad2e3"], "spl_set_id": ["da3148af-f9b6-4725-adae-3595b4c7dc4b"], "package_ndc": ["57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88"], "unii": ["SJT761GEGS"]}, "update_date": "04/17/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "47781-178-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Unavailable", "related_info": "Supporting contracted business only", "openfda": {"application_number": ["ANDA207388"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 15 MG,CLL"], "manufacturer_name": ["Alvogen Inc."], "product_ndc": ["47781-178", "47781-174", "47781-175", "47781-176", "47781-177", "47781-179", "47781-180"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["0374f0f7-9297-810c-38b3-623a72709a7d"], "spl_set_id": ["c907301d-e24d-9609-5529-fed14f94549f"], "package_ndc": ["47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)", "company_name": "Alvogen", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5534-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/15/2025", "update_type": "New", "initial_posting_date": "08/15/2025", "package_ndc": "0591-3983-01", "generic_name": "Celecoxib Capsule", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA200562"], "brand_name": ["CELECOXIB"], "generic_name": ["CELECOXIB"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3983", "0591-3982", "0591-3984", "0591-3985"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CELECOXIB"], "rxcui": ["205322", "205323", "349514", "686379"], "spl_id": ["42c5f4e4-5a65-4062-bf0a-b640659bc6f1"], "spl_set_id": ["05224473-27dc-4f6d-a52a-c40a7af2f2f4"], "package_ndc": ["0591-3982-60", "0591-3983-01", "0591-3983-05", "0591-3984-01", "0591-3984-05", "0591-3985-60"], "nui": ["N0000000160", "M0001335", "N0000175722"], "pharm_class_moa": ["Cyclooxygenase Inhibitors [MoA]"], "pharm_class_cs": ["Anti-Inflammatory Agents, Non-Steroidal [CS]"], "pharm_class_epc": ["Nonsteroidal Anti-inflammatory Drug [EPC]"], "unii": ["JCX84Q7J1L"]}, "update_date": "08/15/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Capsule", "presentation": "Celecoxib, Capsule, 100 mg (NDC 0591-3983-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-125-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA207934"], "brand_name": ["EVEROLIMUS"], "generic_name": ["EVEROLIMUS"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["49884-125", "49884-119", "49884-127", "49884-128"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["EVEROLIMUS"], "rxcui": ["845507", "845515", "998189", "1119400"], "spl_id": ["b474c768-50e2-44da-accf-f1bd3d49ab20"], "spl_set_id": ["45d54974-3fc4-4237-a2fa-3158ca1a8105"], "package_ndc": ["49884-119-52", "49884-119-91", "49884-125-52", "49884-125-91", "49884-127-52", "49884-127-91", "49884-128-52", "49884-128-91"], "nui": ["N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550"], "pharm_class_epc": ["Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]"], "pharm_class_moa": ["Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]"], "pharm_class_pe": ["Decreased Immunologic Activity [PE]"], "unii": ["9HW64Q8G6G"]}, "update_date": "01/06/2026", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 49884-125-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-736-30", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": {"application_number": ["ANDA072368"], "brand_name": ["FLURAZEPAM HYDROCHLORIDE"], "generic_name": ["FLURAZEPAM HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-736", "62135-737"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLURAZEPAM HYDROCHLORIDE"], "rxcui": ["1298088", "1298091"], "spl_id": ["25893c92-c8f1-567a-e063-6294a90a00d4"], "spl_set_id": ["8f476891-1346-4e8c-ac1b-f8cbdc64f5a1"], "package_ndc": ["62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90"], "unii": ["756RDM536M"]}, "update_date": "02/02/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/01/2026", "update_type": "New", "initial_posting_date": "04/01/2026", "package_ndc": "60429-005-12", "generic_name": "Icosapent Ethyl Capsule", "contact_info": "800-706-5575", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {}, "update_date": "04/01/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Capsule", "presentation": "Icosapent Ethyl, Capsule, 1 g (NDC 60429-005-12)", "company_name": "Apotex Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6857-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6857", "0378-6854", "0378-6855", "0378-6856", "0378-6858", "0378-6859", "0378-6860"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-115-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": {"application_number": ["NDA208510"], "brand_name": ["VYVANSE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Takeda Pharmaceuticals America, Inc."], "product_ndc": ["59417-115", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469"], "spl_id": ["81d087b6-4cb4-466a-9693-679edeb062e2"], "spl_set_id": ["704e4378-ca83-445c-8b45-3cfa51c1ecad"], "package_ndc": ["59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0306-02", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA011757"], "brand_name": ["DEPO-MEDROL"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0306", "0009-0274", "0009-0280"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358510", "1358512", "1358610", "1358612", "1358617", "1358619"], "spl_id": ["267dd735-f800-4735-ba1c-d39d00f0cee5"], "spl_set_id": ["823b0010-2b57-4e76-b5ac-4a8c2963438f"], "package_ndc": ["0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12"], "unii": ["43502P7F0P"]}, "update_date": "05/08/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "10/27/2025", "update_type": "New", "initial_posting_date": "10/27/2025", "package_ndc": "0310-6615-02", "generic_name": "Pramlintide Acetate Injection", "contact_info": "800-236-9933", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["NDA021332"], "brand_name": ["SYMLINPEN"], "generic_name": ["PRAMLINTIDE ACETATE"], "manufacturer_name": ["AstraZeneca Pharmaceuticals LP"], "product_ndc": ["0310-6615", "0310-6627"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["PRAMLINTIDE ACETATE"], "rxcui": ["861042", "861043", "861044", "861045"], "spl_id": ["a84753f1-6ac5-4a47-a382-29972938ccaa"], "spl_set_id": ["4aea30ff-eb0d-45c1-b114-3127966328ff"], "package_ndc": ["0310-6615-02", "0310-6627-02"], "unii": ["726I6TE06G"]}, "update_date": "10/27/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Injection", "presentation": "SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02)", "company_name": "AstraZeneca AB", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "06/16/2022", "package_ndc": "42023-240-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "800-828-9393", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA214297"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Endo USA, Inc."], "product_ndc": ["42023-240", "42023-239", "42023-238"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTERIAL", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["9d6bd79b-4885-454e-b127-c5978e501024"], "spl_set_id": ["631f7d3e-5620-4be3-b918-2f0d38a97890"], "package_ndc": ["42023-240-01", "42023-239-01", "42023-238-01"], "unii": ["43502P7F0P"]}, "update_date": "05/01/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)", "company_name": "Par Health, USA LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1007-02", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA019615"], "brand_name": ["DOPAMINE HYDROCHLORIDE AND DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-1007", "0338-1005", "0338-1009"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "rxcui": ["1292887", "1743869", "1743871", "1743877", "1743879"], "spl_id": ["edc9a091-4cb5-4ec7-b6f9-44d2d588bab9"], "spl_set_id": ["cb97d4a0-89ed-407c-a763-209386b6f75c"], "package_ndc": ["0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02"], "unii": ["7L3E358N9L"]}, "update_date": "04/20/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/21/2026", "update_type": "New", "initial_posting_date": "04/21/2026", "package_ndc": "16729-239-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-941-7875, option 2", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA204023"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Accord Healthcare Inc."], "product_ndc": ["16729-239"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["2de0daf8-b7a3-1dca-e063-6394a90a4d0a"], "spl_set_id": ["2b9881f0-4a66-660f-e054-00144ff88e88"], "package_ndc": ["16729-239-30", "16729-239-93"], "unii": ["1018WH7F9I"]}, "update_date": "04/21/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)", "company_name": "Accord Healthcare Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "63323-853-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["HYDROMORPHONE HYDROCHLORIDE"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-853", "63323-851", "63323-852", "63323-854"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897653", "897753", "1724276", "1724338", "1724340", "1724341"], "spl_id": ["9e8522c6-595c-46f9-bb25-272aa4683e0f"], "spl_set_id": ["e034eb96-03e0-46e1-8b92-5e1f94555e7b"], "package_ndc": ["63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0006-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 3 mg (NDC 0378-0006-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "66758-211-31", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021192"], "brand_name": ["LESCOL XL"], "generic_name": ["FLUVASTATIN SODIUM"], "manufacturer_name": ["Sandoz Inc"], "product_ndc": ["66758-211"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLUVASTATIN SODIUM"], "rxcui": ["360507", "687048"], "spl_id": ["726ea2db-f1b0-4b73-a515-02157db88a42"], "spl_set_id": ["726ea2db-f1b0-4b73-a515-02157db88a42"], "package_ndc": ["66758-211-01", "66758-211-31"], "unii": ["PYF7O1FV7F"]}, "update_date": "01/27/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-31", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-096-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-096", "68025-088", "68025-089", "68025-095", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "43066-027-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": {"application_number": ["ANDA212808"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["43066-027", "43066-015", "43066-019", "43066-023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734084", "1734207", "1734475", "1734483"], "spl_id": ["a8d08579-825f-40d9-b1e3-e47b73765ae6"], "spl_set_id": ["781d4b7f-7556-4695-8d48-7772d7a0d8e9"], "package_ndc": ["43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10"], "unii": ["V910P86109"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "71288-115-30", "generic_name": "Azacitidine Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA212128"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-115"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["bad343f5-0c12-47de-93e7-9b2af3670b7c"], "spl_set_id": ["97b0917a-03fa-4cc4-91cf-1bed57a988c9"], "package_ndc": ["71288-115-30"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "08/19/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8884-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Available", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8884", "0406-8891", "0406-8892", "0406-8885", "0406-8893", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)", "company_name": "SpecGx LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0832-5322-10", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["POTASSIUM CHLORIDE"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0832-5322", "0832-5323"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953"], "spl_id": ["39e726b1-eab8-fcf4-e063-6394a90a950a"], "spl_set_id": ["616f0de7-8843-44a1-8fa6-274d889286aa"], "package_ndc": ["0832-5322-11", "0832-5322-10", "0832-5323-11", "0832-5323-10"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-10)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-50", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: May 2026; Estimated Recovery: September 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-339"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0ddf4411-7138-412a-908a-fadf22bdfb79"], "spl_set_id": ["c3ae9880-44bb-4f4e-93d8-8a5e21708a30"], "package_ndc": ["61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0551-18", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA020179"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Company"], "product_ndc": ["0338-0551"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616"], "spl_id": ["e702be26-651e-4d4a-9d79-4df9f53821c9"], "spl_set_id": ["7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e"], "package_ndc": ["0338-0551-11", "0338-0551-18"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA019115"], "brand_name": ["FENTANYL CITRATE"], "generic_name": ["FENTANYL CITRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-9094", "0409-9093"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FENTANYL CITRATE"], "rxcui": ["1735003", "1735004", "1735006", "1735007", "1735008", "1735013"], "spl_id": ["e4eaad6d-c21e-42fd-8fd9-f0b769966d61"], "spl_set_id": ["bfa8018a-4cbc-434b-e09e-782872b0340a"], "package_ndc": ["0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61"], "unii": ["MUN5LYG46H"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-502-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-502", "64850-500", "64850-501", "64850-503", "64850-504", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-255-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207182"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-255", "55150-251", "55150-252", "55150-254", "55150-253", "55150-256"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010033", "1010671"], "spl_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6"], "spl_set_id": ["ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c"], "package_ndc": ["55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50"], "unii": ["V13007Z41A"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "39822-0350-2", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": {"application_number": ["ANDA201746"], "brand_name": ["LINCOMYCIN"], "generic_name": ["LINCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-0350", "39822-0353"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCONJUNCTIVAL"], "substance_name": ["LINCOMYCIN HYDROCHLORIDE"], "rxcui": ["239212"], "spl_id": ["df369d62-f1a4-1a53-e053-2995a90abbf9"], "spl_set_id": ["61f4851d-d919-400d-912a-05eb9dca11d4"], "package_ndc": ["39822-0350-1", "39822-0350-2", "39822-0353-6"], "unii": ["M6T05Z2B68"]}, "update_date": "03/26/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-67", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA206166"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-671", "25021-652"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["1734347", "1734355", "1734479", "1734481"], "spl_id": ["41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184"], "spl_set_id": ["8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d"], "package_ndc": ["25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67"], "unii": ["V910P86109"]}, "update_date": "11/13/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)", "company_name": "InfoRLife SA", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-1510-32", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA016730"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-1510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616", "1795618"], "spl_id": ["0a144591-6cfa-4aed-a067-c95aebc29057"], "spl_set_id": ["60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5"], "package_ndc": ["0264-1510-36", "0264-1510-31", "0264-1510-32"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-481-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA006488"], "brand_name": ["XYLOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-481", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-483", "63323-482", "63323-487"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE BITARTRATE", "LIDOCAINE HYDROCHLORIDE ANHYDROUS"], "rxcui": ["1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029"], "spl_id": ["ea480a68-5927-4278-9deb-2956961da428"], "spl_set_id": ["ba082c2f-64f4-419d-9c88-74f203316e17"], "package_ndc": ["63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31"], "unii": ["EC2CNF7XFP", "30Q7KI53AK"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-024-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Unavailable", "related_info": "Shortage of an active ingredient", "openfda": {"application_number": ["ANDA202830"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Amneal Pharmaceuticals LLC"], "product_ndc": ["65162-024", "65162-023", "65162-025", "65162-026", "65162-027", "65162-028"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850"], "spl_id": ["ba9f3370-3096-4d8c-9571-e28faf54291f"], "spl_set_id": ["c11cb3b6-3dff-477b-a249-b4c3118edc5f"], "package_ndc": ["65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09"], "unii": ["SJT761GEGS"]}, "update_date": "02/09/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/16/2025", "update_type": "New", "initial_posting_date": "06/16/2025", "package_ndc": "0093-4085-63", "generic_name": "Tobramycin Solution", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA091589"], "brand_name": ["TOBRAMYCIN"], "generic_name": ["TOBRAMYCIN"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-4085"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RESPIRATORY (INHALATION)"], "substance_name": ["TOBRAMYCIN"], "rxcui": ["348719"], "spl_id": ["2aeb6242-a55e-4e45-96df-f2d26616e167"], "spl_set_id": ["c5f65e5b-c851-45da-a0e8-215d9a4e6ad3"], "package_ndc": ["0093-4085-63"], "nui": ["N0000175477", "M0000946"], "pharm_class_epc": ["Aminoglycoside Antibacterial [EPC]"], "pharm_class_cs": ["Aminoglycosides [CS]"], "unii": ["VZ8RRZ51VK"]}, "update_date": "06/16/2025", "therapeutic_category": ["Pulmonary/Allergy"], "dosage_form": "Solution", "presentation": "Tobramycin, Solution, 300 mg/5 mL (NDC 0093-4085-63)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-4911-34", "generic_name": "Atropine Sulfate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-442-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA217472"], "brand_name": ["ROCURONIUM"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-442", "65219-444", "65219-695", "65219-697"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["2720024", "2720026"], "spl_id": ["31c4c874-3d24-4c86-a301-ee9faf0b5c00"], "spl_set_id": ["9a622308-7bda-4ca0-9de5-d6b3b4be3384"], "package_ndc": ["65219-442-02", "65219-442-05", "65219-444-04", "65219-444-10", "65219-695-01", "65219-695-05", "65219-697-01", "65219-697-10"], "unii": ["I65MW4OFHZ"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-195-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-088-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-088", "72305-025", "72305-050", "72305-075", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 88 ug (NDC 72305-088-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-00", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA019626"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-7510", "0264-7520"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE, UNSPECIFIED FORM"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795610", "1795612"], "spl_id": ["c9f87749-8dd5-41fd-b393-f63d45fd00ef"], "spl_set_id": ["085614c7-ada4-4e2c-87c0-c9bc2f18365a"], "package_ndc": ["0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20"], "unii": ["IY9XDZ35W2"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-161-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": {"application_number": ["ANDA215330"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["Rhodes Pharmaceuticals LLC"], "product_ndc": ["42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-166", "42858-167"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "spl_id": ["0002e227-1109-4ecc-a8c5-4b4f11fac3cc"], "spl_set_id": ["d918b40d-a461-41bc-b6c0-83dc76c28e32"], "package_ndc": ["42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-1496-35", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "This presentation is temporarily on backorder.", "openfda": {"application_number": ["ANDA083312"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-1496", "0641-1495"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992460", "992858"], "spl_id": ["80a400d2-d293-4180-bfa7-7a8ce0734bc5"], "spl_set_id": ["13d9e59d-eadb-41d5-9f47-9c11a6efb31c"], "package_ndc": ["0641-1495-31", "0641-1495-35", "0641-1496-31", "0641-1496-35"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/23/2025", "update_type": "New", "initial_posting_date": "07/23/2025", "package_ndc": "0245-5316-11", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": {"application_number": ["NDA019123"], "brand_name": ["KLOR-CON"], "generic_name": ["POTASSIUM CHLORIDE"], "manufacturer_name": ["Upsher-Smith Laboratories, LLC"], "product_ndc": ["0245-5316", "0245-5315"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["POTASSIUM CHLORIDE"], "rxcui": ["312529", "628953", "628958", "832718"], "spl_id": ["39e77e07-bdc8-28e9-e063-6394a90a120c"], "spl_set_id": ["1ff53330-065c-4213-9c0c-ac498621d09d"], "package_ndc": ["0245-5315-11", "0245-5315-15", "0245-5315-89", "0245-5315-01", "0245-5316-11", "0245-5316-15", "0245-5316-89", "0245-5316-01"], "unii": ["660YQ98I10"]}, "update_date": "07/23/2025", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology"], "dosage_form": "Tablet", "presentation": "Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-3", "generic_name": "Carboplatin Injection", "related_info_link": "https://dps.fda.gov/drugshortages/discontinuations/carboplatin-injection", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Available", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.)", "openfda": {"application_number": ["ANDA077861"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Apotex Corp."], "product_ndc": ["60505-6282"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["0e68e276-b0df-4f03-e063-6394a90a22b9"], "spl_set_id": ["1c275825-0275-4c73-b650-e4c1519f13b8"], "package_ndc": ["60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)", "company_name": "Teyro Labs", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-062-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": {"application_number": ["ANDA207636"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "product_ndc": ["70069-062", "70069-061", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483"], "spl_id": ["79b226f0-c08a-4f84-bf2b-ae5c60e01d67"], "spl_set_id": ["ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64"], "package_ndc": ["70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10"], "unii": ["V910P86109"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-489-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0104-04", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050317"], "brand_name": ["LINCOCIN"], "generic_name": ["LINCOMYCIN HYDROCHLORIDE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0104", "0009-0555", "0009-0107"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCONJUNCTIVAL"], "substance_name": ["LINCOMYCIN HYDROCHLORIDE"], "rxcui": ["102787", "239212"], "spl_id": ["7e2f3780-88ee-4971-a4ab-3d6cd972c42c"], "spl_set_id": ["c01906fa-2c73-4c13-9765-2fd06628d263"], "package_ndc": ["0009-0555-01", "0009-0104-04", "0009-0107-04"], "unii": ["M6T05Z2B68"]}, "update_date": "02/25/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-608-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-608", "43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-607"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-015-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 15 mg/.4 mL (NDC 82497-015-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-201-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-201", "55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-0109-01", "generic_name": "Carbamazepine Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA070541"], "brand_name": ["CARBAMAZEPINE"], "generic_name": ["CARBAMAZEPINE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-0109", "0093-0778"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CARBAMAZEPINE"], "rxcui": ["308973", "308979"], "spl_id": ["042aa2c6-95ff-410a-abcf-a8ee79fa96d8"], "spl_set_id": ["bfd63965-56e6-4af7-b7ef-45a5105d4d35"], "package_ndc": ["0093-0109-01", "0093-0109-10", "0093-0778-01"], "nui": ["N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Mood Stabilizer [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]"], "unii": ["33CM23913M"]}, "update_date": "06/10/2025", "therapeutic_category": ["Neurology"], "dosage_form": "Tablet", "presentation": "Epitol, Tablet, 200 mg (NDC 0093-0109-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "64850-504-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": {"application_number": ["ANDA211352"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Elite Laboratories, Inc."], "product_ndc": ["64850-504", "64850-500", "64850-501", "64850-502", "64850-503", "64850-505", "64850-506"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["b65e0266-7172-4730-8f93-eb42e08fb7b8"], "spl_set_id": ["e677690f-790f-4626-ad78-097cdb6ea540"], "package_ndc": ["64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-11", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5115-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocations to primary customers only.", "openfda": {"application_number": ["ANDA211840"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-5115", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5116", "0406-5117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["b4be564a-404d-4ca1-bac0-ec9cf40fef93"], "spl_set_id": ["806a1c15-0842-4787-b2ad-09a21fd96b37"], "package_ndc": ["0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01"], "unii": ["SJT761GEGS"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-097-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-097", "68025-088", "68025-089", "68025-095", "68025-096", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0990-7139-36", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Limited Availability", "related_info": "Allocated to Contracted Customers Only. ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7139-36", "openfda": {"application_number": ["NDA017513"], "brand_name": ["STERILE WATER"], "generic_name": ["WATER"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7139", "0990-6139", "0990-7973"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["IRRIGATION"], "substance_name": ["WATER"], "rxcui": ["150985"], "spl_id": ["90930d29-6b1a-438c-b719-c5e7484dcad5"], "spl_set_id": ["e3484bc6-ed7f-43ef-9d49-c131a8dff2dd"], "package_ndc": ["0990-6139-22", "0990-6139-03", "0990-7139-09", "0990-7139-36", "0990-7973-05", "0990-7973-07", "0990-7973-08"], "unii": ["059QF0KO0R"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology", "Other", "Pediatric"], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-700-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA040330"], "brand_name": ["ENDOCET"], "generic_name": ["OXYCODONE AND ACETAMINOPHEN"], "manufacturer_name": ["Par Health USA, LLC"], "product_ndc": ["60951-700", "60951-602", "60951-712", "60951-701"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ACETAMINOPHEN", "OXYCODONE HYDROCHLORIDE"], "rxcui": ["1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288"], "spl_id": ["097fa5e7-7122-439a-8ac9-c85766003509"], "spl_set_id": ["944d3e60-7eee-11de-a413-0002a5d5c51b"], "package_ndc": ["60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70"], "unii": ["362O9ITL9D", "C1ENJ2TE6C"]}, "update_date": "11/03/2025", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "76045-009-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release May 2026. Check wholesalers for inventory.", "openfda": {"application_number": ["NDA019034"], "brand_name": ["DILAUDID"], "generic_name": ["HYDROMORPHONE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["76045-009", "76045-010", "76045-121"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["HYDROMORPHONE HYDROCHLORIDE"], "rxcui": ["897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370"], "spl_id": ["97bfcafb-2037-47dc-a0ae-f7b8007c47df"], "spl_set_id": ["9eebd88a-5632-460f-b7b6-26c8a180540d"], "package_ndc": ["76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11"], "unii": ["L960UP2KRW"]}, "update_date": "04/23/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "63323-326-20", "generic_name": "Cefepime Hydrochloride Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": {"application_number": ["ANDA065441"], "brand_name": ["CEFEPIME"], "generic_name": ["CEFEPIME"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-326", "63323-340"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CEFEPIME HYDROCHLORIDE"], "rxcui": ["1665088", "1665093"], "spl_id": ["8c2fbf43-34bd-49d1-bda8-a2191c8bc54b"], "spl_set_id": ["5e1695e0-1310-4cd8-a5da-ad1a7dcd1792"], "package_ndc": ["63323-326-21", "63323-326-20", "63323-340-21", "63323-340-20"], "unii": ["I8X1O0607P"]}, "update_date": "02/10/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cefepime Hydrochloride, Injection, 1 g (NDC 63323-326-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-737-90", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": {"application_number": ["ANDA072369"], "brand_name": ["FLURAZEPAM HYDROCHLORIDE"], "generic_name": ["FLURAZEPAM HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-737", "62135-736"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLURAZEPAM HYDROCHLORIDE"], "rxcui": ["1298088", "1298091"], "spl_id": ["25893c92-c8f1-567a-e063-6294a90a00d4"], "spl_set_id": ["8f476891-1346-4e8c-ac1b-f8cbdc64f5a1"], "package_ndc": ["62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90"], "unii": ["756RDM536M"]}, "update_date": "02/02/2026", "therapeutic_category": ["Neurology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-203-11", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA212803"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-203"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["b06d36f6-507c-4b04-b79d-d6370a30a551", "53a09c30-7295-4337-89a4-93d3748d6ea3"], "spl_set_id": ["a2e3c748-28ce-4c50-a182-721912919840", "3aadaca7-3661-4bfe-87f8-6368e4ab6536"], "package_ndc": ["71288-203-02", "71288-203-03", "71288-203-04", "71288-203-05", "71288-203-10", "71288-203-11", "71288-203-91", "71288-203-92", "71288-203-93", "71288-203-94"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/23/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2430-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": {"application_number": ["NDA021514"], "brand_name": ["METHYLPHENIDATE TRANSDERMAL SYSTEM"], "generic_name": ["METHYLPHENIDATE"], "manufacturer_name": ["PADAGIS US LLC"], "product_ndc": ["0574-2430", "0574-2410", "0574-2415", "0574-2420"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TRANSDERMAL"], "substance_name": ["METHYLPHENIDATE"], "rxcui": ["753436", "753438", "753440", "753441"], "spl_id": ["b743ef45-2fc0-4086-8a02-6078e6a09eaa"], "spl_set_id": ["7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb"], "package_ndc": ["0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65"], "nui": ["N0000175739", "N0000175729"], "pharm_class_epc": ["Central Nervous System Stimulant [EPC]"], "pharm_class_pe": ["Central Nervous System Stimulation [PE]"], "unii": ["207ZZ9QZ49"]}, "update_date": "05/07/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/29/2024", "change_date": "02/11/2026", "package_ndc": "0406-1170-03", "generic_name": "Naltrexone Hydrochloride Tablet", "contact_info": "800-325-8888", "resolved_note": "Available", "openfda": {"application_number": ["ANDA076264"], "brand_name": ["NALTREXONE HYDROCHLORIDE"], "generic_name": ["NALTREXONE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-1170"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["NALTREXONE HYDROCHLORIDE"], "rxcui": ["1483744"], "spl_id": ["9ed13551-325e-4b82-a266-72fc89ed27dc"], "spl_set_id": ["06ff2d5a-e62b-4fa4-bbdb-01938535bc65"], "package_ndc": ["0406-1170-03", "0406-1170-01"], "unii": ["Z6375YW9SF"]}, "update_date": "02/11/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Tablet", "presentation": "Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-03)", "company_name": "SpecGx LLC", "status": "Resolved", "source": "drug_shortages"}
{"discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "69516-010-30", "generic_name": "Obeticholic Acid Tablet", "contact_info": "1-844-782-4278", "related_info": "Business decision. Products will not be available after November 14, 2025.", "update_date": "09/19/2025", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Tablet", "presentation": "Ocaliva, Tablet, 10 mg (NDC 69516-010-30)", "company_name": "Intercept Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-169-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA203895"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-169", "55150-167", "55150-168", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRACAUDAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "71225-126-05", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-566-2505", "availability": "Available", "openfda": {"application_number": ["ANDA212791"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Slayback Pharma LLC"], "product_ndc": ["71225-126"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718900", "1718906", "1718909"], "spl_id": ["027725dc-e468-446c-b702-ab0f8a9e3be5"], "spl_set_id": ["e5d28ed8-e427-4850-81aa-98702d3b6a5d"], "package_ndc": ["71225-126-02", "71225-126-05", "71225-126-03", "71225-126-06", "71225-126-01", "71225-126-04"], "unii": ["1018WH7F9I"]}, "update_date": "09/17/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)", "company_name": "Slayback Pharma", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-02", "generic_name": "Furosemide Injection", "contact_info": "Sagent Pharmaceuticals: 866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA213902"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-311"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["222ce48f-2856-4be2-b16f-6fca38c0dceb"], "spl_set_id": ["d63c1277-dd7e-4d21-9e80-68143f55e2dc"], "package_ndc": ["25021-311-02", "25021-311-04", "25021-311-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "04/28/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6860-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA202835"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE"], "manufacturer_name": ["Mylan Pharmaceuticals Inc."], "product_ndc": ["0378-6860", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6859"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["63cd6f7c-f976-440e-a35f-e71a9f2fd1bb"], "spl_set_id": ["efbde0f6-b848-4664-b741-c6c630e66108"], "package_ndc": ["0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77"], "unii": ["SJT761GEGS"]}, "update_date": "05/05/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-821-05", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": {"application_number": ["ANDA201835"], "brand_name": ["METHYLPREDNISOLONE ACETATE"], "generic_name": ["METHYLPREDNISOLONE ACETATE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-821", "25021-820"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE"], "substance_name": ["METHYLPREDNISOLONE ACETATE"], "rxcui": ["1358610", "1358617"], "spl_id": ["13e1ca54-4fc4-4e93-a52d-c9320865e3cb"], "spl_set_id": ["f98314ea-a4e4-4f78-987b-3e9b45a08bb4"], "package_ndc": ["25021-820-05", "25021-820-10", "25021-821-05"], "unii": ["43502P7F0P"]}, "update_date": "04/23/2026", "therapeutic_category": ["Rheumatology"], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)", "company_name": "Sagent Pharmaceuticals", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "66993-212-38", "generic_name": "Nilutamide Tablet", "contact_info": "847-283-7921", "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Nilandron, Tablet, 150 mg (NDC 66993-212-38)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "0641-6008-10", "generic_name": "Bumetanide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.", "openfda": {"application_number": ["ANDA079196"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6008", "0641-6007"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["99d2fc38-7e1e-4209-aa57-089794eda8a6"], "spl_set_id": ["681b5e9d-e2c7-4f29-aaad-e06d4a528c11"], "package_ndc": ["0641-6007-01", "0641-6007-10", "0641-6008-01", "0641-6008-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": {"application_number": ["ANDA077856"], "brand_name": ["CLONAZEPAM"], "generic_name": ["CLONAZEPAM"], "manufacturer_name": ["Solco Healthcare LLC"], "product_ndc": ["43547-407", "43547-406", "43547-408"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["CLONAZEPAM"], "rxcui": ["197527", "197528", "197529"], "spl_id": ["dc17b9d4-2890-4f6c-8476-daa39d0cbc9c"], "spl_set_id": ["4acbb7a9-4db5-4497-b8db-9f358b3f6fb4"], "package_ndc": ["43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["5PE9FDE8GB"]}, "update_date": "05/05/2026", "therapeutic_category": ["Neurology", "Pediatric", "Psychiatry"], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "55150-222-20", "generic_name": "Etomidate Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA206126"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-222", "55150-221"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["278b160e-cdc4-451e-9405-cb001f443680"], "spl_set_id": ["0820f15a-046b-4185-a2b3-2e4051ee3d82"], "package_ndc": ["55150-221-10", "55150-222-20"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"presentation": "Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)", "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0409-7620-03", "generic_name": "Heparin Sodium Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "05/08/2026", "therapeutic_category": ["Hematology"], "status": "Current", "dosage_form": "Injection", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4283-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["ANDA088295"], "brand_name": ["LIDOCAINE HYDROCHLORIDE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-4283"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["RETROBULBAR", "TOPICAL"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010844"], "spl_id": ["499e9cfa-ea8d-487c-a8b3-fd7e1917d25f"], "spl_set_id": ["89a4bd73-89f4-4fd7-2c9f-921e1da8f96b"], "package_ndc": ["0409-4283-11", "0409-4283-25", "0409-4283-01"], "unii": ["V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "49702-260-55", "generic_name": "Maraviroc Solution", "contact_info": "877-844-8872", "related_info": "The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026.", "openfda": {"application_number": ["NDA208984"], "brand_name": ["SELZENTRY"], "generic_name": ["MARAVIROC"], "manufacturer_name": ["ViiV Healthcare Company"], "product_ndc": ["49702-260", "49702-223", "49702-224"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "rxcui": ["728223", "728225", "729201", "729203", "1857921", "1857925"], "spl_id": ["c3a27122-8cd6-4889-a1ef-7ef629c270b3"], "spl_set_id": ["46f30ac5-c96b-429e-976d-8c5ee1c0761b"], "package_ndc": ["49702-223-18", "49702-224-18", "49702-260-55"], "nui": ["N0000175572", "N0000175445"], "pharm_class_epc": ["CCR5 Co-receptor Antagonist [EPC]"], "pharm_class_moa": ["Chemokine Co-receptor 5 Antagonists [MoA]"], "unii": ["MD6P741W8A"]}, "update_date": "01/20/2026", "therapeutic_category": ["Antiviral"], "dosage_form": "Solution", "presentation": "Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton  (NDC 49702-260-55)", "company_name": "ViiV Healthcare Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "71357-009-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA214805"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE INJECTION, USP, 400 MEQ/100 ML"], "manufacturer_name": ["MILLA PHARMACEUTICALS INC."], "product_ndc": ["71357-009", "71357-007", "71357-008"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE"], "rxcui": ["237371", "312965"], "spl_id": ["47d8d0e7-6db5-950d-e063-6294a90ab1bf"], "spl_set_id": ["1ea1466d-a492-4056-e063-6394a90a80bf"], "package_ndc": ["71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10"], "unii": ["4550K0SC9B"]}, "update_date": "05/15/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)", "company_name": "Milla Pharmaceuticals", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "69489-721-30", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA018738"], "brand_name": ["EXELDERM"], "generic_name": ["SULCONAZOLE NITRATE"], "manufacturer_name": ["Journey Medical Corporation"], "product_ndc": ["69489-721"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["SULCONAZOLE NITRATE"], "rxcui": ["208118", "313125"], "spl_id": ["af026933-9a3d-4027-90f6-57fe4349d11e"], "spl_set_id": ["5b73e83e-8d3c-4d96-b4f6-9f854430add8"], "package_ndc": ["69489-721-30", "69489-721-05"], "unii": ["1T89100D5U"]}, "update_date": "05/08/2026", "therapeutic_category": ["Dermatology"], "dosage_form": "Solution", "presentation": "Exelderm, Solution, 1.0% 30 mL (NDC 69489-721-30)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-41", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0017", "0338-0023"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618"], "spl_id": ["31bb4a5f-733e-4354-9fbf-138dede4db0f"], "spl_set_id": ["3bb406a9-f5cb-403a-b1bb-5c4facbea3d5"], "package_ndc": ["0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)", "company_name": "Baxter Healthcare", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7809-24", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["NDA018826"], "brand_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "generic_name": ["DOPAMINE HYDROCHLORIDE IN DEXTROSE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-7809", "0409-7810", "0409-0042", "0409-1858"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DOPAMINE HYDROCHLORIDE"], "spl_id": ["188ce800-ff3a-4b22-9a95-2273c3bc99ae"], "spl_set_id": ["08f23f6e-150d-45ea-098e-f2edf64c21a1"], "package_ndc": ["0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12"], "unii": ["7L3E358N9L"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA089646"], "brand_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["EPINEPHRINE", "LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1010688", "1010745", "1010751", "1010759", "1867996", "1867998"], "spl_id": ["c8636a3b-5a45-4584-a9ea-85f506901337"], "spl_set_id": ["2f94f711-14c4-48ec-c5a3-c5ec4b8e8729"], "package_ndc": ["0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10"], "nui": ["N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647"], "pharm_class_moa": ["Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]"], "pharm_class_epc": ["alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]"], "pharm_class_cs": ["Catecholamines [CS]"], "unii": ["YKH834O4BH", "V13007Z41A"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0005-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": ["Transplant"], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2 mg (NDC 0378-0005-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-10", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018667"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-6102"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c529b0df-a5cb-46ce-8131-38674ee756af", "0d4a39f2-904e-434a-9af1-83bb4febf124"], "spl_set_id": ["aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7"], "package_ndc": ["0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/15/2023", "package_ndc": "39822-4200-6", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-390-4411", "availability": "Available", "related_info": "Tamarang is the application holder and X-Gen is the distributor/labeler", "openfda": {"application_number": ["ANDA091115"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-4200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["eedcfb07-4e23-3152-e053-2995a90a6e6a"], "spl_set_id": ["b73f192c-2912-4ec3-9b4f-05a58d9b35ba"], "package_ndc": ["39822-4200-1", "39822-4200-2", "39822-4200-5", "39822-4200-6"], "unii": ["I65MW4OFHZ"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "63323-358-10", "generic_name": "Caspofungin Acetate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA206110"], "brand_name": ["CASPOFUNGIN ACETATE"], "generic_name": ["CASPOFUNGIN ACETATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-358", "63323-356"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CASPOFUNGIN ACETATE"], "rxcui": ["828539", "828755"], "spl_id": ["7cdf103b-418f-42a8-bd1b-ebfd8027124a"], "spl_set_id": ["e76d8d83-3691-451c-a32c-d91448c54d16"], "package_ndc": ["63323-356-01", "63323-356-10", "63323-358-01", "63323-358-10"], "unii": ["VUW370O5QE"]}, "update_date": "01/12/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1660-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA021038"], "brand_name": ["PRECEDEX"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892"], "spl_id": ["d21964a3-39ba-46b8-bbf9-de4b2a5fd9b2"], "spl_set_id": ["548a88c0-afda-427e-75ac-5af0cfa2224c"], "package_ndc": ["0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12"], "unii": ["1018WH7F9I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-736-90", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": {"application_number": ["ANDA072368"], "brand_name": ["FLURAZEPAM HYDROCHLORIDE"], "generic_name": ["FLURAZEPAM HYDROCHLORIDE"], "manufacturer_name": ["Chartwell RX, LLC"], "product_ndc": ["62135-736", "62135-737"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FLURAZEPAM HYDROCHLORIDE"], "rxcui": ["1298088", "1298091"], "spl_id": ["25893c92-c8f1-567a-e063-6294a90a00d4"], "spl_set_id": ["8f476891-1346-4e8c-ac1b-f8cbdc64f5a1"], "package_ndc": ["62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90"], "unii": ["756RDM536M"]}, "update_date": "02/02/2026", "therapeutic_category": ["Oncology", "Other"], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "50458-290-01", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA020083"], "brand_name": ["SPORANOX"], "generic_name": ["ITRACONAZOLE"], "manufacturer_name": ["Janssen Pharmaceuticals, Inc."], "product_ndc": ["50458-290"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["ITRACONAZOLE"], "rxcui": ["311204", "833164"], "spl_id": ["b5d1c275-8665-4f63-8232-e34a02c998c7"], "spl_set_id": ["a4d555fa-787c-40fb-bb7d-b0d4f7318fd0"], "package_ndc": ["50458-290-01", "50458-290-04", "50458-290-28"], "nui": ["N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113"], "pharm_class_epc": ["Azole Antifungal [EPC]"], "pharm_class_cs": ["Azoles [CS]"], "pharm_class_moa": ["Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]"], "unii": ["304NUG5GF4"]}, "update_date": "02/27/2026", "therapeutic_category": ["Anti-Infective", "Other"], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 50458-290-01)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8892-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers", "openfda": {"application_number": ["ANDA040440"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-8892", "0406-8891", "0406-8884", "0406-8885", "0406-8893", "0406-8894"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "1009145"], "spl_id": ["0d3fb5ba-ff79-4862-bc1d-45b8343e115b"], "spl_set_id": ["72ddd1c9-ddbd-4c95-acd9-003189a353a3"], "package_ndc": ["0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-618-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA202725"], "brand_name": ["QUINAPRIL"], "generic_name": ["QUINAPRIL HYDROCHLORIDE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-618", "65862-617", "65862-619", "65862-620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["QUINAPRIL HYDROCHLORIDE"], "rxcui": ["312748", "312749", "312750", "314203"], "spl_id": ["5263abd5-ce46-4918-9bb0-9632861bcbc9"], "spl_set_id": ["93e6e668-5306-4f26-81d8-cbc3a7a5e787"], "package_ndc": ["65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78"], "unii": ["33067B3N2M"]}, "update_date": "04/15/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4911-34", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": ["Anesthesia", "Neurology", "Pediatric"], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2)  (NDC 0409-4911-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-26", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA018893"], "brand_name": ["SODIUM ACETATE"], "generic_name": ["SODIUM ACETATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-3299"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM ACETATE ANHYDROUS"], "rxcui": ["237371"], "spl_id": ["4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb"], "spl_set_id": ["abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f"], "package_ndc": ["0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26"], "unii": ["NVG71ZZ7P0"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition"], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "12/08/2020", "package_ndc": "0990-7171-17", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "ICU Medical acquired these products from Hospira, a Pfizer company. For questions or inquiries regarding these Hospira labeled products, please contact ICU Medical. Legacy Hospira NDC 0409-7171-17", "openfda": {"application_number": ["NDA020041"], "brand_name": ["AMINOSYN II"], "generic_name": ["ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE"], "manufacturer_name": ["ICU Medical Inc."], "product_ndc": ["0990-7171", "0990-7172"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ACETYL L-TYROSINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "PROLINE", "SERINE", "THREONINE", "TRYPTOPHAN", "VALINE"], "rxcui": ["800188", "800192", "800237", "800241"], "spl_id": ["ea005122-3350-4609-83ad-9d093f25162f"], "spl_set_id": ["5b426208-f090-4650-86c3-89040ba45c2d"], "package_ndc": ["0990-7172-17", "0990-7171-17"], "nui": ["N0000175780", "M0000922"], "pharm_class_epc": ["Amino Acid [EPC]"], "pharm_class_cs": ["Amino Acids [CS]"], "unii": ["2ZD004190S", "94ZLA3W45F", "3KX376GY7L", "DA8G610ZO5", "HG18B9YRS7", "TE7660XO1C", "8DUH1N11BX", "4QD397987E", "GMW67QNF9C", "AE28F7PNPL", "47E5O17Y3R", "30KYC7MIAI", "TTL6G7LIWZ", "OF5P57N2ZX", "452VLY9402", "04Y7590D77", "9DLQ4CIU6V"]}, "update_date": "05/08/2026", "therapeutic_category": ["Gastroenterology"], "dosage_form": "Injection", "presentation": "Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-1473-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA075629"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-1473", "0406-1445"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091145", "1091225"], "spl_id": ["7bfd27d5-70ed-440b-949a-140aa3304d4a"], "spl_set_id": ["ed004cf0-eb23-43d2-96dc-20c4ad63824f"], "package_ndc": ["0406-1445-01", "0406-1473-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/13/2025", "update_type": "New", "initial_posting_date": "08/13/2025", "package_ndc": "66658-231-01", "generic_name": "Palivizumab Injection", "contact_info": "866-773-5274", "related_info": "Discontinuation of the manufacture of the drug. Product expected to be available through July 2026.", "openfda": {"application_number": ["BLA103770"], "brand_name": ["SYNAGIS"], "generic_name": ["PALIVIZUMAB"], "manufacturer_name": ["Swedish Orphan Biovitrum AB (publ)"], "product_ndc": ["66658-231", "66658-230"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR"], "substance_name": ["PALIVIZUMAB"], "rxcui": ["1657341", "1657343", "1657361", "1657362"], "spl_id": ["48e6af70-cd93-3f1d-e063-6394a90a8104"], "spl_set_id": ["3a0096c7-8139-44cd-bba4-520ab05c2cb2"], "package_ndc": ["66658-231-01", "66658-230-01"], "nui": ["M0001357", "N0000175615", "N0000175623"], "pharm_class_cs": ["Antibodies, Monoclonal [CS]"], "pharm_class_moa": ["Fusion Protein Inhibitors [MoA]"], "pharm_class_epc": ["Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]"], "unii": ["DQ448MW7KS"]}, "update_date": "08/13/2025", "therapeutic_category": ["Antiviral"], "dosage_form": "Injection", "presentation": "Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)", "company_name": "Swedish Orphan Biovitrum AB", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/01/2017", "package_ndc": "76329-3352-1", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": {"application_number": ["ANDA203449"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["International Medication Systems, Limited"], "product_ndc": ["76329-3352"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["792582"], "spl_id": ["74a86dc7-0929-40d0-9661-9f9063a8fd7d"], "spl_set_id": ["77698221-a01d-4568-a7bc-d3d4e982875d"], "package_ndc": ["76329-3352-1"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "72485-201-01", "generic_name": "Azacitidine Injection", "contact_info": "1-732-637-1971", "availability": "Available", "openfda": {"application_number": ["ANDA207518"], "brand_name": ["AZACITIDINE"], "generic_name": ["AZACITIDINE"], "manufacturer_name": ["Armas Pharmaceuticals Inc."], "product_ndc": ["72485-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS", "SUBCUTANEOUS"], "substance_name": ["AZACITIDINE"], "rxcui": ["485246"], "spl_id": ["ca345575-17a6-43a3-aa02-3d4bb9d136c5"], "spl_set_id": ["5c0a2d5f-8c34-4c04-8425-7543965cedd4"], "package_ndc": ["72485-201-01"], "nui": ["N0000000233", "N0000175595"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "unii": ["M801H13NRU"]}, "update_date": "02/18/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 72485-201-01)", "company_name": "Armas Pharmaceuticals Inc", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0520-76", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-643-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["M023"], "brand_name": ["ACTIDOSE"], "generic_name": ["ACTIVATED CHARCOAL"], "manufacturer_name": ["Padagis US LLC"], "product_ndc": ["0574-0520"], "product_type": ["HUMAN OTC DRUG"], "route": ["ORAL"], "substance_name": ["ACTIVATED CHARCOAL"], "rxcui": ["309150", "1251411"], "spl_id": ["2e960a62-b5d8-4fad-a17c-9d07bdbe06d1"], "spl_set_id": ["76e4fe6a-afd4-4f68-b12d-0b094f750615"], "package_ndc": ["0574-0520-04", "0574-0520-08", "0574-0520-74", "0574-0520-76"], "unii": ["2P3VWU3H10"]}, "update_date": "05/15/2026", "therapeutic_category": ["Other"], "dosage_form": "Oral Suspension", "presentation": "Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76)", "company_name": "Padagis US LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-100-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 100 ug (NDC 72305-100-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "66794-162-02", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-414-1901", "availability": "Available", "openfda": {"application_number": ["ANDA204393"], "brand_name": ["MITIGO"], "generic_name": ["MORPHINE SULFATE"], "manufacturer_name": ["Piramal Critical Care, Inc."], "product_ndc": ["66794-162", "66794-160"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INTRATHECAL"], "substance_name": ["MORPHINE SULFATE"], "rxcui": ["1731522", "1731998", "2055307", "2055311"], "spl_id": ["495a6a51-d35d-2b96-e063-6394a90ac5f3"], "spl_set_id": ["728f3d83-9a63-0c1f-e053-2a91aa0ac7db"], "package_ndc": ["66794-160-02", "66794-162-02"], "unii": ["X3P646A2J0"]}, "update_date": "05/07/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)", "company_name": "Piramal Critical Care Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "11/21/2023", "package_ndc": "39822-5550-6", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "866-390-4411", "availability": "Available", "openfda": {"application_number": ["ANDA040737"], "brand_name": ["PROMETHAZINE HYDROCHLORIDE"], "generic_name": ["PROMETHAZINE HYDROCHLORIDE"], "manufacturer_name": ["XGen Pharmaceuticals DJB, Inc."], "product_ndc": ["39822-5550"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["PROMETHAZINE HYDROCHLORIDE"], "rxcui": ["992858"], "spl_id": ["0e860109-725f-1c28-e063-6394a90a50ef"], "spl_set_id": ["b6f6698f-f23c-452a-9b38-bbb96ab88ae4"], "package_ndc": ["39822-5550-5", "39822-5550-6"], "unii": ["R61ZEH7I1I"]}, "update_date": "05/08/2026", "therapeutic_category": ["Analgesia/Addiction", "Gastroenterology", "Other", "Pulmonary/Allergy"], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-05", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "05/12/2026", "therapeutic_category": ["Analgesia/Addiction", "Pediatric"], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/09/2026", "update_type": "New", "initial_posting_date": "04/09/2026", "package_ndc": "0069-3070-30", "generic_name": "Azithromycin Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA050784"], "brand_name": ["ZITHROMAX"], "generic_name": ["AZITHROMYCIN DIHYDRATE"], "manufacturer_name": ["Pfizer Laboratories Div Pfizer Inc"], "product_ndc": ["0069-3070", "0069-3060", "0069-3110", "0069-3120", "0069-3130", "0069-3140", "0069-4061"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AZITHROMYCIN DIHYDRATE"], "rxcui": ["105260", "141963", "211307", "212446", "226827", "248656", "308459", "308460", "749780", "749783", "750149", "750157"], "spl_id": ["e15f2173-8700-4392-96a4-8560772b6f8a"], "spl_set_id": ["db52b91e-79f7-4cc1-9564-f2eee8e31c45"], "package_ndc": ["0069-3060-30", "0069-3060-75", "0069-3060-86", "0069-3070-30", "0069-3070-75", "0069-3110-19", "0069-3120-19", "0069-3130-19", "0069-3140-19", "0069-4061-01", "0069-4061-75", "0069-4061-89"], "unii": ["5FD1131I7S"]}, "update_date": "04/09/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Tablet", "presentation": "Zithromax, Tablet, 500 mg (NDC 0069-3070-30)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA070552", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-025-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-175", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 25 ug (NDC 72305-025-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "0406-0136-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Allocation to all customers.", "openfda": {"application_number": ["ANDA202608"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["SpecGx LLC"], "product_ndc": ["0406-0136", "0406-0127", "0406-0154"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["2001565", "2001566", "2001568"], "spl_id": ["7a3a8731-e545-455e-83c3-888f4923e901"], "spl_set_id": ["b1b0f2ff-d9df-42ab-b471-226ecf97e075"], "package_ndc": ["0406-0127-01", "0406-0136-01", "0406-0154-01"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylin Er, Tablet, Extended Release, 36 mg (NDC 0406-0136-01)", "company_name": "SpecGx LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "71288-700-06", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA213453"], "brand_name": ["ROCURONIUM BROMIDE"], "generic_name": ["ROCURONIUM BROMIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-700", "71288-718"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ROCURONIUM BROMIDE"], "rxcui": ["1234995"], "spl_id": ["aad39c88-2e2c-49a6-aa13-de852483661f", "37295b13-65a4-40fa-8d6c-53aeb45e2939"], "spl_set_id": ["b23aa80e-2af2-4a66-92ed-b1c8863be704", "b9abaf64-760d-43e0-8669-a9ca70feab11"], "package_ndc": ["71288-700-91", "71288-700-92", "71288-718-91", "71288-718-92", "71288-700-05", "71288-700-06", "71288-718-10", "71288-718-11"], "unii": ["I65MW4OFHZ"]}, "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "72572-074-24", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "related_info": "Civica Label", "openfda": {"application_number": ["ANDA201692"], "brand_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "generic_name": ["CLINDAMYCIN IN 5 PERCENT DEXTROSE"], "manufacturer_name": ["Civica, Inc."], "product_ndc": ["72572-074", "72572-076"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CLINDAMYCIN"], "rxcui": ["309335", "309336"], "spl_id": ["e40b6e7f-1d37-4d0a-ace3-e5accc461e02"], "spl_set_id": ["80217bd6-2bc4-401c-9345-22532b36a24f"], "package_ndc": ["72572-074-01", "72572-074-24", "72572-076-01", "72572-076-24"], "nui": ["N0000009982", "N0000175443", "M0515779", "N0000175731"], "pharm_class_pe": ["Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]"], "pharm_class_epc": ["Lincosamide Antibacterial [EPC]"], "pharm_class_cs": ["Lincosamides [CS]"], "unii": ["3U02EL437C"]}, "update_date": "05/11/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)", "company_name": "Sandoz Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0183-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA200795"], "brand_name": ["GEMCITABINE"], "generic_name": ["GEMCITABINE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-0183", "0409-0181", "0409-0182"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["GEMCITABINE HYDROCHLORIDE"], "rxcui": ["1720960", "1720975", "1720977"], "spl_id": ["3a284abb-8c57-47dc-a138-5a6e6ab92b05", "9c9d382b-8f9a-4fbe-a231-44d73ec83b61"], "spl_set_id": ["dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8"], "package_ndc": ["0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25"], "unii": ["U347PV74IL"]}, "update_date": "09/11/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/03/2025", "update_type": "New", "initial_posting_date": "06/03/2025", "package_ndc": "65862-064-99", "generic_name": "Metoprolol Tartrate Tablet", "contact_info": "866-850-2876", "related_info": "Permanent discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["ANDA077739"], "brand_name": ["METOPROLOL TARTRATE"], "generic_name": ["METOPROLOL TARTRATE"], "manufacturer_name": ["Aurobindo Pharma Limited"], "product_ndc": ["65862-064", "65862-062", "65862-063"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METOPROLOL TARTRATE"], "rxcui": ["866511", "866514", "866924"], "spl_id": ["d265c99d-8e77-4a78-b542-15e957d9d335"], "spl_set_id": ["2b705cb6-cb75-4c2a-907a-4bd45d18bc2c"], "package_ndc": ["65862-062-01", "65862-062-99", "65862-063-60", "65862-063-01", "65862-063-99", "65862-064-60", "65862-064-01", "65862-064-99"], "unii": ["W5S57Y3A5L"]}, "update_date": "06/03/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-99)", "company_name": "Aurobindo Pharma USA", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "72205-102-01", "generic_name": "Bumetanide Injection", "contact_info": "Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": {"application_number": ["ANDA215364"], "brand_name": ["BUMETANIDE"], "generic_name": ["BUMETANIDE"], "manufacturer_name": ["Novadoz Pharmaceuticals LLC"], "product_ndc": ["72205-102", "72205-101"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["BUMETANIDE"], "rxcui": ["282486", "1727569"], "spl_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "spl_set_id": ["387edfd4-be85-41cd-8a6d-14e6a022b5a9"], "package_ndc": ["72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["0Y2S3XUQ5H"]}, "update_date": "04/02/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)", "company_name": "MSN Laboratories Private Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "72485-509-10", "generic_name": "Etomidate Injection", "contact_info": "908-803-2586", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586", "openfda": {"application_number": ["ANDA215028"], "brand_name": ["ETOMIDATE"], "generic_name": ["ETOMIDATE"], "manufacturer_name": ["Armas Pharmaceuticals Inc."], "product_ndc": ["72485-509", "72485-508"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["ETOMIDATE"], "rxcui": ["1654006", "1654008"], "spl_id": ["7444860b-36c1-459d-94ba-d7301d9dc2ca"], "spl_set_id": ["75467058-da52-48fa-8d4e-e1025ec7d461"], "package_ndc": ["72485-508-01", "72485-508-10", "72485-509-01", "72485-509-10"], "nui": ["N0000175975", "N0000175681"], "pharm_class_pe": ["General Anesthesia [PE]"], "pharm_class_epc": ["General Anesthetic [EPC]"], "unii": ["Z22628B598"]}, "update_date": "04/16/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70860-701-03", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Athenex is not active, supplying through Sagent NDC 25021-701-01", "update_date": "04/27/2026", "therapeutic_category": ["Analgesia/Addiction"], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-03)", "company_name": "Gland Pharma Limited", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-485-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5555-01", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": {"application_number": ["ANDA202981"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-5555"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868469"], "spl_id": ["e3a44e63-8594-40b6-a3fa-d135b3149661", "bcb3a2dc-1a3f-4ac7-8ea2-426f0771c246"], "spl_set_id": ["0c24b592-4bc8-456f-acac-9c9525844a06", "ea9f4498-0d43-4043-8dd1-f22537841c21"], "package_ndc": ["0409-5555-11", "0409-5555-01", "0409-5555-12", "0409-5555-02"], "unii": ["8MDF5V39QO"]}, "update_date": "05/08/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-249-50", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA207183"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-249", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-250"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INFILTRATION", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["39649703-e633-4a20-ba71-0c04dbf8ff2a"], "spl_set_id": ["ffecf450-1f01-4721-8e10-251385852612"], "package_ndc": ["55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-113-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Available", "openfda": {"application_number": ["ANDA215771"], "brand_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "generic_name": ["DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE"], "manufacturer_name": ["Granules Pharmaceuticals Inc."], "product_ndc": ["70010-113", "70010-111", "70010-112", "70010-114", "70010-115", "70010-116", "70010-117"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE"], "rxcui": ["541363", "541878", "541892", "577957", "577961", "687043", "1009145"], "spl_id": ["2fab399e-2a43-5134-e063-6294a90ae09a"], "spl_set_id": ["b0b4eccc-34c7-483d-966f-82d588358e1b"], "package_ndc": ["70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03"], "unii": ["6DPV8NK46S", "O1ZPV620O4", "JJ768O327N", "G83415V073"]}, "update_date": "04/20/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)", "company_name": "Granules Pharmaceuticals Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "46163-300-10", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "800-323-5188", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA078177"], "brand_name": ["SODIUM CHLORIDE"], "generic_name": ["SODIUM CHLORIDE"], "manufacturer_name": ["Fresenius Medical Care de Mexico, S.A. de C.V."], "product_ndc": ["46163-300"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM CHLORIDE"], "rxcui": ["1807639"], "spl_id": ["4e7bc97a-4d31-b66d-e063-6294a90a294c"], "spl_set_id": ["9a1220fb-6853-45ae-838c-10d8596e1af7"], "package_ndc": ["46163-300-10"], "unii": ["451W47IQ8X"]}, "update_date": "06/10/2025", "therapeutic_category": ["Gastroenterology", "Other", "Renal"], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 46163-300-10)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-1510-31", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": {"application_number": ["NDA016730"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE"], "manufacturer_name": ["B. Braun Medical Inc."], "product_ndc": ["0264-1510"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795609", "1795616", "1795618"], "spl_id": ["0a144591-6cfa-4aed-a067-c95aebc29057"], "spl_set_id": ["60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5"], "package_ndc": ["0264-1510-36", "0264-1510-31", "0264-1510-32"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)", "company_name": "B. Braun Medical Inc.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-088-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6059-01", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": {"application_number": ["ANDA075243"], "brand_name": ["MIDAZOLAM"], "generic_name": ["MIDAZOLAM"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0641-6059", "0641-6057", "0641-6056", "0641-6061", "0641-6063", "0641-6060"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["MIDAZOLAM HYDROCHLORIDE"], "rxcui": ["311700", "311702"], "spl_id": ["559c03fb-24ea-4b7b-8afd-e33cb3a2340a"], "spl_set_id": ["575d8bf0-7af7-427c-a231-966e2a5e070d"], "package_ndc": ["0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10"], "unii": ["W7TTW573JJ"]}, "update_date": "05/12/2026", "therapeutic_category": ["Anesthesia", "Neurology"], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "05/07/2026", "update_type": "New", "initial_posting_date": "05/07/2026", "package_ndc": "63323-574-93", "generic_name": "Icatibant Acetate Injection", "contact_info": "847-550-2300", "related_info": "Discontinuation of the manufacturer of the drug", "openfda": {"application_number": ["ANDA208317"], "brand_name": ["ICATIBANT"], "generic_name": ["ICATIBANT"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-574"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["SUBCUTANEOUS"], "substance_name": ["ICATIBANT ACETATE"], "rxcui": ["1148141"], "spl_id": ["d1c9afa7-c4ac-4739-85f1-2ae82440210c"], "spl_set_id": ["52c12c15-c00b-4efc-952d-1425c907706a"], "package_ndc": ["63323-574-01", "63323-574-86", "63323-574-93"], "unii": ["325O8467XK"]}, "update_date": "05/07/2026", "therapeutic_category": ["Hematology"], "dosage_form": "Injection", "presentation": "Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-198-30", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA205612"], "brand_name": ["ROPIVACAINE HYDROCHLORIDE"], "generic_name": ["ROPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Eugia US LLC"], "product_ndc": ["55150-198", "55150-195", "55150-196", "55150-197", "55150-199", "55150-200", "55150-201"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "PERINEURAL"], "substance_name": ["ROPIVACAINE HYDROCHLORIDE"], "rxcui": ["905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483"], "spl_id": ["1e5f1368-058a-492c-b4b7-d9329a7745e2"], "spl_set_id": ["3763b7b6-da49-4658-b93d-28f5da24d09e"], "package_ndc": ["55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20"], "unii": ["V910P86109"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)", "company_name": "Eugia US LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/12/2022", "package_ndc": "68118-100-01", "generic_name": "Streptozocin Powder, For Solution", "related_info_link": "https://www.fda.gov/media/187353/download?attachment", "contact_info": "USSZTOrders@esteve.com", "availability": "Available", "openfda": {"brand_name": ["ZANOSAR"], "generic_name": ["STREPTOZOCIN"], "manufacturer_name": ["ESTEVE PHARMACEUTICALS, S.A."], "product_ndc": ["68118-100"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["STREPTOZOCIN"], "rxcui": ["207948", "239180"], "spl_id": ["509e4d98-ccef-8a7f-e063-6394a90a5a78"], "spl_set_id": ["f31d3bff-6fc6-c35f-e053-2995a90a596b"], "package_ndc": ["68118-100-01"], "nui": ["N0000000236", "N0000175558"], "pharm_class_moa": ["Alkylating Activity [MoA]"], "pharm_class_epc": ["Alkylating Drug [EPC]"], "unii": ["5W494URQ81"]}, "update_date": "05/06/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Powder, For Solution", "presentation": "Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)", "company_name": "ESTEVE PHARMACEUTICALS, S.A.", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1746-30", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": {"application_number": ["NDA016964"], "brand_name": ["MARCAINE WITH EPINEPHRINE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["0409-1746", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE"], "rxcui": ["1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614"], "spl_id": ["94e0b63b-40eb-4cbf-ae95-99c429816d82"], "spl_set_id": ["67578b56-7540-487e-1fba-481255620e78"], "package_ndc": ["0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-74", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA209448"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-824"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795477", "1795480", "1795481"], "spl_id": ["0591ab74-99a6-40ee-af96-80bc2ef423dc"], "spl_set_id": ["3b8f2692-4371-4f1a-95af-b41842131fdd"], "package_ndc": ["63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76"], "unii": ["LX22YL083G"]}, "update_date": "04/23/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0902-18", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-533-4535", "availability": "Available", "openfda": {"application_number": ["NDA050441"], "brand_name": ["CLEOCIN PHOSPHATE"], "generic_name": ["CLINDAMYCIN PHOSPHATE"], "manufacturer_name": ["Pharmacia & Upjohn Company LLC"], "product_ndc": ["0009-0902", "0009-0870", "0009-0775", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["CLINDAMYCIN PHOSPHATE"], "rxcui": ["685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582", "205964", "309335", "309336", "309339", "685574"], "spl_id": ["dd9fa453-a2ca-4a53-b39b-c59a44a888aa"], "spl_set_id": ["05a75685-0af5-407c-ac57-e380c882b49d"], "package_ndc": ["0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01"], "unii": ["EH6D7113I8"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anti-Infective"], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)", "company_name": "Pfizer Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "13668-383-05", "generic_name": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet", "contact_info": "908-280-3333", "related_info": "A business decision was made to discontinue manufacture of the product.", "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-05)", "company_name": "Torrent Pharma Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-41", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": {"application_number": ["ANDA203428"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."], "product_ndc": ["23155-473"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["FUROSEMIDE"], "rxcui": ["1719286", "1719290", "1719291"], "spl_id": ["c14acada-333e-43bb-b1cf-81d569e3e918"], "spl_set_id": ["1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec"], "package_ndc": ["23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "04/07/2026", "update_type": "New", "initial_posting_date": "04/07/2026", "package_ndc": "61958-1701-1", "generic_name": "Idelalisib Tablet", "contact_info": "800-445-3235", "related_info": "Discontinuation in the manufacturing of the drug", "openfda": {"application_number": ["NDA205858"], "brand_name": ["ZYDELIG"], "generic_name": ["IDELALISIB"], "manufacturer_name": ["Gilead Sciences, Inc."], "product_ndc": ["61958-1701", "61958-1702"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["IDELALISIB"], "rxcui": ["1544465", "1544471", "1544473", "1544475"], "spl_id": ["ca3e7112-6dfe-403f-af6f-a0051e77d125"], "spl_set_id": ["efbdafa9-d18c-4e85-b4a2-1e620fc74e50"], "package_ndc": ["61958-1701-1", "61958-1702-1"], "nui": ["N0000175605", "N0000175082", "N0000190114"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]"], "unii": ["YG57I8T5M0"]}, "update_date": "04/07/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Tablet", "presentation": "Zydelig, Tablet, 100 mg (NDC 61958-1701-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-208-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["NDA017584"], "brand_name": ["LIDOCAINE"], "generic_name": ["LIDOCAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-208"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["LIDOCAINE HYDROCHLORIDE"], "rxcui": ["1737761"], "spl_id": ["289524c2-d0be-443d-aedf-39d621f217a5"], "spl_set_id": ["f1b26274-a55e-4321-b96c-ce0df830f205"], "package_ndc": ["63323-208-01", "63323-208-05"], "unii": ["V13007Z41A"]}, "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "06/13/2025", "update_type": "New", "initial_posting_date": "06/13/2025", "package_ndc": "0093-7201-98", "generic_name": "Pravastatin Sodium Tablet", "contact_info": "800-545-8800", "openfda": {"application_number": ["ANDA076056"], "brand_name": ["PRAVASTATIN SODIUM"], "generic_name": ["PRAVASTATIN SODIUM"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-7201", "0093-0771", "0093-7202"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["PRAVASTATIN SODIUM"], "rxcui": ["904458", "904467", "904475"], "spl_id": ["72579e23-23ef-4ab7-ad64-24d5ea7997eb"], "spl_set_id": ["99e0e848-f8f3-4b42-b880-8fbc42633948"], "package_ndc": ["0093-0771-98", "0093-0771-10", "0093-7201-98", "0093-7201-10", "0093-7202-98", "0093-7202-10"], "unii": ["3M8608UQ61"]}, "update_date": "06/13/2025", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Tablet", "presentation": "Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-98)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-924-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": {"application_number": ["ANDA212571"], "brand_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "generic_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "manufacturer_name": ["Mylan Institutional LLC"], "product_ndc": ["67457-924", "67457-925"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["1718906", "1718909"], "spl_id": ["b51a1fb0-fcee-4a76-9eaf-91c35813c242"], "spl_set_id": ["f140de5a-f13d-46b4-a742-049c63e474f5"], "package_ndc": ["67457-924-00", "67457-924-50", "67457-925-00", "67457-925-10"], "unii": ["1018WH7F9I"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "07/10/2025", "update_type": "New", "initial_posting_date": "07/10/2025", "package_ndc": "72305-175-90", "generic_name": "Levothyroxine Sodium Tablet", "contact_info": "888-899-7041", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["NDA021292"], "brand_name": ["EUTHYROX"], "generic_name": ["LEVOTHYROXINE SODIUM"], "manufacturer_name": ["Provell Pharmaceuticals, LLC"], "product_ndc": ["72305-175", "72305-025", "72305-050", "72305-075", "72305-088", "72305-100", "72305-112", "72305-125", "72305-137", "72305-150", "72305-200"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LEVOTHYROXINE SODIUM"], "rxcui": ["892246", "892251", "966153", "966160", "966166", "966173", "966177", "966182", "966187", "966196", "966202", "966207", "966220", "966221", "966222", "966224", "966225", "966248", "966249", "966253", "966270", "2104866"], "spl_id": ["8b98dc0b-b9fa-42eb-81a0-07b4679d9332"], "spl_set_id": ["bc3c6830-ba68-4ba3-9896-a12d0ad0b275"], "package_ndc": ["72305-025-30", "72305-025-90", "72305-050-30", "72305-050-90", "72305-075-30", "72305-075-90", "72305-088-30", "72305-088-90", "72305-100-30", "72305-100-90", "72305-112-30", "72305-112-90", "72305-125-30", "72305-125-90", "72305-137-30", "72305-137-90", "72305-150-30", "72305-150-90", "72305-175-30", "72305-175-90", "72305-200-30", "72305-200-90"], "unii": ["9J765S329G"]}, "update_date": "07/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Euthyrox, Tablet, 175 ug (NDC 72305-175-90)", "company_name": "EMD Serono, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-606-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": {"application_number": ["ANDA216266"], "brand_name": ["LISDEXAMFETAMINE DIMESYLATE"], "generic_name": ["LISDEXAMFETAMINE DIMESYLATE CAPSULES"], "manufacturer_name": ["Solco Healthcare US,LLC"], "product_ndc": ["43547-606", "43547-602", "43547-603", "43547-604", "43547-605", "43547-607", "43547-608"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["LISDEXAMFETAMINE DIMESYLATE"], "rxcui": ["854830", "854834", "854838", "854842", "854846", "854850", "1593856"], "spl_id": ["c17f13ef-4b2e-4b45-aff9-e79a2e8a7d53"], "spl_set_id": ["68b10d9f-ca3e-493d-a309-45f1d7e08061"], "package_ndc": ["43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10"], "unii": ["SJT761GEGS"]}, "update_date": "05/14/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "65219-368-02", "generic_name": "Lorazepam Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": {"application_number": ["ANDA217598"], "brand_name": ["LORAZEPAM"], "generic_name": ["LORAZEPAM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["65219-368"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAMUSCULAR", "INTRAVENOUS"], "substance_name": ["LORAZEPAM"], "rxcui": ["1665188"], "spl_id": ["5cd2d0d8-9639-4e96-aafd-4991ad35fabc", "462a13da-259a-40e7-bd5b-f7f42ae025b7"], "spl_set_id": ["b2487467-a63f-48b5-b0de-3a6ce6672d50", "462a13da-259a-40e7-bd5b-f7f42ae025b7"], "package_ndc": ["65219-368-01", "65219-368-02", "65219-368-14", "65219-368-24"], "nui": ["N0000175694", "M0002356"], "pharm_class_epc": ["Benzodiazepine [EPC]"], "pharm_class_cs": ["Benzodiazepines [CS]"], "unii": ["O26FZP769L"]}, "update_date": "04/23/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-31", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Not available at this time.", "openfda": {"application_number": ["ANDA070552", "NDA018304"], "brand_name": ["SENSORCAINE MPF"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457"], "spl_id": ["b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715"], "spl_set_id": ["e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8"], "package_ndc": ["63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31"], "unii": ["7TQO7W3VT8", "30Q7KI53AK"]}, "update_date": "05/08/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "08/01/2025", "update_type": "New", "initial_posting_date": "08/01/2025", "package_ndc": "0591-3916-68", "generic_name": "Clindamycin Phosphate; Benzoyl Peroxide Gel", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the product.", "openfda": {"application_number": ["ANDA205128"], "brand_name": ["CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE"], "generic_name": ["CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["0591-3916"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["TOPICAL"], "substance_name": ["BENZOYL PEROXIDE", "CLINDAMYCIN PHOSPHATE"], "rxcui": ["885131"], "spl_id": ["c2dcadb5-8ef3-4c6a-af4f-bf201184a6d0"], "spl_set_id": ["87622142-000b-460b-977e-92d6735f5337"], "package_ndc": ["0591-3916-68"], "unii": ["W9WZN9A0GM", "EH6D7113I8"]}, "update_date": "08/01/2025", "therapeutic_category": ["Dermatology"], "dosage_form": "Gel", "presentation": "Clindamycin Phosphate; Benzoyl Peroxide, Gel, 25 mg/1 g; 10 mg/1 g (NDC 0591-3916-68)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "06/10/2025", "update_type": "New", "initial_posting_date": "06/10/2025", "package_ndc": "0093-8035-05", "generic_name": "Glyburide Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {"application_number": ["ANDA074686"], "brand_name": ["GLYBURIDE"], "generic_name": ["GLYBURIDE"], "manufacturer_name": ["Teva Pharmaceuticals USA, Inc."], "product_ndc": ["0093-8035", "0093-8034", "0093-8036"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["GLYBURIDE"], "rxcui": ["310536", "310539", "314000"], "spl_id": ["d734cd0e-df7b-40a2-a511-fc04308a764d"], "spl_set_id": ["e84c0dfc-a4e9-4c89-b6ea-45732eb412f5"], "package_ndc": ["0093-8034-01", "0093-8035-01", "0093-8035-05", "0093-8036-01"], "nui": ["N0000175608", "M0020795"], "pharm_class_epc": ["Sulfonylurea [EPC]"], "pharm_class_cs": ["Sulfonylurea Compounds [CS]"], "unii": ["SX6K58TVWC"]}, "update_date": "06/10/2025", "therapeutic_category": ["Endocrinology/Metabolism"], "dosage_form": "Tablet", "presentation": "Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"discontinued_date": "08/04/2025", "update_type": "New", "initial_posting_date": "08/04/2025", "package_ndc": "45963-614-55", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "800-545-8800", "related_info": "Product not anticipated to be available beyond mid-late September 2025", "openfda": {"application_number": ["ANDA078589"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Actavis Pharma, Inc."], "product_ndc": ["45963-614"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["3bbdb61c-9194-416e-9034-5d2b11b5b8ee"], "spl_set_id": ["5e1fdcaa-918f-4cd8-9c7a-4c538d866198"], "package_ndc": ["45963-614-51", "45963-614-55"], "unii": ["042LAQ1IIS"]}, "update_date": "08/04/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-707-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": {"application_number": ["ANDA205327"], "brand_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Trigen Laboratories, LLC"], "product_ndc": ["13811-707", "13811-709", "13811-706", "13811-708", "13811-710"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461"], "spl_id": ["0944cf70-d59a-483b-9698-e96ef955a65a"], "spl_set_id": ["c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f"], "package_ndc": ["13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/04/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3294-46", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["ANDA070434"], "brand_name": ["FUROSEMIDE"], "generic_name": ["FUROSEMIDE"], "manufacturer_name": ["Hikma Pharmaceuticals USA Inc."], "product_ndc": ["0054-3294", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3298"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["FUROSEMIDE"], "rxcui": ["197730", "197731", "197732", "310429", "313988"], "spl_id": ["bc62ddda-7639-4090-99f0-7dd4d13518f3"], "spl_set_id": ["9e493331-dddd-496e-abf8-61747fb67aba"], "package_ndc": ["0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46"], "nui": ["N0000175366", "N0000175590"], "pharm_class_pe": ["Increased Diuresis at Loop of Henle [PE]"], "pharm_class_epc": ["Loop Diuretic [EPC]"], "unii": ["7LXU5N7ZO5"]}, "update_date": "05/12/2026", "therapeutic_category": ["Cardiovascular"], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-095-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": {"application_number": ["NDA216117"], "brand_name": ["RELEXXII"], "generic_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "manufacturer_name": ["Vertical Pharmaceuticals, LLC"], "product_ndc": ["68025-095", "68025-088", "68025-089", "68025-096", "68025-097", "68025-084", "68025-098"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["ORAL"], "substance_name": ["METHYLPHENIDATE HYDROCHLORIDE"], "rxcui": ["1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505"], "spl_id": ["86f477e9-07fc-466b-913e-1a4434c91df4"], "spl_set_id": ["22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d"], "package_ndc": ["68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30"], "unii": ["4B3SC438HI"]}, "update_date": "05/08/2026", "therapeutic_category": ["Psychiatry"], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "10122-100-10", "generic_name": "Deferiprone Tablet", "contact_info": "888-466-6505", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "11/07/2025", "therapeutic_category": ["Hematology"], "dosage_form": "Tablet", "presentation": "Ferriprox, Tablet, 500 mg (NDC 10122-100-10)", "company_name": "Chiesi USA, Inc.", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "81298-7620-3", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "833-268-5559", "availability": "Available", "openfda": {"application_number": ["ANDA216042"], "brand_name": ["SODIUM BICARBONATE"], "generic_name": ["SODIUM BICARBONATE INJECTION,"], "manufacturer_name": ["Long Grove Pharmaceuticals, LLC"], "product_ndc": ["81298-7620"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["SODIUM BICARBONATE"], "rxcui": ["1868486"], "spl_id": ["1a255946-a137-4e13-8203-65dd80b34872"], "spl_set_id": ["a26d709b-b294-4b02-9a88-7e840f099a33"], "package_ndc": ["81298-7620-1", "81298-7620-3"], "unii": ["8MDF5V39QO"]}, "update_date": "01/05/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Pediatric"], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)", "company_name": "Long Grove Pharmaceuticals LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "12/30/2020", "package_ndc": "63323-494-05", "generic_name": "Valproate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Checkwholesalers for inventory", "openfda": {"application_number": ["ANDA076539"], "brand_name": ["VALPROATE SODIUM"], "generic_name": ["VALPROATE SODIUM"], "manufacturer_name": ["Fresenius Kabi USA, LLC"], "product_ndc": ["63323-494"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["VALPROATE SODIUM"], "rxcui": ["1099648"], "spl_id": ["f09a2148-edd9-4918-8359-7554ed263d3a", "fff889dc-6006-43c2-be57-01b2a5724b26"], "spl_set_id": ["3dfb6da1-f66a-4618-9f74-d2d6c16c0b58", "c572ece7-03d3-4c2a-aeb5-61f2023b28ea"], "package_ndc": ["63323-494-41", "63323-494-16", "63323-494-01", "63323-494-05"], "unii": ["5VOM6GYJ0D"]}, "update_date": "04/23/2026", "therapeutic_category": ["Neurology"], "dosage_form": "Injection", "presentation": "Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-262-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2026", "openfda": {"application_number": ["ANDA076517"], "brand_name": ["CARBOPLATIN"], "generic_name": ["CARBOPLATIN"], "manufacturer_name": ["Hospira, Inc."], "product_ndc": ["61703-262", "61703-360", "61703-150", "61703-600"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["CARBOPLATIN"], "rxcui": ["597195"], "spl_id": ["5aa72c15-8033-4559-b257-373371b18958"], "spl_set_id": ["47677091-fd20-49af-933c-c9dd2be21de9"], "package_ndc": ["61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05"], "nui": ["N0000175413", "N0000175073"], "pharm_class_epc": ["Platinum-based Drug [EPC]"], "unii": ["BG3F62OND5"]}, "update_date": "05/08/2026", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0070-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": {"application_number": ["NDA016673"], "brand_name": ["DEXTROSE"], "generic_name": ["DEXTROSE MONOHYDRATE"], "manufacturer_name": ["Baxter Healthcare Corporation"], "product_ndc": ["0338-0070", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0078", "0338-0062", "0338-0074", "0338-0066", "0338-0082"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXTROSE MONOHYDRATE"], "rxcui": ["1795607", "1795609", "1795610", "1795612", "1795616"], "spl_id": ["66eb82f8-6755-42aa-b20c-192a640e8068"], "spl_set_id": ["36e9478c-5df0-4b47-b97d-de3626d7cb29"], "package_ndc": ["0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10"], "unii": ["LX22YL083G"]}, "update_date": "04/20/2026", "therapeutic_category": ["Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric"], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-488-37", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "04/23/2026", "therapeutic_category": ["Anesthesia", "Pediatric"], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current", "source": "drug_shortages"}
{"discontinued_date": "09/26/2025", "update_type": "New", "initial_posting_date": "09/26/2025", "package_ndc": "25021-230-02", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals", "openfda": {"application_number": ["ANDA090675"], "brand_name": ["IRINOTECAN HYDROCHLORIDE"], "generic_name": ["IRINOTECAN HYDROCHLORIDE"], "manufacturer_name": ["Sagent Pharmaceuticals"], "product_ndc": ["25021-230"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["IRINOTECAN HYDROCHLORIDE"], "rxcui": ["1726319", "1726324"], "spl_id": ["beff4b0b-e884-4134-ba9e-290020a94add"], "spl_set_id": ["caab50e6-0dad-4ddd-9a6c-96cc2b87aee7"], "package_ndc": ["25021-230-02", "25021-230-05"], "unii": ["042LAQ1IIS"]}, "update_date": "09/26/2025", "therapeutic_category": ["Oncology"], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued", "source": "drug_shortages"}
{"update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-722-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": {"application_number": ["ANDA216040"], "brand_name": ["BUPIVACAINE HYDROCHLORIDE"], "generic_name": ["BUPIVACAINE HYDROCHLORIDE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc"], "product_ndc": ["71288-722", "71288-721", "71288-724", "71288-725", "71288-727", "71288-728"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL"], "substance_name": ["BUPIVACAINE HYDROCHLORIDE"], "rxcui": ["1724786", "1724787", "1724880", "1724884", "1725078", "1725082"], "spl_id": ["05aa974a-bfed-44d5-9dba-0427a76ff70b"], "spl_set_id": ["daec9ee4-b666-485e-a153-4b5e5acc48a1"], "package_ndc": ["71288-721-11", "71288-722-32", "71288-724-11", "71288-725-32", "71288-727-11", "71288-728-32"], "unii": ["7TQO7W3VT8"]}, "update_date": "05/05/2026", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current", "source": "drug_shortages"}
{"update_type": "Reverified", "initial_posting_date": "04/10/2021", "package_ndc": "71288-505-03", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": {"application_number": ["ANDA204843"], "brand_name": ["DEXMEDETOMIDINE"], "generic_name": ["DEXMEDETOMIDINE"], "manufacturer_name": ["Meitheal Pharmaceuticals Inc."], "product_ndc": ["71288-505"], "product_type": ["HUMAN PRESCRIPTION DRUG"], "route": ["INTRAVENOUS"], "substance_name": ["DEXMEDETOMIDINE HYDROCHLORIDE"], "rxcui": ["309710"], "spl_id": ["74e25a75-2d63-4f39-b6d0-a73392bd1040"], "spl_set_id": ["8fa36783-b94d-4084-8c41-40ee64192074"], "package_ndc": ["71288-505-02", "71288-505-03"], "unii": ["1018WH7F9I"]}, "update_date": "08/19/2025", "therapeutic_category": ["Anesthesia"], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current", "source": "drug_shortages"}